June Amsterdam. Netherlands. FINAL PROGRAMME. #EULAR 2018

Transcription

1 June 2018 Amsterdam Netherlands FINAL PROGRAMME #EULAR

2 The EULAR Strategic Objectives ESOR - By 2023, EULAR will be the leading provider of education in rheumatic and musculoskeletal diseases (RMDs). 2. Congress - By 2023, EULAR will provide the foremost RMD congress experience, building on the heritage of our outstanding annual meeting. 3. QOC - By 2023, EULAR will deliver pre-eminent comprehensive quality of care (QOC) frameworks for the management of people with RMDs. 4. Research - By 2023, EULAR will have established a European centre for RMD research to advance high quality collaborative research. 5. Advocacy - By 2023, EULAR s activities and related advocacy will have increased participation in work by people with RMDs. 6. Governance, Infrastructure, Financials - By 2023, EULAR will have established governance, workflows and infrastructure to deliver the EULAR strategic objectives.

3 GENERAL INFORMATION / 1 All information listed in this programme is at the time of printing, 1 May 2018 Table of Contents Welcome Message 3 Organising Committees 4 General Information 5 - Information about your participation 6 - EULAR Corporate Social Responsibility Statement 9 - Networking opportunities 9 - Scientific information 9 - Information on industry related activities 10 Scientific Programme Congress at a Glance: - Wednesday, 13 June Thursday, 14 June Friday, 15 June Saturday, 16 June Wednesday, 13 June Scientific Programme 19 Thursday, 14 June Scientific Programme 32 - Guided Poster Tours 49 - Scientific Poster Session I 50 Friday, 15 June Scientific Programme 81 - Guided Poster Tours 98 - Scientific Poster Session II 99 Saturday, 16 June Scientific Programme Guided Poster Tours Scientific Poster Session III 138 Health Professionals in Rheumatology Programme and Posters 171 PARE Programme and Posters 183 EULAR Related Meetings 189 Partner Programme Satellite Symposia 191 Company Profiles 201 Acknowledgements 215 Exhibitors' List 216 Exhibition Plan 217 Congress Venue Overview Plan 218 The acronym PARE used in the programme stands for People with Arthritis/Rheumatism in Europe The acronym HPR used in the programme stands for Health Professionals in Rheumatology

4

5 WELCOME MESSAGE / 3 Welcome Message Dear Colleagues, I wish you a warm welcome to the 19 th EULAR Annual European Congress of Rheumatology in Amsterdam. Our annual EULAR Congress has become a major event in the calendar of world rheumatology, and Amsterdam 2018 will again provide a unique event for the exchange of scientific and clinical information. It offers a platform to facilitate interactions between medical doctors, scientists, health professionals, patients and professionals representing the pharmaceutical industry, from across Europe and around the world. This will be a particularly exciting congress - we will launch the EULAR Strategy and highlight remarkable progress in several recent initiatives, including the EULAR School of Rheumatology and our ground breaking 'Don't Delay, Connect Today' campaign. EULAR is built on three fundamental pillars, integrating patient (PARE), health professional and rheumatology national associations. This partnership underpinning the work of EULAR is a unique stimulus to prosper advances in our field, for example via treatment recommendations, political advocacy, and research leadership. Accordingly, our congress is of the highest quality delivering a rich resource of contemporary, yet accessible information, serving a vital role in our unstinting efforts to reduce the impact, burden and cost of rheumatic and musculoskeletal diseases for individuals and society. EULAR 2018 will address a wide range of topics including innovation in population, health service, clinical, translational and basic science. The WIN/HOT track for the busy clinician requiring an update on What is New and How to Treat the major rheumatic diseases has become an admired and must see highlight of the EULAR Congress. Sessions dedicated to People with Arthritis and Rheumatism in Europe (PARE), Health Professionals in Rheumatology (HPR) are further jewels in our programme. High quality health care industry sessions provide in-depth and focussed insights. Our poster presentations and poster tours provide a highly interactive exchange of knowledge and solutions amongst participants. We will be discussing the best of the more than 5,000 submitted abstracts, testament to the rich vein of creativity and energy currently evident in our discipline. In Amsterdam, together we will further promote the reputation of the EULAR Congress as the most innovative and informative venue for clinical research for the practising physician. Finally, it is a particular pleasure to celebrate the participation of the EULAR EMEUNET organisation of young rheumatologists that continues to attract young colleagues to the meeting. Together we must disseminate the message that rheumatology is one of the most attractive and successful disciplines in global medicine. We are very happy to revisit the City of Amsterdam. In 2006, we relished the magnificent ambiance of canals and canalside houses, galleries, astonishing museums (think Rembrandt, Vermeer, Rubens, Steen and Van Gogh), the Anne Frank House, theatres, music and culinary pleasures. The city has flourished since, offering an evermore diverse and enriching experience, hopefully bathed in early summer sunshine! Whereas balmy warmth may be uncertain, there is no doubt that Amsterdam will provide an excellent background for scientific and clinical exchanges, international collaborations and renewal of friendships. We take great pleasure in welcoming you all to EULAR 2018, and hope that your stay in Amsterdam will be informative, educational and, last but not least, enjoyable. Johannes W. J. Bijlsma EULAR President

6 4 / ORGANISING COMMITTEES Organising Committees EULAR EXECUTIVE COMMITTEE President Prof. Johannes W. J. Bijlsma, Netherlands President-Elect Prof. Iain B. McInnes, United Kingdom Past President Prof. Gerd R. Burmester, Germany Vice-President representing national PARE organisations Mr Dieter Wiek, Germany Vice-President representing the Health Professionals in Rheumatology Prof. Tanja Stamm, Austria Treasurer Prof. Annamaria Iagnocco, Italy General Secretary Prof. Ruxandra Ionescu, Romania Editor in Chief of the Annals of the Rheumatic Diseases - The EULAR Journal Prof. Josef S. Smolen, Austria Editor in Chief of RMD Open Prof. Bernard Combe, France Liaison to EMEUNET Dr Elena Nikiphorou, United Kingdom * Liaison to the American College of Rheumatology ACR Prof. Désirée van der Heijde, Netherlands * Liaison Officer, EU Public Affairs Mr Neil Betteridge, United Kingdom * Liaison to the FOREUM Foundation Prof. Steffen Gay, Switzerland * President UEMS Section of Rheumatology Dr Jean Dudler, Switzerland * Executive Director Dr Julia Rautenstrauch, Switzerland EULAR STANDING COMMITTEE CHAIRS (ex officio members of the EULAR Executive Committee) Investigative Rheumatology Prof. Xavier Mariette, France Clinical Affairs Prof. Ulf Müller-Ladner, Germany Education and Training Prof. Nemanja Damjanov, Serbia Epidemiology and Health Services Research Prof. Laure Gossec, France Musculoskeletal Imaging Dr Lene Terslev, Denmark Paediatric Rheumatology Prof. Berent Prakken, Netherlands PARE Ms Nele Caeyers, Belgium Health Professionals in Rheumatology Prof. Annette de Thurah, Denmark EULAR CONGRESS PROGRAMME COMMITTEE Scientific, Health Professionals, PARE The EULAR Executive Committee Members (excluding functions marked with*) The EULAR Standing Committee Chairs Prof. Robert Landewé, Netherlands Chair of the Scientific Programme Committee Prof. Thomas Dörner, Germany Chair of the Abstract Selection Committee Prof. João Fonseca Past-Chair of the Scientific Programme Committee Prof. Francis Berenbaum, France Prof. Leonard Calabrese, United States Prof. Loreto Carmona, Spain Prof. Piet Geusens, Netherlands Prof. Martin Herrmann, Germany Prof. John Isaacs, United Kingdom Mr Marios Kouloumas, Cyprus Prof. Anne-Marie Malfait, United States Dr Elena Neumann, Germany Dr Caroline Ospelt, Switzerland Dr Daniel Prieto-Alhambra, United Kingdom Dr Yeliz Prior, United Kingdom Dr Sofia Ramiro, Netherlands Prof. Alexander So, Switzerland Dr Leonie Taams, United Kingdom Prof. Tsutomu Takeuchi, Japan Prof. Lai-Shan Tam, China Prof. Angela Tincani, Italy Prof. Filip van den Bosch, Belgium Prof. David Walsh, United Kingdom * These functions are not included in the Congress Programme Committee

7 GENERAL INFORMATION / 5 General Information CONGRESS VENUE: DATES AND LOCATION The Annual European Congress of Rheumatology EULAR 2018 is held at: RAI Amsterdam Europaplein NL 1078 GZ Amsterdam Netherlands Website: The congress opens on Wednesday, 13 June 2018 at 12:00 and closes on Saturday, 16 June 2018 at 14:45. The EULAR 2018 Congress Opening Plenary Session takes place on Wednesday, 13 June 2018 from 13:00 to 14:00. A networking platform, for scientific exchange, is held in the evening of Wednesday, 13 June 2018 at the congress venue itself. RAI Amsterdam is situated 8 minutes from Amsterdam s city centre and 15 minutes from Amsterdam Airport Schiphol. EULAR 2018 delegates can easily reach the congress venue by public transport. REGISTRATION AREA OPENING HOURS Tuesday 12 June :00-20:00 Wednesday 13 June :30-20:00 Thursday 14 June :45-19:15 Friday 15 June :45-19:15 Saturday 16 June :00-15:00 SCIENTIFIC SECRETARIAT EULAR Secretariat Seestrasse 240 CH-8802 Kilchberg/Zurich Switzerland Tel: Fax: congress@eular.org Website: / ORGANISING SECRETARIAT In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations EULAR 2018 c/o MCI SUISSE SA Rue du Pré-Bouvier 9 CH-1242 Satigny, Geneva Switzerland Tel: Fax: eular@mci-group.com Website: LOCAL ORGANISING AGENCY For social events, excursions, transfers, company events MCI Amsterdam Schipluidenlaan HE Amsterdam Netherlands Tel: eular18.soc@mci-group.com Website:

8 6 / GENERAL INFORMATION Information about your Participation ADMITTANCE TO THE EULAR CONGRESS In respect of Dutch and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR Congress shall be limited solely to participants who are 18 years of age or older. Registration by anyone who is under 18 is unauthorised and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time. This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision. CANCELLATION OF CONGRESS It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages. EULAR CONGRESS MOBILE APP Since 2003 EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In the last seven years, we have also offered a planning tool, the internet based itinerary planner. Schedules made in the planner can be transferred easily to your smartphone or tablet on ios, Android or WindowsPhone. Apart from general information, the app contains the complete congress programme with all sessions and lectures, all abstracts in full text and all symposia. Links between these elements allow for changes to content to be made easily. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place. A support desk for mobile devices is located in the EULAR Village. Promote the EULAR Congress Mobile App by using the hashtag #EULAR2018App. DATA SCANNING SYSTEM The EULAR 2018 Congress will use a new generation of delegate badges including a chip acting as a sensor. This tool will collect anonymised data with the primary objective of improving future EULAR Congresses by understanding the use EULAR Participants make of available services and opportunities, and by better understanding the various interactions as well as the topics of interest. As a participant at the congress, you will not be impacted but your contribution will be key to the success of future EULAR Congresses. All tracked data will be anonymous and only has a very small operating radius inside the conference rooms and the venue. Please ensure that you return your badge either to the registration area or to the clearly designated collection points - which will be located near to the exits of the conference venue - before your final departure from the event. These badges will be recycled. DRESS CODE Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates. General Information CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES Charging stations for smartphones and other mobile devices are available in the registration area and exhibition area. CLOAKROOM A cloakroom service for coats and reasonably-sized luggage is available during the opening hours of the congress in the registration area, Hall 2. CYBER CAFÉ Two Cyber Cafés are located in the exhibition area and EULAR Village, Hall 1. CONGRESS DOCUMENTS AND BADGES Name badges can be printed and activated at the selfservice stations, located at the registration area in Hall 2 for regular delegates. Invited speakers, guests, PARE and patients can obtain their badges from the manned registration counters. Name badges must be worn visibly at all time during the congress and in the exhibition area. CONGRESS EVALUATION We would be grateful if you could take a few minutes to support the onsite staff member who may approach you to gain your opinion about the congress and the scientific programme. This will help us to continue to improve the congress in the future. CLIMATE Amsterdam is at its best from May (when the tulips are out) to August (when the days are the longest). The climate is moderate maritime, with warm summers and cool winters, and typically high humidity. You always have a chance of seeing rain in Amsterdam. CREDIT CARDS Major Credit Cards (Visa, American Express, Eurocard/ Mastercard, Diners Club) are accepted in most hotels, restaurants and shops. CURRENCY The currency in the Netherlands is Euro (1 Euro= 100 cents).

9 GENERAL INFORMATION / 7 ELECTRICITY The electricity power supply in the Netherlands is 220 Volts with a European standard plug. FOOD AND BEVERAGE During official coffee breaks, complimentary coffee and tea will be served in the EULAR Village and exhibition area, Hall 1. Lunch will be provided from these areas on Thursday and Friday. A self-service restaurant and sandwich bars are available at the congress venue. HELP POINT FOR SMARTPHONES AND MOBILE DEVICES A Help Point for phones and other mobile devices as well as recharge options for such devices will be available in the EULAR Village. The EULAR Mobile Congress App can also be downloaded there. AMSTERDAM & THE NETHERLANDS (FACTS ABOUT) The Netherlands is the main constituent country of the Kingdom of the Netherlands. It is a small, densely populated country located in Western Europe with three island territories in the Caribbean. Amsterdam is the country s capital, while The Hague holds the Dutch seat of government and parliament. The port of Rotterdam is the largest port in Europe and was the world s largest port between 1962 and The name Holland is also frequently and incorrectly used to refer informally to the whole of the country of the Netherlands. Netherlands literally means lower countries, influenced by its low land and flat geography, with only about 50 percent of its land exceeding one metre above sea level. Most of the areas below sea level are man-made. Since the late 16 th century, large areas (polders) have been reclaimed from the sea and lakes, amounting to nearly 17 percent of the country s current land mass. The Netherlands is the world s second-largest exporter of food and agricultural products, after the United States. This is partly due to the fertility of the soil and the mild climate. The Netherlands was the third country in the world to have an elected parliament, and since 1848 it has been governed as a parliamentary democracy and a constitutional monarchy, organised as a unitary state. The Netherlands has a long history of social tolerance and is generally regarded as a liberal country, having legalised abortion, prostitution and euthanasia, while maintaining a progressive drugs policy. In 2001, it became the world s first country to legalise same-sex marriage. The Netherlands is also a part of the Schengen Area and has a market-based mixed economy. In 2013, the United Nations World Happiness Report ranked the Netherlands as the seventh-happiest country in the world, reflecting its high quality of life. When people think of the Netherlands, many of them think of tulips and windmills but the country has much more to offer. Amsterdam was founded in the Middle Ages near a dam on the River Amstel. The city truly blossomed in the early 17 th century, when it became the world s largest centre for trade and art. The historic heart of the city known as the Grachtengordel (canal ring) has remained beautifully intact to this day. Today, with two leading universities and several laboratories, Amsterdam is now firmly on the world map as a knowledge centre. The city attracts many prominent academics as well as those involved in innovative science and research. Amsterdam is a historic city with a modern outlook that meshes business growth with sustainable initiatives. The city is regarded as one of the top 10 most important commercial centres in the world. Amsterdam has been a centre of creativity and culture for centuries. The famous Rijksmuseum features works by 17 th century Dutch Masters such as Rembrandt and Vermeer. The Van Gogh Museum houses some of the eponymous artist s greatest works. Other heritage treasures include the Anne Frank House, the Rembrandt House and the baroque Royal Palace on Dam Square. Even frequent visitors will always find something new to appreciate. Amsterdam is a vibrant, dynamic city in which people feel free. Free to be who they are, and to write or say what they want. The city is famous for its tolerance. This has been expressed since the 17 th century in the city s wide diversity of

10 8 / GENERAL INFORMATION people, businesses and events. With 180 different cultures, Amsterdam is amongst the most diverse cities in the world. A recent report published by the Economist Intelligence Unit found that Amsterdam is among the safest cities in the world, ranking fifth on the global index and second in Europe. Amsterdam is therefore a place in which international EULAR delegates will be able to move freely and safely. Just 15 minutes from the centre of Amsterdam, the villages of Marken and Volendam offer an unrivalled collection of authentic Dutch houses and windmills. GETTING AROUND IN AMSTERDAM Amsterdam has an outstanding public transportation system, but the compact city centre means most facilities and sights are within walking distance of each other. The city s network of canals also offers a unique transport opportunity. Amsterdam s compact size means that almost everything is within walking distance. Nevertheless, the public transport network is efficient, modern, reliable and inexpensive. Amsterdam s public transport company is GVB, which transports one million passengers within greater Amsterdam by tram, bus, metro and ferry every day. An efficient train system completes the offering. Taxis Amsterdam has a variety of taxi firms which supplements its excellent public transportation network. TCA operates 1500 drivers and 1300 vehicles. Taxi fares from RAI Amsterdam to hotels and to the airport in Amsterdam are regulated by special flat rates to guarantee that delegates are not overcharged. Passengers at Amsterdam Airport Schiphol can also opt for electrically powered Tesla taxis. These vehicles make a major contribution to sustainable mobility at the airport. Metro The Amsterdam Metro is a mixed subway and aboveground commuter rail with various lines. Tram 4 runs between the RAI (Europaplein stop), Amsterdam s city centre and Amsterdam Central Station. You can reach the RAI from the Amstel railway station by taking Metro 51 and Bus 65. Metro 51 also runs to Amsterdam Central Station. Metro 50 runs regularly between the Amsterdam Sloterdijk and Gein stations and stops at the RAI Amsterdam station. Cycling Amsterdam is one of the most bicycle-friendly large cities in the world and is a centre of bicycle culture with good facilities for cyclists such as bike paths and bike racks. In 2013, there were about bicycles in Amsterdam outnumbering the amount of citizens in the city. Bicycle rentals are readily available throughout the city. Central Station, Leidseplein and Dam Square are all major rental hubs. INSURANCE AND LIABILITY It is strongly recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EULAR and MCI as organisers cannot accept any responsibility for personal injuries, or loss of, or damage to, private property belonging to congress participants. LANGUAGES/OFFICIAL LANGUAGE The official congress language is English. No simultaneous translation is provided. SOCIAL MEDIA / PHOTOGRAPHY RULES AND REGULATIONS AT EULAR 2018 The intention at EULAR 2018 is to facilitate the sharing of content within the scientific, health professional and patient communities while still respecting the copyrights and intellectual property of the presenters. Picture-taking/ filming and/or live streaming for commercial use and in the commercial area is not permitted. Recording or live streaming of congress presentations/sessions is not allowed in any way (neither image, nor sound). Presenters and chairs have the right to request no photographs during their presentation/session/activities. In compliance with Dutch laws on promotional activities for medical events and satellite symposia, published photographs should not include any trade names, brand names and/or any product advertisement. At all times, when permitted, photographs must be taken in a non-disruptive manner. Full guidelines can be downloaded on PRESS CENTRE The press and media area is located in rooms G101-G111. Facilities such as computers, photocopier, and internet access are available for registered media and press representatives. SECURITY Please pay particular attention to your personal belongings, especially when walking in the city centre or using the public transportation system, and inside the congress venue. Any security problems or concerns within the congress venue should be reported to a member of the EULAR or MCI staff. Security staff will handle all emergency situations and everyone is required to follow instructions announced via the public information system. Emergency exits are marked with green exit signs. SERVICES FOR THE DISABLED All session rooms at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village. SHOPPING IN AMSTERDAM Amsterdam s specialist stores make shopping in the city unique. Amsterdam s best shops are in charming canal houses on cobblestone streets. This village-like atmosphere makes shopping a delight. SMOKING POLICY Smoking is not permitted at the congress venue. SOCIAL MEDIA Share your best moments of EULAR on your social media platforms by using the hashtag #EULAR2018. Please also refer to the EULAR Social Media Policy which can be downloaded at TELEPHONES Please respect your fellow colleagues and friends by operating your mobile devices in silent mode in all session rooms and poster areas.

11 GENERAL INFORMATION / 9 TIME The Netherlands follows Central European Time (CET) which is UTC +1 hour in winter and UTC + 2 in summer. TIPPING Locals in Amsterdam usually tip when they have received good service. In general, people tend to tip 10 percent in restaurants (however restaurants do not charge extra on the bill). Tipping taxicab drivers and hotel personnel is also customary in Amsterdam. TRANSPORTATION EULAR provides transportation passes to duly registered delegates, who booked the accommodation through MCI, the official congress housing bureau, enabling them to travel on the public transportation network between their hotel and the congress venue during the EULAR Congress. EULAR Corporate Social Responsibility Statement EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place. For the Amsterdam congress, EULAR has made the following sustainable arrangements: HEALTHY FOOD All buffets for lunches and coffee breaks offer healthy options meaning that there is always a choice of fresh fruit or vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritised. PRINTING EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. No abstract book and no preliminary programme for EULAR 2019 will be printed. All abstracts will be available online as well as the preliminary programme. This will save printing approximately 24,000,000 pages. LOCAL SUPPLIERS EULAR wishes to have a positive local impact. When sourcing materials and suppliers, EULAR gives priority to local partners to avoid a negative impact on the environment and to positively impact the local economy. SERVICES FOR THE DISABLED EULAR wishes to make the congress experience comfortable for all attendees. All rooms and areas at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly within the EULAR Village. Networking Opportunities OPENING PLENARY SESSION Wednesday, 13 June :00-14:00 - Hall 7.1 The Opening Plenary Session will take place this year in the early afternoon. NETWORKING PLATFORM Wednesday, 13 June :00-22:00 - Strand Zuid All registered participants are cordially invited to meet and greet old and new friends. EULAR CONGRESS DINNER Friday, 15 June :30-24:00 Price: EUR 95 per person (not included in the registration fee) The EULAR 2018 Congress Dinner will take place on board the Ocean Diva. The Congress Dinner is always a great opportunity to fine dine and meet with friends and colleagues from around the world in a relaxed atmosphere, this year enjoying the unmatched charm and fascination of Amsterdam. In the city of canals, how could we better welcome our participants and friends than on a superb vessel? The Ocean Diva, an impressive cruise ship, will take us for a tour on the Amsterdam waters in a trendy, high quality and friendly Dutch atmosphere. Seats being very limited, rush to register and don t miss the unique opportunity of networking with colleagues and friends while enjoying Dutch cuisine at its best! Scientific Information CERTIFICATE OF ATTENDANCE A certificate of attendance will be sent by to all attendees who fill out the congress evaluation survey. Please update your contact details at the Yellow Towers available throughout the congress venue in order to ensure that the certificate reaches you. CONTINUING MEDICAL EDUCATION (CME) CREDITS CME approval was still under review at the time of printing. Please consult the EULAR Website or the EULAR App for further information. POSTERS The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in halls 1, 5 and 6 from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed on a permanent basis close to the PARE Room, located in Hall 5. Official poster viewing will take place at the following times: Thursday 14 June :45-13:30 Friday 15 June :45-13:30 Saturday 16 June :30-12:00

12 10 / GENERAL INFORMATION Guided poster tours on selected topics will take place during the official poster viewing times. Delegates interested in the work of the EULAR Study Groups have the possibility to browse through electronic posters of the different projects and working groups near the EULAR Village. SPEAKERS PREVIEW ROOM The speakers preview room is located in room K101/K102, near Hall 2, and is open at the following times: Wednesday 13 June :00-20:00 Thursday 14 June :00-19:00 Friday 15 June :00-19:00 Saturday 16 June :00-14:30 The preview room is equipped with computers. All speakers are required to check-in their presentation at least 2 hours before their session, or on the day before for the early morning sessions. SCIENTIFIC SESSIONS (ACCESS TO) The meeting rooms for scientific sessions vary in size. Should the room be full, we invite you to use the overflow facilities located in the registration area, Hall 2 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law. Pharmaceutical companies can only actively promote prescription medicines in their interactions with healthcare professionals that are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession) As such and in full respect of the applicable regulations, EULAR has decided to implement the following processes: The commercial and the non-commercial parts of the exhibition will be clearly identified Healthcare professionals who are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession) will be clearly identified to enable pharmaceutical companies to appropriately engage with them Congress participants registered as PARE representatives or as patients will be clearly identified and will not have access to the commercial part of the exhibition and satellite symposia including brand advertisement. The access to all other official parts of the congress including the non-commercial part of the exhibition is unrestricted We kindly ask all registered participants to follow the specific instructions they will receive together with the congress documents. Onsite staff and dedicated signs are there to help participants navigate the exhibition halls. PRIVATE EVENTS POLICY All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat. Information on Industry Related Activities EXHIBITION During the congress, EULAR will present an attractive exhibition to the congress participants. The abstract poster presentation areas are placed around the exhibition in Halls 1, 5 and 6. Coffee and other refreshments are available within the exhibition during official breaks. The exhibition hours are as follows: Wednesday 13 June :00-18:00 Thursday 14 June :00-17:15 Friday 15 June :00-17:15 Saturday 16 June :45-14:00 EXHIBITION ACCESS (RESTRICTED) For medical conferences taking place in Europe, all participants as well as all contributors are subject to European laws, rules and regulations clarified by the Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2011 on the Community code relating to medicinal products for human use. The relevant European laws, rules and regulations and their Dutch application clearly state that: Patients and patient advocates should have no access to the areas where prescription medicines are promoted and should not receive any materials containing product advertisements (irrespective of their nationality) SATELLITE SYMPOSIA (ACCESS TO) The meeting rooms for satellite symposia vary in size. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a satellite symposium. The maximum capacity of the rooms are determined by the local safety and security regulations and must be respected by law. Access to satellite symposia featuring product advertisement is restricted to healthcare professionals that are entitled to prescribe or supply prescription medicines (in the country where the professional is practicing its profession). SATELLITE SYMPOSIA (TIMINGS) A number of satellite symposia are organised during EULAR 2018 at the following times: Wednesday 13 June :15-19:45 Thursday 14 June :15-09:45 14 June :30-19:00 Friday 15 June :15-09:45 15 June :30-19:00 Further information is available in the satellite booklet, included in your congress bag and on pages 191 to 199 of this programme. Satellite symposia are governed by the EULAR Guidelines. All symposia and special events must be approved by EULAR. Other symposia are strictly prohibited during the official programme, as outlined in the EULAR Code of Practice.

13 GENERAL INFORMATION / 11 ALL DATES AND TIMES DATE REGISTRATION AREA SPEAKERS PREVIEW POSTERS VIEWING NETWORKING OPPORTUNITIES EXHIBITION SATELLITE SYMPOSIA Tuesday 12 June :00-20:00 Wednesday 13 June :30-20:00 08:00-20:00 13:00-14:00 Opening plenary session 20:00-22:00 Networking platform 12:00-18:00 18:15-19:45 Thursday 14 June :45-19:15 08:00-19:00 11:45-13:30 08:00-17:15 08:15-09:45 17:30-19:00 Friday 15 June :45-19:15 08:00-19:00 11:45-13:30 20:30-24:00 EULAR Congress Dinner 08:00-17:15 08:15-09:45 17:30-19:00 Saturday 16 June :00-15:00 08:00-14:30 10:30-12:00 08:45-14:00 Future Congresses Annual European Congress of Rheumatology 2019 Madrid, Spain, June 2019 Annual European Congress of Rheumatology 2020 Frankfurt, Germany, 3-6 June 2020

14 Keep in touch with rheumatology Update your contact details at the yellow towers! Receive your access codes to the recorded sessions* Receive your free subscription to the EULAR Journal - Annals of the Rheumatic Diseases (ARD)** Receive your EULAR 2018 Certificate of Attendance * if purchased ** the patient and exhibitor registration categories do not include the complimentary subscription to the ARD

15 CONGRESS AT A GLANCE / WEDNESDAY 13 JUNE 2018 / 13 Congress at a Glance Scientific Programme PARE Programme Health Professionals Programme (HPR) Satellite symposia Networking opportunities Paediatric Rheumatology Programme WEDNESDAY, 13 JUNE 2018 TIME Hall 7.1 Hall 3 Auditorium Elicium 2 Hall 7.2 Forum Elicium 1 13:00-14:00 EULAR 2018 Opening Plenary session 14:15-15:45 What is New (WIN) / How to Treat (HOT) WIN: Systemic lupus: issues about pregnancy WIN: Recent advances in the treatment of lupus Challenges in Clinical Practice session Little arthritis in PsA and axspa with newly onset arthritis - does it matter? Clinical Science Session Cancer and inflammation From Bench to Bedside Psychological distress and pain; not all in the mind Challenges in Clinical Practice session Inflammation in the shadow of fibromyalgia From Bench to Bedside Shaping the future in systemic sclerosis Basic and Translational Science session Basic mechanisms of inflammation 15:45-16:15 COFFEE BREAK 16:15-17:45 Abstract session Opening Plenary Abstract session Abstract session From NSAIDs to bdmards in SpA: what is new? Abstract session RA therapy - new molecules and new strategies Abstract session Doctor, how bad will my rheumatoid arthritis become? RA - prognosis, predictors and outcomes Abstract session Immunobiology of vasculitis Abstract session Envisioning new horizons for people with osteoarthritis Abstract session Fracture risk and consequences 18:15-19:45 Satellite symposium*** Satellite symposium*** Satellite symposium*** Satellite symposium*** Satellite symposium*** Basic and Translational Science session Burning bones 20:00-22:00 NETWORKING PLATFORM - STRAND ZUID TIME Amtrium Emerald PARE Room E106/E107 D201/D202 D203/D204 14:15-15:45 HPR session Health Professionals Welcome session The Young Rheumatologist Statistics made simple: a practical approach to complex concepts PARE session E-health for better care EULAR Projects in Paediatric Rheumatology EULAR Projects in Paediatric Rheumatology and UCAN Practical skills session* Crystal I Practical skills session* Ultrasound basic I 15:45-16:15 COFFEE BREAK Joint session HPR/PARE Abstract session PARE session Abstract session Abstract session Abstract session 16:15-17:45 New drugs - new perspectives: clinical and regulatory issues concerning biosimilars Movement in musculoskeletal pain; from risk to management Don t Delay, Connect Today! Let s improve diagnosis and treatment of orphan diseases New driving molecules in systemic sclerosis A rollercoaster from bench to bedside and back again: paediatric rheumatology in the 21 st century 18:15-19:45 Health Professionals session Delay in treatment and the role of health professionals Satellite symposium*** Satellite symposium*** * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2 *** See detailed satellite symposia programme on pages 191 to 199

16 14 / CONGRESS AT A GLANCE / THURSDAY 14 JUNE 2018 Congress at a Glance THURSDAY, 14 JUNE 2018 TIME Hall 7.1 Hall 3 Auditorium Elicium 2 Hall 7.2 Forum Satellite symposium*** Satellite symposium*** Satellite symposium*** Satellite symposium*** Satellite symposium*** 08:15-09:45 09:45-10:15 COFFEE BREAK What is New (WIN) / How to Treat (HOT) Abstract session Abstract session Abstract session Abstract session Abstract session 10:15-11:45 WIN: Advances in the diagnosis and monitoring of vasculitis HOT: Recent advances in the treatment of systemic vasculitides Biologics in RA. Improving and maintaining the response SLE, Sjögren s and APS - new criteria, novel diagnostic tools and co-morbidities The A-B-C of PsA (Assessment, Biologicals, Co-morbidities) RA: such a pain, and beyond Quickly emerging: science in SSc, myositis and related syndromes 11:45-13:30 POSTER VIEWING AND LUNCH 11:50-13:30 GUIDED POSTER TOURS** 13:30-15:00 What is New (WIN) / How to Treat (HOT) WIN: What is new in the treatment of myositis? HOT: Recent advances in the treatment of systemic sclerosis Clinical Science session Can we halt progression of structural damage in axial SpA? Clinical Science session Reproductive issues in rheumatology Challenges in Clinical Practice session Clinical challenges in giant cell arteritis in 2018 Clinical Science session Do we still need biopsies to diagnose Sjögren s and autoimmune myositis? Paediatric Rheumatology session How monogenetic autoinflammatory diseases help to understand and treat rheumatic diseases 15:00-15:30 COFFEE BREAK 15:30-17:00 What is New (WIN) / How to Treat (HOT) WIN: About diagnosis and classification of spondyloarthritis HOT: Recent advances in the management of spondyloarthritis Challenges in Clinical Practice session To taper or not to taper in RA Clinical Science session Can we improve the care of gout? Clinical Science session Why does BMI matter? Clinical Science session Musculoskeletal pain; feeding the opioid epidemic From Bench to Bedside What is lupus - Syndrome or different entities? Satellite symposium*** Satellite symposium*** Satellite symposium*** 17:30-19:00 ** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2 *** See detailed satellite symposia programme on pages 191 to 199

17 CONGRESS AT A GLANCE / THURSDAY 14 JUNE 2018 / 15 Scientific Programme Satellite symposia PARE Programme Networking opportunities Health Professionals Programme (HPR) Paediatric Rheumatology Programme Elicium 1 Amtrium Emerald PARE Room E106/E107 D201/D202 D203/D204 Basic and Translational Science session Satellite symposium*** Satellite symposium*** Satellite symposium*** Fat and fatty acids: targets for therapy? COFFEE BREAK Abstract session Can imaging improve diagnosis and outcome in rheumatic diseases HPR Abstract session Singing power to the people Abstract session Fires and firefighters: switching the immune system on and off PARE session Inclusive school environment for young people with RMDs Abstract session The building blocks of systemic inflammation Abstract session The crystal maze - etiology and management Abstract session Treatments: friend or foe? POSTER VIEWING AND LUNCH GUIDED POSTER TOURS** Basic and Translational Science session HPR session Clinical Science session PARE session EULAR Projects Practical skills session* Practical skills session* Joint EULAR - EFIS session: I ve got a B in my bonnet Sustainable healthcare in rheumatology and the role of health professionals SSc: From registries to trials - do we have sufficient data and the appropriate design? Patient involvement in research: the future of collaborative research. Lessons from the field of rheumatology and beyond EULAR Projects in Musculoskeletal Imaging Crystal II MRI COFFEE BREAK Basic and Translational Science session HPR session Practical skills session* PARE session EULAR Projects in Health Professionals Practical skills session* Practical skills session* Genetics, epigenetics and disease: is it all in the genes? It s your move: promoting physical activity in people with RMDs Data visualisation: tables and graphs for publication and presentation I Challenges of patient organisations in the 21 st century The EULAR Exercise Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis Capillaroscopy I Ultrasound advanced I Basic and Translational Science session Satellite symposium*** Satellite symposium*** Satellite symposium*** Immune senescence and ageing * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2 ** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2 *** See detailed satellite symposia programme on pages 191 to 199

18 16 / CONGRESS AT A GLANCE / FRIDAY 15 JUNE 2018 Congress at a Glance FRIDAY, 15 JUNE 2018 TIME Hall 7.1 Hall 3 Auditorium Elicium 2 Hall 7.2 Forum Satellite symposium*** Satellite symposium*** Satellite symposium*** 08:15-09:45 09:45-10:15 COFFEE BREAK What is New (WIN) / How to Treat (HOT) Abstract session Abstract session Abstract session Abstract session Abstract session 10:15-11:45 WIN: Infectious complications of rheumatic disease (treatment) HOT: Advances in the management of osteoporosis Biologics in RA. More, more and more about safety Clinical and therapeutic aspects of vasculitis Axial spondyloarthritis: on the interface between healthy and diseased Present and future treatments for SLE, Sjögren and APS From cartilage to bone 11:45-13:30 POSTER VIEWING AND LUNCH 11:50-13:30 GUIDED POSTER TOURS** 13:30-15:00 What is New (WIN) / How to Treat (HOT) WIN: Check-point inhibitors: what are they used for? HOT: Immune related adverse events upon check-point inhibitors Challenges in Clinical Practice session Challenges in systemic lupus diagnosis From Bench to Bedside Pathophysiology and biomarkers in PsA: what impact? Clinical Science session The art of diagnosis of axial SpA The Young Rheumatologist Understanding the language of basic research, epidemiology and health services articles Clinical Science session Joint EULAR - ESSR session: the role of MR imaging in rheumatic diseases and its clinical implications 15:00-15:30 COFFEE BREAK 15:30-17:00 What is New (WIN) / How to Treat (HOT) WIN: How to diagnose rheumatoid arthritis early? HOT: Recent advances in the treatment of rheumatoid arthritis Clinical Science session Advances in biologic therapy of small vessel vasculitis Clinical Science session Tapering and flaring in PsA and SpA Clinical Science session Prevention of OA: yes we can! Clinical Science session Big data for musculoskeletal research Paediatric Rheumatology session From big data to personalised medicine in paediatric rheumatic diseases Satellite symposium*** Satellite symposium*** 17:30-19:00 ** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2 *** See detailed satellite symposia programme on pages 191 to 199

19 CONGRESS AT A GLANCE / FRIDAY 15 JUNE 2018 / 17 Scientific Programme Satellite symposia PARE Programme Networking opportunities Health Professionals Programme (HPR) Paediatric Rheumatology Programme Elicium 1 Amtrium Emerald PARE Room E106/E107 D201/D202 D203/D204 Basic and Translational Science session Satellite symposium*** Satellite symposium*** Satellite symposium*** Special delivery: intercellular communication COFFEE BREAK Abstract session HPR Abstract session Abstract session PARE Abstract session Abstract session Abstract session Abstract session Seeking the pathophysiology of rheumatoid arthritis and spondylarthritis Supporting selfmanagement From gene to function More money or more education and collaboration? The changing therapeutic landscape of PsA T/B be or not T/B: adaptive or innate immunity - that is the question POSTER VIEWING AND LUNCH GUIDED POSTER TOURS** Basic and Translational Science session HPR session Practical skills session* Joint session PARE/Clinical EULAR Projects Practical skills session* Practical skills session* The stromal link to inflammation New approaches in measuring what matters to patients Data visualisation: tables and graphs for publication and presentation II Innovative treatments for a better quality of life EULAR Projects in Investigative Rheumatology Laboratory course - from the clinic to the lab and back New assessments in clinical practice COFFEE BREAK Basic and Translational Science session Triple T: T cells, technologies and therapies HPR session Navigating the world of digital health Clinical Science session The rheumatologistorthopedic surgeon connection in secondary fracture prevention PARE session What s new: latest advances in treatment in JIA and osteoarthritis EULAR Projects in Epidemiology and Health Services Assessment and prevention of RMDs, what have we learned? Practical skills session* Capillaroscopy II Practical skills session* Ultrasound advanced II Basic and Translational Science session Satellite symposium*** Satellite symposium*** Satellite symposium*** High-end imaging: looking for the invisible * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2 ** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2 *** See detailed satellite symposia programme on pages 191 to 199

20 18 / CONGRESS AT A GLANCE / SATURDAY 16 JUNE 2018 Congress at a Glance Scientific Programme PARE Programme Health Professionals Programme (HPR) Networking opportunities Paediatric Rheumatology Programme SATURDAY, 16 JUNE 2018 TIME Auditorium Elicium 2 Hall 7.2 Forum Elicium 1 09:00-10:30 What is New (WIN) / How to Treat (HOT) WIN: What can new insights in the pathogenesis of psoriasis and psoriatic arthritis teach the rheumatologist? HOT: New approaches in the treatment of psoriatic arthritis Challenges in Clinical Practice session The GI tract in systemic sclerosis - is there light at both ends? Clinical Science session RA: is it all in your head? Paediatric Rheumatology session Battling hyperinflammation in paediatric rheumatic diseases Basic and Translational Science session Gut bacteria: the boss of the immune system 10:30-12:00 POSTER VIEWING AND COFFEE BREAK 10:30-12:00 GUIDED POSTER TOURS** 12:00-13:30 EULAR Projects in Clinical Affairs Recommendation session ESSCA Challenges in Clinical Practice session Fractures: more than bone alone Clinical Science session Emerging topics in the management of the antiphospholipid syndrome From Bench to Bedside The links between gout and kidney function Basic and Translational Science session Big data in pre-clinical research 13:45-14:45 Clinical and Basic Translational Highlight session TIME Amtrium Emerald PARE Room E106/E107 09:00-10:30 HPR session Multi-disciplinary management of complex persistent pain From Bench to Bedside Osteoarthritis: a vascular disease PARE session Workshop: Is there a diet for people with RMDs? EULAR Projects in Education and Training Challenging projects in education and training 10:30-12:00 POSTER VIEWING AND COFFEE BREAK 10:30-12:00 GUIDED POSTER TOURS** 12:00-13:30 HPR session How do you sleep? From Bench to Bedside Stratifying connective tissue diseases Joint session PARE/HPR Work and rehabilitation - key priorities for people with RMDs The Young Rheumatologist The challenges of rheumatology trainees in the clinical learning environment 13:45-14:45 HPR Highlight session PARE Highlight session * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2 ** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area, Hall 2

21 SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 19 Scientific Programme Wednesday 13 June :15-15:45 Hall 3 13 June 2018 Challenges in Clinical Practice session Little arthritis in PsA and axspa with newly onset arthritis - does it matter? Learning objectives: To gain insight into how to translate data from clinical trials (of patients with PsA with polyarthritis) to daily clinical practice with patients with oligoarthritis To identify extra-spinal musculoskeletal manifestations in axspa and their impact in the monitoring and treatment of patients with axspa Helena Marzo-Ortega (United Kingdom) Laura Coates (United Kingdom) Elena Nikiphorou (United Kingdom) 14:20 Abstract N SP0002 Case 1 presentation: PsA beyond the typical poly-articular phenotype: how to deal with this in clinical practice? 07:30-20:00 Registration area (Hall 2) Registration 13:00-14:00 Hall 7.1 EULAR 2018 Opening Plenary session 14:15-15:45 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN session Angela Tincani (Italy) 14:20 Abstract N SP0001 WIN: Systemic lupus: issues about pregnancy Thomas Dörner (Germany) 15:00 WIN: Recent advances in the treatment of lupus Douglas Veale (Ireland) 14:30 Case 1 discussion: How to use RCT data to guide treatment decisions in real life? Alexandre Sepriano (Portugal) 15:00 Abstract N SP0003 Case 2 presentation: AxSpA patient with peripheral manifestations Maxime Dougados (France) 15:10 Abstract N SP0004 Case 2 discussion: Extra-spinal manifestations in axspa, are they forgotten? 14:15-15:45 Auditorium Clinical Science session Cancer and inflammation Learning objectives: To understand the interplay between cancer and RMDs, especially inflammatory disorders, both from a basic and clinical perspective Eva Baecklund (Sweden) Karen Visser (Netherlands) Maria Suarez-Almazor (United States) 14:20 RMD as comorbidity in cancer patients Xavier Mariette (France) 14:40 The role of TNF in cancer Campbell Roxburgh (United Kingdom) 15:00 Abstract N SP0005 Inflammation in cancer: friend or foe

22 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 A. Horne (Sweden) 15:20 B. Delcoigne, J. Askling Abstract N OP0001 Risk of malignancy in children with juvenile idiopathic arthritis: a register-based cohort study S. C. Kim (United States) 15:30 A. Pawar, R. J. Desai, S. Gale, M. Klearman, K. Sarsour, D. H. Solomon, S. Schneeweiss Abstract N OP0002 No difference in the risk of malignancy in tocilizumab versus TNF inhibitor initiators in patients with rheumatoid arthritis: a multi-database cohort study 14:15-15:45 Elicium 2 From Bench to Bedside Psychological distress and pain; not all in the mind Learning objectives: To understand how psychological distress changes central pain processing, augmenting the sensory component of pain To gain an appreciation of how pain and affect share common mechanisms To develop a framework for psychological interventions within the physical and medical management of arthritis pain Jonathan Cavanagh (United Kingdom) Alexander So (Switzerland) Victoria Chapman (United Kingdom) 14:20 What do preclinical models tell us about why psychological distress is so bad for arthritis pain? Benedikt Sundermann (Germany) 14:40 Abstract N SP0006 Distress and pain; integrated brain pathways Rob Smeets (Netherlands) 15:00 Abstract N SP0007 Dealing with psychological distress to optimise outcomes for arthritis pain A. M. Rathbun (United States) 15:20 Z. Evans, M. Shardell, M. Yau, J. Gallo, E. Stuart, M. Schuler, M. Hochberg Abstract N OP0003 Association between disease severity and onset of depression in knee osteoarthritis B. A. C. Nascimento (Brazil) 15:30 B. K. Vitturi, B. R. Alves, F. Campos, D. Y. Torigoe Abstract N OP0004 Cognitive impairment in rheumatoid arthritis patients: a case-control study 14:15-15:45 Hall 7.2 Challenges in Clinical Practice session Inflammation in the shadow of fibromyalgia Learning objectives: To understand the mechanisms by which the central nervous system amplifies pain from inflamed joints and symptoms such as fatigue Be alert to and recognise fibromyalgia and central symptom augmentation in people with arthritis How to use these skills to optimise the balance between disease modifying and pain management approaches for the individual David Walsh (United Kingdom) Annette van der Helm-van Mil (Netherlands) Anne-Priscille Trouvin (France) 14:20 Abstract N SP0008 Case 1 presenter: It s in the brain but it s not psychologic: when nociceptive turns to nociplastic Serge Perrot (France) 14:30 Case 1 discussant: Clinical case with RA in whom apparent high disease activity is confounded by FM; how does changing diagnosis change management and outcome? Neelam Hassan (United Kingdom) 15:00 Abstract N SP0009 Case 2 presenter: Fibromyalgia onset of systemic lupus erythematosus? Ernest Choy (United Kingdom) 15:10 Case 2 discussant: Clinical case with FM later diagnosed with CTD; how does changing diagnosis change management and outcome? 14:15-15:45 Forum From Bench to Bedside Shaping the future in systemic sclerosis Learning objectives: To understand the key mechanisms in SSc pathophysiology that facilitate new treatment options To show how animal models can facilitate new drug developments To pinpoint which drugs most likely will make it to clinics Caroline Ospelt (Switzerland) John Pauling (United Kingdom) Christopher Denton (United Kingdom) 14:20 Abstract N SP0010 Fibroblast-Matrix-Vessel: the unhappy triad

23 Jörg Distler (Germany) 14:40 Abstract N SP0011 Is there a universal translator? Which (animal) models tell us most? Daniel Furst (United States) 15:00 Abstract N SP0012 Novel SSc drugs that really will make it to clinics! H. Bittern (Germany) 15:20 A. Carvalho-Marques, O. Cabral-Marques, C. Fouodo, I. König, H. Heidecke, G. Riemekasten, S. Schinke Abstract N OP0005 Patterns of 31 new autoantibodies against G proteincoupled receptors and growth factors in systemic sclerosis can be described by latent factors R. Spiera (United States) 15:30 L. Hummers, L. Chung, T. Frech, R. Domsic, V. Hsu, D. E. Furst, J. Gordon, M. Mayes, R. Simms, E. Lee, N. Dgetluck, S. Constantine, B. White Abstract N OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial JBT101-SSc :15-15:45 Elicium 1 Basic and Translational Science session Basic mechanisms of inflammation Learning objectives: Provide a state-of-the-art on basic mechanisms of inflammation Discuss how these mechanistic insights may be translated into clinical benefit Marco Gattorno (Italy) Tadej Avcin (Slovenia) Mohamed Lamkanfi (Belgium) 14:20 Inflammasome biology matters Y. Zhao (China) 14:40 W. Li, K. Vasilev Abstract N OP0007 Growth differentiation factor 11 attenuates inflammatory arthritis through antagonising NF-κB signaling pathway Daniel Kastner (United States) 14:50 New insights into monogenic autoinflammatory diseases M. Saito (Japan) 15:10 Abstract N OP0008 Modeling an autoinflammatory immunoproteasome disease nakajo-nishimura syndrome with human pluripotent stem cell-derived myeloid cell lines Johannes Roth (Germany) 15:20 Abstract N SP0013 S100-alarmins: potential therapeutic targets for arthritis SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 21 14:15-15:45 Amtrium Health Professionals session Health Professionals Welcome session Learning objectives: To give attendees a view into the HPR 'machinery' Tanja Stamm (Austria) Wilfred F. Peter (Netherlands) Rikke H. Moe (Norway) 14:20 Abstract N SP0014 Welcome to Amsterdam by the new chair of ESCHPR Mwidimi Ndosi (United Kingdom) 14:38 What is a EULAR Study Group? Example from the study group on patient education (STOPE) Kate Betteridge (United Kingdom) 14:56 Abstract N SP0015 What s new? Presentation of the HPR Newsletter Annette de Thurah (Denmark) 15:14 Places to go and things to see during the congress Faculty 15:32 Q&A 14:15-15:45 Emerald The Young Rheumatologist Statistics made simple: a practical approach to complex concepts Learning objectives: To learn how to report statistical analysis in clinical journals and how to describe the analytical methods and the corresponding results in a comprehensible way to the practicing clinician To understand the conceptual difference between confounding, effect modification and mediation and how to handle these in statistical analysis of observational data To learn how to build multivariable models taking both clinical and statistical criteria into account and how to decide upon the best model Lewis Carpenter (United Kingdom) Sofia Ramiro (Netherlands) Pedro Machado (United Kingdom) 14:20 How to report statistics in rheumatology journals: reaching out to the clinical reader Sam Norton (United Kingdom) 14:40 Confounders, effect modifiers and mediators: is it all the same? 13 June 2018

24 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 Stian Lydersen (Norway) 15:00 Abstract N SP0016 Stepwise or not to stepwise? The do s and don'ts of multivariable modelling E. Myasoedova (United States) 15:20 J. M. Davis III, S. J. Achenbach, E. L. Matteson, C. S. Crowson Abstract N OP0009 Rising prevalence of functional disability in patients with rheumatoid arthritis over 20 years D. H. Solomon (United States) 15:30 C. H. Feldman, K. Yoshida, B. Pan, M. Frits, N. Shadick, M. E. Weinblatt, S. E. Connolly, E. Alemao Abstract N OP0010 Use of claims and electronic medical record data to predict RA disease activity 14:15-15:45 PARE Room PARE session E-health for better care Learning objectives: To present digital health care solutions that enable better access to health care To show how apps can contribute to patient health care and to organisation attractiveness To outline relevant issues of data protection and patient safety Kristijonas Mazuras (Lithuania) Gerlinde Bendzuck (Germany) Jutta Richter (Germany) 14:20 Abstract N SP0017 Bits and bytes: fitting medical information - PICASO the platform for improved personal, coordinated care Victoria Romero Pazos (Spain) 14:40 Ésaude - a digital platform that unites tools to provide personalised health Mitchell Silva (Belgium) 15:00 Abstract N SP0018 Smart wearables - the right tool for health monitoring and improving quality of health? S. R. Stones (United Kingdom) 15:20 on behalf of Young PARE working group Abstract N OP0011-PARE A week to tweet: findings from young PARE s online course for twitter novices S. Trope (France) 15:30 J.-D. Cohen, C. Beauvais, G. Dugoua Jacques, D. Poivret, A. Saraux, D. Vacher, H. Barkatz, P. Lacoste, V. Weill, G. Thibaud on behalf of ANDAR patient organisation Abstract N OP0012-HPR Creation of the first digital training designed for patients with rheumatoid arthritis by patient organisation in rheumatology 14:15-15:45 E106/E107 EULAR Projects in Paediatric Rheumatology EULAR Projects in Paediatric Rheumatology and UCAN Learning objectives: Insight in the strength of collaboration across borders Understanding of what the UCAN project means for paediatric rheumatology worldwide Nico Wulffraat (Netherlands) Wineke Armbrust (Netherlands) Rae Yeung (Canada) 14:20 UCAN as a tool for personalised medicine in paediatric rheumatology Nicola Ruperto (Italy) 14:38 UCAN and PRINTO aligned to link bed and bedside: perspective from the bed Sebastian Vastert (Netherlands) 14:56 Abstract N SP0019 UCAN and PRINTO aligned to link bed and bedside: perspective from the benchside Vicki Seyfert-Margolis (United States) 15:14 Abstract N SP0020 How digital tools can help to cross borders in international collaborations P. Drechsel (Germany) 15:32 J. Klotsche, M. Niewerth, G. Horneff, K. Minden Abstract N OP0013 Pregnancy outcomes in DMARD exposed patients with juvenile idiopathic arthritis - results of the biologic register JUMBO

25 14:15-15:45 D201/D202 Practical skills session* Crystal I Learning objectives: To learn how to use a microscope to detect and interpret crystals in synovial fluid from scratch Anne K. Tausche (Germany) Eliseo Pascual (Spain) Tutor(s): Francisca Sivera (Spain) José Pimentao (Portugal) Francesca Oliviero (Italy) Eleonora Norkuviene (Lithuania) 14:15-15:45 D203/D204 Practical skills session* Ultrasound basic I George A. W. Bruyn (Netherlands) Wolfgang A. Schmidt (Germany) Esperanza Naredo (Spain) 14:20 Abstract N SP0021 How to assess dactylitis + demo Marcin Szkudlarek (Denmark) 14:40 Abstract N SP0022 How to assess bone erosions - indications, pitfalls and new techniques + demo Ulrich Fredberg (Denmark) 15:00 Abstract N SP0023 How to assess mechanical and inflammatory tendinitis + demo Maria-Antonietta d Agostino (France) 15:20 How to assess and score enthesitis in clinical practice + demo Tutor: Sara Nysom (Denmark) 15:45-16:15 Exhibition and EULAR Village (Hall 1) Coffee break SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 23 16:15-17:45 Hall 7.1 Abstract session Opening Plenary Abstract session Thomas Dörner (Germany) Robert B. M. Landewé (Netherlands) D. Solomon (United States) 16:20 R. J. Glynn, J. G. MacFadyen, P. Libby, T. Thuren, B. M. Everett, P. M. Ridker Abstract N OP0014 Serum urate, gout, and cardiovascular disease in a randomised controlled trial of canakinumab: a cantos secondary analysis P. B. M. Poppelaars (Netherlands) 16:30 L. H. D. van Tuyl, M. Boers Abstract N OP0015 Mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years follow up G. Cai (Australia) 16:40 D. Aitken, L. Laslett, C. Hill, L. March, A. E. Wluka, Y. Wang, L. Blizzard, F. Cicuttini, T. Winzenberg, G. Jones Abstract N OP0016 A multicentre randomised controlled trial of zoledronic acid for osteoarthritis of the knee with bone marrow lesions J. R. Curtis (United States) 16:50 R. Chen, Z. Li, T. Arora, K. G. Saag, N. C. Wright, S. Daigle, M. Kilgore, E. Delzell Abstract N OP0017 The impact of the duration of bisphosphonate drug holidays on hip fracture rates S. Møller-Bisgaard (Denmark) 17:00 K. Hørslev-Pedersen, B. Ejbjerg, M. Hetland, L. Ørnbjerg, D. Glinatsi, J. Møller, M. Boesen, R. Christensen, K. Stengaard-Pedersen, O. R. Madsen, B. Jensen, J. Villadsen, E.-M. Hauge, P. Bennett, O. Hendricks, K. Asmussen, M. Kowalski, H. Lindegaard, S. M. Nielsen, H. Bliddal, N. Krogh, T. Ellingsen, A. H. Nielsen, L. Balding, A. G. Jurik, H. Thomsen, M. Østergaard Abstract N OP0018 The value of adding MRI to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial D. J. Wallace (United States) 17:10 R. A. Furie, Y. Tanaka, K. C. Kalunian, M. Mosca, M. A. Petri, T. Dorner, M. H. Cardiel, I. N. Bruce, E. Gomez, T. Carmack, J. M. Janes, M. D. Linnik, M. Silk, R. Hoffman Abstract N OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebocontrolled study 13 June 2018 * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

26 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 M. Aringer (Germany) 17:20 K. H. Costenbader, R. Brinks, D. Boumpas, D. Daikh, D. Jayne, D. Kamen, M. Mosca, R. Ramsey-Goldman, J. S. Smolen, D. Wofsy, B. Diamond, S. Jacobsen, W. J. McCune, G. Ruiz-Irastorza, M. Schneider, M. B. Urowitz, G. Bertsias, B. Hoyer, N. Leuchten, C. Tani, S. Tedeschi, Z. Touma, B. Anic, F. Assan, T. M. Chan, A. E. Clarke, M. K. Crow, L. Czírják, A. Doria, W. Graninger, S. Hasni, P. Izmirly, M. Jung, B. Kiss, X. Mariette, I. Padjen, J. M. Pego-Reigosa, J. Romero-Díaz, I. Rúa-Figueroa, R. Seror, G. Stummvoll, Y. Tanaka, M. Tektonidou, C. Vasconcelos, E. Vital, D. J. Wallace, S. Yavuz, R. P. Naden, T. Dörner, S. R. Johnson Abstract N OP0020 Validation of new systemic lupus erythematosus classification criteria J. C. Robson (United Kingdom) 17:30 P. C. Grayson, C. Ponte, R. Suppiah, A. Craven, S. Khalid, A. Judge, A. Hutchings, D. Gray, J. Rosa, J. Barrett, R. A. Watts, P. A. Merkel, R. Luqmani Abstract N OP0021 Draft classification criteria for the anca associated vasculitides 16:15-17:45 Hall 3 Abstract session From NSAIDs to bdmards in SpA: what is new? Anna Moltó (France) Adrian Ciurea (Switzerland) L. Couvaras (France) 16:20 D. Wendling, V. Pauly, V. Pradel, A. Moltó, P. Lafforgue, T. Pham Abstract N OP0022 Is a primary good response to NSAIDs predictive of the subsequent response to the first TNF inhibitor in patients with recent axial spondyloarthritis? U. Lindström (Sweden) 16:30 T. Olofsson, S. Wedrén, I. Qirjazo, J. Askling Abstract N OP0023 Effect of anterior uveitis, psoriasis and inflammatory bowel disease on drug-survival for TNF-inhibitors in ankylosing spondylitis U. Lindström (Sweden) 16:40 T. Olofsson, S. Wedrén, I. Qirjazo, J. Askling Abstract N OP0024 What happens to patients with ankylosing spondylitis who start a first biologic? A Swedish study of treatment trajectories in clinical practice V. Rios Rodriguez (Germany) 16:50 K.-G. Hermann, H. Haibel, C. Althoff, O. Behmer, J. Sieper, D. Poddubnyy Abstract N OP0025 Identification of predictors of structural damage progression in the sacroiliac joints in patients with early axial spondyloarthritis on a long-term anti-tnf treatment N. V. Kwatra (United States) 17:00 M. Magrey, P. J. Mease, J. Sieper, R. Landewe, X. Wang, A. Lertratanakul, J. K. Anderson, N. M. Mostafa Abstract N OP0026 Adalimumab serum concentration fails to predict achievement of sustained remission or absence of flare for patients with non-radiographic axial spondyloarthritis in the ABILITY-3 study B. S. Koo (Republic of Korea) 17:10 S. Jo, E. Kwon, J. H. Shin, T.-H. Kim Abstract N OP0027 Characteristics of cytokines and changes in interleukin-17 levels in the synovial fluid of patients with ankylosing spondylitis on treatment with biologics T. Dubinina (Russian Federation) 17:20 V. Mazurov, S. Erdes, E. Kunder, N. Soroka, P. Shesternya, S. Smakotina, T. Raskina, D. Krechikova, A. Eremeeva, E. Dokukina, E. Chernyaeva, R. Ivanov Abstract N OP0028 Efficacy and safety of BCD-085, a novel IL-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study J. Paccou (France) 17:30 M. Nachury, C. Duchemin, P. Desreumaux, R.-M. Flipo, B. Pariente Abstract N OP0029 Clinical effect of vedolizumab on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease D. van der Heijde (Netherlands) 17:40 L. S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, M. K. Farmer, D. Baeten, T. Kumke, M. Oortgiesen, M. Dougados Abstract N LB0001 Dual neutralisation of IL-17A and IL-17F with bimekizumab in patients with active ankylosing spondylitis (AS): 12- week results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study

27 16:15-17:45 Auditorium Abstract session RA therapy - new molecules and new strategies Thams Hugle (Switzerland) Raphaele Seror (France) E. G. Brilman (Netherlands) 16:20 J. A. van der Pol, P. H. de Jong, A. E. Weel, J. M. Hazes, T. W. Huizinga, C. F. Allaart Abstract N OP0030 Corticosteroid bridging strategies with methotrexate monotherapy in early rheumatoid and undifferentiated arthritis; a comparison of efficacy and toxicity in the treach and improved studies R. Costello (United Kingdom) 16:30 A. Marsden, M. Movahedi, M. Lunt, R. Emsley, W. G. Dixon Abstract N OP0031 The importance of assessing multiplicative and additive interaction: examining the effect of glucocorticoid therapy on mortality in patients with rheumatoid arthritis and concomitant type II diabetes M. A. Lopez-Olivo (United States) 16:40 J. H. Tayar, N. V. Zamora, G. Pratt, M. E. Suarez-Almazor Abstract N OP0032 Malignancies and serious infections in randomised controlled trials of Janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis R. B. Mueller (Switzerland) 16:50 H. Schulze-Koops, D. E. Furst, S. Cohen, K. Kwok, A. Maniccia, L. Wang, E. Akylbekova, G. Ackermann, J. von Kempis Abstract N OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies V. Stouten (Belgium) 17:00 J. Joly, S. Pazmino, K. van der Elst, D. De Cock, R. Westhovens, P. Verschueren on behalf of the CareRA study group Abstract N OP0034 Long-term effectiveness of the COBRA Slim remission induction and treat to target strategy in patients with early rheumatoid arthritis lacking classical markers of poor prognosis: 2 year results of the CareRA trial J. Smolen (Austria) 17:10 S. Cohen, P. Emery, W. Rigby, Y. Tanaka, Y. Zhang, A. Friedman, A. Othman, H. Camp, A. Pangan Abstract N OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 25 G. Burmester (Germany) 17:20 J. Kremer, F. van den Bosch, Y. Li, Y. Zhou, A. Othman, A. Pangan, H. Camp Abstract N OP0036 A phase 3 randomised, placebo-controlled, doubleblind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs J. Kaine (United States) 17:30 J. Tesser, R. DeMasi, L. Takiya, L. Wang, M. Snyder, H. Fan, V. Bandi, J. Wollenhaupt Abstract N OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies 16:15-17:45 Elicium 2 Abstract session Doctor, how bad will my rheumatoid arthritis become? RA - prognosis, predictors and outcomes Cornelia Allaart (Netherlands) Arthur Pratt (United Kingdom) C. H. Brahe (Denmark) 16:20 S. Krabbe, M. Østergaard, L. Ørnbjerg, D. Glinatsi, H. Røgind, H. S. Jensen, A. Hansen, J. Nørregaard, S. Jacobsen, L. Terslev, T. K. Huynh, D. V. Jensen, N. Manilo, K. Asmussen, P. B. Frandsen, M. Boesen, Z. Rastiemadabadi, L. M. Carlsen, J. Møller, N. S. Krogh, M. L. Hetland Abstract N OP0038 Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in remission in routine care - 2-year outcomes and identification of predictors J. Gwinnutt (United Kingdom) 16:30 K. Hyrich, M. Lunt, A. Barton, S. Verstappen on behalf of RAMS coinvestigators Abstract N OP0039 High disease activity and disability at one year in two clusters of patients with rheumatoid arthritis defining themselves as in an acceptable state at treatment initiation G. Lliso-Ribera (United Kingdom) 16:40 F. Humby, A. Nerviani, M. A. Boutet, S. Kelly, M. Bombardieri, M. Lewis, R. Hands, V. Rocher, F. Bene, C. Buckley, P. C. Taylor, I. B. McInnes, C. Pitzalis Abstract N OP0040 Synovial cell infiltration in ACPA-ve patients displays similar signatures to other seronegative inflammatory arthritis. Results from the pathobiology of early arthritis cohort (PEAC) 13 June 2018

28 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 L. E. Burgers (Netherlands) 16:50 J. A. van der Pol, T. W. J. Huizinga, C. F. Allaart, A. H. M. van der Helm-van Mil Abstract N OP0041 Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in RA? Results of a longitudinal study comparing an intensive DAS-steered treatment strategy with treat-to-target in routine care L. Hunt (United Kingdom) 17:00 J. Nam, E. M. Hensor, K. Mankia, E. Rowbotham, A. J. Grainger, P. Emery Abstract N OP0042 In ACPA positive at-risk individuals, which MRI and US findings best predict development of clinical synovitis? K. F. Baker (United Kingdom) 17:10 A. Skelton, D. Lendrem, B. Thompson, A. G. Pratt, J. D. Isaacs Abstract N OP0043 Predictors of drug-free remission in rheumatoid arthritis: results from the prospective biomarkers of remission in rheumatoid arthritis (BioRRA) study J. Widdifield (Canada) 17:20 S. Bernatsky, A. Huang, E. C. Sayre, M. Paterson, D. Lacaille Abstract N OP0044 After how long of disease duration does the increased mortality risk appear in recent onset rheumatoid arthritis? D. Keebler (United States) 17:30 E. Teng, J. Chia, D. Lee, J. Galanter, J. Peake, K. Tuckwell Abstract N OP0045 Adverse event reporting rates and placebo/standard-ofcare-arm ACR responses vary by region in rheumatoid arthritis trials 16:15-17:45 Hall 7.2 Abstract session Immunobiology of vasculitis Eamonn S. Molloy (Ireland) Maria C. Cid (Spain) D. O. Bunch (United States) 16:20 J. Deng, E. A. McInnis, P. Bekker, J. L. Hillson, T. J. Schall, C. J. Jennette, P. Nachman, J. Deng Abstract N OP0046 Effect of a selective C5AR antagonist, avacopan (CCX168), on plasma complement levels in ANCA associated vasculitis (AAV) A. von Borstel (Netherlands) 16:30 L. L. Lintermans, P. Heeringa, A. Rutgers, C. A. Stegeman, J. S. Sanders, W. H. Abdulahad Abstract N OP0047 Circulating CD24HICD38HI regulatory B cells influence TH17 cell responses in patients with ANCA-associated vasculitides Y. Wada (Japan) 16:40 M. Sudo, T. Kuroda, M. Nakano, I. Narita Abstract N OP0048 The utility of serum angiopoietin-1 and angiopoietin-2 in patients with anti-neutrophil cytoplasmic autoantibodyassociated vasculitis R. Hid Cadena (Netherlands) 16:50 R. D. Reitsema, W. H. Abdulahad, M. G. Huitema, A. M. Boots, P. Heeringa, E. Brouwer Abstract N OP0049 Aberrant vista expression on CD45RA+CD25DIM TH cells in giant cell arteritis A. C. Hessels (Netherlands) 17:00 J. Tuin, J. S. F. Sanders, M. G. Huitema, E. F. C. van Rossum, F. J. W. Koper, A. P. van Beek, C. A. Stegeman, A. Rutgers Abstract N OP0050 Gene polymorphisms of the glucocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 1 affect relevant clinical outcomes in ANCA associated vasculitis D. Prieto-Peña (Spain) 17:10 J. Loricera, J. Martín-Varillas, M. Calderón-Goercke, J. Nárvaez, E. Aurrecoechea, I. Villa, S. Castañeda, C. Gómez-Arango, A. Mera, E. Pérez-Pampín, V. Aldasoro, N. Álvarez-Rivas, N. Fernández-Llanio, M. Álvarez-Buergo, L. Marena-Rojas, F. Sivera, E. Galíndez-Agirregoikoa, R. Solans-Laqué, S. Romero-Yuste, I. Martínez-Rodríguez, I. Banzo, V. Calvo-Río, N. Palmou-Fontana, B. Atienza-Mateo, J. Hernández, M. González-Gay, R. Blanco Abstract N OP0051 Evolution of the vascular involvement objectified by PET/TAC in patients with giant cell arteritis treated with tocilizumab A. Antovic (Sweden) 17:20 M. Kostic, F. Mobarrez, A. Nordin, J. Vojinovic, A. Bruchfeld, I. Gunnarsson Abstract N OP0052 Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody - associated vasculitis A. Mekinian (France) 17:30 N. Wesner, L. Drevon, A. Guedon, J. B. Fraison, S. Trad, J. E. Kahn, A. Aouba, J. Gillard, M. Ponsoye, T. Hanslik, C. Gourguechon, E. Liozon, K. Laribi, J. Rossignol, O. Hermine, L. Ades, F. Carrat, P. Fenaux, O. Fain Abstract N OP0053 Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes: French retrospective case control study

29 16:15-17:45 Forum Abstract session Envisioning new horizons for people with osteoarthritis Roberta Ramonda (Italy) Jeremie Sellam (France) E. Mulrooney (Norway) 16:20 K. Magnusson, H. B. Hammer, T. L. Gaarden, K. Engedal, T. K. Kvien, I. K. Haugen Abstract N OP0054 Pain in hand osteoarthritis and the associations with radiographic osteoarthritis severity and psychological factors Z. Zhu (China) 16:30 J. Chang, Z. Liao, T. Meng, S. Zheng, F. Cicuttini, T. Winzenberg, A. Wluka, D. Jiang, W. Han, C. Ding Abstract N OP0055 A novel method for assessing proximal tibiofibular joint on MR images in patients with knee osteoarthritis F. Roemer (Germany) 16:40 M. Englund, A. Turkiewicz, A. Struglics, A. Guermazi, L. S. Lohmander, S. Larsson, R. Frobell Abstract N OP0056 Molecular and structural biomarkers of inflammation at 2 years after acute ACL injury do not predict structural knee osteoarthritis at 5 years A. Diaz (France) 16:50 C. Morisset, I. Fournel, A.-L. Soilly, C. Bussiere, A. Cherasse, T. Conrozier, D. Loeuille, M. Timsit, D. Wendling, J.-M. Casillas, J.-F. Maillefert, C. Binquet, P. Ornetti Abstract N OP0057 Efficacy and safety of a distraction-rotation knee brace (ODRA) in medial knee osteoarthritis - a phase III randomised controlled trial (ergonomie study) M. Minten (Netherlands) 17:00 E. Mahler, M. Leseman-Hoogenboom, S. Boks, M. Kloppenburg, J. W. Leer, P. Poortmans, F. van den Hoogen, A. den Broeder, C. van den Ende Abstract N OP0058 Low-dose radiation therapy as treatment for hand and knee osteoarthritis: two double-blinded RCT s F. Eckstein (Austria) 17:10 M. Hochberg, A. Guermazi, H. Guehring, A. Aydemir, S. Wax, P. Fleuranceau-Morel, A. Reinstrup Bihlet, I. Byrjalsen, J. Ragnar Andersen Abstract N OP0059 Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase II study SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 27 M. Jansen (Netherlands) 17:20 N. Besselink, R. van Heerwaarden, R. Custers, J.-T. van der Woude, K. Wiegant, S. Spruijt, P. Emans, P. van Roermund, S. Mastbergen, F. Lafeber Abstract N OP0060 Knee joint distraction compared with high tibial osteotomy and total knee arthroplasty: two-year clinical, structural, and biomarker outcomes S. Kennedy (United States) 17:30 H. Ghandehari, C. Swearingen, J. Tambiah, M. Hochberg Abstract N OP0061 Treatment of knee osteoarthritis with SM04690 improved WOMAC A1 'pain on walking' - results from a 52 week, randomised, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, WNT pathway inhibitor S. Reichenbach (Switzerland) 17:40 S. Heldner, A. Lenz, D. Felson, P. Jüni Abstract N LB0002 Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK) 16:15-17:45 Elicium 1 Abstract session Fracture risk and consequences Daniel Prieto-Alhambra (United Kingdom) Willem F. Lems (Netherlands) M. Sehgal (United States) 16:20 A. Mithal, A. Mithal, G. Singh Abstract N OP0062 Osteoporotic hip fractures in men: a rising concern P. Ungprasert (Thailand) 16:30 K. Wijarnpreecha, C. Thongprayoon, W. Cheungpasitporn Abstract N OP0063 Peripheral arterial disease and risk of osteoporotic hip fracture: a systematic review and meta-analysis of cohort studies L. Senolt (Czech Republic) 16:40 O. Ruzickova, K. Pavelka, O. Sleglova Abstract N OP0064 General bone loss in patients with erosive and non-erosive hand osteoarthritis during three years C. Romera-Lopez (Spain) 16:50 C. Fernández-Carballido, M. Martínez-Vidal, T. Pedraz Abstract N OP0065 Osteoporosis and vertebral fractures are associated with disease activity and radiographic damage in patients with axial spondyloarthritis 13 June 2018

30 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 P. Szafors (France) 17:00 C. Lukas, T. Barnetche, J. Morel, C. Gaujoux-Viala, B. Combe, H. Che Abstract N OP0066 Risk of fracture and low mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis A. Casabella (Italy) 17:10 B. Ruaro, S. Paolino, C. Pizzorni, E. Alessandri, C. Seriolo, D. Fasciolo, G. Botticella, L. Molfetta, P. Odetti, B. Seriolo, M. Cutolo Abstract N OP0067 Dickkopf-1 (DKK1) serum levels and bone quality (TBS evaluation) in patients with systemic sclerosis and rheumatoid arthritis R. Mazzucchelli (Spain) 17:20 E. Pérez-Fernandez, J. Quirós, N. Crespí-Villarías, A. García-Vadillo Abstract N OP0068 Short term effects of ambient air pollution on osteoporotic hip fracture. An ecological study in a period of 16 years J. C. Alvarenga (Brazil) 17:30 S. Boyd, R. Pereira Abstract N OP0069 The relationship between estimated bone strength by finite element analysis at the peripheral skeleton to areal BMD and TBS at lumbar spine in adults 16:15-17:45 Amtrium Joint session HPR/PARE New drugs - new perspectives: clinical and regulatory issues concerning biosimilars Learning objectives: To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars Yvonne van Eijk-Hustings (Netherlands) Dieter Wiek (Germany) Tore K. Kvien (Norway) 16:20 Abstract N SP0024 An up-date on biosimilars Tracy French (United Kingdom) 16:38 Abstract N SP0025 Shared decision making in switching to biosimilars Franz König (Austria) 16:56 Statistical and regulatory aspects of biosimilars Dieter Wiek (Germany) 17:14 Abstract N SP0026 Biosimilars - the changing views of EULAR's Member Organisations of PARE M. Cvancarova Småstuen (Norway) 17:32 M. Brandvold, R. Andenæs Abstract N OP0070-HPR Is patients satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey 16:15-17:45 Emerald Abstract session Movement in musculoskeletal pain; from risk to management David Walsh (United Kingdom) Laure Gossec (France) A. L. Beukenhorst (United Kingdom) 16:20 J. McBeth, J. C. Sergeant, D. M. Schultz, W. G. Dixon Abstract N OP0071 The prevalence of pain flares: impact of definition K. Aili (Sweden) 16:30 M. Andersson, A. Bremander, E. Haglund, I. Larsson, S. Bergman Abstract N OP0072 Sleep problems and fatigue as a predictor for the onset of chronic widespread pain over a 5- and 18-year perspective. A 20-year prospective study K. L. Druce (United Kingdom) 16:40 J. McBeth Abstract N OP0073 Central sensitisation predicts fatigue independently of musculoskeletal pain J.-H. Kang (Republic of Korea) 16:50 K.-E. Lee, D.-J. Park, S.-H. Kim, S.-S. Nah, J. H. Lee, S.-K. Kim, Y.-A. Lee, S.-J. Hong, H.-S. Kim, H.-S. Lee, H. A. Kim, C.-I. Joung, S.-H. Kim, S.-S. Lee Abstract N OP0074 Association between brain-derived neurotrophic factor gene polymorphisms and fibromyalgia in a Korean population: a multi-center study G. Tran (United Kingdom) 17:00 E. Hensor, P. O Connor, S. Kingsbury, P. Conaghan Abstract N OP0075 Ultrasound-detected shoulder pathologies cluster into groups with different clinical associations: data from a prospective study of 500 community referrals for shoulder pain B. Gavilán-Carrera (Spain) 17:10 R. A. Mekary, M. Borges-Cosic, P. Acosta-Manzano, I. C. Álvarez-Gallardo, V. Segura-Jiménez Abstract N OP0076 Isotemporal substitution of sedentary time with physical activity in fibromyalgia: association with quality of life and disease impact. The Al-Ándalus project

31 A. Ozyasar (Turkey) 17:20 A. G. Karatepe Abstract N OP0077 Effectiveness of 8-weeks supervised and non-supervised aerobic exercise programs on clinic findings, functional status and quality of life in the patients with fibromyalgia syndrome A. Caliskan Uckun (Turkey) 17:30 B. Köse, F. G. Yurdakul, Y. Garip, H. Bodur Abstract N OP0078 Is the efficacy of physical therapy related to the pain in the patient s mind? 16:15-17:45 PARE Room PARE session Don t Delay, Connect Today! Learning objectives: To enable national patient organisations to adopt the EULAR Campaign at national level To share best practices of successful activities around the EULAR Campaign Helena Canhão (Portugal) Boryana Boteva (Bulgaria) Gerd R. Burmester (Germany) 16:20 Why we need the Don t Delay Connect Today campaign Tanja Stamm (Austria) 16:40 How HPRs can support the campaign Ruxandra Ionescu (Romania) 17:00 Abstract N SP0027 Don't Delay, Connect Today - implementation of the EULAR Campaign in Romania H. L. Bankova (Bulgaria) 17:20 B. Boteva Abstract N OP0079-PARE Awareness week for rheumatic diseases May 2017 K. Koutsogianni (Greece) 17:30 E. Tsourlidaki, J. Papadakis, R. Stara, L. Papadaki on behalf of the Arthritis Foundation of Crete Abstract N OP0080-PARE Photo album of people with rheumatic diseases under the title: there are some people our people!!! SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 29 16:15-17:45 E106/E107 Abstract session Let s improve diagnosis and treatment of orphan diseases George A. W. Bruyn (Netherlands) Goran Radunovic (Serbia) J. H. Stone (United States) 16:20 Z. S. Wallace, Y. Zhang, C. A. Perugino, R. Naden, H. Choi on behalf of For the EULAR/ACR IgG4-Related Disease Classification Criteria Development Group Abstract N OP0081 Phenotypic subgroups in IgG4-related disease - a cluster analysis G. Hatemi (Turkey) 16:30 A. Mahr, M. Takeno, D.-Y. Kim, M. Melikoglu, S. Cheng, S. McCue, M. Paris, Y. Wang, Y. Yazici Abstract N OP0082 Apremilast for Behçet s syndrome: a phase III randomised, placebo-controlled, double-blind study (RELIEF) T. Koga (Japan) 16:40 R. Sumiyoshi, S. Sato, K. Migita, T. Shimizu, M. Umeda, F. Nonaka, S. Fukui, S.-Y. Kawashiri, N. Iwamoto, K. Ichinose, M. Tamai, H. Nakamura, T. Origuchi, A. Yachie, T. Maeda, A. Kawakami Abstract N OP0084 Serum fibroblast growth factor 2 is a useful biomarker to distinguish adult onset Still disease from sepsis J. B. Kuemmerle-Deschner (Germany) 16:50 U. A. Walker, H. H. Tilson, P. N. Hawkins, T. van der Poll, K. Franke, A. Speziale, E. Vritzali, H. H. Hoffman Abstract N OP0085 Safety of long-term (up to 6 years) canakinumab therapy (<2, 2 <4 and 4 <8mg/kg) in patients aged <4 to 65 years from beta-confident registry Y. Guex-Crosier (Switzerland) 17:00 C. S. Foster, K. Nakai, H. Goto, K. Douglas, S. Pathai, M. Kron, A. P. Song, J. van Calster, A. Adán Abstract N OP0086 Long-term efficacy and safety of adalimumab by immunosuppressant use in patients with non-infectious uveitis in the visual III trial S. Tiosano (Israel) 17:10 R. Shapira, O. Gendelman, D. Comaneshter, E. Pras, A. D. Cohen, H. Amital Abstract N OP0087 Increased risk of ischemic heart disease and mortality among FMF patients - perspective from a big database 13 June 2018

32 13 June / SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 M. Kostine (France) 17:20 E. Mauric, L. Rouxel, T. Barnetche, R. Veillon, F. Martin, C. Dutriaux, L. Dousset, A. Pham-Ledard, S. Prey, M. Beylot-Barry, A. Daste, M. Gross-Goupil, J. Lallier, A. Ravaud, E. Forcade, B. Bannwarth, M.-E. Truchetet, C. Richez, N. Mehsen-Cetre, T. Schaeverbeke on behalf of the FHU ACRONIM Abstract N OP0088 Immune-related adverse events of cancer immunotherapy - when inflammatory side effects are associated with survival: a single-centre prospective cohort study B. Mehta (United States) 17:30 W. Briggs, P. Efthimiou Abstract N OP0083 Temporal trends and mortality of hospitalised patients with adult onset Stills disease: a nationwide estimate 16:15-17:45 D201/D202 Abstract session New driving molecules in systemic sclerosis Gabriele Valentini (Italy) Mike O. Becker (Switzerland) G. Boleto (France) 16:20 C. Guignabert, S. Pezet, A. Cauvet, J. Sadoine, L. Tu, C. Nicco, C. Gobeaux, F. Batteux, Y. Allanore, J. Avouac Abstract N OP0089 Abatacept is effective in experimental digestive and lung tissue fibrosis U. A. Walker (Switzerland) 16:30 V. K. Jaeger, D. Lebrecht, A. G. Nicholson, A. U. Wells, S. George, A. Gazdhar, M. Tamm, N. Venhoff, T. Geiser Abstract N OP0090 Mitochondrial DNA mutations and respiratory chain dysfunction in lung fibrosis of systemic sclerosis C. Antinozzi (Italy) 16:40 C. Corinaldesi, V. Riccieri, V. Raparelli, M. Vasile, F. Del Galdo, G. Valesini, A. Lenzi, S. Basili, C. Crescioli Abstract N OP0091 CXCL10/CXCL11 serum measurement as potential predictor of systemic sclerosis I. Antonopoulos (Greece) 16:50 D. Daoussis, D. J. Papachristou, T. Dimitroulas, T. Sidiropoulos, S.-N. Liossis Abstract N OP0092 Decreased Dickkopf-1 expression in clinically uninvolved skin from patients with systemic sclerosis W. Marut (Netherlands) 17:00 A. Affandi, J. Broen, L. Bossini-Castillo, A. Ottria, R. Tieland, L. van Bon, M. Rossato, L. de Kroon, J. van Roon, J. Martin, R. Lafyatis, T. Radstake Abstract N OP0093 Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis E. Romano (Italy) 17:10 M. Manetti, I. Rosa, B. S. Fioretto, L. Ibba-Manneschi, M. Matucci-Cerinic, S. Guiducci Abstract N OP0094 SLIT2/ROBO4 axis may contribute to angiogenesis disturbance in systemic sclerosis (SSc) C. Frantz (France) 17:20 S. Pezet, J. Avouac, Y. Allanore Abstract N OP0095 Soluble CD163 as a potential biomarker in systemic sclerosis 16:15-17:45 D203/D204 Abstract session A rollercoaster from bench to bedside and back again: paediatric rheumatology in the 21 st century Lovro Lamot (Croatia) Eve Smith (United Kingdom) J. Nakamura (Japan) 16:20 S. Watanabe, H. Kimura, H. Mizukami, N. Nagi-Miura, N. Ohno, M. Takahashi, S. Minota Abstract N OP0096 Adeno-associated virus vector-mediated interleukin-10 induction prevents vascular inflammation in a murine model of Kawasaki disease C. Fisher (United Kingdom) 16:30 D. Eleftheriou, D. Sen, Y. Ioannou Abstract N OP0097 Stimulated monocyte-derived macrophages from patients with enthesitis related arthritis secrete higher levels of IL23 and lower levels of interferon gamma compared to healthy controls M. Kostik (Russian Federation) 16:40 E. Suspitsin, A. Levina, M. Guseva, M. Dubko, L. Snegireva, T. Likhacheva, A. Kazantseva, M. Makhova, A. Sokolenko, E. Imyanitov, V. Chasnyk Abstract N OP0098 Clinical picture and spectrum of conditions associated with NLRP12 gene mutations S. J. W. Shoop-Worrall (United Kingdom) 16:50 S. M. M. Verstappen, J. E. McDonagh, W. Thomson, K. L. Hyrich on behalf of CAPS Abstract N OP0099 Remission in JIA can be predicted from one year following diagnosis in a UK multicentre inception cohort

33 I. Redeker (Germany) 17:00 F. Hoffmann, K. Albrecht, J. Klotsche, A. Zink, K. Minden Abstract N OP0100 Increase in direct healthcare costs in juvenile idiopathic arthritis over the past 10 years - results of a health insurance claims data analysis H. Chaplin (United Kingdom) 17:10 Y. Ioannou, D. Sen, H. Lempp, S. Norton Abstract N OP0101 Exploring pain and the impact of JIA on adolescents and young adults: a mixed-methods study A. M. Barendregt (Netherlands) 17:20 C. van Gulik, P. Groot, K. Dolman, M. van den Berg, A. Nassar Sheikh Rashid, D. Schonenberg-Meinema, C. Lavini, K. Rosendahl, R. Hemke, T. W. Kuijpers, M. Maas, C. M. Nusman Abstract N OP0102 Prolonged image acquisition time after contrast agent administration results in increased synovial thickness on post-contrast MRI of JIA patients: standardisation is key F. De Benedetti (Italy) 17:30 H. Brunner, N. Ruperto, D. Lovell, I. Calvo-Penedes, G. Horneff, M. L. Gamir Gamir, M. Hufnagel, J. Hsu, M. Bao, W. Douglass, N. L. Mallalieu, C. Wells, C. M. Mela on behalf of PRINTO and PRCSG Investigators Abstract N OP0103 Identification of optimal subcutaneous doses of tocilizumab in children with systemic juvenile idiopathic arthritis 18:15-19:45 Elicium 1 Basic and Translational Science session Burning bones Learning objectives: Bone turnover is affected by systemic and local inflammation How to target bone inflammation in rheumatology Detailed structure analysis is possible and a quickly advancing field Jörg Distler (Germany) Rik Lories (Belgium) Ellen M. Gravallese (United States) 18:20 Abstract N SP0028 Bone inflammation in arthritis F. R. Spinelli (Italy) 18:40 R. Mancini, M. Leopizzi, T. Colasanti, A. Pecani, F. Ceccarelli, F. Conti, G. Valesini, C. Alessandri Abstract N OP0104 Antibodies against carbamylated proteins are involved in osteoclastogenesis by inducing RANKL expression in osteoblasts in vitro SCIENTIFIC PROGRAMME / WEDNESDAY 13 JUNE 2018 / 31 Georg Schett (Germany) 18:50 Monitoring and treatment of bone inflammation M. Y. Ansari (United States) 19:10 M. N. Khan, I. Ahmad, T. M. Haqqi Abstract N OP0105 ZCCHC6 deletion downregulates IL-6 and reduces the severity of experimental osteoarthritis in mice Matthias Gunzer (Germany) 19:20 Abstract N SP0029 Fine structure analysis to detect bone pores 18:15-19:45 Amtrium Health Professionals session Delay in treatment and the role of health professionals Learning objectives: To provide awareness of different types of treatment delay in RMDs To provide knowledge of reasons and present possible interventions to address patient delay Jette Primdahl (Denmark) Erika Mosor (Austria) Rebecca Stack (United Kingdom) 18:20 Abstract N SP0030 Reasons for delay in help seeking at the onset of symptoms Kristien van der Elst (Belgium) 18:38 Abstract N SP0031 Are illness perception and coping style associated with patient delay? Souzi Makri (Belgium) 18:56 Abstract N SP0032 The patients perspective on delay in treatment Bruno Fautrel (France) 19:14 Abstract N SP0033 Delay in treatment from the GP perspective S. J. Bartlett (Canada) 19:32 O. Schieir, M.-F. Valois, C. Hitchon, G. Boire, B. Haraoui, C. Thorne, D. Tin, J. Pope, E. C. Keystone, V. P. Bykerk on behalf of CATCH (Canadian Early Arthritis Cohort) Investigators Abstract N OP0106 Who is not reaching remission in early RA and why? Predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment 20:00-22:00 Strand Zuid Networking Platform 13 June 2018

34 32 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 Scientific Programme Thursday 14 June June 2018 M.-L. Hülser (Germany) 09:10 C. Schreiyaeck, Y. Luo, A. Bozec, G. Schett, U. Müller-Ladner, E. Neumann Abstract N OP0108 Diet induced metabolic changes in an osteoarthritis mouse model Leo Joosten (Netherlands) 09:20 Abstract N SP0036 Free fatty acids: good or bad in rheumatology? 09:45-10:15 Exhibition and EULAR Village (Hall 1) Coffee break 10:15-11:45 Hall :45-19:15 Registration area (Hall 2) Registration 08:15-09:45 Elicium 1 Basic and Translational Science session Fat and fatty acids: targets for therapy? Learning objectives: Adipose tissue derived factors alter inflammatory responses Inflammation in turn also alters the adipose tissue Adipokines and free fatty acids affect systemic but also local inflammation Ladislav Senolt (Czech Republic) Maria Bokarewa (Sweden) Henk Schipper (Netherlands) 08:20 Abstract N SP0034 Adipose tissue and inflammation S. Bosello (Italy) 08:40 E. De Lorenzis, G. Canestrari, G. Natalello, C. Di Mario, L. Gigante, A. Barini, A. Barini, L. Verardi, B. Tolusso, G. Ferraccioli, E. Gremese Abstract N OP0107 Adipocytokines imbalance is associated with vascular damage in systemic sclerosis Jorge Caamano (United Kingdom) 08:50 Abstract N SP0035 Lymphoid cluster formation in adipose tissue What is New (WIN) & How to Treat (HOT) session WIN & HOT session Hendrik Schulze-Koops (Germany) 10:20 WIN: Advances in the diagnosis and monitoring of vasculitis John H. Stone (United States) 11:00 HOT: Recent advances in the treatment of systemic vasculitides 10:15-11:45 Hall 3 Abstract session Biologics in RA. Improving and maintaining the response Gianfranco Ferraccioli (Italy) Aurelie Najm (France) L. Garcia Montoya (United Kingdom) 10:20 M. Y. Md Yusof, J.-B. Candelier, P. Pentony, L. Duquenne, A. C. Rawstron, E. M. Vital, P. Emery Abstract N OP0109 In RA patients with initial response to rituximab, early depth of B cell depletion is associated with long-term maintenance of therapy U. Arad (Israel) 10:30 O. Elkayam Abstract N OP0110 Serum tocilizumab through concentrations are associated with clinical disease activity index scores in adult rheumatoid arthritis patients

35 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 33 Y. Kaneko (Japan) 10:40 M. Kato, Y. Tanaka, M. Inoo, H. Kobayashi-Haraoka, K. Amano, M. Miyata, Y. Murakawa, H. Yasuoka, S. Hirata, E. Tanaka, N. Miyasaka, H. Yamanaka, K. Yamamoto, T. Takeuchi Abstract N OP0111 Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective, randomised, controlled study (the second year of the SURPRISE study) M. J. l'ami (Netherlands) 10:50 J. Ruwaard, C. L. Krieckaert, M. T. Nurmohamed, T. Rispens, G. Wolbink Abstract N OP0112 Therapeutic drug monitoring to optimize switching between biologic agents in rheumatoid arthritis E. van Mulligen (Netherlands) 11:00 A. E. A. M. Weel, T. M. Kuijper, J. J. Luime, J. M. W. Hazes, P. H. P. de Jong Abstract N OP0113 Gradual tapering TNF blockers versus conventional synthetic DMARDs in patients with rheumatoid arthritis in sustained remission: first year results of the randomised controlled TARA-study Y. Ishikawa (United States) 11:10 M. Hashimoto, H. Ito, M. Tanaka, N. Yukawa, T. Fujii, T. Mimori, C. Terao Abstract N OP0114 ANA development is associated with poor response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis W. Dankers (Netherlands) 11:20 P. H. de Jong, S. G. Heil, S. A. van den Berg, A. E. Weel, J. M. Hazes, E. M. Colin, E. Lubberts Abstract N OP0115 Improved response to etanercept is associated with serum vitamin D levels in rheumatoid arthritis S. Hawley (United Kingdom) 11:30 R. Cordtz, L. Dreyer, C. J. Edwards, N. K. Arden, C. Cooper, A. Judge, S. Ali, K. Hyrich, D. Prieto-Alhambra Abstract N OP0116 Impact of TNF inhibitors on need for joint replacement in patients with rheumatoid arthritis: a matched cohort analysis of UK biologics registry data 10:15-11:45 Auditorium Abstract session SLE, Sjögren s and APS - new criteria, novel diagnostic tools and co-morbidities Lai-Shan Tam (China) Ian Bruce (United Kingdom) C. C. Mok (Hong Kong) 10:20 K. H. Chan, L. Y. Ho, Y. F. Fung, W. F. Fung, P. C. Woo Abstract N OP0117 Safety and immune response of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial B. Parker (United Kingdom) 10:30 A. Mohammed, M. Jefferies, P. Pemberton, M. Lunt, I. N. Bruce on behalf of Systemic Lupus International Collaborating Clinics Abstract N OP0118 Development of metabolic syndrome in patients with SLE: results from an inception cohort M. G. Tektonidou (Greece) 10:40 E. Kravvariti, G. Konstantonis, P. P. Sfikakis Abstract N OP0119 Progression of subclinical atherosclerosis in systemic lupus erythematosus of low disease activity: three-year follow-up and comparison to rheumatoid arthritis S. Retamozo (Spain) 10:50 N. Acar-Denizli, W. Fai Ng, M. Zeher, A. Rasmussen, R. Seror, X. Li, C. Baldini, J.-E. Gottenberg, D. Danda, L. Quartuccio, R. Priori, G. Hernandez-Molina, B. Armagan, A. A. Kruize, S.-K. Kwok, M. Wahren-Herlenius, S. Praprotnik, D. Sene, E. Bartoloni, R. Solans, M. Rischmueller, T. Mandl, Y. Suzuki, D. Isenberg, V. Valim, P. Wiland, G. Nordmark, G. Fraile, H. Bootsma, T. Nakamura, R. Giacomelli, V. Devauchelle-Pensec, B. Hofauer, M. Bombardieri, V. Fernandes Moça Trevisani, D. Hammenfors, S. G. Pasoto, T. A. Gheita, F. Atzeni, J. Morel, C. Vollenveider, P. Brito-Zerón, M. Ramos-Casals Abstract N OP0120 Influence of epidemiology and ethnicity on systemic expression of primary Sjögren syndrome in 9974 patients 14 June 2018 F. Ceccarelli (Italy) 11:00 A. Chistolini, C. Perricone, E. Rando, C. Pirone, E. Cipriano, I. Leccese, L. Massaro, F. Morello, F. R. Spinelli, C. Alessandri, G. Valesini, F. Conti Abstract N OP0121 Lupus anticoagulant is associated with thrombotic events in healthy carriers: results from a prospective longitudinal study

36 34 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE June 2018 M. Petri (United States) 11:10 D. W. Goldman, L. S. Magder Abstract N OP0122 Validation of remission and lupus low disease activity state as predictors of organ damage in SLE P. Conigliaro (Italy) 11:20 M. Cesareo, C. Canofari, G. Aloe, G. Alvaro, P. Triggianese, A. G. Salandri, M. S. Chimenti, R. Perricone Abstract N OP0123 Evaluation of retinal microvasculature by optical coherence tomographic angiography in systemic lupus erythematosus patients mirrors systemic involvement K. Dutton (United Kingdom) 11:30 A. Psarras, Y. El-Sherbiny, M. Y. Md Yusof, P. Emery, E. Vital Abstract N OP0124 In SLE patients in sustained low disease activity, novel interferon assays predict flares and glucocorticoid requirements 10:15-11:45 Elicium 2 L. Coates (United Kingdom) 10:50 E. Alonso, X. Baraliakos, F. Blanco Garcia, J. Braun, V. Chandran, J. L. Fernandez-Sueiro, O. FitzGerald, P. Gallagher, D. Gladman, E. Gubar, T. Korotaeva, E. Loginova, E. Lubrano, J. Mulero, J. Pinto-Tasende, R. Queiro, J. Sanz Sanz, A. Szentpetery, P. Helliwell Abstract N OP0128 The phenotype of axial psoriatic arthritis: is it dependent on HLA-B27 status? S. Lopriore (Italy) 11:00 F. Cacciapaglia, S. Perniola, M. G. Anelli, G. Lopalco, C. Scioscia, L. Coladonato, G. Laselva, G. Lapadula, F. Iannone Abstract N OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors J. A. Avina-Zubieta (Canada) 11:10 A. Dominique, T. A. Simon, H. Tavakoli Abstract N OP0130 Risk of cancer in patients with psoriasis/psoriatic arthritis: a population-based study in the province of British Columbia Abstract session The A-B-C of PsA (Assessment, Biologicals, Co-morbidities) Laura Coates (United Kingdom) Dennis McGonagle (United Kingdom) S. Puksic (Norway) 10:20 J. Sexton, P. Bolton-King, B. Michelsen, T. K. Kvien, H. B. Hammer Abstract N OP0125 DAPSA and ultrasound show different perspectives of psoriatic arthritis activity: results from a longitudinal observational study of patients starting treatment with biologic DMARDs P. Bosch (Austria) 10:30 R. Husic, A. Ficjan, J. Gretler, A. Lackner, W. Graninger, C. Duftner, J. Hermann, C. Dejaco Abstract N OP0126 Evaluating low disease activity definitions in psoriatic arthritis using ultrasound T. H. Cheng (Hong Kong) 10:40 Q. Shang, E. K. M. Li, P. C. H. Wong, L. H. P. Tam, T. Y. Zhu, M. M. Chang, J. J. W. Lee, C. K. Wong, A. P. W. Lee, L. S. Tam Abstract N OP0127 Can achieving minimal disease activity (MDA) prevent progression of subclinical atherosclerosis and arterial stiffness? A two-year prospective cohort study in psoriatic arthritis A. Ramming (Germany) 11:20 A. Soare, S. Weber, L. Maul, S. Rauber, A. M. Gheorghiu, I. Houssni, A. Kleyer, M. Luber, J. Rech, G. Schett, J. Distler Abstract N OP0131 Innate lymphoid cells correlate with disease activity and bone remodeling in psoriatic arthritis D. Wu (China) 11:30 J. F. Griffith, S. H. Lam, P. Wong, J. Yue, L. Shi, E. K. Li, I. T. Cheng, T. K. Li, T. Y. Zhu, V. W. Hung, L. Qin, L.-S. Tam Abstract N OP0132 Structural and microstructural intra-articular bone changes at the metacarpal heads in patients with psoriatic arthritis compared to controls: a HR-PQCT study 10:15-11:45 Hall 7.2 Abstract session RA: such a pain, and beyond Vivian Bykerk (United States) Elena Nikiphorou (United Kingdom) J. Lampa (Sweden) 10:20 T. Olofsson, J. K. Wallman, A. Jöud, M. E. Schelin, S. Ernestam, R. van Vollenhoven, S. Saevarsdottir Abstract N OP0133 Unacceptable, refractory pain despite inflammation control in early rheumatoid arthritis and its relation to treatment strategy: results from the randomised controlled SWEFOT trial

37 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 35 C. R. Silva (Portugal) 10:30 C. Duarte, R. Ferreira, E. Santos, J. A. da Silva Abstract N OP0134 Multifactorial explanatory model of fatigue in patients with rheumatoid arthritis: a path analysis Abstract N OP0141 Ultrasound diagnostic and predictive value of interstitial lung disease in systemic sclerosis. Diagnostic and predictive value of ultrasound in the assessment of interstitial lung disease Y.-C. Tsai (Taiwan, Province of China) 10:40 S.-F. Luo, M.-J. Chiou, C.-F. Kuo Abstract N OP0135 Foetal-neonatal and maternal outcomes in women with rheumatoid arthritis H. Westerlind (Sweden) 10:50 M. Holmqvist, L. Ljung, T. Frisell, J. Askling Abstract N OP0136 Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome K. Krueger (Germany) 11:00 R. Eder, C. Mueller, K. Rietzler Abstract N OP0137 Assessing the risk of RA patients for comorbid conditions through a structured nurse-led interview - the ERIKO study N. B. Karaca (Turkey) 11:10 G. Arın, A. Özçadırcı, F. B. Oflaz, S. Apraş Bilgen, E. Ünal Abstract N OP0138 Investigation of biopsychosocial assessments in patients with rheumatic disease N. M. T. Roodenrijs (Netherlands) 11:20 M. J. H. de Hair, J. W. G. Jacobs, P. M. J. Welsing, D. M. F. M. van der Heijde, J. M. van Laar, G. Nagy on behalf of the Task Force Difficult-to-Treat RA Abstract N OP0139 Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey R. Mu (China) 11:30 C. Li, J. Yang, H. Wei, J. Huang, W. Fan, Y. Wang, H. Wang, J. Zou, X. Shi, X. Xin, J. Wu, H. Sun, L. Wang, F. Xiao, H. Xiao, B. Wu, Y. Liu, Y. Jia, Z. Li Abstract N OP0140 Pattern and influential factors in promoting treat-to-target (T2T) for follow-up RA patients with a rheumatologistpatient interactive smart system of disease management (SSDM): a cohort study from China 10:15-11:45 Forum Abstract session Quickly emerging: science in SSc, myositis and related syndromes Maurizio Cutolo (Italy) Pedro Machado (United Kingdom) Y. Allanore (France) 10:30 M. Elhai, O. Distler, V. Smith, M. Matucci-Cerinic, J. J. Alegre-Sancho, M.-E. Truchetet, Y. Braun-Moscovici, F. Iannone, F. Chotchaeva, A. Lescoat, E. Siegert, I. Castellví, P. Airò, S. Vettori, E. Hachulla, A. Erler, L. Ananieva, M. Krusche, F. López-Longo, J. Distler, N. Hunzelmann, A.-M. Hoffmann-Vold, V. Riccieri, V. Hsu, M. Pozzi, C. Ancuta, E. Rosato, C. Mihai, M. Kuwana on behalf of EUSTAR Abstract N OP0142 Rituximab in systemic sclerosis: safety and efficacy data from the EUSTAR network N. Del Papa (Italy) 10:40 E. Zaccara, W. Maglione, G. Di Luca, R. Andracco, C. Vitali Abstract N OP0143 Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomised controlled study C. Bruni (Italy) 10:50 D. P. Tashkin, V. Steen, Y. Allanore, O. Distler, J. Grotts, M. Matucci-Cerinic, D. E. Furst on behalf of EUSTAR, Scleroderma Lung Study I and II centres Abstract N OP0144 Intravenous versus oral cyclophosphamide (CYC) for the treatment of interstitial lung involvement (ILD) and skin involvement in systemic sclerosis (SSc): safety and efficacy evaluation in a large multi-centre scleroderma cohort R. Janardana (India) 11:00 A. Irodi, P. P. Chebbi, L. Rv, D. Danda, G. Mahasampath Abstract N OP0145 Scleroderma related interstitial lung disease and mycophenolate: long-term outcomes N. Ciang (Hong Kong) 11:10 R. Ng, A. Leung, J. Chan, K. Kwok, G. Ho, R. Ho Abstract N OP0146 Idiopathic inflammatory myopathies & interstitial lung disease S. Zhang (China) 11:20 B. Yan Abstract N OP0147 Aberrant activation of type I interferon system in anti- MDA5 dermatomyositis patients 14 June 2018 J. Gutiérrez (Mexico) 10:20 M. Gutierrez, K. Almaguer, F. Gonzalez, K. Camargo, C. Soto, A. Bernal-Gonzalez, C. Bertolazzi, D. Clavijo-Cornejo, E. Cruz-Arenas, C. Pineda, M. Gutierrez

38 36 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 M. J. S. Parker (United Kingdom) 11:30 A. Oldroyd, M. E. Roberts, R. G. Cooper, J. B. Lilleker, A. L. Herrick, H. Chinoy Abstract N OP0148 A validation of the 2017 EULAR/ACR idiopathic inflammatory myopathies classification criteria in an expert-defined single-centre ten year incident cohort R. M. Ten Brinck (Netherlands) 11:00 D. M. Boeters, H. W. van Steenbergen, A. H. van der Helm-van Mil Abstract N OP0153 Resolution of symptoms of patients with clinically suspect arthralgia is paralleled by disappearance of MRI-detected subclinical inflammation; a longitudinal study 14 June :15-11:45 Elicium 1 Abstract session Can imaging improve diagnosis and outcome in rheumatic diseases Philip Conaghan (United Kingdom) Mikkel Østergaard (Denmark) S. Møller-Bisgaard (Denmark) 10:20 K. Hørslev-Pedersen, B. Ejbjerg, D. Glinatsi, M. Hetland, L. Ørnbjerg, J. Møller, M. Boesen, R. Christensen, K. Stengaard-Pedersen, O. R. Madsen, B. Jensen, J. Villadsen, E.-M. Hauge, P. Bennett, O. Hendricks, K. Asmussen, M. Kowalski, H. Lindegaard, S. M. Nielsen, H. Bliddal, N. Krogh, T. Ellingsen, A. H. Nielsen, L. Balding, A. G. Jurik, H. Thomsen, M. Østergaard Abstract N OP0149 An MRI guided treat-to-target strategy in rheumatoid arthritis patients in clinical remission improved MRI inflammation but not damage progression - results from the imagine-ra randomised controlled trial L. B. Nordberg (Norway) 10:30 S. Lillegraven, A.-B. Aga, J. Sexton, E. Lie, H. B. Hammer, I. C. Olsen, T. Uhlig, D. van der Heijde, T. K. Kvien, E. A. Haavardsholm Abstract N OP0150 Ultrasound power Doppler activity predicts clinical joint swelling in early rheumatoid arthritis patients: secondary analyses from the ARCTIC trial A. G. Pratt (United Kingdom) 10:40 K. Iqbal, D. W. Lendrem, B. Hargreaves, B. Thompson, J. D. Isaacs Abstract N OP0151 Routinely recorded musculoskeletal ultrasound findings impact clinicians diagnostic behaviour maximally in autoantibody-seronegative patients attending an early arthritis clinic R. Singh (United Kingdom) 10:50 I. Sahbudin, M. Maybury, K. Raza, A. Filer Abstract N OP0152 Is sonographic phenotype of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Birmingham early arthritis cohort M. Stein (Canada) 11:10 E. Rampakakis, J. S. Sampalis Abstract N OP0154 Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: interim analysis of the ECHO study S. N. Christiansen (Denmark) 11:20 M. Østergaard, O. Slot, L. Terslev Abstract N OP0155 Ultrasound as an outcome measurement tool for optimised monitoring of gout. Validation of the OMERACT ultrasound definitions of gout elementary lesions B. D. Nielsen (Denmark) 11:30 I. T. Hansen, A. Haraldsen, S. Kramer, K. K. Keller, P. Therkildsen, E.-M. Hauge, L. C. Gormsen Abstract N OP0156 Simple assessment of conventional 18F-FDG PET/CT accurately diagnoses cranial arteritis in glucocorticoidnaïve GCA patients: a case-control study 10:15-11:45 Amtrium HPR Abstract session Singing power to the people Thea Vliet Vlieland (Netherlands) Agnes Kocher (Switzerland) M. Røisland (Norway) 10:20 M. Rygg, E. B. Nordal, A. M. Selvaag Abstract N OP0157-HPR Agreement between JIA patients and parents on disease perception analysed by the Norwegian version of the JAMAR questionnaire R. Zuidema (Netherlands) 10:30 B. van Gaal, I. Meek, E. van den Ende, S. van Dulmen, J. Fransen, R. Nijhuis Abstract N OP0158-HPR Effectiveness of an e-health tailored self-management program for patients with rheumatoid arthritis: an explorative RCT S. Rongen-van Dartel (Netherlands) 10:40 W. Müskens, F. Lamers-Karnebeek, B. Radovits-Persijn, E. Denissen-Cranenburg, C. Vogel, F. Hoeks-van Dinther, A. Wennemers, P. van Riel Abstract N OP0159-HPR Reumanet Bernhoven: introduction and evaluation of an online self-management tool and personal health environment for patients with rheumatoid arthritis (RA)

39 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 37 E. Santos (Portugal) 10:50 C. Duarte, R. Ferreira, A. M. Pinto, R. Geenen, J. A. P. da Silva on behalf of Promoting happiness through excellence of care Abstract N OP0160-HPR Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modeling approach S. Halls (United Kingdom) 11:00 E. Dures, S. Hewlett, S. Ryan, R. Jenkins, J. van Tonder Abstract N OP0161-HPR The development of self-management training for innovative departments (STRIDE): a skills-training programme for rheumatology teams to enhance support for self-management F. Pérez-Ruiz (Spain) 11:10 A. So, P. Kandaswamy, R. Karra, K. Kelton, S. Perk, T. Bardin Abstract N OP0162-HPR Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials Y. Prior (United Kingdom) 11:20 L. Sammut, C. Vasilica on behalf of the MSKHUB Patient and Public Research Advisory Group (PRAG) and the MSKHUB Health Professionals Reference Group (HPRG) Abstract N OP0163-HPR Development of an online self-management platform for people with rheumatic and musculoskeletal conditions (mskhub.com) A. Moltó (France) 11:30 A. Etchieto, S. Poiraudeau, L. Gossec, P. Claudepierre, M. Soubrier, F. Fayet, D. Wendllng, P. Gaudin, E. Dernis, S. Guis, S. Pouplin, A. Ruyssen-Witrand, M. Dougados Abstract N OP0164-HPR Impact of a nurse-led program of patient self-assessment and self-management axial spondyloarthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDSPA) 10:15-11:45 Emerald Abstract session Fires and firefighters: switching the immune system on and off Lars Rönnblom (Sweden) Femke van Wijk (Netherlands) K. Li (United States) 10:30 K. Campbell, S. Garcet, C. Brodmerkel, J. Krueger Abstract N OP0166 Comparative evaluation of cellular and molecular changes associated with response to selective IL-23 blockade vs dual IL-12/23 blockade in psoriasis skin K. Yoshimoto (Japan) 10:40 N. Seki, K. Suzuki, K. Sugahara, K. Chiba, T. Takeuchi Abstract N OP0167 A low molecular weight baff signaling inhibitor, BIK- 13, ameliorates B cell activation in vitro and in vivo autoimmune models and consequently suppresses production of igg and cytokines K. Jeucken (Netherlands) 10:50 P. Kucharzewska, C. X. Maracle, J. P. van Hamburg, H. K. Olsson, S. W. Tas Abstract N OP0168 NIK-IKK complex interaction controls NF-KB-dependent inflammatory activation of the endothelium in response to LTβR ligation D. M. Boeters (Netherlands) 11:00 L. E. Burgers, T. W. Huizinga, A. H. van der Helm-van Mil Abstract N OP0169 A combination of proteins as measured within the multibiomarker disease activity score at presentation of RA identifies a group of ACPA-negative RA patients with high likelihood of developing DMARD-free sustained remission D. M. De Graaf (Netherlands) 11:10 F. L. van de Veerdonk, E. Z. Eisenmesser, L. A. B. Joosten, C. A. Dinarello Abstract N OP0170 Human IL-38 reduces joint inflammation in a mouse model of gouty arthritis C. Romero-Sanchez (Colombia) 11:20 J. A. Chaparro-Sanabria, J. M. Bello-Gualtero, R. Valle-Oñate, L. Chila, D. M. Castillo, G. Lafaurie, P. Chalem Ch, W. Bautista-Molano Abstract N OP0171 Leptin levels, overweight and P gingivalis presence contribute to the mechanism of systemic inflammation in first-degree relatives of rheumatoid arthritis individuals A. Scanu (Italy) 11:30 C. Giraudo, F. Galuppini, V. Lazzarin, G. Pennelli, S. Sivolella, F. Oliviero, P. Galozzi, M. Rugge, R. Stramare, R. Luisetto, L. Punzi Abstract N OP0172 LPS-induced periodontitis promotes arthritis development in mice 14 June 2018 M. Frank Bertoncelj (Switzerland) 10:20 T. Masterson, K. Klein, E. Karouzakis, O. Distler, C. Ospelt Abstract N OP0165 Joint-specific differences in the activation of the JAK-stat pathway in rheumatoid arthritis

40 38 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE June :15-11:45 PARE Room PARE session Inclusive school environment for young people with RMDs Learning objectives: To showcase the role of patient organisations in supporting children with RMDs to access education To present the ideal world versus the reality - the view of the young people with RMDs Peter Boyd (Ireland) Alessia Alunno (Italy) Els Janssens (Belgium) 10:20 Abstract N SP0037 Bednet: learning opportunities for bedridden children Sophie Ainsworth (United Kingdom) 10:38 Abstract N SP0038 Raising awareness of invisible illnesses in schools and education Tanita Wilhelmer (Austria) 10:56 Abstract N SP0039 I graduated! Education for children and adolescents with RMDs Mirjam Kepic (Slovenia) 11:14 Abstract N SP0040 Parents support for children with RMDs in education L. van Nieuwkoop (Netherlands) 11:32 L. van Geene, R. Janssen Abstract N OP0173-PARE Youth-r-coach, a program for youth with a chronic disease 10:15-11:45 E106/E107 Abstract session The building blocks of systemic inflammation Yi Zhao (China) Christopher Sjowall (Sweden) A. Psarras (United Kingdom) 10:20 A. Alase, A. Antanaviciute, I. Carr, M. Wittmann, G. Tsokos, P. Emery, E. M. Vital Abstract N OP0180 Type I interferon is produced by non-haematopoietic tissue resident cells but not PDCS in pre-clinical autoimmunity and SLE W. I. White (United States) 10:30 N. L. Seto, M. P. Playford, K. A. Casey, M. A. Smith, P. Carlucci, B. Yu, L. Wang, G. Illei, N. Mehta, M. J. Kaplan Abstract N OP0174 Alteration of mediators of vascular inflammation by anifrolumab in the phase IIB muse study in SLE W. Lambers (Netherlands) 10:40 H. Westra, B. Doornbos-van der Meer, M. Jonkman, H. Bootsma, K. de Leeuw Abstract N OP0175 Interferon signature might serve as early biomarker for development of lupus and correlates strongly with myxovirus-resistance protein A E. Rivière (France) 10:50 N. Tchitchek, G. Nocturne, J. Pascaud, S. Boudaoud, A. Thai, N. Allaire, B. Jagla, M. Mingueneau, X. Mariette Abstract N OP0176 RNA sequencing detection of gene dysregulation in B cells sorted from salivary gland tissue and peripheral blood reveals new pathways involved in Sjögren s syndrome pathophysiology U. Nakshbandi (Netherlands) 11:00 E. A. Haacke, H. Bootsma, F. K. L. Spijkervet, A. Vissink, B. van der Vegt, F. G. M. Kroese Abstract N OP0177 BCL6 identifies ectopic germinal centers in salivary gland biopsies in primary Sjögren s syndrome patients A. Ruiz Roman (Spain) 11:10 A. Muñoz Jimenez, J. M. Lucena, M. A. Montes Cano, B. Sanchez Sanchez, N. Garrido Puñal, E. Blanco Alonso, R. Gil, J. Quijada Carrera, E. Rubio Romero, J. Povedano Gomez Abstract N OP0178 Analysis of B cells subsets in first degree relatives of patients with systemic lupus erythematosus R. J. Bende (Netherlands) 11:20 L. M. Slot, T. A. Wormhoudt, M. J. Kwakkenbos, A. H. van Kampen, A. Jongejan, J. E. Guikema, C. J. van Noesel Abstract N OP0179 Molecular documentation of the clonal evolution of a diffuse large B cell lymphoma out of clonally expanded rheumatoid factor-expressing B cells in a Sjögren s syndrome patient J. Unger (Austria) 11:30 M. Mattsson, R. Dragoi, C. Boström, F. Buttgereit, A. Lackner, T. Witte, B. Raffeiner, P. Peichl, J. Hermann, C. Dejaco, T. Stamm Abstract N OP0181 Patient perspectives of people with primary Sjögren s syndrome: a multicentre qualitative European study

41 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 39 10:15-11:45 D201/D202 10:15-11:45 D203/D204 Abstract session The crystal maze - etiology and management Hyon K. Choi (United States) Frederic Lioté (France) J. A. Singh (United States) 10:20 J. D. Cleveland Abstract N OP0182 Gout and dementia in the elderly: a medicare claims study F. Perez-Ruiz (Spain) 10:30 S. P. Chinchilla, J. Atxotegi Abstract N OP0183 Association between HFE genotypes and clinical severity characteristics of calcium pyrophosphate crystal arthritis L. Calabrese (United States) 10:40 T. Fields, A. Yeo, P. Lipsky Abstract N OP0184 The frequency of flares in subjects with chronic refractory gout treated with pegloticase is related to variation in the level of plasma urate G. Singh (United States) 10:50 A. Mithal Abstract N OP0185 Emergency department visits for gout: a dramatic increase in the past decade F. P. Ramos (Brazil) 11:00 A. T. Barbosa, R. B. Souza, F. Seragioli, R. D. N. Giorgi, R. F. Rosa Abstract N OP0186 Nephrolithiasis as a complication of gout: a crosssectional study with helical computed tomography L. Dai (China) 11:10 Q. Li, S.-H. Zeng, X.-Y. Du, Y.-H. Xu, K.-M. Yang, J.-J. Liang, Y.-Q. Mo Abstract N OP0187 Fructose-containing beverages is an independent risk factor for gout early-onset in south China E. H. Kang (Republic of Korea) 11:20 A. Shin, M. H. Kim, Y.-J. Ha, Y. J. Lee, Y. Song, S. C. Kim Abstract N OP0188 Effects of allopurinol versus febuxostat on cardiovascular risk in Korean patients with gout: a nation-wide cohort study H. K. Ea (France) 11:30 C. Collet, H. Morel, M. Ricquebourg, M. Cohen-Solal, J.-L. Laplanche, T. Pascart, T. Bardin, F. Lioté, P. Richette Abstract N OP0189 Identification of new and rare variants in ABCG2, SLC22A1 and ALDH16A1 genes in crystal-proven earlyonset gout Abstract session Treatments: friend or foe? Daniel Aletaha (Austria) Meghna Jani (United Kingdom) A. Anis (Canada) 10:20 M. Atiquzzaman, J. Kopec, M. E. Karim, H. Wong Abstract N OP0190 The role of NSAIDs in the association between osteoarthritis and cardiovascular diseases: a populationbased cohort study K. Soeltoft (Denmark) 10:30 J. Hallas, M. C. M. Wasko, A. B. Pedersen, S. P. Ulrichsen, T. Ellingsen Abstract N OP0191 All-cause mortality and cardiovascular death in hydroxychloroquine users in rheumatoid arthritis patients - a population based Danish cohort study J. R. Curtis (United States) 10:40 F. Xie, L. Chen, H. Yun, E. Levitan, P. Muntner Abstract N OP0192 Methotrexate use and the risk for cardiovascular disease among rheumatoid patients initiating biologic diseasemodifying antirheumatic drugs J. R. Curtis (United States) 10:50 F. Xie, H. Yun, E. Levitan, P. Muntner Abstract N OP0193 Tocilizumab and the risk for cardiovascular disease events among rheumatoid arthritis patients: a direct comparison in real world setting J. Hwang (Republic of Korea) 11:00 J. H. Hwang, Y. Eun, H. Kim, J. Lee, J. K. Ahn Abstract N OP0194 The association between serum uric acid and arterial stiffness in a low-risk, large population of middle-aged Korean E. Alemao (United States) 11:10 Z. Guo, M. E. Weinblatt, N. A. Shadick Abstract N OP0195 Role of seropositivity on mortality in RA and the impact of treatment with DMARDs A. Tison (France) 11:20 G. Quere, L. Misery, E. Funck-Brentano, F.-X. Danlos, B. Bonniaud, C. Scalbert, T. Lesimple, S. Martinez, M. Marcq, C. Chouaid, C. Dubos, F. Brunet-Possenti, C. Stavris, L. Y. Chiche, D. Cornec, M. Kostine on behalf of Groupe de Cancérologie Cutanée (GCC), Groupe Français de Pneumo-Cancérologie (GFPC), Club Rhumatisme et Inflammation (CRI) Abstract N OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study 14 June 2018

42 40 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 X. Pundole (United States) 11:30 M. Sarangdhar, M. E. Suarez-Almazor Abstract N OP0197 Rheumatic and musculoskeletal adverse events associated with immune checkpoint inhibitors: data mining of the US food and drug administration adverse event reporting system Alexandre Sepriano (Portugal) Lianne Gensler (United States) Désirée van der Heijde (Netherlands) 13:35 Abstract N SP0043 How to capture clinically relevant structural progression in axspa 14 June :45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 11:50-13:30 Poster area Guided poster tours Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Thursday, please refer to page 49. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour. 13:30-15:00 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN & HOT session Hector Chinoy (United Kingdom) 13:35 Abstract N SP0041 WIN: What is new in the treatment of myositis? Jacob M. van Laar (Netherlands) 14:15 Abstract N SP0042 HOT: Recent advances in the treatment of systemic sclerosis Xenofon Baraliakos (Germany) 13:55 Abstract N SP0044 What do we learn from RCTs on the treatment effect on structural progression in axspa? Robert B. M. Landewé (Netherlands) 14:15 Do observational studies give us the answer on the treatment effect on structural progression in axspa? L. S. Gensler (United States) 14:35 M. Gianfrancesco, M. H. Weisman, M. A. Brown, M. Lee, T. Learch, M. Rahbar, J. D. Reveille, M. M. Ward Abstract N OP0198 Combined effects of tumor necrosis factor inhibitors and NSAIDs on radiographic progression in ankylosing spondylitis M. Dougados (France) 14:45 W. P. Maksymowych, P. Claudepierre, M. de Hooge, R. G. Lambert, R. Landewé, A. Molto, D. van der Heijde, J. F. Bukowski, H. Jones, I. Logeart, L. Marshall, R. Pedersen, A. Szumski, B. Vlahos Abstract N OP0199 Sustained remission of inflammation is associated with reduced structural damage on sacroiliac joint magnetic resonance imaging in patients with early axial spondyloarthritis: evidence to support the concept of treat-to-target 13:30-15:00 Auditorium 13:30-15:00 Hall 3 Clinical Science session Can we halt progression of structural damage in axial SpA? Learning objectives: To learn how to best measure structural progression in axspa, both at a research and clinical practice level To review what we have learnt from RCTs on the effect of treatment (namely TNFI) on structural progression in axspa To discuss the pitfalls of RCTs when addressing the effect of treatment on structural progression and the possible role for observational studies to address this question Clinical Science session Reproductive issues in rheumatology Learning objectives: To evaluate the relationship between oestrogens and systemic autoimmune diseases To select options for contraception, medically assisted reproductive techniques and hormonal replacement therapy To discuss the possible sexual impairment of men and women with rheumatic diseases To understand the clinical approach to pregnant patients with different rheumatic diseases in the real life setting Radboud Dolhain (Netherlands) Karen Schreiber (United Kingdom) Maurizio Cutolo (Italy) 13:35 Abstract N SP0045 Oestrogens, immune response and autoimmune diseases

43 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 41 Frauke Förger (Switzerland) 13:53 Hormonal treatment in patients with different autoimmune rheumatic diseases Monika Østensen (Norway) 14:11 Abstract N SP0046 What we need to consider in physician-patient communication on sexual problems in different rheumatic conditions Rebecca Fischer-Betz (Germany) 14:29 Abstract N SP0047 Challenges in the management of different rheumatologic disorders during pregnancy: lessons from the registries M. E. B. Clowse (United States) 14:47 A. E. Scheuerle, C. Chambers, A. Afzali, A. Kimball, J. J. Cush, M. Cooney, L. Shaughnessy, M. Vanderkelen, F. Förger Abstract N OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database 13:30-15:00 Hall 7.2 Clinical Science session Do we still need biopsies to diagnose Sjögren s and autoimmune myositis? Learning objectives: To address the opportunities of imaging to avoid biopsies in diagnostics and new therapies in Sjögren Hendrika Bootsma (Netherlands) Eugen Feist (Germany) Sandrine Jousse-Joulin (France) 13:35 Abstract N SP0050 Opportunities and challenges of imaging in Sjögren s Louise Diederichsen (Denmark) 13:55 Value of imaging in myositis in 2018 Hendrika Bootsma (Netherlands) 14:15 The value of histologic confirmation in Sjögren s and myositis 14 June :30-15:00 Elicium 2 Challenges in Clinical Practice session Clinical challenges in giant cell arteritis in 2018 Learning objectives: To discuss recent advances of pathogenesis and therapeutics in the context of daily clinical decisions Eamonn S. Molloy (Ireland) Kirsten de Groot (Germany) Francesco Muratore (Italy) 13:35 Abstract N SP0048 Case 1 presentation: A case of pulseless stroke Carlo Salvarani (Italy) 13:45 Case 1 discussion: Visual loss and strokes in GCA: clinical manifestations, diagnosis and management Mark A. Matza (United States) 14:15 Abstract N SP0049 Case 2 presentation: Head games with GCA and GCS John H. Stone (United States) 14:25 Case 2 discussion: Advances in therapy of GCA: the role of biologics S. Sciascia (Italy) 14:35 J. Yazdany, M. Cuadrado, M. Radin, M. Dall Era, I. Aggarwal, R. Fenoglio, A. Barreca, M. Papotti, I. Cecchi, E. Rubini, K. Schreiber, D. Roccatello Abstract N OP0201 Clinical outcomes and response to anti-thrombotic treatment among patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study C. Vitali (Italy) 14:45 M. Dolcino, R. Andracco, A. Pelosi, P. Fiore, W. Maglione, E. Zaccara, N. Del Papa, A. Puccetti Abstract N OP0202 Gene expression profiles in primary Sjögren s syndrome with and without systemic manifestations 13:30-15:00 Forum Paediatric Rheumatology session How monogenetic autoinflammatory diseases help to understand and treat rheumatic diseases Learning objectives: Insight in the relationship between mechanisms and clinical features in autoinflammatory diseases Recognise how monogenetic diseases can help to better understand the pathophysiology of complex rheumatic diseases Petra Hissink-Mueller (Netherlands) Tadej Avcin (Slovenia) Dirk Foell (Germany) 13:35 Pathogenesis of autoinflammatory diseases mimicking adult-onset rheumatic conditions

44 42 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE June 2018 Seza Ozen (Turkey) 14:00 Abstract N SP0051 Clinical presentation of autoinflammatory diseases in children and adults: how not to miss these patients Marco Gattorno (Italy) 14:25 New therapeutic options: IL-1 and beyond J. F. Swart (Netherlands) 14:50 S. de Roock, R. J. Nievelstein, I. Slaper-Cortenbach, J. J. Boelens, N. Wulffraat Abstract N OP0203 Safety and efficacy of intravenous administration of bonemarrow derived mesenchymal stromal cells in therapy refractory juvenile idiopathic arthritis patients, a phase IB/ IIA pilot-study 13:30-15:00 Elicium 1 Basic and Translational Science session Joint EULAR - EFIS session: I ve got a B in my bonnet Learning objectives: Describe different aspects of B cell biology and function relevant to rheumatic disease Provide an overview of the latest developments in this area of research Xavier Mariette (France) Andreas Radbruch (Germany) Leendert Trouw (Netherlands) 13:35 Abstract N SP0052 Posttranslational modification of autoantibodies in RA 13:30-15:00 Amtrium Health Professionals session Sustainable healthcare in rheumatology and the role of health professionals Learning objectives: To describe how integrated care in rheumatology contributes to sustainable healthcare To provide and overview of the roles of various members of the integrated healthcare team To discuss barriers and challenges towards expanding the role of integrated care Annette de Thurah (Denmark) Sandra Mintz (United States) Hubertus J.M. Vrijhoef (Netherlands) 13:35 Abstract N SP0055 How can integrated healthcare contribute to sustainable healthcare in rheumatology? Yvonne van Eijk-Hustings (Netherlands) 14:00 Sustainable healthcare, and the role of the nurses Barbara Slusher (United States) 14:25 Abstract N SP0056 Sustainable healthcare - it takes a village A.-M. T. Sweeney (Denmark) 14:50 O. R. Madsen, L. Dreyer, A. Hansen Abstract N OP0206-HPR Outpatient follow up on demand for patients with rheumatoid arthritis - a two-year randomised controlled trial A. Musters (Netherlands) 13:55 M. H. van Beers-Tas, M. E. Doorenspleet, P. L. Klarenbeek, B. D. van Schaik, A. H. van Kampen, F. Baas, D. van Schaardenburg, N. de Vries Abstract N OP0204 Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis - a validation cohort Andreas Radbruch (Germany) 14:05 Abstract N SP0053 Memory plasma cells in systemic auto-immune diseases - a roadblock to tolerance induction C. Fehres (Netherlands) 14:25 N. van Uden, N. Yeremenko, L. Fernandez, G. Franco Salinas, L. van Duivenvoorde, B. Huard, J. Morel, H. Spits, M. Hahne, D. Baeten Abstract N OP0205 April induces a novel subset of IGA+ regulatory B cells that suppress inflammation through the expression of IL-10 and PD-L1 Claudia Mauri (United Kingdom) 14:35 Abstract N SP0054 Regulatory B cells in rheumatic disease (or in systemic auto-immune diseases) 13:30-15:00 Emerald Clinical Science session SSc: from registries to trials - do we have sufficient data and the appropriate design? Learning objectives: To understand the structure and importance of registries in SSc To understand the power of predictive parameters for clinical practice To outline the needs and future trial designs Otylia Kowal-Bielecka (Poland) Tania Santiago (Portugal) Marco Matucci-Cerinic (Italy) 13:35 Abstract N SP0057 The course of SSc: what can we learn from registries? Gabriela Riemekasten (Germany) 13:55 Outcome of organ dysfunction: what can be predicted?

45 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 43 Oliver Distler (Switzerland) 14:15 Future trial designs to predict and improve outcome C. Frantz (France) 14:35 D. Huscher, E. Hachulla, A. Balbir-Gurman, G. Riemekasten, E. Siegert, P. Airo, B. Joven, S. Vettori, F. Cozzi, S. Ullman, L. Czirjak, Y. Allanore on behalf of EUSTAR group Abstract N OP0207 The outcomes of limited cutaneous systemic sclerosis patients: a EUSTAR database study A. H. L. Low (Singapore) 14:45 G. G. Teng, S. Pettersson, P. F. De Sessions, Q. Fan, A. Law, A. Santosa, A. Lim, J. Thumboo Abstract N OP0208 A proof-of-concept double-blind randomised placebocontrolled trial of probiotics in systemic sclerosis associated gastrointestinal disease C. G. Schoemaker (Netherlands) 14:45 W. Armbrust, J. F. Swart, E. Versluis, W. Olsder, N. M. Wulffraat Abstract N OP0210-PARE Dutch juvenile idiopathic arthritis patients, carers and clinicians creating a research agenda together following the James Lind alliance method 13:30-15:00 E106/E107 EULAR Projects EULAR Projects in Musculoskeletal Imaging Lene Terslev (Denmark) Esperanza Naredo (Spain) 14 June :30-15:00 PARE Room PARE session Patient involvement in research: The future of collaborative research. Lessons from the field of rheumatology and beyond Learning objectives: To learn from best practices of patient engagement in different disease areas To explore patient involvement in guideline development and health care innovations To explore how to evaluate patient involvement Jürgen Clausen (Germany) Laure Gossec (France) Courtney Coleman (United Kingdom) 13:35 Abstract N SP0058 Patient involvement in research in pneumology Iain B. McInnes (United Kingdom) 13:55 EULAR s RheumaMap - research to transform the lives of people with RMDs Codruta Zabalan (Romania) 14:15 Abstract N SP0059 EULAR s Patient research partner network - patients future involvement in research E. R. Dorris (Ireland) 14:35 N. Nestor, A. G. Wilson Abstract N OP0209-PARE The patient voice in arthritis research: a collaborative approach to embedding PPI into research strategy Peter Mandl (Austria) 13:35 Implementation and role of modern musculoskeletal imaging in rheumatological practice in Europe Gilles Fournier (Denmark) 13:55 Abstract N SP0060 First step in producing EULAR Recommendations for the use of imaging in patient with mechanical back pain Maria-Antonietta d Agostino (France) 14:15 EULAR Recommendations for the reporting of musculoskeletal ultrasound studies in rheumatology Frédérique Gandjbakhch (France) 14:35 Preview on EULAR Recommendations /Criteria for the appropriate use of musculoskeletal ultrasound in rheumatology clinical practice 13:30-15:00 D201/D202 Practical skills session* Crystal II Learning objectives: To learn how to use a microscope to detect and interpret crystals in synovial fluid from scratch Eliseo Pascual (Spain) Anne K. Tausche (Germany) Tutor(s): Francisca Sivera (Spain) José Pimentao (Portugal) Francesca Oliviero (Italy) Eleonora Norkuviene (Lithuania) * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

46 44 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE :30-15:00 D203/D204 Practical skills session* MRI 15:30-17:00 Hall 3 Challenges in Clinical Practice session To taper or not to taper in RA 14 June 2018 Learning objectives: To learn how to use MRI for assessment of inflammation and damage in psoriatic arthritis, osteoarthritis, axial spondyloarthritis and rheumatoid arthritis in clinical practice Mikkel Østergaard (Denmark) Kay-Geert Hermann (Germany) Mikkel Østergaard (Denmark) 13:35 Abstract N SP0061 How to use MRI in the diagnosis and management of psoriatic arthritis + clinical cases Philip Conaghan (United Kingdom) 13:55 Abstract N SP0062 How to use MRI in the diagnosis and management of osteoarthritis + clinical cases Signe Moeller-Bisgaard (Denmark) 14:15 Should we use MRI in clinical remission to guide step-down or step-up of therapy? + Clinical cases Kay-Geert Hermann (Germany) 14:35 How to read full MRIs of axial and peripheral joints in RA and SpA - an introduction Learning objectives: To understand the usefulness of biomarkers and imaging in evaluation of RA Maya Buch (United Kingdom) Jacques Morel (France) Kenneth Baker (United Kingdom) 15:35 Abstract N SP0065 Case 1 presentation: Non-biological DMARD case presentation John D. Isaacs (United Kingdom) 15:45 Case 1 discussion: To taper or not to taper non-biological DMARD Joanna Kedra (France) 16:15 Abstract N SP0066 Case 2 presentation: Biological DMARD case presentation Bruno Fautrel (France) 16:25 Abstract N SP0067 Case 2 discussion: To taper or not to taper biological DMARD 15:30-17:00 Auditorium 15:00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN & HOT session Victoria Navarro-Compán (Spain) 15:35 Abstract N SP0063 WIN: About diagnosis and classification of spondyloarthritis Sofia Ramiro (Netherlands) 16:15 Abstract N SP0064 HOT: Recent advances in the management of spondyloarthritis Clinical Science session Can we improve the care of gout? Learning objectives: To outline the key developments in advanced imaging in gout To understand and discuss the utility of the current sets of guidelines available for gout The strategies that can be employed to improve gout therapy Alexander So (Switzerland) Eliseo Pascual (Spain) Nicola Dalbeth (New Zealand) 15:35 Abstract N SP0068 DECT imaging in gout - ready for prime time? Abhishek Abhishek (United Kingdom) 15:55 Abstract N SP0069 Improving adherence in gout therapy Thomas Bardin (France) 16:15 Abstract N SP0070 What are gout guidelines good for? * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

47 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 45 H. B. Hammer (Norway) 16:35 L. Karoliussen, L. Terslev, E. A. Haavardsholm, T. K. Kvien, T. Uhlig Abstract N OP0211 Ultrasound shows rapid reduction of uric acid load during a treat-to-target approach in gout patients: results from a longitudinal study (NOR-GOUT) P. Narongroeknawin (Thailand) 16:45 K. Bunphong Abstract N OP0212 Mobile phone text messages for improving allopurinol adherence: a randomised controlled trial of text message reminders 15:30-17:00 Hall 7.2 Clinical Science session Musculoskeletal pain; feeding the opioid epidemic Learning objectives: To be aware of the increasing problem of medical opioid abuse on both sides of the Atlantic The limitations of opioids as analgesics for chronic musculoskeletal pain How novel opioid analgesics might yet cause more benefit than harm 14 June :30-17:00 Elicium 2 Clinical Science session Why does BMI matter? Learning objectives: To understand common pathophysiological mechanisms linking adiposity and inflammation To obtain insights into the role of obesity in the development of RA To understand the impact of BMI and obesity on disease/treatment outcomes in RA Vivian Bykerk (United States) Stefano Alivernini (Italy) Iain B. McInnes (United Kingdom) 15:35 Fat and inflammation in RA - biological concepts Till Uhlig (Norway) 15:55 Abstract N SP0071 Is obesity a risk for RA? Patrick Kiely (United Kingdom) 16:15 Abstract N SP0072 Does obesity influence RA outcomes? L. Baganz (Germany) 16:35 A. Richter, K. Albrecht, M. Schneider, G.-R. Burmester, A. Zink, A. Strangfeld Abstract N OP0213 What is the impact of poor prognostic factors on the achievement of low disease activity or remission in patients with rheumatoid arthritis? L. Linde (Denmark) 16:45 M. L. Hetland Abstract N OP0214 Baseline comorbidities and overweight predict functional status and health-related quality of life 9 years later - a longitudinal cohort study of 428 patients with rheumatoid arthritis receiving standard care Francis Berenbaum (France) Candy McCabe (United Kingdom) Blair Smith (United Kingdom) 15:35 Abstract N SP0073 Opioid prescribing; what s the problem? Weiya Zhang (United Kingdom) 15:55 Opioids; do they really work for arthritis pain, or is the benefit mainly placebo? Christoph Stein (Germany) 16:15 Abstract N SP0074 Are all opioids the same? P. Muilu (Finland) 16:35 V. Rantalaiho, H. Kautiainen, L. J. Virta, K. Puolakka Abstract N OP0215 Time-related trends in opioid purchases among patients with early inflammatory arthritides E. R. Vina (United States) 16:45 L. Hausmann, D. S. Obrosky, A. Youk, D. Weiner, S. Ibrahim, C. K. Kwoh Abstract N OP0216 Examining modifiable psychological & social health factors associated with use of osteoarthritis oral analgesic treatment 15:30-17:00 Forum From Bench to Bedside What is lupus - syndrome or different entities? Learning objectives: To understand the updated pathogenic mechanisms of systemic lupus To discuss the possible role of autoantibodies as biomarkers To understand the clinical evolution of patients towards a full blown disease picture Ljudmila Stojanovic (Serbia) Georges Bertsias (Greece)

48 46 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE June 2018 David Daikh (United States) 15:35 Pathogenic mechanisms of SLE - what we know in 2018? Pier Luigi Meroni (Italy) 15:53 Abstract N SP0075 Autoantibodies - not always what they seem Marta Mosca (Italy) 16:11 Early SLE versus mimickers - what should we consider in 2018? Sindhu Johnson (Canada) 16:29 Presentation of the new SLE classification criteria M. B. Lauvsnes (Norway) 16:47 A. B. Tjensvoll, S. S. Maroni, I. Kvivik, T. B. Grimstad, O. J. Greve, E. Harboe, L. G. Gøransson, C. Putterman, R. Omdal Abstract N OP0217 A permeable blood-brain barrier is not required for neuropsychatric manifestations in SLE and PSS 15:30-17:00 Elicium 1 Basic and Translational Science session Genetics, epigenetics and disease: is it all in the genes? Learning objectives: To understand how genetic and epigenetic traits influence each other To learn how genetic/epigenetic data can inform about disease mechanisms To understand how rare genetic variants can be analysed and what they can tell us about disease pathogenesis Anne Barton (United Kingdom) Diane van der Woude (Netherlands) Kenneth G. C. Smith (United Kingdom) 15:35 Abstract N SP0076 Applying genomic approaches and insights to the clinical management of rheumatological disease Julian Knight (United Kingdom) 16:00 Functional genomics to understand disease mechanisms Stephen Eyre (United Kingdom) 16:25 What can we learn from the genetic architecture? M. L. Vecellio (United Kingdom) 16:50 A. Cortes, C. J. Cohen, R. Fischer, B. P. Wordsworth Abstract N OP0218 Investigating the regulatory snps at the RUNX3 locus associated with ankylosing spondylitis 15:30-17:00 Amtrium Health Professionals session It s your move: promoting physical activity in people with RMDs Learning objectives: To understand current, state-of-the-art physical activity in RMDs Els van den Ende (Netherlands) Thomas Davergne (France) Keegan Knittle (Finland) 15:35 Abstract N SP0077 New insights into strategies to effectively promote physical activity Zhivko Yankov (Bulgaria) 15:53 Patient s perspective on physical activity: good reasons for being active Karen Hambly (United Kingdom) 16:11 Abstract N SP0078 The patient perspective on physical activity and work participation in RMDs Maura D. Iversen (United States) 16:29 Abstract N SP0079 Major achievements and future challenges in physical activity T. Thomsen (Denmark) 16:47 M. Aadahl, N. Beyer, M. L. Hetland, K. B. Løppenthin, J. Midtgaard, R. Christensen, S. M. Nielsen, M. Østergaard, P. Jennum, B. A. Esbensen Abstract N OP0219-HPR The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial 15:30-17:00 Emerald Practical skills session* Data visualisation: tables and graphs for publication and presentation I Learning objectives: To learn how tables and graphs should be designed for publication and presentation Maarten Boers (Netherlands) 15:35 Abstract N SP0080 Data visualisation: tables and graphs for publication and presentation * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

49 SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE 2018 / 47 15:30-17:00 PARE Room PARE session Challenges of patient organisations in the 21 st century Learning objectives: To outline organisations challenges in a society that is getting older - less - more colorful To showcase how organisations can achieve sustainability To portrait organisations efforts to overcome gaps in patient health care Neil Betteridge (United Kingdom) Corinna Elling-Audersch (Germany) Winfried Kösters (Germany) 15:35 Abstract N SP0081 Patient organisations challenges in a world that is getting older - less - more colorful Elsa Mateus (Portugal) 15:55 Abstract N SP0082 How a user-led organisation for RMDs enables citizen participation in Portugal Katerina Koutsogianni (Greece) 16:15 Abstract N SP0083 Gaps in patient treatment - what patient organisations can do Bente Appel Esbensen (Denmark) Thijs Swinnen (Belgium) Maura D. Iversen (United States) 15:35 Abstract N SP0084 Why physical activity and exercise works Anne-Kathrin Rausch Osthoff (Switzerland) 15:53 Abstract N SP0085 The evidence for physical activity in inflammatory arthritis and osteoarthritis Karin Niedermann (Switzerland) 16:11 Abstract N SP0086 The development and purpose of the EULAR Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis Michael Nurmohamed (Netherlands) 16:29 Abstract N SP0087 How to deal with cardiovascular risk factors for physical activity and implement the PA recommendations in the rheumatologic practice S. Pettersson (Sweden) 16:47 I. Demmelmaier, B. Nordgren, A. B. Dufour, C. H. Opava Abstract N OP0222-HPR Physical capacity contributes marginally in explaining variations of fatigue in persons moderately affected by rheumatoid arthritis 14 June 2018 V. Krafft (Switzerland) 16:35 S. M. Engel Abstract N OP0220-PARE Development of the Swiss national strategy musculoskeletal diseases by the Swiss league against rheumatism T. Ngcozana (United Kingdom) 16:45 A. Bhatia Abstract N OP0221-PARE Know their numbers: what do RA patients know about their own biomedical data? 15:30-17:00 E106/E107 EULAR Projects in Health Professionals The EULAR Excercise Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis Learning objectives: To learn about the work of the task force that developed the EULAR Recommendations for physical activity in inflammatory and osteoarthritis, i.e. the process and its results 15:30-17:00 D201/D202 Practical skills session* Capillaroscopy I Learning objectives: How to differentiate normal from abnormal capillaroscopic images How to score to capillaroscopic images How to distinguish the major capillaroscopic patterns Maurizio Cutolo (Italy) Vanessa Smith (Belgium) Vanessa Smith (Belgium) 15:35 Abstract N SP0088 The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease Alberto Sulli (Italy) 15:55 Scoring the capillaroscopic images Ariane L. Herrick (United Kingdom) 16:15 Abstract N SP0089 How to distinguish the major capillaroscopic patterns Maurizio Cutolo (Italy) 16:35 How capillaroscopy can predict disease severity and prognosis * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

50 48 / SCIENTIFIC PROGRAMME / THURSDAY 14 JUNE :30-17:00 D203/D204 Practical skills session* Ultrasound advanced I 17:30-19:00 Elicium 1 Basic and Translational Science session Immune senescence and ageing 14 June 2018 Mads Ammitzboll (Denmark) Marion Kortekaas (Netherlands) Ingrid Möller (Spain) 15:35 Abstract N SP0090 US for pulley lesions - clinical relevance + demo David Bong (Spain) 15:55 Abstract N SP0091 US for peripheral nerve entrapments + demo Sandrine Jousse-Joulin (France) 16:15 Abstract N SP0092 US for scoring Sjögren disease Nemanja Damjanov (Serbia) 16:35 US for impingement syndromes + demo Tutor: Sara Nysom (Denmark) Learning objectives: Describe the relevance of senescence in the functioning of the immune system Novel insights into senescence and inflammation To learn about therapeutic opportunities involving immune rejuvenation Berent J. Prakken (Netherlands) Erik Lubberts (Netherlands) Arne Akbar (United Kingdom) 17:35 Cellular senescence and inflammation Deena Gibson (United Kingdom) 18:00 The neonatal immune system and inflammation M. Varela-Eirín (Spain) 18:25 A. Varela-Vázquez, C. Paíno, A. Casado-Díaz, J. M. Quesada-Gómez, E. Fonseca, T. Aasen, A. Tabernero, J. R. Caeiro, A. Blanco, M. D. Mayán Abstract N OP0223 Targeting chondrocyte plasticity via CONNEXIN43 modulation attenuates cellular senescence in osteoarthritis Femke van Wijk (Netherlands) 18:35 Abstract N SP0093 Rejuvenation of the immune system following haematopoietic stem cell transplantation * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

51 GUIDED POSTER TOURS / THURSDAY 14 JUNE 2018 / 49 Guided Poster Tours Thursday, 14 June 2018 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour. 11:50-13:30 Poster area Poster tour T1: Genetics - from cause to cure Caroline Ospelt (Switzerland), Rachel Knevel (Netherlands) Abstracts N : THU0001-THU0010 See page 50 Poster tour T2: Adapting the adaptive immune system in health and disease Leonie Taams (United Kingdom), Hans-Ulrich Scherer (Netherlands) Abstracts N : THU0023-THU0032 See page 51 Poster tour T3: Seeking the origins of rheumatoid arthritis João E. Fonseca (Portugal) Felice Rivellese (United Kingdom) Abstracts N : THU0050-THU0059 See page 52 Poster tour T4: RA: not just about the joints! Elena Nikiphorou (United Kingdom) Jacob M. van Laar (Netherlands) Abstracts N : THU0135-THU0144 See page 56 Poster tour T5: Anti-TNF: old drugs now but still full of promises Xavier Mariette (France) Diane van der Woude (Netherlands) Abstracts N : THU0182-THU0191 See page 58 Poster tour T9: SSc, myositis, related syndromes - a bouquet of surprises Ulf Müller-Ladner (Germany), Peter Korsten (Germany) Abstracts N : THU0387-THU0396 See page 67 Poster tour T10: New data on osteoporosis and fracture prevention Piet Geusens (Netherlands) Sandrine Bours (Netherlands) Abstracts N : THU0469-THU478 See page 70 Poster tour T11: Pain in the joint; managing a widespread problem David Walsh (United Kingdom) Francesco Carubbi (Italy) Abstracts N : THU0516-THU0525 See page 72 Poster tour T12: A colourful journey through the landscape of paediatric rheumatology Berent J. Prakken (Netherlands) Gabriella Giancane (Netherlands) Abstracts N : THU0546-THU0555 See page 73 Poster tour T13: Life is not a smooth trip - how pregnancy and life events interfere in rheumatic disease management Laure Gossec (France), Santiago Rodrigues-Manica (Portugal) Abstracts N : THU0671-THU0680 See page June 2018 Poster tour T6: Spondyloarthritis: causes, questions and consequences Robert B. M. Landewé (Netherlands), Marloes van Onna (Netherlands) Abstracts N : THU0227-THU0236 See page 60 Poster tour T7: The impact of treatment on the burden of psoriatic disease Filip van den Bosch (Netherlands) Laura Coates (United Kingdom) Abstracts N : THU0280-THU0289 See page 62 Poster tour T8: Cardiovascular co-morbidites in SLE Eric F. Morand (Australia) Antonis Fanouriakis (Greece) Abstracts N : THU0334-THU0341 See page 65 Poster tour T14: Winds of change Annette de Thurah (Denmark) Anne-Kathrin Rausch Osthoff (Switzerland) Abstracts N : THU0710-HPR-THU0719-HPR See page :00-13:30 Poster area Poster tour T15: PARE Poster Tour I Dieter Wiek (Germany) Elsa Mateus (Portugal) Abstracts N : PARE0001-PARE0008 See page 188

52 50 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 Scientific Poster Session I 14 June 2018 Thursday, 14 June 2018 Poster viewing 11:45-13:30 Guided poster tours 11:50-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. TOPIC: GENOMICS, GENETIC BASIS OF DISEASE AND ANTIGEN PRESENTATION Poster tour T1: Abstracts N : Genetics - from cause to cure Caroline Ospelt (Switzerland), Rachel Knevel (Netherlands) THU0001-THU0010 THU0001 DIFFERENTIAL METHYLATION AS A PREDICTOR OF METHOTREXATE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS / N. Nair* - D. Plant - S. M. Verstappen - J. D. Isaacs - A. W. Morgan - K. L. Hyrich - A. Barton - A. G. Wilson on behalf of MATURA THU0002 NOVEL PATHOGENIC STOP CODON MUTATION IN THE NF-KB P65 SUBUNIT (RELA) ASSOCIATED WITH BOTH BEHÇET S DISEASE LIKE SYNDROME AND NEUROMYELITIS OPTICA IN AN IRISH FAMILY / F. Adeeb* - E. R. Dorris - S. Tariq - W. L. Ng - A. G. Stack - A. G. Wilson - A. D. Fraser THU0003 COMPREHENSIVE EVALUATION OF THE EFFECTS OF RARE AND COMMON EXONIC ABCG2 VARIANTS ON GOUT SUSCEPTIBILITY / T. Higashino* - T. Takada - H. Nakaoka - Y. Toyoda - B. Stiburkova - K. Wakai - H. Ooyama - I. Inoue - T. R. Merriman - N. Shinomiya - H. Matsuo THU0004 A DE NOVO NON-SENSE ERAP1 POLYMORPHISM IN TWO HLA-B*27-NEGATIVE TWINS WITH AXIAL SPONDYLOARTHRITIS / M. C. Padula* - G. Martelli - R. Giuzio - C. Amato - T. Carbone - M. Gilio - P. Leccese - G. Tramontano - A. A. Padula - S. D Angelo THU0005 WHOLE GENOME LINKAGE AND EXOME SEQUENCING ANALYSES IN TAKAYASU ARTERITIS FAMILIES / E. Tahir Turanlı - I. Karacan - S. N. Esatlioglu - S. Sahin - O. Kasapcopur - A. Tolun - E. Seyahi* THU0006 APPLICATION OF MACHINE LEARNING METHODS FOR PREDICTION MODELLING OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS / F. Jalali-najafabadi* - N. Dand - P. Ho - C. H. Smith - J. N. Barker - N. McHugh - R. B. Warren - A. Barton - J. Bowes THU0007 GENETIC VARIANTS IN SLE SUSCEPTIBILITY LOCI, XKR6 AND GLT1D1, ARE ASSOCIATED WITH CHILDHOOD-ONSET SLE IN A KOREAN COHORT / Y. B. Joo* - J. Lim - B. P. Tsao - S. K. Nath - K. Kim - S.-C. Bae THU0008 LINKING GENETICS TO T CELL PHENOTYPE IN JIA: RATIONAL FOR IL-2 THERAPY / A. Yarwood* - A. Hinks - S. Smith - J. Bowes - S. Eyre - W. Thomson THU0009 TOWARDS PRECISION MEDICINE IN CONNECTIVE TISSUE DISEASES: GENOMIC AND TRANSCRIPTOMIC STUDIES / T. Briggs* - J. A. Reynolds - G. Rice - V. Bondet - E. Bruce - Y. Crow - D. Duffy - B. Parker - I. N. Bruce THU0010 POLYMORPHISMS IN PHASE I-METABOLIZING ENZYME AND HORMONE RECEPTOR GENES INFLUENCE THE RESPONSE TO ANTI-TNF THERAPY / L. M. Canet - J. M. Sánchez-Maldonado - A. Rodríguez-Ramos - C. B. Lupiañez - H. Canhão - M. Martínez-Bueno - A. Escudero - J. Segura-Catena - S. B. Sørensen - M. L. Hetland - M. J. Soto-Pino - M. Á. Ferrer - A. García - B. Glintborg - I. Filipescu - E. Pérez-Pampin - A. González-Utrilla - M. Á. López-Nevot - P. Conesa-Zamora - A. A. den Broeder - S. da Vita - S. E. Hove Jacobsen - E. Collantes - L. Quartuccio - J. E. Fonseca - M. J. Coenen - V. Andersen - R. Cáliz-Cáliz - J. Sainz* THU0011 LOCATION AND INTERACTION OF IGG HYPERVARIABLE REGIONS WITH PORPHYROMONAS GINGIVALIS PEPTIDYLARGININE DEIMINASE CITRULLINATED PEPTIDES, A HIGHLIGHT TO UNDERSTAND THE ASSOCIATION MODEL OF RHEUMATOID ARTHRITIS AND PERIODONTAL DISEASE: IN SILICO ANALYSIS / M. Acevedo-Godoy - P. Hernandez - A. Amaya - D. M. Castillo - J. E. Castellanos - J. M. Bello-Gualtero - W. Bautista-Molano - C. Romero-Sanchez* * Presenting author

53 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 51 THU0012 TARGETED RE-SEQUENCING OF 128 RHEUMATOID ARTHRITIS SUSCEPTIBILITY GENES UNCOVERS NOVEL RISK LOCI IN THE SINGAPORE CHINESE POPULATION / J. M. Y. Yong* - L. L. Goh - C. W. Lim - P. P. Q. Lim - G. L.-X. Toh - E. T. Koh - K. P. Leong on behalf of the TTSH RA study group THU0013 DOWNREGULATION OF MICRORNA MAY CONTRIBUTE TO ACTIVATION OF THE INTERFERON SIGNALLING PATHWAY IN THE IDIOPATHIC INFLAMMATORY MYOPATHIES / J. E. Parkes* - H. Chinoy - P. J. Day - J. A. Lamb THU0014 GENETIC SCREENING FOR IDENTIFYING HUMAN GENES REGULATING FIBROSIS IN SYSTEMIC SCLEROSIS / M. Krishnan* - U. Unniyampurathu - S. Albani - A. H. L. Low THU0015 ESTROGEN DEPENDENT REGULATION OF MICRO-RNA IN RHEUMATOID ARTHRITIS / K. Andersson - R. Pullerits - H. Forsblad-d Elia - M. Erlandsson - S. T. Silfverswärd - M. Bokarewa* THU0016 TRANSMITOCHONDRIAL CYBRIDS SHOW THAT OXPHOS VIA, BUT NO GLYCOLYSIS VIA, IS INVOLVED IN THE ATP REDUCTION OF OA HUMAN CHONDROCYTES / M. Fernández-Moreno* - A. Dalmao-Fernandez - T. Hermida-Gomez - A. Rustan - J. Lund - M. E. Vazquez-Mosquera - S. Relano-Fernandez - I. Rego-Perez - F. Blanco-Garcia THU0017 DNA METHYLATION OF REGULATORY SITES OF HAND OSTEOARTHRITIS SUSCEPTIBILITY GENES IN FINNISH WOMEN / S. Hämäläinen* - S. Solovieva - T. Vehmas - A. Hirvonen - P. Leino-Arjas THU0018 MIRNAS-146A AND -499 GENE EXPRESSION AND THEIR POLYMORPHISMS AS DIAGNOSTIC MARKERS FOR RHEUMATOID ARTHRITIS / G. A. Ayeldeen - Y. H. Nassar - H. A. Ahmed - O. G. Shaker - T. A. Gheita* THU0019 ARE MICRORNAS A MOLECULAR CLOCK? THE NEWCASTLE THOUSAND FAMILIES COHORT STUDY / T. L. Jones* - D. A. Young - M. S. Pearce - A. Skelton - F. N. Birrell THU0020 TOCILIZUMAB DECREASES THE PRO-INFLAMMATORY ROLE OF PLATELETS IN RHEUMATOID ARTHRITIS: IDENTIFICATION OF A NEW MECHANISM OF ACTION ASSOCIATED WITH POSITIVE RESPONSE? / C. Prum Delepine - C. Derambure - F. Vidal - A. Pinta - D. Pau - E. Conde da Silva Fraga - O. Boyer - E. Senbel - P. Gaudin - O. Vittecoq - T. Lequerre* THU0021 DIFFERENTIAL EFFECTS OF TR14 VERSUS DICLOFENAC ON COX/LOX PATHWAYS REVEALED BY RNASEQ / G. St. Laurent, III - I. Toma - B. Seilheimer - M. Tackett - J. Zhou - M. Ri - D. Shtokalo - Y. Vyatkin - T. Jepson - K. Cesnulevicius - T. Mccaffrey* THU0022 ANALYSIS OF 47 NON-MHC ANKYLOSING SPONDYLITIS SUSCEPTIBILITY LOCI REVEALS SHARED ASSOCIATED VARIANTS ACROSS CAUCASIANS AND CHINESE HAN / X. Zheng* - Q. Li - X. Li - Y. Zhang - X. Wu - Q. Wei - S. Cao - M. Yang - Z. Lin - Z. Liao - J. Qi - Q. Lv - L. Wang - J. Liu - J. Gu 14 June 2018 TOPIC: ADAPTIVE IMMUNITY (T CELLS AND B CELLS) IN RHEUMATIC DISEASES Poster tour T2: Abstracts N : Adapting the adaptive immune system in health and disease Leonie Taams (United Kingdom), Hans-Ulrich Scherer (Netherlands) THU0023-THU0032 THU0023 COMPLEX IMMUNOPHENOTYPING STRATIFIES PATIENTS WITH PRIMARY SJÖGREN S SYNDROME, SYSTEMIC LUPUS ERYTHEMATOSUS AND SECONDARY SJÖGREN S SYNDROME ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS INTO DISTINCT CLINICALLY RELEVANT GROUPS WITH POTENTIAL THERAPEUTIC IMPLICATIONS / N. Thompson - A. Gandhi - R. Radmmore - V. Gupta - G. Robinson - L. Martin-Gutierrez - D. Isenberg - E. Jury - C. Ciurtin* THU0024 TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS AND THE BREAK OF B CELL TOLERANCE TO AUTOANTIGENS / E. C. de Moel* - L. Rozeman - A. Grummels - E. M. E. Verdegaal - J. A. Bakker - E. H. Kapiteijn - T. W. J. Huizinga - J. B. Haanen - R. E. M. Toes - D. van der Woude THU0025 FLORID SYNOVITIS AFTER PD1 ANTAGONIST THERAPY IS CHARACTERISED BY A MARKED ABSENCE OF PD1+ INFILTRATING T CELLS / W. Murray-Brown* - T. Wilsdon - H. Weedon - S. Proudman - M. D. Smith - J. Walker - M. D. Wechalekar THU0026 ORGANIZED B CELLS AND PLASMA CELLS IN THE AORTA OF GIANT CELL ARTERITIS PATIENTS / J. Graver* - M. Sandovici - E. Haacke - A. Boots - E. Brouwer THU0027 NON-RESPONSE TO RITUXIMAB THERAPY IN REUMATOID ARTHRITIS ASSOCIATES WITH INCOMPLETE DISRUPTION OF THE B CELL RECEPTOR REPERTOIRE IN THE PERIPHERAL BLOOD / S. Pollastro* - P. L. Klarenbeek - M. Doorenspleet - B. D. van Schaik - R. Esveldt - R. M. Thurlings - M. Boumans - D. M. Gerlag - P. P. Tak - K. Vos - F. Baas - A. H. van Kampen - N. de Vries THU0028 INTERLEUKIN-6 RECEPTOR INHIBITION, AS FIRST-LINE B-DMARD, AFFECTS B CELL SUBPOPULATIONS DISTRIBUTION THROUGH EPIGENETIC MODIFICATIONS IN RHEUMATOID ARTHRITIS PATIENTS / S. Alivernini* - B. Tolusso - A. L. Fedele - C. Di Mario - L. Petricca - G. Di Sante - M. R. Gigante - G. Ferraccioli - E. Gremese THU0029 CTLA-4-IG TREATMENT INDUCES MODULATION OF B CELL FUNCTION AND DIFFERENTIATION / J. Thiel* - R. Lorenzetti - I. Janovska - C. R. Smulski - L. Walter - J. Staniek - T. Schleyer - R. E. Voll - N. Venhoff - M. Rizzi THU0030 MOLECULAR MECHANISMS OF AUTOPHAGIC MEMORY IN PATHOGENIC T CELLS IN HUMAN RHEUMATOID ARTHRITIS / P. Kumar* - J. Y. Leong - S. Saidin - B. Paleja - J. V. Loosdregt - C. Chua - T. Arkachaisri - A. Consolaro - M. Gattorno - A. Martini - G. W. Williams - K. D Pischel - M. Lotz - S. Albani THU0031 PHENOTYPE OF FOXP3+ REGULATORY T CELLS EXPANDED BY THE IL-2 MUTEIN, AMG 592 IN HEALTHY SUBJECTS IN PHASE 1, FIRST-IN-HUMAN STUDY / K. S. Gorski* - J. Stern - Y.-H. Hsu - A. Anderson - M. Boedigheimer - N. Tchao THU0032 CCR6+CD4+ T CELLS DRIVE ANTIGEN-INDUCED ARTHRITIS VIA THE IL-23R PATHWAY / W. Razawy* - N. Salioska - P. Asmawidjaja - A.-M. Mus - M. Van Meurs - I. Haspels-Brouwers - N. Kops - M. Oukka - V. Kuchroo - E. Lubberts THU0033 AGE-ASSOCIATED B CELLS IN EARLY DRUG-NAÏVE RHEUMATOID ARTHRITIS PATIENTS / A. E. Anderson* - G. Vidal-Pedrola - D. Scheel-Toellner - A. Pratt - A. Mellor - J. Isaacs THU0034 SALMONELLA TYPHI VI IGG AS A MARKER OF IMMUNOSUPPRESSION IN RHEUMATIC DISEASE / L. Williams - G. Candelas - C. Tange* - J. Ochoa-Grullón - P. Macarrón - C. Morado - K. H. Llano - C. Martínez-Prada - A. Rodríguez de la Peña - B. Fernandez - J.-Á. Jover - S. Harding - S. Sanchez-Ramon - A. Parker * Presenting author

54 52 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0035 A CD8 ALPHA-NEGATIVE SUBSET OF CD4+SLAMF7+ CYTOTOXIC T CELLS IS EXPANDED IN PATIENTS WITH IGG4-RELATED DISEASE AND DECREASES FOLLOWING GLUCOCORTICOID TREATMENT / E. Della Torre* - E. Bozzalla Cassione - C. Sciorati - M. Lanzillotta - E. Bozzolo - L. Rovati - H. Mattoo - C. Perugino - J. Stone - L. Dagna - S. Pillai - A. Manfredi THU0036 ABATACEPT INCREASES REGULATORY B CELL EFFECT ON T CELL PROLIFERATION THROUGH THE PRODUCTION OF IL-10 AND TGF-ΒETA IN VITRO AND IN RHEUMATOID ARTHRITIS PATIENTS / G. Carvajal Alegria* - P. Gazeau - A. Saraux - V. Devauchelle-Pensec - D. Cornec - J.-O. Pers - P. Pochard THU0037 LEPTIN ENHANCED THE EXPRESSION OF AUTOANTIBODIES AND INFLAMMATORY CYTOKINES OF B CELLS VIA ACTIVATING ERK1/2 AND JAK/STAT3,5 PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS / H. Chen* - F. Yuan - Y. Zou THU0038 INCREASE OF CIRCULATING MEMORY B CELLS AFTER GLUCOCORTICOID-INDUCED REMISSION IDENTIFIES PATIENTS AT RISK OF IGG4-RELATED DISEASE RELAPSE / M. Lanzillotta* - E. Della Torre - R. Milani - E. Bozzolo - E. Bozzalla Cassione - L. Rovati - M. Falconi - F. Ciceri - L. Dagna THU0039 INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR REGULATES THE PHENOTYPE AND FUNCTION OF CD21+ B CELLS / M. Erlandsson - C. Wasen - G. Gravina - M. I. Bokarewa* THU0040 ENHANCEMENT OF EARLY HUMAN B CELL DEVELOPMENT BY JAK INHIBITION / J. Thiel - N. Venhoff - I. Janowska - A. Troilo - N. Frede - M. Erlacher - M. Kunze - R. Lorenzetti - J. Staniek - B. Bannert - D. Kyburz - C. Glaser - M.-T. Schleyer - R. E. Voll - M. Rizzi* THU0041 THE EFFECTS OF ABATACEPT ON HUMAN B CELL ACTIVITIES / M.-H. Chen* - C.-T. Ssu - C.-Y. Tsai - C.-M. Leu THU0042 CANCER IMMUNOTHERAPY ARRAY: A NOVEL SCREENING TOOL FOR IMMUNE SYSTEM PROFILING IN CANCER IMMUNOTHERAPY BRIDGING AUTOIMMUNITY AND CANCER / P. Schulz-Knappe* - P. Budde - H.-D. Zucht - S. Konings - L. Steeg - E. Friedrich - C. Gutjahr - R. Steil - S. Bhandari - M. Tuschen THU0043 AUTOANTIBODY PROFILING IN PROSTVAC AND IPILIMUMAB TREATED PROSTATE CANCER PATIENTS REVEALS POTENTIAL BIOMARKERS OF IMMUNE-RELATED ADVERSE EVENTS / P. Budde - J. L. Marte - H.-D. Zucht - S. Bhandari - M. Tuschen - P. Schulz-Knappe* - R. A. Madan - J. L. Gulley - J. Schlom THU0044 IMPAIRED AUTOPHAGY INDUCES DEFECTIVE FUNCTION OF REGULATORY B CELLS IN ANKYLOSING SPONDYLITIS / C. Shuizhong - X. Zhongyu - Z. Guan - S. Huiyong* - W. Yanfeng THU0045 EXPANSION OF ACTIVATED CXCR5+ICOS+ TFH CELLS AND PLASMABLASTS INDUCED BY SEASONAL INFLUENZA VACCINE IS IMPAIRED IN ANTI-IL-6R TREATED RHEUMATOID ARTHRITIS PATIENTS / V. C. Romao* - A. Agua-Doce - J. Polido-Pereira - R. Barros - I. P. Lopes - M. I. Seixas - M. J. Saavedra - E. Sacadura-Leite - H. Rebelo-de-Andrade - J. E. Fonseca - L. Graca THU0046 SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY (SM04755) AS A POTENTIAL TOPICAL TREATMENT FOR PSORIASIS / V. Deshmukh* - M. Pedraza - L. Lamangan - Y. Yazici THU0047 1,25(OH)2D3 AND DEXAMETHASONE ADDITIVELY SUPPRESS SYNOVIAL FIBROBLAST ACTIVATION BY CCR6+ TH MEMORY CELLS AND ENHANCE THE EFFECT OF TNF-ALPHA BLOCKADE / W. Dankers* - C. González-Leal - N. Davelaar - P. S. Asmawidjaja - A. M. Mus - J. M. Hazes - E. M. Colin - E. Lubberts THU0048 PRO-INFLAMMATORY IL-17A-PRODUCING CCR6+ T HELPER MEMORY CELLS CHANGE INTO ANTI- INFLAMMATORY CELLS WITH REGULATORY CAPACITY UPON EXPOSURE TO ACTIVE VITAMIN D / W. Dankers* - N. Davelaar - J. P. van Hamburg - J. van de Peppel - E. M. Colin - E. Lubberts THU0049 DEVELOPMENT OF TFH-TH1 LIKE CELLS THROUGH EPIGENETIC MODIFICATION BY STATS FAMILY FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / X. Ma* - S. Nakayamada - S. Kubo - K. Sakata - K. Yamagata - Y. Tanaka TOPIC: RHEUMATOID ARTHRITIS - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS Poster tour T3: Abstracts N : Seeking the origins of rheumatoid arthritis João E. Fonseca (Portugal), Felice Rivellese (United Kingdom) THU0050-THU0059 THU0050 HYPOXIA INDUCES PRODUCTION OF CITRULLINATED PROTEINS IN HUMAN FIBROBLAST-LIKE SYNOVIOCYTES THROUGH REGULATING HIF1Α / R. Yu* - C. Li - L. Sun - L. Jian - Z. Ma - J. Zhao - X. Liu THU0051 TNF RECEPTOR 2 PLAYS AN IMMUNOREGULATORY AND ANTI-INFLAMMATORY ROLE IN ARTHRITIS / W.-Y. Tseng* - I.-S. Huang - F. Clanchy - K. Mcnamee - F. Mccann - R. O. Williams THU0052 A CIRCULATING PROTEIN SIGNATURE CORRELATES WITH SYNOVIAL PATHOTYPES IN RHEUMATOID ARTHRITIS PATIENTS / C. Ruiz-Romero* - F. Picchi - P. Fernández-Puente - L. González-Rodríguez - R. Hands - V. Calamia - M. Camacho-Encina - C. Bessant - C. Pitzalis - F. J. Blanco THU0053 ANTI-FRACTALKINE MONOCLONAL ANTIBODY AMELIORATES JOINT DESTRUCTION IN COLLAGEN-INDUCED ARTHRITIS MODEL BY INHIBITION OF OSTEOCLAST PRECURSOR CELL SURVIVAL AND MIGRATION / Y. Kuboi* - K. Hoshino-Negishi - M. Ohkuro - W. Ikeda - T. Nakatani - N. Ishii - N. Yasuda - T. Imai THU0054 LONG NON-CODING RNA GAPLINC PROMOTES PROLIFERATION AND INVASION OF FIBROBLAST-LIKE SYNOVIOCYTES AS MICRORNA SPONGING IN RA PATIENTS / B. Y. Mo* - Y. F. Pan - X. BI - X. Q. Luo THU0055 AN ANATOMICALLY DISTINCT PATHOGENIC FIBROBLAST SUBSET DRIVES INFLAMMATION IN ARTHRITIS / A. P. Croft* - J. Campos - J. Marshall - J. Turner - F. Barone - A. Filer - C. Buckley THU e IS A MOLECULAR SWITCH REGULATING MACROPHAGE POLARIZATION IN INFLAMMATORY ARTHRITIS / W. Fu* - A. Hettinghouse - C. Liu THU0057 MECHANICAL STRAIN DETERMINES THE SITE-SPECIFIC DIRECTION OF INFLAMMATION AND TISSUE DAMAGE IN ARTHRITIS / I. Cambré* - D. Gaublomme - A. Burssens - P. Jacques - L. Meuris - S. Lambrecht - S. Carter - A. De Muynck - N. Callewaert - G. Kollias - R. Lories - G. Schett - D. Elewaut * Presenting author

55 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 53 THU0058 TAS8274, A HIGHLY SELECTIVE JANUS KINASE 3 INHIBITOR, SHOWS POTENT EFFICACY, BUT DOES NOT AFFECT HOST DEFENSE, IN PRECLINICAL MOUSE MODELS / H. Hayashi* - S. Demizu - K. Tanaka - M. Mitsuya - A. Saito - T. Utsugi - E. Sasaki - Y. Iwasawa THU0059 PLASMA EXOSOMAL MIR-92A ARE INVOLVED IN THE OCCURRENCE AND DEVELOPMENT OF BONE DESTRUCTION IN RA PATIENTS BY INHIBITING APOPTOSIS OF FIBROBLAST-LIKE SYNOVIOCYTES / Y. Xin - Z. S. Yang - X. Y. Fei - L. Y. Ke - J. Juan - F. Ting - Z. Z. Xu - Z. Gu* THU0060 ALTERATIONS OF SPLICING IN LEUKOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS AND ITS INFLUENCE ON THE AUTOIMMUNE, INFLAMMATORY AND ATHEROTHROMBOTIC PROFILE OF THE DISEASE. POTENTIAL ROLE OF U4ATAC / A. Ibáñez-Costa* - C. Perez-Sanchez - S. Pedraza-Arévalo - M. del Río-Moreno - P. Ruiz-Limón - N. Barbarroja - Y. Jiménez-Gómez - M. C. Ábalos - P. Segui - E. Collantes - J. P. Castaño - R. M. Luque - C. Lopez-Pedrera THU0061 RESTRICTED AXL SYNOVIAL EXPRESSION AND INCREASED CLEAVAGE OF AXL ECTODOMAIN CORRELATE WITH HIGHLY INFLAMED SYNOVITIS AND MORE SEVERE RHEUMATOID ARTHRITIS / A. Nerviani* - D. Mauro - S. Pagani - G. Lliso-Ribera - F. Rivellese - M. Lewis - M. Bombardieri - F. Humby - C. Pitzalis THU0062 WNT5A INVOLVEMENT IN MIGRATION, INVASION AND THE PRO-INFLAMMATORY PHENOTYPE OF RHEUMATOID SYNOVIOCYTES / A. Rodríguez-Trillo* - N. Mosquera - A. Mera - A. González - C. Conde THU0063 CD11C+ DENDTRITIC CELLS IN INFLAMMATORY ARTHRITIS / A. Puchner* - V. Saferding - M. Bonelli - H. Leiss - R. Pfeifle - G. Kroenke - J. Smolen - K. Redlich - S. Blüml THU0064 ANTIBODIES AGAINST CARBAMYLATED PROTEINS FROM PATIENTS WITH RHEUMATOID ARTHRITIS ACTIVATE ENDOTHELIAL CELLS / A. Pecani* - T. Colasanti - F. R. Spinelli - C. Barbati - F. Conti - G. Valesini - C. Alessandri THU0065 RESULTS OF TREATMENT OF ARTHROSCOPIC AND TRADITIONAL SYNOVECTOMY OF THE KNEE JOINT IN RHEUMATOID ARTHRITIS / A. Kasimov* - I. Khujanazarov THU0066 CIRCULATING MIRNAS AS POTENTIAL BIOMARKERS OF DISEASE AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS / C. López-Pedrera* - N. Barbarroja - P. Ruiz-Limón - S. Remuzgo-Martínez - I. Arias de la Rosa - M. C. Ábalos-Aguilera - Y. Jimenez-Gomez - R. Ortega - E. Collantes - A. Escudero - R. Lopez-Mejías - M. A. Gonzalez-Gay - C. Perez-Sanchez THU0067 ASSOCIATION OF HIGH TITERS OF ANTI-CARBAMYLATED PROTEINS ANTIBODIES WITH DECREASED BONE MINERAL DENSITY IN EARLY ARTHRITIS PATIENTS / C. Regueiro* - A. M. Ortiz - M. D. Boveda - S. Castañeda - I. Gonzalez-Alvaro - A. Gonzalez THU0068 IDENTIFICATION AND VERIFICATION OF BIOMARKER CANDIDATES FOR MONITORING RHEUMATOID ARTHRITIS ACTIVITY BY MASS SPECTROMETRY / L. González-Rodríguez* - V. Calamia - P. Fernández-Puente - C. Ruiz-Romero - L. Lourido - M. Camacho-Encina - A. Juliá - A. Fernández-Nebro - J. Tornero - S. Marsal - F. J. Blanco on behalf of IMID Consortium THU0069 IN RA, BECOMING SERONEGATIVE OVER THE 1ST YEAR OF DMARD TREATMENT DOES NOT TRANSLATE TO BETTER CHANCES OF SUSTAINED DRUG-FREE REMISSION IN THE LONG-TERM / E. C. de Moel* - V. F. A. M. Derksen - L. A. Trouw - H. Bang - Y. P. Goekoop-Ruiterman - G. M. Steup-Beekman - T. W. J. Huizinga - C. F. Allaart - R. E. M. Toes - D. van der Woude THU0070 THE TRANSCRIPTION FACTORS IKAROS AND AIOLOS ARE EXPRESSED IN THE SYNOVIAL MEMBRANE OF EARLY RHEUMATOID ARTHRITIS PATIENTS IN ASSOCIATION WITH SYNOVIAL LYMPHOID AGGREGATES / F. Rivellese - M. Congia - D. Mauro* - M. Bombardieri - M. Lewis - C. Pitzalis THU0071 MUSCLE LIPOTOXICITY ON SARCOPENIA DEVELOPMENT IN A MODEL OF COLLAGEN-INDUCED ARTHRITIS / G. Vial* - A. Pinel - D. Bechet - F. Wauquier - Y. Wittrant - C. Chevenet - M. Soubrier - A. Tournadre - F. Capel THU0072 GENE SIGNATURE OF PLASMACYTOID DENDRITIC CELLS REVEALS NOVEL PATHWAYS CONTRIBUTING TO TOLERANCE IN RHEUMATOID ARTHRITIS PATIENTS / G. Papadaki* - P. Goutakoli - J. R. Grün - A. Grützkau - A. Fanouriakis - G. A. Pavlopoulos - I. Iliopoulos - G. Bertsias - D. Boumpas - P. Sidiropoulos - P. Verginis THU0073 A SUBSET OF NEUTROPHIL HIGHLY EXPRESSING CD49D AND VEGFR1 CAN ENHANCE PANNUS FORMATION VIA INCREASE FLS MIGRATION AND INVASION ABILITY BY UP-REGULATING MMP3 AND 13 / H. Y. Li* - Y. L. Cao - X. cao - C. L. su - Q. P. yang - Q. P. yang - Y. liu - B. Y. luo - Y. zhao - T. N. Marion THU0074 EFFECTS OF RITUXIMAB ON THE INFLAMMATORY AND PRO-THROMBOTIC PROFILES OF NON-B CELLS OF THE IMMUNE AND VASCULAR SYSTEMS OF RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / I. Cecchi* - C. Pérez-Sánchez - M. Á. Aguirre - L. Pérez-Sánchez - P. Ruiz-Limón - I. Arias de la Rosa - M. C. Ábalos-Aguilera - Y. Jiménez-Gómez - R. Ortega - E. Collantes - A. Escudero - M. Radin - N. Barbarroja - D. Roccatello - S. Sciascia - C. Lopez-Pedrera THU0075 IMPACT OF OBESITY ON RHEUMATOID ARTHRITIS (RA) ONSET AND PROGRESSION. IN VIVO AND IN VITRO EFFECTS OF SYNTHETIC DMARDS ON THE RA-ASSOCIATED METABOLIC ALTERATIONS / I. Arias De La Rosa* - M. Ruiz-Ponce - A. Escudero - P. Ruiz-Limón - C. Pérez-Sánchez - M. D. C. Ábalos-Aguilera - Y. Jiménez-Gómez - E. Collantes - C. López-Pedrera - N. Barbarroja THU0076 ANTIBODIES TO CITRULLINATED PROTEIN ANTIGENS (ACPAS) INDUCE ADIPOSE TISSUE DYSFUNCTION IMPAIRING ADIPOCYTE DIFFERENTIATION, LIPID ACCUMULATION AND PROMOTING MACROPHAGE POLARIZATION. IN VITRO EFFECT OF BIOLOGIC DMARDS / I. Arias De La Rosa* - M. Ruiz-Ponce - P. Ruiz-Limón - Y. Jiménez-Gómez - C. Pérez-Sánchez - I. Cecchi - M. D. C. Ábalos-Aguilera - E. Collantes-Estévez - A. Escudero - C. López-Pedrera - N. Barbarroja THU0077 INCREASED FOLLICULAR HELPER T CELL REGULATES AUTOANTIBODY HYPOSIALYLATION IN GLUCOSE-6- PHOSPHATE ISOMERASE INDUCED ARTHRITIS / I. Kurata* - I. Matsumoto - A. Osada - H. Ebe - H. Kawaguchi - Y. Kondo - H. Tsuboi - T. Sumida THU0078 BERBERINE AMELIORATES BONE EROSIONS IN COLLAGEN-INDUCED ARTHRITIS RAT MODELS VIA SUPPRESSING THE EXPRESSION OF IL-17A / J. Yue* - J. Xu - H. Li - J. Wang - N. Zheng - H. Yao - L.-S. Tam - L. Qin THU0079 ADIPONECTIN AGGRAVATES BONE EROSION BY PROMOTING OSTEOPONTIN PRODUCTION IN SYNOVIAL TISSUE OF RHEUMATOID ARTHRITIS / J. Qian* - L. Xu - X. Sun - Y. Wang - W. Xuan - Q. Zhang - P. Zhao - Q. Wu - R. Liu - N. Che - F. Wang - W. Tan - M. Zhang 14 June 2018 * Presenting author

56 54 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0080 SERUM IRISIN AND MYOSTATIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. M. D. S. Silva - R. C. D. E. Santo - E. C. Freitas - N. F. T. Braz - É. L. M. Vieira - M. F. B. D. R. Guimarães - A. C. S. E. Silva - A. M. Kakehasi - R. M. Xavier* THU0081 IDENTIFICATION OF NOVEL AUTOANTIBODIES IN THE SYNOVIAL FLUID FROM PATIENTS WITH RHEUMATOID ARTHRITIS / K.-I. Goto* - T. Kawamoto - A. Nakajima - M. Tahara - T. Ebata THU0082 IMPAIRED LEFT VENTRICULAR RELAXATION AND ITS ASSOCIATION WITH INFLAMMATORY MARKERS IN COLLAGEN-INDUCED ARTHRITIS / L. Mokotedi* - F. S. Michel - C. Mogane - P. H. Dessein - A. M. Millen THU0083 CD30 APTAMER-SLAT-SHRNA CHIMERAS INHIBIT TH17 DIFFERENTIATION BY RORΓT IN RHEUMATOID ARTHRITIS / L. Hui* - G.-D. Zhang - B.-B. Cui - H.-H. Tang - L.-J. Xue - Y. Liu - C.-Q. Chu THU0084 HISTONE DEACETYLASE 1 (HDAC1): A NOVEL THERAPEUTIC TARGET IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Göschl* - L. Mueller - V. Saferding - S. Knapp - J. Backlund - C. Scheinecker - J. Smolen - W. Ellmeier - G. Steiner - M. Bonelli THU0085 CR6086, A NOVEL EP4 ANTAGONIST WITH IMMUNOMODULATORY PROPERTIES, DECREASES BONE LOSS IN THE RAT COLLAGEN-INDUCED ARTHRITIS (CIA) MODEL: A MICROTOMOGRAPHY (MICROCT) STUDY / M. Lanza* - G. Caselli - F. Ferrari - A. Grotti - R. Cavagnoli - M. Perrella - F. Daubine - V. Ayer - L. C. Rovati THU0086 INTERLEUKIN 17 RECEPTOR D (IL-17RD) REDUCES INCIDENCE OF COLLAGEN INDUCED ARTHRITIS / M. Molendijk* - A. M. Mus - P. S. Asmawidjaja - D. Baeten - E. Lubberts THU0087 MICRORNA P IN SERUM EXOSOME IS ASSOCIATED WITH DISEASE ACTIVITY OF RHEUMATOID ARTHRITIS IN KOREA / M.-K. Lim* - J. Song - S. A. Kim - J. Yoo THU0088 MONOCYTE DOWNREGULATION OF MITOCHONDRIAL TRANSLOCATOR PROTEIN MAY BE A CONTRIBUTORY MECHANISM TO INFLAMMATION IN RA / N. Narayan* - H. Mandhair - T. Sekine - A. Sabokbar - P. C. Taylor THU0089 IL-17A+GM-CSF+ NEUTROPHILS ARE THE MAJOR INFILTRATING CELLS IN INTERSTITIAL LUNG DISEASE IN AN AUTOIMMUNE ARTHRITIS MODEL / O. C. Kwon* - E.-J. Lee - E.-J. Chang - W. J. Seo - J. S. Oh - S. Hong - C.-K. Lee - B. Yoo - Y.-G. Kim THU0090 PREVALENCE AND CLINICAL PHENOTYPE OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN PALINDROMIC RHEUMATISM / R. Castellanos-Moreira* - S. Cabrera-Villalba - M. José Gomara - V. Ruiz-Esquide - G. Salvador - S. D. C. Rodriguez-Garcia - O. Camacho - J. Ramírez - M. V. Hernández - A. Cuervo - J. A. Gómez-Puerta - J. D. Cañete - I. Haro - R. Sanmarti THU0091 TIE2 INDUCES AN INFLAMMATORY PHENOTYPE IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS DRIVEN BY ANGIOPOIETIN-2 / S. García Pérez* - P. A. Kabala - B. Malvar Fernández - M. W. Tang - S. A. Hartgring - C. Conde - M. Sleeman - D. L. Baeten - P. P. Tak - J. Connor - K. A. Reedquist - T. R. Radstake THU0092 INTRA-CYTOPLASMIC CYTOKINES IN CD20 POSITIVE LYMPHOCYTE SUBPOPULATIONS IN RHEUMATOID ARTHRITIS (RA) PATIENTS / S. Aamar* - A. Kerpel - R. Rabinowitz - P. Levy - O. Zelig - N. Schlesinger - M. Schlesinger THU0093 NADPH OXIDASES ASSOCIATED PRODUCTION OF REACTIVE OXYGEN SPECIES IN RHEUMATOID ARTHRITIS / S.-J. Yoo* - S. W. Kang - J. Kim - I. S. Yoo - C. K. Park THU0094 ROLE OF SPHINGOSINE-1-PHOSPHATE RECEPTOR 3 SIGNALING IN COLLAGEN-INDUCED ARTHRITIS / T. Inoue* - H. Nagahara - S. Kaneshita - T. Kida - Y. Kukida - K. Fujioka - M. Wada - M. Kohno - Y. Kawahito THU0095 DIFFERENTIAL COMPLEMENT ACTIVATION IN RHEUMATOID ARTHRITIS PATIENTS / T. C. R. Mcdonnell* - C. Bradford - D. Raj - C. Ciurtin - E. C. Jury - J. J. Manson THU0096 A MAPK ACTIVATED KINASE 2 INHIBITOR ATTENUATES INFLAMMATORY AND DESTRUCTIVE ARTHRITIS IN HUMAN EX VIVO MODELS / T. W. Kragstrup* - A. Mellemkjær - M. Nielsen - L. Heftdal - P. Schafer - B. Deleuran THU0097 PHOSPHODIESTERASES 4 (PDE4) INHIBITOR AMELIORATES EXPERIMENTAL ARTHRITIS / W. Chen* - Z. Xu - H. Wee - G. S. Lewis - N. Olsen - J. Lin - S. G. Zheng THU0098 COMBINATION THERAPY OF RAPAMYCIN AND A GLUTAMINE ANTAGONIST FACILITATES THE EXPANSION OF MYELOID-DERIVED SUPPRESSOR CELLS AND AMELIORATES ARTHRITIS IN SKG MICE / Y. Ueda* - J. Saegusa - T. Okano - S. Sendo - H. Yamada - Y. Ichise - I. Naka - S. Takahashi - K. Akashi - A. Onishi - A. Morinobu THU0099 MYELOID SIRTUIN 6 DEFICIENCY ACCELERATES EXPERIMENTAL AND HUMAN ARTHRITIS BY INCREASING MACROPHAGE INFILTRATION INTO SYNOVIUM / Y. S. Suh* - Y.-H. Cheon - M. Y. Kim - S. J. Woo - H. S. Noh - B.-H. Park - S.-I. Lee TOPIC: RHEUMATOID ARTHRITIS - PROGNOSIS, PREDICTORS AND OUTCOME THU0100 WORK IMPAIRMENT IN RHEUMATOID ARTHRITIS IS HIGHLY CORRELATED WITH DEPRESSION / A. D. Houssien* - J. Galloway THU0101 TISSUE METABOLITE OF TYPE I COLLAGEN, C1M, AND CRP PREDICTS STRUCTURAL PROGRESSION OF RHEUMATOID ARTHRITIS / A. C. Bay-Jensen* - A. Platt - M. Jenkins - M. Weinblatt - I. Byrjalsen - K. Musa - M. C. Genovese - M. A. Karsdal THU0102 HIGH RATES OF RESIDUAL DISEASE ACTIVITY DESPITE CURRENT THERAPIES IN A REAL LIFE RHEUMATOID ARTHRITIS COHORT: DATA FROM 1096 PATIENTS / K. Thomas - A. Lazarini* - E. Kaltsonoudis - A. Drosos - P. Tsatsani - S. Gazi - L. Pantazi - K. A. Boki - P. Katsimbri - D. Boumpas - K. Fragkiadaki - M. Tektonidou - P. P. Sfikakis - K. Karagianni - L. Sakkas - E. Grika - P. Vlachoyiannopoulos - G. Evangelatos - A. Iliopoulos - T. Dimitroulas - A. Garyfallos - K. Melissaropoulos - P. Georgiou - M. Areti - C. Georganas - P. Vounotrypidis - G. Kitas - D. Vassilopoulos on behalf of Greek Rheumatology Society RA study group THU0103 EVALUATION OF SERUM Β-2 MICROGLOBULIN LEVELS AND ITS RELATIONSHIP WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / A. B. Kelesoglu Dincer - M. Torgutalp - E. G. Aydemir Gülöksüz - M. E. yayla - E. Uslu Yurteri - I. E. Okatan - S. Sezer - G. Kinikli - T. M. Turgay - A. Ateş* THU0104 THE TEMPORAL PROFILE OF ANTIBODIES DIRECTED AGAINST POST-TRANSLATIONAL MODIFICATIONS VARIES ACCORDING TO ISOTYPE AND TARGET IN PATIENTS WITH NEW-ONSET RHEUMATOID ARTHRITIS / B. Dyke* - M. Juarez - H. Bang - C. D. Buckley - A. Filer - K. Raza * Presenting author

57 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 55 THU0105 RELATIONSHIP BETWEEN DAS28 CATEGORIES AND RAID PATIENT REPORTED OUTCOME IN RHEUMATOID ARTHRITIS; SIGNIFICANT ADVANTAGE OF TARGETING DAS REMISSION / C. Smith* - M. Sharif - A. A. Prideaux - P. D. Kiely THU0106 CONVERTING PATIENT-REPORTED OUTCOME MEASURES OF FATIGUE AND PAIN TO PROMIS SCORES: DATA FROM PHASE 3 BARICITINIB RHEUMATOID ARTHRITIS TRIALS / C. O. Bingham III* - C. Gaich - A. M. DeLozier - A. Quebe - L. Sun - S. Otawa - J. Pope THU0107 EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANTI-TNF-ALPHA THERAPY / D. Anghel* - L. Panturu - V. C. Jurcut - M. M. Muresan - E. L. Dilirici - M. M. Negru - R. A. Bursuc THU0108 PATIENT REPORTED OUTCOME MEASURES FOLLOWING KNEE AND HIP REPLACEMENT FOR INDIVIDUALS WITH RHEUMATOID ARTHRITIS: EVIDENCE FROM ROUTINELY-COLLECTED DATA / E. Burn* - N. K. Arden - C. J. Edwards - C. Cooper - D. Murray - R. Pinedo-Villanueva - D. Prieto-Alhambra THU0109 AUTOANTIBODY PROFILING FOR RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND NO OR LIMITED EXPOSURE TO METHOTREXATE / L. Martinez Gamboa - H. Bang - M. Issa - S. Zuckerman - A. Cardoso - T. Holzkaemper - F. De Leonardis - I. de la Torre - Y. Tanaka - E. Feist* THU0110 EARLY TREATMENT AND LOW DOSE CORTICOSTEROIDS MIGHT DECREASE MORTALITY IN EARLY ARTHRITIS: RESULTS FROM THE RECORD LINKAGE OF CLINICAL AND ADMINISTRATIVE DATABASES / G. Sakellariou* - C. A. Scirè - F. Rumi - G. Carrara - C. Cerra - S. Migliazza - R. Caporali - C. Montecucco THU0111 FREQUENCY AND PREDICTORS OF SUSTAINED REMISSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS / G. Zanframundo* - S. Bugatti - A. Manzo - F. Benaglio - G. Sakellariou - C. Montecucco - R. Caporali THU0112 THE INFLUENCE OF AGE AND SEX ON THE PROGRESSION OF RHEUMATOID ARTHRITIS / I. Gjertsson* - J. Nilsson - M. Andersson - M. Leu Agelii on behalf of BARFOT study group THU0113 LINKING SYSTEMIC ANGIOGENIC MARKERS TO SYNOVIAL VASCULARIZATION IN RHEUMATOID ARTHRITIS / A. Leblond - S. Pezet - A. P. Trouvin - M. Elhai - V. Gonzalez - Y. Allanore - J. Avouac* THU0114 INFLUENCE OF AUTOANTIBODY STATUS IN TIME TO INITIATE DMARDS IN PATIENTS WITH EARLY RHEUMATOID ARTRHITIS / J. Molina Collada* - M. G. González Álvarez - V. Navarro-Compán - L. Nuño Nuño - D. Peiteado - A. Villalba - P. Bogas - A. Balsa THU0115 PSYCHOLOGICAL AND FUNCTIONAL STATES PREDICT DISEASE FLARE FOLLOWING TNF INHIBITOR TAPERING IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF DATA FROM THE OPTIMISING TNF TAPERING IN RA (OPTTIRA) COHORT / K. Bechman* - F. E. Sin - F. Ibrahim - S. Norton - D. Scott - A. Cope - J. Galloway THU0116 LIPID PROFILE AND CARDIOVASCULAR RISK IN SUBJECTS AT RISK FOR DEVELOPING RHEUMATOID ARTHRITIS / L. van Boheemen* - M. van Beers - Tas - D. van Schaardenburg - M. T. Nurmohamed THU0117 CHEMOKINE CCL18 ENRICHED IN SYNOVIAL FLUID IS INVOLVED IN JOINT DESTRUCTION THROUGH PROMOTING MIGRATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS / Y.-Q. Mo - G.-C. Zhang - J. Jing - J.-D. Ma - L. Dai* THU0118 PATIENT-AND PHYSICIAN-REPORTED BARRIERS TO ACHIEVING RHEUMATOID ARTHRITIS (RA) DISEASE CONTROL / M. I. Danila* - L. Chen - R. O Beirne - E. M. Ruderman - L. R. Harrold - J. A. Melnick - M. M. Safford - J. M. Kremer - J. R. Curtis THU0119 SMOKING IS NEGATIVELY ASSOCIATED WITH CLINICAL RESPONSE TO CONCOMITANT PREDNISONE USE IN EARLY RHEUMATOID ARTHRITIS / M. Safy* - M. De Hair - P. Welsing - J. Van Laar - J. Jacobs THU0120 VITAMIN D IN INDIVIDUALS BEFORE ONSET OF RHEUMATOID ARTHRITIS - RELATION TO VITAMIN D BINDING PROTEIN AND ITS ASSOCIATED GENETIC VARIANTS / M. Brink* - L. Johansson - E. Nygren - L. Ärlestig - J. Hultdin - S. Rantapää-Dahlqvist THU0121 MORTALITY RATE AND PREVALENCE OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS: 5-YEAR KARRA PROSPECTIVE STUDY / N. R. Kim* - J. W. Kang - J. S. Eun - J. H. Kim - J. Y. Kang - J. S. Seo - G. B. Bae - S. J. Lee - E. J. Nam - Y. M. Kang THU0122 IMAGING CHARACTERISATION OF REMISSION IN RHEUMATOID ARTHRITIS / N. Purkayastha* - W. S. Tan - A. Mahto - M. Lewis - G. Lliso - A. Nerviani - V. Rocher - F. Humby - C. Pitzalis - S. Kelly THU0123 MEDICATION ADHERENCE AND COST-RELATED MEDICATION NON-ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, A MIXED METHOD STUDY IN IRAN / P. Heidari* - W. Cross - M. Nazarinia - K. Crawford THU0124 LOW INFLAMMATION ON MAGNETIC RESONANCE IMAGING IN PATIENTS WITH RHEUMATOID ARTHRITIS THAT ACHIEVED SUSTAINED CLINICAL REMISSION ON ADALIMUMAB: DATA FROM THE PREDICTRA STUDY / P. Emery* - G. Burmester - E. Naredo - I. Lagunes - Y. Zhang - X. Wang - M. Hojnik - P. G. Conaghan THU0125 PREVENTION OF THE PROGRESSIVE BIOCHEMICAL CARTILAGE DESTRUCTION UNDER METHOTREXATE THERAPY IN EARLY RHEUMATOID ARTHRITIS / P. Sewerin* - A. Müller-Lutz - S. Odendahl - M. Eichner - M. Schneider - B. Ostendorf - C. Schleich THU0126 IMPACT OF RESIDENTIAL AREA ON THE PROFILE OF RHEUMATOID ARTHRITIS PATIENTS INITIATING THEIR FIRST BIOLOGIC DMARD: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / R. Joshi* - M. Movahedi - E. Rampakakis - C. Thorne - A. Cesta - J. S. Sampalis - C. Bombardier on behalf of other OBRI Investigators THU0127 THE SEVERITY OF KERATOCONJUNCTIVITIS SICCA IN RHEUMATOID ARTHRITIS CORRELATES WITH THE MEDICAL OUTCOME STUDY 36-ITEM SHORT FORM HEALTH SURVEY (SF-36) SCORE BUT NOT THE DISABILITY INDEX (HAQ-DI) / R. O. Akintayo* - B. H. Olaosebikan THU0128 DO BIOLOGICAL DMARDS PREVENT LONG-TERM ARTICULAR DAMAGE BY RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL CARE? / S. Baghban* - L. Krens - M. Henstra - M. Vermeer - K. van der Elst - H. Bernelot Moens THU0129 PREDICTIVE VALUE OF CD19 SERUM LEVELS FOR LONG-TERM THERAPEUTIC RESPONSE AND UTILITY AS BIOMARKER FOR OPTIMIZATION, IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB / S. Melchor* - E. Rodríguez - J. L. Pablos - P. E. Carreira THU0130 EXPLORING THE MINIMUM PAIRED JOINT SET OF ULTRASONOGRAPHY TO PREDICT CLINICALLY SIGNIFICANT RESIDUAL SYNOVITIS IN RHEUMATOID ARTHRITIS PATIENTS WITH REMISSION / T. Wibowo* - S. Kawada - Y. Ishida - Y. Yoshimine - Y. Manabe - K. Kawamoto - H. Nakahara - S. Higa - K. Maeda - A. Ogata 14 June 2018 * Presenting author

58 56 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0131 THU0132 THU0134 LEVELS OF CXCL13 AND SICAM1 CORRELATE WITH DISEASE ACTIVITY SCORE IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ) / T. Sornasse* - C. Gabay - M. Townsend - R. Laubender - J. Wang - K. Tuckwell THE PATIENT GLOBAL ASSESSMENT RATING VARIES MINIMALLY IF USING ARTHRITIS OR GLOBAL HEALTH CONDITION AND AGREEMENT IS HIGH BETWEEN COMMON COMPOSITE DISEASE ACTIVITY MEASURES AND REMISSION CLASSIFICATION USING EITHER: RESULTS FROM A NATIONAL EARLY RA COHORT STUDY / V. P. Bykerk* - O. Schieir - M.-F. Valois - E. C. Keystone - G. Boire - J. E. Pope - D. Tin - B. Haraoui - C. Hitchon - C. Thorne - S. J. Bartlett on behalf of CATCH Investigators ULTRASOUND DETECTED TENOSYNOVITIS PREDICTS ARTHRITIS ONSET IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS / Y. Kisten* - H. Rezaei - E. af Klint - G. Fei - A. Antovic - A. H. Hensvold - A. I. Catrina TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS Poster tour T4: Abstracts N : RA: not just about the joints! Elena Nikiphorou (United Kingdom), Jacob M. van Laar (Netherlands) THU0135-THU0144 THU0135 USING FRAX AND PERIPHERAL BONE MINERAL DENSITY FOR IDENTIFYING POTENTIAL CANDIDATES FOR OSTEOPOROSIS THERAPY AMONG RHEUMATOID ARTHRITIS PATIENTS / O. Nikitinskaya* - N. Toroptsova THU0136 MAJOR CARDIOVASCULAR EVENTS IN 434 RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB FROM A SINGLE-CENTRE / A. Giollo* - S. Gandrala - T. Vojinovic - A. Burska - M. Y. Md Yusof - E. M. Vital - E. M. A. Hensor - M. H. Buch THU0137 RHEUMATOID ARTHRITIS AS AN EMERGENCY DEPARTMENT RISK FACTOR FOR ACUTE CORONARY SYNDROME / M. Bergström* - J. Askling - A. Discacciati - M. Frick - T. Jernberg - R. Linder - L. Ljung - P. Svensson THU0138 OCCURRENCE OF IN-STENT RESTENOSIS AFTER CORONARY DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / O. C. Kwon* - W. J. Seo - J. S. Oh - S. Hong - C.-K. Lee - B. Yoo - Y.-G. Kim THU0139 INCREASED HOMOCYSTEINE LEVEL FOR 7 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: TOMORROW STUDY / K. Inui* - T. Koike - Y. Sugioka - T. Okano - K. Mamoto - Y. Yamada - K. Mandai - M. Tada - H. Nakamura THU0140 EFFECTS OF STATIN-TREATMENT ON CORONARY PLAQUES IN PATIENTS WITH INFLAMMATORY JOINT DISEASES / M. Svanteson* - S. Rollefstad - N. E. Kløw - E. Ikdahl - J. Sexton - Y. Haig - A. G. Semb THU0141 LONG-TERM EFFECTS ON BONE MINERAL DENSITY AFTER FOUR YEARS OF TREATMENT WITH TWO INTENSIVE COMBINATION STRATEGIES, INCLUDING INITIALLY HIGH DOSE PREDNISOLONE, IN EARLY RHEUMATOID ARTHRITIS PATIENTS: THE COBRA-LIGHT TRIAL / M. J. Lucassen* - M. M. ter Wee - D. den Uyl - N. P. Konijn - M. T. Nurmohamed - D. van Schaardenburg - P. J. Kerstens - I. E. Bultink - L. H. Van Tuyl - M. Boers - W. F. Lems THU0142 THE PROGNOSIS OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Meissner* - M. Schäfer - B. Manger - M. Zänker - W. Ochs - J. Listing - A. Strangfeld THU0143 VASCULAR WALL INFLAMATION IN RHEUMATOID ARTHRITIS PATIENTS DECREASES AFTER 6 MONTHS OF ANTI-INFLAMMATORY THERAPY WITH METHOTREXATE OR ADALIMUMAB AS MEASURED BY 18F-FDG-PET/CT / A. Blanken* - R. Agca - A. Voskuijl - R. Boellaard - C. van der Laken - M. Nurmohamed THU0144 PERFORMANCE OF THE ERS-RA CARDIOVASCULAR RISK PREDICTION TOOL: EXTERNAL VALIDATION IN A LARGE SWEDISH COHORT WITH RA / L. Ljung* - P. Ueda - K. P. Liao - J. D. Greenberg - C. J. Etzel - D. H. Solomon - J. Askling THU0145 CHANGES IN BONE METABOLISM AND TRABECULAR BONE SCORE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / A. Corrado* - A. Mele - E. Sanpaolo - A. Trotta - R. Colia - F. P. Cantatore THU0146 GLYCEMIC PROFILE AND INSULIN RESISTANCE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / A. M. Brandy-García* - A. Lorenzo Martín - S. Alonso Castro - M. Alperi López - F. J. Ballina García THU0147 TREATMENT RESPONSE IN ANTIDEPRESSANTS-TREATED RA PATIENTS WITH DEPRESSIVE AND ANXIETY DISORDERS RECEIVING DMARDS AND BIOLOGICS ON A FIVE-YEAR FOLLOW-UP / A. Abramkin* - T. Lisitsyna - D. Veltishchev - O. Seravina - O. Kovalevskaya - E. Nasonov THU0148 SCREENING SYSTEM FOR EARLY ARTHRITIS WITH HEALTH PROFESSIONAL ASSISTANTS - A PROJECT OF THE T2T INITIATIVE IN GERMANY / C. Jacobsen* - V. Höhne-Zimmer - T. Braun - V. Köhler - T. Leipold - B. Tenckhoff - K. Karberg - G. R. Burmester - J. Detert THU0149 TRENDS IN THE INCIDENCE OF INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN: AN OBSERVATIONAL COHORT STUDY OF HOSPITAL DISCHARGES FROM 1999 TO 2015 (TREND-AR STUDY) / C. Martinez-Prada* - R. Mazzuccheli - I. Morado - E. Perez-Fernández - J. Quirós - J. L. Morell-Hita - M. Peña - N. Crespi - C. Barbadillo - H. Godoy - M. Fernández-Prada - M. Galindo - O. Guzón-Illescas - A. Herranz - V. Villaverde - A. García-Vadillo THU0150 IMPACT OF COMORBIDITY BURDEN AND OBESITY ON THE EFFECTIVENESS OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS / D. Pappas* - C. Etzel - M. Crabtree - J. Best - S. Zlotnick - J. Kremer THU0151 ASSESSMENT OF COMPLIANCE OF RHEUMATOID ARTHRITIS PATIENTS IN COGNITIVE DYSFUNCTION / E. Grunina* - A. Tkachev THU0152 SERUM PRESEPSIN AS A NOVEL BIOMARKER FOR BACTERIAL INFECTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB / E. Oguro* - S. Tsuji - K. Kuzuya - Y. Okita - H. Matsuoka - S. Teshigawara - M. Yoshimura - Y. Harada - M. Matsushita - S. Ohshima - J. Hashimoto - Y. Saeki THU0153 THE EFFECT OF 5-YEARS B-DMARDS TREATMENT ON DIFFERENT 10-YEARS CARDIOVASCULAR RISK SCORES APPLIED IN RHEUMATOID ARTHRITIS PATIENTS / F. Cacciapaglia* - M. Fornaro - D. Renna - F. Cafarelli - G. Lopalco - M. G. Anelli - C. Scioscia - G. Lapadula - F. Iannone * Presenting author

59 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 57 THU0154 A PROGRAM FOR SCREENING AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH CHRONIC ARTHRITIS: 2-YEAR RESULTS / G. Albert-Espi - N. Martinez-Alberola - R. Martin-Domenech - C. Fernandez-Carballido - T. Pedraz-Penalva - F. Sivera* THU0155 CUSTOMIZED CONSTRUCTION OF DEVICES AS INTEGRATION OF OCCUPATIONAL THERAPY INTERVENTION IN RHEUMATOLOGY BY 3D PRINTING TECHNOLOGY AND CO-DESIGN: FURTHER DEVELOPMENT AND VERIFICATION OF LONG-TERM EFFECTIVENESS / G. Sandri* - F. Gherardini - C. Anastasio - V. Bettelli - A. Bottini - M. T. Mascia THU0156 DEPRESSION AMELIORATED BY ORTHOPEDIC SURGICAL INTERVENTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / H. Ishikawa* - A. Abe - T. Kojima - M. Kojima - N. Ishiguro - S. Ito - A. Murasawa THU0157 ALTERED DNA-METHYLATION IN CHILDREN BORN TO MOTHERS WITH RHEUMATOID ARTHRITIS DURING PREGNANCY / H. Ince-Askan* - J. M. Hazes - R. J. Dolhain THU0158 INCREASED PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS IS PARTIALLY REFLECTED BY DISEASE SEVERITY AT THE TIME OF DIAGNOSIS- 11-YEAR PROSPECTIVE FOLLOW-UP / I. Björsenius* - S. Rantapää-Dahlqvist - S. Wållberg-Jonsson - A. Södergren THU0159 BARRIERS TO RHEUMATOID ARTHRITIS TREATMENT OPTIMISATION: REAL-WORLD DATA FROM THE ARTHRITISPOWER REGISTRY / J. L. Stark* - M. Yassine - W. B. Nowell - K. Gavigan - S. Ginsberg - M. S. Serna - J. R. Curtis THU0160 JUXTA-ARTICULAR BONE HEALTH AFFECTS NEW CAROTID PLAQUE FORMATION INDEPENDENT WITH GLUCOCORTICOID THERAPY IN POSTMENOPAUSAL PATIENTS WITH RHEUMATOID ARTHRITIS / J. W. Kang* - N. R. Kim - J. S. Eun - J. H. Kim - J. Y. Kang - J. S. Seo - G. B. Bae - S. J. Lee - E. J. Nam - Y. M. Kang THU0161 TRENDS IN THE INCIDENCE OF AMYLOIDOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN: AN OBSERVATIONAL COHORT STUDY OF HOSPITAL DISCHARGES FROM 1999 TO 2015 (TREND-AR STUDY) / J. L. Morell Hita* - R. Mazzucchelli - E. Perez Fernandez - J. Quiros - C. Macía Villa - N. Crespi - M. Peña - C. Barbadillo - M. Espinosa - H. Godoy - M. Fernandez Prada - M. Galindo - A. Garcia Vadillo - O. Guzon Illescas - A. Herranz - C. Martinez Prada - C. Morado Quiñoa - V. Villaverde on behalf of TREND-AR THU0162 RESIDUAL SYNOVITIS IN ANKLES AND FEET DETECTED BY ULTRASONOGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Inamo* - Y. Kaneko - K. Sakata - T. Takeuchi THU0163 EXTRA-ARTICULAR MANIFESTATIONS IN RHEUMATOID ARTHRITIS: A COMPREHENSIVE ANALYSIS IN A LARGE COHORT / K. R. Bonfiglioli* - H. Carriço - L. Mota - A. B. Vargas-Santos - C. Albuquerque - R. Giorgi - S. Radominski - I. Pereira - M. F. Guimarães - M. Bertolo - P. Louzada Jr. - M. F. Cunha - C. Brenol - G. Castelar-Pinheiro THU0164 EFFICACY OF BIOLOGIC DMARDS IN DEPRESSIVE SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. J. Ng* - K.-Y. Huang - C.-H. Tung - M.-C. Lu - N.-S. Lai THU0165 OBESITY AS ONE OF THE COMMODITIES WAS THE ROBUSTEST PREDICTION FACTORS FOR POST THERAPEUTIC CLINICAL REMISSION OF RHEUMATOID ARTHRITIS WITH SHORT DISEASE DURATION - RESULTS FROM KANSAI CONSORTIUM FOR WELL-BEING OF RHEUMATIC DISEASE PATIENTS / K. Murakami* - M. Hashimoto - K. Murata - W. Yamamoto - R. Hara - M. Katayama - A. Ohnishi - K. Akashi - S. Yoshida - K. Nagai - Y. Son - H. Amuro - T. Hirano - K. Ebina - K. Nishitani - M. Tanaka - H. Ito - K. Ohmura - T. Mimori THU0166 THE DIASTOLIC DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Feiskhanova* THU0167 FALLS IN RHEUMATOID ARTHRITIS (RA) AND ITS RELATION TO DISEASE ACTIVITY, DISABILITY AND PHYSICAL PERFORMANCE TESTS / J. Z. Gaino* - M. B. Bertolo - C. S. Nunes - C. M. Barbosa - Z. Sachetto - M. Davitt - E. D. P. Magalhães THU0168 RELATIONSHIPS BETWEEN BODY FAT COMPOSITION ASSESSED WITH BIOELECTRICAL IMPEDANCE ANALYSIS, SERUM ADIPOKINES AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. G. Anelli* - V. Venerito - G. Lopalco - F. Cacciapaglia - C. Scioscia - M. Giannotta - G. Righetti - F. Montini - D. Natuzzi - R. Bizzoca - N. Lacarpia - R. Fanizzi - G. Lapadula - F. Iannone THU0169 RELATIONSHIP OF FRAILTY AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE CHIKARA STUDY / M. Tada* - Y. Yamada - K. Mandai - N. Hidaka THU0170 RISK FACTOR FOR SERIOUS PULMONARY COMPLICATION IN PATIENTS WITH PRE-EXISTING LUNG DISEASE IN RHEUMATOID ARTHRITIS / N. Sugitani* - T. Gono - S. Watanabe - E. Watanabe - H. Yabe - C. Terai THU0171 IDENTIFICATION OF METHOTREXATE-INDUCED PULMONARY TOXICITY CASES IN A FULLY SEARCHABLE ROUTINE CLINICAL DATABASE / N. Hasler* - S. Irani - P. Schütz - P. Hasler THU0172 SLEEP QUALITY IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS SHOULD BE KEPT IN MIND / O. Deniz* - H. Satis - C. Cavusoglu - R. B. Salman - O. Varan - N. Atas - S. Coteli - R. T. Dogrul - H. Babaoglu - A. Oncul - H. D. Varan - M. C. Kizilarslanoglu - A. Tufan - B. Goker THU0173 TRENDS IN HIP FRACTURE INCIDENCE IN RHEUMATOID ARTHRITIS: A NATIONAL OBSERVATINAL COHORT STUDY / R. Mazzucchelli* - E. Perez-Fernandez - N. Crespí - J. Quirós - C. Macía Villa - M. Espinosa - J. L. Morell Hita - M. Peña - V. Villaverde - C. Martinez-Prada - C. Morado Quiroga - C. Barbadillo - M. Fernández-Prada - H. Godoy - M. Galindo - A. García-Vadillo - O. Guzón Illescas - A. Herranz THU0174 SEXUAL FUNCTION OF WOMEN WITH RHEUMATOID ARTHRITIS IN COMPARISON WITH HEALTHY VOLUNTEERS / A. Fazaa - R. Ben Saad* - K. ouennich - S. Miladi - S. kassab - C. salma - K. Ben Abdelghani - A. laatar THU0175 ASSESMENT OF INSULIN RESISTANCE IN A RHEUMATOID ARTHRITIS INCEPTION COHORT: NESTED CASE-CONTROL STUDY / S. Manrique-Arija* - N. Mena-Vázquez - I. Ureña-Garnica - S. Abad-Sanchez - L. Ginel - C. Fuego-Varela - M. Rojas-Gimenez - L. Cano-Garcia - F. G. Jimenez-Nuñez - G. Diaz-Cordoves - M. C. Ordoñez-Cañizares - C. M. Romero-Barco - R. Caparrós - M. V. Irigoyen - A. Fernandez-Nebro THU0176 THE EFFECT OF METHOTREXATE ON GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Asai* - K. Nagai - T. Kojima - N. Takahashi - N. Ishiguro THU0177 CAN SIMPLE EDUCATIONAL FLASHCARDS CHANGE ATTITUDES TO VACCINATION IN AN UNDER-VACCINATED RHEUMATOID ARTHRITIS COHORT? / S. Raghunath* - T. Kovitwanichkanont - D. Wang - N. Walpola - L. Kyi - S. Pignataro - S. Morton - E. Thompson - M. Leech THU0178 CLINICAL SIGNIFICANCE OF PERIODONTITIS IN RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATION WITH DISEASE ACTIVITY, FUNCTIONAL STATUS AND RADIOLOGRAPHIC SCORE / T. A. Gheita* - H. M. Fathi - N. Khairy - W. A. El-Battawy 14 June 2018 * Presenting author

60 58 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 THU0179 MIR-382-5P TARGETING IL-33 GENE AS BIOMARKER TO PREDICT SUBCLINICAL ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / T. H. Cheng* - Q. Shang - E. K. M. Li - M. Li - W. Y. Mak - K. Y. Kwok - I. C. W. Yim - P. C. H. Wong - V. W. N. Lao - S. H. T. Pang - E. W. L. Kun - L. S. Tam THU0180 SHOULD WE INCLUDE ULTRASOUND IN THE 1987 ACR AND 2010 ACR/EULAR CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS? / W. Hamdi* - M. Sellami - H. Riahi - K. Maatallah - D. Kaffel - M. Chelli-Bouaziz - M. F. Ladeb - M. M. Kchir THU0181 GLUCOCORTICOID USE IS AN INDEPENDENT RISK FACTOR FOR SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS - FROM THE CHIKARA STUDY - / Y. Yamada* - M. Tada - K. Mandai - N. Hidaka - K. Inui - H. Nakamura 14 June 2018 TOPIC: RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS Poster tour T5: Anti-TNF: old drugs now but still full of promises Xavier Mariette (France), Diane van der Woude (Netherlands) Abstracts N : THU0182-THU0191 THU0182 A COMPARATIVE CLINICAL STUDY OF PF , A CANDIDATE ADALIMUMAB BIOSIMILAR, AND REFERENCE ADALIMUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS / R. Alten* - R. M. Fleischmann - M. Pileckyte - S. Y. Hua - C. Cronenberger - A. E. Bock - K. L. Sewell THU0183 LESS PAIN OVER 2 YEARS WITH BIOLOGICAL COMPARED TO CONVENTIONAL COMBINATION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED CONTROLLED SWEFOT TRIAL / T. Olofsson - J. K. Wallman - A. Jöud - M. E. Schelin - S. Ernestam - R. van Vollenhoven - S. Saevarsdottir - J. Lampa* THU0184 IMPACT OF IMMUNOGENICITY ON CLINICAL EFFICACY AND ADMINISTRATION RELATED REACTION IN TNF INHIBITORS: A POOLED-ANALYSIS FROM THREE BIOSIMILAR STUDIES IN PATIENTS WITH RHEUMATOID ARTHRITIS / P. Emery* - M. Weinblatt - J. S. Smolen - E. Keystone - M. Genovese - J. Vencovsky - J. Kay - E. Hong - Y. Baek - J. Ghil THU0185 THE VALUE OF ADALIMUMAB TROUGH LEVELS AND CLINICAL ASSESSMENTS IN PREDICTING CLINICAL RESPONSE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE / J. Smolen* - N. Mostafa - X. Huang - P. Noertersheuser - B. Kluender - K. Chen - J. Kalabic - I. Sainsbury - R. Oerlemans - S. Florentinus - G. Burmester THU0186 RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE. MULTICENTRIC RETROSPECTIVE STUDY OF 118 PATIENTS TREATED WITH BIOLOGICAL NO ANTI-TNF / C. Fernández-Díaz* - S. Castañeda - B. Garcia-Magallon - J. Narvaez-García - M. Retuerto - T. Perez-Sandoval - M. Martin-Lopez - P. Rubio-muñoz - M. Carrasco-Cubero - D. Reina-Sainz - A. Urruticoechea - C. Ojeda-Garcia - S. Rodriguez-Muguruza - P. Carreira - L. Belmar-Vega - E. Cervantes - B. Robles-flores - L. Arboleya - G. Bonilla - I. Hernandez-Rodriguez - O. Maiz-Alonso - D. Palma - C. Delgado - R. Expósito-Molinero - F. Ortiz-Sanjuan - A. Ruibal-Escribano - S. Ordoñez - M. Moreno - I. Villa blanco - C. Fito - J. Blanco-Madrigal - J. Bernal - S. Romero - N. Mena-Vazquez - M. Lopez-corbeto - T. J. Mas - T. R. Vazqzez - M. A. Gonzalez-Gay - R. Blanco THU0187 CIRCULATING AUTOANTIBODIES AS INDICATORS TO PREDICT THE CLINICAL RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS / L. Lourido* - C. Ruiz-Romero - F. Picchi - E. Pérez-Pampín - C. Regueiro - A. Mera-Varela - A. Gonzalez - K. Hambardzumyan - S. Saevarsdottir - P. Nilsson - F. J. Blanco THU0188 EFFICACY OF INFLIXIMAB FOR SUPPRESSING RADIOGRAPHIC PROGRESSION OF CERVICAL LESIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARISON WITH METHOTREXATE; THREE YEARS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - T. Kojima - Y. Hirano - N. Takahashi - N. Ishiguro on behalf of TBCR study group THU0189 ONE-YEAR TREATMENT RETENTION AFTER A NATIONWIDE NON-MEDICAL SWITCH FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT IN 2,061 PATIENTS WITH INFLAMMATORY ARTHRITIS FOLLOWED IN THE DANBIO REGISTRY / B. Glintborg* - I. J. Sørensen - E. Omerovic - F. Mehnert - N. Manilo - K. Danebod - D. V. Jensen - H. Nordin - A. G. Loft - O. Hendricks - S. Chrysidis - B. L. Andersen - J. L. Raun - H. Lindegaard - J. Espesen - S. H. Jakobsen - I. M. J. Hansen - E. B. Dalsgaard - D. D. Pedersen - S. Kristensen - A. Linauskas - L. S. Andersen - J. Grydehøj - N. Krogh - M. L. Hetland THU0190 CLINICAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS RECEIVING ADALIMUMAB WHO DID OR DID NOT PARTICIPATE IN THE PATIENT SUPPORT PROGRAM: A SUBANALYSIS OF THE PASSION STUDY / A. Ostor* - S. Wassenberg - P. Zueger - J. Kalabic - M. Wu - I. Lagunes Galindo - F. van den Bosch THU0191 NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: INITIAL RESULTS FROM A PHASE I/III RANDOMISED CONTROLLED TRIAL / R. Westhovens* - D. H. Yoo - J. Jaworski - E. Matyska-Piekarska - S. Smiyan - D. Ivanova - A. Zielinska - E.-K. Raussi - A. Batalov - S. J. Lee - S. Y. Lee - J. H. Suh THU0192 RETENTION RATES FOR ETANERCEPT: COMPARING THE ORIGINAL WITH A BIOSIMILAR / A. Strangfeld* - L. Baganz - P. Herzer - J. Braun - A. Gräßler - A. Zink THU0193 EFFICACY AND SAFETY OF BCD-055 (INFLIXIMAB BIOSIMILAR) IN RHEUMATOID ARTHRITIS. RESULTS OF BCD /LIRA PHASE 3 CLINICAL STUDY / A. Lila* - L. Denisov - T. Plaksina - S. Smakotina - E. Kunder - N. Soroka - A. Kastanayan - O. Nesmeyanova - O. Antipova - E. Ilivanova - A. Eremeeva - E. Dokukina - E. Chernyaeva - R. Ivanov THU0194 CD4+ T CELLS, IMMUNOGLOBULINS AND RISK OF INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS OVER MULTIPLE CYCLES OF RITUXIMAB / F. Martins - A. Bensalem* - T. Bejan-Angoulvant - A. Lhommas - J. Mélet - S. Mammou - G. Thibault - L. Bernard - P. Goupille - D. Mulleman THU0195 PREVALENCE OF OCCULT HEPATITIS B CARRIER STATUS AND ITS ASSOCIATED FACTORS IN PATIENTS WITH RHEUMATIC DISEASES UNDERGOING BIOLOGICAL THERAPIES / C. C. Mok* - L. Y. Ho - K. L. Chan - S. M. Tse - C. H. To * Presenting author

61 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 59 THU0196 DO CONTEXTUAL FACTORS INFLUENCE SURVIVAL ON DRUG OF BIOSIMILARS IN CLINICAL PRACTICE? / D. Di Giuseppe* - T. Frisell - E. Lindqvist - L. Jacobsson - C. Turesson - C. Sjöwall - J. Askling on behalf of ARTIS group THU0197 EFFECTS OF TOCILIZUMAB, AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, ON SERUM LIPID AND ADIPOKINE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Hoffman - M. A. Rahat - J. Feld - M. Elias - I. Rosner - L. Kaly - I. Lavi - D. Zisman* THU0198 IMMUNOGENICITY ASSOCIATED WITH A TRANSITION FROM ADALIMUMAB REFERENCE PRODUCT TO ABP 501 IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Krishnan* - D. Mytych - N. Zhang - H. Wang - A. Kaliyaperumal THU0199 A PILOT STUDY TO ASSESS THE RELATIONSHIP BETWEEN SMOKING AND DRUG INEFFICACY IN RHEUMATOID ARTHRITIS - PART OF A QUALITY IMPROVEMENT PROJECT AIMED AT SMOKING CESSATION / G. Starritt* - D. Brennan THU0200 SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS; A HIGH NUMBER OF PATIENTS ACHIEVE DOPPLER REMISSION AFTER 24 WEEKS / H. B. Hammer* - I. M. J. Hansen - P. Jarvinen - M. Leirisalo-Repo - M. Ziegelasch - B. Agular - L. Terslev THU0201 A POOLED ANALYSIS OF THREE TNF-Α INHIBITOR BIOSIMILAR STUDIES IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING RADIOGRAPHIC PROGRESSION BY DISEASE ACTIVITY STATES / J. S. Smolen * - M. Weinblatt - P. Emery - E. Keystone - M. Genovese - G. Myung - E. Hong - I. Baek - S. Lee - J. Ghil THU0202 COMPARATIVE EFFECTIVENESS OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS IN COMBINATION WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN BIO-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS / K. Lauper* - T. K. Kvien - C. Codreanu - M. V. Hernández - F. Ianonne - E. K. Kristianslund - G. Lukina - D. C. Nordström - K. Pavelka - Z. Rotar - M. J. Santos - S. L. Gale - M. John - Y. Luder - D. S. Courvoisier - C. Gabay THU0203 COMPARISON OF THE RETENTION RATE OF BIOLOGICAL DMARDS ~ THE DATA FROM PATIENTS WITH RA WHO WERE FOLLOWED UP FOR OVER 10 YEARS / K. Fukuda* - T. Matsubara - K. Funahashi - T. Itami - K. Okuda - S. Hayashi - Y. Sakai - R. Kuroda THU0204 REAL WORLD EXPERIENCE OF BIOSIMILAR SWITCHING AT THE NORFOLK & NORWICH UNIVERSITY HOSPITAL, UNITED KINGDOM / L. Steel* - T. Marshall - M. Loke THU0205 THE EFFECT OF CERTOLIZUMAB DRUG CONCENTRATION AND ANTI-DRUG ANTIBODIES ON TNF NEUTRALIZATION / L. C. Berkhout* - E. H. Vogelzang - M. H. Hart - N. I. Derksen - R. Wieringa - W. A. van Leeuwen - C. L. Krieckaert - A. de Vries - M. T. Nurmohamed - G. Wolbink - T. Rispens THU0206 ADD-ON SHORT-COURSE TOCILIZUMAB ACCELERATES DOSE TAPERING OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS: RESULTS FROM A CHINESE PROSPECTIVE COHORT STUDY / J.-W. Wang - Y.-Q. Mo - X.-Y. Wang - L.-F. Chen - J.-D. Ma - J.-Z. Lin - D.-H. Zheng - L. Dai* THU0207 FINDING THE OPTIMAL TREATMENT STRATEGY FOR DISEASE ACTIVITY-GUIDED DOSE REDUCTION OF ADALIMUMAB AND ETANERCEPT IN RHEUMATOID ARTHRITIS: A MODELLING STUDY / L. M. Verhoef* - D. P. Bos - C. H. van den Ende - F. H. van den Hoogen - B. Fautrel - M. E. Hulscher - W. Kievit - A. A. den Broeder THU0208 EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PATIENTS AFTER FAILURE TO ANTITNF OR NAÏVE PATIENTS IN REAL WORLD SETTING. ONE YEAR FOLLOW-UP EXPERIENCE / M. Fernández Prada* - V. Torrente-Segarra - R. Expósito Molinero - N. P. Garrido Puñal - A. Sánchez-Andrade Fernández - J. R. Lamúa - A. Olivé - J. V. Tovar on behalf of RENACER study group THU YEARS FOLLOW-UP OF A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN SUSTAINED CLINICAL REMISSION AND OPTIMIZATION OF BIOLOGICAL THERAPY / M. L. Ladehesa Pineda* - M. C. Castro Villegas - M. Romero Gómez - L. Bautista Aguilar - C. López Medina - L. Pérez Sánchez - I. Gómez García - P. Carreto Font - A. Escudero Contreras - E. Collantes Estévez - P. Font Ugalde THU0210 SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH CSDMARDS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE OSCAR STUDY / M. Safy* - M. J. De Hair - M. E. Borm - M. R. Kok THU0211 SIX MONTHS AFTER TREATMENT DISCONTINUATION TNF IS STILL IN COMPLEX WITH ADALIMUMAB / M. J. l Ami* - L. C. Berkhout - M. T. Nurmohamed - R. F. van Vollenhoven - M. Boers - J. Ruwaard - F. Hooijberg - T. Rispens - G. Wolbink THU0212 REINVESTMENT OF BIOSIMILAR SAVINGS: WHAT ARE THE BEST OPTIONS? / M. Martin* - R. Campbell - J. Jacob THU0213 ADHERENCE AND PERSISTENCE TO DISEASE MODIFYING ANTI RHEUMATIC DRUGS IN COLOMBIAN PATIENTS WITH RHEUMATOID ARTHRITIS / N. Pertuz-Charris* - F. L. Ochoa-Jaramillo - D. Gil-Calderón - M. A. Alzate-Vinasco - V. Vélez-Marín - D. Hernández-Parra - R. Pineda-Tamayo THU0214 PREDICTIVE FACTORS FOR ACHIEVEMENT OF LOW DISEASE ACTIVITY AT 52 WEEKS ARE DIFFERENT BETWEEN YOUNG AND ELDERLY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ABATACEPT / N. Takahashi* - T. Kojima - S. Asai - N. Ishiguro on behalf of the TBCR study group THU0215 EFFICACY OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH AND WITHOUT PREVIOUS RESPONSE TO TOCILIZUMAB / P. Verschueren* - P. Emery - H. van Hoogstraten - Q. Dong - E. K. Mangan - A. den Broeder THU0216 SERUM CXCL16 LEVELS IN RF+/ACPA+ RHEUMATOID ARTHRITIS PATIENTS BEFORE AND AFTER TREATMENT WITH DMARDS / R. Ramamoorthy* - T. N. Tamilselvam - B. Kumar THU0217 SIMILAR EFFICACY AND SAFETY OF SARILUMAB 150 MG OR 200 MG Q2W REGARDLESS OF PRIMARY (1 ) OR SECONDARY (2 ) FAILURE WITH TNF INHIBITORS / R. Fleischmann* - A. Spindler - A. Kivitz - D. Ching - E. K. Mangan - T. Kimura - M. Iglesias-Rodriguez - G. R. Burmester THU0218 THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY / S. Uslu* - G. Can - S. Senel - E. Dalkilic - N. Inanc - S. Akar - S. B. Kocaer - M. Birlik - S. Capar - N. Akkoc - F. Onen THU0219 BENEFICIAL EFFECT OF ANTI-IL-6 BLOCKADE ON INSULIN RESISTANCE AND INSULIN SENSITIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Remuzgo-Martínez* - R. López-Mejías - F. Genre - V. Mijares - J. Calvo-Alen - R. Blanco - J. Llorca - S. Castañeda - M. A. González-Gay 14 June 2018 * Presenting author

62 60 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0220 DISCONTINUATION OF BIOLOGIC DMARDS IN A REAL-LIFE POPULATION OF PATIENTS IN REMISSION: OUTCOME AND PREDICTORS / S. Arnold* - V. K. Jaeger - A. Scherer - U. A. Walker - D. Kyburz THU0221 CLINICAL OUTCOMES OF ABATACEPT VERSUS TNF INHIBITORS IN ACPA-POSITIVE PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE BIOLOGIC REGISTER KOBIO / S.-K. Lee* - S. Oh - H.-A. Kim - Y.-B. Park - S.-S. Lee - K. Shin THU0222 MULTISWITCHING - FROM REFERENCE PRODUCT ETANERCEPT TO BIOSIMILAR AND BACK AGAIN - REAL- WORLD DATA FROM A CLINIC-WIDE MULTISWITCH EXPERIENCE / V. Sigurdardottir* - A. Svärd THU0223 IMPACT OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DEPRESSIVE SYMPTOMS IN THE MONARCH PHASE 3 TRIAL OF SARILUMAB / V. Strand* - O. Hagino - S. Guillonneau - S. Boklage - M. Reaney - J. Sadeh - N. Narcisse - E. Mangan - T. Kimura THU0224 RENACER STUDY: EFFICACY AND SAFETY ASSESSMENT OF CZP THERAPY IN THE TREATMENT OF 501 PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AMONG SPANISH POPULATION IN CLINICAL PRACTICE / V. Torrente-Segarra* - M. Fernandez - R. Expósito - N. P. Garrido - A. Sanchez-Andrade - J. R. Lamua - A. Olivé - J. V. Tovar on behalf of RENACER study group THU0225 THE PROGRESSION OF LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPIES / Y. Yalçınkaya* - M. Can - S. Karakurt - N. Coşkun - E. Albayrak - H. Mursaloglu - A. Topcu - M. Demir - E. Dalkılıc - N. Inanc THU0226 SERIAL INTERFERON-GAMMA RELEASE ASSAYS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC AGENTS / Y. J. Huang* - Y. F. Fang - Y. F. Chen - P. H. Tsai - C. F. Kuo - K. H. Yu - S. F. Luo TOPIC: SPONDYLOARTHRITIS - CLINICAL ASPECTS (OTHER THAN TREATMENT) Poster tour T6: Abstracts N : Spondyloarthritis: causes, questions and consequences Robert B. M. Landewé (Netherlands), Marloes van Onna (Netherlands) THU0227-THU0236 THU0227 SPINAL FRACTURE RISK IN ANKYLOSING SPONDYLITIS IN WESTERN AUSTRALIA / M. Ognjenovic* - W. Raymond - H. Keen - C. Inderjeeth - D. Preen - J. Nossent THU0229 ABSOLUTE REDUCTION OF PERIPHERAL CD4+CD25+FOXP3+T REGULATORY CELLS IN PATIENTS WITH SPONDYLOARTHROPATHY-RELATED OCULOPATHY / X. Liu* - G. Chai - Y. Duan - C. Gao - X. Li THU0230 PERFORMANCE OF AN ONLINE SELF-REFERRAL QUESTIONNAIRE COMPARED TO A PHYSICIAN-BASED REFERRAL APPROACH TO IDENTIFY PATIENTS WITH A HIGH PROBABILITY OF AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE OPTIREF STUDY / F. Proft* - L. Spiller - M. Protopopov - M. Schmidt - V. Rios Rodriguez - B. Muche - J. Rademacher - S. Lüders - A.-K. Weber - I. Spiller - J. Sieper - D. Poddubnyy THU0231 DO DEGREE OF FAMILY RELATIONSHIP AND ETHNICITY IMPACT THE ASSOCIATION BETWEEN A POSITIVE FAMILY HISTORY FOR SPONDYLOARTHRITIS AND PRESENCE OF HLA-B27? RESULTS FROM THE WORLDWIDE ASAS COHORT / M. van Lunteren* - A. Sepriano - R. Landewé - J. Sieper - M. Rudwaleit - D. van der Heijde - F. A. van Gaalen THU0232 IS A POSITIVE FAMILY HISTORY OF SPONDYLOARTHRITIS RELEVANT FOR DIAGNOSING AXIAL SPONDYLOARTHRITIS ONCE HLA-B27 STATUS IS KNOWN? DATA FROM THE ASAS, DESIR AND SPACE COHORTS / M. van Lunteren* - A. Sepriano - R. Landewé - I. J. Berg - M. Dougados - L. Gossec - L. Jacobsson - R. Ramonda - M. Rudwaleit - J. Sieper - D. van der Heijde - F. A. van Gaalen THU0233 SICK LEAVE AND ITS PREDICTORS IN ANKYLOSING SPONDYLITIS: LONG-TERM RESULTS FROM THE OUTCOME IN ANKYLOSING SPONDYLITIS INTERNATIONAL STUDY / C. Webers* - S. Ramiro - R. Landewé - D. van der Heijde - F. van den Bosch - M. Dougados - A. van Tubergen - A. Boonen THU0234 BMI DOES NOT AFFECT CLINICAL OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TIGHT CONTROL STRATEGY / D. Birra* - G. Peluso - L. Gigante - E. De Lorenzis - G. Canestrari - G. Tanti - G. Natalello - D. Bruno - G. Ferraccioli - E. Gremese THU0235 ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS HOSPITALIZATION TRENDS IN THE US: DATA FROM NATIONAL INPATIENT SAMPLE / P. Karmacharya - P. Shrestha - R. Dhital - D. R. Poudel* THU0236 ANKYLOSING SPONDYLITIS RELATED FACTORS PREDICT THE PRESENCE OF CARDIAC CONDUCTION DISTURBANCES - A SWEDISH LONGITUDINAL COHORT STUDY / K. Bengtsson* - E. Klingberg - A. Deminger - L. T. Jacobsson - L. Bergfeldt - H. Forsblad-d Elia THU0237 INFLAMMATORY LESIONS OF THE SACROILIAC JOINTS, BUT NOT OF THE SPINE, ARE OF HIGH UTILITY FOR AXSPA RECOGNITION: RESULTS OF THE ILOS-DESIR STUDY / A. Moltó* - L. Gossec - M. Lefevre-Colau - V. Foltz - R. Beaufort - J. Laredo - P. Richette - P. Dieudé - P. Goupille - A. Feydy - M. Dougados THU0238 ULTRASONOGRAPHIC EVALUATION OF DISTAL PATELLAR ENTHESIS IN PATIENTS AFFECTED BY ENTHEROPATIC SPONDILOARTHRITIS / A. Batticciotto* - G. Prato - M. Antivalle - M. C. Ditto - M. Agosti - E. Cumbo - R. Talotta - F. Atzeni - P. Sarzi-Puttini THU0239 PROGRESSION OF STRUCTURAL DAMAGE ON MRI OF THE SPINE AND SACROILIAC JOINTS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS LIMITED: THE 5 -YEAR RESULTS IN THE DESIR COHORT / A. Sepriano* - S. Ramiro - R. Landewé - M. Dougados - D. van der Heijde THU0240 THE SIZE AND FREQUENCY OF BONE MARROW EDEMA ON SACROILIAC JOINT MRI DIFFERS IN A CLUSTER-WISE COMPARISON OF PATIENTS WITH FINDINGS SUGGESTIVE OF AXIAL SPONDYLOARTHRITIS / A. A. Christiansen* - A. G. Loft - K. Hørslev-Petersen - S. Juhl-Pedersen - U. Weber - L. T. Hermansen - B. Arnbak - A. Zejden - B. Schiøttz-Christensen - C. Manniche - O. Hendricks THU0241 MUSCULOSKELETAL INVOLVEMENT IN INFLAMMATORY BOWEL DISEASE S PATIENTS: A MONO CENTRIC EXPERIENCE / A. Delle Sedie* - L. Ceccarelli - L. Carli - F. Costa - S. Marchi - M. Mosca THU0242 PREGNANCY OUTCOMES AND DISEASE ACTIVITY IN WOMEN WITH AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / A. Moltó* - L. Gensler - M. E. B. Clowse - H. Marzo-Ortega - A. Artignan - D. Goff-Leggett - S. Leonard - H. K. Resemann - E. Thurtle - N. de Peyrecave - C. Ecoffet - F. Förger * Presenting author

63 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 61 THU0243 CASE FATALITY OVER 365 DAYS AFTER FIRST ACUTE CORONARY SYNDROME IN PATIENTS WITH ANKYLOSING SPONDYLITIS / A. Södergren* - J. Askling - K. Bengtsson - H. Forsblad-D Elia - T. Jernberg - U. Lindström - L. Ljung - Ä. Mantel - L. T. Jacobsson THU0244 HIGH PREVALENCE OF CLINICAL SPONDYLOARTHRITIS FEATURES IN PATIENTS WITH HIDRADENITIS SUPPURATIVA / A. Rondags - K. R. van Straalen - S. Arends - H. H. van der Zee - E. Prens - B. Horvath - A. Spoorenberg* THU0245 RELATIVE RISK CHART SCORE FOR THE ASSESSMENT OF THE CARDIOVASCULAR RISK IN YOUNG PATIENTS WITH ANKYLOSING SPONDYLITIS / B. Atienza-Mateo* - J. L. Martín-Varillas - L. C. Domínguez-Casas - N. Vegas-Revenga - J. Rueda-Gotor - F. Genre - A. Corrales - R. Blanco - P. Fuentevilla - V. Portilla - R. Expósito - C. Mata -T. Pina - C. González-Juanatey - L. Rodriguez-Rodriguez - M. Á. González-Gay THU0246 CAN DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS BE ADEQUATELY ASSESSED BY A MODIFIED DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA) BASED ON 28 JOINTS? / B. Michelsen* - J. Sexton - J. Smolen - D. Aletaha - N. S. Krogh - D. van der Heijde - T. K. Kvien - M. L. Hetland THU0247 SPA-NET: A DISEASE-SPECIFIC INTEGRATED EHEALTH SYSTEM AND QUALITY REGISTRY FOR SPONDYLOARTHRITIS IN DAILY PRACTICE IN THE NETHERLANDS / C. Webers* - E. Beckers - Y. van Eijk - H. Vonkeman - M. van de Laar - P. van Riel - M. Efdé - A. Boonen - A. van Tubergen THU0248 ASSOCIATION OF KINESIOPHOBIA, AEROBIC EXERCISE, FUNCTIONAL IMPAIRMENT AND DISEASE ACTIVITY OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS / D. Peres - N. Tordi - Y. Sagawa - D. Wendling - C. Prati* THU0249 MORE THAN 60% PATIENTS WITH SPONDYLOARTHRITIS REPORT PERIPHERAL MANIFESTATIONS: AN ANCILLARY ANALYSIS OF THE ASAS-COMOSPA STUDY / C. López-Medina* - A. Moltó - M. Dougados THU0250 IMPACT OF GUT INVOLVEMENT IN EARLY SPONDYLOARTHRITIS. THE DESIR COHORT / D. Wendling* - X. Guillot - C. Prati - C. Miceli-Richard - A. Molto - R. Lories - M. Dougados THU0251 CHARACTERISTICS OF NEWLY DIAGNOSED AXIAL SPONDYLOARTHRITIS PATIENTS IN RHEUMATOLOGY PRACTICES ACROSS GERMANY / D. Poddubnyy* - E. Edelmann - V. Rios Rodriguez - S. Sartingen - T. Mosch - J. Sieper THU0252 THE RATE OF US VERIFIED HIP INVOLVEMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS / E. Agafonova* - T. Dubinina - A. Dyomina - O. Rumyantseva - S. Erdes THU0253 THE CHRONIC SPINAL PAIN IN SPONDYLOARTHROPATHIES, OSTEOARTHRITIS, AND FIBROMYALGIA: THE ROLE OF CENTRAL SENSITIZATION / F. F. Ayhan* - Ö. F. Çelik - M. A. Güler THU0254 RELATION BETWEEN SUBCLINICAL ULTRASONOGRAPHIC CHANGES OF THE ANTERIOR CHEST WALL JOINTS AND PULMONARY FUNCTION TESTS IN ANKYLOSING SPONDYLITIS PATIENTS / F. I. Abdelrahman* - M. Mortada - W. Mansour - A. B. Abdulsattar THU0255 LOW BONE MINERAL DENSITY IS COMMON IN AXIAL SPONDYLOARTHROPATHY / G. Fitzgerald* - T. Anachebe - F. O Shea THU0256 HIGH DISEASE ACTIVITY, REDUCED PHYSICAL FUNCTION, LONG DISEASE DURATION, FATIGUE AND LIVING WITHOUT A PARTNER ARE FACTORS RELATED TO WORSE HEALTH RELATED QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS / H. Forsblad-D elia* - L. Law - J. Beckman Rehnman - A. Deminger - E. Klingberg - L. T.H. Jacobsson THU0257 ASSOCIATIONS BETWEEN TRABECULAR BONE SCORE AND VERTEBRAL FRACTURES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / H. R. Kim* - Y. S. Hong - K. Y. Kang THU0258 DIAGNOSTIC VALUE OF ANTI-CD74 AUTOANTIBODIES IN AXIAL SPONDYLOARTHRITIS AND AXIAL PSORIATIC ARTHRITIS. RESULTS OF OPEN-LABEL, CROSS-SECTIONAL, CONTROLLED, MULTICENTER PROGRESS STUDY / I. Z. Gaydukova* - A. Rebrov - A. Maslyanskiy - S. Lapin - E. Vasilenko - V. Mazurov THU0259 FREQUENCY AND PATTERN OF THE UVEITIS IN SPONDYLOARTHRITIS WITH BIOLOGICAL THERAPY / I. Calvo* - E. Guerrero - O. Ibarguengoitia - D. Montero - M. L. Garcia - E. Ruiz - I. Torre - O. Fernandez - J. M. Blanco - A. R. Intxaurbe - C. Perez - I. Gorostiza - E. Galindez THU0260 THE UVEITIS IMPACT STUDY: A SURVEY BY THE SPONDYLITIS ASSOCIATION OF AMERICA / J. T. Rosenbaum* - R. Howard - L. M. Savage THU0261 CARDIOVASCULAR RISK STRATIFICATION IN ANKYLOSING SPONDYLITIS: LATERAL LUMBAR RADIOGRAPHY IS USEFUL TO DETECT HIGH-CARDIOVASCULAR RISK PATIENTS / J. L. Martín-Varillas* - B. Atienza-Mateo - N. Vegas-Revenga - L. Dominguez-Casas - J. Rueda-Gotor - F. Genre - A. Corrales - R. Blanco - P. Fuentevilla - V. Portilla - R. Expósito - C. Mata - T. Pina - C. González-Juanatey - L. Rodríguez-Rodríguez - J. A. Parra - M. A. González-Gay THU0262 IDENTIFYING PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM A COHORT OF PATIENTS WITH CHRONIC BACK PAIN IN ORTHOPEDICS CARE (AWARE STUDY) / J. Braun* - T. Mosch - I. Fischer - U. Kiltz THU0263 ANALYSIS ON CHARACTERISTICS OF 82 PATIENTS WITH ANKYLOSING SPONDYLITIS IN JAPAN / K. Tada* - S. Kobayashi - E. Hayashi - M. Ogasawara - H. Inoue - K. Yamaji - N. Tamura THU0264 IMPACT OF EXTRA-ARTICULAR MANIFESTATIONS ON PATIENT-REPORTED OUTCOMES IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: INTERIM RESULTS FROM THE COMPLETE STUDIES / L. Bessette* - M. Khraishi - B. Florica - Y. Setty - M. Teo - V. Remple THU0265 PATIENTS WITH AXIAL SPONDYLOARTHRITIS RARELY HAVE 1 OR 2 INFLAMMATORY BACK PAIN PARAMETERS / M. de Hooge* - G. V. Varkas - D. Elewaut - F. van den Bosch THU0266 THE VALUE OF BELONGING TO PATIENTS ASSOCIATION FOR AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE ATLAS-2017 / M. Garrido-Cumbrera* - D. Gálvez-Ruiz - E. Collantes Estevez - C. Blanch Mur - V. Navarro-Compán THU0267 GASTROINTESTINAL INVOLVEMENT IN SPONDYLOARTHRITIS IS NOT ALL IBD: INCREASED RISK OF DIVERTICULITIS WITH LONGER DISEASE DURATION IN THE ASAS-COMOSPA COHORT / M. H. Derakhshan* - N. Goodson - J. Packham - R. Sengupta - A. Molto - H. Marzo-Ortega - S. Siebert on behalf of BRITSpA and the ASAS-COMOSPA investigators THU0268 THE FREQUENCY OF JUVENILE SPONDYLOARTHROPATHIES IN CHILDHOOD FAMILLIAL MEDITERRANEAN FEVER / E. Ozer - D. Seker - H. E. Taner - A. Adrovic - S. Sahin - O. Koker - K. Barut - O. Kasapcopur* 14 June 2018 * Presenting author

64 62 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0269 DEVELOPMENT OF ANKYLOSING SPONDYLITIS IN PATIENTS WITH REACTIVE ARTHRITIS AND PERIPHERAL SPONDYLOARTHROPATHY: HOSPITAL BASED STUDY IN NORTH INDIA / R. Misra* - S. Ahmed - A. Chaudhury - A. Lawrence - V. Agarwal - A. Aggarwal THU0270 THE PROPENSITY TO FAT METAPLASIA OF SACROILIAC JOINT IN SPONDYLOARTHROPATHY: RESULTS FROM THE SINGLE REGIONAL CENTER COHORT / S. Y. Lee* - S. W. Lee - W. T. Chung - J. W. Jung THU0271 EMERGENCE OF SEVERE SPONDYLOARTHROPATHY RELATED ENTHESEAL PATHOLOGY FOLLOWING VEDOLIZUMAB THERAPY FOR INFLAMMATORY BOWEL DISEASE / S. Dubash* - T. Marianayagam - T. Al-Araimi - C. Pagnoux - A. Weizman - M.-L. Tran Minh - M. Allez - P. Richette - H. Marzo-Ortega - D. McGonagle THU0272 WHICH SCORING METHOD DEPICTS SPINAL RADIOGRAPHIC DAMAGE IN (EARLY) AXIAL SPONDYLOARTHRITIS BEST? FIVE-YEAR RESULTS FROM THE DESIR COHORT / S. Ramiro* - P. Claudepièrre - A. Sepriano - M. van Lunteren - A. Molto - A. Feydy - M. A. D Agostino - D. Loeuille - M. Dougados - M. Reijnierse - D. van der Heijde THU0273 PREVALENCE OF VERTEBRAL FRACTURES IN ANKYLOSING SPONDYLITIS: A META-ANALYSIS / J. Sahuguet - J. Mancini - P. Lafforgue - T. Pham* THU0274 ASSESSMENT OF RADIOGRAPHIC SACROILIITIS ON ANTERO-POSTERIOR LUMBAR RADIOGRAPHS AS COMPARED TO CONVENTIONAL PELVIC RADIOGRAPHS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / V. Rios Rodriguez* - M. Llop - M. Protopopov - J. Sieper - H. Haibel - M. Rudwaleit - D. Poddubnyy THU0275 THE RELATIONSHIP BETWEEN MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE AND THE SPONDYLOARTHRITIS RESEARCH CONSORTIUM OF CANADA ENTHESITIS INDEX IN ANKYLOSING SPONDYLITIS: FRIENDS OR ENEMIES? / W. Hamdi* - M. Sellami - H. Riahi - K. Maatallah - D. Kaffel - M. Chelli-Bouaziz - M. F. Ladeb - M. M. Kchir THU0276 MRI LESION DEFINITIONS IN AXIAL SPONDYLOARTHRITIS: A CONSENSUS REAPPRAISAL FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) / W. P. Maksymowych* - R. G. Lambert - M. Østergaard - M. de Hooge - S. J. Pedersen - A. N. Bennett - R. Burgos-Vargas - I. Eshed - R. Landewé - P. Machado - H. Marzo-Ortega - D. Poddubnyy - M. Rudwaleit - J. Sieper - D. van der Heijde - I. van der Horst-Bruinsma - U. Weber - X. Baraliakos THU0277 WHICH MRI LESIONS IN THE SACROILIAC JOINT ARE ASSOCIATED WITH THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS AFTER 2 YEARS FOLLOW UP IN THE ECHOGRAPHY IN SPONDYLOARTHRITIS COHORT (ECHOSPA)? / W. P. Maksymowych* - D. Loeuille - S. Wichuk - J. Paschke - O. Judet - M. Breban - M.-A. D Agostino - R. G. Lambert THU0278 SERUM CALPROTECTIN IS CORRELATED WITH DISEASE ACTIVITY IN EARLY AXIAL SPONDYLOARTHRITIS BUT DOES NOT PREDICT RADIOGRAPHIC PROGRESSION AT 2 YEARS: RESULTS FROM THE DESIR COHORT / X. Romand* - M. H. Paclet - A. Courtier - M.-V.-C. Nguyen - F. Berenbaum - D. Wendling - P. Gaudin - A. Baillet THU0279 GENDER DIFFERENCE IN PSYCHOLOGICAL STATUS AND SLEEP QUALITY IN THE PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Jiang* - Q. Lv - J. Qi - D. Huang - X. Zhang - M. Yang - Y. Zhang - J. Gu TOPIC: PSORIATIC ARTHRITIS Poster tour T7: Abstracts N : The impact of treatment on the burden of psoriatic disease Filip van den Bosch (Netherlands), Laura Coates (United Kingdom)) THU0280-THU0289 THU0280 EARLY AND LONG-TERM TREATMENT RESPONSE AS WELL AS HIGH TOLERABILITY LEAD TO HIGH TREATMENT SATISFACTION OF A THERAPY WITH USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - RESULTS OF THE NON-INTERVENTIONAL STUDY SUSTAIN / J. Wendler - E. Movshovich - J. Behrens - F. Hamann - P. Wagener - F. Behrens* THU0281 DO IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE DURING DMARD TREATMENT DIFFER BETWEEN PSORIATIC AND RHEUMATOID ARTHRITIS PATIENTS? DATA FROM THE PROSPECTIVE OBSERVATIONAL NOR- DMARD STUDY, INCLUDING BASELINE COMPARISONS WITH NORWEGIAN GENERAL POPULATION CONTROLS / B. Michelsen* - T. Uhlig - J. Sexton - H. B. Hammer - E. K. Kristianslund - G. Haugeberg - J. H. Loge - T. K. Kvien THU0282 THE IMPACT OF COMORBIDITIES ON PHYSICAL FUNCTION IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) ATTENDING RHEUMATOLOGY CLINICS / C. Fernández-Carballido* - M. Martín-Martínez - C. García-Gómez - S. Castañeda - C. González-Juanatey - F. Sánchez - R. García-Vicuña - C. Erausquin - J. Lopez-Longo - M. Sánchez-González - A. Corrales - E. Quesada - E. Chamizo - C. Barbadillo - J. Bachiller - T. Cobo - A. Turrión - E. Giner - J. Llorca - M. González-Gay THU0283 PATIENTS WITH PSORIATIC ARTHRITIS WHO ARE NOT ELIGIBLE FOR RANDOMISED CLINICAL TRIALS FOR TNF INHIBITORS HAVE SIMILAR TREATMENT RESPONSE AND DRUG SURVIVAL. RESULTS FROM THE ICEBIO REGISTRY / O. Palsson* - B. Guðbjörnsson - G. A. Jóhannsdóttir - A. Gunnarsdóttir - P. S. Gunnarsson - T. J. Love - E. Rúnarsdóttir THU0284 HAQ IN PSORIATIC ARTHRITIS IS DRIVEN BY GENDER, INFLAMMATION AND AGEING: OBSERVATIONAL DATA FROM COHORT STUDIES IN UK, DENMARK, ICELAND AND SWEDEN / L. E. Kristensen* - T. S. Jørgensen - L. C. Coates - P. Frederiksen - B. Gudbjornsson - J. K. Wallman - N. McHugh - M. C. Kapetanovic - L. Dreyer - W. Tillett THU0285 THE EFFECT OF FAMILY HISTORY ON DISEASE PHENOTYPES IN 1393 PSORIATIC ARTHRITIS PATIENTS / D. Solmaz - S. B. Ureyen - G. Kimyon - E. K. Gunal - A. Dogru - O. Bayindir - E. Dalkilic - C. Ozisler - M. Can - S. Akar - G. Y. Cetin - S. Yavuz - L. Kilic - E. F. Tarhan - O. Kucuksahin - A. Omma - E. Gonullu - F. Yildiz - E. D. Ersozlu - M. Cinar - M. A. Tufan - A. Erden - S. Yilmaz - S. Pehlevan - T. Duruoz - U. Kalyoncu - S. Z. Aydin* on behalf of PsArt-ID (Psoriatic Arthritis-International Database) THU0286 PREDICTORS FOR ORTHOPAEDIC SURGERY IN PATIENTS WITH PSORIATIC ARTHRITIS. RESULTS FROM A RETROSPECTIVE COHORT STUDY OF 590 PATIENTS DIAGNOSED , AND FOLLOWED UP UNTIL 2017 / T. W. Nystad* - Y. Husum - O. N. Furnes - B.-T. S. Fevang * Presenting author

65 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 63 THU0287 THE PREVALENCE OF REMISSION IN A REAL-LIFE COHORT OF PSORIATIC ARTHRITIS PATIENTS TREATED WITH SYNTHETIC OR BIOLOGIC DISEASE MODIFYING DRUGS / E. G. Favalli* - A. Fassio - S. Bugatti - A. Batticciotto - L. Quartuccio - M. Filippini - S. Parisi - M. Biggioggero - G. Zanframundo - I. Giovannini - M. C. Ditto - L. Idolazzi THU0288 IMPLEMENTATION OF THE TREAT TO TARGET CONCEPT IN EVALUATION OF PSORIATIC ARTHRITIS PATIENTS / M. Abu Elhija* - A. Haddad - I. Lavi - T. Gazitt - D. Zisman THU0289 BURDEN OF PSORIATIC ARTHRITIS IN DIFFERENT DEFINITIONS OF DISEASE ACTIVITY: COMPARING MINIMAL DISEASE ACTIVITY AND DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS / K. Wervers* - M. Vis - I. Tchetverikov - A. H. Gerards - M. R. Kok - C. W. Appels - W. L. van der Graaff - J. H. van Groenendael - L.-A. Korswagen - J. J. Veris-Van Dieren - J. M. Hazes - J. J. Luime on behalf of Cicero THU0290 EFFECTS OF BIOLOGIC DMARDS ON PHYSICAL FUNCTION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF NETWORK META-ANALYSES / A. Ruyssen-Witrand* - C. Sapin - S. Hartz - S. Liu Leage THU0291 INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AND INFLAMMATORY BOWEL DISEASE AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: DATA FROM 3 LARGE RANDOMISED CLINICAL TRIALS / M. Gooderham - B. E. Elewski - D. M. Pariser - H. Sofen - A. M. Mendelsohn* - N. Cichanowitz - Q. Li - C. La Rosa THU0292 DIAGNOSTIC EXPERIENCES OF PATIENTS WITH PSORIATIC ARTHRITIS: MISDIAGNOSIS IS COMMON / A. Ogdie* - W. B. Nowell - E. Applegate - K. Gavigan - S. Venkatachalam - M. de la Cruz - E. Flood - E. J. Schwartz - B. Romero - P. Hur THU0293 THE TRAJECTORY OF RADIOGRAPHIC PROGRESSION SLOWS AMONGST PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ANTI-TNF / A. Allard* - A. Antony - G. Shaddick - D. Jadon - C. Cavill - E. Korendowych - N. McHugh - W. Tillett THU YEAR EFFICACY AND SAFETY OF APREMILAST TREATMENT IN SUBJECTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THE PALACE STUDIES / A. Kavanaugh* - D. D. Gladman - C. J. Edwards - G. Schett - B. Guerette - N. Delev - L. Teng - M. Paris - P. J. Mease THU0295 FACTORS ASSOCIATED WITH PATIENT-PHYSICIAN DISCORDANCE IN A PROSPECTIVE COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS: AN ASIAN PERSPECTIVE / C. Wang* - Y. H. Kwan - W. Fong - S. Q. Xiong - Y. Y. Leung THU0296 CLINICAL RESULTS OF PATIENTS WITH PERIPHERAL PSORIATIC ARTHRITIS NOT RECEIVING BIOLOGICAL THERAPY IN A MULTIDISCIPLINARY UNIT / C. E. Pérez-Velásquez* - M. L. García-Vivar - S. Pérez-Barrio - E. Galindez-Agirregoikoa - E. Ruiz-Lucea - I. Torre-Salaberri - O. Fernandez-Berrizbeitia - J. M. Blanco-Madrigal - A. R. Intxaurbe-Pellejero - E. Guerrero-Basterretxea - I. Calvo-Zorrilla - O. Ibarguengoitia-Barrena - D. Montero-Seisdedos - N. Rivera-García - M. J. Allande - I. Gorostiza-Hormaeche THU0297 EVALUATION OF CARDIOVASCULAR RISK FACTORS AMONG PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND PERIPHERAL SPONDYLOARTHRITIS / M. R. Camacho-Sánchez - C. López-Medina* - L. Bautista-Aguilar - L. Ladehesa-Pineda - L. Pérez-Sánchez - I. Gómez-García - A. J. Vélez García-Nieto - E. Collantes-Estévez - M. D. López-Montilla THU0298 PERITENON EXTENSOR TENDON INFLAMMATION, SYNOVITIS AND ENTHESOPATHY IN PSORIATIC ARTHRITIS: WHAT IS THE CONNECTION? / C. Macía Villa* - S. Falcao - H. B. Hammer - M. Gutierrez - E. De Miguel THU0299 AN INTEGRATED ANALYSIS OF CHANGES IN LIPID LEVELS AND INCIDENCE OF CARDIOVASCULAR EVENTS FOLLOWING TOFACITINIB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS ACROSS PHASE 3 AND LONG-TERM EXTENSION STUDIES / D. D. Gladman* - C. Charles-Schoeman - I. B. McInnes - D. J. Veale - B. Thiers - D. Graham - C. Wang - T. V. Jones - R. Wolk - R. DeMasi THU0300 NETWORK META-ANALYSIS OF TOFACITINIB VS BDMARDS OR APREMILAST FOR THE TREATMENT OF TNF INHIBITOR-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS / D. D. Gladman* - A.-M. Orbai - J. Gomez-Reino - S. Chang-Douglass - E. Leoncini - H. E. Burton - K. S. Kanik - T. Hendrikx - J. C. Cappelleri - M.-A. Hsu THU0301 A NOVEL ROLE FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE QUESTIONNAIRE (PSAID) / K. Johnson - J. Ye - V. Chandran - D. Gladman* THU0302 SURVIVAL OF DISEASE-MODIFYING DRUGS (DMARD) IN PATIENTS WITH RECENT DIAGNOSIS OF PSORIATIC ARTHRITIS IN DAILY CLINICAL PRACTICE / D. Freites Nuñez* - L. León - Z. Rosales - J. Font - C. Lajas - E. Pato - L. Rodríguez - B. Fernández - J.-A. Jover - L. Abasolo THU0303 THE EARLY PSORIATIC ARTHRITIS SCREENING QUESTIONNAIRE IDENTIFIES PATIENTS WITH PSORIATIC ARTHRITIS AMONGST TREATED PATIENTS WITH PSORIASIS / K. Nadeau - F. Briggs - S. O Neill - D. Sumpton - G. Cains - J. Woods - D. Chessman* THU0304 ASSOCIATION OF ANXIETY, DEPRESSION AND FATIGUE WITH DISEASE ACTIVITY, JOINTS EROSION AND SKIN LESION SEVERITY IN EARLY PSORIATIC ARTHRITIS PATIENTS / E. E. Gubar* - E. Y. Loginova - A. D. Koltakova - S. I. Glukhova - T. V. Korotaeva THU0305 MINIMAL DISEASE ACTIVITY (MDA) ATTAINMENT AFTER STARTING BIOLOGICAL (B) DMARDS AND NON- BDMARDS TREATMENT IN PSORIATIC ARTHRITIS PATIENTS (PTS) IN ROUTINE CARE: RUSSIAN PSORIATIC ARTHRITIS REGISTRY (RU-PSART) DATA / E. Loginova* - T. Korotaeva - A. Koltakova - E. Gubar - Y. Korsakova - E. Nasonov - A. Lila - M. Sedunova - T. Salnikova - I. Umnova - I. Bondareva - U. Zagidulina - P. Zemtsova on behalf of the RU-PsART study group THU0306 CLINICAL SPECIALTY SETTING AS A DETERMINANT FOR DISEASE MANAGEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM LOOP, A CROSS-SECTIONAL, MULTI-COUNTRY, OBSERVATIONAL STUDY / W.-H. Boehncke - R. Horváth - E. Dalkiliç - S. A. L. Lima - M. Okada - M. Hojnik - F. Ganz - E. Lubrano* THU0307 QT INTERVAL AND ITS CORRELATIONS WITH TRADITIONAL RISK FACTORS OF DEVELOPMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH ACTIVE EARLY PSORIATIC ARTHRITIS / E. Markelova* - D. Novikova - T. Korotaeva - I. Kirillova - E. Loginova THU0308 CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH NEW ONSET PSORIATIC AND RHEUMATOID ARTHRITIS: CORRELATION WITH ULTRASONOGRAPHIC SYNOVITIS / G. Sakellariou* - G. Lombardi - B. Vitolo - M. Gomarasca - M. Faraldi - R. Caporali - G. Banfi - C. Montecucco THU0309 TEN YEARS FOLLOW-UP STUDY OF CLINICAL DISEASE STATUS AND TREATMENT IN PSORIATIC ARTHRITIS PATIENTS FROM AN OUTPATIENT CLINIC IN SOUTHERN NORWAY / G. Haugeberg* - S. Tengesdal - I. J. W. Hansen - B. Michelsen - A. Diamantopoulos - A. Kavanaugh 14 June 2018 * Presenting author

66 64 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0310 BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: A REAL-WORLD COHORT OF 439 PATIENTS / J.-G. Letarouilly* - J.-H. Salmon - P. Coquerelle - V. Goeb - M.-H. Guyot - E. Houvenagel - F. Maury - L. Marguerie - G. Morel - G. Baudens - E. Solau-Gervais - N. Ramdane - R.-M. Flipo THU0311 IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM TWO PHASE 3 STUDIES (FUTURE 2 AND FUTURE 3) / J. K. Wallman* - G. Schett - I. B. McInnes - E. Quebe-Fehling - L. Rasouliyan - L. Pricop - A. E. Fasth - C. Gaillez on behalf of the FUTURE 2 and FUTURE 3 study groups THU0312 RISK OF INFECTION IN PATIENTS WITH PSORIASIS/PSORIATIC ARTHRITIS: A POPULATION-BASED STUDY IN THE PROVINCE OF BRITISH COLUMBIA / J. A. Avina-Zubieta* - A. Dominique - T. A. Simon - H. Tavakoli THU0313 IXEKIZUMAB IMPROVES NAIL AND SKIN LESIONS THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS / J. F. Merola - P. Rich - J. P. Dutz - D. Adams - L. Kerr - L. E. Kristensen* THU0314 IXEKIZUMAB MAKES VERY LOW DISEASE ACTIVITY AND REMISSION WITH PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS FOR UP TO 1 YEAR: SPIRIT-P1 AND SPIRIT-P2 TRIALS / L. C. Coates* - M. E. Husni - E. Lespessailles - L. Kerr - G. Gallo THU0315 PATIENT-PERCEIVED INVOLVEMENT IN DISEASE MANAGEMENT DRIVES PATIENT-PHYSICIAN ALIGNMENT IN SATISFACTION WITH DISEASE CONTROL IN PSORIATIC ARTHRITIS / L. Gossec* - A.-M. Orbai - S. Lobosco - R. Moon - O. Massey - J. Piercy - J. C. Cappelleri - L. Fallon - P. Young - A. B. Romero - M.-A. Hsu THU0316 GENDER DIFFERENCES IN BIOLOGIC TREATMENT OUTCOMES - A STUDY OF 1750 PATIENTS WITH PSORIATIC ARTHRITIS USING DANISH HEALTH CARE REGISTERS / P. Højgaard - C. Ballegaard - R. Cordtz - K. Zobbe - M. Clausen - L. E. Kristensen - B. Glintborg - L. Dreyer* THU0317 CREATING A EUROPEAN DATABASE OF PSORIATIC ARTHRITIS PATIENTS TREATED IN ROUTINE CARE - FIRST, PRELIMINARY RESULTS FROM THE EUROSPA RESEARCH NETWORK COLLABORATION / L. M. Ørnbjerg* - M. Østergaard - F. Onen - M. Birlik - Z. Rotar - M. Tomsic - B. Gudbjornsson - T. J. Love - M. J. Nissen - A. Ciurea - D. Nordström - N. Trokovic - M. J. Santos - A. Barcelos - E. K. Kristianslund - T. Kvien - C. Codreanu - E.-M. Hauge - J. Askling - F. Iannone - H. Mann - M. V. Hernandez - G. Macfarlane - M. van de Sande - L. H. Hyldstrup - N. S. Krogh - M. Hetland THU0318 TREATING PSORIATIC ARTHRITIS TO TARGET: COMORBIDITIES, NON-ADHERENCE AND FACTORS RELATED TO THE HEALTH SYSTEM PREVENT ESCALATION OF THERAPY IN REAL LIFE / M. Ferreira* - R. Xavier - E. Abbeg - O. Martins - F. Menegat - C. Kohem - A. Gasparin - N. Andrade - V. Hax - D. Viecceli - C. Brenol - J. C. Brenol - P. Palominos THU0319 OVERALL SAFETY OF 7-WEEK SECUKINUMAB EXPOSURE DURING PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS / M. Meroni* - E. Generali - G. M. Guidelli - M. Parodi - M. Cutolo - C. Selmi THU0320 A SHORT, EASILY READABLE, ONLY 3-ITEM TOOL - BRISTOL RHEUMATOID ARTHRITIS FATIGUE SCALE (BRAF) - IS VALID IN PATIENTS WITH PSORIATIC ARTHRITIS / M. Haroon* - K. Iqbal - M. Ashraf - P. Gallagher - O. FitzGerald THU0321 ACUTE PHASE MARKERS IN PSORIATIC ARTHRITIS IDENTIFY PATIENTS WITH A MORE SEVERE PHENOTYPE / M. Haroon* - M. Ahmad - O. Mason - O. FitzGerald THU0322 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 FUTURE 2 STUDY / P. Nash* - I. B. McInnes - P. Rahman - A. B. Gottlieb - B. Kirkham - K. Ding - L. Pricop on behalf of the FUTURE 2 study group THU0323 TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS / P. Helliwell* - L. C. Coates - O. FitzGerald - P. Nash - E. R. Soriano - M. E. Husni - M.-A. Hsu - K. S. Kanik - T. Hendrikx - J. Wu - E. Kudlacz THU0324 DISEASE ACTIVITY AND PATIENT CHARACTERISTICS BY COMORBIDITY AMONG PSORIATIC ARTHRITIS (PSA) PATIENTS IN A US REGISTRY / P. J. Mease* - H. J. Litman - N. A. Accortt - S. Rebello - J. D. Greenberg - H. Feng - M. M. Gharaibeh - G. A. Aras - D. H. Collier THU0325 SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE WITH UP TO 5 YEARS TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND MODERATE TO SEVERE PLAQUE PSORIASIS: UPDATED POOLED SAFETY ANALYSES / P. J. Mease* - I. B. McInnes - K. Reich - P. Nash - A. Widmer - K. Abrams - L. Pricop - T. Fox THU0326 DISCONTINUATION AND SWITCHING PATTERNS OF TUMOR NECROSIS FACTOR INHIBITOR (TNFI) THERAPY IN TNFI-NAIVE AND TNFI-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS IN THE US CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY / P. Mease* - M. Liu - B. Gershenson - P. Hur - J. Greenberg THU0327 REAL WORLD (RW) EXPERIENCE WITH AN ANTI-IL-17A INHIBITOR IN BIOLOGIC NAÏVE AND BIOLOGIC EXPERIENCED PSORIATIC ARTHRITIS (PSA) PATIENTS / R. Moon* - J. Hill - N. Booth - S. Lobosco THU0328 MIR-499 POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO PSORIATIC ARTHRITIS - PRELIMINARY STUDY / R. Sokolik* - J. Swierkot - M. Iwaszko - M. Kozlowski - L. Korman - P. Wiland - K. Bogunia-Kubik THU0329 AN ITALIAN OBSERVATIONAL PROSPECTIVE STUDY ON PREDICTORS OF CLINICAL RESPONSE TO GOLIMUMAB AT 6 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / R. Scrivo* - A. Giardino - C. Salvarani - R. Foti - A. Afeltra - O. Viapiana - F. Salaffi - F. Iannone on behalf of the Predicting MDA in PsA study group THU0330 OBESITY IN PSORIATIC ARTHRITIS: COMPARATIVE PREVALENCE WITH SKIN PSORIASIS AND ASSOCIATED FACTORS / R. Queiro* - A. Lorenzo - E. Pardo - A. Brandy - S. Alonso - M. Alperi - L. Arboleya - J. Ballina THU0331 RELATIONSHIP BETWEEN THE NAIL ULTRASONOGRAPHIC EVALUATIONS AND CLINICAL FEATURES IN PATIENTS WITH PSORIATIC ARTHRITIS / S. Acer* - H. S. Baklacıoğlu - D. Erdem - M. T. Duruöz THU0332 FATIGUE REMAINS A DOMINATNG SYMPTOM DESPITE TUMOUR NECROSIS FACTOR INHIBITOR THERAPY IN PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY / T. S. Jørgensen* - M. Skougaard - C. Ballegaard - P. Mease - V. Strand - L. Dreyer - L. E. Kristensen THU0333 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1) / V. Chandran* - R. Fleischmann - E. Lespessailles - P. S. Helliwell - O. Benichou - J. Erickson - C. Shuler * Presenting author

67 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 65 TOPIC: SLE, SJÖGREN S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT) Poster tour T8: Abstracts N : Cardiovascular co-morbidites in SLE Eric F. Morand (Australia), Antonis Fanouriakis (Greece) THU0334-THU0341 THU0334 PATTERNS OF ASPIRIN USE IN SLE PREGNANCIES WITHIN A MULTINATIONAL INCEPTION COHORT AND RELATIONSHIP TO PREECLAMPSIA RISK FACTORS / A. Mendel* - S. Bernatsky - E. Vinet on behalf of SLICC Investigators THU0335 FACTORS ASSOCIATED WITH DEVELOPMENT AND MORTALITY OF PULMONARY HYPERTENSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / J. S. Kim* - D. Kim - Y. B. Joo - S. Won - J. Lee - J. Shin - S.-C. Bae THU0336 PREDICTORS OF SUBCLINICAL CAROTID ATHEROMATOSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RELEVANCE OF ACTIVITY, DAMAGE AND SEVERITY INDEXES / J. C. Quevedo - H. Sánchez* - I. Rua-Figueroa - B. Tejera - A. de Vera - A. González-Delgado - C. Rodríguez-Lozano - I. Ferraz-Amaro THU0337 NONBACTERIAL THROMBOTIC ENDOCARDITIS (NBTE) IN SLE: PREVALENCE, CLINICAL CHARACTERISTICS AND SEROLOGICAL PROFILE / D. V. Tanna* - M. Bindroo - D. Raval - W. Kazi - S. Bajad - R. Gupta THU0338 OUTCOME OF STROKE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NESTED CASE-CONTROL STUDY / L. K. Tsoi - C. C. Mok* - Y. P. Fu THU0339 IMPACT OF CAROTID ULTRASOUND ON THE CARDIOVASCULAR RISK STRATIFICATION OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / J. C. Quevedo Abeledo - H. Sánchez* - I. Rua-Figueroa - B. Tejera - A. Naranjo - C. Rodríguez-Lozano - I. Ferraz-Amaro THU0340 PROLONGED REMISSION IS ASSOCIATED WITH A REDUCED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Fasano* - D. P. Margiotta - L. Pierro - A. Riccardi - A. Afeltra - G. valentini THU0341 LOW VITAMIN D IS ASSOCIATED WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Petri* - W. Fu - D. W. Goldman THU0342 THE LUPUS FOUNDATION OF AMERICA RAPID EVALUATION OF ACTIVITY IN LUPUS (LFA-REAL) PROVIDES A SIMPLE BUT RELIABLE MEASUREMENT OF SLE DISEASE ACTIVITY / A. Thanou* - C. Arriens - T. Aberle - J. A. James - J. T. Merrill - A. D. Askanase THU0343 HOW PATIENTS ABILITY BELIEFS ABOUT MATH MATTER TO SLE PATIENTS DISEASE / A. S. Meara* - M. K. Tompkins - K. Morris - E. Sullivan - S. P. Ardoin - E. peters THU0344 ASSESSMENT OF THE PSYCHOMETRIC PROPERTIES OF PATIENT-REPORTED OUTCOMES OF DEPRESSION IN SLE / A. Kwan* - S. Marzouk - H. Ghanean - K. Ali - N. Anderson - J. Su - Z. Touma THU0345 SENSITIVITY AND SPECIFICITY OF ANTIBODIES AGAINST CARBAMYLATED PROTEINS IN A MONOCENTRIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERITAMATOSUS AND RHEUMATOID ARTHRITIS / B. Özdemir* - O. Kucuksahin - T. H. Yeşil - S. Akan - S. Erten THU0346 DETERMINANTS OF SONOGRAPHIC GLANDULAR DAMAGE IN A LARGE COHORT OF PATIENTS WITH PRIMARY SJÖGREN S SYNDROME AND ITS IMPACT ON SALIVARY GLAND DYSFUNCTION / C. Baldini* - N. Luciano - F. Ferro - E. Calabresi - E. Elefante - V. Donati - S. Bombardieri - M. Mosca THU0347 AQUAPORIN-4 IMMUNOGLOBULIN G ANTIBODY POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER AND SYSTEMIC AUTOIMMUNE DISEASES OVERLAP SYNDROME: A SINGLE CENTER EXPERIENCE / E. Martin Nares* - G. Hernández Molina - H. Fragoso Loyo THU0348 TIME ON DIALYSIS ADVERSELY AFFECTS RENAL TRANSPLANT OUTCOME IN LUPUS NEPHRITIS / E. Ntatsaki* - V. Vassiliou - A. Velo Garcia - A. D. Salama - D. A. Isenberg THU0349 ANTIBODIES TO PHOSPHATIDYLSERINE-PROTHROMBIN COMPLEX AND ANNEXIN V AS RISK FACTORS FOR THE DEVELOPMENT OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / E. Belolipetskaia* - I. Beliaeva - V. Mazurov - S. Lapin - O. Tkachenko - V. Guseva - O. Inamova THU0350 TIME DEPENDENT ASSOCIATION OF ACTIVE RENAL DISEASE WITH IRREVERSIBLE ORGAN DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS / E. Morand* - R. Kandane-Rathnayake - W. Louthrenoo - S.-F. Luo - Y.-J. Wu - A. Lateef - V. Golder - S. Sockalingam - S. Navarra - L. Zamora - L. Hamijoyo - Y. Katsumata - M. Harigai - M. Chan - S. O Neill - F. Goldblatt - C. S. Lau - A. Hoi - M. Nikpour THU0351 SUSCEPTIBILITY TO CEREBRAL ISCHEMIA IN EARLY LUPUS PATIENTS: A PILOT STUDY OF CO-REGISTRATION WITH CONVENTIONAL BRAIN MRI, DIFFUSION- AND PERFUSION-WEIGHTED IMAGING / E. Silvagni* - A. Revenaz - A. Bortoluzzi - E. Groppo - M. Padovan - M. Borrelli - S. Ceruti - C. A. Scirè - E. Fainardi - M. Govoni THU0352 ASSOCIATION BETWEEN MEMORY B CELLS AND PHENOTYPIC FEATURES OF SJÖGREN S SYNDROME / F. Barcelos* - C. Martins - A. L. Papoila - C. Geraldes - J. Cardigos - G. Nunes - T. Lopes - N. Alves - J. Vaz-Patto - J. C. Branco - L. M. Borrego THU0353 LUNG ULTRASOUND OF PLEURAL IRREGULARITIES (PI-US) IN PRIMARY SJÖGREN S SYNDROME (PSS)-ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD): CLINICAL, FUNCTIONAL, RADIOGRAPHIC AND ULTRASONOGRAPHIC SHORT-TERM FOLLOW-UP / F. Ferro* - A. Bulleri - A. Delle Sedie - S. Barsotti - N. Luciano - E. Elefante - M. Mosca - C. Baldini THU0354 IMPACT OF BIOLOGIC THERAPY IN SJÖGREN S SYNDROME PATIENTS WITH OVERLAPPING AUTOIMMUNE DISEASES OR EXTRAGLANDULAR MANIFESTATIONS. A SYSTEMATIC REVIEW OF LITERATURE / G. E. Fragoulis* - E. Nikiphorou - A. Alunno - F. Ng - A. G. Tzioufas THU0355 DAMAGE ACCRUAL AND MORTALITY RATES AMONG DIFFERENT AGE GROUPS IN A COHORT OF PATIENTS WITH LUPUS / G. A. Ramirez* - B. Tejera-Segura - R. Lopez - A. Rahman - D. A. Isenberg THU0356 SYNERGISTIC EFFECT OF CUMULATIVE CORTICOSTEROID DOSE AND IMMUNOSUPPRESSANTS ON AVASCULAR NECROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / H.-H. Kwon* - S.-Y. Bang - S. Won - Y. Park - J.-H. Yi - Y. B. Joo - H.-S. Lee - S.-C. Bae THU0357 FEATURES ASSOCIATED WITH LOSS TO FOLLOW-UP IN THE YEAR PRIOR TO DEATH IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE ANALYSIS FROM A NATIONAL REFERRAL CENTER / I. Padjen* - M. Erceg - M. Cerovec - M. Bakula - M. Mayer - R. Stevanovic - B. Anic * Presenting author 14 June 2018

68 66 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0358 USEFULNESS OF 18F-FDG POSITRON EMISSION TOMOGRAPHY (PET) FOR LYMPHOMA DIAGNOSIS IN PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / J. Keraen* - E. Blanc - F. Besson - M. Meyer - V. Le Guern - G. Nocturne - J. Henry - R. Belkhir - X. Mariette - R. Seror THU0359 RELATIONSHIP BETWEEN DAMAGE CLUSTERING AND MORTALITY IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: CLUSTER ANALYSES IN A LARGE COHORT FROM THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY / J. M. Pego-Reigosa* - T. C. Salman-Monte - I. Rua-Figueroa - J. Calvo-Alén - F. J. López-Longo - M. Galindo - A. Olivé - V. Torrente-Segarra on behalf of RELESSER and EASSER groups THU0360 A VALIDATION STUDY OF THE GLOBAL ANTIPHOSPHOLIPID SYNDROME SCORE (GAPSS) IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND PREGNANCY MORBIDITY / K. Schreiber* - M. Radin - I. Cecchi - M. J. Cuadrado - L. Marozio - D. Roccatello - S. Sciascia THU0361 CHARACTERIZATION OF NOVEL AUTOANTIBODIES TO AHNAK1 SPECIFICALLY PRESENTED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / K. Nozawa* - Y. Matsushita - K. Doe - Y. Takasaki - K. Yamaji - N. Tamura THU0362 INCIDENCE OF MAJOR INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / K. Yap* - L. Kyi - J. Chang - P. Nguyen - R. Kandane-Rathnayake - A. Hoi THU0363 ASSOCIATION OF DEPRESSION WITH SOCIOECONOMIC STATUS, ANTICARDIOLIPIN ANTI-BODIES, AND ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE KORNET REGISTRY / K.-E. Lee* - J.-H. Kang - D.-J. Park - S.-S. Lee THU0364 RELATIONSHIP BETWEEN DISEASE ACTIVITY INDEX SCORES AND PHYSICIAN GLOBAL ASSESSMENT IN EARLY AND NON-EARLY SYSTEMIC LUPUS ERYTHEMATOSUS / M. Garabajiu* - V. Sadovici-Bobeica - L. Mazur-Nicorici - M. Cebanu - V. Salaru - M. Mazur THU0365 POTENTIAL PREDICTIVE FACTORS INFLUENCING ESSDAI OF PRIMARY SJÖGREN S SYNDROME PATIENTS / M. Maślińska* - J. Dmowska-Chalaba - M. Mańczak - B. Kwiatkowska THU0366 STUDY OF THE ROLE OF MICRO-RNA 20A EXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS IN AN EGYPTIAN COHORT / M. S. Elkhalifa* - M. Zehairy - M. Tayel - A. Elkeraie - D. Elkaffash - N. Baddour THU0367 PREVALENCE AND SIGNIFICANCE OF ANTI-PHOSPHATIDYLSERINE ANTIBODIES: A POOLED ANALYSIS IN 5992 PATIENTS / M. Radin* - I. Cecchi - E. Rubini - S. Karen - D. Roccatello - M. Mahler - S. Sciascia THU0368 ARE ANTI-PHOSPHATIDYLSERINE PROTHROMBIN ANTIBODIES A USEFUL SCREENING TOOL FOR THE LUPUS ANTICOAGULANT? / M. M. Pham* - G. Orsolini - C. S. Crowson - M. R. Snyder - R. K. Pruthi - K. G. Moder THU0369 CREATION OF A WEIGHTED SLICC SLE CLASSIFICATION CRITERIA AND COMPARISON WITH PROPOSED EULAR/ ACR SLE CLASSIFICATION CRITERIA / M. Petri* - D. W. Goldman - L. S. Magder on behalf of SLICC THU0370 THE SIGNIFICANCE OF NON-MYDRIATIC FUNDUS EXAMINATION OPERATED BY RHEUMATOLOGISTS IN SCREENING FOR RETINOPATHY OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / M. Yang* - Q. Lv - Z. Lin - J. Qi - X. Guo - J. Gu THU0371 CORRELATION BETWEEN IRREGULAR MENSTRUATION AND DISEASE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS: 1 YEAR COHORT STUDY / N. Oguro* - N. Yajima - M. Saito THU0372 ULTRASONOGRAPHIC SCORING OF THE MAJOR SALIVARY GLANDS: IS THERE A RELATIONSHIP WITH DISEASE ACTIVITY AND FUNCTIONAL STATUS OF THE GLANDS? / N. Inanc* - Y. Yalcinkaya - G. Mumcu - Z. Erturk - A. U. Unal - P. Atagunduz - H. Direskeneli THU0373 THE MARKERS USEFUL IN PREDICTING LUPUS NEPHRITIS IN CLINICAL PRACTICE / P. Dąbrowski* - K. Marczak - A. Gala-Błądzińska - K. Gargasz - M. Dąbrowska THU0374 FACTORS ASSOCIATED WITH HIGH-DOSE CORTICOSTEROID USE IN SLE PATIENTS POST INITIATION OF SLE THERAPY / K. Schroeder - J. Paik - R. W. Hoffman* - S. Gelwicks THU0375 QUALITY OF LIFE IN INDIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN DURABLE REMISSION: PSYCHOSOCIAL AND DEMOGRAPHIC FACTORS / R. P. Goswami* - R. Chatterjee - A. Mitra - B. Bhattacharya - A. Ghosh - P. Ghosh THU0376 CHARACTERISTICS OF PRIMARY SJÖGREN S SYNDROME PATIENTS WITH MORPHOLOGICAL CHANGES OF THE PAROTID GLANDS IN MR IMAGING / S. Zhao* - H. Zhang - C. Chu - X. Feng - L. Sun THU0377 INFLUENCE OF UNDIAGNOSED VERTEBRAL FRACTURES ON ORGAN DAMAGE IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Shkireeva* - O. M. Lesnyak - E. G. Zotkin THU0378 WIRE-LOOP LESION IS ASSOCIATED WITH SEROLOGICAL IMMUNE ABNORMALITY, BUT NOT RENAL PROGNOSIS IN LUPUS NEPHRITIS / T. Zoshima* - S. Hara - M. Kawano THU0379 CORONARY ARTERY DISEASE IN SLE: A CASE-CONTROLLED ANGIOGRAPHIC STUDY / T. Chazal* - M. Kerneis - P. Guedeney - J. Haroche - A. Mathian - P. Ruffat - F. Cohen-Aubart - G. Montalescot - Z. Amoura THU0380 DIAGNOSTIC UTILITY OF ANTI-DFS-70 AUTOANTIBODIES IN A UNIVERSITY RHEUMATOLOGY CENTER / U. Salzer - A. C. Venhoff - I. Jandova - R. E. Voll - J. Thiel - N. Venhoff* THU0381 HIGH LEVELS OF CIRCULATING TYPE I, II AND III INTERFERONS DEFINE DISTINCT PATIENT SUBSETS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / V. Oke* - I. Gunnarsson - J. M. Dorschner - A. Zickert - T. B. Niewold - E. Svenungsson THU0382 FATIGUE IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CONTRIBUTING FACTORS AND EFFECTS ON THE QUALITY OF LIFE / X. Du* - Y. Zhuang - Q. Zhao - H. Chen - B. Shen THU0383 PERFORMANCE OF MUSCULOSKELETAL INVOLVEMENT OF SYSTEMIC LUPUS ERYTHEMATOSIS: AN ULTRASOUND STUDY IN 114 PATIENTS / Y. Geng* THU0384 SALIVARY GLAND ULTRASONOGRAPHY AND STIMULATED SALIVARY FLOW CORRELATED WITH SALIVARY GLAND BIOPSY AMONG PATIENTS WITH SJÖGREN SYNDROME AND SICCA SYMPTOMS: EXPERIENCE FROM A SINGLE MEDICAL CENTER IN TAIWAN / Y. P. Tsao* - M. H. Chen - S. Y. Wu - C. Y. Wu - W. S. Chen - C. C. Lai - C. Y. Tsai THU0385 URINARY INFLAMMATORY CELLS REFLECT HISTOPATHOLOGICAL KIDNEY INJURY IN PATIENTS WITH LUPUS NEPHRITIS / Y. Wada* - M. Sudo - M. Sakatsume - T. Kuroda - M. Nakano - I. Narita THU0386 DIFFERENCE OF IMAGE FEATURES ON COMPUTED TOMOGRAPHY BETWEEN LUPUS ENTERITIS AND MESENTERIC VASCULITIS OF OTHER CONNECTIVE TISSUE DISEASES / Y. Yoshida* - T. Kondo - K. Yukawa - T. Tokunaga - T. Kuranobu - K. Oi - T. Nojima - S. Hirata - E. Sugiyama * Presenting author

69 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 67 TOPIC: SCLERODERMA, MYOSITIS AND RELATED SYNDROMES Poster tour T9: Abstracts N : SSc, myositis, related syndromes - a bouquet of surprises Ulf Müller-Ladner (Germany), Peter Korsten (Germany) THU0387-THU0396 THU0387 HIGH-THROUGHPUT QUANTITATIVE HISTOLOGY IN SYSTEMIC SCLEROSIS SKIN DISEASE USING COMPUTER VISION / C. Correia* - M. Hinchcliff - M. Mahoney THU0388 DIFFERENCES IN CLINICAL COURSES AND SERUM MARKERS OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-AMINOACYL-TRANSFER RNA SYNTHETASE ANTIBODY AND ANTI-MELANOMA DIFFERENTIATION- ASSOCIATED GENE 5 ANTIBODY-POSITIVE POLYMYOSITIS/DERMATOMYOSITIS / K. Akashi* - Y. Nose - T. Shirai - Y. Fujikawa - T. Nagamoto - T. Okano - S. Takahashi - S. Sendo - A. Onishi - J. Saegusa - A. Morinobu THU0389 BORDERLINE PULMONARY HYPERTENSION WAS ASSOCIATED WITH REDUCED CARDIAC OUTPUT DURING EXERCISE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES / A. Marra - C. Nagel - B. Egenlauf - P. Xanthouli* - S. Harutyunova - N. Blank - H.-M. Lorenz - C. Fiehn - N. Benjamin - C. Fischer - E. Bossone - A. Cittadini - E. Grünig THU0390 PATIENTS WITH SYSTEMIC SCLEROSIS DEVELOP FOCAL FIBROSIS OVER TIME, AND INCREASED ECV DIFFUSE FIBROSIS SEEN IN POOR PROGNOSTIC GROUP - A FIRST LONGITUDINAL CARDIAC MRI STUDY / R. B. Dumitru* - L.-A. Bissell - B. Erhayiem - G. Fent - E. M. Hensor - A. Giollo - A. Kidambi - J. Greenwood - F. Del Galdo - S. Plein - M. H. Buch THU0391 CLINICAL VALUE OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ESOPHAGEAL DYSMOTILITY IN SYSTEMIC SCLEROSIS / C. Sobrino Grande* - C. Pijuan Moratalla - N. Almeida Arostegui - L. Gorospe Sarasúa - C. de la Puente Bujidos THU0392 SYSTEMIC SCLEROSIS AND PRIMARY BILIARY CHOLANGITIS: AN OVERLAP SYNDROME? PRELIMINARY DATA FROM A MULTICENTRE EUSTAR STUDY / G. Lepri* - P. Airò - O. Distler - K. Andréasson - Y. Braun-Moscovici - E. De-Langhe - C. Bruni - M. Matucci-Cerinic - Y. Allanore on behalf of EUSTAR co-authors THU0393 THE PREDICTOR OF MALNUTRITION IN SYSTEMIC SCLEROSIS (PREMASS) SCORE: A VALIDATED COMBINED INDEX PREDICTIVE OF FUTURE WEIGHT LOSS IN SYSTEMIC SCLEROSIS / G. Bagnato* - E. Pigatto - A. Bitto - N. Irrera - C. G. Pizzino - G. Abignano - A. Ferrera - D. Sciortino - M. Hutichinson - F. Squadrito - M. Buch - P. Emery - E. Zanatta - S. Gangemi - W. N. Roberts - A. Saitta - F. Cozzi - F. Del Galdo THU0394 ENTHESITIS IN SYSTEMIC SCLEROSIS (SSC): AN ULTRASOUND (US) PILOT STUDY / R. Terenzi* - R. Karalilova - S. Bellando-Randone - S. Guiducci - M. Manetti - E. Romano - D. E. Furst - G. Pacini - A. Batalov - M. Matucci-Cerinic THU0395 INFLUENCE OF SETTING AN UPPER LIMIT OF THE MRSS AS AN INCLUSION CRITERION IN SSC CLINICAL TRIALS ON THE RATIO OF SKIN FIBROSIS PROGRESSION VS. IMPROVEMENT - AN ANALYSIS OF THE GENISOS COHORT / C. Mihai* - R. Dobrota - S. Assassi - M. Mayes - O. Distler on behalf of GENISOS collaboration THU0396 COMBINED POSITRON EMISSION TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF SYSTEMIC SCLEROSIS GASTROINTESTINAL INVOLVEMENT / S.-A. Ng* - S. Marchesseau - Y. Wang - J. Schaefferkoetter - W. Xie - D. Ng - J. Totman - A. H. Low THU0397 THE PROGNOSTIC VALUE OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS AND A TWO-YEAR FOLLOW-UP OF FORCED VITAL CAPACITY / A. A. A. Mohamed* - M. Hassanien THU0398 UNEXPLAINED IRON DEFICIENCY IS FREQUENT IN SYSTEMIC SCLEROSIS / A. Sari* - A. Gill - S. I. Nihtyanova - V. H. Ong - C. P. Denton THU0399 FEMALE SEXUAL DYSFUNCTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES / B. Hermankova* - M. Spiritovic - H. Smucrova - S. Oreska - H. Storkanova - K. Pavelka - L. Senolt - H. Mann - J. Vencovsky - M. Tomcik THU0400 INCIDENCE AND RISK FACTORS FOR GANGRENE IN PATIENTS WITH SYSTEMIC SCLEROSIS FROM THE EUSTAR COHORT / C. Mihai* - O. Distler - A. M. Gheorghiu - P. I. Constantin - R. Dobrota - S. Jordan - V. Smith - E. Hachulla - J. Henes - E. Siegert - S. Vettori - U. Müller-Ladner - M. Matucci-Cerinic - Y. Allanore on behalf of EUSTAR THU0401 GLOBAL LONGITUDINAL STRAIN AS EARLY PREDICTOR OF SYSTOLIC DYSFUNCTION IN SYSTEMIC SCLEROSIS / C. Fischetti* - F. Guerra - A. Ferrarini - L. Zuliani - G. Stronati - P. Fraticelli - M. G. Danieli - A. Capucci - A. Gabrielli THU0402 DO WE HAVE GOOD INSTRUMENTS TO PREDICT MAJOR CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS? / C. Radu* - L. Groseanu - T. Gudu - A. Balanescu - D. Predeteanu - V. Bojinca - D. Opris-Belinski - A. Borangiu - I. Saulescu - S. Daia-Iliescu - C. Constantinescu - D. Mazilu - F. Berghea - M. M. Negru - V. Vlad - M. Abobului - R. Ionescu THU0403 SERUM LEVELS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND INTERLEUKIN-1 FAMILY CYTOKINES ARE ELEVATED IN SYSTEMIC SCLEROSIS / E. Lin* - F. Vincent - J. Harris - R. Kandane-Rathnayake - G.-S. Ngian - J. Sahhar - E. Morand - T. Lang THU0404 ESOPHAGEAL INVOLVEMENT PREDICTS PULMONARY FUNCTION DETERIORATION IN PATIENTS WITH SYSTEMIC SCLEROSIS / E. De Lorenzis - G. Natalello* - L. Berardini - G. Canestrari - L. Verardi - L. Gigante - S. Bosello - L. Richeldi - G. Ferraccioli - E. Gremese THU0405 THE ASSOCIATION BETWEEN BASELINE SERUM RESISTIN LEVELS AND THE DEVELOPMENT OF NEW DIGITAL ULCERS IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS / F. Pignataro* - D. P. E. Margiotta - G. Sambataro - L. Navarini - A. Gigante - E. Rosato - A. Afeltra THU0406 IV CYCLOPHOSPHAMIDE VS. RITUXIMAB FOR THE TREATMENT OF EARLY DIFFUSE SCLERODERMA LUNG DISEASE: OPEN LABEL, RANDOMISED, CONTROLLED TRIAL / G. Sircar - R. P. Goswami - D. Sircar - D. Rath - S. Mondal - P. S. Mahapatra - A. Ghosh - P. Ghosh* THU0407 EVALUATION OF SOLUBLE AND MEMBRANE HLA-G IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ROLE OF THESE MOLECULES IN THE PATHOGENESIS OF THE DISEASE / G. Murdaca* - P. contini - S. Negrini - M. Borro - F. Puppo 14 June 2018 * Presenting author

70 68 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0408 CHARACTERISTICS OF MILD TO MODERATE LUNG DISEASE IN SYSTEMIC SCLEROSIS AND IMPACT OF SURVIVAL; DATA FROM THE POPULATION-BASED, NATIONWIDE NORWEGIAN COHORT / H. Fretheim* - M. Seip - A.-K. Halse - H. Bitter - M. Wallenius - M. Aaløkken - T. Garen - Ø. Midtvedt - Ø. Molberg - A.-M. Hoffmann-Vold THU0409 MANAGEMENT OF SYSTEMIC SCLEROSIS (SSC) RELATED DIGITAL ULCERS (DU) IN EXPERT TERTIARY CENTRES: RESULTS FROM THE ANALYSIS OF THE MULTICENTRE OBSERVATIONAL REAL-LIFE DESSCIPHER/EUSTAR STUDY / J. Blagojevic* - G. Abignano - Y. Allanore - J. Avouac - L. Cometi - L. Czirják - C. Denton - O. Distler - M. Frerix - S. Guiducci - D. Huscher - V. K. Jaeger - V. Lóránd - B. Maurer - S. Nihtyanova - G. Riemekasten - E. Siegert - G. Valentini - S. Vettori - U. A. Walker - U. Müller-Ladner - F. Del Galdo - M. Matucci-Cerinic THU0410 SURVIVAL OF PATIENTS WITH MUSCLE BIOPSY PROVEN IDIOPATHIC INFLAMMATORY MYOPATHY BASED ON A STUDY IN A TERTIARY UNIVERSITY CENTRE / K. Gulyás* - E. Pál - T. Minier - T. Berki - L. Czirják - C. Varjú THU0411 MYASTHENIA GRAVIS WITHOUT THYMIC PATHOLOGY AND POLYMYOSITIS: A RARE ASSOCIATION / L. Castelnovo* - P. Faggioli - A. Tamburello - A. G. Gilardi - A. Laria - A. M. Lurati - K. A. Re - D. Mazzocchi - M. G. Marrazza - A. Mazzone THU0412 ABSOLUTE REDUCTION OF PERIPHERAL CD4 + REGULATORY T CELL SUBSET OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS RESTORATION BY SHORT-TERM AND LOW DOSE IL-2 TREATMENT / L. Shang* - J. Yuan - Q. Li - X. Liu - J. Luo - C. Gao - X. Li - H. Gao THU0413 NORMALIZATION OF NAILFOLD MICROVASCULATURE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SEVERE SYSTEMIC SCLEROSIS / M. Boonstra* - D. C. Noordhoek - L. J. Beaart-van de Voorde - T. W. Huizinga - J. K. de Vries-Bouwstra THU0414 ASSOCIATION OF THE ESOPHAGEAL DILATION AND INTERSTITIAL LUNG DISEASE ON CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN PATIENTS WITH IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY / F. Salaffi - M. Di Carlo* - M. Carotti - P. Fraticelli - A. Gabrielli - A. Giovagnoni THU0415 ANTI-PM/SCL ANTIBODY CLINICAL ASSOCIATIONS IN PATIENTS WITH SYSTEMIC SCLEROSIS. ANALYSIS OF THE MULTICENTER EUSTAR COHORT / M. G. Lazzaroni* - A. Furloni - I. Cavazzana - S. Zingarelli - F. Franceschini - A. Tincani - S. Bellando-Randone - C. Caimmi - E. Hachulla - Y. Allanore - P. Airo on behalf of EUSTAR co-authors THU0416 VERTEBRAL FRACTURE PREVALENCE AND MEASUREMENT OF THE SCANOGRAPHIC BONE ATTENUATION COEFFICIENT ON CT SCAN IN 70 PATIENTS WITH SYSTEMIC SCLERODERMA / M. Fauny* - E. Bauer - E. Albuisson - J. Perrier-Cornet - J. Deibener - F. Chabot - D. Mandry - O. Huttin - I. Chary-Valckenaere - D. Loeuille THU0417 WHOLE BODY DISTRIBUTION AND CLINICAL ASSOCIATIONS OF TELANGIECTASIA IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY / M. Jouvray* - D. Launay - S. Dubucquoi - V. Sobanski - C. Podevin - M. Lambert - S. Morell-Dubois - H. Maillard - P.-Y. Hatron - E. Hachulla - J. Giovannelli THU0418 LONG -TERM EFFICACY AND SAFETY OF MONOTHERAPY VERSUS COMBINATION THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (PAH): A RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA REGISTRY (RESCLE) / M. Pestaña-Fernández* - M. Rubio-Rivas - N. Villalba-Jiménez - B. Marí-Alfonso - A. Guillén-Del-Castillo - M. Freire - J. A. Vargas-Hitos - J. A. Todolí-Parra - M. Rodríguez-Carballeira - G. Espinosa-Garriga - X. Corbella Virós - V. Fonollosa-Pla - C. P. Simeón-Aznar on behalf of RESCLE THU0419 ASSOCIATION OF INFLAMMATORY MARKERS C-REACTIVE PROTEIN AND ERYTHROCYTE SEDIMENTATION RATE WITH PULMONARY FUNCTION TESTS AND EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ESCSG-AI) IN SYSTEMIC SCLEROSIS - ASSOCIATED INTERSTITIAL LUNG DISEASE IN FOLLOW UP STUDY / O. B. Ovsyannikova* - O. Koneva - L. Ananieva THU0420 AN EXTENT OF INTERSTITIAL LUNG DISEASE IS A POTENTIAL PREDICTOR OF RESPONSE TO A-B CELL THERAPY IN THE PATIENTS WITH SSC / O. Koneva* - O. Desinova - O. Ovasyannikova - L. Garzanova - M. Starovoytova - L. Ananieva THU0421 PREVALENCE AND CLINICAL CORRELATES OF SMALL AIRWAY OBSTRUCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS / P. Ostojic* - M. Vujovic - A. Blanka Protic THU0422 PERFORMANCE OF EULAR/ACR 2017 IDIOPATHIC INFLAMMATORY MYOPATHIES CLASIFICATION CRITERIA IN A REAL WORLD COHORT / R. A. Gómez* - A. Braillard Poccard - M. Pino - G. Medina - D. Dubisnky THU0423 EPIDEMIOLOGY AND SURVIVAL OF SYSTEMIC SCLEROSIS-SYSTEMIC LUPUS ERYTHEMATOSUS OVERLAP SYNDROME / S. Alharbi * - Z. Ahmad - A. Bookman - Z. Touma - J. Sanchez-Guerrero - N. Mitsakakis - S. R. Johnson THU0424 ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS: COMPARISON OF CLINICAL, RADIOGRAPHIC AND SONOGRAPHIC FINDINGS / S. Thietart* - K. Louati - E. Gaigneux - M. Gatfosse - S. Riviere - J. Sellam - F. Berenbaum - O. Fain - A. Mekinian THU F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY AND LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS / S. Bellando Randone* - L. Tartarelli - E. Cavigli - L. Tofani - C. Bruni - G. Lepri - J. Blagojevic - A. Moggi Pignone - C. Mihai - J. Avouac - A. Passeri - M. T. De Cristofaro - O. Distler - Y. Allanore - S. Guiducci - M. Matucci Cerinic THU0426 ETHNIC VARIATION IN SYSTEMIC SCLEROSIS MORBIDITY AND MORTALITY / H. Al-Sheikh - Z. Ahmad - S. R. Johnson* THU0427 COMPARABLE CARDIOVASCULAR DISEASE AND NEOPLASM RATES BUT HIGHER FREQUENCY OF DEPRESSION IN SYSTEMIC SCLEROSIS VERSUS RHEUMATOID ARTHRITIS: A MULTICENTRE COMPARATIVE STUDY OF COMORBIDITIES / S. Panopoulos* - M. G. Tektonidou - A. Drosos - S.-N. Liossis - T. Dimitroulas - L. Sakkas - D. Boumpas - P. Voulgari - D. Daoussis - K. Thomas - G. Georgiopoulos - G. Vosvotekas - D. Vassilopoulos - P. P. Sfikakis THU0428 SKIN SCORE CHANGES IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) PATIENTS ARE ASSOCIATED WITH OVERALL DISEASE SEVERITY / T. Nevskaya* - M. Baron - B. Zheng - C. A. Baxter - D. R. Ramey - J. E. Pope on behalf of Canadian Scleroderma research group THU0429 NAILFOLD VIDEO CAPILLAROSCOPY AND DETERIORATION OF SKIN INVOLVEMENT AND LUNG FUNCTION TESTS IN SYSTEMIC SCLEROSIS: A 3-YEAR PROSPECTIVE STUDY / V.-K. Bournia* - K. Kottas - A. Iliopoulos - P. P. Sfikakis - P. Vlachoyiannopoulos THU0430 DESCRIPTION AND PROGNOSIS FACTORS OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE OUTCOME ON SERIAL HRCT / A. Forestier - N. Le Gouellec - A. Duhamel - G. Kramer - T. Perez - V. Sobanski* - S. Morell Dubois - M. Lambert - P.-Y. Hatron - E. Hachulla - H. Behal - R. Matran - D. Launay - M. Remy Jardin * Presenting author

71 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 69 THU0431 ARE EXTREMITY TELANGIECTASES RELATED TO SEVERE DISEASE IN SYSTEMIC SCLEROSIS? / Y. Yalçınkaya* - O. Pehlivan - Z. Ertürk - U. Gazel - A. Aksoy - F. Alibaz-Oner - P. Atagunduz - H. Direskeneli - N. Inanc THU0432 PERICARDIAL EFFUSION IS AN INDEPENDENT FACTOR PREDICTIVE OF SCLERODERMA RENAL CRISIS / Y. Fujisawa* - S. Hara - T. Zoshima - K. Ito - I. Mizushima - H. Fuji - K. Yamada - M. Kawano TOPIC: VASCULITIS THU0433 THE PREVALENCE OF SPONDYLOARTHROPATHY IN PATIENTS WITH TAKAYASU ARTERITIS / S. Güzel - B. Armağan - Ö. Varan - A. Erden - H. Küçük - H. Babaoğlu - N. Atas - L. Kılıç - B. Göker - S. Haznerdaroğlu - M. A. Öztürk - U. Kalyoncu - A. Akdoğan - A. Tufan* THU0434 PREDICTORS OF LONG-TERM GLUCOCORTICOID THERAPY IN POLYMYALGIA RHEUMATICA: DISCONTINUATION IS MORE COMMON FOR PATIENTS TREATED WITH AMINOBISPHOSPHONATES / A. Giollo* - F. Bettili - F. Ghellere - O. Viapiana - L. Idolazzi - D. Gatti - M. Rossini THU0435 LONG-TERM OUTCOME AND PROGNOSIS FACTORS OF COMPLICATIONS IN THROMBOANGIITIS OBLITERANS (BUERGER S DISEASE): A MULTICENTER STUDY OF 224 PATIENTS / A. Le Joncour* - S. Soudet - A. Dupont - O. Espitia - F. Koskas - P. Cluzel - P.-Y. Hatron - P. Cacoub - M. Resche-Rigon - M. Lambert - D. Saadoun THU0436 INCIDENCE, PREVALENCE, MORTALITY AND CHRONIC RENAL DAMAGE OF ANCA-ASSOCIATED GLOMERULONEPHRITIS IN A 20 YEAR POPULATION-BASED COHORT / A. Berti* - E. Cornec-Le Gall - D. Cornec - E. Matteson - C. S. Crowson - S. Sethi - F. Fervenza - U. Specks THU0437 ILLNESS PERCEPTION AND ITS CORRELATES IN PATIENTS WITH IN ANCA-ASSOCIATED VASCULITIS - PRELIMINARY REPORT / A. Masiak* - K. Nowicka-Sauer - D. Banaszkiewicz - B. Grygiel-Górniak - M. Komorniczak - A. Hajduk - Z. Zdrojewski THU0438 COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS ASSOCIATED TO CYSTOID MACULAR EDEMA DUE TO BEHÇET S DISEASE. MULCITENTER STUDY OF 40 CASES / B. Atienza-Mateo* - V. Calvo-Río - J. L. Martín-Varillas - R. Demetrio-Pablo - E. Beltrán - M. Gandía - M. Mesquida - A. Adan - M. V. Hernández - D. Díaz - E. Valls - L. Martinez - M. Cordero - M. Díaz - J. M. Herreras - O. Maiz - A. Blanco - I. Torre - M. García - F. Francisco - S. Insua - R. Almodóvar - O. Ruiz - F. Jiménez - J. Manero - J. M. Nolla - M. Hernandez - M. A. González-Gay - R. Blanco THU0439 TOCILIZUMAB IN GIANT CELL ARTERITIS. NATIONAL MULTICENTER STUDY OF 134 PATIENTS OF CLINICAL PRACTICE / D. Prieto-Peña* - J. Loricera - J. Martín-V - M. Calderón-G - V. Aldasoro - M. Varela-G - R. Ibánez-B - I. Villa - E. Aurrecoechea - S. Castañeda - A. Humbría - E. Díez - C. Moriano - S. Romero-Y - J. Narváez - C. Gómez-A - A. Mera - E. Pérez-P - R. Dos Santos - C. Barbazán - R. Melero - E. Becerra-F - Á. García - M. Revenga - C. Larena - E. Miguel - N. Álvarez-R - C. Galisteo - F. Sivera - A. Olivé-M - A. Prior - M. Álvarez - L. Marena-R - C. Fernández-L - F. Navarro - E. Raya - N. Ortego - E. Galíndez-A - B. Arca - S. Fernández - R. Solans-L - A. Conesa - C. Hidalgo - C. Vázquez - J. Román-I - F. Ortiz-S - P. Lluch - S. Manrique-A - P. Vela - C. Torres-M - J. Nieto - C. Ordas-C - E. Salgado-P - C. Gómez - J. Toyos - I. Hernández - F. Maceiras-P - N. Fernández-L - A. García - N. Palmou-F - V. Calvo-R - C. González-V - L. Domínguez-C - A. Corrales - J. Hernández - M. González-Gay - R. Blanco THU0440 SOLUBLE CTLA-4 IS ELEVATED IN PATIENTS WITH POLYMYALGIA RHEUMATICA AND CORRELATES WITH VASCULAR INFLAMMATION DETECTED BY PET/CT / D. Camellino* - M. Marchiano - G. Pesce - G. Bianchi - M. Bagnasco - M. A. Cimmino - D. Saverino THU0441 ENDOTHELIAL DISFUNCTION IN POLYMYALGIA RHEUMATICA / D. Birra* - L. Santoro - S. Bosello - A. Nesci - G. Peluso - G. Ferraccioli - E. Gremese - A. Santoliquido - A. Zoli THU0442 IS BEHCET S SYNDROME GETTING MILDER? A RETROSPECTIVE ANALYSIS OF INITIAL PRESENTATION FINDINGS THROUGHOUT 4 DECADES / E. Dincses* - Y. Ozguler - D. Ucar - Y. Ozyazgan - S. Ugurlu - G. Hatemi - M. Melikoglu - S. Yurdakul - H. Yazici - E. Seyahi THU0443 A PROBABILITY SCORE FROM A FAST TRACK CLINIC TO AID THE MANAGEMENT OF SUSPECTED GIANT CELL ARTERITIS / F. Laskou* - F. Coath - S. Mackie - S. Banerjee - T. Aung - B. Dasgupta THU0444 AORTIC DILATATION IN PATIENTS WITH LARGE VESSEL VASCULITIS: A LONGITUDINAL CASE CONTROL STUDY USING POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY / F. Crescentini* - F. Muratore - L. Spaggiari - G. Pazzola - L. Boiardi - N. Pipitone - C. Salvarani THU0445 PRIMARY DIAGNOSIS OF LARGE VESSEL VASCULITIS BY TISSUE HISTOLOGY AFTER SURGERY OF AORTIC VALVE AND ASCENDING AORTA / G. Assmann* - I. Karliova - F. Langer - M. Schreiber - M. Pfreundschuh - H.-J. Schaefers THU0446 USEFULNESS OF COLOR DOPPLER ULTRASONOGRAPHY IN FOLLOW UP OF GIANT CELL ARTERITIS / H. Mukoyama* - K. Nishimura - K. Kadoba - R. Saito - D. Waki - T. Yokota THU0447 NO ADVANTAGE OF METHOTREXATE IN THE TREATMENT OF GIANT CELL ARTERITIS / I. Monjo Henry* - L. Coronel - I. Castaño - D. Peiteado - S. García-Carazo - A. Balsa - E. de Miguel THU0448 IS THERE AN ASSOCIATION BETWEEN ADULT IGA VASCULITIS AND CANCER? / J. Ostrovršnik* - Ž. Rotar - R. Ješe - M. Tomšič - A. Hočevar THU0449 DIAGNOSTIC PERFORMANCE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN A COHORT OF UNSELECTED SPANISH PATIENTS / J. Loureiro-Amigo* - J. Mestre Torres - C. L. Franco Jarava - A. Marín Sánchez - R. Solans Laqué THU0450 DIAGNOSTIC RELEVANCE OF ORGAN BIOPSIES IN ANCA ASSOCIATED VASCULITIS / J. Kronfeldner* - J. Eifert - S. Quickert - P. Oelzner - M. Busch - C. Kroegel - G. Wolf - T. Neumann THU0451 CAUSE OF DEATH IN PATIENTS DIAGNOSED WITH GIANT CELL ARTERITIS IN WESTERN NORWAY / L. K. Brekke* - A. P. Diamantopoulos - B.-T. Fevang - J. Assmus - C. G. Gjesdal THU0452 ANTI-INTERLEUKIN-6 (TOCILIZUMAB) EXPERIENCE IN TAKAYASU S ARTERITIS PATIENTS / L. Kilic* - O. Karadag - A. Erden - A. Sari - B. Armagan - E. Firat - U. Kalyoncu - S. Apras Bilgen - S. Kiraz - I. Ertenli - A. Akdogan THU0453 EFFICACY OF AB INITIO OR VERY EARLY INTRODUCTION OF IMMUNOSUPPRESSIVE THERAPY IN GIANT CELL ARTERITIS: A MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY / L. Quartuccio* - E. Cavallaro - F. Angelotti - R. Capecchi - G. Vitiello - D. Cammelli - A. Tavoni - S. De Vita 14 June 2018 * Presenting author

72 70 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0454 INCREASED FDG UPTAKE OF THE MUSCLES IN POLYMYALGIA RHEUMATICA (PMR) / M. A. Cimmino* - N. Vecchiola - M. Bauckneht - D. Camellino - S. Morbelli - S. Paolino - M. Cutolo - G. Sambuceti THU0455 AGE IS MORE CLOSELY ASSOCIATED WITH POSITIVE TEMPORAL ARTERY BIOPSY OVER BIOPSY LENGTH IN LARGE VETERANS ADMINISTRATION DATABASE STUDY / M. B. Morcos* - S. Chung - B. Ng THU0456 THE CLINICO-HISTOPATHOLOGICAL ALGORITHM FOR DIFFERENTIAL DIAGNOSIS OF BUERGER S DISEASE, TAKAYASU ARTERITIS AND ATHEROSCLEROTIC OCCLUSIVE DISEASE / M. Bagriy* - O. Zimba THU0457 INTERLEUKIN-6 EXPRESSION IN INFLAMED AND NON-INFLAMED TEMPORAL ARTERIES FROM PATIENTS WITH GIANT CELL ARTERITIS / N. Pipitone* - F. Muratore - I. Tamagnini - A. Cavazza - L. Cimino - L. Boiardi - G. Restuccia - M. Bonacini - S. Croci - C. Salvarani THU0458 INVESTIGATION OF THE ROLE OF M-TOR PATHWAY IN KIDNEY NEEDLE BIOPSIES OF PATIENTS WITH ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODY-ASSOCIATED VASCULITIS / Z. Soypacaci - O. Cakmak - F. Cakalagaoglu - O. Gercik* - I. Ertekin - A. Uzum - R. Ersoy - S. Akar THU0459 SURVIVAL OF BIOPSY PROVEN GIANT CELL ARTERITIS IN NORTHERN ITALY: CORRELATION WITH CLINICAL, LABORATORY AND HISTOPATHOLOGICAL FINDINGS / P. Macchioni* - L. Boiardi - F. Muratore - M. Catanoso - A. Cavazza - P. Mancuso - L. Cimino - G. Restuccia - C. Salvarani THU0460 FULLY INTEGRATED 18F-FDG PET/MR IN LARGE VESSEL VASCULITIS / R. Padoan* - F. Crimì - M. Felicetti - F. Padovano - L. Punzi - C. Lacognata - R. Stramare - D. Cecchin - F. Bui - P. Zucchetta - F. Schiavon THU0461 COMPARISON BETWEEN CLINICAL PROFILE AND OUTCOME OF PATIENTS WITH JUVENILE ONSET AND ADULT ONSET TAKAYASU ARTERITIS / R. A Goel* - D. Danda - G. Joseph - A. Nair - R. Ravindran - V. Jeyaseelan THU0462 LONG-TERM FOLLOW-UP RESULTS OF TAKAYASU ARTERITIS COHORT: A TERTIARY-SINGLE CENTER STUDY / S. Kaymaz Tahra* - F. Alibaz-Oner - H. Direskeneli THU0463 COMPLEMENT FACTORS OF THE ALTERNATIVE PATHWAY IN GPA AND MPA / S. Fukui* - K. Ichinose - K.-E. Sada - M. Harigai - A. Kawakami on behalf of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) THU0464 INCREASED FREQUENCY OF OBSTRUCTIVE SLEEP APNEA SYNDROME IN BEHCET S SYNDROME PATIENTS WITH VENA CAVA SUPERIOR THROMBOSIS / A. Gokturk - S. N. Esatoglu* - Y. Ozguler - E. Atahan - B. Musellim - V. Hamuryudan - H. Yazici - E. Seyahi THU0465 A LONGITUDINAL STUDY OF NEUTROPHIL PHENOTYPE CHANGES IN GIANT CELL ARTERITIS / T. Kuret* - K. Lakota - P. Žigon - M. Ogrič - S. Sodin-Šemrl - S. Čučnik - M. Tomšič - A. Hočevar THU0466 SEXUAL DYSFUNCTION AND DEPRESSION IN BEHCET`S DISEASE - ARE THERE DIFFERENCES REGARDING PATIENT S ORIGIN / T. Xenitidis* - A.-C. Pecher - T. Schmalen - M. Henes - J. C. Henes THU0467 EFFICACY AND PATENCY OF REVASCULARISATION IN PATIENTS WITH THROMBOANGIITIS OBLITERANS (BUERGER S DISEASE) / T. Mirault* - M. Delahaye - A. Galloula - M. Guillet - S. Zarka - M.-C. Courtois - M. Sapoval - G. Goudot - E. Messas THU0468 SERUM ANGIOGENESIS BIOMARKERS PREDICT DISEASE OUTCOME IN GIANT CELL ARTERITIS / Y. van Sleen* - M. Sandovici - W. Abdulahad - J. Bijzet - A. Boots - E. Brouwer TOPIC: OSTEOPOROSIS Poster tour T10: New data on osteoporosis and fracture prevention Piet Geusens (Netherlands), Sandrine Bours (Netherlands) Abstracts N : THU0469-THU478 THU0469 QUANTIFYING THE TREATMENT WITH GLUCOCORTICOIDS AS A RISK FACTOR FOR THE OCCURRENCE OF OSTEOPOROSIS AND FRACTURES IN PATIENTS WITH RA / E. Wiebe* - R. Biesen - K. N. Zeiner - D. C. Freier - S. Hermann - G.-R. Burmester - F. Buttgereit THU0470 NON-CLONAL ELEVATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAINS IS PREDICTIVE OF HIP FRACTURE IN BOTH WOMEN AND MEN / S. Amin* - E. J. Atkinson - S. J. Achenbach - A. Dispenzieri - R. A. Kyle - S. V. Rajkumar THU0471 RISK FACTORS OF LOW BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. V. Monov* - D. Monova - M. Stambolova - R. Shumnalieva THU0472 FACTORS ASSOCIATED WITH READINESS FOR ADOPTING OSTEOPOROSIS TREATMENT CHANGE / M. I. Danila* - E. J. Rahn - A. S. Mudano - R. C. Outman - P. Li - D. T. Redden - F. A. Anderson - S. L. Greenspan - A. Z. LaCroix - J. W. Nieves - S. L. Silverman - E. S. Siris - N. B. Watts - S. Ladores - K. M. Meneses - J. R. Curtis - K. G. Saag THU0473 TREND OF MORTALITY AFTER OSTEOPOROTIC HIP FRACTURE IN A PERIOD OF 17 YEARS / R. Mazzucchelli* - O. Guzón-Illescas - E. Pérez-Fernandez - M. Peña - J. Quirós - N. Crespí-Villarías - A. García-Vadillo THU0474 UTILIZATION OF ANTI-OSTEOPOROTIC DRUGS IN REAL-WORLD DATA: AN ANALYSIS OF PERSISTENCE TO THERAPY AND RISK OF FRACTURE / V. Orlando - V. M. Monetti - F. Guerriero - A. Moretti - V. Russo - A. Piscitelli - G. Iolascon - E. Menditto* THU0475 INCIDENCE AND DETERMINANTS OF VERTEBRAL AND PERIPHERAL FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PROSPECTIVE LONGITUDINAL COHORT STUDY / F. El Hadiyen* - M. Tsang-A-Sjoe - M. ter Wee - A. Voskuyl - W. Lems - I. Bultink THU0476 SPONTANEOUS VERTEBRAL FRACTURES AFTER DENOSUMAB DISCONTINUATION: A REPORT OF 6 CASES / H. Florez* - J. Ramírez - A. Monegal - N. Guañabens - P. Peris THU0477 FACTORS ASSOCIATED WITH THE INITIATION OF TREATMENT AFTER FRAGILITY FRACTURE IN A FRACTURE LIAISON SERVICE / A. Saavedra* - A. Naranjo - S. Ojeda - R. Lopez - A. Molina - C. Alonso - I. Bernardos - C. Rodriguez-Lozano THU0478 BEFORE AND AFTER MENOPAUSE, OSTEOPOROSIS RISK FACTORS ARE DIFFERENT IN WOMEN WITH RHEUMATOID ARTHRITIS / J.-F. Chen* - T.-T. Cheng - S.-F. Yu - Y.-C. Chen - C.-Y. Hsu - H.-M. Lai - F.-M. Su - B. Y.-J. Su - W.-C. Chiu * Presenting author

73 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 71 THU0479 THE ANTIOSTEOPOROTIC TREATMENT IS SCARCE AMONG PATIENTS WITH VERTEBRAL FRACTURE REFLECTED IN THE RADIOLOGICAL REPORT: DATA FROM A FRACTURE UNIT-FLS / A. Pons-Bas* - J. Rosas - M. Hernández - C. Cano - E. Ivars - M. Lorente - J. Hernández - G. Santos-Soler - A. García - E. Salas - H. Arcos - J. M. Senabre-Gallego - J. Alvarado - J. Jiménez - C. López - M. López - A. Molinos - B. Statti - V. Miñanos - J. Monteagudo - X. Barber on behalf of AIRE-MB group THU0480 MULTI-DISCIPLINARY FRACTURE LIAISON SERVICE IN THE NORTH AREA OF GRAN CANARIA; 6 YEARS EXPERIENCE / A. Naranjo* - S. Ojeda - S. Rodríguez - A. Saavedra - F. Santana - A. Molina - A. Gonzalez - N. Martin - M. Afonso - C. Dominguez - I. Beirutti - O. Suarez - T. Marrero - C. Rodriguez-Lozano THU0481 PHYSICAL PERFORMANCE FACTORS INFLUENCING GAIT SPEED IN PATIENTS SURGICALLY TREATED FOR OSTEOPOROTIC HIP FRACTURES / B. R. Kim* THU0482 RELATIONSHIP BETWEEN MILD VERTEBRAL BODY DEFORMITY AND KELLGREN-LAWRENCE S OSTEOARTHRITIS LEVEL WITH THE PREVALENCE OF NON-TRAUMATIC DORSAL AND LUMBAR BACK PAIN IN FEMALE PATIENTS WITH RISK OF OSTEOPOROTIC VERTEBRAL COLLAPSE / C. A. Guillen-Astete* - C. Ijoán - J. R. Quiñones-Torres - M. Vázquez Díaz THU0483 BONE MINERAL DENSITY AND PREVALENCE OF OSTEOPOROSIS IN HIV-INFECTED PATIENTS IN COMPARISON WITH A REFERENCE SPANISH POPULATION: THE IMPORTANCE OF LOCAL NORMATIVE RANGES / C. Sobrino* - J. Loarce - F. López - J. Gallego - M. J. Vivancos - M. Pérez Elías - J. L. Casado - M. Vazquez THU0484 REBOUND-ASSOCIATED MULTIPLE VERTEBRAL FRACTURES AFTER DISCONTINUATION OF DENOSUMAB: NINE CASES REPORT / E. Fernández* - D. Benavent - G. Bonilla - I. Monjo - S. García - M. Bernad - A. Balsa - P. Aguado THU0485 PREDICTING 1-YEAR MORTALITY AFTER A FRAGILITY HIP FRACTURE - THE EXPERIENCE OF A FRACTURE LIAISON SERVICE / F. Aguiar* - M. Guerra - S. Ganhão - D. Gonçalves - T. Martins-Rocha - R. M. Ferreira - A. Águeda - R. Vieira - G. Terroso - C. Vaz - L. Costa THU0486 THE VITAMIN D RECEPTOR EXPRESSION IN SKELETAL MUSCLE OF WOMEN WITH DISTAL RADIUS FRACTURE / H. S. Gong* - K. Kim THU0487 AN AUDIT OF THE USE OF PERCUTANEOUS VERTEBROPLASTY FOR OSTEOPOROTIC VERTEBRAL FRACTURES IN A UK RHEUMATOLOGY CLINIC / J. Pinnell* - H. Merris - M. Dhillon - K. Chaudhuri THU0488 AGE AT THE TIME OF HIP FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS IS GREATER THAN IT WAS 10 YEARS AGO, BUT IS STILL YOUNGER THAN THAT OF THE GENERAL POPULATION / K. Arai* - J. Ajiro THU0489 THE IMPACT OF CALCIUM INTAKE AND PHYSICAL EXERCISE ON PEAK BONE MINERAL DENSITY / L. Brites - M. L. Marques* - A. Marques - A. Daniel - M. Santiago - J. Pereira da Silva THU0490 TEMPORAL INCREASES IN SIDE EFFECT CONCERNS OF OSTEOPOROSIS MEDICATIONS AMONG WOMEN WITH PREVIOUS FRACTURES / M. I. Danila* - E. J. Rahn - A. S. Mudano - R. C. Outman - P. Li - D. T. Redden - F. A. Anderson - S. L. Greenspan - A. Z. LaCroix - J. W. Nieves - S. L. Silverman - E. S. Siris - N. B. Watts - S. Ladores - K. M. Meneses - J. R. Curtis - K. G. Saag THU0491 FACTORS ASSOCIATED WITH ANNUAL PERCENTAGE CHANGES IN BONE MINERAL DENSITY: A-14 YEARS PROSPECTIVE POPULATION-BASED STUDY / M. L. Marques* - L. Brites - A. Marques - A. Daniel - M. Santiago - J. A. Pereira da Silva THU0492 PRELIMINARY STUDY OF THE BONE MASS IN LUNG TRANSPLANTED PATIENTS IN TREATMENT WITH DENOSUMAB / M. Barceló-Bru* - B. Rodríguez-Diez THU0493 ARE BISPHOSPHONATES SOLELY RESPONSIBLE FOR ATYPICAL FEMORAL FRACTURES? A CASE SERIES / M. S. Jamal* - C. Cockill - S. Knights THU0494 THE EFFICACY OF DENOSUMAB IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS DID NOT DEPEND ON PRIOR TREATMENT BUT WAS AFFECTED BY THE DOSAGE OF GLUCOCORTICOID / N. Iwamoto* - Y. Ueki - T. Aramaki - K. Ichinose - K. Eguchi - A. Kawakami THU0495 INDICES OF VERTEBRAL PAIN SYNDROME, PHYSICAL PERFORMANCE AND QUALITY OF LIFE IN OLDER AGE WOMEN WITH VERTEBRAL FRACTURES DEPENDING ON THEIR QUANTITY AND LOCALIZATION / N. Grygorieva* - V. Povoronyuk - O. Rybina THU0496 SKELETAL DEFICIT DUE TO ALTERED BONE QUALITY IN TYPE 1 DIABETES MELLITUS / S. Mohsin* - J. J. Sunny - K. Menon - S. Kaimala on behalf of CMHS, UAEU THU0497 IS THE SECONDARY OSTEOPOROSIS SOMETHING SECONDARY? EXPERIENCE OF A SECONDARY OSTEOPOROSIS CONSULTATION / S. García-Carazo* - P. Aguado Acin - L. Nuño - A. Villalba - A. Balsa THU0498 CORE ENDURANCE AND POSTURAL STABILITY IMPAIRMENTS IN OSTEOPOROTIC WOMEN: A CASE-CONTROL STUDY / S. Toprak Celenay* - D. Ozer Kaya THU0499 THE EFFECT OF CONCOMITANT TYPE OF VITAMIN D, BIOLOGICAL DMARDS AND DISEASE ACTIVITY FOR THERAPEUTIC EFFECT OF DENOSUMAB IN OSTEOPOROSIS PATIENTS WITH RHEUMATOID ARTHRITIS / S. Anno* - K. Inui - T. Okano - K. Mamoto - Y. Sugioka - M. Tada - T. Koike - H. Nakamura THU0500 EFFECTS OF LONG-TERM USE OF UNFRACTIONATED HEPARIN (UFH) OR LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH NEPHROTIC SYNDROME / S. V. Monov* - D. Monova - R. Shumnalieva THU0501 WHAT DOES TRABECULAR BONE SCORE CONTRIBUTE TO A FRACTURE LIAISON SERVICE? / S. Ojeda* - A. Naranjo - A. Saavedra - F. Santana - A. Molina - T. Marrero - O. Suarez - C. Rodriguez-Lozano THU0502 ASSESSMENT OF SEVERITY OF ATHEROSCLEROTIC LESIONS OF CAROTID ARTERIES IN MEN WITH CORONARY HEART DISEASE DEPENDING ON BONE MINERAL DENSITY AND RISK OF OSTEOPOROTIC FRACTURES / T. Raskina* - A. Voronkina - M. Letaeva - A. Kokov - O. Barbarash - E. Maluta THU0503 COST ANALYSIS OF ANTI-OSTEOPOROTIC DRUGS IN REAL-WORLD CLINICAL PRACTICE / V. Orlando* - V. M. Monetti - F. Guerriero - V. Russo - R. Piscitelli - M. Ruggeri - E. Menditto THU0504 UTILIZATION OF ANTI-OSTEOPOROTIC DRUGS IN REAL-WORLD DATA: A STUDY OF GENDER-RELATED DIFFERENCES / V. Orlando - V. M. Monetti - F. Guerriero - V. Russo* - A. Moretti - A. Piscitelli - R. Piscitelli - G. Iolascon - E. Menditto THU0505 INFLUENCE OF ORAL PREDNISOLONE ON EFFECT OF DENOSUMAB ON OSTEOPOROSIS IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS; 36 MONTHS OF FOLLOW-UP - A MULTICENTER REGISTRY STUDY / Y. Kanayama* - Y. Hirano - N. Takahashi - S. Asai - N. Ishiguro - T. Kojima on behalf of TBCR-BONE study group * Presenting author 14 June 2018

74 72 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 TOPIC: FIBROMYALGIA 14 June 2018 THU0506 CROSS-SECTIONAL ANALYSIS OF THE ASSOCIATIONS BETWEEN FIBROMYALGIA AND CANCER / A. Lichtenstein* - S. Tiosano - D. Comaneshter - A. D. Cohen - H. Amital THU0507 HETEROGENITY OF FIBROMYALGIA: PSYCHOPATHOLOGICAL CHARACTERISTICS OF DIFFERENT SUBTYPES AND EFFICACY OF THERAPY / A. Sarapulova* - O. Teplyakova THU0508 EVALUATION OF TISSUE SPECIFIC AUTOANTIBODIES IN FIBROMYALGIA PATIENTS WITH SICCA AND/OR XEROSTOMIA / E. Applbaum* - A. Lichtbroun THU0509 THE ROLE OF THIOL-DISULFIDE HOMEOSTASIS IN THE ETIOPATHOGENESIS OF FIBROMYALGIA / E. Sahingoz* - B. Nacir - M. Alisik - E. Ogus - O. Erel - H. Genc THU0510 HYPERSENSITIVITY, ALEXITHYMIA AND DISEASE CHARACTERISTICS OF PATIENTS PRESENTING WITH SYMPTOMS OF FIBROMYALGIA / H. Jacobs* - B. A. Grillet - D. De Bacquer THU0511 EFFECTS OF ADD-ON TRANSCRANIAL DIRECT CURRENT STIMULATION ON PAIN IN KOREAN PATIENTS WITH FIBROMYALGIA / J.-H. Kang* - K.-E. Lee - D.-J. Park - S.-S. Lee THU0512 HYPERBARIC OXYGEN THERAPY (HBOT) TREATMENT IN FIBROMYALGIA / M. Muratore* - L. Quarta - P. Sarzi Puttini - C. Cosentino - A. Grimaldi - E. Quarta THU0513 IS THERE A ROLE OF SERUM NESFATIN-1 LEVEL IN FIBROMYALGIA? / B. Bilgici - Y. Akyol - Y. Ulus - S. S. Urkmez - O. Kuru* THU0514 FAT BUT FIT. THE COMBINED ASSOCIATION OF BODY MASS INDEX AND CARDIORESPIRATORY FITNESS WITH THE FIBROMYALGIA SEVERITY AND TENDERNESS: THE AL-ÁNDALUS PROJECT / P. Acosta-Manzano* - B. Gavilán-Carrera - V. Segura-Jiménez - M. Borges-Cosic - I. C. García-Rodríguez - V. A. Aparicio THU0515 SOMATOSENSORY TEMPORAL DISCRIMINATION IS IMPAIRED IN FIBROMYALGIA / Z. Gunendi* - M. Polat - D. Vurallı - B. Cengiz Poster tour T11: Pain in the joint; managing a widespread problem David Walsh (United Kingdom), Francesco Carubbi (Italy) Abstracts N : THU0516-THU0525 THU0516 THU0517 THU0518 THU0519 THU0520 THU0521 EFFICACY AND SAFETY OF VITAMIN D3 IN PATIENTS WITH FIBROMYALGIA. RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL / L. I. Lozano Plata* - M. A. Garza Elizondo - D. Vega Morales - J. A. Esquivel Valerio - D. A. Galarza Delgado - K. Silva Luna - R. Díaz Niño de Rivera - A. Garza Guerra - G. Serna Peña - I. Hernández Galarza - L. E. Ramírez Monterrubio - J. P. Carrizales Luna IDENTIFICATION OF CANDIDATE GENES ASSOCIATED WITH FIBROMYALGIA SUSCEPTIBILITY IN SOUTHERN SPANISH WOMEN: THE AL-ÁNDALUS PROJECT / F. Estevez-Lopez* - D. Camiletti-Moirón - V. A. Aparicio - V. Segura-Jiménez - I. C. Álvarez-Gallardo - A. Soriano-Maldonado - M. Borges-Cosic - P. Acosta-Manzano - R. Geenen - M. Delgado-Fernández - L. J. Martínez-González - J. R. Ruiz - M. J. Álvarez-Cubero THE DIAGNOSTIC VALUE OF SELECTED MICRORNAS IN PATIENTS WITH FIBROMYALGIA ASSOCIATED WITH RHEUMATOID ARTHRITIS: A PILOT STUDY / L. J. Ghib* - R. Cojocneanu-Petric - L. Budisan - L. Muntean - I. Filipescu - I. Berindan-Neagoe - S. Rednic PREDICTION OF PERSISTENT KNEE PAIN BY PRESSURE PAIN DETECTION THRESHOLDS: RESULTS FROM THE KNEE PAIN IN THE COMMUNITY COHORT (KPIC) / D. F. Mcwilliams - N. Frowd - L. Marshall - J. Stocks - A. Sarmanova - G. S. Fernandes - M. Hall - W. Zhang - M. Doherty - A. M. Valdes - D. A. Walsh* ASSESSMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH FIBROMYALGIA BY CAROTID-FEMORAL PULSE WAVE VELOCITY - RESULTS OF A PROSPECTIVE STUDY / K. Triantafyllias* - M. Stortz - M. de Blasi - C. Leistner - J. Weinmann-Menke - A. Schwarting A SIMPLE INDEX BASED ON SCORES ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) PROVIDES INFORMATION QUITE SIMILAR TO ACR CRITERIA FOR FIBROMYALGIA IN ROUTINE CARE / J. Schmukler - I. Castrejon - T. Pincus* TOPIC: BACK PAIN, MECHANICAL MUSCULOSKELETAL PROBLEMS, LOCAL SOFT TISSUE DISORDERS THU0522 EXPERIMENTAL TENDINOPATHY TREATMENT WITH SM04755, A TOPICAL SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY / V. Deshmukh* - T. Seo - Y. Yazici THU0523 DO WE NEED STEROID INJECTION AFTER ULTRASOUND GUIDED PERCUTANEOUS LAVAGE OF A ROTATOR CUFF CALCIFICATION? RESULTS AT 3 MONTHS OF A DOUBLE BLINDED RANDOMISED CONTROLLED STUDY / C. Darrieutort-Laffite* - S. Varin - G. Coiffier - J.-D. Albert - G. Cormier - B. Le Goff THU0524 IS THERE ANY EFFECT OF KINESIOTAPING ON RADIAL NERVE IN PATIENTS WITH UNILATERAL LATERAL EPICONDYLITIS? A RANDOMISED-SINGLE BLIND STUDY / B. Mansiz-Kaplan* - S. Vural - O. F. Celik - H. Genc THU0525 EFFECT OF LOCAL INSULIN INJECTION IN THE TREATMENT OF MILD TO MODERATE CARPAL TUNNEL SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS / A. H. Ismail* - S. R. Kamel - H. A. Sadek - O. A. Sayed THU0526 ACUTE PARASPINAL MUSCLE NECROSIS WITH CRACK COCAINE AND HEROIN; A CASE REPORT / A. Masood* - L. Attipoe - D. D Cruz - S. Al-Saraj - S. Williams - K. Sabzevari THU0527 EFFECTS OF MANUAL THERAPY, SACROİLİAC AND LUMBAR EXERCİSES İN PATİENTS WİTH SACROİLİAC JOİNT DYSFUNCTİON SYNDROME / A. Javadov - A. Ketenci* THU0528 THE RELIEF OF CHRONIC LOW BACK PAIN (CLBP) IMMEDIATELY AFTER ONE SESSION OF LOW LEVEL LASER ACUPUNCTURE THERAPY (LLLAT) / D. Houssien* - A. Houssien * Presenting author

75 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 73 THU0529 THE COMPARISON OF PHYSICAL ACTIVITY LEVEL IN PREGNANT WOMEN WITH AND WITHOUT LOW BACK PAIN / E. Üzelpasacı* - S. Topuz - C. Orhan - E. Baran - G. Nakip - S. Özgül - S. Beksaç - T. Akbayrak THU0530 CHRONIC LOW BACK PAIN AND DEPRESSION: SIGNIFICANT DECREASE WITH GLUCOSAMINE-CHONDROITIN SULFATE TREATMENT IN A LARGE, COMMUNITY-BASED, PILOT, OPEN PROSPECTIVE INTERVENTIONAL STUDY / G. Singh* - L. Alexeeva - D. Goryachev - A. Barinov - A. Mithal THU0531 COMPARISON OF THREE DIFFERENT TRIGGER POINT TREATMENT IN THE MANAGEMENT OF LOW BACK PAIN: A PILOT STUDY / I. O. Dayanır* - E. Kaya Mutlu - M. A. Akçetin - A. O. Akdemir THU0532 TO ASSESS WHETHER THERE IS AN ASSOCIATION BETWEEN HYPERMOBILITY AND SPORTS INJURY / J. A. Nathan* - K. Davies THU0533 PREVALENCE OF LOW BACK PAIN AND KINESIOPHOBIA IN ELDERLY RESIDENTS OF SAO PAULO CITY: A CROSS-SECTIONAL PRELIMINARY DATA / K. E. Chang* - J. W. C. Silva - I. M. B. Souza - P. A. Moura - F. J. R. França - J. E. Pompeu - A. P. Marques THU0534 THE EFFECT OF LUMBER STABILIZATION EXERCISE ON THE BALANCE AND CLINICAL HEALTH / K. Barut* - E. Taştaban - F. Sendur THU0535 SAFETY AND EFFICACY OF PLATELET-RICH PLASMA IN TREATMENT OF CARPAL TUNNEL SYNDROME; A RANDOMISED CONTROLLED TRIAL / L. Bagherzadeh* - S. A. Raeissadat - A. Karimzadeh - M. Hashemi THU0536 KNOWLEDGE OF AND EXPECTATIONS ABOUT FUNCTIONAL RESTORATION PROGRAM FOR CHRONIC LOW BACK PAIN ARE OFTEN FALSE: A MIRROR SURVEY OF 40 PATIENTS AND 59 PHYSICIANS IN 2017 / L. Pierre* - F. Bailly - M. Assadourian - V. Foltz - A. Potel - L. Morardet - S. Ascione - M. Le Ralle - A. Dupeyron - N. Ibrahim - I. Griffoul-Espitalier - B. Duplan - J. Beaudreuil - B. Fautrel - L. Gossec THU0537 ASSOCIATION BETWEEN BIG FIVE PERSONALITY TRAITS AND RESPONSE TO MULTIDISCIPLINARY PROGRAM IN PATIENTS WITH CHRONIC LOW BACK PAIN: A PROSPECTIVE STUDY / M. E. Ibrahim* - K. Weber - S. Genevay THU0538 PATIENTS WITH CHRONIC LOW BACK PAIN ORIENTED TO FUNCTIONAL RESTORATION PROGRAM ARE YOUNGER, WITH HIGHER SMOKING AND LONGER SICK LEAVE: A CROSS- SECTIONAL STUDY OF 166 PATIENTS / M. Assadourian* - F. Bailly - P. Letellier - S. Ascione - M. Le Ralle - A. Potel - L. Morardet - V. Foltz - A. Dupeyron - N. Ibrahim - I. Griffoul-Espiltalier - B. Duplan - J. Beaudreuil - B. Fautrel - L. Gossec THU0539 MECHANICAL TRACTION FOR LUMBAR RADICULAR PAIN: SUPINE OR PRONE? A RANDOMISED CONTROLLED TRIAL / M. Bilgilisoy Filiz* - Z. Kılıç - A. Uçkun - T. Çakır - S. Koldaş Doğan - N. F. Toraman THU0540 INCREASED WORK CAPACITY IN CHRONIC LOW BACK PAIN PATIENTS AFTER A MULTIDIMENSIONAL PROGRAM ASSOCIATED WITH DECREASE IN FEAR AND APPREHENSION / M. Norberg* - L. Belgrand THU0541 THE EFFECT OF PHYSICAL THERAPY ON CLINICAL AND QUALITY OF LIFE IN CHRONIC NECK PAIN PATIENTS: A RANDOMISED CONTROLLED TRIAL / N. Şahin* - M. Şahin THU0542 EVALUATION OF THE EFFECTIVENESS OF ULTRASOUND GUIDED EPIDURAL CORTICOSTEROID INJECTION AND PULSED ELECTROMAGNETIC FIELD STIMULATION IN CHRONIC LOW BACK PAIN / S. A. Tabra* - M. ElSergany - M. E. Mowafy - H. Khallaf - G. Elsharnopy THU0543 COMPARISON OF THE EFFECTIVENESS OF LOW LEVEL LASER THERAPY AND STEROID INJECTION IN MODERATE CARPAL TUNNEL SYNDROME: A RANDOMISED CONTROLLED TRIAL / S. Badıl Güloğlu* - M. Bilgilisoy Filiz - K. K. Kılıç - S. Koldaş Doğan - I. Erdem Toslak - N. F. Toraman THU0544 STUDY OF THE EFFECTS OF OZONE VERSUS STEROID INJECTION ON PATIENTS WITH RECALCITRANT TENNIS ELBOW; A CLINICAL TRIAL / S. A. Raeissadat* - M. H. Abdollahzadeh THU0545 CHARACTERISING A MOUSE MODEL OF TEMPOROMANDIBULAR JOINT (TMJ) ARTHRITIS TO STUDY OROFACIAL PAIN AND INFLAMMATION / X. Kodji* - J. D. S. Valente - F. Lundy - I. El Karim - S. D. Brain 14 June 2018 TOPIC: PAEDIATRIC RHEUMATOLOGY Poster tour T12: A colourful journey through the landscape of paediatric rheumatology Berent J. Prakken (Netherlands), Gabriella Giancane (Netherlands) Abstracts N : THU0546-THU0555 THU0546 CHILDREN WITH PSORIASIS ALSO SHOW ENTHESOPATHY SIGNS RELATED TO SKIN DISEASE ACTIVITY / T. C. Meneghetti* - T. M. Padilha - V. F. Azevedo - V. O. Carvalho THU0547 REAL-WORLD EFFECTIVENESS OF EARLY AGGRESSIVE TREATMENT WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR THE TREATMENT OF NEWLY DIAGNOSED POLYARTICULAR FORM OF JUVENILE IDIOPATHIC ARTHRITIS / B. Huang* - E. M. Morgan - C. Chen - J. Guo - D. J. Lovell - H. I. Brunner on behalf of PCATS THU0548 STANDARDIZED PROCEDURES FOR ULTRASOUND IMAGING IN PAEDIATRIC RHEUMATOLOGY: PROGRESS OF EULAR/PRES TASK FORCE / J. Vojinovic* - P. Collado - I. Janta - L. Carmona - C. Malattia - S. Magni-Manzoni - G. Susic - N. Tzaribachev - V. Ravagnani - L. Rossi-Semerano - D. Kljucevsek - S. Lanni - I. Sudoł-Szopinska - D. Windschall - P. Balint - S. Jousse-Joulin - C. Modesto - N. Boutry - A. Iagnocco - E. Naredo THU0549 ABSENCE OF ASSOCIATION BETWEEN DRUG EXPOSURE AND INFECTION IN PATIENTS WITH POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DMARDS TREATED WITH SC AND IV ABATACEPT / N. Ruperto* - H. Brunner - N. Tzaribachev - I. Louw - I. Calvo - G. Horneff - M. Henrickson - M. E. Rama - M. Fischbach - T. Miraval - M. M. Ally - X. Li - R. Wong - M. Nys - B. Murthy - K. Lin - J. A. Passarell - A. Martini - D. J. Lovell on behalf of the PRINTO and PRCSG working groups. THU0550 NEW IL10 RECEPTOR GENE MUTATION ASSOCIATED TO A SPECTRUM OF INFLAMMATORY APHTHOSIS AND CROHN S DISEASE / R. Dagher* - V. Modica - N. El Rifai - E. Chouery - M. C. Fadous Khalife THU0551 TREATMENT STRATEGY STUDY IN NEW ONSET DMARD NAIVE JUVENILE IDIOPATHIC ARTHRITIS FIRST RESULTS ON 24 MONTHS CLINICAL OUTCOME / P. Hissink Muller* - D. Brinkman - D. Schonenberg-Meinema - W. van den Bosch - Y. Koopman-Keemink - I. Brederije - P. Bekkering - T. Kuijpers - M. van Rossum - L. van Suijlekom-Smit - J. M. van den Berg - S. Boehringer - C. F. Allaart - R. ten Cate * Presenting author

76 74 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0552 ARTICULAR AND EXTRA-ARTICULAR DAMAGE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS - RESULTS FROM THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (ICON) / J. Klotsche* - C. Sengler - M. Niewerth - J. Kuemmerle-Deschner - F. Weller - T. Hospach - G. Ganser - I. Foeldvari - K. Minden THU0553 TNF-INHIBITOR AND LEFLUNOMIDE COMBINATION THERAPY IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CLINICAL PRACTICE - LESSONS FROM THE GERMAN BIOLOGICS JIA REGISTRY (BIKER) / M. Napp - G. Horneff* on behalf of BIKER registry working group THU0554 RITUXIMAB (RTX) IN PAEDIATRIC DISEASES: DESCRIBING ITS PHARMACODYNAMICS WITH A FOCUS ON B CELL DEPLETION AND REPOPULATION, INFECTIONS AND ANTI-DRUG ANTIBODIES / A. Nassar-Sheikh Rashid* - R. Kampinga - M. Peters - M. Oosterveld - T. W. Kuijpers - J. M. van den Berg - D. Schonenberg-Meinema THU0555 GUIDELINES FOR JUVENILE IDIOPATHIC ARTHRITIS MANAGEMENT: IS THERE A ROOM FOR COMBINED METHOTREXATE AND LEFLUNOMIDE THERAPY IN THE TREATMENT RECOMMENDATIONS / Y. Atef - H. Lotfy - N. El Aroussy - D. Mekkawy - W. Hassan - S. I. Nasef - G. El Deriny - M. Eissa - Y. Farag - M. El Gaafary - Y. El Miedany* on behalf of PRINTO Egypt THU0556 IMPACT OF METHOTREXATE ON GROWTH IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / A. Fazaa* - M. Sellami - K. Ouenniche - S. Miladi - S. Kassab - S. Chekili - K. Ben Abdelghani - A. Laatar THU0557 THERAPEUTIC DRUG MONITORING OF BIOLOGICALS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA): AN OVERVIEW OF CURRENT PRACTICE IN ANTI-TNF THERAPY / A. Nassar-Sheikh Rashid* - D. Schonenberg- Meinema - A. de Vries - T. Rispens - T. W. Kuijpers - G. Wolbink - J. M. van den Berg THU0558 INCREASED FREQUENCY OF FEBRILE SEIZURES IN TWO PERIODIC FEVER SYNDROMES: FAMILIAL MEDITERRANEAN FEVER AND PFAPA SYNDROME / H. Kilic - A. Gurup - K. Barut - E. Pehlivan - S. Sahin - A. Adrovic* - O. Kasapcopur - S. Saltik THU0559 THE PERFORMANCE OF THE NEWLY PROPOSED EULAR/ACR CLASSIFICATION CRITERIA IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS-A PRELIMINARY STUDY / S. Sahin - S. Bektas - A. Adrovic* - O. Koker - K. Barut - O. Kasapcopur THU0560 CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: FOUR TERTIARY SPANISH HOSPITALS EXPERIENCE. A MULTICENTRIC STUDY / A. García Fernández* - J. Arroyo Palomo - D. Clemente Garrulo - B. Serrano Benavente - J. Novoa Medina - J. C. Nieto González - S. Machín García - A. M. Brandy García - J. C. López Robledillo - I. Monteagudo Sáez - A. L. Boteanu THU0561 ANAKINRA FIRST- OR SECOND-LINE IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / A. Klein* - A. Hospach - I. Foeldvari - G. Horneff THU0562 EVOLUTION OF SERUM CALPROTECTIN IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN CLINICAL PRACTICE / B. Magallares López* - L. Martínez-Martínez - M. C. Hernandez-Lafuente - E. Moltó - Y. Alvaro - H. Park - I. Castellví - M. Millán - C. Díaz-Torné - P. Moya - A. Laiz - H. Corominas - J. Casademont - E. Carreras - C. Juarez THU0563 ULTRASOUND CHANGES IN JOINTS INDUCED BY INTRA-ARTICULAR CORTICOSTEROID INJECTION IN JUVENILE IDIOPATHIC ARTHRITIS / B. Sozeri* - L. G. Bolac - M. Kariminikoo THU0564 EFFICIENCY AND SAFETY EVALUATION OF BIOSIMILAR INFLIXIMAB FOR TREATMENT OF PAEDIATRIC NON- INFECTIOUS UVEITIS IN SINGLE CENTER / B. Sozeri* - E. Kardes - L. G. Bolac - B. I. Sezgin Akçay THU0565 NEEDS ASSESSMENT OF TRAINING IN PAEDIATRIC RHEUMATOLOGY AMONG SPANISH PAEDIATRICIANS. MULTICENTER DESCRIPTIVE STUDY / C. Udaondo* - S. Murias - R. Alcobendas - A. Remesal THU0566 ASSESSMENT OF BEHAVIORAL DISORDERS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / D. Dop* - C. E. Niculescu THU0567 TESTING PERFORMANCE MEASURES IDENTIFIES GAPS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) CARE / C. Barber - D. Lacaille* - L. Lix - K. Kroeker - D. A. Marshall - N. Shiff THU0568 BIOSIMILAR USE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN A REAL-WORLD SETTING IN THE UNITED KINGDOM / D. De Cock* - L. Kearsley-Fleet - R. Davies - E. Baildam - M. Beresford - H. Foster - T. Southwood - W. Thomson - K. Hyrich on behalf of the BCRD investigator group THU0569 A RANDOMISED, DOUBLE-BLIND, PARALLEL STUDY TO COMPARE RATES OF REMISSION (INACTIVE DISEASE) IN PATIENTS WITH JIA ON MTX TREATMENT ALONE VERSUS A COMBINATION OF MTX AND ETANERCEPT / E. Alexeeva* - T. Dvoryakovskaya - R. Denisova - I. Nikishina - E. Zholobova - V. Malievskiy - G. Santalova - E. Stadler - L. Balykova - Y. Spivakovskiy - I. Becker - G. Horneff THU0570 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FMF (CRFMF), TRAPS AND HIDS/MKD: RESULTS FROM THE PIVOTAL PHASE 3 CLUSTER TRIAL / F. De Benedetti* - J. Frenkel - A. Simon - J. Anton - H. Lachmann - M. Gattorno - S. Ozen - I. Kone-Paut - E. Ben-Chetrit - M. B. Wozniak - J. G. Wang - E. Vritzali THU0571 PROTEOMIC IDENTIFICATION OF SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS PHENOTYPIC BIOMARKERS / F. Gohar - A. McArdle - M. Jones - N. Callan - B. Hernandez - M. Miranda-Garcia - M. Lavric - C. Kessel - D. Holzinger - O. FitzGerald - S. R. Pennington - D. Foell* THU0572 ORGANIZED SPORTS IN CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA): A COMPARISON OF PATIENT AND GENERAL POPULATION PARTICIPATION / F. Milatz* - M. Niewerth - N. Geisemeyer - R. Berendes - M. Hufnagel - N. Onken - A. Thon - F. Weller-Heinemann - K. Minden THU YEAR TRENDS AND CORRELATES OF SCHOOL SPORTS ATTENDANCE AMONG CHILDREN AND ADOLESCENTS WITH JIA ENROLLED IN THE GERMAN NATIONAL PAEDIATRIC RHEUMATOLOGIC DATABASE / F. Milatz* - J. Klotsche - M. Niewerth - N. Geisemeyer - S. Hansmann - M. Hartmann - T. Kallinich - J. Peitz - R. Trauzeddel - K. Minden THU0574 LONG-TERM PHARMACOVIGILANCE OF BIOLOGICS FOR JUVENILE IDIOPATHIC ARTHRITIS: THE BIKER- REGISTRY / G. Horneff* - G. Ganser - I. Foeldvari - F. Weller-Heinemann - A. Hospach - K. Minden - A. Klein THU0575 ANAKINRA FOR FIRST LINE STEROID FREE TREATMENT IN SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS / G. Horneff* - A. C. Schulz - A. Klein - K. Eising THU0576 CARDIOVASCULAR RISK IN LONG-TERM JUVENILE IDIOPATHIC ARTHRITIS / I. Aranda-Valera* - I. Arias de la Rosa - R. Roldan Molina - C. Ábalos-Aguilera - C. Pérez-Sánchez - A. Escudero - R. López-Pedrera - E. Collantes-Estévez - N. Barbarroja * Presenting author

77 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 75 THU0577 DO RAYNAUD PHENOMENON NEGATIVE JUVENILE SYSTEMIC SCLERODERMA PATIENTS HAVE A DIFFERENT PATTERN OF ORGAN INVOLVEMENT AS RAYNAUD PHENOMENON POSITIVE PATIENTS? / I. Foeldvari* - J. Klotsche - O. Kasapcopur - A. Adrovic - K. Torok - V. Stanevicha - M. T. Terreri - E. Alexeeva - M. Katsikas - V. Smith - F. Sztajnbok - T. Avcin - R. Cimaz - J. Anton - M. Kostic - T. Lehman - W.-A. Sifuentes-Giraldo - S. Appenzeller - M. Janarthanan - M. Moll - D. Nemcova - M. J. Santos - C. Battagliotti - L. Berntson - J. Brunner - P. Costa Reis - D. Eleftheriou - L. Harel - T. Kallinich - K. Minden - S. Nielsen - Y. Uziel - A. Stevens - C. Pilkington - N. Helmus THU0578 PATIENTS AND PHYSICIAN RELATED OUTCOMES IMPROVE SIGNIFICANTLY OVER 12 MONTHS FOLLOW UP IN PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS. RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. / I. Foeldvari* - J. Klotsche - M. T. Terreri - M. Katsikas - V. Stanevicha - T. Avcin - R. Cimaz - M. Kostic - W.-A. Sifuentes-Giraldo - F. Sztajnbok - J. Anton - D. Nemcova - M. J. Santos - C. Battagliotti - L. Berntson - J. Brunner - D. Eleftheriou - L. Harel - M. Janarthanan - T. Kallinich - M. Moll - S. Nielsen - V. Smith - K. Torok - A. Stevens - C. Pilkington - N. Helmus THU0579 VALIDATION OF CONTRAST-ENHANCED MRI SCORES ON (TENO)SYNOVITIS OF THE WRIST IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS BY COMPARISON WITH CHILDREN UNAFFECTED BY CLINICAL ARTHRITIS / J. M. van der Krogt* - E. C. van Gulik - R. Hemke - J. M. van den Berg - D. Schonenberg - A. Kindermann - K. M. Dolman - M. A. Benninga - T. W. Kuijpers - M. Maas - C. M. Nusman THU0580 THE ACR RECOMMENDATIONS FOR JIA IN DAILY CLINICAL PRACTICE: ARE THEY FOLLOWED OR WOULD TREAT-TO-TARGET THERAPY LEAD TO BETTER RESULTS? / J. F. Swart* - S. de Roock - P. van Dijkhuizen - N. Wulffraat THU0581 USE OF BIOLOGICAL THERAPIES IN ADULT PATIENTS DIAGNOSED WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM BIOBADASER, THE SPANISH REGISTRY OF ADVERSE EVENTS WITH BIOLOGIC THERAPIES / J. J. Bethencourt Baute* - C. Sanchez-Piedra - F. Sanchez-Alonso - D. Ruiz-Montesinos - J. Manero - C. Rodriguez-Lozano - E. Perez-Pampin - A. Ortiz - S. Manrique - M. V. Hernandez - C. Campos - A. Sellas - A. Sifuentes - J. García-González - J. J. Gomez-Reino - F. Díaz-Gonzalez - S. Bustabad-Reyes on behalf of BIOBADASER study group THU0582 A SYSTEMATIC REVIEW OF EMPLOYMENT OUTCOMES OF ADULTS WITH CHILDHOOD-ONSET SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES / K. Gu* - T. Gottschalk - L. S. H. Lim THU0583 PAIN INTERFERENCE ASSOCIATED FACTORS IN A COHORT OF FINNISH YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS / K. Rebane* - T. Orenius - L. Ristolainen - H. Relas - H. Kautiainen - R. Luosujärvi - H. Säilä - K. Aalto THU0584 VITAMIN D STATUS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AND ITS ASSOCIATION WITH DISEASE ACTIVITY AND PROGRESSION - RESULTS FROM THE INCEPTION COHORT ICON / C. Sengler - J. Zink - J. Klotsche - D. Foell - M. Niewerth - I. Liedmann - G. Horneff - J.-P. Haas - K. Moenkemoeller - A. Thon - K. Minden* THU0585 PERSONALISED TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS - FUTURE OR FICTION? PRELIMINARY RESULTS OF USING S100A8A9, S100A12 AND VASCULAR ENDOTHELIAL CADHERIN AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS / K. Orczyk* - E. Smolewska THU0586 METHOTREXATE DRUG SURVIVAL AND ADVERSE EFFECTS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / L. Kearsley-Fleet* - L. Vicente González - D. Steinke - R. Davies - D. De Cock - E. Baildam - M. W. Beresford - H. E. Foster - T. R. Southwood - W. Thomson - K. L. Hyrich on behalf of the Biologics for Children with Rheumatic Diseases (BCRD) investigator group, and the British Society for Paediatric and Adolescent Rheumatology Etanercept cohort study (BSPAR-ETN) THU0587 CLINICAL AND THERAPEUTIC ASPECTS OF A SOUTH ASIAN POPULATION OF SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS IN A TERTIARY CARE PEADIATRIC RHEUMATOLOGY CENTER IN SRI LANKA / M. Adikari* - A. Subasinghe - M. de Silva THU0588 REDUCTION IN THE UTILIZATION OF PREDNISONE AND/OR METHOTREXATE FOLLOWING THE INITIATION OF ETANERCEPT IN PAEDIATRIC PATIENTS / M. Khraishi * - B. Millson - J. Woolcott - H. Jones - L. Marshall THU0589 PHYSICAL ACTIVITY IN CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / M. Sellami* - A. Fazaa - S. Miladi - K. Ouenniche - S. Kassab - S. Chekili - K. Ben Abdelghani - A. Laatar THU0590 THE ROLE OF STAT4 RS G/T AND IFR5 RS G/T GENE POLYMORPHISM IN JUVENILE IDIOPATHIC ARTHRITIS SUSCEPTIBILITY AMONG RUSSIAN PAEDIATRIC POPULATION / M. Krylov* - E. Fedorov - S. Salugina - N. Konovalova - D. Varlamov THU0591 SERUM 25 OH VITAMIN D IN PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS: IN RELATION TO DISEASE ACTIVITY, DURATION AND BONE MINERAL DENSITY / M. H. Abu-Zaid* - H. H. Abdelnabi - A. M. El-Barbary THU0592 PUBERTAL DELAY DESPITE INTENSIVE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A LONGITUDINAL STUDY / P. Van Pelt* - A. Hokken-Koelega - R. Dolhain - A. Kruize - H. Bijlsma - N. Wulffraat THU0593 MULTICENTRIC OSTEOLYSIS WITH NODULOSIS AND ARTHROPATHY (MONA): REPORT OF THE FIRST LEBANESE FAMILY / R. Dagher* - E. Saliba - M. Rizkallah - M. C. Fadous Khalife - A. Megarbane THU0594 SHIARI-JAVADI CRITERIA FOR THE DIAGNOSIS OF GENERALIZED JOINT HYPERMOBILITY IN CHILDREN / R. Shiari* - V. J. Parvaneh THU0595 CLINICAL AND THERAPEUTICAL DIFFERENCES BETWEEN ADULTS AND CHILDREN IN A COLOMBIAN COHORT WITH INFLAMMATORY IDIOPATIC MYOPATHY / R. Fuentes* - M. Cañola - J. C. Diaz-Coronado - A. Rojas-Villarraga - D. Hernandez-Parra - P. Perez-Estrada - J. C. Salazar-Uribe - R. Pineda-Tamayo THU0596 MEASUREMENT OF SERUM CALPROTECTIN MRP8/14 IN PAEDIATRIC PATIENTS DIAGNOSED WITH JUVENILE IDIOPATHIC ARTHRITIS AND AUTOINFLAMMATORY DISEASES / S. Murias* - C. Udaondo - R. M. Alcobendas - A. Remesal - D. Pascual-Salcedo THU0597 PULMONARY MANIFESTATIONS IN MIXED CONNECTIVE TISSUE DISEASE WITH JUVENILE AND ADULT ONSET - ARE THERE ANY DIFFERENCES? / S. O. Hetlevik* - S. Reiseter - Ø. Molberg - B. Flatø - R. Gunnarsson - T. M. Aaløkken - M. B. Lund - V. Lilleby THU0598 SAFETY OF TOCILIZUMAB IN PATIENTS AGED <2 YEARS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS TREATED FOR ONE YEAR / S. Wimalasundera* - I. Calvo Penades - R. Cuttica - H.-I. Huppertz - R. Joos - D. Milojevic - M. Rosenkranz - K. Schikler - T. Constantin - W. Douglass - C. Wells - Y. Kimura - C. Wouters 14 June 2018 * Presenting author

78 76 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0599 EVALUATION OF EFFICACY AND SAFETY OF CANAKINUMAB IN JAPANESE PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN PHASE III CLINICAL TRIAL, COMPOSED PREDOMINANTLY OF PATIENTS WITH PRIOR USE OF TOCILIZUMAB / S. Takei* - R. Hara - H. Umebayashi - N. Iwata - T. Imagawa - M. Shimizu - M. Tomiita - N. Seko - T. Kitawaki - G. Wang - S. Yokota THU0600 HIGH VACCINE COVERAGE RATES ARE NOT ENOUGH: VACCINATION DELAY AND RISK FOR VACCINE- PREVENTABLE DISEASES IN PAEDIATRIC PATIENTS WITH RHEUMATIC DISEASES WITH AND WITHOUT IMMUNOSUPPRESSIVE THERAPY / T. Welzel* - T. Zumbrunn - J. Bonhoeffer - E. Cannizzaro Schneider - M. Hofer - D. Kaiser - V. Hentgen - A. Woerner on behalf of Juvenile Inflammatory Rheumatism (JIR) Cohort THU0601 CARRIER RATE OF FAMILIAL MEDITERRANEAN GENE (MEFV) MUTATION IN PARENTS OF CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / V. Ziaee* - Y. Aghighi - L. Shahbaznejad - S.-R. Raeeskarami - F. Tahghighi - A. Shakoori - H. R. Ajeedeh THU0602 TARGETING GENERATION Z: DEVELOPMENT AND VALIDATION OF AN ILLUSTRATED TRANSITION READINESS QUESTIONNAIRE FOR ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / H. Lotfy - M. El Gaafary - N. El Aroussy - D. Mekkawy - Y. Farag - Y. El Miedany* on behalf of PRINTO Egypt THU0603 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN JUVENILE IDIOPATHIC ARTHRITIS: MOVING TOWARDS TARGETED INDIVIDUALIZED TREATMENT STRATEGY / S. I. Nasef - G. El Deriny - M. Eissa - M. A. Mortada - W. Hassan - D. Mekkawy - Y. El Miedany* THU0604 JUVENILE INFLAMMATORY ARTHRITIS: THE DEVELOPMENT AND VALIDATION OF AN ILLUSTRATED QUESTIONNAIRE TO MEASURE CHILDREN S MOTIVATION / Y. El Miedany* - H. Lotfy - N. El Aroussy - D. Mekkawy - S. I. Nasef - W. Hassan - M. Eissa - G. El Deriny - S. Almedany - Y. Farag - M. El Gaafary on behalf of PRINTO Egypt THU0605 FACILITATING PATIENT CENTRED CARE: THE DEVELOPMENT OF ILLUSTRATED MULTIDIMENSIONAL PATIENT REPORTED OUTCOME MEASURE FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / Y. El Miedany* - H. Lotfy - N. El Aroussy - D. Mekkawy - S. I. Nasef - W. Hassan - G. El Deriny - Y. Farag - M. Eissa - S. Almedany - M. El Gaafary on behalf of PRINTO Egypt TOPIC: OTHER ORPHAN DISEASES THU0606 EFFECT OF INTERLEUKIN-1 ANTAGONISTS ON THE QUALITY OF LIFE IN FAMILIAL MEDITERRANEAN FEVER PATIENTS / Ö. Varan - H. Küçük - H. Babaoğlu - N. Atas - H. Satıs - R. Bilici Salman - A. Tufan* - B. Göker - S. Haznedaroğlu - M. A. Öztürk THU0607 AUTOINFLAMMATORY SYNDROMES: CLINICAL AND GENETIC CHARACTERIZATION OF A COHORT OF ADULT PATIENTS IN A SINGLE REFERENCE CENTER / A. Ruiz Roman* - S. Garcia Morillo - M. A. Montes Cano - M. Lisbona Muñoz - C. Aguilera Cros - A. Muñoz Jimenez - E. Rubio Romero THU0608 THE RELATIONSHIP BETWEEN SERUM SOLUBLE KLOTHO, FGF-23 LEVELS AND FLOW-MEDIATED DILATATION (FMD) IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) / M. Çelik - F. Candan - M. E. Derin - I. Karadağ - M. Timuçin - H. O. Doğan - A. C. Urhan - M. Şahin - A. Şahin* THU0609 CLINICAL CHARACTERISTICS AND OUTCOME OF SPANISH PATIENTS WITH ACUTE MYELITIS ASSOCIATED WITH AUTOIMMUNE DISEASES / A. González García* - W. A. Sifuentes Giraldo - S. Sainz de la Maza - I. Barbolla Díaz - J. L. Patier de la Peña - L. Manzano Espinosa THU0610 SERUM CALPROTECTIN LEVELS IN BEHÇET S DISEASE: RELATIONSHIPS BETWEEN DISEASE ACTIVITY AND CLINICAL PARAMETERS / M. Torgutalp - A. B. Kelesoglu Dincer - E. M. Yayla - E. Uslu Yurteri - E. I. Okatan - G. E. Aydemir Guloksuz - S. Sezer - E. Us - G. Kinikli - M. T. Turgay - A. Ates* THU0611 ANAKINRA TREATMENT IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: A SINGLE-CENTER EXPERIENCE / B. Ergezen* - S. Ugurlu - H. Ozdogan THU0612 BONE SARCOIDOSIS: A RETROSPECTIVE MULTICENTER STUDY OF 27 CASES / C. Glanowski* - R. Mestiri - L. Bialé - T. Carmoi - D. Lechevalier - G. Leroux - D. Saadoun - C. Chapelon-Abric - P. Cacoub THU0613 THE FREQUENCY AND CHARACTERISTICS OF HEADACHE IN BEHCET S DISEASE AND ITS EVALUATION BY TRANSCRANIAL DOPPLER ULTRASONOGRAPHY / F. Salgür - D. Üsküdar Cansu - N. Uzuner - C. Korkmaz* THU0614 INTERSTITIAL LUNG DISEASE IN PATIENTS WITH ANTISYNTHETASE SYNDROME AND ANTI-RO52 ANTIBODIES POSITIVE / C. Aguilera Cros* - A. Ruiz Román - L. Méndez Díaz - G. Morote Ibarrola - N. Garrido Puñal - M. Arcila Durán - M. A. Montes Cano - J. A. Rodriguez Portal THU0615 IMMUNE RELATED ADVERSE EVENTS (IRAES) ASSOCIATED WITH CHECKPOINT INHIBITORS: 12 CASES FROM A SINGLE CENTER / D. Ennis - F. To - S. Jamal* THU0616 ELEVATED THYROID STIMULATING HORMONE AS A POTENTIAL BIOMARKER FOR RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FOLLOWING PD-1 INHIBITOR THERAPY / D. F. L. Liew* - J. L. Y. Leung - C. McMaster - F. Djukiadmodjo - B. Liu - J. Cebon - A. G. Frauman - R. R. C. Buchanan THU0617 IS THE NUMBER OF IGG4+ PLASMA CELLS SEEN BY IMMUNOSTAINING USEFUL BEYOND ITS DIAGNOSTIC UTILITY IN IGG4-RELATED DISEASE? / E. Martin Nares* - J. Guerrero Castillo - A. Angeles Angeles - G. Hernández Molina THU0618 HYPOPHOSPHATASIA IN FRENCH TERTIARY CARE HOSPITALS / E. Ebstein* - T. Thomas - B. Cortet - K. Briot - C. Roux THU0619 THE FREQUENCY OF EXON-10 MUTATIONS IN MEFV GENE IN PROBABLE DIAGNOSED FMF PATIENTS ACCORDING TO TEL HASHOMER CRITERIA / F. Cosan* - S. Arda - O. M. Gedar Totuk THU0620 ON DEMAND USE OF ANAKINRA FOR THE ATTACKS OF FAMILIAL MEDITERRANEAN FEVER (FMF) / H. Babaoglu* - O. Varan - H. Kucuk - N. Atas - H. Satis - R. B. Salman - M. A. Ozturk - B. Goker - S. Haznedaroglu - A. Tufan THU0621 PERSISTENT PRURITIC SKIN LESIONS WITH DYSKERATOTIC CELLS IN UPPER LAYER OF EPIDERMIS ARE SPECIFIC AND ASSOCIATED WITH HIGH LEVELS OF SERUM IL-18 IN ADULT-ONSET STILL S DISEASE / H. Nishikawa* - Y. Taniguchi - N. Maeda-Aoyama - K. Nakajima - S. Inotani - Y. Shimamura - K. Inoue - K. Arii - S. Sano - Y. Terada * Presenting author

79 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 77 THU0622 HISTOPATHOLOGY AND EXPRESSIONS OF CHEMOKINES, CXCL10, CXCL13, AND CXCR3, AND AN ENDOGENOUS LIGAND S100A8/A9 IN LYMPH NODES OF PATIENTS WITH ADULT-ONSET STILL S DISEASE / H.-A. Kim* - J. H. Han THU0623 SERUM IGG4 LEVELS AT DIAGNOSIS CAN PREDICT THE OUTCOMES OF UNTREATED PATIENTS WITH IGG4- RELATED DISEASE: A RETROSPECTIVE STUDY / I. Mizushima* - N. Suzuki - M. Yoshida - A. Takeji - T. Matsunaga - T. Zoshima - S. Hara - K. Ito - H. Fujii - K. Yamada - M. Kawano THU0624 COLCHICINE: AN EFFECTIVE TREATMENT OPTION FOR UNCLASSIFIED AUTOINFLAMMATORY DISEASES IN CHILDREN / J. B. Kuemmerle-Deschner* - A.-L. Schock - S. Hansmann - S. M. Benseler THU0625 IGG4-RELATED DISEASE MANIFESTATIONS DIFFER BETWEEN ASIAN AND NON-ASIAN SUBJECTS / Z. S. Wallace - K. Okazaki - C. Perugino - H. Umehara - T. Saeki - M. Kawano - Y. Zen - R. Naden - J. H. Stone* on behalf of For the EULAR/ACR IgG4-related disease classification criteria development group THU0626 CORRELATION AMONG SERUM AMYLOID A LEVELS, CLINICAL MANIFESTATIONS, TREATMENT AND DISEASE ACTIVITY IN PATIENTS WITH BEHÇET S DISEASE / J. Sota* - A. Vitale - O. M. Lucherini - R. Franceschini - B. Frediani - I. Orlando - M. Galeazzi - C. Fabiani - G. M. Tosi - L. Cantarini THU0627 DEMOGRAPHICS AND PRESENTING ORGAN INVOLVEMENT IN A COHORT OF PATIENTS WITH SARCOIDOSIS / K. Sheth* - G. Jeyashanmugaraja - J. Simard - S. Shoor THU0628 DIFFERENCES IN CLINICAL MANIFESTATIONS OF BEHCET S SYNDROME BY GENDER: CROSS-SECTIONAL ANALYSIS IN A UK COHORT / L. Chadwick* - T. Blake - N. J. Goodson - D. Situnayake - R. J. Moots THU0629 A STUDY OF WBMRI IN ESTIMATING DISEASE ACTIVITY OF PM/DM AND THE FOLLOWING DISEASES DIAGNOSIS / Y. Li* - D. Jiang - X. Zheng - L. Lu - Z. Li - Y. Guo - J. Tang - X. He - D. Xu - G. Gao THU0630 IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS IN SPANISH PATIENTS / L. Villalobos* - W. A. Giraldo-Sifuentes - P. Moran-Alvarez - J. Arroyo Palomo - A. Briones-Figueroa - C. Rita - J. L. Morell-Hita THU0631 REFRACTORY AND SEVERE UVEITIC CYSTOID MACULAR EDEMA IMPROVES WITH TOCILIZUMAB IN DIFFERENT IMMUNE-MEDIATED INFLAMMATORY DISEASES / N. Vegas-Revenga* - V. Calvo-Río - M. Mesquida - A. Adán - M. Hernandez - E. Beltrán - E. Valls Pascual - D. Díaz-Valle - G. Díaz-Soriano - M. Hernandez-Grafella - L. Martínez-Costa - I. Calvo - A. Atanes - L. Linares - C. Modesto - E. Aurrecoechea - M. Cordero - R. Demetrio-Pablo - L. Domínguez-Casas - J. Hernández - M. González-Gay - R. Blanco THU0632 IDENTIFICATION OF ABERRANT T CELL PHENOTYPE IN EPISODIC ANGIOEDEMA WITH HYPEREOSINOPHILIA (GLEICH SYNDROME) IN 30 PATIENTS: FREQUENCY, CLINICLAL IMPLICATION AND PROGNOSIS / N. Abisror* - A. Mekinian - A. Dechartres - O. Fain - J. E. Kahn - G. Lefevre - A. Berezne - N. Noel - C. Morati - J. Haroche - M. Hunault-Berger - C. Agard - M. Groh - L. Geffray - P.Y. Jeandel - S. Trouillier - T. Quemeneur - J. F. Dufour THU0633 ACUTE FROM OF SARCOIDOSIS (LÖFGREN SYNDROME) IN RHEUMATOLOGY PRACTICE / O. N. Egorova* - B. S. Belov - S. G. Radenska-Lopovok THU0634 RISK OF SUDDEN CARDIAC DEATH IN PATIENTS WITH SARCOIDOSIS: A POPULATION-BASED RETROSPECTIVE COHORT STUDY / A. A. Chahal - P. A. Brady - C. S. Crowson - V. K. Somers - E. L. Matteson - P. Ungprasert* THU0635 PREGNANCY OUTCOMES IN MIXED CONNECTIVE TISSUE DISEASE: RESULTS FROM A MULTICENTRE COHORT STUDY / M. Radin - K. Schreiber - M. Cuadrado - I. Cecchi - A. Laura - F. Franceschini - T. Caleiro - E. Gibbone - M. Khamashta - J. Buyon - P. Izmirly - M. Aguirre Zamorano - D. Roccatello - L. Marozio - S. Sciascia* THU0636 CANAKINUMAB TREATMENT IN ADULT-ONSET STILL S DISEASE: CASE SERIES / S. Ugurlu* - G. Guzelant - B. Yurttas - B. Ergezen - E. Dalkilic - T. Kasifoglu - B. Yagiz - H. Ozdogan THU0637 EVALUATIONS OF COMPLEMENT PATHWAYS IN IGG4 RELATED DISEASE / S. Fukui* - Y. Fujita - T. Origuchi - A. Kawakami THU0638 CLINICAL CHARACTERISTIC OF A GROUP OF PATIENTS WITH PSTPIP1-ASSOCIATED MYELOID-RELATED PROTEINEMIA INFLAMMATORY SYNDROME (PAMI) / V. I. Burlakov* - A. Kozlova - I. Mersiyanova - A. Laberko - E. Viktorova - O. Shvets - D. Yukhacheva - G. Gordeeva - E. Raykina - V. Zakharova - J. Rodina - A. Shcherbina THU0639 CHINESE EXPERIENCE WITH METHOTREXATE AS MAINTENANCE THERAPY IN IGG4-RELATED DISEASE / F. Lian - J. Zhou - Y. Wang* - H. Xu - L. Liang - X. Yang 14 June 2018 TOPIC: PUBLIC HEALTH, HEALTH SERVICES RESEARCH AND HEALTH ECONOMICS THU0640 PHARMACOLOGICAL TREATMENT AMONG NEWLY DIAGNOSED PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN THE UNITED STATES / A. Marshall* - K. Gupta - M. Pazirandeh - M. Bonafede - D. McMorrow THU0641 MUSCULOSKELETAL DISEASE CLINIC MANAGED BY A RHEUMATOLOGY DEPARTMENT / A. J. Aznar Esquivel* - H. Sánchez-Pérez - A. López-Hijazo - S. Bustabad-Reyes THU0642 LIVING IN IMMIGRANT COMMUNITIES DOES NOT IMPACT TOTAL KNEE ARTHROPLASTY OUTCOMES: EXPERIENCE FROM A HIGH-VOLUME CENTER IN THE UNITED STATES / B. Mehta* - J. Szymonifka - S. A. Dey - I. Y. Navarro-Millan - S. V. Grassia - L. A. Mandl - A. R. Bass - L. A. Russell - M. L. Parks - M. P. Figgie - Y.-Y. Lee - J. T. Nguyen - S. M. Goodman THU0643 IMPACT OF SHOULDER ULTRASOUND IN QUALITY OF CARE INDICATORS IN PATIENTS WITH RECENT ONSET OF PAIN / C. A. Guillen-Astete* - R. Penedo Alonso - C. De La Casa Resino THU0644 PERCEPTIONS OF BIOSIMILARS AMONG PRACTICING RHEUMATOLOGISTS: RESULTS FROM A MULTICOUNTRY STUDY IN EUROPE / C. Karki* - S. Shah - L. Archer - A. Baskett - E. Baynton - L. Ha - B. Shah-Manek THU0645 IMPACT OF SECOND-LINE THERAPY WITH ABATACEPT VERSUS OTHER TARGETED DMARDS ON THE RISK FOR INFECTION-RELATED HOSPITALIZATIONS AND ASSOCIATED COSTS AMONG RA PATIENTS IN THE UNITED STATES / D. Paul* - L. McDonald - A. Marshall - T. Curtice - M. Lingohr-Smith - B. Menges - J. Lin THU0646 EVALUATING THE QUALITY OF CARE FOR RHEUMATOID ARTHRITIS / C. Barber - D. Marshall - E. Szefer - D. Thompson - D. Lacaille* THU0647 LONGITUDINAL STUDY OF LONG-TERM POVERTY AND PERSISTENT DEPRESSIVE SYMPTOMS IN SLE / E. Yelin* - J. Yazdany - L. Trupin - N. McCormick - P. Katz * Presenting author

80 78 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0648 AS A PRACTITIONER I FEEL ENRICHED : RHEUMATOLOGY TUTORS EXPERIENCES OF DELIVERING A MANUALISED GROUP COGNITIVE-BEHAVIOURAL FATIGUE PROGRAMME TO PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / E. Dures* - A. Hammond - S. Hewlett on behalf of the RAFT group THU0649 UNDERSTANDING ETHNIC DIFFERENCES IN THE UTILIZATION OF EXERCISE FOR OSTEOARTHRITIS / E. R. Vina* - D. Ran - M. J. Hannon - C. K. Kwoh THU0650 EARLY HELP SEEKING OR SELF-MANAGEMENT: A QUANTITATIVE ASSESSMENT IN THE CONTEXT OF RHEUMATOID ARTHRITIS / G. Simons* - J. Belcher - K. Kumar - M. Falahee - C. D. Mallen - R. J. Stack - K. Raza THU0651 THE INFLUENCE OF AGE, GENDER, EMPLOYMENT STATUS, OR EDUCATION ON THE CHOICE OF BIO-SIMILAR VS. BIO-ORIGINAL VARIANT OF THE SAME BDMARD IN PATIENTS WITH RA OR AS STARTING BIOLOGICAL THERAPY - REAL LIFE DATA FROM THE CZECH BIOLOGICS REGISTRY ATTRA / J. Zavada* - L. Nekvindova - K. Pavelka - J. Vencovsky on behalf of collaborators of the ATTRA registry THU0652 COMPARATIVE COST PER RESPONSE FOR FOUR CLINICAL OUTCOMES OF TOCILIZUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN A HEAD-TO-HEAD RANDOMISED DOUBLE-BLIND SUPERIORITY TRIAL (ADACTA) IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Best* - J. Pei THU0653 CHANGES IN RHEUMATOLOGY PROVISION AND PRACTICE IN A PUBLICLY-FUNDED SINGLE PAYER HEALTHCARE SYSTEM / J. Widdifield* - S. Bernatsky - V. Ahluwalia - C. Barber - L. Eder - C. Hofstetter - B. Kuriya - V. Ling - A. Lyddiatt - M. Paterson - J. Pope - C. Thorne THU0655 PATIENTS EVALUATION OF DUTCH HEALTH CARE IN SYSTEMIC SCLEROSIS: UNMET NEEDS AND PREFERENCES / J. Spierings* - C. H. van den Ende - M. R. Schriemer - J. K. de Vries-Bouwstra - M. C. Vonk THU0656 SYSTEMIC LUPUS ERYTHEMATOSUS IN COLOMBIA: A BIBLIOMETRIC ANALYSIS / J. E. Barahona-Correa* THU0657 EFFECTS OF ADALIMUMAB INITIATION ON CORTICOSTEROID UTILIZATION AND MEDICAL COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Qiao - K. L. Winthrop* - J. Griffith - C. M. Kaplan - C. A. Spivey - A. Postlethwaite - J. Wang THU0658 RECOMMENDATIONS FOR THE ASSESSMENT AND OPTIMIZATION OF ADHERENCE TO DISEASE-MODIFYING DRUGS IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES: A PROCESS BASED ON LITERATURE REVIEWS AND CONSENSUS / L. Gossec* - A. Molto - X. Romand - D. Puyraimond-Zemmour - M. Lavielle - C. Beauvais - E. Senbel - R.-M. Flipo - S. Pouplin - C. Richez - A. Saraux - L. Gutermann - P. Gaudin - D. Wendling - M. Dougados THU0659 EURORHEUMAVISION; ARE THE LARGEST EUROPEAN RHEUMATOLOGY SOCIETIES THE ONES WITH THE MOST ORAL COMMUNICATIONS? / M. Paulino Huertas* THU0660 GOLIMUMAB IMPROVES SOCIO- AND HEALTH ECONOMIC PARAMETERS IN PATIENTS WITH RA, PSA AND AS: REAL WORLD-DATA FROM A NON-INTERVENTIONAL CLINICAL STUDY IN GERMANY / K. Krüger - G. R. Burmester - M. H. Thomas* - S. Wassenberg THU0661 OSTEOPOROSIS SCREENING, PRIMARY PREVENTION, AND TREATMENT IN GLUCOCORTICOID TREATED INDIVIDUALS WITH RHEUMATOLOGIC DISEASE / P. Onkka* - S. Khandelwal - N. Shakoor - J. Block - L. Fogg THU0662 IMPACT OF THE INTERVENTION OF A MULTIDISCIPLINARY ADHERENCE TEAM IN CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHROPATHIES IN COLOMBIA / R. Pineda-Tamayo* - K. Sanchez - M.-A. Alzate - D. Hernandez-Parra - D. Echeverry - P. Ortiz-Salazar - A. Rojas-Villarraga THU0663 RHEUMATOLOGY ADOLESCENT AND YOUNG ADULT CARE: REAL WORLD CHALLENGES AND OPPORTUNITIES / R. Malaiya* - S. Steer - S. Das - C. Mathews - U. Davies - E. Godbold - S. Lamb - S. Vale - V. Goncalves - M. Sumbwanyambe - S. Thurlbeck - N. Wilkinson on behalf of Rheumatology Adolescent & Young Adult (RAYA) collaboration THU0664 TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS / C. H. Feldman - J. Lii - C. Gopalakrishnan - J. M. Franklin - S. C. Kim* THU0665 PHARMACOVIGILANCE SURVEILLANCE OF AUTOIMMUNE DISEASES INDUCED BY BIOLOGICAL AGENTS: A REVIEW OF CASES (AEBIOGEAS-SEMI REGISTRY) / M. Ramos-Casals - S. Retamozo* - A. Flores-Chavez - B. Kostov - A. Sisó-Almirall - M. Pérez-de-Lis - R. Pérez-Alvarez - P. Brito-Zerón THU0666 COSTS ASSOCIATED WITH SWITCHING SUBCUTANEOUS TUMOR NECROSIS FACTOR-Α INHIBITOR IN THE TREATMENT OF IMMUNE-MEDIATED RHEUMATIC DISEASE / J. Dalén - A. Svedbom - K. Luttropp - S. Kachroo* THU0667 DISEASE, WORK AND PERSONAL RELATED FACTORS ASSOCIATED WITH PRESENTEEISM IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY (NRAS) / S. Verstappen* - M. Gignac - L. Lunt - D. Beaton - A. Bosworth - M. Bezzant - K. Walker-Bone THU0668 CHOICE OF INITIAL BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG IMPACTS HEALTHCARE RESOURCE USE AMONG PATIENTS WITH RAPIDLY PROGRESSING RHEUMATOID ARTHRITIS / A. J. Klink - K. Tuell - R. Szymialis - T. Curtice* - K. Gupta - D. Nero - B. A. Feinberg THU0669 A SELF-REPORT SYMPTOM CHECKLIST ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) TO CAPTURE A POSITIVE REVIEW OF SYSTEMS AS A STANDARD, QUANTITATIVE, AND INFORMATIVE SCIENTIFIC CLUE TO FIBROMYALGIA SIMILAR TO MODIFIED CRITERIA FOR FIBROMYALGIA / T. Pincus* - S. Jamal - I. Castrejon THU0670 A REUMATOLOGIST S EVALUATION OF HOW EFFICIENCIES IN THE MANAGEMENT OF PAINFUL LUMBAR SYNDROME IN WORK DISABILITY CREATES BENEFITS & SAVINGS / V. M. Flores Rodríguez* - F. Díaz Gonzalez - S. Bustabad Reyes - M. Carballo Correa * Presenting author

81 SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE 2018 / 79 TOPIC: EPIDEMIOLOGY, RISK FACTORS FOR DISEASE OR DISEASE PROGRESSION Poster tour T13: Life is not a smooth trip - how pregnancy and life events interfere in rheumatic disease management Laure Gossec (France), Santiago Rodrigues-Manica (Portugal) Abstracts N : THU0671-THU0680 THU0671 STANDARDISED MORTALITY RATES FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN WESTERN AUSTRALIA FROM 1980 TO 2015 / W. D. Raymond* - D. Preen - H. Keen - C. Inderjeeth - J. Nossent THU0672 IMPACT OF PREGNANCY ON PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH AXIAL SPONDYLOARTHRITIS / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius THU0673 DISEASE ACTIVITY DURING AND AFTER PREGNANCY IN WOMEN WITH PSORIATIC ARTHRITIS / K. Ursin* - S. Lydersen - J. Skomsvoll - M. Wallenius THU0674 RHEUMATIC DISEASES AND PREGNANCY: A SINGLE CENTRE DEDICATED CLINIC EXPERIENCE / F. Motta* - V. Ramoni - B. Vitolo - A. Milanesi - F. Beneventi - S. Quaglini - R. Caporali - C. Montecucco THU0675 THE IMPACT OF AUTOIMMUNE RHEUMATIC DISEASES ON BIRTH OUTCOMES IN AN ETHNICALLY DIVERSE COHORT OF WOMEN IN THE UNITED STATES / J. L. Strouse - B. M. Donovan - M. Fatima - R. Fernandez-Ruiz - L. Jelliffe-Pawlowski - R. J. Baer - C. Smith - G. Bandoli - R. Paynter - N. Parikh - K. Ryckman - N. Singh* THU0676 A SYSTEMATIC REVIEW AND META-ANALYSIS OF VIRAL EXPOSURES AS A RISK FACTOR FOR RHEUMATOID ARTHRITIS / F. Kudaeva* - M. R. Speechley - J. E. Pope THU0677 PNEUMOCOCCAL ANTIBODY PROTECTION IN RHEUMATOLOGICAL PATIENTS RECEIVING BDMARD THERAPY - A CROSS-SECTIONAL STUDY / S. Rasmussen* - K. Fuursted - K. Nielsen - N. Parks - M. Sørensen - P. Leutscher - C. Rasmussen THU0678 TREND OF VENOUS THROMBOEMBOLISM AMONG SELECT RHEUMTOLOGIC DISEASES: AN AUDIT OF LARGE NATIONAL US DATABASE / D. R. Poudel* - R. Dhital - P. Paudel - S. Basnet - P. Sharma - P. Shrestha - P. Karmacharya THU0679 INCREASED HOSPITALIZATION RATES FOLLOWING HEART FAILURE DIAGNOSIS IN RHEUMATOID ARTHRITIS / E. Myasoedova* - J. M. Davis, III - S. J. Achenbach - E. L. Matteson - S. Setoguchi - S. E. Gabriel - C. S. Crowson THU0680 SURVIVAL ANALYSIS OF PATIENTS WITH CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE / T. Xu* - X. Zhang THU0681 ESTABLISHING THE BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX (BASMI) NORMATIVE VALUES IN A MALAYSIAN POPULATION: THE IMPORTANCE OF SEX AND AGE FACTORS / A. F. Nurul Aain* - I. S. Lau - S. C. Gun - S. Wahinuddin - P. S. Ong - H. Heselynn - B. E. Tan - H. C. Chong - A. Hilmi - M. Asmah - M. I. Asmahan - Y. L. Loh - A. L. Lim - H. Noor Shahrazat - C. L. Teh - G. R. Ling - E. Y. Y. Chong - A. H. Ruhaila - A. M. Suhaida - R. Shamala - R. Azmillah - M. Z. Mollyza - S. Salsabil - L. K. Tan - M. Shahnaz - C. L. Too THU0682 HUMAN HISTOCOMPATIBILITY ANTIGENS (HLA) CLASS 1 IN ANTERIOR UVEITIS PATIENTS WITH AND WITHOUT SPONDYLOARTHRITIS / A. Godzenko* - I. Guseva - I. Razumova THU0683 PREDICTORS FOR PRETERM DELIVERY AMONG PREGNANT WOMEN WITH RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS / C. J. F. Smith* - F. Förger - C. Chambers THU0684 PREVALENCE OF RHEUMATIC DISEASES IN ADULT POPULATION IN SPAIN. EPISER 2016 STUDY / D. Seoane-Mato* - C. Sánchez-Piedra - F. Díaz-González - S. Bustabad on behalf of EPISER 2016 working group THU0685 CARDIOVASCULAR RISK ESTIMATION IN SLE PATIENTS: A COMPARISON OF THREE ALGORITHMS / D. Chimera* - C. Tani - C. Stagnaro - E. Elefante - R. Vagelli - L. Carli - M. Mosca THU0686 CHANGES IN HEALTH-RELATED QUALITY OF LIFE OVER 5 TO 8 YEARS IN 1347 PATIENTS WITH EARLY ARTHRITIS OR EARLY INFLAMMATORY BACK PAIN / D. Puyraimond-Zemmour* - B. Granger - A. Molto - C. Gaujoux-Viala - F. Guillemin - A. Ruyssen-Witrand - M. Dougados - B. Fautrel - L. Gossec THU0687 THE IMPACT OF URATE-LOWERING THERAPY ON KIDNEY FUNCTION (IMPULSKF): PRELIMINARY RESULTS / D. D. Ivanov* - O. V. Sinjchenko - I. Y. Golovach - T. B. Bevzenko - M. D. Ivanova THU0688 DO CERTAIN DMARDS INCREASE RISK OF NEW-ONSET TYPE 2 DIABETES? EVALUATION OF PATIENTS BASELINE CHARACTERISTICS / E. Alemao* - Z. Guo - L. Ferri - L. Burns THU0689 VARIABILITY OF PAIN LEVELS IS EXPLAINED BY SELF-REPORTED DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: A 3-MONTHS PROSPECTIVE STUDY OF 165 PATIENTS / F. Bailly* - C. Jacquemin - H. Servy - B. Fautrel - L. Gossec THU0690 RETROSPECTIVE ANALYSIS OF TEMPORAL ARTERY BIOPSY AND ITS IMPACT IN THE MANAGEMENT OF GIANT CELL ARTERITIS / G. Kasavkar* - A. Sinha THU0691 ASSOCIATION BETWEEN PERIODONTITIS AND CLINICAL RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS UNDER BIOLOGICAL TREATMENT / H.-H. Chen* - D.-Y. Chen - L.-G. Huang THU0692 RISK OF END-STAGE RENAL DISEASE REQUIRING DIALYSIS IN ANKYLOSING SPONDYLITIS PATIENTS STARTING MEDICAL THERAPY: A NATIONWIDE, POPULATION-BASED, COHORT STUDY / H.-H. Chen* - D.-Y. Chen - T.-Y. Hsieh - K.-L. Lai - Y.-M. Chen - C.-W. Tseng - C.-T. Lin THU0693 GOUT AND THE RISK OF PARKINSON S DISEASE IN THE ELDERLY / J. A. Singh* - J. D. Cleveland THU0694 THE EXCESS RISK OF DISABILITY IN PEOPLE WITH NEUROPATHIC PAIN WHEN COMPARED TO THOSE WITH NOCICEPTIVE PAIN IS EXPLAINED BY PAIN CATASTROPHISING AND PHYSICAL INACTIVITY / J. Mcbeth* - M. Mulvey - J. Anderson - A. Rashid - K. Druce THU0695 DOES HORMONE REPLACEMENT THERAPY PREVENT UNDIFFERENTIATED ARTHRITIS PROGRESSING TO RHEUMATOID ARTHRITIS / K. Miyachi* - A. Ihara - B. Sasse THU0696 IS AUTOIMMUNITY RELATED TO NAILFOLD VIDEOCAPILLAROSCOPY PATTERNS PROGESSION? DATA FROM A TERTIARY CENTER / L. Torrens* - C. Soleto - J. C. Nieto-González - A. Silva - A. López-Cerón - J. G. Ovalles-Bonilla - I. Janta - C. Sáenz - C. M. González - I. Monteagudo 14 June 2018 * Presenting author

82 80 / SCIENTIFIC POSTER SESSION I / THURSDAY 14 JUNE June 2018 THU0697 RISK OF MAJOR CONGENITAL MALFORMATIONS ASSOCIATED WITH EXPOSURE TO CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN WOMEN WITH INFLAMMATORY ARTHRITIS: A POPULATION- BASED COHORT STUDY / M. A. De Vera* - E. C. Sayre - N. W. Tsao - A. Howren THU0698 CLINICAL OUTCOME OF ULTRASONOGRAPHIC DETECTED UNDIFFERENTIATED SYNOVITIS IN PATIENTS WITH POLYARTHLAGIA / M. Mortada* - F. I. ABDELRAHMAN - S. Alyan THU0699 PREDICTORS OF FRACTURE AND LOW BONE MINERAL DENSITY IN PATIENTS WITH HISTORY OF PARENTAL FRACTURE / M. Dey* - M. Bukhari THU0700 PERINATAL EXPOSURE TO DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN WOMEN WITH INFLAMMATORY ARTHRITIS AND THE RISK OF SMALL-FOR-GESTATIONAL-AGE NEWBORNS: A POPULATION-BASED COHORT STUDY / N. W. Tsao* - E. C. Sayre - A. Howren - M. A. De Vera THU0701 UPDATED INCIDENCE AND COSTS OF HIP FRACTURES IN ELDERLY ITALIAN POPULATION / P. Piscitelli* - M. Feola - C. Neglia - C. Rao - E. Rizzo - U. Tarantino THU0702 SECULAR TRENDS OF HIP FRACTURES IN FRANCE BETWEEN 2002 AND 2013: IMPACT OF THE REFERENCE VALUES / R. Garofoli* - M. Cohen-Solal - A. Ostertag THU0703 IDENTIFYING CLINICAL, PSYCHOLOGICAL AND WORK RELATED FACTORS ASSOCIATED WITH PRESENTEEISM: THE INTERNATIONAL EULAR-PRO AT-WORK PRODUCTIVITY STUDY / S. Verstappen* - D. Lacaille - C. Hoffstetter - S. Talli - G. Saellariou - S. Dadoun - C. Mihai - S. Hagel - A. Bosworth - S. Ramiro - J. Canas da Silva - G. Crepaldi - J. Wallman - S. Leggett - A. Boonen on behalf of EULAR-PRO Worker productivity group THU0704 A NEW ASSESSMENT TOOL FOR ULNAR DRIFT IN PATIENTS WITH RHEUMATOID ARTHRITIS USING PATHOPHYSIOLOGICAL PARAMETERS OF THE METACARPOPHALANGEAL JOINT / S. Toyama* - R. Oda - D. Tokunaga - M. Asada - Y. Kawahito - H. Fujiwara - T. Kubo THU0705 OCCURRENCE OF ANKYLOSING SPONDYLITIS (AS) AMONG RELATIVES OF PROBANDS WITH RADIOGRAPHIC AS AND NON-RADIOGRAPHIC AS / AXIAL SPONDYLOARTHRITIS (SPA) / S. van der Linden* - P. Villiger - H. Baumberger - M. Brown - A. Boonen - M. A. Khan THU0706 PRESENCE OF EXTRACTABLE NUCLEAR ANTIGENS (ENA) ANTIBODIES IN A LARGE POPULATION-BASED COHORT FROM THE NETHERLANDS / S. Arends* - L. Brouwer - C. Roozendaal - B. Doestzada - H. Bootsma - K. de Leeuw THU0707 ANALYSIS OF ANTINUCLEAR ANTIBODIES IN BREAST CANCER PATIENTS / A. Neppel - M. C. C. Machoski - T. A. F. G. Santos* - R. Nisihara - T. L. Skare THU0708 DISPARITY IN OSTEOARTHRITIS KNEE PREVALENCE- A TALE OF TWO CITIES IN IRAN (TEHRAN) AND INDIA (PUNE): FINDINGS FROM WHO ILAR COPCORD POPULATION SURVEY (STAGE I) / A. Jamshidi - T. Kianifard* - R. Ghorpade - M. Shayan - M. Mahmoudi - A. Chopra THU0709 REUMAHEART - A PORTUGUESE POPULATION BASED STUDY ON CARDIOVASCULAR RISK FACTORS / V. M. Da Silva Domingues* - A. Rodrigues - S. Dias - J. Branco - H. Canhão on behalf of EpiReuma * Presenting author

83 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 81 Scientific Programme Friday 15 June 2018 Marije Koenders (Netherlands) 09:20 Abstract N SP0095 Inflammatory cytokines as key messengers of the immune system 09:45-10:15 Exhibition and EULAR Village (Hall 1) Coffee break 10:15-11:45 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN & HOT session Olivier Lortholary (France) 10:20 WIN: Infectious complications of rheumatic diseases (treatment) Christian Roux (France) 11:00 Abstract N SP0096 HOT: Advances in the management of osteoporosis 15 June :15-11:45 Hall 3 07:45-19:15 Registration area (Hall 2) Registration 08:15-09:45 Elicium 1 Basic and Translational Science session Special delivery: intercellular communication Learning objectives: Discuss different types of intercellular communication Describe how this is relevant to rheumatic diseases Leonie Taams (United Kingdom) Florence Apparailly (France) Daniel Davis (United Kingdom) 08:20 Abstract N SP0094 Membrane nanotubes: reaching out to other cells W. Fu (United States) 08:40 J. Wei, A. Hettinghouse, W. He, C. Liu Abstract N OP0224 ADAMTS-12 protects against inflammatory arthritis through interacting with proinflammatory CTGF Marca H. M. Wauben (Netherlands) 08:50 Extracellular vesicles as couriers of the immune system M. H. van den Bosch (Netherlands) 09:10 A. B. Blom, E. J. Geven, E. N. Blaney Davidson, P. M. van der Kraan, P. L. van Lent Abstract N OP0225 S100A9 mediates acute nociceptive pain in experimental synovitis Abstract session Biologics in RA. More, more and more about safety Bernard Combe (France) Diederik De Cock (United Kingdom) S. K. Chen (United States) 10:20 K. P. Liao, J. Liu, S. C. Kim Abstract N OP0226 Risk of hospitalised infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study M. George (United States) 10:30 J. Baker, K. Winthrop, E. Alemao, L. Chen, S. Connolly, T. Simon, Q. Wu, F. Xie, S. Yang, J. Curtis Abstract N OP0227 Timing of abatacept before elective arthroplasty and postoperative outcomes M. George (United States) 10:40 J. Baker, K. Winthrop, E. Alemao, L. Chen, S. Connolly, T. Simon, Q. Wu, F. Xie, S. Yang, J. Curtis Abstract N OP0228 Comparative risk of biologic therapies and risk of glucocorticoids in patients with rheumatoid arthritis undergoing elective arthroplasty

84 82 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE June 2018 M. Jani (United Kingdom) 10:50 W. G. Dixon, M. Lunt, D. De Cock, J. D. Isaacs, A. W. Morgan, A. G. Wilson, D. Plant, K. Watson, A. Barton, K. Hyrich on behalf of BSRBR Control Centre Consortium Abstract N OP0229 The association of biologic drug-levels with infection risk: results from the British society for rheumatology biologics register for rheumatoid arthritis G. Boleto (France) 11:00 J. Avouac, J. Wipff, M. Forien, M. Dougados, C. Roux, A. Kahan, P. Dieudé, Y. Allanore Abstract N OP0230 Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-centre study A. Barbulescu (Sweden) 11:10 J. Askling, T. Frisell on behalf of ARTIS Abstract N OP0231 Gastro-intestinal perforations among rheumatoid arthritis patients treated with biologic DMARDs: a nationwide Swedish cohort study K. Hambardzumyan (Sweden) 11:20 C. Hermanrud, P. Marits, N. Vivar, S. Ernestam, J. K. Wallman, R. F. van Vollenhoven, A. Fogdell-Hahn, S. Saevarsdottir Abstract N OP0232 Female gender and positive rheumatoid factor predict low serum infliximab levels and positive anti-drug antibodies, which associate with treatment failure on infliximab in patients with early rheumatoid arthritis. Report from the SWEFOT trial population G. R. Burmester (Germany) 11:30 R. Panaccione, K. Gordon, J. Rosenbaum, D. Arikan, W. Lau, R. Tarzynski-Potempa Abstract N OP0233 Long-term safety of adalimumab in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years 10:15-11:45 Auditorium Abstract session Clinical and therapeutic aspects of vasculitis Francesco Muratore (Italy) Dimitrios Vassilopoulos (Greece) D. Saadoun (France) 10:30 P. Cacoub, S. N. Si ahmed, Y. ferfar, S. Pol, D. Thabut, C. Hezode, L. Alric, C. Comarmond, G. Ragab, L. Quatuccio, M. Hegazy, T. Poynard, M. Resche Rigon Abstract N OP0235 Interferon-free antivirals for hepatitis C virus-associated cryoglobulinemia vasculitis: a long-term follow-up study A. Berti (Italy) 10:40 E. Matteson, C. S. Crowson, U. Specks, D. Cornec Abstract N OP0236 Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCAassociated vasculitis: a 20 year population-based cohort study N. L. Mallalieu (United States) 10:50 J. H. Stone, P. Villiger, M. Klearman, L. Brockwell, S. Dimonaco, J. E. Charion Abstract N OP0237 A comparison of PK and PD outcomes of tocilizumab in giant cell arteritis after SC and IV dosing S. Monti (Italy) 11:00 A. Craven, C. Klersy, C. Montecucco, R. Caporali, R. Watts, P. A. Merkel, R. Luqmani Abstract N OP0238 Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. Analysis from the DCVAS study J. Nossent (Australia) 11:10 W. Raymond, H. Keen, C. Inderjeeth, D. Preen Abstract N OP0239 Pregnancy outcomes in patients with IgA vasculitis A. Rubbert-Roth (Switzerland) 11:20 T. Neumann, P. Rein, H. Prillwitz, J. von Kempis Abstract N OP0240 Favourable longterm outcome in patients with giant cell arteritis treated with tocilizumab. Real-life data from a Swiss centre A. Mekinian (France) 11:30 M. Resche-Rigon, C. Comarmond, A. Soriano, J. constans, P. alric, P. Jego, F. Bussato, R. Dhote, E. lazaro, I. Kone pault, C. Landron, C. Lavigne, B. Lioger, M. Michaud, M. Ruivard, K. Sacre, J. E. Gottenberg, T. Goulenok, C. Salvarini, P. Cacoub, O. Fain, D. Saadoun on behalf of French Takayasu network Abstract N OP0241 Efficacy of tocilizumab in Takayasu arteritis: multicenter French retrospective study of 46 patients E. H. Park (Republic of Korea) 10:20 E. Y. Lee, Y. J. Lee, Y. J. Ha, B. Y. Choi, W.-H. Yoo, J. C. Paeng, H. Y. Suh, J. S. Park, S. Shon, Y. W. Song Abstract N OP0234 Infliximab therapy in patients with Takayasu arteritis

85 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 83 10:15-11:45 Elicium 2 Abstract session Axial spondyloarthritis: on the interface between healthy and diseased Denis Poddubnyy (Germany) Manouk de Hooge (Belgium) X. Baraliakos (Germany) 10:20 H. Boehm, A. Samir Barakat, G. Schett, J. Braun Abstract N OP0242 Fatty lesions detected on MRI scans in patients with ankylosing spondylitis are based on the deposition of fat in the vertebral bone marrow X. Baraliakos (Germany) 10:30 D. Feldmann, A. Ott, C. O. Schmidt, M. Albers, A. Richter, J. Braun Abstract N OP0243 Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals < 45 years in the general population as part of a large community study (SHIP) J. de Winter (Netherlands) 10:40 M. de Hooge, M. van de Sande, J. de Jong, L. van Hoeven, A. de Koning, I. J. Berg, R. Ramonda, D. Baeten, D. van der Heijde, A. Weel, R. Landewé Abstract N OP0244 An ASAS-positive MRI of the sacroiliac joints can also occur in healthy individuals, runners and women with postpartum back pain S. Seven (Denmark) 10:50 P. Hededal, M. Østergaard, L. Morsel-Carlsen, I. J. Sørensen, B. Bonde, G. Thamsborg, O. Hendricks, N. R. Jørgensen, S. J. Pedersen Abstract N OP0245 Ability of MRI of the sacroiliac joints to differentiate patients with axial spondyloarthritis from women, who have given birth, patients with disc herniation, persons with hard physical work, long-distance runners and healthy males A. Sepriano (Netherlands) 11:00 S. Ramiro, R. Landewé, M. Dougados, D. van der Heijde Abstract N OP0246 Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: the 5 years data of the DESIR cohort A. Sepriano (Netherlands) 11:10 S. Ramiro, F. Araújo, P. Machado, A. Rodrigues, N. Gouveia, M. Eusébio, H. Canhão, J. Branco on behalf of EpiReumaPt Team Abstract N OP0247 Performance of referral strategies for spondyloarthritis: a population-based nationwide study R. B. M. Landewé (Netherlands) 11:20 J. Sieper, U. Kiltz, X. Wang, M. Li, J. Anderson Abstract N OP0248 Potential differences in axial spondyloarthritis disease activity categorisation using different minimum values for high-sensitivity CRP in ankylosing spondylitis disease activity score calculation and different definitions of disease flare R. G. Lambert (Canada) 11:30 W. P. Maksymowych, M. Østergaard, U. Weber, S. J. Pedersen, J. Sieper, D. Poddubnyy, S. Wichuk, P. Machado, X. Baraliakos Abstract N OP0249 The contribution of structural MRI lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort 10:15-11:45 Hall 7.2 Abstract session Present and future treatments for SLE, Sjögren and APS David Isenberg (United Kingdom) Alessia Alumno (Italy) T. Dörner (Germany) 10:20 M. Zeher, U. Laessing, F. Chaperon, S. De Buck, A. Hasselberg, M.-A. Valentin, S. Ma, M. Cabanski, C. Kalis, C. Burkhart, P. Gergely Abstract N OP0250 A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary Sjögren s syndrome E. Morand (Australia) 10:30 J. T. Merrill, D. A. Isenberg, A. H. Kao, C. Vazquez Mateo, S. Wax, P. Chang, K. Pudota, C. Aranow, D. Wallace Abstract N OP0251 Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase IIB address II study and its long-term extension R. F. van Vollenhoven (Netherlands) 10:40 S. V. Navarra, R. A. Levy, M. Thomas, A. Heath, T. Lustine, A. Adamkovic, J. Fettiplace, M. L. Wang, B. Ji, D. Roth Abstract N OP0252 Organ damage progression and long-term safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE): an extension of pivotal phase III BLISS studies 15 June 2018

86 84 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE June 2018 R. Furie (United States) 10:50 M. A. Dooley, D. Wofsy, T. Takeuchi, A. Malvar, A. Doria, J. Romero-Díaz, T. M. Chan, A. Elegbe, G. B. Appel, D. Jayne, M. A. Maldonado Abstract N OP0253 A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis M. Urowitz (Canada) 11:00 R. L. Ohsfeldt, R. C. Wielage, J. J. Dever, M. Zakerifar, Y. Asukai, S. Ramachandran, A. V. Joshi Abstract N OP0254 A propensity score-matched (PSM) analysis of organ damage in patients with systemic lupus erythematosus (SLE) from the pooled bliss long-term extension (LTE) trials versus the Toronto lupus cohort (TLC) H. Sánchez Pérez (Spain) 11:10 D. Isenberg Abstract N OP0255 Identification of clinical and serological predictive factors of response to rituximab treatment in systemic lupus erythematosus (SLE) patients W.-S. Chen (Taiwan, Province of China) 11:20 C.-Y. Tsai, C.-C. Chang Abstract N OP0256 Hydroxychloroquine reduces risk of incident diabetes mellitus in primary Sjögren syndrome patients: a propensity score matched population-based cohort study T. Colasanti (Italy) 11:30 F. R. Spinelli, C. Barbati, L. Massaro, F. Ceccarelli, M. Vomero, F. Morello, V. Orefice, F. Conti, G. Valesini, C. Alessandri Abstract N OP0257 Decrease of autophagy in peripheral blood mononuclear cells from systemic lupus erythematosus patients treated with belimumab 10:15-11:45 Forum Abstract session From cartilage to bone Georg Schett (Germany) Stephan Blüml (Austria) T. M. Haqqi (United States) 10:30 N. M. Khan Abstract N OP0259 ZCCHC5, a LTR retrotransposon-derived neofunctionalised gene, is essential for the transcriptional activity of SOX9 and the expression of COL2A1 in chondrocytes and is downregulated in OA cartilage L. M. Topping (United Kingdom) 10:40 C. Vinci, H. Rhys, L. Norling, A. Nissim Abstract N OP0260 Targeting neutrophil microvesicles to damaged cartilage using antibodies to post-translationally modified collagen II L. Zhu (United Kingdom) 10:50 H. Ismail, A. Chanalaris, M. Gardiner, T. L. Vincent on behalf of ECHO Abstract N OP0261 Retinoic acid is regulated by cartilage injury and is antiinflammatory in hand osteoarthritis E. M. van Helvoort (Netherlands) 11:00 J. Popov-Celeketic, K. Coeleveld, A. Doornenbal, M. Tryfonidou, C. Wijne, F. Lafeber, S. Mastbergen Abstract N OP0262 Disease modifying effects of the canine IL4-10 fusion protein in the canine groove model of osteoarthritis C.-H. Lee (Republic of Korea) 11:10 J. M. Baek, Y. J. Choi, W.-H. Yoo, M. S. Lee, J.-Y. Kim Abstract N OP0263 Claudin-11 regulates bone homeostasis via bi-directional EPHB4-EPHRINB2 signaling Y. Henrotin (Belgium) 11:20 N. Rabbani, U. Ahmed, C. Lambert, C. Legrand, A. Anwar, K. Rajpoot, S. Pasha, R. K. Davidson, I. M. Clark, P. J. Thornalley Abstract N OP0264 Glucosepane: a new biomarker of the severity of osteoarthritis C. Fenton (United Kingdom) 11:30 C. Doig, S. Fareed, A. Naylor, C. Wehmeyer, C. Buckley, G. Lavery, M. Cooper, K. Raza, R. Hardy Abstract N OP0265 Local reactivation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 mediates the development of glucocorticoid-induced bone loss 10:15-11:45 Elicium 1 D. Amantini (France) 10:20 L. Lepescheux, P. Clement-Lacroix, D. Merciris, S. Meurisse, M. Borgonovi, C. Cottereaux, P. Mollat, F. Brebion, R. Gosmini, F. De Ceuninck, I. Botez, E. van der Aar, T. Christophe, N. Vandervoort, R. Blanqué, D. Comas, P. Deprez Abstract N OP0258 Efficacy of the highly selective ADAMTS-5 inhibitor GLPG1972 in the rat meniscectomy model Abstract session Seeking the pathophysiology of rheumatoid arthritis and spondylarthritis João E. Fonseca (Portugal) Dirk Elewaut (Belgium)

87 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 85 L. G. van Baarsen (Netherlands) 10:20 M. J. de Hair, J. F. Semmelink, I. Y. Choi, D. M. Gerlag, P. P. Tak Abstract N OP0266 Synovial tissue profiling in auto anti-body positive at risk individuals reveals gene signatures associated with later development of rheumatoid arthritis B. Kolarz (Poland) 10:30 M. Dryglewska, M. Ciesla, A. Selwa, M. Majdan Abstract N OP0267 The PADI4 gene promoter methylation level is associated with anti-padi4 antibodies level and RA activity C.-R. Wang (Taiwan, Province of China) 10:40 S.-Y. Chen, A.-L. Shiau, C.-L. Wu Abstract N OP0268 Apoptosis of synovial fibroblasts induced by P53-derived hybrid peptides through dissociating the binding of P73 with IASPP to increase PUMA and BAX expression S. R. Finlay (United Kingdom) 10:50 S. Alivernini, A. Elmesmari, B. Tolusso, L. Perticca, C. Di Mario, A. Capacci, A. Filer, G. Ferraccioli, I. McInnes, E. Gremese, M. Kurowska-Stolarska Abstract N OP0269 Activation of MERTK+CD206+ subpopulation of human synovial tissue-resident macrophages limits inflammatory response K. Mankia (United Kingdom) 11:00 P. Pentony, L. Hunt, Y. El-Sherbiny, L. Duquenne, D. Corscadden, T. Do, J. Meade, D. Devine, P. Emery Abstract N OP0270 IGA anti-ccp antibodies are detectable in the saliva but not sputum of individuals at risk of developing rheumatoid arthritis D. Benfaremo (Italy) 11:10 M. M. Luchetti, F. Ciccia, C. Avellini, T. Spadoni, S. Svegliati, M. Ciferri, A. Gabrielli Abstract N OP0271 Gastrointestinal damage and microbial translocation are involved in the development of immune system activation in inflammatory bowel disease-associated spondyloarthritis G. R. Gulino (Belgium) 11:20 M. van Mechelen, R. Lories Abstract N OP0272 Inflammation at barrier tissues such as skin and gut triggers mild joint inflammation and is influenced by biomechanical stress induced by forced-running L. van Duivenvoorde (Netherlands) 11:30 M. van Tok, D. Pots, I. Blijdorp, M. Armaka, G. Kollias, M. van de Sande, D. Baeten Abstract N OP0273 Transmembrane TNF signaling through TNF-RI induces SpA-like inflammation, whereas signaling through TNF-RII is crucial for new bone formation 10:15-11:45 Amtrium Abstract session HPR Supporting self-management Mwidimi Ndosi (United Kingdom) Fernando Estévez-López (Spain) G. Fernandes (Brazil) 10:20 F. Jennings, M. Cabral, R. Santos, J. Natour Abstract N OP0274-HPR A functional exercise programme improves pain and health related quality of life in patients with fibromyalgia: a randomised controlled trial S. G. Mckenna (Ireland) 10:30 M. P. Herring, A. Donnelly, A. Fraser, L. Comber, N. Kennedy Abstract N OP0275-HPR The effects of exercise on depressive and anxiety symptoms in rheumatoid arthritis: a systematic review and meta-analysis I. Ahlstrand (Sweden) 10:40 P. Wagman, C. Håkansson, M. Björk Abstract N OP0276-HPR Occupational balance and its relation to performance of valued life activities in persons with rheumatoid arthritis in working age M. C. Vassalli (Brazil) 10:50 A. Jones, J. Natour, R. Silva Abstract N OP0277-HPR Evaluation of the effectiveness of a progressive resistance training program for patients with fibromyalgia: a randomised controlled trial S. A. Just (Denmark) 11:00 F. Humby, H. Lindegaard, L. Meric de Bellefon, P. Durez, E. Vieira-Sousa, R. Teixeira, M. Stoenoiu, J. Werlinrud, S. Rosmark, P. V. Larsen, C. Pitzalis, A. Filer Abstract N OP0278-HPR Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across Europe M. Martin (United Kingdom) 11:10 A. Gilbert, C. Jeffries Abstract N OP0279-HPR A national survey of the utilisation and experience of hydrotherapy in the management of axial spondyloarthritis: the patients perspective A. Bremander (Sweden) 11:20 K. Malm, M. L. Andersson on behalf of the BARFOT study group Abstract N OP0280-HPR Physical activity in established RA and variables associated with physical activity maintenance over a seven year period 15 June 2018

88 86 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 M. van Heuckelum (Netherlands) 11:30 E. Mathijssen, M. Vervloet, A. Boonen, A. Pasma, R. Hebing, H. Vonkeman, M. Wenink, B. van den Bemt, L. van Dijk Abstract N OP0281-HPR Preferences of patients with rheumatoid arthritis regarding disease modifying anti-rheumatic drugs: a discrete choice experiment G. Cavalli (Italy) 10:50 R. van Deuren, P. Arts, M. Steehouwer, C. Gilissen, P. Sfriso, P. Galozzi, S. Colafrancesco, R. Priori, L. Cantarini, O. M. Lucherini, S. Rodolfi, G. De Luca, E. Baldissera, F. van de Veerdonk, L. Dagna, A. Hoischen, C. A. Dinarello Abstract N OP0285 Identification of rare coding variants in IL-1-related pathways in patients with adult-onset Still s disease 15 June :15-11:45 Emerald Abstract session From gene to function Leonid Padyukov (Sweden), Annette van der Helm-van Mil (Netherlands) E. López-Isac (Spain) 10:20 M. Acosta-Herrera, S. Assassi, C. P. Simeón, P. E. Carreira, I. Castellví, N. Ortego-Centeno, L. Beretta, C. Lunardi, A. Gabrielli, G. Moroncini, N. Hunzelmann, T. Witte, J. H. Distler, A. Franke, A. E. Voskuyl, J. de Vries-Bouwstra, C. Wijmenga, R. Hesselstrand, A. Nordin, A.-M. Hoffmann-Vold, A. Herrick, J. Worthington, C. P. Denton, M. A. Brown, Y. Allanore, T. R. Radstake, C. Fonseca, M. D. Mayes, J. Martín Abstract N OP0282 New systemic sclerosis risk loci identified through a meta- GWAS strategy M. Acosta-Herrera (Spain) 10:30 M. Kerick, D. Gonzalez-Serna, C. Wijmenga, A. Franke, L. Padyukov, T. Vyse, M. E. Alarcon-Riquelme, M. D. Mayes, J. Martin on behalf of the Myositis Genetics Consortium & Scleroderma Genetics Consortium Abstract N OP0283 Cross-disease meta-analysis in four systemic autoimmune diseases to identify shared genetic etiologies P.-A. Juge (France) 10:40 J. S. Lee, E. Ebstein, H. Furukawa, E. Dobrinskikh, S. Gazal, C. Kannengiesser, S. Ottaviani, N. Tsuchiya, S. Oka, S. Tohma, J. Rojas-Serrano, M.-I. Gonzalez-Perez, M. Mejia, I. Buendia-Roldan, R. Falfan-Valencia, E. Manali, S. A. Papiris, T. Karageorgas, D. Boumpas, K. Antoniou, C. van Moorsel, J. van der Vis, Y. de Man, J. Grutters, Y. Wang, R. Borie, L. Wemeau-Stervinou, B. Wallaert, R.-M. Flipo, H. Nunes, D. Valeyre, N. Saidenberg, S. Marchand-Adam, K. Deane, A. Walts, T. Fingerlin, E. Matteson, T. Niewold, D. Assayag, A. Gross, P. Wolters, M. Schwarz, M. Holers, J. Solomon, T. Doyle, M.-P. Debray, C. Boileau, B. Crestani, D. Schwartz, P. Dieudé Abstract N OP0284 MUC5B promoter variant RS is a risk factor for rheumatoid arthritis - interstitial lung disease M. H. Al-Mossawi (United Kingdom) 11:00 E. Lau, S. Danielli, N. Yager, J. de Wit, E. Mahe, L. Rizvi, J. Knight, B. Fairfax, P. Bowness Abstract N OP0286 Genotypic effects of ankylosing spondylitis associated IL7R polymorphisms are mediated through monocytes in inflammation A. Yarwood (United Kingdom) 11:10 C. Taylor, A. Hinks, S. Smith, K. Duffus, A. McGovern, W. Thomson, S. Eyre Abstract N OP0287 Gene enhancers associated with an increased risk of developing JIA fail to down regulate RUNX1 after cell stimulation K. Duffus (United Kingdom) 11:20 M. Imran, T. Katopodi, H. Ray-Jones, G. Orozco, A. Adamson, S. Eyre Abstract N OP0288 Transcriptional perturbation of RA-risk enhancer by CRISPR-DEADCAS9 regulates long range gene targets S. Nagpal (United States) 11:30 V. Krishna, X. Yin, D. Pocalyko, A. Walsh, K. Bachman, I. Anderson, L. Madakamutil Abstract N OP0289 Integration of chromatin conformation, transcriptome and genome-wide landscape of BRD2 and BRD4 binding motifs identifies mechanisms of bet inhibitor action in rheumatoid arthritis synovial fibroblasts 10:15-11:45 PARE Room Abstract session PARE Abstract session Learning objectives: From abstract to concrete - the variety of activities of PARE organisations Kate Betteridge (United Kingdom) Polina Pchelnikova (Russian Federation) Magdalena Misuno (Poland) 10:20 Edgar Stene Prize 2018: My personal champion - supporting my everyday life with a rheumatic and musculoskeletal disease (RMD) C. R. Ziegler (Denmark) 10:30 Abstract N OP0290-PARE Keep an eye out for invisible pains - a Danish campaign

89 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 87 J. F. M. Holla (Netherlands) 10:40 J. Brontsema, N. Schenk, R. Jansen, R. Vreenegoor, M. Fluit, W. F. Peter, I. E. Bultink Abstract N OP0291-PARE Running with rheumatism: a 7-week training programme for novice runners with inflammatory rheumatic disease A. Lacovou (Cyprus) 10:50 Abstract N OP0292-PARE The creation of the aqua re-action. A methodologically based aquatic physical intervention/rehabilitation program for people with RMDs P. Wegscheider (Austria) 11:00 G. Schaffer Abstract N OP0293-PARE Problems, goals and urgent wishes of young Austrians diagnosed with rheumatic disorders: a report A. Higginbottom (United Kingdom) 11:20 S. Blackburn, R. Taylor, C. Rhodes, L. Campbell, K. Dziedzic Abstract N OP0294-PARE Addressing key challenges of lay involvement in musculoskeletal research: co-applicants and trial steering committees S. De Jong (Netherlands) 11:20 Abstract N OP0295-PARE Kweek begrip : the launch of our creative campaign across the Netherlands on worldarthritisday aims to increase awareness about RMDs in general and people living with RMDs in particular N. Haroon (Canada) 11:30 B. Kuriya, J. Widdifield, J. Luo, S. Vigod Abstract N OP0296 The risk of deliberate self-harm in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study 10:15-11:45 E106/E107 Abstract session More money or more education and collaboration? Bruno Fautrel (France) Juliane Stocker (Netherlands) S. A. Bergstra (Netherlands) 10:20 J. Tavares-Costa, M. Garzo-Elizondo, K. Salomon-Escoto, N. Govind, C. Allaart, R. Landewé Abstract N OP0297 Disease activity in rheumatoid arthritis patients is influenced by countries socioeconomics: results from the METEOR registry M. A. Lopez-Olivo (United States) 10:30 A. Matusevich, S. B. Cantor, G. Pratt, M. E. Suarez-Almazor Abstract N OP0298 The comparative effectiveness of cycling tumor necrosis factor inhibitor (TNFI) versus swapping to a nontnfi on patient-reported functional ability of patients with rheumatoid arthritis E. van Mulligen (Netherlands) 10:40 A. E. A. M. Weel, T. M. Kuijper, J. J. Luime, J. M. W. Hazes, P. H. P. de Jong Abstract N OP0299 Cost-effectiveness of tapering TNF blockers versus conventional synthetic DMARDs in rheumatoid arthritis: first year results of the randomised controlled TARA-study A. Barr (United Kingdom) 10:50 D. Pickles, N. Fadl, J. Dou, C. Vandevelde, S. Dubash, J. E. Freeston, H. Marzo-Ortega Abstract N OP0300 Reducing avoidable biologic drug wastage through collaboration between patients and care providers: the Leeds spondyloarthritis service experience S. S. Pazmino (Belgium) 11:00 R. Westhovens, J. Joly, V. Stouten, D. De Cock, K. van der Elst, P. Verschueren on behalf of the CareRA study group Abstract N OP0301 Two year cost-effectiveness analysis of the carera trial in early RA: a piggy back study A. Ahrari (Canada) 11:10 S. S. Barrett, S. Rohekar, P. Basharat, G. Rohekar, S. Haig, J. Pope Abstract N OP0302 An evaluation of utilisation patterns and appropriateness of laboratory tests among new referrals to rheumatologists: choosing unwisely! A. Moltó (France) 11:20 A. Etcheto, S. Poiraudeau, L. Gossec, P. Claudepierre, M. Soubrier, F. Fayet, D. Wendling, P. Gaudin, E. Dernis, S. Guis, S. Pouplin, A. Ruyssen-Witrand, M. Dougados Abstract N OP0303 Systematic screening of comorbidities improves vaccination rates, skin cancer screening and vitamin D supplementation in patients with axial spondyloarthritis: results of the COMEDSPA prospective, controlled, one year randomised trial M. Kostine (France) 11:30 A. Najm, J. Pauling, A. C. Ferreira, K. Stevens, E. Smith, I. Eguiluz Gracia, S. Ramiro, E. Nikiphorou, A. Molto, A. Alunno, P. Studenic, A. Sepriano, J. Rodríguez Carrio, C. Richez on behalf of EMEUNET, YNP, PReS EMERGE and EAACI JM. Abstract N OP0304 Multidisciplinary collaboration among young specialists: results of an ongoing international survey by young organisations 15 June 2018

90 88 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE June :15-11:45 D201/D202 Abstract session The changing therapeutic landscape of PsA Douglas Veale (Ireland) Kurt de Vlam (Belgium) E. Kampylafka (Germany) 10:20 I. d Oliveira, C. Linz, V. Lerchen, M. Englbrecht, D. Simon, M. Sticherling, J. Rech, A. Kleyer, G. Schett, A. J. Hueber Abstract N OP0305 Disease interception in psoriasis patients with subclinical joint inflammation by interleukin 17 inhibition with secukinumab - data from a prospective open label study D. van der Heijde (Netherlands) 10:30 P. Mease, R. Landewé, S. Mpofu, P. Rahman, H. Tahir, A. Singhal, E. Boettcher, S. Navarra, X. Zhu, A. Readie, L. Pricop, K. Abrams Abstract N OP0306 Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-tnf therapy and concomitant methotrexate use P. J. Mease (United States) 10:40 H. Kellner, A. Morita, A. J. Kivitz, K. A. Papp, S. Aslanyan, B. Berner, S. Chen, A. Eldred, F. Behrens Abstract N OP0307 Efficacy and safety of risankizumab, a selective IL-23P19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial A. Deodhar (United States) 10:50 A. B. Gottlieb, W.-H. Boehncke, B. Dong, Y. Wang, Y. Zhuang, W. Barchuk, X. L. Xu, E. Hsia Abstract N OP0308 Efficacy and safety results of guselkumab in patients with active psoriatic arthritis over 56 weeks from a phase 2A, randomised, double-blind, placebo-controlled study P. Mease (United States) 11:00 D. Gladman, A. Kavanaugh, P. Nakasato, B. Guerette, L. Teng, P. Nash Abstract N OP0309 Characterization of clinical benefits in subjects classified as ACR20 non-responders at week 104 of apremilast treatment: sub-analysis of 3 long-term, phase III trials J. Pinto-Tasende (Spain) 11:10 F. Maceiras-Pan, C. García-Porrúa, J. A. Mosquera-Martinez, L. Fernandez-Dominguez, B. Correa-Rey, M. Pombo-Suarez Abstract N OP0310 Prevalence of risk factors and cardiovascular events across psoriatic arthritis patients treated with biological therapy A.-S. Vandendorpe (Belgium) 11:20 K. De Vlam, R. Lories Abstract N OP0311 Notable evolutions in the characteristics of psoriatic arthritis clinical trials populations in the era of biological treatments M. Elmamoun (Canada) 11:30 M. Eraso, A. Maharaj, V. Chandran, L. Coates on behalf of ILAR-PsA recommendations group, Adebajo A, Sharma A, Toloza S, Vega-E L, Vega-H O, Abogamal A, Ajibade A, Ayanlowo O, Azevedo V, Bautista-M W, Carneiro S, Goldenstein-S C, Hernandez-V F, Ima-E U, Lima A, Medina-R J, Mody G, Narang T, Ortega-L A, Ranza R Abstract N OP0312 International league of associations for rheumatology (ILAR) treatment recommendations for psoriatic arthritis in resource-poor countries 10:15-11:45 D203/D204 Abstract session T/B be or not T/B: adaptive or innate immunity - that is the question Hendrik Schulze-Koops (Germany) Marije Koenders (Netherlands) R. D. Vergroesen (Netherlands) 10:20 L. M. Slot, F. S. van de Bovenkamp, M. T. Koning, T. W. J. Huizinga, T. Rispens, R. E. M. Toes, H. U. Scherer Abstract N OP0313 Molecular analysis of anti-citrullinated protein antibody variable regions indicates aberrant selection processes during ACPA B cell development A. Floudas (Ireland) 10:30 M. Biniecka, C. Low, D. J. Veale, U. Fearon Abstract N OP0314 B cell phenotype and function in the synovium of ACPA+ and ACPA- rheumatoid arthritis patients J. Y. Leong (Singapore) 10:40 J. G. Yeo, P. Chen, F. Ally, C. Chua, S. N. Hazirah, P. Lu, L. Lai, L. D. T. Bathi, T. Arkachaisri, D. J. Lovell, S. Albani Abstract N OP0315 Juvenile idiopathic arthritis patients exhibit persistence in CD4 memory T cells and distinct transcriptomic signature despite biologics therapy G. Dekkema (Netherlands) 10:50 T. Bijma, W. Abdulahad, P. Jellema, A. van den Berg, B. J. Kroesen, C. Stegeman, P. Heeringa, J.-S. Sanders Abstract N OP0316 Increased expression of microrna-142-3p is associated with the functional defect of regulatory T cells in antineutrophil cytoplasmic antibody associated vasculitis

91 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 89 M. Camacho Encina (Spain) 11:00 V. Calamia, F. Picchi, J. VanDuin, J. Qiu, C. Ruiz Romero, J. LaBaer, F. J. Blanco Abstract N OP0317 Screening of an autoantibody signature of early knee osteoarthritis: data from the osteoarthritis initiative R. G. Chirivi (Netherlands) 11:10 J. W. van Rosmalen, K. Kambas, G. Schmets, H. Kalisvaart, G. Bogatkevich, T. Shaw, H. van Es, J. M. Raats Abstract N OP0318 Netosis-inhibiting T-ACPA therapy for use in different netdriven human autoimmune diseases K. Jablonski (United States) 11:20 B. Sandoval, P. Harb, A. Kalyanasundaram, J. M. Hampton, W. N. Jarjour, N. Schlesinger, N. A. Young Abstract N OP0319 Low and moderate physical activity reduces localised IL- 1β in an acute mouse model of gout by down-regulating TLR2 expression on circulating neutrophils M. H. van den Bosch (Netherlands) 11:30 I. Di Ceglie, T. Vogl, J. Roth, C. S. Goodyear, P. M. van der Kraan, A. B. Blom, P. L. van Lent Abstract N OP0320 S100A9 hampers osteoclast differentiation from circulating precursors by reducing the expression of rank 13:30-15:00 Hall 3 Challenges in Clinical Practice session Challenges in systemic lupus diagnosis Learning objectives: To be able to identify a very rare lung involvement in SLE To discuss how to differentiate specific and aspecific neuropsychiatric SLE features Pier Luigi Meroni (Italy) Guillermo Pons-Estel (Argentina) Margherita Zen (Italy) 13:35 Abstract N SP0099 Case 1 presentation: Painful dyspnea Andrea Doria (Italy) 13:45 Case 1 discussion: Shrinking lung Antonis Fanouriakis (Greece) 14:15 Abstract N SP0100 Case 2 presentation: Neuropsychiatric lupus or not? Dimitrios Boumpas (Greece) 14:25 Case 2 discussion: Diagnosis of neuropsychiatric SLE: the problem of attribution 15 June :45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 11:50-13:30 Poster area Guided poster tours Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Friday, please refer to page 98. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour. 13:30-15:00 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN & HOT session Ellen Kapiteijn (Netherlands) 13:35 Abstract N SP0097 WIN: Check-point inhibitors: what are they used for? Leonard Calabrese (United States) 14:15 Abstract N SP0098 HOT: Immune related adverse events upon check-point inhibitors 13:30-15:00 Auditorium From Bench to Bedside Pathophysiology and biomarkers in PsA: what impact? Learning objectives: To review new insights into pathophysiology in PsA To identify markers of synovial inflammation and biomarkers in PsA To gain further insight into clinical consequences of different pathophysiological disease mechanisms and drivers in clinical decision-making Douglas Veale (Ireland) Dirk Elewaut (Belgium) Rik Lories (Belgium) 13:35 Pathophysiology of PsA: what is the role of cells and cytokines? Bernard Lauwerys (Belgium) 13:53 Synovial markers in inflammatory arthritis: is this the new holy grail? Christopher T. Ritchlin (United States) 14:11 Serum biomarkers in PsA: a novel tool in diagnosis and therapeutic monitoring? Georg Schett (Germany) 14:29 Does it matter to the clinician: can pathophysiological knowledge lead to better patient care?

92 90 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 I. Miyagawa (Japan) 14:47 S. Nakayamada, K. Nakano, S. Kubo, S. Iwata, Y. Miyazaki, M. Yoshikawa, H. Yoshinari, Y. Tanaka Abstract N OP0321 Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis 13:30-15:00 Hall 7.2 The Young Rheumatologist Understanding the language of basic research, epidemiology and health services articles 15 June :30-15:00 Elicium 2 Clinical Science session The art of diagnosis of axial SpA Learning objectives: To gain further insights into early phases of axial SpA, and how to diagnose it, addressing its challenges To review the pros and cons of imaging and laboratory testing in early axspa To discuss how to disentangle the different types of back pain present in axspa - inflammatory, degenerative and both To discuss the impact of an early diagnosis of axspa, and what consequences it has for the patient receiving it Victoria Navarro-Compán (Spain) Atul Deodhar (United States) Martin Rudwaleit (Germany) 13:35 What is early axial SpA? Challenges for an early diagnosis Anna Moltó (France) 13:55 The symptom of back pain - disentangle between inflammatory, degenerative or both? Filip van den Bosch (Belgium) 14:15 Clinical impact of an early diagnosis in axial SpA V. Navarro-Compán (Spain) 14:35 R. E. Nieto, C. Plasencia, D. Peiteado, A. Villalba, A. Balsa Abstract N OP0322 Are we treating with biological therapies women patients with real non-radiographic axial spondyloarthritis? A. Ortolan (Italy) 14:45 M. van Lunteren, S. Ramiro, R. Ramonda, R. Landewé, H. Dagfinrud, L. Jacobsson, D. van der Heijde, F. A. van Gaalen Abstract N OP0323 Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the spondyloarthritis caught early cohort Learning objectives: To properly understand the meaning of basic research, epidemiology and health services terminology and findings reported in published articles Iain B. McInnes (United Kingdom) Loreto Carmona (Spain) Iain B. McInnes (United Kingdom) 13:35 Understanding the language of basic research articles William G. Dixon (United Kingdom) 13:55 Abstract N SP0101 Understanding the language of epidemiology articles Loreto Carmona (Spain) 14:15 Abstract N SP0102 Understanding the language of health services articles K. L. Grøn (Denmark) 14:35 E. Arkema, B. Glintborg, F. Mehnert, M. Østergaard, L. Dreyer, M. Nørgaard, N. S. Krogh, J. Askling, M. Heltand on behalf of all departments that have contributed with data and the ARTIS study group Abstract N OP0324 Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in Denmark and Sweden J. Gandrup (United States) 14:45 J. Li, Z. Izadi, T. Ellingsen, J. Yazdany, G. Schmajuk Abstract N OP0325 Effect of three health it interventions on RA disease activity score documentation in an academic rheumatology clinic 13:30-15:00 Forum Clinical Science session Joint EULAR - ESSR session: the role of MR imaging in rheumatic diseases and its clinical implications Learning objectives: To learn about the radiologist s and rheumatologist s perspective of RA and SpA and to discuss possible differences Joachim Sieper (Germany) Monique Reijnierse (Netherlands) Benedikt Ostendorf (Germany) 13:35 Abstract N SP0103 Indications and clinical implications of MR imaging in RA

93 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 91 Faculty 13:50 Q&A Andrew Grainger (United Kingdom) 13:55 MRI in early and established RA - what is the added value Faculty 14:10 Q&A Mikkel Østergaard (Denmark) 14:15 Abstract N SP0104 Indications and clinical implications of MR imaging in SpA Faculty 14:30 Q&A Iris Eshed (Israel) 14:35 Abstract N SP0105 MRI in early and established SpA - what is the added value Faculty 14:50 Q&A 13:30-15:00 Elicium 1 Basic and Translational Science session The stromal link to inflammation Learning objectives: Chronic inflammation affects local stromal cells Stromal cells adapt to long-term inflammation with alterations in surface molecules, epigenetic and metabolomics changes Inflammatory memory alters the response to inflammatory factors of stromal cells Steffen Gay (Switzerland) Kerstin Klein (Switzerland) Chris Buckley (United Kingdom) 13:35 Stromal inflammatory memory: cellular priming and alterations R. Stratton (United Kingdom) 13:55 Z. Taki, B. Abdi Ahmed, E. Gostjeva, C. Venturini, C. Denton, A. Salama, H. Lopez Abstract N OP0326 Modelling the interaction between disease microenvironment and mesenchymal stem cells in scleroderma Costantino Pitzalis (United Kingdom) 14:05 Treatment resistance: a role of fibroblasts and stromal cells? W. Marut (Netherlands) 14:25 A. Affandi, T. Carvalheiro, A. Ottria, J. Haan, M. Brandt, R. Tieland, M. Brans, B. Malvar-Fernandez, C. Bekker, M. van der Linden, B. Giovannone, D.-J. Heijnen, A. Kowalska, R. Lafyatis, C. Cheng, S. de Jager, J. van Roon, T. Radstake Abstract N OP0327 CXCL4 drives fibrosis by promoting several key cellular and molecular processes Jörg Distler (Germany) 14:35 Abstract N SP0106 Fibroblasts: their roles in matrix and vessels 13:30-15:00 Amtrium Health Professionals session New approaches in measuring what matters to patients Learning objectives: To be able to describe and discuss new quantitative approaches in the area of measuring what matters to patients Anthony Redmond (United Kingdom) Valentin Ritschl (Austria) Valentin Ritschl (Austria) 13:35 Abstract N SP0107 What can Bayes statistics contribute to measuring patient perspectives? Hilary Bekker (United Kingdom) 13:55 Abstract N SP0108 Decision aid tools Mara Kaldeweide (Germany) 14:15 Patient s view on measuring what matters to patients J. Primdahl (Denmark) 14:35 D. V. Jensen, R. H. Meincke, K. V. Jensen, C. Ziegler, S. W. Nielsen, L. Dalsgaard, M. Kildemand, M. L. Hetland, B. A. Esbensen Abstract N OP0328-HPR Patients views on routine collection of patient-reported outcomes in rheumatology care - a DANBIO focus group study M. Oude Voshaar (Netherlands) 14:45 Z. Das Gupta, M. A. van de Laar, H. E. Vonkeman on behalf of International Consortium for Health Outcome Measurement (ICHOM) working group for inflammatory arthritis minuscules Abstract N OP0329-HPR Outcomes that matter to people living with inflammatory arthritis; a global standard set, developed by the international consortium for health outcome measurement (ICHOM) working group for inflammatory arthritis 15 June 2018

94 92 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE :30-15:00 Emerald Practical skills session* Data visualisation: tables and graphs for publication and presentation II Learning objectives: To learn how tables and graphs should be designed for publication and presentation 13:30-15:00 E106/E107 EULAR Projects EULAR Projects in Investigative Rheumatology Learning objectives: To review the last advances of some of the study groups involved in investigative rheumatology 15 June 2018 Maarten Boers (Netherlands) 13:35 Abstract N SP0080 Data visualisation: tables and graphs for publication and presentation 13:30-15:00 PARE Room Joint session PARE/Clinical Innovative treatments for a better quality of life Learning objectives: To present new innovative drugs To outline health interventions and technology assessment in support of people with RMDs To learn what drug safety parameters the patient has to consider when being treated with innovative drugs Xavier Mariette (France) Timothy R. Radstake (Netherlands) Johan Ronnelid (Sweden) 13:35 Abstract N SP0110 Autoantibody standardization in autoimmune diseases Francesca Barone (United Kingdom) 13:55 From pathophysiology of Sjögren s syndrome to new clinical trials Maurizio Cutolo (Italy) 14:15 Abstract N SP0111 How neuro endocrine immunology impact rheumatic diseases? Vanessa Smith (Belgium) 14:35 Abstract N SP0112 Microcirculation in rheumatic diseases José A. P. da Silva (Portugal) Eva Tzigounaki-Kritza (Greece) Johannes W. J. Bijlsma (Netherlands) 13:35 Why JAK inhibitors can make a difference? Jürgen Clausen (Germany) 13:55 Abstract N SP0109 Involvement of a patient organisation in health technology assessment Ailsa M. Bosworth (United Kingdom) 14:15 Patient rights and safety concerns in an era of innovative therapies A. M. Bosworth (United Kingdom) 14:35 S. Arora Abstract N OP0330-PARE Love your heart, an online, interactive cardiovascular risk assessment programme for people with RA/IA L. Alemo Munters (Sweden) 14:45 A. Beerman Abstract N OP0331-PARE Behavior change experiences and needs of persons with rheumatic disease 13:30-15:00 D201/D202 Practical skills session* Laboratory course - from the clinic to the lab and back Learning objectives: To discuss importance of ANA diagnostic and antiphospholipid syndrome To learn more about vasculitis and systemic autoimmunity To discuss new trends in biomarkers in inflammatory joint disease Gerd R. Burmester (Germany) Thomas Dörner (Germany) Thomas Dörner (Germany) 13:35 ANA diagnostic and antiphospholipid syndrome (APS) as inherited coagulation disorder Pierre Miossec (France) 14:00 Vasculitis, systemic autoimmunity Eugen Feist (Germany) 14:25 Abstract N SP0113 New trends in biomarkers in inflammatory joint disease * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

95 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 93 13:30-15:00 D203/D204 15:30-17:00 Hall 3 Practical skills session* New assessments in clinical practice Learning objectives: To learn how to perform a reliable physical examination To properly judge value of inflammatory biomarkers in clinical decision-making To properly value ultrasonography in clinical decision making Annamaria Iagnocco (Italy) Michael Doherty (United Kingdom) Michael Doherty (United Kingdom) 13:35 Abstract N SP0114 How to perform quick and reliable physical examination in rheumatology Miriana Sefik-Bukilica (Serbia) 13:55 Abstract N SP0115 Value of inflammatory biomarkers in clinical decision making Lene Terslev (Denmark) 14:15 Abstract N SP0116 Value of ultrasound in clinical decision making Annamaria Iagnocco (Italy) 14:35 Abstract N SP0117 Ultrasound scanning of RA patients in remission Clinical Science session Advances in biologic therapy of small vessel vasculitis Learning objectives: To familiarise the audience with with new advances in treating SV vasculitis David Saadoun (France) Leonard Calabrese (United States) David Jayne (United Kingdom) 15:35 Complement inhibition in AAV Frank Moosig (Germany) 15:55 Abstract N SP0119 The evolving role of mepolizumab in EGPA Benjamin Terrier (France) 16:15 Abstract N SP0120 Current controversies in the use of rituximab for induction and maintenance of AAV disease P. Brogan (United Kingdom) 16:35 G. Cleary, O. Kasapcopur, S. Rangaraj, R. Yeung, P. Brunetta, J. Cooper, P. Pordeli, P. B. Lehane Abstract N OP0332 Paediatric open-label clinical study of rituximab for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) 15 June :00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 Hall 7.1 What is New (WIN) & How to Treat (HOT) session WIN & HOT session Karim Raza (United Kingdom) 15:35 WIN: How to diagnose rheumatoid arthritis early? Maya Buch (United Kingdom) 16:15 Abstract N SP0118 HOT: Recent advances in the treatment of rheumatoid arthritis M. Felicetti (Italy) 16:45 S. Monti, M. Bond, A. Berti, R. Padoan, G. Paolazzi, G. Brunori, L. Quartuccio, R. Caporali, F. Schiavon Abstract N OP0333 Survival in ANCA associated vasculitides: a retrospective multicentric analysis in northern Italy 15:30-17:00 Auditorium Clinical Science session Tapering and flaring in PsA and SpA Learning objectives: To provide an overview of the current literature on tapering of DMARDs (incl. biologicals) in the setting of both peripheral and axial locomotor manifestations To discuss the concept of flare in PsA and SpA and how to manage it, both in its identification and clinical management Philippe Carron (Belgium) Uta Kiltz (Germany) Laura Coates (United Kingdom) 15:35 Abstract N SP0121 Tapering in PsA - to do or not to do? Denis Poddubnyy (Germany) 15:55 Abstract N SP0122 Tapering in axial disease - to do or not to do?

96 94 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 Helena Marzo-Ortega (United Kingdom) 16:15 The concept of flare and how to deal with it R. B. M. Landewé (Netherlands) 16:35 J. Sieper, P. Mease, R. Inman, X. Wang, M. Li, A. Pangan, J. Anderson Abstract N OP0334 Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (nr-axspa) P. Carron (Belgium) 16:45 G. Varkas, T. Renson, A.-S. De Craemer, D. Elewaut, F. van den Bosch Abstract N OP0335 High need for anti-tnf therapy after withdrawal strategy in early peripheral spondyloarthritis 15:30-17:00 Hall 7.2 Clinical Science session Big data for musculoskeletal research Learning objectives: To understand the challenges and opportunities arising from the use of big data for MSK research To learn about ongoing and future applications of BD/ ML for rheumatologists including fracture prediction and phenotyping of OA To learn about the strengths and limitations of BD and relate methods for the evaluation of risk and benefit of drugs and devices for the treatment of arthritis and osteoporosis 15 June :30-17:00 Elicium 2 Clinical Science session Prevention of OA: Yes we can! Learning objectives: To understand why the prevalence of knee osteaorthritis has doubled since 1950 even after normalization for age and weight To envision how these new data could have an impact on prevention Francis Berenbaum (France) Ida K. Haugen (Norway) David Felson (United States) 15:35 Abstract N SP0123 Why has the prevalence of knee OA doubled in recent years? Martin Englund (Sweden) 15:55 Abstract N SP0124 Physical activity and exercise: opportunities and challenges Jeremie Sellam (France) 16:15 We are what we eat! M. Cook (United Kingdom) 16:35 A. K. Sorial, M. Lunt, T. Board, T. O Neill Abstract N OP0336 The effect of timing and duration of statin exposure on the risk of revision following total hip or knee arthroplasty: a population-based cohort study Daniel Prieto-Alhambra (United Kingdom) Annemariek Driessen (Netherlands) Sara Khalid (United Kingdom) 15:35 Abstract N SP0125 How big data and machine learning could change the game Harrie Weinans (Netherlands) 16:15 Big data and machine learning for precision medicine in OA Alexandre Sepriano (Portugal) 16:35 Abstract N SP0126 Big data for treatment effectiveness and safety B. Mehta (United States) 16:55 J. Szymonifka, S. A. Dey, I. Y. Navarro-Millan, L. A. Mandl, A. R. Bass, L. A. Russell, M. L. Parks, M. P. Figgie, J. T. Nguyen, S. M. Goodman Abstract N OP0338 Relationship of provider density on total joint replacement outcomes L. Rodriguez-Rodriguez (Spain) 17:05 J. M. Lezcano, J. Ivorra-Cortes, R. López Mejías, J. Martín, B. Fernandez-Gutiérrez, M. A. González-Gay, A. Balsa, I. González-Álvaro, F. Salazar, L. Abásolo Abstract N OP0339 Development of a predictive model of radiological damage in patients with rheumatoid arthritis based on artificial intelligence F. Pan (Australia) 16:45 J. Tian, F. Cicuttini, C. Ding, G. Jones Abstract N OP0337 Association between metabolic syndrome and trajectories of knee pain: a 10.7-year follow-up study

97 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 95 15:30-17:00 Forum Paediatric Rheumatology session From big data to personalised medicine in paediatric rheumatic diseases Learning objectives: Understanding how pathogenic knowledge can be translated into novel tools for diagnosis, classification and treatment of rheumatic diseases Awareness of how new immunologic technology can lead to precision medicine Eve Smith (United Kingdom) Yukiko Kimura (United States) Alexandre Belot (France) 15:35 Abstract N SP0127 The bumpy road from signaling pathways to personalised medicine in childhood SLE Annet van Royen (Netherlands) 16:00 Abstract N SP0128 Finding the needle in the haystack and using it: galectin 90 as a biomarker of juvenile dermatomyositis Salvatore Albani (Singapore) 16:25 How the human immunome revolutionizes personalised treatment of paediatric inflammatory diseases G. Giancane (Italy) 16:50 C. Lavarello, A. Pistorio, F. Zulian, B. Magnusson, T. Avcin, F. Corona, V. Gerloni, S. Pastore, R. Marini, S. Martino, A. Pagnier, M. Rodiere, C. Soler, V. Stanevicha, R. Ten Cate, Y. Uziel, J. Vojinovic, E. Fueri, A. Ravelli, A. Martini, N. Ruperto on behalf of PRINTO Abstract N OP0340 Evidence-based recommendations for corticosteroid tapering/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial 15:30-17:00 Elicium 1 Basic and Translational Science session Triple T: T cells, technologies and therapies Learning objectives: Update on latest technological developments to study T cell state and fate Describe how peptide therapy can influence T cell function in autoimmune disease Discuss latest insights on T cell tolerance in RA Erik Lubberts (Netherlands) Andrew Cope (United Kingdom) Frits Koning (Netherlands) 15:35 Application of single cell technology to understand T cell heterogeneity P. Fortea-Gordo (Spain) 15:55 L. Nuño, A. Villalba, D. Peiteado, I. Monjo, P. Sanchez-Mateos, A. Puig-Kröger, E. de Miguel, A. Balsa, M. E. Miranda Carus Abstract N OP0341 Increased frequency of circulating CD4+CXCR5- PD1HI peripheral helper T (CTPH) cells in patients with seropositive early rheumatoid arthritis (RA) Leonie Taams (United Kingdom) 16:05 Abstract N SP0129 Studying T cell function in RA and PsA B. Paleja (Singapore) 16:25 A. Low, P. Kumar, S. Saidin, A. Lajam, L. D/O Thanna Bathi, L. Lai, C. Chua, S. Albani Abstract N OP0342 Altered frequency and function of mait cells in systemic sclerosis revealed by high dimensional mass cytometry and transcriptome analysis Ranjeny Thomas (Australia) 16:35 Abstract N SP0130 Towards T cell tolerance in RA 15:30-17:00 Amtrium Health Professionals session Navigating the world of digital health Learning objectives: To discuss the challenges for patients to seek, find and appraise health information from electronic resources Ann Bremander (Sweden) Mari Klokkerud (Norway) Elizabeth Heron (United Kingdom) 15:35 Abstract N SP0131 Digital health literacy, state of the art Constance Drossaert (Netherlands) 15:53 Abstract N SP0132 Measuring digital health literacy Maria Suarez-Almazor (United States) 16:11 Multi-media patient education based on entertainment education delivered to patients with low HL Line Raunsbaek - Knudsen (Denmark) 16:29 Abstract N SP0133 Patient experiences from a tele-health intervention on disease activity in RA. The keen and the reluctant patient M. Ferwerda (Netherlands) 16:47 S. van Beugen, H. van Middendorp, H. Visser, H. Vonkeman, M. Creemers, P. van Riel, W. Kievit, A. Evers Abstract N OP0343-HPR An economic evaluation of a tailored guided internetbased cognitive behavioural intervention for patients with rheumatoid arthritis as an addition to usual care 15 June 2018

98 96 / SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE :30-17:00 Emerald 15:30-17:00 PARE Room 15 June 2018 Clinical Science session The rheumatologist-orthopedic surgeon connection in secondary fracture prevention Learning objectives: To understand the procedures of the orthopedic surgeon in the treatment of the fracture To learn how patients with a recent fracture should be transferred to the fracture liaison service To learn about the assessment of risk of subsequent fracture for decisions about fracture prevention Roland D. Chapurlat (France) Piet Geusens (Netherlands) Karsten Dreinhöfer (Germany) 15:35 The care of fracture Kristina Åkesson (Sweden) 15:55 Abstract N SP0134 The connection between fracture care and secondary fracture prevention Willem F. Lems (Netherlands) 16:15 Abstract N SP0135 The EULAR/EFORT recommendations for patients with recent fracture C. Libanati (Belgium) 16:35 F. Cosman, D. B. Crittenden, S. Ferrari, A. Khan, N. E. Lane, K. Lippuner, T. Matsumoto, C. E. Milmont, A. Grauer Abstract N OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab PARE session What s new: Latest advances in treatment in JIA and osteoarthritis Learning objectives: To show the latest advances in treatment and care in JIA and osteoarthritis Philip Conaghan (United Kingdom) Victoria Romero Pazos (Spain) Margreet Kloppenburg (Netherlands) 15:35 Abstract N SP0136 Latest advances in treatment and management of OA L. Campbell (United Kingdom) 16:05 JIGSAW-E Patient Champions, S. Blackburn, J. Meesters, M. De Wit, D. Schiphof, T. Vliet Vlieland, S. Bierma-Zeinstra, N. Østerås, S. Pais, E. Roos, N. Evans, K. Dziedzic Abstract N OP0346-PARE A partnership in implementation: adapting an osteoarthritis guidebook across European cultures - with patients, for patients Tadej Avcin (Slovenia) 16:15 Latest advances in treatment and management of JIA Y. El Miedany (United Kingdom) 16:45 H. Lotfy, N. El Aroussy, D. Mekkawy, S. I. Nasef, W. Hassan, Y. Farag, S. Almedany, G. El Deriny, M. Eissa, M. El Gaafary on behalf of PRINTO Egypt Abstract N OP0347 Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking W. F. Lems (Netherlands) 16:45 K. G. Saag, N. Pannacciulli, P. Geusens, J. D. Adachi, O. D. Messina, J. Morales-Torres, R. Emkey, P. W. Butler, X. Yin Abstract N OP0345 Denosumab compared with risedronate in glucocorticoidtreated subjects: results from the final 24-month analysis of a randomised, double-blind, double-dummy study 15:30-17:00 E106/E107 EULAR Projects in Epidemiology and Health Services Assessment and prevention of RMDs, what have we learned? Laure Gossec (France) Axel Finckh (Switzerland) Johan Askling (Sweden) 15:35 What randomised trials and observational studies have taught us in rheumatoid arthritis Suzanne Verstappen (United Kingdom) 16:00 Abstract N SP0137 Prevention of RMDs - what have we learned? Francis Guillemin (France) 16:25 Abstract N SP0138 Why not all effective interventions are worthwhile

99 SCIENTIFIC PROGRAMME / FRIDAY 15 JUNE 2018 / 97 15:30-17:00 D201/D202 17:30-19:00 Elicium 1 Practical skills session* Capillaroscopy II Ariane L. Herrick (United Kingdom) Alberto Sulli (Italy) Vanessa Smith (Belgium) 15:35 Abstract N SP0088 The importance to differentiate normal from abnormal capillaroscopic images for an early diagnosis of disease Alberto Sulli (Italy) 15:55 Scoring the capillaroscopic images Ariane L. Herrick (United Kingdom) 16:15 Abstract N SP0089 How to distinguish the major capillaroscopic patterns Maurizio Cutolo (Italy) 16:35 How capillaroscopy can predict disease severity and prognosis 15:30-17:00 D203/D204 Practical skills session* Ultrasound advanced II Marion Kortekaas (Netherlands) Mads Ammitzboll (Denmark) Ingrid Möller (Spain) 15:35 Abstract N SP0090 US for pulley lesions - clinical relevance + demo Basic and Translational Science session High-end imaging: looking for the invisible Learning objectives: To learn about new, in vivo imaging possibilities to understand the events in inflamed tissues To learn about the possibilities of in vitro imaging with 30nm voxel size Stephanie Finzel (Germany) Martin Herrmann (Germany) Stefan Uderhardt (United States) 17:35 Abstract N SP0139 The role of phagocytes at the inflammatory site James Brewer (United Kingdom) 18:00 Abstract N SP0140 Imaging the arthritic joint Silke Christiansen (Germany) 18:25 Abstract N SP0141 The ultra high resolution x-ray microscope in the analysis of calcified tissues B. Rocha (Spain) 18:50 B. Cillero-Pastor, C. Ruiz-Romero, A. Cuervo, R. M. Heeren, J. D. Cañete, F. J. Blanco Abstract N OP0348 Mass spectrometry imaging analysis of synovium differentiate patients with psoriatic and rheumatoid arthritis 15 June 2018 David Bong (Spain) 15:55 Abstract N SP0091 US for peripheral nerve entrapments + demo Sandrine Jousse-Joulin (France) 16:15 Abstract N SP0092 US for scoring Sjögren disease Nemanja Damjanov (Serbia) 16:35 US for impingement syndromes + demo Tutor: Sara Nysom (Denmark) * In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area, Hall 2

100 98 / GUIDED POSTER TOURS / FRIDAY 15 JUNE 2018 Guided Poster Tours Friday, 15 June 2018 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour. 15 June :50-13:30 Poster area Poster tour F1: Digging deep: basic and translational science in paediatric rheumatology Berent J. Prakken (Netherlands), Klaus Tenbrock (Germany) Abstracts N : FRI0001-FRI0006 See page 99 Poster tour F2: Let s discuss RA outcomes John D. Isaacs (United Kingdom), Kenneth Baker (United Kingdom) Abstracts N : FRI0042-FRI0051 See page 101 Poster tour F3: The hydra beast in RA: a multifaceted disease Elena Nikiphorou (United Kingdom) Peter C. Taylor (United Kingdom) Abstracts N : FRI0090-FRI0099 See page 103 Poster tour F4: SpA pathophysiology: of mice and men... Dirk Elewaut (Belgium) Filip van den Bosch (Belgium) Abstracts N : FRI0148-FRI0157 See page 106 Poster tour F5: Spondyloarthritis: it looks as if it is only imaging that matters Robert B. M. Landewé (Netherlands), Anna Moltó (France) Abstracts N : FRI0169-FRI0177 See page 107 Poster tour F6: Gout epidemiology and therapy Alexander So (Switzerland) Abhishek Abhishek (United Kingdom) Abstracts N : FRI0220-FRI0229 See page 109 Poster tour F7: The enemy in us Martin Herrmann (Germany) Yi Zhao (China) Abstracts N : FRI0255-FRI0263 See page 110 Poster tour F9: Shaping pathophysiology: new molecules - new views on pathways in SSc, myositis and related syndromes Ulf Müller-Ladner (Germany), Jeska de Vries (Netherlands) Abstracts N : FRI0396-FRI0406 See page 116 Poster tour F10: Clinical and therapeutic advances in vasculitis Leonard Calabrese (United States) Valentin Schäfer (Germany) Abstracts N : FRI0474-FRI0483 See page 120 Poster tour F11: Novelties in osteoarthritis: clinical aspects Francis Berenbaum (France), Féline Kroon (Netherlands) Abstracts N : FRI0520-FRI0529 See page 122 Poster tour F12: You can do better studies if you know how Loreto Carmona (Spain) Antonis Fanouriakis (Greece) Abstracts N : FRI0600-FRI0609 See page 125 Poster tour F13: Searching for outcome measures João E. Fonseca (Portugal) Vasco C. Romao (Portugal) Abstracts N : FRI0640-FRI0649 See page 127 Poster tour F14: Education for better patients care Nemanja Damjanov (Serbia), Mirjana Bukilica (Serbia) Abstracts N : FRI0691-FRI0700 See page 129 Poster tour F15: Bread and butter for clinicians Annette de Thurah (Denmark) Andrea Marques (Portugal) Abstracts N : FRI0737-HPR-FRI0746 See page 180 Poster tour F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren's and APS Angela Tincani (Italy) Micaela Fredi (Italy) Abstracts N : FRI0302-FRI0311 See page :00-13:30 PARE Poster area Poster tour F16: PARE Poster Tour II Nele Caeyers (Belgium) Boryana Boteva (Bulgaria) Abstracts N : PARE0009-PARE0017 See page 188

101 Scientific Poster Session II SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 99 Friday, 15 June June 2018 Poster viewing 11:45-13:30 Guided poster tours 11:50-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. TOPIC: BASIC SCIENCE IN PAEDIATRIC RHEUMATOLOGY Poster tour F1: Abstracts N : Digging deep: basic and translational science in paediatric rheumatology Berent J. Prakken (Netherlands), Klaus Tenbrock (Germany) FRI0001-FRI0006 FRI0001 FRI0002 FRI0003 FRI0004 FRI0005 FRI0006 EXTENDED OLIGOARTICULAR AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE A SIMILAR B CELL PHENOTYPE WHEN COMPARED TO ESTABLISHED RHEUMATOID ARTHRITIS / R. A. Moura* - A. Brito - S. Oliveira - R. L. Teixeira - V. C. Romão - V. Teixeira - R. Campanilho-Marques - F. Oliveira-Ramos - J. E. Fonseca ANALYSIS OF B CELLS AND T CELLS SUBPOPULATIONS AND COLLAGEN SPECIFIC T CELL REPERTOIRE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / G. Di Sante* - M. C. Caparello - B. Tolusso - C. Di Mario - M. Valentini - F. Ria - G. Ferraccioli - R. Cimaz - E. Gremese EPIGENETIC ALTERATIONS LEADING TO SPECIFIC EXPRESSION PATTERNS OF IMMUNE RESPONSE REGULATING GENE MIGHT BE RESPONSIBLE FOR DISTINCTIVE MICROBIOTA COMPOSITION AND DISEASE DEVELOPMENT IN JUVENILE SPONDYLOARTHRITIS PATIENTS / L. Lamot* - K. Gotovac Jercic - A. Blazekovic - T. Catela Ivkovic - M. Vidovic - M. Lamot - S. Kapitanovic - F. Borovecki - M. Harjacek GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR IS SECRETED AT HIGHER LEVELS FROM STIMULATED MONOCYTE-DERIVED MACROPHAGES FROM PATIENTS WITH ENTHESITIS RELATED ARTHRITIS AND IS SIGNIFICANTLY ENHANCED BY THE UNFOLDED PROTEIN RESPONSE / C. Fisher* - D. Eleftheriou - D. Sen - Y. Ioannou THE RELATIONSHIP BETWEEN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS AND THE TRANSCRIPTION FACTORS NF-KAPPAB AND PPAR-GAMMA / S. Sahin - S. Durmus - A. Adrovic - K. Barut - R. Gelisgen - H. Uzun - O. Kasapcopur* ASSOCIATION BETWEEN INTERLEUKIN-10 POLYMORPHISMS AND JUVENILE IDIOPATHIC ARTHRITIS: A META- ANALYSIS / J. H. Jung* - J.-H. Kim - G. G. Song - S. J. Choi TOPIC: RHEUMATOID ARTHRITIS - PROGNOSIS, PREDICTORS AND OUTCOME FRI0007 FRI0008 PERFORMANCE OF MUSCULOSKELETAL ULTRASONOGRAPHY (MSUS) AND OPTIMAL CUTOFF CRITERIA FOR PATIENTS AT RISK FOR RHEUMATOID ARTHRITIS: A META-ANALYSIS / A. Castro* - J. Diaz - S. Kumar TISSUES ARE DIFFERENTLY MODULATED BY TOCILIZUMAB AND METHOTREXATE; ASSESSMENT OF CONNECTIVE TISSUE METABOLITES IN THE AMBITION STUDY / A. C. Bay-Jensen* - A. S. Siebuhr - C. S. Thudium - M. A. Karsdal * Presenting author

102 100 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0009 A COMPARISON OF THE JOINT SYNOVITIS AND TENOSYNOVITIS USING ULTRASONOGRAPHY AND HISTOPATHOLOGICAL FINDINGS IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Abe* - H. Ishikawa - A. Murasawa - K. Wakaki FRI0010 PREDICTION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS BY BOTH MAGNETIC RESONANCE IMAGING AND ULTRASOUND / A. Takatani* - M. Tamai - N. Ohki - Y. Nakashima - Y. Endou - S. Tsuji - T. Shimizu - M. Umeda - S. Fukui - R. Sumiyoshi - A. Nishino - T. Koga - S. Kawashiri - N. Iwamoto - T. Igawa - K. Ichinose - K. Arima - H. Nakamura - T. Origuchi - S. Sato - M. Uetani - A. Kawakami FRI0011 ULTRASONOGRAPHIC CRITERIA FOR THE DIAGNOSIS OF EROSIVE RHEUMATOID ARTHRITIS DISEASE USING OSTEOARTHRITIC PATIENTS AS CONTROLS COMPARED TO VALIDATED RADIOGRAPHIC CRITERIA / C. Roux* - F. Gandjbakhch - A. Pierreisnard - M. Couderc - C. Lukas - R. Masri - J.-P. Sommier - I. Clerc-Urmes - C. Baumann - I. Chary-Valckenaere - D. Loeuille FRI0012 SHARING THE BURDEN OF RHEUMATOID ARTHRITIS THROUGH REMOTE MONITORING OF RHEUMATOID ARTHRITIS (REMORA): IMPLICATIONS FOR PATIENTS AND CLINICIANS / C. A. Sharp* - L. Austin - M. Machin - J. Humphreys - P. Mellor - J. McCarthy - S. van der Veer - L. Davies - J. Ainsworth - C. Sanders - W. Dixon FRI0013 CONVERTING PATIENT-REPORTED PHYSICAL FUNCTION OUTCOMES SCORES TO PROMIS METRIC SCORES IN PHASE 3 TRIALS OF BARICITINIB IN RHEUMATOID ARTHRITIS / C. O. Bingham III* - C. Gaich - A. M. DeLozier - A. Quebe - L. Sun - S. Otawa - J. Pope FRI0014 LOW-DOSE ASPIRIN MAY HAVE A ROLE AS PRIMARY PROPHYLAXIS OF CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS: EVIDENCE FROM AN ITALIAN MULTICENTRIC RETROSPECTIVE STUDY / D. Iacono* - S. Fasano - I. Pantano - V. D Abrosca - P. Ruscitti - D. P. E. Margiotta - L. Navarini - N. Maruotti - F. P. Cantatore - A. Afeltra - R. Giacomelli - G. Valentini FRI0015 TREATING RHEUMATOID ARTHRITIS TO TARGET: IS LOW DISEASE ACTIVITY GOOD ENOUGH? / E. Nikiphorou* - S. Norton - A. Young - L. Carpenter - J. Dixey - D. Walsh - P. Kiely on behalf of ERAS-ERAN working group FRI0016 NO RELATIONSHIPS BETWEEN ACPA AND PERIODONTITIS IN EARLY RHEUMATOID ARTHRITIS / F. Mechid* - C. Zehraoui - M. Meddad - S. Salah - M. Benidir - S. Merad - N. Saidi - O. Cheikh - N. Blidi - C. Dahou FRI0017 AN EXPLORATORY STUDY ON THE ROLE OF VITAMIN D SUPPLEMENTATION IN IMPROVING PAIN AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / G. Adami* - O. Viapiana - L. Bogliolo - F. P. Cantatore - M. Varenna - N. Malavolta - A. Del Puente - M. Muratore - G. Orsolini - D. Gatti - M. Rossini on behalf of study group on Osteoporosis and Metabolic Skeletal Diseases of the Italian Society of Rheumatology (SIR) FRI0018 THE ABILITY OF DISEASE ACTIVITY MEASURES TO PREDICT MAJOR THERAPEUTIC CHANGE IN US VETERANS WITH RHEUMATOID ARTHRITIS / G. Cannon* - C.-C. Teng - N. A. Accortt - D. H. Collier - T.-C. Lin - B. C. Sauer FRI0019 ARE DISEASE ACTIVITY, DISABILITY OR PSYCHOLOGICAL FACTORS MOST ASSOCIATED WITH PATIENTS WITH RHEUMATOID ARTHRITIS BEING SATISFIED WITH THEIR CONDITION AFTER 12 MONTHS FOLLOWING TREATMENT ONSET? / J. Gwinnutt* - K. Hyrich - M. Lunt - A. Barton - S. Verstappen on behalf of RAMS coinvestigators FRI0020 ANTI-CEP-1 ANTIBODIES AND OTHER AUTOANTIBODIES IN EARLY ARTHRITIS / M. Ponikowska - J. Świerkot* - B. Nowak - L. Korman - P. Wiland FRI0021 PREDICTORS OF RHEUMATOID ARTHRITIS DEVELOPMENT IN PATIENTS WITH EARLY UNDIFFERENTIATED ARTHRITIS: A 2-YEARS FOLLOW-UP STUDY / J. Molina Collada* - M. G. G. Álvarez - V. Navarro-Compán - L. Nuño Nuño - A. Villalba - D. Peiteado - P. Bogas - A. Balsa FRI0022 RAPID AND SUSTAINED REMISSION CONTRIBUTES TO IMPROVED PSYCHOSOCIAL OUTCOMES AFTER 1 YEAR OF TREATMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: DATA FROM THE CARERA TRIAL / K. van der Elst* - P. Verschueren - V. Stouten - S. Pazmino - D. De Cock - J. Joly - P. Moons - R. Westhovens FRI0023 FIVE-YEAR PROGRESSION OF RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND QUALITY OF LIFE IN 2002 AND HAVE REDUCTIONS IN DISEASE ACTIVITY IN RECENT YEARS RESULTED IN IMPROVEMENTS IN QUALITY OF LIFE? / L. Carpenter* - S. Norton - E. Nikiphorou - P. Kiely - J. Dixey - P. Creamer - D. Walsh - A. Young FRI0024 DO AGE AND EDUCATION INFLUENCE THE DISEASE ACTIVITY SCORE? AN EXPLORATIVE ANALYSIS IN THE NORWEGIAN COHORT STUDY NOR-DMARD / M. Van Onna* - P. Putrik - E. Lie - T. Kvien - A. Boonen - T. Uhlig FRI0025 SERUM MEDIATED PEPTIDYLARGININE DEIMINASE (PAD) ACTIVATION IN EARLY RHEUMATOID ARTHRITIS / M. K. Jonsson* - K. Falkowski - A. Aliko - A.-B. Aga - S. Lillegraven - J. Sexton - B.-T. S. Fevang - P. Mydel - E. A. Haavardsholm FRI0026 U-ACT-EARLY TRIAL 3 YEARS FOLLOW-UP. THE LONGER EFFECTIVENESS OF TREAT-TO-TARGET STRATEGIES IN EARLY RA WITH TOCILIZUMAB, METHOTREXATE, OR THEIR COMBINATION / M. Verhoeven* - M. de Hair - P. Welsing - A. Pethö-Schramm - M. Borm - X. Teitsma - J. van Laar - F. Lafeber - J. Bijlsma - J. Jacobs FRI0027 PATIENT-BASED DISEASE ACTIVITY SCORE PREDICTS FLARE BETTER THAN IMPROVEMENT - BLOOD TEST PROVIDES INSIGNIFICANT CONTRIBUTION / M.-H. A. Leung* - C.-S. Lau - E. Choy FRI0028 DEVELOPMENT AND IMPLEMENTATION OF AN EDUCATIONAL VIDEO THAT INSTRUCTS PATIENTS WITH RHEUMATOID ARTHRITIS FOR SELF-ASSESSMENT OF DISEASE ACTIVITY: METHODOLOGY OF THE AUTO-DAS IN MIDDLE EASTERN ARAB COUNTRIES STUDY / N. Ziade* - G. Abi Karam - A. Daher - M. Abu Jbara - A. Ayko - E. Alam - T. Arayssi - H. Badsha - S. al Emadi - H. Halabi - G. Harifi - B. Khan - L. el Kibbi - M. al-mashaleh - A. F. Masri - B. Masri - J. Menassa - M. Merashli - G. Merheb - J. Messaykeh - K. Mroue - S. Saad - N. Salloum - I. Uthman - B. el-zorkany on behalf of Auto-DAS Middle Eastern Arab Countries FRI0029 CLINICAL SIGNIFICANCE OF ETA PROTEIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS / O. Shovman* - B. Gilburd - A. Watad - H. Amital - P. Langevitz - N. L. Bragazzi - M. Adawi - D. Pérez - G. Bornstein - M. Lidar - M. Blank - Y. Azuri - N. K. Biln - A. Marotta - Y. Shoenfeld FRI0030 COMPARISON OF CLINICAL AND ULTRASOUND MEASURES OF DISEASE ACTIVITY IN A LARGE NATIONAL REAL LIFE COHORT OF RA PATIENTS / P. Zufferey* - D. Courvoisier - M. Nissen - B. Moeller - H. R. Ziswiler - L. Brulhart - G. Tamborrini - A. Ciurea - M. A. D agostino - A. Finckh FRI0031 CHANGE IN FUNCTIONAL DISABILITY IN ACPA-POSITIVE ARTHRALGIA PATIENTS PRIOR TO PROGRESSION TO INFLAMMATORY ARTHRITIS / P. Pentony* - S. Twigg - J. L. Nam - K. Mankia - L. Hunt - E. M. Hensor - P. Emery FRI0032 ROLE OF ULTRASOUND IN ASSESSING DISEASE ACTIVITY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED BY TWO TREAT-TO-TARGET STRATEGIES / P. Wong* - D. Wu - Q. W. Mak - I. T. Cheng - T. K. Li - E. K. Li - L. S. Tam * Presenting author

103 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 101 FRI0033 TRENDS IN THE INCIDENCE OF ORTHOPEDIC SURGERY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN. A NATIONAL OBSERVATIONAL COHORT STUDY / R. Mazzucchelli* - J. Quirós - M. Peña - E. Perez-Fernandez - N. Crespí - C. Macía Villa - M. Espinosa - V. Villaverde - J. L. Morell Hita - C. Martinez-Prada - A. García-Vadillo - C. Morado Quiroga - M. Fernández-Prada - C. Barbadillo - H. Godoy - M. Galindo - O. Guzón Illescas - A. Herranz FRI0034 EFFICACY OF ETANERCEPT BY BODY MASS INDEX IN WOMEN AND MEN WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF THREE RANDOMISED TRIALS / R. Alten* - E. Mysler - A. Wajdula - H. E. Jones - R. Pedersen - L. Marshall FRI0035 DISEASE REMISSION IS MORE COMMON BUT LESS STRINGENT IN ANTI-CITRULLINATED PROTEIN ANTIBODY- POSITIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS / A. Manzo - S. Bugatti* - G. Zanframundo - F. Benaglio - G. Sakellariou - C. Montecucco - R. Caporali FRI0036 SUSTAINED REMISSION RELATED FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: IS IT POSSIBLE TO PREDICT SUSTAINED REMISSION? / S. Yilmaz-Oner - U. Gazel* - M. Can - P. Atagunduz - H. Direskeneli - N. Inanc FRI0037 CHARACTERISTICS OF RECENT ELDERLY-ONSET RHEUMATOID ARTHRITIS PATIENTS / T. Oshige* - Y. Kaneko - T. Takeuchi FRI0038 CORRELATION BETWEEN CLINICAL AND ULTRASONOGRAPHIC REMISSION? THE EFFECT OF NON- INFLAMMATORY PATIENT-BASED FACTORS ON DIFFERENT REMISSION DEFINITIONS / Ü. Gazel* - S. Yılmaz-Öner - G. Özen - Y. Yalçınkaya - Z. Ertürk - M. P. Atagündüz - H. Direskeneli - N. İnanç FRI0039 MEASURING HEALTH REALTED QUALITY OF LIFE (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ONE YEAR TREATMENT WITH CSDMARDS AND BIOLOGIC DMARDS / V. V. Boyadzhieva* - N. Stoilov - G. Petrova - R. Stoilov FRI0040 DEVELOPMENT AND VALIDATION OF CLINICAL PREDICTORS FOR INADEQUATE RESPONSE TO TREAT-TO- TARGET METHOTREXATE THERAPY IN NEWLY DIAGNOSED RA PATIENTS / X. M. Teitsma* - J. W. Jacobs - P. M. Welsing - P. H. de Jong - J. M. Hazes - A. E. Weel - A. Pethö-Schramm - M. E. Borm - J. M. van Laar - F. P. Lafeber - J. W. Bijlsma FRI0041 ASSOCIATIONS BETWEEN TYMS POLYMORPHISMS AND RESPONSIVENESS TO OR TOXICITY OF METHOTREXATE IN RHEUMATOID ARTHRITIS / Y. H. Lee* - Y. H. Seo 15 June 2018 Poster tour F2: Abstracts N : Let s discuss RA outcomes John D. Isaacs (United Kingdom), Kenneth Baker (United Kingdom) FRI0042-FRI0051 FRI0042 TENDER JOINTS HAVE LOW AGREEMENT WITH PATIENT S EVALUATION OF SPONTANEOUS JOINT PAIN, JOINT SWELLING AND ULTRASOUND VERIFIED SYNOVITIS IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS / H. B. Hammer* - J. Sexton - B. Michelsen - S. Provan - T. Uhlig - T. K. Kvien FRI0043 TRENDS IN ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A 10- TO 20-YEAR FOLLOW-UP STUDY IN 3 CONSECUTIVE INCIDENCE COHORTS / S. A. Provan* - S. Lillegraven - E. A. Haavardsholm - T. K. Kvien - J. Sexton - T. Uhlig FRI0044 EXCEEDING PREDEFINED THRESHOLDS FOR MRI BONE OEDEMA AND EROSION AND HAQ-DI CAN PREDICT RELAPSE AFTER WITHDRAWAL OF ALL TREATMENT IN MTX-NAÏVE PATIENTS WITH RA IN REMISSION AFTER 12 MONTHS OF ABATACEPT THERAPY IN THE AVERT TRIAL / H. A. Ahmad* - J. F. Baker - M. Østergaard - P. Emery - T. Huizinga - Y. Elbez - S. Banerjee - P. G. Conaghan FRI0045 EVALUATION OF SERUM PROTEIN LEVELS AT BASELINE AS PREDICTORS OF RESPONSE TO METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: RESULTS FROM SWEFOT TRIAL POPULATION / K. Hambardzumyan* - C. Hamsten - H. Idborg - L. Lourido - S. Saevarsdottir - P. Nilsson - R. F. van Vollenhoven - P.-J. Jakobsson FRI0046 PATIENTS PRESENTING WITH NEW MUSCULOSKELETAL SYMPTOMS IN THE WRISTS, HANDS AND FEET ENRICHES DETECTION OF ANTI-CCP ANTIBODIES IN PRIMARY CARE - A NATIONAL COHORT STUDY / P. Pentony* - K. Karkalemis - J. L. Nam - K. Mankia - L. Hunt - E. M. Hensor - P. Emery FRI0047 MRI INTEROSSEOUS TENDON INFLAMMATION OCCURS IN ANTI-CCP POSITIVE AT-RISK INDIVIDUALS AND MAY PRECEDE THE DEVELOPMENT OF SYNOVITIS / K. Mankia* - M. A. D Agostino - E. Hensor - E. Rowbotham - L. Hunt - I. Moller - M. Miguel - J. L. Nam - A. L. Tan - J. Freeston - L. Garcia-Montoya - A. Grainger - P. Emery FRI0048 MORTALITY AND MORBIDITY OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE DURING A 10-YEAR PERIOD: A LONGITUDINAL COHORT STUDY OF 103 JAPANESE PATIENTS / S. Shimoyama* - Y. Fujieda - M. Kato - K. Oku - T. Bohgaki - O. Amengual - S. Yasuda - T. Atsumi FRI0049 SIGNIFICANT IMPROVEMENT OF RHEUMATOID ARTHRITIS (RA) OUTCOME WITH REPEATED SELF-ASSESSMENT APPLYING SMART SYSTEM OF DISEASE MANAGEMENT (SSDM) MOBILES TOOLS: A COHORT STUDY OF RA PATIENTS EMPOWERING / J. Yang* - J. Huang - Y. Wang - H. Wei - R. Mu - W. Fan - H. Wang - X. Duan - X. Shi - Y. Zhang - F. He - J. Xue - H. Li - J. Dong - Z. Zhang - F. Zhang - B. Wu - H. Liu - F. Xiao - H. Xiao - B. Wu - Y. Liu - Y. Jia - F. Zhang FRI0050 TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR / G. Schett* - S. Finzel - S. Kraus - A. Regensburger - R. Kocijan - J. Rech FRI0051 THE RISK OF ASEPTIC ARTHROPLASTY LOOSENING IN PATIENTS WITH RHEUMATOID ARTHRITIS / C. Böhler* - P. Weimann - F. Alasti - J. S. Smolen - R. Windhager - D. Aletaha * Presenting author

104 102 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS 15 June 2018 FRI0052 HIGHER URIC ACID IS ASSOCIATED WITH A LOWER DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS / A. Al-Herz* - A. Aldei - K. Saleh - A. Al-Awadhi - W. Al-Kandari - E. Hasan - A. Ghanem - M. Hussain - E. Nahar - F. Abutiban - A. Alenizi - Y. Ali - H. Alhajeri - S. Hayat - A. Khadrawy - A. Fazal - K. Mokaddem - A. Zaman - G. Mazloum - Y. Bartella - S. Hamed - R. Alsouk - A. Al-Saber FRI0053 THE CHANGING FACE OF RHEUMATOID ARTHRITIS AT THE END OF THE 20TH CENTURY - A COMPARATIVE POSTMORTEM CLINICOPATHOLOGIC STUDY OF 237 RHEUMATOID ARTHRITIS PATIENTS WITH AA AMYLOIDOSIS AND SYSTEMIC VASCULITIS / M. Bély - Á. Apáthy* FRI0054 RISK FACTORS FOR POSTPARTUM FLARE IN RHEUMATOID ARTHRITIS - A ROMANIAN COHORT / A. Bobirca* - F. Bobirca - I. Ancuta - M. Micu - C. Ancuta - M. Bojinca - C. Mihai - V. Stoica FRI0055 SAFETY OF ETANERCEPT IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS: A POOLED ANALYSIS / C. J. Edwards* - K. Roshak - J. Bukowski - R. Pedersen - M. Thakur - L. Marshall - H. Jones FRI0056 CLINICAL FEATURES AT THE ONSET OF LYMPHOPROLIFERATIVE DISORDER IN PATIENTS WITH RHEUMATOID ARTHRITIS / D. Kobayashi* - S. Ito - Y. Wada - I. Narita - K. Nakazono FRI0057 EFFECTS OF ANTI-TNF THERAPY ON VASCULAR BIOMARKER LEVELS IN RHEUMATOID ARTHRITIS / E. Végh* - A. Hamar - Á. Horváth - S. Szántó - G. Szücs - A. Pusztai - A. Domján - K. Hodosi - G. Kerekes - R. Gesztelyi - J. Zsuga - Z. Prohászka - Z. Szekanecz FRI0058 SERUM AND SYNOVIAL SURVIVIN ARE ASSOCIATED WITH EROSIVE NOT ACTIVE RHEUMATOID ARTHRITIS / E. Baraka* - M. Serag El Din - A. El Shambky - M. Aboul Gheir FRI0059 INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS OF A COHORT TREATED WITH METHOTREXATE MONOTHERAPY / E. Chamizo-Carmona* - C. Carrasco Cubero - S. M. Rojas Herrera - J. Malave Calzada - R. Veroz Gonzalez - L. M. Chaves Chaparro FRI0060 ARE OLDER RA PATIENTS FRAIL, OR LONELY AND DEPRESSED? / F. Cleutjens* - A. Boonen - M. van Onna FRI0061 CARDIOVASCULAR RISK FACTOR AND DISEASE BURDEN IN BELGIAN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES OF NORTH AFRICAN COMPARED TO EUROPEAN DESCENT / F. Fleurinck* - L. Tsang - M. Walschot - M. Reyskens - A. O. Solomon - A. Millen - P. Dessein FRI0062 CORTICOSTEROID INJECTION FOR PLANTAR HEEL PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS / G. Whittaker* - S. E. Munteanu - H. B. Menz - D. R. Bonanno - J. M. Gerrard - K. B. Landorf FRI0063 RAPAMYCIN INDUCES REMISSION IN PATIENTS WITH REFRACTORY RHEUMATOID ARTHRITIS / H. Yao* - H. Niu - N. Yan - X. Sun - Z. Li - M. Chen - C. Gao - X. Li - C. Wang FRI0064 RIGHT VENTRICLE DIASTOLIC DYSFUNCTION IN EARLY RHEUMATOID ARTHRITIS PATIENTS: RISK FACTORS AND THE EFFECT OF ANTIRHEUMATIC THERAPY / I. G. Kirillova* - D. Novikova - T. Popkova - H. Udachkina - E. Markelova - A. Volkov - Y. Gorbunova FRI0065 DHCR7 AND GENETIC POLYMORPHISMS IN THE ASSOCIATION BETWEEN VITAMIN D AND LIPID PROFILE IN RA: NEW PLAYERS IN CARDIOVASCULAR DISEASE? / J. Rodríguez-Carrio* - M. Alperi-López - M. Naves-Díaz - A. Dusso - P. López - F. J. Ballina-García - J. B. Cannata-Andía - A. Suárez FRI0066 IMPACT OF SERUM ADIPOKINES IN EARLY STAGES OF RHEUMATOID ARTHRITIS / J. A. Chaparro* - J. M. Bello-Gualtero - W. Bautista-Molano - L. Chila - M. A. Cano - R. Valle-Oñate - P. Chalem - C. Romero-Sánchez FRI0067 TRENDS IN THE INCIDENCE OF FELTY S SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN: AN OBSERVATIONAL COHORT STUDY OF HOSPITAL DISCHARGES FROM 1999 TO 2015 (TREND-AR STUDY) / J. L. Morell* - R. Mazzucchelli - E. Perez Fernandez - J. Quiros - C. Macia Villa - N. Crespi - M. Peña - C. Barbadillo - M. Espinosa - H. Godoy - M. Fernandez-Prada - M. Galindo - A. Garcia Vadillo - O. Guzon Illescas - A. Herranz - C. Martinez Prada - C. Morado Qiñoa - V. Villaverde on behalf of TREND-AR FRI0068 ULTRASONOGRAPHIC SUBCLINICAL CARDIOVASCULAR FINDINGS IN HISPANIC RA PATIENTS: A CASE- CONTROL STUDY / J. R. Azpiri-López* - D. A. Galarza-Delgado - I. J. Colunga-Pedraza - A. H. Guillén-Lozoya - J. A. Dávila-Jiménez - E. E. Abundis-Márquez FRI0069 DIFFERENCE OF CLINICAL IMPLICATION REGARDING THE NUMBERS OF AUTOANTIBODIES AT PRESENTATION IN KOREAN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / J. Y. Pyo* - C.-H. Mun - S. M. Jung - S. W. Lee - J. Song - S. K. Lee - Y. B. Park FRI0070 COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR RHEUMATOID ARTHRITIS WAS SUPERIOR TO TRADITIONAL/ CONVENTIONAL DMARDS WHEN ANALYSED WITH NUMBER NEEDED TO TREAT (NNT) METHOD / K. Harigane* - Y. Mochida - K. Sahara - N. Mitsugi FRI0071 OUTCOMES FROM RHEUMATOLOGY AND REPRODUCTIVE HEALTH CLINIC / K. Murray* - L. Moore - C. O Brien - A. Clohessy - C. Brophy - P. Minnock - A. B. Mongey - E. Molloy - O. FitzGerald - S. Higgins - M. Higgins - F. McAuliffe - D. J. Veale FRI0072 THE IMPACT OF ANTI-TNF-THERAPY ON ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS / K. Heinz* - P. Oelzner - T. Eidner - K. Goetze - A. Saemann - G. Wolf - T. Neumann FRI0073 CHANGES OF BONE MINERAL DENSITY OVER 10 YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / L. Theander* - M. Willim - J. Å. Nilsson - M. Karlsson - K. Åkesson - C. Turesson FRI0074 FACTORS ASSOCIATED WITH THE DEVELOPEMENT OF SEVERE RESPIRATORY INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS INCLUDED IN A VACCINATION PROGRAM / L. C. Domínguez Casas* - P. Rodriguez-Cundin - V. Calvo-Río - N. Vegas-Revenga - V. Portilla - F. Antolin - M. Rebollo-Rodrigo - A. Corrales - N. Palmou-Fontana - D. Prieto-Peña - M. Calderón Goercke - R. Blanco - M. Gonzalez-Gay FRI0075 RISK OF HEPATITIS B INFECTION REACTIVATION IN RHEUMATIC DISEASES PATIENTS TREATED WITH ANTI- CD20 THERAPY / M. Fornaro* - G. Lopalco - V. Venerito - M. Barone - L. Cantarini - C. Fabiani - G. Emmi - E. Silvestri - G. Lapadula - F. Iannone FRI0076 CHRONIC WIDESPREAD PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SEVEN YEAR FOLLOW-UP OF PAIN DISTRIBUTION AND FACTORS FOR IMPROVEMENT / M. L. Andersson* - B. Svensson - S. Bergman on behalf of the BARFOTstudy group * Presenting author

105 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 103 FRI0077 HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB: POST-HOC ANALYSIS FROM CLINICAL TRIALS / M. Harigai* - K. Winthrop - T. Takeuchi - T.-Y. Hsieh - Y.-M. Chen - J. S. Smolen - G. R. Burmester - C. Walls - W.-S. Wu - C. Dickson - R. Liao - M. C. Genovese FRI0078 PROSPECTIVE FOLLOW-UP OF A COHORT OF PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS IN TREATMENT WITH DMARD / N. Mena-Vázquez* - C. Gomez-Cano - L. Perez-Albaladejo - S. Manrique-Arija - C. Romero-Barco - C. Aguilar-Hurtado - I. Ureña-Garnica - F. Jiménez-Núñez - M. Ordóñez-Cañizares - C. Fuego - M. Padin-Martin - R. Caliz-Caliz - A. Fernández-Nebro FRI0079 ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL DYSFUNCTION IN FEMALES WITH RHEUMATOID ARTHRITIS AND COMORBID HYPERTENSION / O. Sirenko* - O. Kuryata - T. Lysunets FRI0080 THE ROLE OF PAIN IN RHEUMATOID ARTHRITIS (RA) PATIENTS ASSESSMENTS OF THEIR HEALTH / P. Katz* - Y. C. Lee - A. Quebe - L. Sun - H. Patel - C. Gaich - N. Boytsov - K. Michaud FRI0081 THE IMPORTANCE OF TRANSFERRIN SATURATION, SERUM FERRITIN, LOG FERRITIN AND TRANSFERRIN / LOG FERRITIN IN DIFFERENTIATING IRON DEFICIENCY ANEMIA FROM ANEMIA OF CHRONIC DISEASE IN RHEUMATOID ARTHRITIS PATIENTS / R. A. Abdel Noor* - M. H. Abu-Zaid - S. A. Elshweikh - E. S. Rabee - G. E. Khedr FRI0082 PREDICTORS OF FATIGUE AND PERSISTENT FATIGUE IN EARLY RHEUMATOID ARTHRITIS: A LONGITUDINAL OBSERVATIONAL STUDY / S. Rodríguez-Muguruza* - B. Combe - F. Guillemin - B. Fautrel - A. Olive - S. Marsal - O. Valero - N. Rincheval - C. Lukas FRI0083 ADJUSTMENT OF THE THRESHOLD MAY IMPROVE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Velmakin - E. Troitskaya* - S. Villevalde - Z. Kobalava FRI0084 INTENSE AEROBIC AND RESISTANCE EXERCISE REDUCES THE FREQUENCY OF PERIPHERAL BLOOD REGULATORY CELL POPULATIONS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS / S. Andersson* - E. Lange - D. Kucherski - S. Svedlund - K. Önnheim - J. Lord - I.-L. Mårtensson - K. Mannerkorpi - I. Gjertsson FRI0085 A STUDY OF THE RELATIONSHIP BETWEEN SERUM VITAMIN D LEVEL AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS / S. Datta* - A. Kar - T. K. Bhaumik - T. Santra FRI0086 IS THE DISCORDANCE BETWEEN THE DOCTOR AND THE PATIENT A DETERMINANT OF ADHERENCE? / T. Oton* - J. Calvo-Alén - L. Cea-Calvo - L. Carmona FRI0087 REGIONAL AGE- AND SEX-SPECIFIC INTIMA-MEDIA THICKNESS CRITERIA IN YOUNG PATIENTS WITH RHEUMATOID ARTHRITIS / V. Omelchenko - E. Letyagina - M. Korolev* - R. Khapaev - T. Pospelova - V. Konenkov FRI0088 PSYCHOLOGICAL IMPACT IN RHEUMATOID ARTHRITIS: ROLE OF SPECIFIC TREATMENT AND ASSOCIATED MEASURES / X. Grapton* - P. Lemesle - L. Arabian - V. Strotz FRI0089 ASSESSMENT OF COGNITIVE FUNCTION IN RHEUMATOID ARTHRITIS / Z. Kardos* - C. Oláh - M. Andrejkovics - E. Bodnár - K. Hodosi - K. Fazekas - Á. Flórián - K. Lukács - Á. Miksi - Z. Baráth - L. Tamási - Z. Szekanecz 15 June 2018 Poster tour F3: Abstracts N : The hydra beast in RA: a multifaceted disease Elena Nikiphorou (United Kingdom), Peter C. Taylor (United Kingdom) FRI0090-FRI0099 FRI0090 ASSOCIATION OF BODY COMPOSITION WITH DISEASE ACTIVITY AND DISABILITY IN RHEUMATOID ARTHRITIS / K. M. Son* - S. Y. Lee - S. H. Kang - Y. I. Seo - H. A. Kim FRI0091 SOMATOSENSORY DYSFUNCTION IN RHEUMATOID ARTHRITIS - A QUANTITATIVE SENSORY TESTING ASSESSMENT / T. M. Rocha* - M. Barbosa - S. Pimenta - M. Bernardes - A. Bernardo - R. Lucas - L. Costa - J. Vollert - C. Maier FRI0092 THE ASSOCIATION OF PSYCHOLOGICAL STRESS WITH INFLAMMATION IN PATIENTS WITH CLINICALLY SUSPECT ARTHRALGIA - A STUDY DURING RHEUMATOID ARTHRITIS DEVELOPMENT / A. C. Boer* - R. M. ten Brinck - A. W. M. Evers - A. H. M. van der Helm-van Mil FRI0093 DON T MISS THE DEPRESSION! COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND THEIR IMPACT ON PATIENT-REPORTED OUTCOMES: RESULTS OF CLAIMS DATA LINKED TO A QUESTIONNAIRE SURVEY / K. Albrecht* - A. Luque Ramos - J. Callhoff - I. Redeker - F. Hoffmann - A. Zink FRI0094 DOES SUBCLINICAL INFLAMMATION EXPLAIN JOINT PAIN IN PATIENTS WITH ARTHRALGIA SUSPICIOUS FOR PROGRESSION TO RHEUMATOID ARTHRITIS? - RESULTS OF A CROSS-SECTIONAL MRI-STUDY / L. E. Burgers* - R. M. ten Brinck - D. M. Boeters - A. H. M. van der Helm-van Mil FRI0095 ANTI-TNFA VERSUS RITUXIMAB IN REFRACTORY PERIPHERAL ULCERATIVE KERATITIS ASSOCIATED TO RHEUMATIC DISEASES. MULTICENTER STUDY OF 24 PATIENTS / L. C. Domínguez Casas* - V. Calvo-Río - O. Maíz-Alonso - A. Blanco - E. Beltran - L. Martinez Acosta - M. C. Alvarez de Buergo - E. Rubio-Romero - D. Díaz-Valle - R. López-González - A. García- Aparicio - A. Juan Mas - E. Pons - R. Demetrio-Pablo - N. Vegas-Revenga - R. Blanco - M. Gonzalez-Gay FRI0096 IS SIDE EFFECTS AND TREATMENT RESPONSE TO METHOTREXATE ASSOCIATED TO COMORBIDITY IN EARLY RHEUMATOID ARTHRITIS / K. L. Pedersen* - J. Hallas - I. M. J. Hansen - P. Ahlquist - T. Ellingsen FRI0097 EXPRESSION OF UNCOUPLING PROTEIN-1 IN SUBCUTANEOUS FAT REDUCES THE TOTAL CHOLESTEROL LEVEL AND CARDIOVASCULAR RISK IN FEMALE RA PATEINTS / L. I. Lyngfelt* - M. C. Erlandsson - M. Nadali - K. M. Andersson - S. T. Silfverswärd - R. Pullerits - M. I. Bokarewa FRI0098 HEPATIC SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO RECEIVED ISONIAZID FOR LATENT TUBERCULOSIS: POST-HOC ANALYSIS FROM PHASE 3 BARICITINIB STUDIES / T.-Y. Hsieh* - W.-N. Huang - H.-P. Tony - A. Balsa - K. Winthrop - M. Harigai - C. Dickson - W.-S. Wu - I. de la Torre - R. Liao - L. Chen - S. Kumar - B. Combe FRI0099 LIVER ENZYME ABNORMALITIES AFTER TOFACITINIB TREATMENT IN PATIENTS WITH HEPATIC STEATOSIS FROM THE RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND PSORIASIS CLINICAL PROGRAMMES / E. R. Soriano* - H. Madariaga - O. Castañeda - G. Citera - E. E. Schneeberger - M. H. Cardiel - T. Hendrikx - D. Graham - H. Shi - D. Ponce de Leon * Presenting author

106 104 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 TOPIC: RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS 15 June 2018 FRI0100 MULTI-OMICS ANALYSIS IDENTIFIES A GENE SIGNATURE ASSOCIATED WITH THE CLINICAL RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS / A. Aterido* - J. Tornero - F. Blanco - B. Fernández-Gutiérrez - A. González - J. D. Cañete - J. Maymó - M. Alperi-López - À. Olivé - H. Corominas - V. Martínez-Taboada - I. González - A. Fernández-Nebro - A. Erra - S. Sánchez-Fernández - M. López-Lasanta - M. López-Corbeto - R. Tortosa - L. Codó - S. Marsal - A. Julià FRI0101 UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS. AN OBSERVATIONAL STUDY AND A REAL-LIFE EXPERIENCE FROM A SINGLE UNIVERSITY CENTER / E. Kaltsonoudis - E. Pelechas - P. V. Voulgari - A. A. Drosos* FRI0102 REDUCTION OF ANTIDRUG ANTIBODY LEVELS AFTER SWITCHING TO RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH PREVIOUS FAILURE TO INFLIXIMAB OR ADALIMUMAB / A. Martinez-Feito* - C. Plasencia - V. Navarro-Compan - B. Hernández-Breijo - D. Pascual-Salcedo - P. Nozal - C. Diego - I. Monjo - L. Nuño - A. Balsa FRI0103 ONE-YEAR FOLLOW-UP OF A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS, WHO SWITCHED FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT, FOCUSING ON PATIENTS WHO SWITCHED BACK TO ORIGINATOR. AN OBSERVATIONAL DANBIO STUDY / B. Glintborg* - I. J. Sørensen - E. Omerovic - F. Mehnert - N. Manilo - K. Danebod - D. V. Jensen - H. Nordin - A. G. Loft - O. Hendricks - S. Chrysidis - B. L. Andersen - J. L. Raun - H. Lindegaard - J. Espesen - S. H. Jakobsen - I. M. J. Hansen - E. B. Dalsgaard - D. D. Pedersen - S. Kristensen - A. Linauskas - L. S. Andersen - J. Grydehøj - N. S. Krogh - M. L. Hetland FRI0104 PREDICTORS FOR THE RESPONSE TO ANTI-TNF THERAPY AND THE IMPACT OF SMOKING IN RHEUMATOID ARTHRITIS- RESULTS ON A GROUP OF PATIENTS IN ROMANIA / B. I. Gavrila* - C. S. Ciofu - L. Macovei - A. M. Gheorghiu - M. Sasu - C. Mihai - V. Stoica - I. Ancuta - M. Bojinca FRI0105 CONCOMITANT USE OF CORTICOSTEROIDS AT THE BASELINE DOES NOT AFFECT THE DRUG SURVIVAL OF ABATACEPT IN RHEUMATOID ARTHRITIS / S. S. KOCA - B. Öz* - A. Karatas - H. E. Dalkılıç - G. Can - Y. Pehlivan - S. Senel - A. Yazıcı - N. İnanç - A. Çefle - Z. Ertürk - S. Akar - B. Yagiz - B. Göker - A. M. Birlik - F. Önen FRI0106 IMPACT OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS ON WORK IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS: A META ANALYSIS OF RANDOMISED CONTROLLED TRIALS AND CONTROLLED COHORTS / C. Traverson* - A. tubery - C. Hua - F. Barchechath-Flaisler - C. Lukas - B. Combe - J. Morel - C. Gaujoux-Viala FRI0107 FIVE SUCCESSFUL PREGNANCIES WITH ANTENATAL ANAKINRA EXPOSURE / C. J. F. Smith* - C. Chambers FRI0108 GOLIMUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), PSORIASIS ARTHRITIS (PSA) AND AXIAL SPONDYLOARTHRITIS (AXSPA): INTERIM RESULTS FROM A NON-INTERVENTIONAL STUDY IN AUSTRIA (GO ACTIVE) / C. Dejaco* - T. Mueller - O. Zamani - U. Kurtz - S. Egger - J. Resch-Passini - A. Totzauer - W. Eisterer - B. Yazdani-Biuki - T. Schwingenschloegl - P. Peichl - A. Kraus - G. W. Naerr - V. Rickert FRI0109 DRUG IMMUNOGENICITY AND THE DEVELOPMENT OF PARADOXICAL ADVERSE EVENTS WITH BIOLOGIC THERAPIES / C. Ancuta* - C. Pomirleanu - R. Paiu - G. Strugariu - L. Petrariu - E. Ancuta - A. Chiriac - R. Chirieac FRI0110 THE IMPACT OF SEROPOSITIVITY ON THE EFFECTIVENESS OF ABATACEPT VERSUS TNF INHIBITORS IN RHEUMATOID ARTHRITIS. REAL LIFE DATA FROM SEVERAL EUROPEAN REGISTRIES (THE PAN-ABA STUDY) / D. Courvoisier* - D. Mongin - M. Hetland - K. Pavelka - C. Turesson - S. A. Bergstra - T. K. Kvien - M. J. Santos - V. Hernandez - F. Iannone - J.-E. Gottenberg - X. Mariette - S. Kubo - Y. Tanaka - D. Choquette - R. Ionescu - A. Finckh FRI0111 ANALYSIS OF REAL-LIFE INFLIXIMAB AND ADALIMUMAB DATA: DRUG SWITCHING AND FATE OF ANTIDRUG ANTIBODIES AND TROUGH LEVELS OVER TIME / D. Ho* - S. Valtanen - M. Havana - L. Kröger - K. Eklund - T. S. Jokiranta FRI0112 PERSISTENCE ON TUMOR NECROSIS FACTOR INHIBITOR (TNFI) MONOTHERAPY AFTER ACHIEVING REMISSION OR LOW DISEASE ACTIVITY (LDA) ON COMBINATION THERAPY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / D. A. Pappas* - H. J. Litman - T. Lesperance - S. Rebello - E. Karis - G. Kricorian - W. Hua - N. Accortt FRI0113 SWITCHING TO ANTI-IL-6 BIOLOGICS AFTER ANTI-TNF THERAPY IN CHILDREN WITH JIA / E. Alexeeva* - T. Dvoryakovskaya - M. Soloshenko - R. Denisova - K. Isaeva - A. Mamutova - V. Gladkikh - A. Moskalev FRI0114 EFFICACY AND RETENTION RATE OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: DATA FROM A LARGE REAL-LIFE MULTICENTRE RETROSPECTIVE COHORT / E. G. Favalli* - A. Becciolini - P. Sarzi Puttini - F. Atzeni - R. Bortolotti - S. Monti - C. Lomater - R. Gorla - C. Bazzani - R. Caporali on behalf of LORHEN group FRI0115 INDIRECT STANDARDIZED ASSESSMENT OF INJECTION SITE PAIN FOLLOWING SUBCUTANEOUS ADMINISTRATION OF CITRATE-FREE FORMULATION OF ADALIMUMAB AND ITS BIOSIMILAR ABP 501 / E. Krishnan* - N. Zhang - H. Wang - R. Kaushik FRI0116 IMPACT OF PRIOR BIOLOGIC USE ON TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB IN ROUTINE CLINICAL CARE: RESULTS FROM THE PASSION STUDY / F. van den Bosch* - S. Wassenberg - P. Zueger - J. Kalabic - M. Wu - K. Monastiriakos - A. Ostor FRI0117 TOCILIZUMAB USE DIRECTLY AFTER SDMARD FAILURE SHOWS HIGHER RESPONSE RATES AND A LONGER TREATMENT DURATION / F. Behrens* - W. A. Biewer - G.-R. Burmester - M. Feuchtenberger - J.-P. Flacke - M. Hofmann - P. Kästner - H. Kellner - T. Klopsch - C. Kühne - H.-P. Tony - C. Amberger FRI0118 DEKAVIL (F8IL10) - UPDATE ON THE RESULTS OF CLINICAL TRIALS INVESTIGATING THE IMMUNOCYTOKINE IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Galeazzi - G. Sebastiani - R. Voll - O. Viapiana - J. Dudler - P. Zufferey - E. Selvi - S. Finzel - F. S. Bootz* - D. Neri on behalf of DEKAVIL STUDY GROUP FRI0119 EFFECT OF DISCONTINUING TNF INHIBITORS DURING PREGNANCY ON THE COURSE OF RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS / F. Förger* - G. Bandoli - Y. Luo - L. Robinson - D. L. Johnson - C. D. Chambers FRI0120 EVALUATION OF RITUXIMAB, TOCILIZUMAB AND ABATACEPT IN A FRENCH MULTICENTER RHUPUS COHORT / G. Laustriat* - O. Fogel - D. Wendling - S. Ottaviani - S. Guignard - J. Morel - J. E. Gottenberg - A. Cantagrel on behalf of CRI (Club Rhumatisme Inflammation) * Presenting author

107 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 105 FRI0121 CHARACTERISTICS OF PATIENTS WITH EARLY RHEUMATOID ARTHRITIS WHO HAVE A DELAYED RESPONSE TO TREATMENT WITH METHOTREXATE IN MONOTHERAPY OR IN COMBINATION WITH ADALIMUMAB / J. Smolen* - X. Bu - X. Wang - J. Suboticki - A. Kavanaugh FRI0122 DRUG SURVIVAL OF ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS OVER 10 YEARS IN REAL-WORLD SETTING OF CZECH REGISTRY ATTRA / K. Pavelka* - J. Zavada - Z. Kristkova - L. Szczukova FRI0123 COMPARATIVE EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN A PAN- EUROPEAN COLLABORATION OF REGISTRIES / K. Lauper* - M. J. Santos - F. Ianonne - Z. Rotar - D. C. Nordström - C. Codreanu - T. K. Kvien - E. K. Kristianslund - K. Pavelka - G. Lukina - M. V. Hernández - S. L. Gale - K. Sarsour - Y. Luder - D. S. Courvoisier - C. Gabay FRI0124 PREVENTION OF EXTENSIVE BONE MARROW EDEMA AND CONSEQUENT RAPID RADIOGRAPHIC PROGRESSION BY SHORT TERM USAGE OF BIOLOGICS IN DRARDS RESISTANT PATIENTS WITH EARLY DESTRUCTIVE RHEUMATOID ARTHRITIS / K. Katayama* - T. Okubo - T. Sato - R. Fukai - Y. Kon - Y. Makino - S. Kodama - H. Ito FRI0125 QUANTIFICATION OF TUMOR NECROSIS FACTOR IN ANKYLOSING SPONDYLITIS PATIENTS DURING ADALIMUMAB TREATMENT / L. Berkhout* - J. Ruwaard - M. J. l Ami - G. Wolbink - T. Rispens FRI0126 PATIENTS CONCERNS ABOUT AND PERCEPTION OF BIOSIMILARS IN RHEUMATOLOGY: A FRENCH SURVEY / L. Frantzen* - J.-D. Cohen - S. Tropé - M. Beck - R. Diebold - M. Sittler - A. Munos - L. Arnaud - J.-E. Gottenberg - J. Sibilia - N. Afif - C. Sordet on behalf of CERBER: Comité d Etudes et de Réflexion sur les Biosimilaires en Rhumatologie FRI0127 OPEN-LABEL NON-MANDATORY TRANSITIONING FROM ORIGINATOR ETANERCEPT TO BIOSIMILAR SB4: 6-MONTH RESULTS FROM A CONTROLLED COHORT STUDY / L. Tweehuysen* - V. J. B. Huiskes - B. J. F. van den Bemt - J. E. Vriezekolk - S. Teerenstra - F. H. J. van den Hoogen - C. H. van den Ende - A. A. den Broeder FRI0128 INTEGRATED SAFETY DATA ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS / M. E. Husni* - S. Schwartzman - A. Deodhar - S. Kafka - S. D. Chakravarty - E. C. Hsia - D. D. Harrison - J. H. Leu - Y. Zhou - K. H. Lo - A. Kavanaugh FRI0129 SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY / M. Matucci-Cerinic* - H. Schulze-Koops - M. Buch - A. Kavanaugh - Y. Allanore - E. J. Kucharz - G. Babic FRI0130 CERTOLIZUMAB PEGOL EXPOSURE DURING PREGNANCY IN WOMEN WITH RHEUMATOID ARTHRITIS: EVALUATION OF THE LONG-TERM NEWBORN OUTCOMES / M. Meroni* - M. De Santis - M. Caprioli - A. Ceribelli - N. Isailovic - P. Rossi - M. Cutolo - C. Selmi FRI0131 POTENTIAL FACTORS ASSOCIATED WITH LONG-TERM CONTINUATION OF ETANERCEPT / M. Kamiya* - N. Okada - H. Kikuchi - S. Soen FRI0132 FACTORS INFLUENCING SATISFACTION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB / M. Fusama* - K. Yukioka - T. Seki - T. Kuroiwa - K. Kawamoto - Y. Manabe - Y. Yoshimine - W. Tansuri - S. Kawata - Y. ishida - M. Yaga - S. higa - M. Inoue - C. Yukioka - K. Higashi - T. Kuritani - A. Ogata - K. Maeda - A. Shintani - H. Sano - M. Yukioka - H. Nakahara FRI0133 CENTRAL ROLE OF TOCILIZUMAB IN FIBROBLAST DOMINATED MODELS OF INFLAMMATORY AUTOIMMUNE ARTHRITIS / M. A. Nielsen* - B. Deleuran - T. W. Kragstrup FRI0134 IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY? / N. Inanc* - G. Ozen - Y. Yalcinkaya - E. Dalkilic - S. S. Koca - G. Can - A. Karataş - Y. Pehlivan - A. Yazıcı - A. Cefle - A. Tufan - S. Akar - S. Senel - B. Oz - N. Akkoc - F. Onen FRI0135 HAVE PREVALENCE OF JOINT SURGERY DECREASED WITH THE USE OF BIOTHERAPY IN RHEUMATOID ARTHRITIS? / O. Saidane* - M. Sellami - R. Barhoumi - A. Ben Tekaya - H. Ajlani - R. Tekaya - I. Mahmoud - L. Abdelmoula FRI0136 PERSISTENCE OF MONOTHERAPY OR COMBINATION THERAPY WITH DISEASE-MODIFYING AGENTS IN PATIENTS WITH PSORIATIC ARTHRITIS IN A REAL-WORLD SETTING / P. J. Mease* - N. A. Accortt - S. Rebello - C. Etzel - R. W. Harrison - G. A. Aras - M. M. F. Gharaibeh - J. D. Greenberg - D. H. Collier FRI0137 EFFICACY, SAFETY AND IMMUNOGENICITY FROM WEEK 30 TO WEEK 54 IN A RANDOMISED, DOUBLE-BLIND PHASE III STUDY COMPARING A PROPOSED INFLIXIMAB BIOSIMILAR (PF /GP1111) WITH REFERENCE INFLIXIMAB / R. Alten* - V. Tseluyko - T. Hala - S. Mehmedagic - M. Pileckyte - E. Dokoupilová - D. Jovic - M. Rehman - M. Zhang - L. Sewell - S. Hackley - S. Salts - C. Cronenberger - K. Schumacher - O. von Richter - B. Batko FRI0138 TREAT TO TARGET STRATEGY PLUS CERTOLIZUMAB IN COMPARISON TO CONTINUED, FIXED CSDMARD PLUS CORTICOSTEROIDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS (REMISSION BY INTRA-ARTICULAR INJECTION PLUS CERTOLIZUMAB, THE RICE STUDY): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL / R. Mueller* - M. Spaeth - C. von Restorff - C. Ackermann - J. von Kempis FRI0139 COMPARATIVE SAFETY OF ABATACEPT IN RHEUMATOID ARTHRITIS WITH COPD: A REAL-WORLD POPULATION- BASED OBSERVATIONAL STUDY / S. Suissa* - P. Ernst - S. Dell Aniello - S. Shen - T. A. Simon FRI0140 INDIVIDUALISED INFLIXIMAB TREATMENT: A TREATMENT STRATEGY BASED ON THERAPEUTIC DRUG MONITORING / S. W. Syversen* - G. L. Goll - K. K. Jørgensen - Ø. Sandanger - J. Gehin - C. Mørk - T. K. Kvien - J. Jahnsen - N. Bolstad - E. A. Haavardsholm FRI0141 VACCINATION DECISIONS AND INCIDENCE OF NEONATAL INFECTIONS IN MOTHERS EXPOSED TO BIOLOGICALS DURING PREGNANCY / S. J. Bond* - L. Young - K. Poulsen - H. L. Barrett - A. L. Taylor - C. Barrett FRI0142 THE COMPARISON OF THE ULTRASONOGRAPHIC SYNOVIAL FINDINGS BETWEEN INTRAVENOUS ADMINISTRATION AND SUBCUTANEOUS INJECTION OF TOCILIZUMAB / T. Okano* - K. Inui - Y. Yamada - K. Mandai - K. Mamoto - Y. Sugioka - M. Tada - T. Koike - H. Nakamura 15 June 2018 * Presenting author

108 106 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 FRI0143 FRI0144 FRI0145 FRI0146 FRI0147 INFLUENCE OF LOW-DOSE GLUCOCORTICOID TREATMENT ON PERSISTENCE ON BIOLOGIC DMARDS THERAPY: REAL-LIFE DATA FROM THE ITALIAN GISEA REGISTRY / V. Codullo* - A. Manfredi - G. Lapadula - E. Gremese - A. Bortoluzzi - E. G. Favalli - R. Gorla - F. Salaffi - E. Fusaro - R. Foti - L. Cantarini - A. Cauli - F. P. Cantatore - A. Carletto - F. Conti - S. D Angelo - O. Epis - R. Ramonda - F. Atzeni - P. C. Sarzi-Puttini - R. Caporali PATIENT-REPORTED OUTCOMES WITH SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS ARE SIMILAR REGARDLESS OF PRIMARY OR SECONDARY FAILURE WITH TUMOR NECROSIS FACTOR INHIBITORS / V. Strand* - S. Boklage - E. Mangan - M. Reaney - M. Iglesias-Rodriguez - T. Kimura A BAYESIAN NETWORK META-ANALYSIS ON EFFICACY OF BIOLOGICS AND SMALL MOLECULES IN EARLY RHEUMATOID ARTHRITIS / V. Venerito* - F. Cacciapaglia - G. Lapadula - F. Iannone CORRELATION BETWEEN THE RHEUMATOID FACTOR POSITIVITY AND THE HIGHER DISCONTINUATION RATE OF BIOLOGICAL THERAPY IN RHEUMATOID ARTHRITIS: A FINE-GRAY PROPORTIONAL HAZARD REGRESSION ANALYSIS / Y. Ogawa* - N. Takahashi - T. Kojima - N. Ishiguro ANALYSIS OF RADIOGRAPHIC JOINT DESTRUCTION IN THE PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE WITHDRAWN, SPACED AND CONTINUED BIOLOGICS AFTER ACHIEVING SUSTAINED REMISSION FROM LOCAL BIOLOGICS REGISTRY / Y. Takakubo* - J. Nagai - H. Oki - Y. Naganuma - S. Yang - J. Ito - Y. Suzuki - K. Sasaki - M. Takagi TOPIC: SPONDYLOARTHRITIS - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS 15 June 2018 Poster tour F4: Abstracts N : SpA pathophysiology: of mice and men... Dirk Elewaut (Belgium), Filip van den Bosch (Belgium) FRI0148-FRI0157 FRI0148 A STUDY OF MICROBIAL TRANSLOCATION IN AN ANIMAL MODEL OF SPONDYLOARTHRITIS / M. Asquith* - M. Schleisman - S. Davin - L. Karstens - J. T. Rosenbaum FRI0149 INFLAMMATION INTENSITY-DEPENDENT EXPRESSION OF OSTEOINDUCTIVE WNT PROTEINS IS CRITICAL FOR ECTOPIC NEW BONE FORMATION IN ANKYLOSING SPONDYLITIS / H. Liu* - X. Li - J. Wang FRI0150 MTOR BLOCKADE BY RAPAMYCIN DECREASES ARTHRITIS AND SPONDYLITIS DEVELOPMENT AND SEVERITY IN HLA-B27 TRANSGENIC RATS / S. Chen - M. van Tok - D. Pots - J. Taurog - M. van de Sande - D. Baeten - L. van Duivenvoorde* FRI0151 PROTEIN INHIBITOR OF ACTIVATED STAT3 PREVENTS PERIPHERAL ARTHRITIS AND GUT INFLAMMATION BY REGULATING TH17/TREG CELL IMBALANCE VIA STAT3 SIGNALING IN MICE MODEL OF SPONDYLOARTHRITIS / E. Kwon* - H. K. Min - M. Y. Kim - J. Choi - S.-Y. Lee - H.-B. Seo - K. Jung - H. S. Na - J.-G. Ryu - S.-K. Kwok - M.-L. Cho - S.-H. Park FRI0152 INFLAMMASOMES ACTIVATION OCCURS IN THE INFLAMED TISSUES OF AS PATIENTS AND DRIVES IL-23 EXPRESSION / F. Ciccia* - A. Rizzo - G. Guggino - R. Alessandro - S. Raimondo - F. Macaluso - S. Peralta - S. Milling - D. Elewaut FRI0153 ROLE OF ROR GAMMA T INHIBITION IN THE IL-23 MINICIRCLE MODEL AND SPA PATIENT TISSUE CULTURES / K. Hoyt* - J. Galdamez - M. Panzenbeck - D. Souza - E. Glynn - J. Pelletier - M. Lewis - G. Nabozny - E. Purdue - L. A. Mandl - J. Wahle FRI0154 ADDED VALUE OF BIOMARKERS COMPARED TO ROUTINE CLINICAL PARAMETERS FOR THE PREDICTION OF RADIOGRAPHIC SPINAL PROGRESSION IN AXIAL SPONDYLOARTHRITIS / J. Rademacher* - L. Tietz - L. Le - A. Hartl - M. Rudwaleit - J. Sieper - U. Mansmann - D. Poddubnyy FRI0155 GENES REGULATING BONE HOMEOSTASIS ARE DIFFERENTIALLY EXPRESSED AT PERIPHERAL VERSUS AXIAL ENTHESIAL SITES IN AN ANIMAL MODEL OF SPONDYLOARTHRITIS / Z. Stavre* - Y. Maeda - T. Huang - E. Gravallese FRI0156 AN ANTIMICROBIAL MECHANISM, NETOSIS, IS POTENTIALLY INVOLVED IN ANKYLOSING SPONDYLITIS PATHOGENESIS / P. Ruiz-Limon* - M. C. Castro - C. Lopez-Pedrera - M. C. Abalos-Aguilera - N. Barbarroja - C. Perez-Sachez - I. Arias-de la Rosa - R. Ortega - P. Font - J. A. Gonzalez-Reyes - J. M. Villalba - C. Lopez-Medina - A. Escudero - E. Collantes - Y. Jimenez-Gomez FRI0157 ALTERED EXPRESSION OF THE SPLICEOSOME COMPONENTS IN LEUKOCYTES SUBSETS FROM PATIENTS WITH ANKYLOSING SPONDYLITIS: ASSOCIATION TO DISEASE PATHOGENESIS AND THERAPEUTIC RESPONSE / L. Ladehesa* - M. C. Castro - C. Lopez-Pedrera - R. Ortega - S. Pedraza - M. del Río - M. C. Abalos-Aguilera - P. Ruiz-Limon - C. Perez-Sanchez - A. Ibañez-Costa - Y. Parra-Manso - N. Barbarroja - I. Arias-de la Rosa - P. Font - A. Escudero - J. P. Castaño - R. M. Luque - E. Collantes - Y. Jimenez-Gomez FRI0158 PROSTAGLANDIN E2 AND ITS RECEPTOR SUBTYPE EP4 ARE INVOLVED IN ANKYLOSING SPONDYLITIS DISEASE PROGRESSION / A. Srinath* - N. Haroon - G. Guggino - I. Sari - F. Zeng - R. Alessandro - A. Rizzo - F. Ciccia FRI0159 ANTIBODIES TO POST-TRANSLATIONALLY MODIFIED COLLAGEN II IN SPONDYLOARTHRITIS / C. Vinci* FRI0160 INTERLEUKIN-17A INDUCES INFLAMMATORY RESPONSE VIA NLRP3 INFLAMMASOME IN ANKYLOSING SPONDYLITIS / D. Kim* - S.-W. Lee - J. J. Song - Y.-B. Park - M.-C. Park FRI0161 ROLE OF GITR/GITRL IN MODULATING TH9 RESPONSE IN PSORIATIC ARTHRITIS / G. Guggino* - D. di Liberto - A. Rizzo - M. La Manna - A. Ferrante - L. Saieva - R. Alessandro - G. Sireci - F. Ciccia FRI0162 THE LINK BETWEEN ANGIOGENESIS AND OSTEOGENESIS IN SPONDYLOARTHRITIS / M. H. Kaaij* - J. P. van Hamburg - G. Kollias - D. L. P. Baeten - L. M. van Duivenvoorde - S. W. Tas FRI0163 DEVELOPMENT OF A PRECLINICAL TESTING PIPELINE FOR A NOVEL TRANSMEMBRANE TNF-DRIVEN SPONDYLOARTHRITIS MODEL / K. Kranidioti - L. Ntari - E. Argyropoulou - C. Geka - N. Karagianni* - M. C. Denis - G. Kollias FRI0164 ANTI-PFDN5 ANTIBODY AS A BIOMARKER FOR UVEITIS IN ANKYLOSING SPONDYLITIS / O. C. Kwon* - E.-J. Lee - E.-J. Chang - W. J. Seo - J. S. Oh - S. Hong - C.-K. Lee - B. Yoo - Y.-G. Kim * Presenting author

109 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 107 FRI0165 FRI0166 FRI0167 FRI0168 MICRORNAS DYSREGULATION IN MONOCYTES AND T CD4 LYMPHOCYTES FROM PATIENTS WITH AXIAL SPONDYLOARTHRITIS / O. Fogel* - A. Bugge Tingaard - M. Fagny - N. Sigrist - E. Roché - L. Leclère - J.-F. Deleuze - M. Dougados - C. Miceli-Richard - J. Tost CHARACTERISATION OF PHOSPHODIESTERASE 4 (PDE4) BLOCKADE IN THE SYNOVIUM OF PSORIATIC ARTHRITIS PATIENTS: A FOCUS ON SYNOVIAL INVASIVENESS AND T CELL POLYFUNCTIONALITY / S. M. Wade* - M. Canavan - T. McGarry - S. C. Wade - D. J. Veale - U. Fearon EXPRESSION LEVELS OF IL-17, IL-22 AND IL-23 RECEPTORS IN FOUR OSTEOBLAST MODELS AND THE EFFECTS OF IL-17, IL-22 AND IL-23 ON OSTEOBLASTS / J.-R. Zhang - S.-M. Dai* PHENOTYPIC, FUNCTIONAL AND MOLECULAR CHARACTERISATION OF IL-17+CD8+ T CELLS IN HUMAN HEALTH AND PSORIATIC ARTHRITIS / U. Srenathan* - K. J. Steel - M. L. Ridley - B. W. Kirkham - L. S. Taams TOPIC: SPONDYLOARTHRITIS - CLINICAL ASPECTS (OTHER THAN TREATMENT) Poster tour F5: Abstracts N : Spondyloarthritis: it looks as if it is only imaging that matters Robert B. M. Landewé (Netherlands), Anna Moltó (France) FRI0169-FRI0177 FRI0169 FIRST VALIDATION OF CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SACROILIAC JOINT BY THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) MRI GROUP / W. P. Maksymowych* - U. Weber - S. J. Pedersen - X. Baraliakos - P. Machado - J. Sieper - D. Poddubnyy - S. Wichuk - R. G. Lambert - M. Østergaard FRI0170 CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) CLASSIFICATION COHORT / W. P. Maksymowych* - S. J. Pedersen - X. Baraliakos - P. Machado - U. Weber - J. Sieper - S. Wichuk - D. Poddubnyy - M. Østergaard - R. G. Lambert FRI0171 WHICH IMAGING OUTCOMES FOR AXSPA ARE MOST SENSITIVE TO CHANGE? A 5-YEAR ANALYSIS OF THE DESIR COHORT / A. Sepriano* - S. Ramiro - D. van der Heijde - M. Dougados - P. Claudepierre - A. Feydy - M. Reijnierse - D. Loeuille - R. Landewé FRI0172 INFLAMMATION ON MRI OF THE SACROILIAC JOINTS IS HIGHLY PREDICTIVE OF STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS PATIENTS IN CLINICAL PRACTICE: DATA FROM THE ASAS AND DESIR COHORTS / A. Sepriano* - S. Ramiro - R. Landewé - M. Dougados - D. van der Heijde - M. Rudwaleit FRI0173 IDENTIFICATION OF A TYPICAL PATTERN OF MRI LESIONS OF SACROILIAC JOINTS IN PATIENTS WITH OSTEITIS CONDENSANS ILII AS COMPARED TO AXIAL SPONDYLOARTHRITIS / D. Poddubnyy* - N. Gobejishvili - T. Diekhoff - H. Weineck - M. Llop - V. Rios Rodriguez - J. Sieper - K.-G. Hermann FRI0174 SPINAL RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPA: 5-YEAR DATA FROM THE DESIR COHORT / S. Ramiro* - D. van der Heijde - A. Sepriano - M. van Lunteren - A. Molto - A. Feydy - M. A. D Agostino - D. Loeuille - M. Dougados - M. Reijnierse - P. Claudepièrre FRI0175 RATES AND PREDICTORS OF RADIOGRAPHIC SACROILIITIS PROGRESSION AFTER CENTRAL READING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FROM THE ASAS COHORT: A 5-YEAR FOLLOW-UP STUDY / M. Protopopov* - F. Proft - A. Sepriano - R. Landewé - D. van der Heijde - J. Sieper - M. Rudwaleit - D. Poddubnyy FRI0176 PERFORMANCE OF SPINAL AND SACROILIAC JOINT MRI FINDINGS IN PATIENTS WITH AXSPA / S. Lee* - I. Sari - E. S. Tunc - R. D. Inman - N. Haroon FRI0177 ASSESSING THE VALUE OF WHOLE BODY MAGNETIC RESONANCE IMAGING AS TO CLINICAL EXAMINATION TO PREDICT REMISSION AND RELAPSE IN EARLY PERIPHERAL SPONDYLOARTHRITIS / T. Renson* - P. Carron - S. Krabbe - L. Jans - A.-S. De Craemer - M. de Hooge - P. Jacques - M. Ostergaard - D. Elewaut - F. van den Bosch FRI0179 INTEGRATED LONGITUDINAL ANALYSIS INCREASES PRECISION AND REDUCES BIAS: A COMPARATIVE 5-YEAR ANALYSIS IN THE DESIR COHORT / A. Sepriano* - S. Ramiro - D. van der Heijde - M. Dougados - P. Claudepierre - A. Feydy - M. Reijnierse - D. Loeuille - R. Landewé FRI0180 DIAGNOSIS JOURNEY OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE UNITED STATES / A. Ogdie* - W. B. Nowell - R. Reynolds - K. Gavigan - S. Venkatachalam - M. de la Cruz - E. Flood - E. J. Schwartz - B. Romero - Y. Park FRI0181 TWELVE YEARS FOLLOW-UP OF PATIENTS WITH SPONDYLOARTHRITIS IN AN ENDEMIC CITY DEMONSTRATES HIGH RISK OF ACTIVE TUBERCULOSIS INFECTION / A. Morsch* - D. Silva - G. Garziera - M. Ferreira - C. Kohem - R. Xavier - A. Gasparin - C. Brenol - R. Bohn - N. de Andrade - D. Viecceli - F. Menegat - P. Palominos FRI0182 EROSIONS AT THE SACROILIAC JOINTS AND FATTY LESIONS AT THE SPINE ARE THE MOST DISCRIMINANT LESIONS FOR RECENT ONSET AXSPA RECOGNITION / A. Moltó* - L. Gossec - M. Lefevre-Colau - R. Beaufort - V. Foltz - J. Laredo - P. Richette - P. Dieudé - P. Goupille - A. Feydy - M. Dougados FRI0183 CLINICAL PERIPHERAL ENTHESITIS IN THE DESIR PROSPECTIVE LONGITUDINAL AXIAL SPONDYLOARTHRITIS COHORT / V. Nadon - A. Moltó* - A. Etcheto - L. Bessette - L. Michou - M.-A. D Agostino - P. Claudepierre - D. Wendling - M. Dougados FRI0184 HIGH PREVALENCE OF HIDRADENITIS SUPPURATIVA, ESPECIALLY IN FEMALE AXIAL SPONDYLOARTHRITIS PATIENTS WITH HIGH DISEASE ACTIVITY AND POOR QUALITY OF LIFE / A. Rondags - S. Arends - F. Wink - B. Horvath - A. Spoorenberg* FRI0185 FACTORS DETERMINING WORK INSTABILITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / A. S. Buche* - L. Preston - N. Barkham FRI0186 CONCOMITANT CSDMARDS INFLUENCE CLINICAL RESPONSE TO TNF INHIBITORS ONLY IN OVERWEIGHT PATIENTS WITH AXIAL SPONDYLOARTHRITIS / B. Hernández-Breijo* - V. Navarro-Compán - A. Martínez-Feito - A. Jochems - A. Villalba - D. Peiteado - E. L. Kneepkens - P. Nozal - G. J. Wolbink - T. Rispens - D. Pascual-Salcedo - A. Balsa - C. Plasencia-Rodríguez 15 June 2018 * Presenting author

110 108 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0187 LIPOPROTEIN (A) AND POSSIBLE RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS. RESULTS OF THE CARMA STUDY / C. García-Gómez* - M. Martín-Martínez - C. Fernández-Carballido - S. Castañeda - C. González-Juanatey - F. Sánchez-Alonso - M. González Fernández - R. Sanmartí - J. García Vadillo - B. Fernández Gutiérrez - M. García Arias - F. Manero - J. Senabre - A. Rueda - S. Ros - J. Pina - A. Erra - I. Möller - J. Llorca - M. González-Gay on behalf of CARMA study group FRI0188 FACTORS ASSOCIATED WITH PATIENT-PHYSICIAN DISCORDANCE IN GLOBAL ASSESSMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: AN ASIAN PERSPECTIVE / C. Wang* - W. Fong - Y. H. Kwan - J. K. Phang - N. L. Lui - Y. Y. Leung - J. Thumboo - P. Cheung FRI0189 PERIPHERAL MANIFESTATIONS IN SPONDYLOARTHRITIS: IMPACT ON PATIENT-REPORTED OUTCOMES (PROS) AND TREATMENT. DATA FROM ASAS-COMOSPA / C. López-Medina* - A. Moltó - M. Dougados FRI0190 RELATIONSHIP BETWEEN FECAL CALPROTECTIN, HLAB-27 AND ACUTE PHASE REACTANTS IN PATIENTS WITH SPONDYLOARTHRITIS WITHOUT PRIOR DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE / C. Ramos Giraldez* - M. Espinosa Malpartida - C. Merino Argumánez - B. Ruíz Antorán - J. Campos Esteban - C. Barbadillo Mateos - H. Godoy Tundidor - B. Agudo Castillo - Y. González Lama - J. L. Andréu Sánchez - J. Sanz Sanz FRI0191 SIMILARITIES AND DIFFERENCES BETWEEN OSTEITIS CONDENSANS ILII AND AXIAL SPONDYLOARTHRITIS PATIENTS PRESENTING WITH CHRONIC BACK PAIN IN A RHEUMATOLOGY SETTING / D. Poddubnyy* - H. Weineck - J. Listing - T. Diekhoff - K.-G. Hermann - J. Sieper FRI0192 PREDICTORS OF SEVERE HIP INVOLVEMENT IN ANKYLOSING SPONDYLITIS: DATA FROM NATIONAL INPATIENT SAMPLE / P. Karmacharya - D. R. Poudel* - P. Shrestha - R. Dhital - J. M. Davis III FRI0193 PROGNOSTIC MARKERS IN AXIAL SPONDYLOARTHRITIS (PROMISE) - CROSS SECTIONAL EVALUATION OF SERUM BIOMARKERS IN AXSPA, MECHANICAL BACK PAIN AND HEALTHY CONTROLS / E. Reilly* - C. Fisher - R. Sengupta FRI0194 ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) BASED ON A QUICK QUANTITATIVE CRP ASSAY PERFORMS SIMILARLY WELL TO ASDAS BASED ON CONVENTIONAL CRP IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / F. Proft* - B. Muche - M. Schmidt - L. Spiller - V. Rios Rodriguez - J. Rademacher - A.-K. Weber - S. Lüders - M. Protopopov - I. Spiller - J. Sieper - D. Poddubnyy FRI0195 CLINICAL CHARACTERISTICS OF 897 CHINESE ANKYLOSING SPONDYLITIS/SPONDYLOARTHRITIS REAL WORLD COHORT: DATA FROM A CHINESE COHORT WITH SMART MANAGEMENT SYSTEM FOR SPONDYLOARTHRITIS (SMSP) / X. Ji - J. Zhu - J. ZHANG - F. Huang* on behalf of SMSP co-authors FRI0196 TRADITIONAL DXA UNDERESTIMATES BONE MINERAL DENSITY OF THE SPINE IN AXIAL SPONDYLOARTHROPATHY / G. Fitzgerald* - T. Anachebe - F. O Shea FRI0197 ASSOCIATION OF THE ELECTROCARDIOGRAPHIC DISTURBANCES WITH AORTIC ROOT DILATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS / H. S. Park* - A. Laiz - C. Alonso - S. Jeria Navarro - A. García-Guillén - M. Millan - P. Moya - B. Magallares - I. Castellvi - C. Diaz-Torne - S. Fernandez - J. Casademont - H. Corominas FRI0198 WHICH FACTORS INFLUENCE PSYCHOLOGICAL WELL-BEING OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS? - DATA FROM A CROSS-SECTIONAL SURVEY LINKED TO INSURANCE CLAIMS / I. Redeker* - F. Hoffmann - J. Callhoff - H. Haibel - J. Sieper - A. Zink - D. Poddubnyy FRI0199 FUNCTIONING CATEGORIES BY ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND CONCOMITANT FIBROMYALGIA / I. Shapoval* - M. Stanislavchuk - L. Perebetiuk - G. Movchan FRI0200 INSIGHT INTO THE QUALITY OF LIFE OF PATIENTS WITH ANKYLOSING SPONDYLITIS: REAL-WORLD DATA FROM A US-BASED LIFE IMPACT SURVEY / J. T. Rosenbaum* - L. Pisenti - Y. Park - R. Howard FRI0201 HEALTHY INDIVIDUALS AT INCREASED RISK FOR AXIAL SPONDYLOARTHRITIS WOULD CONSIDER USING MEDICATION IN A PREVENTIVE SETTING / J. J. de Winter* - H. M. De Jong - P. T. Nieuwkerk - I. E. van der Horst-Bruinsma - D. L. Baeten - M. G. van de Sande FRI0202 INERTIAL MOTION SENSORS USING THE VIMOVE SYSTEM IS A VALID METHOD TO ASSESS SPINAL MOBILITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / I. C. Aranda-Valera - J. L. Garrido-Castro* - I. Martinez-Sanchez - C. Gonzalez - P. Gardiner - P. M. Machado - E. Collantes on behalf of imaxspa study group FRI0203 THE LINK BETWEEN COPD AND ANKYLOSING SPONDYLITIS: A POPULATION BASED STUDY / K. Sharif* - A. Watad - S. Tiosano - Y. Yavne - D. Comanehster - A. Cohen - H. Amital FRI0204 RADIOGRAPHIC PROGRESSION OF SPONDYLOARTRITIS PATIENTS AFTER 13 YEARS OF FOLLOW UP: DATA FROM THE REGISPONSER DATABASE / L. Pérez Sánchez* - P. Font - C. López - L. Bautista - L. Ladehesa - I. Gómez - A. Escudero - E. Collantes - M. C. Castro FRI0205 COMPARISON OF WORK DISABILITY, DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS VS. PSORIATIC ARTHRITIS: INTERIM RESULTS FROM THE COMPLETE STUDY / M. Khraishi* - L. Bessette - B. Haraoui - B. Florica - Y. Setty - M. Teo - V. Remple FRI0206 GENDER DIFFERENCES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE ATLAS-2017 / M. Garrido-Cumbrera* - D. Gálvez-Ruiz - P. Zarco - O. Braçe - V. Navarro-Compán FRI0207 THE INCORPORATION OF THE ANTERO-POSTERIOR LUMBAR SPINE VIEW IN THE MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE ONLY MARGINALLY IMPROVES DETECTION OF RADIOGRAPHIC SPINAL PROGRESSION IN AXIAL SPONDYLOARTHRITIS / M. Llop* - V. Rios Rodriguez - J. Sieper - H. Haibel - M. Rudwaleit - D. Poddubnyy FRI0208 ANKYLOSING SPONDYLITIS QUALITY OF LIFE: DEFINING MINIMAL CLINICALLY IMPORTANT CHANGE / N. Richard* - N. Haroon - G. A. Tomlinson - I. Sari - Z. Touma - R. D. Inman FRI0209 RECOMMENDATIONS FOR ACQUISITION AND CONSIDERATIONS FOR INTERPRETATION OF MRI OF THE SPINE AND SACROILIAC JOINTS IN THE INVESTIGATION OF AXIAL SPONDYLOARTHRITIS IN THE UK / T. Bray - A. Jones - M. A. Hall-Craggs - A. Bennett - P. G. Conaghan - A. Grainger - R. Hodgson - C. Hutchinson - M. Leandro - P. Mandl - D. McGonagle - P. O Connor - R. Sengupta - M. Thomas - A. Toms - N. Winn - H. Marzo-Ortega - P. M. Machado* FRI0210 EXTRA-ARTICULAR MANIFESTATIONS ARE ASSOCIATED WITH WORSE QUALITY OF LIFE AND CLINICAL OUTCOME IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / R. van der Meer* - S. Arends - S. Kruidhof - R. Bos - H. Bootsma - F. Wink - A. Spoorenberg * Presenting author

111 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 109 FRI0211 ASSOCIATION OF NEUROPATHIC-LIKE PAIN CHARACTERISTICS WITH CLINICAL AND RADIOGRAPHIC FEATURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S.-H. Lee* - H.-R. Kim - K.-A. Lee FRI0212 THE RELATIONSHIP BETWEEN ANTI-TNF THERAPY USE AND METABOLIC SYNDROME IN PATIENTS WITH ANKYLOSING SPONDYLITIS / A. Ferhatosmanoğlu - S. Çelik* - N. Alpay Kanıtez - N. Caf - S. Yilmaz-Oner - C. Bes FRI0213 THE PERFORMANCE OF 12 FLARE DEFINITIONS INCLUDING THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS)-ENDORSED DEFINITION OF CLINICALLY IMPORTANT WORSENING IN ASDAS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH ADALIMUMAB FOR 5 YEARS / S. Juhl Pedersen* - I. J. Sørensen - A. G. Loft - J. Hindrup - G. Kollerup - G. Thamsborg - K. Asmussen - O. Hendricks - J. Nørregaard - M. Østergaard FRI0214 CLINICAL EVALUATION CORRELATES POORLY WITH ULTRASOUND AND MAGNETIC RESONANCE IMAGING OF JOINTS AND ENTHESES IN EARLY PERIPHERAL SPONDYLOARTHRITIS / T. Renson* - P. Carron - S. Krabbe - L. Jans - A.-S. De Craemer - M. de Hooge - P. Jacques - M. Ostergaard - D. Elewaut - F. van den Bosch FRI0215 ASAS CONSENSUS ON SPANISH NOMENCLATURE FOR SPONDYLOARTHRITIS / V. Navarro-Compán* - T. Otón - E. Loza - R. Almodóvar - R. Ariza-Ariza - W. Bautista-Molano - R. Burgos-Vargas - E. Collantes-Estévez - E. de Miguel - C. González-Fernández - J. Gratacós-Masmitja - S. Ibáñez - X. Juanola - J. Maldonado-Cocco - A. Moltó - J. Mulero-Mendoza - C. Pacheco-Tena - C. Ramos-Remus - J. Sanz Sanz - R. Valle-Oñate - P. Zarco - H. Marzo-Ortega FRI0216 DETECTION OF STRUCTURAL LESIONS ON T1 WEIGHTED MRI VERSUS RADIOGRAPHY OF THE SI JOINTS IN EARLY AXIAL SPONDYLOARTHRITIS: 2-YEAR DATA / W. P. Maksymowych - P. Claudepierre - M. de Hooge - R. G. Lambert - R. Landewé - A. Molto - D. van der Heijde - J. F. Bukowski - H. Jones - I. Logeart - L. Marshall - R. Pedersen - A. Szumski - B. Vlahos - M. Dougados* FRI0217 DIAGNOSTIC ASCERTAINMENT OF AXIAL SPONDYLOARTHRITIS IN PATIENTS PRESENTING WITH UNDIAGNOSED BACK PAIN: WHAT IS THE IMPACT OF MRI IN RHEUMATOLOGICAL PRACTICE? / R. G. Lambert - R. Carmona - J. Yeung - J. Chan - L. Martin - S. Aydin - D. Mosher - A. Masetto - S. Keeling - O. Ziouzina - S. Rohekar - J. Paschke - A. Carapellucci - W. P. Maksymowych* FRI0218 VALIDATION OF ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) MRI LESION DEFINITIONS IN AXIAL SPONDYLOARTHRITIS: DATA FROM THE ECHOGRAPHY IN SPONDYLOARTHRITIS COHORT (ECHOSPA) / W. P. Maksymowych* - D. Loeuille - S. Wichuk - J. Paschke - O. Judet - M. Breban - M.-A. D Agostino - R. G. Lambert FRI0219 ANALYSIS OF THE DIFFERENT VALUE OF MAGNETIC RESONANCE IMAGING CHANGES IN THE SACROILIAC JOINTS FOR A DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS AS JUDGED BY RHEUMATOLOGISTS AND RADIOLOGISTS / X. Baraliakos* - A. Ghadir - M. Fruth - U. Kiltz - J. Braun 15 June 2018 TOPIC: CRYSTAL DISEASES, METABOLIC BONE DISEASES AND BONE DISEASES OTHER THAN OSTEOPOROSIS Poster tour F6: Abstracts N : Gout epidemiology and therapy Alexander So (Switzerland), Abhishek Abhishek (United Kingdom) FRI0220-FRI0229 FRI0220 ULTRASOUND IN ASSESSMENT OF DISEASE COURSE IN GOUT: THE 24 MONTH SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY / E. Norkuviene* - M. Petraitis - I. Apanaviciene - S. Ottaviani - A. Baranauskaite FRI0221 GOUT IS ASSOCIATED WITH AN INCREASED RISK OF CANCER - A NATIONWIDE COHORT STUDY INCLUDING OVER 70,000 GOUT PATIENTS / K. Zobbe* - D. Prieto-Alhambra - R. Cordtz - L. Mellemkjær - P. Højgaard - L. E. Kristensen - L. Dreyer FRI0222 ASSOCIATION BETWEEN BLOOD LEAD LEVELS AND GOUT: THE UNITED STATES NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY / T. T. Cheung - M. F. Tsoi* - B. M. Y. Cheung - W. C. S. Lau FRI0223 IS PERFORMANCE OF THE 2015 ACR/EULAR GOUT CLASSIFICATION CRITERIA AFFECTED BY DISEASE DURATION AND GENDER? RESULTS FROM AN ITALIAN MULTICENTRE STUDY FOCUSED ON THE MANAGEMENT OF CRYSTAL-INDUCED ARTHRITIDES (ATTACK STUDY) / N. Ughi* - A. Zanetti - P. Frallonardo - A. Hoxha - M. Lorenzin - A. Ariani - F. Ceccarelli - M. A. Cimmino - C. Scirocco - B. Raffeiner - A. Bortoluzzi - A. Di Matteo - F. Furini - M. Manara - F. Salaffi - G. Carrara - C. A. Scirè - R. Ramonda FRI0224 MANAGEMENT TO REDUCING LIVER FUNCTION IMPAIRMENT WHEN INITIATING FEBUXOSTAT FOR GOUT BASED ON THE PREDICTION NOMOGRAM / J. Yu* FRI0225 ELECTRONIC CONSULTATION UTILITY IN THE MANAGEMENT OF GOUT / J. Chang* - M. DiFiore - M. Wong FRI0226 ASSESSMENT OF THERAPY ADHERENCE AND TREATMENT RESULTS IN GOUT PATIENTS WHO ATTENDED SCHOOLS FOR PATIENTS AND IN THOSE WHO DID NOT / M. Eliseev* - O. Zhelyabina - M. Chikina - S. Vladimirov FRI0227 RISK FACTORS FOR SKIN REACTIONS TO ALLOPURINOL IN THE KINH POPULATION OF VIETNAM / T. Bardin* - L. G. Le - T. M. K. Buy - A. D. Do - H. Le - M. D. Do - V. A. Hoang - A. N. Le - Q. D. Nguyen - N. H. Le - P. Richette - M. Resche-Rigon - T. P. Mai FRI0228 URATE CORRELATES TO CORONARY ARTERY CALCIFICATION BUT NOT TO INTIMA MEDIA THICKNESS / M. I. Dehlin* - P. Drivelegka - V. Sigurdardottir - O. Angerås - L. T. Jacobsson - H. Forsblad d Elia FRI0229 THE VALIDITY OF THE OMERACT ULTRASOUND DEFINITIONS OF GOUT ELEMENTARY LESIONS IN THE DIAGNOSIS OF GOUT / S. N. Christiansen* - M. Østergaard - O. Slot - L. Terslev FRI0230 CROWNED DENS SYNDROME, YET ANOTHER RHEUMATIC DISEASE IMPOSTER / A. Awisat* - M. Rozenbaum - D. Rimar - N. Boulman - L. Kaly - G. Slobodin - N. Jiries - H. Hussien - I. Rosner FRI0231 STUDY OF URATE TRANSPORTERS IN PRIMARY HYPERURICEMIA AND GOUT / B. Stiburkova* - K. Pavelcova - J. Bohata - K. Kozakova - L. Petru - J. Zavada - K. Pavelka FRI0232 ULTRASONOGRAPHIC FEATURES OF GOUTY DACTYLITIS OF THE HANDS / C. A. Guillen-Astete* - B. Laso-Jimeno FRI0233 DOES GOUT PROTECT FROM PARKINSON S DISEASE: A CASE-CONTROL STUDY FROM AN URBAN POPULATION / C. Diaz-Torne* - M. A. Pou - F. Orfila - S. Jeria - S. Fernandez - H. Park - I. Castellvi - H. Corominas * Presenting author

112 110 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0234 SEL-212: SELECTIVE MITIGATION OF ANTI-DRUG ANTIBODIES AGAINST PEGSITICASE TO CONTROL SERUM URIC ACID IN HYPERURICEMIC SUBJECTS / E. Sands* - A. J. Kivitz - L. Johnston PhD - W. DeHaan - T. K. Kishimoto FRI0235 EFFECT OF SERUM URIC ACID (SUA) ON GOUT FLARES (GF) AND TOPHI RESOLUTION IN GOUT PATIENTS. POOLED POST HOC ANALYSIS OF CLEAR 1 & CLEAR 2 TRIALS / F. Perez-Ruiz* - P. Richette - R. G. Karra - I. Wild - H. Hagedorn - P. Kandaswamy - T. Bardin FRI0236 ASSOCIATIONS BETWEEN COMORBIDITY AND URATE DEPOSITION IN SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA: A PILOT STUDY / G. Kerr* - S. Dowell - A. Wells - R. Haddad - P. DeMarco - J. Joseph - J. Ude - S. Hochberg - J. Huang - D. Nashel FRI0237 PEGLOTICASE TREATMENT SIGNIFICANTLY DECREASES MEAN ARTERIAL BLOOD PRESSURE IN PATIENTS WITH CHRONIC GOUT / H. Choi* - R. Johnson - A. Yeo - P. Lipsky FRI0238 THE LEVEL OF LEPTIN IN PATIENTS WITH GOUT AND ITS ASSOCIATION WITH THE GOUT ACTIVITY SCORE / I. Orlova* - M. Stanislavchuk FRI0239 ABSOLUTE NUMBERS OF PERIPHERAL TH17 AND TH2 CELLS INCREASED IN PATIENTS WITH GOUT / J. Yuan* - L. Zhao - J. Luo - C. Gao - X. Li - H. Gao - L. Shang - Q. Li FRI0240 CLINICAL TRIAL TO DETERMINE WHETHER ALTERING THE REGIMEN OF PEGLOTICASE ADMINISTRATION CAN INCREASE THE FREQUENCY OF SUBJECTS HAVING SUSTAINED LOWERING OF SERUM URATE / K. Saag* - M. Feinman - H. S. Baraf - R. Fleischmann - A. Kavanaugh - P. Lipsky FRI0241 THE EFFECT OF FEBUXOSTAT ON INFLAMMATORY AND CARDIOVASCULAR BIOMARKERS IN HYPERURICEMIC HYPERTENSIVE PATIENTS / L. McLean* - L. Gunamardhana - U. Thienel - J. Wu - G. Smithson FRI0242 IMPAIRMENT IN THE RATES OF INCIDENCE, MORTALITY, STAYS AND ANNUAL COSTS OF HOSPITALIZATIONS FOR GOUT IN THE SPANISH NATIONAL HEALTH SYSTEM / M. Hernández Hurtado* - M. Á. Martínez Huedo - A. Balsa Criado - D. Peiteado López - E. De Miguel Mendieta FRI0243 ANAKINRA FOR CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS: AN EFFICIENT, SAFE ALTERNATIVE TREATMENT / M. Thomas* - M. Forien - E. Palazzo - P. Dieudé - S. Ottaviani FRI0244 LIFE STYLE FACTORS AND COMORBIDITIES IN GOUT PATIENTS COMPARED TO THE GENERAL POPULATION / M. I. Dehlin* - L. Scheepers - A. Landgren - L. T. Jacobsson - U. Lindström - E. Klingberg - U. Bergsten FRI0245 PREDICTORS FOR CLINICALLY DIAGNOSED GOUT - 30 YEARS FOLLOW-UP IN THE MALMÖ PREVENTIVE PROJECT COHORT, SWEDEN / M. C Kapetanovic* - P. Nilsson - C. Turesson - M. Englund - N. Dalbeth - L. Jacobsson FRI0246 INVESTIGATING THE EFFECT OF SERUM URATE LEVELS ON GOUT FLARE RATES IN A LARGE-SCALE U.S. ADMINISTRATIVE CLAIMS DATABASE / P. Herzog* - A.-C. Fu - J. Lim - D. C. Taylor FRI0247 GOUT CHARACTERISTICS AND ITS ASSOCIATION WITH THE PRESENCE OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY / S. J. Lopez Salguero* - M. Andrés Collado FRI0248 VALIDITY OF RANDOM URINARY URIC ACID-TO-CREATININE RATIO FOR ESTIMATING 24-HOUR URINE URIC ACID EXCRETION IN PATIENTS WITH GOUT / S. Choi* - S.-J. Moon - E.-J. Kang - K.-H. Lee FRI0249 AUDIT OF THE MANAGEMENT OF GOUT -ARE WE DOING IT RIGHT? / T. J. Khan* - S. Kamath - E. Roddy FRI0250 BELIEFS ABOUT MEDICINES AMONG GOUT PATIENTS - DATA FROM THE NOR-GOUT STUDY / T. Uhlig* - L. F. Karoliussen - J. Stjärne - E. A. Haavardsholm - T. K. Kvien - H. B. Hammer FRI0251 PREVALENCE OF GOUT AND THE USE OF URATE LOWERING AGENTS IN US GENERAL POPULATION NHANES / T. T. Cheung* - M. F. Tsoi - B. M. Y. Cheung - W. C. S. Lau FRI0252 TESTING FOR A CAUSAL ROLE OF MITOCHONDRIAL VARIATION IN THE DEVELOPMENT OF GOUT / T. R. Merriman* - A. Shaukat - A. Gosling - M. Bixley - N. Dalbeth - L. Stamp - E. Matisoo-Smith - J. Harre Hindmarsh - L. Joosten - T. Jansen - M. Janssen - A.-K. Tausche - P. Riches FRI0253 TRENDS FOR GOUT IN ADULTS IN AN URBAN AREA FOR A 5-YEAR PERIOD: INCIDENCE, PREVALENCE AND HOSPITALIZATION RATES / V. Dostanko* - V. Yagur - V. Apanasovich - N. Dostanko - A. Rekun FRI0254 CLINICAL FEATURES AND RISK FACTORS FOR DEVELOPING GOUT ATTACKS DURING ANTI-TUBERCULOSIS MEDICATION: A CASE-CONTROL STUDY IN SOUTH KOREA / Y.-J. Ha* - S. W. Chung - J. Lee - E. H. Kang - Y. J. Lee - Y. W. Song TOPIC: SLE, SJÖGREN S AND APS - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS Poster tour F7: Abstracts N : The enemy in us Martin Herrmann (Germany), Yi Zhao (China) FRI0255-FRI0263 FRI0255 INJECTION OF CD40 DNA VACCINE AMELIORATES THE AUTOIMMUNE PATHOLOGY OF NON-OBESE DIABETIC MICE WITH SJÖGREN S SYNDROME / Y.-B. Zhou* - X. Yuan - Q.-K. Wang - H. Zhang - G.-S. Wang - X.-P. Li - Y.-P. Wang - X.-M. Li FRI0256 EFFECTS OF ANIFROLUMAB ON OXIDATIVE STRESS AND MACROPHAGE ACTIVATION: NOVEL BIOMARKERS AND IMPACT OF TYPE I INTERFERON BLOCKADE IN SYSTEMIC LUPUS ERYTHEMATOSUS / X. Guo* - S. Wang - L. Wang - L. K. Roskos - W. I. White FRI0257 THE STAT4 SLE RISK ALLELE RS [T] IS ASSOCIATED WITH INCREASED IL-12-INDUCED IFN-GAMMA PRODUCTION IN T CELLS FROM SLE PATIENTS / N. Hagberg* - M. Joelsson - D. Leonard - S. Reid - M.-L. Eloranta - J. Mo - M. Nilsson - A.-C. Syvänen - Y. T. Bryceson - L. Rönnblom FRI0258 COMPARISON OF ELISA AND MULTIPLEX TECHNIQUES FOR QUANTIFYING A URINE BIOMARKERS PANEL FOR LUPUS NEPHRITIS IN CHILDREN / E. M. Smith* - M. W. Beresford FRI0259 IN VITRO INDUCED REGULATORY T CELLS CAN AMELIORATE SEVERITY OF PRISTANE INDUCED LUPUS (PIL) / B. Jacobs* - H. Leiss - I. Gessl - A. Puchner - J. Smolen - G. Stummvoll * Presenting author

113 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 111 FRI0260 POLYMORPHISMS OF STAT4 AND MIR146A PREDICT THE ACHIEVEMENT OF 5 YEARS REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Perricone* - C. Ciccacci - F. Ceccarelli - G. Mettola - I. Leccese - F. R. Spinelli - C. Alessandri - C. Politi - A. Latini - G. Novelli - G. Valesini - P. Borgiani - F. Conti FRI0261 ASSESSMENT OF AUTOPHAGE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RESPECT OF HYPERLIPIDEMIA AND IMMUNOSUPPRESSIVE DRUGS / A. S. Hamada* - M. I. Aref - W. A. Salahdin FRI0262 MONITORING DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIGITAL ELISA QUANTIFICATION OF SERUM INTERFERON-Α / S. Mouries-Martin* - A. Mathian - K. Dorgham - H. Devilliers - F. Cohen-Aubart - L. N. Garrido Castillo - J. Haroche - M. Hie - M. Pineton De Chambrun - M. Miyara - M. Pha - D. Lê Thi Huong - F. Rozenberg - G. Gorochov - Z. Amoura FRI0263 CHARACTERIZATION OF EPITHELIUM-ASSOCIATED FCRL4+ B CELLS FROM PAROTID GLANDS OF PATIENTS WITH SJÖGREN S SYNDROME USING SINGLE CELL RNA SEQUENCING / G. M. Verstappen* - J. A. Ice - H. Bootsma - S. A. Pringle - E. A. Haacke - F. K. Spijkervet - C. J. Lessard - F. G. Kroese FRI0264 ROLE OF P-GP IN PATHOGENIC CONVERSION OF TH17 CELLS IN LUPUS NEPHRITIS LEADING TO GLUCOCORTICOID RESISTANCE / A. Jaiswal* - M. K. Rai - V. Agarwal - N. Prasad FRI0265 ANGIOGENIC T CELLS IN PRIMARY SJÖGREN S SYNDROME: A DOUBLE-EDGED SWORD / A. Alunno* - M. Manetti - O. Bistoni - S. Cipriani - L. Ibba Manneschi - R. Gerli FRI0266 CD16+ MONOCYTE SUBSETS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, PRIMARY ANTIPHOSPHOLIPID SYNDROME, AND ANTIPHOSPHOLIPID SYNDROME WITH LUPUS ARE ASSOCIATED WITH SPECIFIC CLINICAL/SEROLOGICAL FEATURES OF THESE DISEASES / C. Perez-Sanchez* - N. Barbarroja - M. A. Aguirre - P. Ruiz-Limon - M. C. Abalos - Y. Jimenez-Gomez - I. Arias de la Rosa - P. Segui - R. Ortega - E. Collantes - A. Escudero - L. Le Lann - C. Jamin - M. Alarcon - J. O. Pers - C. Lopez-Pedrera FRI0267 CHARACTERIZATION OF THE MOLECULAR PROFILE OF ALTERED GENES AND PATHWAYS IN MONOCYTES OF ANTIPHOSPHOLIPID SYNDROME PATIENTS RELATED TO THEIR ATHEROTHROMBOTIC STATUS. EFFECTS OF IN VIVO UBIQUINOL SUPPLEMENTATION / C. Perez-Sanchez* - M. A. Aguirre - L. Perez-Sanchez - M. Luque-Tevar - N. Barbarroja - P. Ruiz-Limon - Y. Jimenez-Gomez - I. Arias de la Rosa - M. C. Abalos - P. Segui - J. M. Villalba - E. Collantes - M. J. Cuadrado - C. Lopez-Pedrera FRI0268 GLUCOCORTICOID-INDUCED LEUCINE ZIPPER (GILZ) REPRESENTS A CHECKPOINT LIMITING TYPE I INTERFERON (IFN) PRODUCTION IN SLE / C. T. Nataraja* - E. F. Morand - J. Thomas - J. Harris - S. A. Jones FRI0269 DEFICIENCY OF GLUCOCORTICOID-INDUCED LEUCINE ZIPPER (GILZ) DISINHIBITS IFN PATHWAYS AND EXACERBATES NEPHRITIS IN THE LYN-DEFICIENT MURINE MODEL OF LUPUS / C. T. Nataraja* - E. F. Morand - J. Thomas - J. Harris - S. A. Jones FRI0270 IDENTIFICATION OF NOVEL DYSREGULATED INTERFERON-INDUCIBLE NON-CODING RNAS IN SJÖGREN S SYNDROME / N. Means - J. A. Ice - I. Adrianto - A. M. Stolarczyk - M. L. Joachims - A. Rasmussen - J. M. Guthridge - J. A. James - R. H. Scofield - K. L. Sivils - C. J. Lessard* FRI0271 DIMETHYL FUMARATE INHIBITS UBE2L3 MEDIATED TLR7 SIGNALLING AND AUTOREACTIVE B CELL DEVELOPMENT IN SLE / D. Mauro* - V. Tsang - I. Lucey-Clayton - F. Rivellese - S. Pagani - F. Alam - E. Pontarini - A. Nerviani - A. Pakozdi - R. Rajakariah - D. Pyne - T. J. Vyse - C. Pitzalis - M. J. Lewis FRI0272 PHARMACODYNAMIC EFFECTS OF ATACICEPT TREATMENT IN A CYNOMOLGUS MONKEY KLH ANTIGEN CHALLENGE MODEL / E. Samy* - A. Bender - Y. Wu - V. Castagna - E. Bertotti - R. Boggio - A. Paoletti - S. Riva - P. Schneider - P. Haselmayer - J. DeMartino FRI0273 RNA SEQUENCING DETECTION OF GENE DYSREGULATION IN EPITHELIAL SORTED CELLS FROM SALIVARY GLAND TISSUE REVEALS INTERESTING PATHWAYS INVOLVED IN SJÖGREN S SYNDROME PATHOPHYSIOLOGY / E. Rivière* - N. Tchitchek - G. Nocturne - S. Boudaoud - J. Pascaud - A. Virone - A. Thai - N. Allaire - B. Jagla - M. Mingueneau - X. Mariette FRI0274 ELEVATED REACTIVITY OF CD38HIGHIGD+ B CELLS AGAINST BAFF CONTRIBUTES TO IGG OVERPRODUCTION IN PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / E. Ishioka-Takei* - K. Yoshimoto - K. Suzuki - H. Yasuoka - K. Yamaoka - T. Takeuchi FRI0275 ALTERED PROTEIN TYROSINE PHOSPHATASES ACTIVITY AND DISEASE SPECIFIC EXPRESSION PATTERN OF CD45 AND CD148 ON VARIOUS LYMPHOCYTE SUBSETS IN AUTOIMMUNE DISEASES / F. Szelinski* - S. Fleischer - S. Weißenberg - K. Reiter - T. Dörner FRI0276 ABERRANT DISTRIBUTION OF CD3+CD56+ NKT-LIKE CELLS IN PATIENTS WITH SJÖGREN S SYNDROME / H. Chen* - L. Zhao - W. Xu - Z. Chen - J. Sun - F. Zhang FRI0277 METFORMIN REDUCES SALIVARY GLAND INFLAMMATION BY CONTROLLING B CELL DIFFERENTIATION AND REGULATING BALANCE OF TH17 AND TREG CELL IN NON-OBESE DIABETIC MICE / J.-W. Kim* - S.-M. Kim - J. Lee - S.-K. Kwok - J. H. Ju - S.-H. Park FRI0278 ALTERATIONS IN MEMORY AND VISIO-SPATIAL LEARNING IN A PRISTANE-INDUCED LUPUS BALB/C MICE / J. Luciano Jaramillo* - F. Sandoval Garcia - E. A. Martinez Garcia - M. Vazquez Del Mercado - B. T. Martin Marquez FRI0279 DECREASED SPHINGOSIN-1-PHOSPHATE RECEPTOR 1 (S1P1) EXPRESSION IN ENDOTHELIAL PROGENITOR CELLS (EPCS) FROM SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS / J. Romo-Tena* - D. Gómez-Martín - L. P. Blanco - C. Carmona-Rivera - R. Carazo-Vargas - J. Alcocer-Varela - M. J. Kaplan FRI0280 A MOLECULAR NETWORK FOR FATIGUE IN PRIMARY SJÖGREN S SYNDROME / K. Bårdsen* - C. Brede - I. Kvivik - J. T. Kvaløy - K. Jonsdottir - A. B. Tjensvoll - P. Ruoff - R. Omdal FRI0281 TRANSCRIPTOMIC PROFILING OF PDCS FROM PATIENTS WITH PSS IDENTIFIES CONSISTENTLY ALTERED GENE NETWORKS THAT INDICATE AN ACTIVATED PHENOTYPE AND ENHANCED ANTI-VIRAL STATE / M. R. Hillen* - A. Pandit - S. L. M. Blokland - S. A. Y. Hartgring - K. M. G. van der Wurff-Jacobs - A. A. Kruize - M. Rossato - J. A. G. van Roon - T. R. D. J. Radstake FRI0282 MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 ON MONOCYTES IS A NOVEL BIOMARKER OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS / M. Ushikubo* - S. Saito - J. Kikuchi - M. Takeshita - K. Yoshimoto - H. Yasuoka - K. Yamaoka - N. Seki - K. Suzuki - H. Oshima - T. Takeuchi FRI0283 DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI) DEMONSTRATES HIPPOCAMPUS PERMEABILITY IN SLE / M. Mackay* - B. Diamond - D. Eidelberg - A. Hoang - P. C. Sanelli 15 June 2018 * Presenting author

114 112 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0284 ALTERED PATTERNS OF HISTONE ACETYLATION POINT TO MECHANISMS OF TRANSCRIPTIONAL DYSREGULATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / B. Anić - A. Blažeković - D. Bosnić - M. Sentić - M. Mayer* - M. Cerovec - K. Gotovac Jerčić - F. Borovečki FRI0285 DETECTION OF OLIGOCLONAL B CELL POPULATIONS BY SPECTRATYPING ANALYSIS IN THE RENAL TISSUE OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS / P. Sfikakis* - K. Kolovou - M. Roumelioti - D. Paleologou - M. Tektonidou - C. Kyrtsoni - J. Boletis - P. Panayiotidis - S. Marinaki FRI0286 RANK-L IS EXPRESSED BY SALIVARY GLAND EPITHELIAL CELLS IN PRIMARY SJÖGREN S SYNDROME: A NOVEL ACTOR IN ECTOPIC LYMPHOID STRUCTURE NEOGENESIS / P.-M. Duret* - R. Veber - R. Felten - F. Monneaux - C. Mueller - J. Sibilia - H. Dumortier - J.-E. Gottenberg FRI0287 SEROLOGIC EVIDENCE OF VIRAL REACTIVATION AND INCREASED DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / R. Wood* - L. Guthridge - E. Thurmond - C. Guthridge - H. Chen - W. dejager - S. Macwana - R. L. Bourn - S. Kamp - R. Lu - C. Arriens - E. F. Chakravarty - A. Thanou - J. Merrill - J. Guthridge - J. A. James FRI0288 THYMIC STROMAL LYMPHOPOIETIN (TSLP) BIOLOGICAL EFFECTS ON HUMAN PERIPHERAL BLOOD B LYMPHOCYTES IN PRIMARY SJÖGREN S SYNDROME / S. Gandolfo* - M. Bulfoni - C. Fabro - E. Doriguzzi Breatta - L. Quartuccio - C. Di Loreto - D. Cesselli - S. De Vita FRI0289 ROLE OF CXCL13 AND CXCL12 IN SJÖGREN S SYNDROME: ASSOCIATION WITH HISTOLOGICAL, CLINICAL AND LABORATORY FEATURES / S. Colafrancesco* - R. Priori - E. Pipi - J. Campos - S. Nayar - B. Cerbelli - F. Arienzo - C. Giordano - M. Bombardieri - G. Valesini - F. Barone FRI0290 PRO-INFLAMMATORY CYTOKINES PROMOTE GLOBAL AND GENE-SPECIFIC CHANGES IN DNA METHYLATION IN SALIVARY GLANDS FROM SJÖGREN S SYNDROME PATIENTS / C. Lagos - S. Aguilera* - P. Carvajal - D. Jara - I. Castro - S. González - U. Urzua - M. J. Barrera - C. Molina - C. Leyton - M.-J. González FRI0291 CHARACTERIZATION OF MONOCYTE POPULATIONS IN PERIPHERAL BLOOD OF SLE PATIENTS / S. M. Anderson* - D. Shah - D. Webb - P. Adusumalli - S. Visvanathan - J. Fine - G. Nabozny - M. Ramanujam FRI0292 DYSFUNCTION OF TFH, TREG AND TR1 CELLS IN APOE-/- FASLGLD C57BL/6 MICE WITH LUPUS SYMPTOMS AND ATHEROSCLEROSIS / S. Wang* - G. Yao - L. Sun FRI0293 IMBALANCE IN CIRCULATING SUBSETS OF INNATE LYMPHOID CELLS IS LINKED TO DISEASE ACTIVITY AND TYPE I INTERFERON SIGNATURE IN PRIMARY SJÖGREN S SYNDROME / S. L. Blokland* - L. L. van den Hoogen - E. F. Leijten - A. A. Kruize - T. R. Radstake - J. A. van Roon FRI0294 INJURED PODOCYTES EXPRESS COMPLEMENT FACTOR H AND PROCESS IMMUNE COMPLEX DEPOSITION IN GLOMERULAR SUBENDOTHELIAL AREA / T. Zoshima* - S. Hara - M. Nagata - M. Kawano FRI0295 INHIBITION OF CATHEPSIN S LEADS TO SUPPRESSION OF ANTIGEN SPECIFIC T CELLS FROM PATIENTS WITH PRIMARY SJÖGREN SYNDROME / P. Hargreaves - M. Theron - F. A. Kolb - M. Manchester - B. Reis - A. Tiaden - D. Kyburz - T. Manigold* FRI0296 KZR-616, A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME, BLOCKS THE DISEASE PROGRESSION IN MULTIPLE MODELS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Muchamuel* - J. L. Anderl - R. A. Fan - H. W. B. Johnson - C. J. Kirk - E. Lowe FRI0297 MACROPHAGE-DERIVED LCN2 CONTRIBUTES TO DEVELOPMENT OF LUPUS NEPHRITIS / W. Chen* - L. Sun FRI0298 ALTERED FREQUENCIES OF CIRCULATING INNATE LYMPHOID CELLS AND ITS SUBSETS ARE CORRELATED WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / Y. Jiang* - Y. Zhao - Y. Liu - X. Mo FRI0299 MUCOSAL-ASSOCIATED INVARIANT T CELL DEFICIENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS IS REALTED TO AN INTRINSIC DEFECT IN THE CA2+/CALCINEURIN/NFAT1 SIGNALING PATHWAY / Y.-W. Park* - Y.-N. Cho - H.-M. Jin - S.-J. Kee FRI0300 POLYMORPHISM OF 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (C677T) IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, ITS ASSOCIATION WITH CARDIOVASCULAR LESIONS / Y. Seheda* - S. Shevchuk - I. Kuvikova - O. Galiutina FRI0301 SERUM EXOSOMES INVOLVED IN THE PROGRESSION OF LUPUS NEPHRITIS / Z. Zhang* - W. Xue - J. Ji - T. Fu - J. Yang - Z. Gu TOPIC: SLE, SJÖGREN S AND APS - TREATMENT Poster tour F8: Abstracts N : Back to the future: how to mix the old and new treatments for SLE, Sjögren s and APS Angela Tincani (Italy), Micaela Fredi (Italy) FRI0302-FRI0311 FRI0302 FRI0303 FRI0304 FRI0305 SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED THROMBOTIC MICROANGIOPATHIES IN 60 PATIENTS: CLINICAL FEATURES, PROGNOSIS AND TREATMENT IN A FRENCH MULTICENTRIC COHORT / P. Couture* - M. Hié - M. Pineton de Chambrun - L. Galicier - N. Costedoat-Chalumeau - A. Deroux - T. Kanouni - M. Roumier - I. Melki - A. Mathian - P. Coppo - Z. Amoura EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A PHASE 2, RANDOMISED PLACEBO-CONTROLLED STUDY / R. van Vollenhoven* - B. H. Hahn - G. C. Tsokos - C. Wagner - P. Lipsky - B. Hsu - M. Chevrier - R. Gordon - M. Triebel - S. Rose LONG-TERM AND LOW-DOSE IL-2 THERAPY MAINTAINS THE TH17/TREG BALANCE IN PERIPHERAL BLOOD OF PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / M. Miao* - Z. Hao - Y. Guo - X. Zhang - S. Zhang - J. Luo - C. Zhang - X. Zhao - X. Liu - X. Wu - D. Xu - J. Zhao - C. Gao - X. Li PHASE 2 TRIAL OF INDUCTION THERAPY WITH ANTI-CD20 (RITUXIMAB) FOLLOWED BY MAINTENANCE THERAPY WITH ANTI-BAFF (BELIMUMAB) IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS / C. Aranow* - M. Dall Era - M. Byron - L. Ding - D. Smilek - B. Diamond - D. Wofsy on behalf of the CALIBRATE investigators and Lupus Nephritis Trials Network * Presenting author

115 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 113 FRI0306 DEVELOPMENT OF BAFF AND ICOSL BISPECIFIC INHIBITOR AMG 570 FOR SLE TREATMENT / H. Hsu* - M. Zhang - K. Miner - G. Kevin - J. Whoriskey - R. Jacobsen - C. Chen - K. Ishida FRI0307 TBK1 INHIBITION DOWNREGULATES EXPRESSION OF INTERFERON TYPE I AND THE UPREGULATED EXPRESSION OF RIG-LIKE RECEPTORS AND DNA-SENSING RECEPTORS IN INTERFERON POSITIVE PRIMARY SJÖGREN S SYNDROME PATIENTS / I. Bodewes* - E. Huijser - C. van Helden-Meeuwsen - L. Tas - R. Huizinga - V. Dalm - M. van Hagen - N. Groot - S. Kamphuis - P. van Daele - M. Versnel FRI0308 CORTICOSTEROIDS COMBINED WITH DOUBLET OR SINGLE-AGENT IMMUNOSUPPRESSIVE THERAPY FOR ACTIVE PROLIFERATIVE LUPUS NEPHRITIS / B. Liu* - Y. Yu - Y. Tang - S. Fu - P. Liang - A. Xu FRI0309 THE IMPACT OF BELIMUMAB AND RITUXIMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I. Parodis* - A. H. Lopez Benavides - A. Zickert - S. Pettersson - S. Möller - E. Welin Henriksson - A. Voss - I. Gunnarsson FRI0310 ACHIEVEMENT OF LOW DISEASE ACTIVITY IN LUPUS PATIENTS TREATED WITH BELIMUMAB IS INDEPENDENT OF SEROLOGIC STATUS AT BASELINE: A REAL-LIFE OBSERVATIONAL STUDY / A. Fanouriakis* - C. Adamichou - S. Koutsoviti - S. Panopoulos - C. Staveri - A. Klagou - C. Tsalapaki - L. Pantazi - S. Konsta - C. P. Mavragani - D. Dimopoulou - S. Ntali - G. Katsikas - K. A. Boki - D. Vassilopoulos - P. Konstantopoulou - S.-N. Liossis - A. Elezoglou - M. Tektonidou - P. Sidiropoulos - A. Erden - P. P. Sfikakis - G. Bertsias - D. T. Boumpas FRI0311 THE EFFECT OF B CELL TARGETED THERAPIES ON AUTOANTIBODIES AND EXCESSIVE NEUTROPHIL EXTRACELLULAR TRAP FORMATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / L. S. Van Dam* - Z. Osmani - T. Kraaij - S. W. Kamerling - J. A. Bakker - H. U. Scherer - T. J. Rabelink - R. E. Voll - D. Isenberg - C. van Kooten - Y. O. Teng FRI0312 ARTHRITIS IN PRIMARY SJÖGREN S SYNDROME: CHARACTERISTICS, OUTCOME AND TREATMENT FROM FRENCH MULTICENTER RETROSPECTIVE STUDY / A. Mirouse* - R. Séror - E. Vicaut - X. Mariette - M. Dougados - A.-L. Fauchais - A. Deroux - N. Costedoat-Chalumeau - J. Sellam - J.-B. Arlet - C. Lavigne - O. Fain - A. Mékinian on behalf of Club Rhumatismes Inflammation and SNFMI FRI0313 A RITUXIMAB AND BELIMUMAB COMBINATION THERAPY IN SLE PATIENTS / A. A. Mesnyankina* - S. K. Soloviev - E. N. Aleksandrova - A. P. Aleksankin - A. A. Novikov - E. A. Aseeva - E. L. Nasonov FRI0314 RISK OF OPHTHALMOLOGIC COMPLICATIONS AS A RESULT OF HYDROXYCHLOROQUINE THERAPY / A. Khaleel* FRI0315 SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF BIIB059, A MONOCLONAL ANTIBODY TARGETING BDCA2 FOLLOWING INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) SINGLE OR MULTIPLE DOSES ADMINISTRATION IN HEALTHY VOLOUNTEERS (HV) AND SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / C. Barbey* - H. Naik - C. Musselli - R. Christmann - L. Stevenson - D. Rabah - P. Gulati - N. Franchimont FRI0316 THE PRESENCE OF ANTI-RITUXIMAB ANTIBODIES PREDICTS INFUSION-RELATED REACTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUS / C. Wincup* - M. Menon - E. Smith - E. C. Jury - D. A. Isenberg - C. Mauri on behalf of ABIRISK Consortium FRI0317 REASONS FOR HOSPITALIZATION AND IMMUNOSUPPRESSANT USE IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ADMITTED TO A TERTIARY ACADEMIC MEDICAL CENTER / C. Anastasiou* - O. Dulai - A. Baskaran - J. Proudfoot - S. Verhaegen - K. Kalunian FRI0318 HEALTH CARE RESOURCE UTILIZATION (HCRU) AND COST ANALYSES OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AS A FUNCTION OF DISEASE SEVERITY: ANALYSIS OF REAL-WORLD CLAIMS DATA FROM A GERMAN SICKNESS FUND / E. R. Hammond* - H. Friedel - E. Garal-Pantaler - M. Pignot - E. Velthuis - X. Wang - H. Nab - B. Desta - A. Schwarting FRI0319 A PRACTICAL SIMPLE DOSE ESCALATION REGIMEN FOR MILD HYDROXYCHLOROQUINE-INDUCED HYPERSENSITIVITY REACTION / E. Takamasu* - Y. Nasa - H. Takahashi - S. Sugii - N. Yokogawa FRI0320 ANTIMALARIALS PROTECTIVE EFFECTS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINA / F. Wang* - W. Zhang - X. Feng - L. Sun FRI0321 SURVIVAL RATE AND CAUSES OF WITHDRAWAL OF BELIMUMAB TREATMENT IN SLE IN A REAL LIFE SETTING / F. Morello* - F. R. Spinelli - F. Ceccarelli - L. Massaro - L. Novelli - F. Miranda - C. Perricone - S. Truglia - C. Alessandri - G. Valesini - F. Conti FRI0322 RATIONALE FOR THE ATACICEPT DOSE FOR A PHASE III STUDY IN PATIENTS WITH HIGHLY ACTIVE AND AUTO- ANTIBODY POSITIVE SLE / J. Shen* - O. Papasouliotis - E. Samy - P. Haselmayer - P. Chang - V. Ona - A. Kao FRI0323 APREMILAST THERAPY IN REFRACTORY SKIN LUPUS LESIONS / J. L. Martín-Varillas* - J. Loricera - S. Armesto - E. Cuende - V. Calvo-Río - C. González-Vela - B. Atienza-Mateo - J. L. Hernández - M. A. González-Gay - R. Blanco FRI0324 IMMUNOSUPPRESSION FOR PRIMARY SJÖGREN S SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS / L. Chu* - K. Cui - J. Pope FRI0325 RITUXIMAB IN PRIMARY SJÖGREN S SYNDROME: A SYSTEMATIC REVIEW ON ITS EFFICACY / M. Greco* - J. Del Pino Montes - P. Díaz del Campo - M. Fernández Castro - F. Francisco - J. L. Andreu FRI0326 IMMUNE CELLULAR PROFILE ASSOCIATED WITH DIFFERENT TREATMENT OUTCOME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ON CYCLOPHOSPHAMIDE / G. Gabcova - M. Skacelova* - Z. Mikulkova - P. Horak - S. Zehnalova - A. Smrzova - F. Mrazek - V. Smotkova Kraiczova - M. Kudelka - E. Kriegova FRI0327 RELIABILITY OF LA AND DIAGNOSTIC PERFORMANCE OF APS/PT IN DIFFERENT CLINICAL SETTINGS OF APS: A MULTICENTER STUDY / M. Radin* - I. Cecchi - E. Rubini - A. M. Scotta - R. Rolla - B. Montaruli - P. Pergolini - G. Mengozzi - E. Muccini - D. Roccatello - S. Sciascia FRI0328 TARGETED THERAPY USING INTRADERMAL INJECTION OF ETANERCEPT FOR REMISSION INDUCTION IN DISCOID LUPUS ERYTHEMATOSUS (TARGET-DLE): FIRST RESULTS FROM A PROOF-OF-CONCEPT PHASE 2 TRIAL / M. Y. Md Yusof* - M. Wittmann - C. Fernandez - D. Wilson - S. Edward - G. Abignano - A. Alase - L. Sharples - P. Laws - M. J. Goodfield - E. M. Vital - P. Emery FRI0329 THE NET-EFFECT OF COMBINING RITUXIMAB WITH BELIMUMAB IN SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS / O. Teng* - T. Kraaij - S. Kamerling - E. de Rooy - P. van Daele - O. Bredewold - J. Bakker - I. Bajema - H. Scherer - R. Toes - T. Huizinga - T. Rabelink - C. van Kooten 15 June 2018 * Presenting author

116 114 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0330 RITUXIMAB THERAPY IN SLE: EARLY RETREATMENT IS ASSOCIATED WITH LOWER DISEASE ACTIVITY AND A REDUCTION IN CORTICOSTEROID USE / R. L. Batten* - S. Batool - C. E. Kidd - A. Lorenzi - J. Vila - K. Walker - B. Griffiths FRI0331 TROUGH CONCENTRATION OF MYCOPHENOLIC ACID CORRELATES WITH RENAL FUNCTION AND SERUM ALBUMIN LEVEL IN JAPANESE PATIENTS WITH SLE / R. Hiwa* - K. Murakami - M. Mori - S. Nakagawa - S. Akizuki - N. Kuramoto - R. Nakashima - M. Hashimoto - H. Yoshifuji - M. Tanaka - K. Ohmura - T. Mimori FRI0332 THE EXTENT OF TUBULOINTERSTITIAL INFLAMMATION PREDICTS THE PROGNOSIS OF TREATED PATIENTS WITH LUPUS NEPHRITIS / S. J. Lee* - Y. J. Kim - S. Jae Seok - N. R. Kim - E. J. Nam - Y. M. Kang FRI0333 B CELLS DEPLETION AS RESCUE THERAPY FOR EXTRA-CRITERIA MANIFESTATIONS OF PRIMARY ANTIPHOSPHOLIPID SYNDROME / S. Sciascia* - M. Radin - I. Cecchi - E. Rubini - D. Rossi - M. Bazzan - D. Roccatello FRI0334 COMPARISON OF DIFFERENT DEFINITIONS OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A STUDY BASED ON THE BLISS-76 CLINICAL TRIAL / S. Emamikia* - C. Gentline - E. Arkema - L. Arnaud - K. Chatzidionysiou - R. van Vollenhoven FRI0335 HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES - A 20 YEARS SINGLE CENTER EXPERIENCE / T. Alexander* - L. Templin - A. Grützkau - H. Hirseland - A. Thiel - G. Burmester - A. Radbruch - R. Arnold - F. Hiepe FRI0336 BELIEF ABOUT MEDICINE QUESTIONNAIRE PREDICTS THERAPEUTIC ADHESION TO HYDROXYCHLOROQUINE DURING SYSTEMIC LUPUS ERYTHEMATOSUS / Y. Rozban* - H. Devilliers - M. Hié - P. Micheline - A. Mathian - F. Cohen-Aubart - H. Julien - N. Zahr - Z. Amoura FRI0337 FACTORS ASSOCIATED WITH POOR THERAPEUTIC ADHERENCE TO HYDROXYCHLOROQUINE DURING SYSTEMIC LUPUS / Y. Rozban* - H. Devilliers - M. Hié - M. Pha - A. Mathian - F. Cohen-Aubart - J. Haroche - J.-S. Hulot - N. Zahr - Z. Amoura FRI0338 HYDROXYCHLOROQUINE MAY HELP TO IMPROVE THE IN VITRO FERTILIZATION-EMBRYO TRANSFER OUTCOMES IN ANA AND DS-DNA POSITIVE PATIENTS / F. Lian - J. Zhou - Y. Wang* - H. Xu - X. Yang FRI0339 SLEDAI-2K RESPONDER INDEX-50 IS EFFECTIVE IN DEMONSTRATING PARTIAL RESPONSE IN A PHASE 2, RANDOMISED PLACEBO-CONTROLLED STUDY OF USTEKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS / Z. Touma* - M. B. Urowitz - D. D. Gladman - C. Wagner - B. Hsu - M. Chevrier - S. Rose - B. Zhou - R. Gordon FRI0340 DOSAGE OF HYDROXYCHLOROQUINE (PLAQUENIL) ONLINE SURVEY BY PATIENT ORGANISATION NVLE / Z. Osmani* - W. Zacouris-Verweij - S. Otter on behalf of Lupus APS committee TOPIC: SLE, SJÖGREN S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT) FRI0341 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) VERSUS CLINICAL REMISSION AS TREATMENT TARGETS IN THE FIRST 18 MONTHS OF SYSTEMIC LUPUS ERYTHEMATOSUS MANAGEMENT / A. Floris* - M. Piga - G. Cappellazzo - E. Chessa - M. Congia - A. Cauli - A. Mathieu FRI0342 DOES UNDERSTANDING SLE MATTER TO DISEASE ACTIVITY IN SLE PATIENTS? / A. S. Meara* - P. Hackenberger - J. Yedimenko - C. Rodman - S. P. Ardoin - E. Peters FRI0343 BLOOD CONCENTRATIONS OF COMPLEMENT SPLIT PRODUCT IC3B AND SERUM C3 ASSOCIATE WITH SLE DISEASE ACTIVITY / A. H. Kim* - V. Strand - D. Sen - Q. Fu - N. Mathis - M. Schmidt - R. Bruchas - N. Staten - P. Olson - C. Stiening - J. Atkinson FRI0344 SERUM FREE LIGHT CHAINS AS A FLARE BIOMARKER IN SYSTEMIC LUPUS ERYTHEMATOSUS / A. B. Rodriguez Cambron* - J. Jimenez Jimenez - M. A. Blazquez Cañamero - M. J. García De Yébenes - F. Rey Pazos - C. Macía Villa - M. Alcalde Villar - F. Cabero Del Pozo - P. Collado Ramos - E. Alvarez Andrés - A. Cruz Valenciano FRI0345 ASSOCIATION BETWEEN CIGARETTE SMOKING AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - AN UPDATED META-ANALYSIS OF CASE-CONTROL AND COHORT STUDIES / M. H. Y. Chua - I. A. T. Ng - A. Mak* FRI0346 NEUTROPENIA IN SYSTEMIC LUPUS: PREVALENCE, SPECIFIC FEATURES AND CLINICAL CONSEQUENCES. RESULTS FROM THE LARGE UPPER RHINE DATABASE LBBR / A. Meyer* - P.-E. Gavand - G. Blaison - T. Martin - A.-S. Korganow - A. Guffroy on behalf of LBBR study group FRI0347 PERFORMANCE OF POTENTIAL DEFINITIONS OF REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) VERSUS QUALITY OF LIFE OVER 5 YEARS IN SWEDISH PATIENTS WITH RECENT-ONSET SLE / M. Björk - R. Heijke - M. Frodlund - S. Ramagopalan - E. Alemao - C. Sjöwall* FRI0348 MBL2 GENE POLYMORPHISMS AND ITS ASSOCIATION WITH INFECTION IN BRAZILIAN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A 10-YEAR STUDY / C. F. Saldanha* - G. K. da Silva - N. Glesse - J. C. T. Brenol - J. A. B. Chies - O. A. Monticielo FRI0349 LOW TITER ANTI-PHOSPHOLIPID ANTIBODIES CONVEY AN INCREASED OBSTETRIC RISK / C. B. Chighizola* - F. Pregnolato - M. G. Raimondo - C. Comerio - C. Sobrino Grande - L. Trespidi - M. O. Borghi - M. Gerosa - B. Acaia - M. W. Ossola - A. Bulfoni - P. L. Meroni FRI0350 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS-50) IS A SIGNIFICANT PREDICTOR FOR DAMAGE ACCRUAL AND MORTALITY: A NORWEGIAN COHORT ANALYSIS / C. Sharma* - W. Raymond - G. Eilertsen - J. Nossent FRI0351 CLINICAL CHARACTERISTICS AND OUTCOMES OF EARLY-ONSET AND LATE-ONSET LUPUS NEPHRITIS AND ITS RISK FACTORS / C.-B. Choi* - S. Won - S.-C. Bae FRI0352 DAMAGE ACCRUAL IN A LARGE MONOCENTRIC COHORT OF PRIMARY SJÖGREN S SYNDROME PATIENTS: DETERMINANTS AND IMPACT ON PATIENT REPORTED OUTCOMES / C. Baldini* - F. Ferro - N. Luciano - E. Calabresi - E. Elefante - M. Mosca - S. Bombardieri FRI0353 DEVELOPMENT AND VALIDATION OF QUESTIONNAIRES TO ASSESS HEALTHCARE UTILIZATION AND ACCESS IN COHORTS OF PATIENTS WITH PRIMARY SJÖGREN S SYNDROME AT THE DIAGNOSIS AND DURING THE DISEASE COURSE / C. Seghieri* - T. Grillo Ruggieri - C. Baldini - L. Quartuccio - R. Priori - E. Bartoloni - F. Carubbi - M. Orlandi - S. Gandolfo - S. De Vita - S. Bombardieri on behalf of Italian Rheumatology Society-pSS study group and of the HarmonicSS - HARMONIzation and integrative analysis of regional, national and international Cohorts on pss towards improved stratification, treatment and health policy making group * Presenting author

117 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 115 FRI0354 URINE METABOLOMIC FINGERPRINT AS DIAGNOSTIC BIOMARKER FOR LUPUS NEPHRITIS / D. A. Herrera Van Oostdam* - C. Abud Mendoza - R. Flores Ramírez - M. Rodríguez Aguilar - M. Pierdant Pérez - M. U. Martínez Martínez FRI0355 PREDICTIVE ABILITY OF AVAILABLE 10 YEARS CARDIO-VASCULAR RISK ALGORITHMS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE STUDY ON 2 ITALIAN LUPUS COHORT / D. P. E. Margiotta* - S. Fasano - L. Navarini - L. Pierro - A. Riccardi - G. Dolcini - G. Valentini - A. Afeltra FRI0356 ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS IS CONSISTENTLY ASSOCIATED WITH INCREASED MORTALITY: A META-ANALYSIS / E. R. Hammond* - I. B. Murimi - D. H. Lin - H. Nab - H. Kan - O. Onasanya - J. C. Tierce - X. Wang - B. Desta - G. C. Alexander FRI0357 VALIDATION OF A DISEASE-SPECIFIC HEALTH - RELATED QUALITY OF LIFE MEASURE FOR RUSSIAN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL-RUSSIAN / E. Aseeva* - L. Vorobyova - S. Soloviev - G. Koilubaeva - S. Glukhova FRI0358 FACTORS ASSOCIATED WITH PULMONARY MANIFESTATIONS IN SJÖGREN SYNDROME / E. Judez* - C. Sanchez-Piedra - M. Fernández Castro - J. L. Andreu - J. Rosas - V. Martínez Taboada - A. Olivé on behalf of SjögrenSer project (GEEAS-SER) FRI0359 ROUTINE CLINICAL PATHOLOGY MEASUREMENTS ARE ASSOCIATED WITH RISK OF ORGAN DAMAGE ACCRUAL IN SLE / K. Zhang - S. Boyd - F. Petitjean - A. Hoi - R. Koelmeyer - E. Morand* - H. Nim FRI0360 DISEASE SEVERITY OF PROLIFERATIVE LUPUS NEPHRITIS IN MAGHREBIANS / F. Tamirou* - N. Costedoat-Chalumeau - G. Medkouri - E. Daugas - E. Hachulla - N. Jourde-Chiche - A. Karras - V. le Guern - V. Gnemmi - M. Jadoul - F. A. Houssiau FRI0361 PREGNANCY OUTCOMES AND THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM OUR 30 YEARS EXPERIENCE PREGNANCY CLINIC / F. Crisafulli* - M. G. Lazzaroni - L. Andreoli - M. C. Gerardi - L. Antolini - G. Parma - C. Benigno - A. Lojacono - S. Zatti - V. Cappa - S. Calza - F. Franceschini - A. Tincani FRI0362 PREVALENCE, RISK FACTORS, AND IMPACT ON MORTALITY OF NEUROPSYCHIATRIC LUPUS: A LARGE PROSPECTIVE SINGLE-CENTER STUDY / G. Y. Ahn* - D. Kim - S. Won - S. T. Song - H.-J. Jeong - I. W. Sohn - S. Lee - Y. B. Joo - S.-C. Bae FRI0363 POSITIVE REMODELING INDEX AND LOW ATTENUATION NON-CALCIFIED CORONARY PLAQUES: MARKERS OF VULNERABLE CORONARY PLAQUES IN SYSTEMIC LUPUS? / G. Stojan* - L. Magder - M. Petri FRI0364 CLINICAL AND DIAGNOSTIC SIGNIFICANCE OF IMMUNOGLOBULIN A RHEUMATOID FACTOR IN PRIMARY SJÖGREN S SYNDROME / H.-R. Kim* - K.-A. Lee - S.-H. Lee FRI0365 FACTORS ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / I.-W. Baek* - K.-J. Kim - Y.-J. Park - W.-U. Kim - C.-S. Cho FRI0366 PRIMARY RESPIRATORY DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM THE SPANISH RHEUMATOLOGY SOCIETY LUPUS REGISTRY (RELESSER) COHORT / J. Narvaez* - H. Borrell - F. Sánchez-Alonso - I. Rúa-Figueroa - F. J. Lopez-Longo - M. Galindo - J. Calvo-Alen - A. Fernández-Nebro - A. Olivé - J. L. Andreu - R. Blanco - M. Andres - J. J. Alegre - T. Cobo-Ibañez - G. Bonilla - A. Boteanu - E. Díez-Álvarez - M. Freire - M. Gantes - P. Garcia de la Peña - R. Garcia-Vicuña - J. Hernández Beiraín - M. L. Horcada - J. Ibañez - A. Juan Mas - N. Lozano-Rivas - J. L. Marenco - I. Castelvi - C. Montilla-Morales - M. Moreno - A. Pecondon-Español - E. Ruiz Lucea - A. Sanchez-Atrio - G. Santos-Soler - F. Toyos - E. Uriarte Isacelaya - T. R. Vazquez-Rodriguez - J. M. Nolla - J. M. Pego-Reigosa on behalf of EAS-SER (Systemic Diseases study group of the Spanish Society of Rheumatology) FRI0367 ASSOCIATION OF VITALITY AND SUBSEQUENT PHYSICAL FUNCTIONING IN SYSTEMIC LUPUS ERYTHEMATOSUS: ANALYSIS OF DATA FROM THE GERMAN LULA COHORT / J. Mucke* - G. Chehab - R. Fischer-Betz - J. Richter - B. Winkler-Rohlfing - M. Schneider - R. Brinks FRI0368 COMPARISON OF CLINICAL AND LABORATORY PROFILES IN 3575 SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH AND WITHOUT SJÖGREN S SYNDROME: DATA FROM A NATIONWIDE PATIENT REGISTRY (RELESSER) / J. G. Ovalles-Bonilla* - F. J. López-Longo - I. Rúa-Figueroa - M. Galindo - J. Calvo-Alen - R. D. González - B. Serrano - I. Janta - C. González - I. Monteagudo - J. C. Nieto - J. Martínez - C. N. Saenz - J. M. Pego-Reigosa FRI0369 PREGNANCY OUTCOMES IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES: INTERIM RESULTS FROM A SINGLE CENTRE COHORT STUDY / K. Schreiber* - M. Frishman - M. J. Cuadrado - K. Breen - S. Robinson - B. J. Hunt FRI0370 CLINICAL FEATURES AND OUTCOMES OF LUPUS NEPHRITIS WITH PODOCYTE INJURY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / K. Suzuki* - Y. Kaneko - R. Anan - H. Takei - T. Takeuchi FRI0371 CLINICAL CHARACTERISTICS AND OUTCOME OF ISOLATED LUPUS NEPHRITIS / K. Bugdayli - V. R. Chowdhary* - C. S. Crowson - L. Zand - M. P. Alexander - L. D. Cornell FRI0372 COMPARISON OF CLINICAL FEATURES BETWEEN YOUNG AND ELDERLY ONSET IN PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / M. Kojima* - Y. Kaneko - M. Tsukamoto - T. Takeuchi FRI0373 LONG-TERM FOLLOW-UP OF 320 CHILDREN BORN TO MOTHERS WITH SYSTEMIC AUTOIMMUNE DISEASES: A MULTICENTRE ITALIAN SURVEY FROM 24 RHEUMATOLOGY CENTERS / M. G. Lazzaroni* - C. Nalli - L. Andreoli - C. Carini - E. Bartoloni-Bocci - R. Gerli - C. B. Chighizola - M. Gerosa - P. L. Meroni - L. Sinigaglia - P. Conigliaro - R. Perricone - A. Corrado - F. Cantatore - S. D Angelo - M. Favaro - M. Larosa - A. Doria - A. Ruffatti - E. Generali - C. Selmi - M. Meroni - M. Cutolo - M. Padovan - M. Govoni - G. Pazzola - C. Salvarani - S. Peccatori - G. Paolazzi - I. Prevete - G. D. Sebastiani - G. Minisola - A. Brucato - V. Ramoni - R. Caporali - C. Montecucco - C. Tani - V. Signorini - M. Mosca - M. Trevisani - N. Malavolta - M. Vadacca - A. Afeltra - E. Vivaldelli - A. Maier - E. Visalli - R. Foti - L. Zuliani - A. Gabrielli - C. Campochiaro - E. Baldissera - M. G. Sabbadini - N. Romeo - A. Tincani FRI0374 MILDER CLINICAL PRESENTATION OF LUPUS NEPHRITIS AND IMPROVED RENAL SURVIVAL DURING THE LAST 50 YEARS: A MULTICENTRIC STUDY / M. Gatto* - G. Moroni - F. Raffiotta - P. G. Vercelloni - S. Quaglini - L. Sacchi - D. Gainfreda - A. Vaglio - R. A. Sinico - A. Doria 15 June 2018 * Presenting author

118 116 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0375 DELAYED LUPUS NEPHRITIS IN THE COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS PREDICTS A POORER RENAL RESPONSE TO INDUCTION THERAPY, RENAL FLARES, AND WORSE LONG-TERM RENAL OUTCOMES: A MULTICENTER, RETROSPECTIVE COHORT STUDY / M. Nakano* - K. Kubo - Y. Shirota - Y. Iwasaki - N. Tanaka - Y. Takahashi - S. Tateishi - H. Yamashita - M. Miyazaki - H. Sato - T. Igari - H. Kanda - H. Kaneko - T. Ishii - K. Fujio - A. Mimori FRI0376 DYSLIPIDEMIA AS A NEWLY RECOGNISED FACTOR ASSOCIATED WITH DAMAGE ACCRUAL IN EARLY DIAGNOSED SLE: RESULTS FROM THE MULTICENTER EARLY LUPUS PROJECT INCEPTION COHORT / M. Piga* - A. Zanetti - G. Carrara - C. A. Scirè - I. Prevete - G. D. Sebastiani - L. Coladonato - F. Iannone - A. Bortoluzzi - M. Govoni - C. Tani - M. Mosca - L. Iaccarino - A. Doria - M. Fredi - A. Tincani - F. R. Spinelli - F. Conti - F. Bellisai - M. Galeazzi - A. Mathieu FRI0377 THE RELATIONSHIP BETWEEN REMISSION AND HEALTH RELATED QUALITY OF LIFE IN A COHORT OF SLE PATIENTS / M. W. P. Tsang-A-Sjoe* - I. E. M. Bultink - M. Heslinga - L. H. van Tuyl - R. F. van Vollenhoven - A. E. Voskuyl FRI0378 ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION / M. Jordhani* - J. Seiti - V. Duraj - D. Ruci FRI0379 INFLAMMATORY JOINT INVOLVEMENT IS ASSOCIATED WITH SEVERE DRY EYE IN PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / M. Fernandez Castro* - C. Sanchez-Piedra - J. L. Andreu - V. Martínez Taboada - A. Olive - J. Rosas on behalf of SJÖGRENSER project (GEEAS-SER) FRI0380 ASSESSMENT OF SUBMANDIBULAR GLAND QUALITATIVE CHANGES USING SHEAR WAVE ELASTOGRAPHY IN PATIENTS WITH SJÖGREN S SYNDROME / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Nakazawa - T. Iwasaki - T. Hashimoto FRI0381 ARE THE ANTIPHOSPHOLIPID ANTIBODIES A NEW INDEPENDENT RISK FACTOR FOR ACCELERATED ATHEROSCLEROSIS / N. Stoilov* - V. Boyadzhieva - R. Rashkov - S. Stefanov FRI0382 A STUDY OF MCP1 AND LIPOCALIN AS URINARY BIOMARKERS IN LUPUS NEPHRITIS / R. Ramamoorthy* - T. N. Tamilselvam - B. Kumar FRI0383 CHANGES IN WHITE MATTER MICROSTRUCTURE CORRELATE WITH SF-36 MENTAL COMPONENT SUBSCORE IN INFLAMMATORY NPSLE / R. C. Monahan* - L. Beaart- van de Voorde - C. Magro-Checa - T. Huizinga - H. Middelkoop - M. van Buchem - I. Ronen - A. Kaptein - G. Steup-Beekman FRI0384 PRIMARY SJÖGREN S SYNDROME STRATIFIED BASED ON THE SEVERITY OF PATIENT-REPORTED FATIGUE / S. Gandolfo* - E. Doriguzzi Breatta - C. Fabro - S. Zandonella Callegher - L. Quartuccio - S. De Vita FRI0385 CLINICAL CHARACTERISTIC FEATURES OF BRAINSTEM ENCEPHALITIS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / S. Hirohata* - Y. Matsueda - Y. Arinuma - H. Kikuchi FRI0386 WORK DISABILITY AND QUALITY OF LIFE AMONG MULTI-ETHNIC MALAYSIAN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS / S. S. Shaharir* - F. Abu Bakar - M. S. Mohamed Said - R. Mohd FRI0387 FACTORS ASSOCIATED WITH OSTEOPOROSIS AND FRACTURE IN PATIENTS WITH SJÖGREN PRIMARY SYNDROME / T. Salman Monte* - V. Torrente-Segarra - C. Sanchez-Piedra - M. Fernández Castro - J. L. Andreu - A. Olivé - J. Rosas - V. Martínez Taboada on behalf of SJÖGRENSER project (GEEAS-SER) FRI0388 RISK OF PREVENTABLE ADMISSIONS AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS PRIOR AND SUBSEQUENT DIAGNOSIS / C.-F. Kuo - T.-T. Chung* - J.-S. Chen - M.-J. Chiou FRI0389 BIOMARKERS AS DISEASE ACTIVITY INDICANTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / V. Zivkovic* - T. Cvetkovic - B. Mitic - B. Stamenkovic - S. Stojanovic - M. Stojanovic - B. Radovanovic Dinic FRI0390 IMPAIRED OVARIAN RESERVE IN PATIENTS AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE- CONTROL STUDY / V. A. Pacucci* - F. Ceccarelli - V. D Ambrosio - T. Colasanti - C. Aliberti - F. R. Spinelli - C. Perricone - S. Truglia - F. Miranda - C. Alessandri - G. Perrone - A. Giancotti - G. Valesini - F. Conti FRI0391 THE RELATIONSHIP BETWEEN ESTROGEN RECEPTORS AND HYPERURICEMIA IN YOUNG FEMALE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / H.-J. Liu - L. Dai - X.-Y. Cai* - J.-D. Ma - Y.-Q. Mo FRI0392 THE RELATIONSHIP BETWEEN SALIVARY FLOW RATES, ORAL HEALTH ASSESSMENT AND ULTRASONOGRAPHIC SCORING OF THE MAJOR SALIVARY GLANDS IN SJÖGREN SYNDROME / Y. Yalçınkaya* - G. Mumcu - Z. Erturk - A. U. Unal - P. Atagunduz - H. Direskeneli - N. Inanc FRI0393 MATERNAL AND FETAL OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS / I. Y. Yii - L. Yang - H. K. Tan - L. K. Tan - J. Thumboo - Y. J. Poh* FRI0394 THE ROLE OF D-DIMER TEST AS A SCREENING TOOL FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AS COMPARED TO MATCHED CONTROL SUBJECTS / Y. J. Oh* - E. H. Park - J. W. Park - Y. W. Song - E. B. Lee FRI0395 SLE DISEASE ACTIVITY INDEX GLUCOCORTICOID INDEX (SLEDAI-2KG) IDENTIFIES MORE RESPONDERS THAN SLEDAI-2K / Z. Touma* - D. Gladman - J. Su - N. M. Anderson - M. B. Urowitz TOPIC: SYSTEMIC SCLEROSIS, MYOSITIS AND RELATED SYNDROMES - ETIOLOGY, PATHOGENESIS AND ANIMAL MODELS Poster tour F9: Shaping pathophysiology: new molecules - new views on pathways in SSc, myositis and related syndromes Ulf Müller-Ladner (Germany), Jeska de Vries (Netherlands) Abstracts N : FRI0396-FRI0406 FRI0396 THE ATM KINASE AND PTEN, DRIVE MYOFIBROBLASTS DIFFERENTIATION BY ACTIVATING THE TGFΒ AUTOCRINE LOOP / S. Xu* - I. Papaioannou - M. Ponticos - C. Denton - A. Wells - E. Renzoni - D. Abraham FRI0397 PECULIAR EXPRESSION OF AUTOPHAGY BIOMARKERS IN NECROTIZING AUTOIMMUNE MYOPATHY MUSCLE / M. Giannini* - F. Girolamo - A. Amati - A. Lia - L. Serlenga - D. D Abbicco - M. Tampoia - F. Iannone * Presenting author

119 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 117 FRI0398 SL-401, A NOVEL TARGETED THERAPY DIRECTED TO THE INTERLEUKIN-3 RECEPTOR (CD123), KILLS PLASMACYTOID DENDRITIC CELLS FROM SYSTEMIC SCLEROSIS PATIENTS / M.-D. Ah Kioon - R. Lindsay* - J. Chen - J. Gordon - R. Spiera - F. Barrat - C. Brooks FRI0399 RNAI-BASED IDENTIFICATION OF NOVEL DRUG TARGETS TO REDUCE ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDOMT) IN HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS: A TARGET DISCOVERY APPROACH FOR SCLERODERMA / C. Corallo* - J. Benschop - M. Grimbergen - J. Crawford - J. Meuldijk - R. A. Janssen - N. E. Vandeghinste - N. Giordano - M. A. Tessari FRI0400 THE AP1 TRANSCRIPTION FACTOR CJUN AMPLIFIES HEDGEHOG-INDUCED FIBROBLAST ACTIVATION AND TISSUE FIBROSIS / C. Bergmann - B. Merlevede* - C. Beyer - L. Hallenberger - A. Brandt - C. Dees - S. Pötter - A. Bozec - G. Schett - J. Distler FRI0401 THE TYROSINE PHOSPHATASE SHP2 CONTROLS TGFΒ-INDUCED STAT3 SIGNALING TO REGULATE FIBROBLAST ACTIVATION AND FIBROSIS / A. Zehender* - J. Huang - A.-H. Györfi - A.-E. Matei - C. Dees - C. Beyer - K. Gelse - A. Ramming - C. Bergmann - W. Birchmeier - O. Distler - G. Schett - J. Distler FRI0402 MICRORNA-125B REGULATES APOPTOSIS IN SYSTEMIC SCLEROSIS / A. Kozlova* - E. Pachera - B. Maurer - A. Jüngel - J. H. Distler - G. Kania - O. Distler FRI0403 MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS IN MYOSITIS: A CENTRAL PATHOGENIC PATHWAY FROM MOUSE TO MAN / O. Boyer* - A. Meyer - C. Boitard - C. Abad FRI0404 CHARACTERIZATION OF A MONOCYTES/MACROPHAGES CELL SUBSET CO-EXPRESSING BOTH M1 AND M2 PHENOTYPE MARKERS IN SYSTEMIC SCLEROSIS PATIENTS / S. Soldano* - A. C. Trombetta - B. Ruaro - V. Tomatis - R. Brizzolara - P. Montagna - S. Paolino - C. Pizzorni - V. Smith - P. Contini - A. Sulli - M. Cutolo FRI0405 A NOVEL ANIMAL MODEL FOR SYSTEMIC SCLEROSIS INDUCED BY IMMUNIZATION OF ANGIOTENSIN II RECEPTOR 1 / X. Yue* - F. Petersen - X. Wang - H. Heidecke - G. Riemekasten - X. Yu FRI0406 INCREASED FREQUENCY OF CIRCULATING CD163+ NON-CLASSICAL MONOCYTES IN SCLERODERMA AND ENHANCED DUAL POLARISATION TOWARDS M1 AND M2-LIKE PHENOTYPES IN MONOCYTE-DERIVED MACROPHAGES / A. Tam* - L. Reinke-Breen * - G. Trujillo - S. Xu - C. P. Denton - D. J. Abraham - G. Jarai - V. H. Ong FRI0407 DIPEPTIDYL-PEPTIDASE-4 (DPP4) IS A POTENTIAL NEW MOLECULAR TARGET FOR TREATMENT OF FIBROSIS / A. M. Soare* - H. Györfy - A. Matei - C. Dees - Y. Zhang - T. Wohlfahrt - C.-W. Chen - A. Ramming - G. Schett - J. Distler FRI0408 INVARIANT NATURAL KILLER T CELLS IN SYSTEMIC SCLEROSIS / A.-C. Pecher* - F. Kettemann - J. Henes - S. Duerr-Stoerzer - C. Schneidawind - L. Kanz - D. Schneidawind FRI0409 MYOSITIS SPECIFIC ANTI-HISTIDYL TRNA SYNTHETASE (HISRS) AUTOANTIBODIES DISPLAY HIGH REACTIVITY AGAINST HISRS CONFORMATIONAL EPITOPES AND ASSOCIATE WITH LUNG AND JOINT INVOLVEMENT / C. Cerqueira - N. Renard - A. Notarnicola* - E. Wigren - P.-J. Jakobsson - S. Gräslund - I. E. Lundberg FRI0410 TGFΒ PROMOTES FIBROSIS BY MYST1-DEPENDENT EPIGENETIC REGULATION OF AUTOPHAGY / A. Zehender* - N.-Y. Lin - A. Stefanica - C.-W. Chen - A. Soare - T. Wohlfahrt - S. Rauber - C. Bergmann - A. Ramming - O. Distler - J. Distler FRI0411 DUAL PRO-INFLAMMATORY AND ANTI-FIBROTIC ROLE OF IL-17A IN SYSTEMIC SCLEROSIS SKIN / A. M. Dufour - M. Alvarez - S. Lemeille - M.-E. Truchetet - N. C. Brembilla - C. Chizzolini* FRI0412 B CELL DEPLETION AMELIORATES TISSUE FIBROSIS THROUGH REGULATING MACROPHAGE DIFFERENTIATION IN A BLEOMYCIN-INDUCED SYSTEMIC SCLEROSIS MODEL MOUSE / H. Numajiri* - A. Yosizaki - T. Fukasawa - S. Ebata - Y. Asano - S. Sato FRI0413 ARYL HYDROCARBON RECEPTOR EXPRESSION IS ASSOCIATED WITH LUNG INVOLVEMENT IN SYSTEMIC SCLEROSIS / H. Takei* - H. Yasuoka - K. Yoshimoto - K. Yamaoka - T. Takeuchi FRI0414 EVALUATION OF A NOVEL MULTI-ANALYTE ASSAY FOR THE DETECTION OF AUTOANTIBODIES IN THE DIAGNOSIS OF SYSTEMIC SCLEROSIS / P. L. Meroni - T. Schioppo - F. Ingegnoli - M. O. Borghi - J. L. Milo* - C. Bentow - A. Seaman - G. Valentini - S. Vettori - P. Di Benedetto - V. Liakouli - R. Giacomelli - M. Mahler FRI0415 HUMAN SKELETAL MUSCLE XENOGRAFTS TO MODEL SPORADIC INCLUSION BODY MYOSITIS / K. Britson* - K. Russell - K. Wagner - L. W. Ostrow - T. E. Lloyd FRI0416 XIAP AS NOVEL INTEGRATOR OF TGF ΒETA SIGNALING AND CANONICAL WNT SIGNALING IN TISSUE FIBROSIS / C. Bergmann - L. Hallenberger* - B. Merlevede - A. Brandt - C. Dees - C.-W. Chen - M. Stock - C. Beyer - O. Distler - G. Schett - J. Distler FRI0417 CD86 EXPRESSION ON CULTURED SKIN FIBROBLASTS FROM SYSTEMIC SCLEROSIS PATIENTS: IN VITRO EFFECTS OF CTLA4-IG / M. Cutolo* - P. Montagna - S. Soldano - A. C. Trombetta - P. Contini - B. Ruaro - A. Sulli - S. Scabini - E. Stratta - R. Brizzolara FRI0418 IN VITRO EFFECTS OF CTLA4-IG TREATMENT ON CULTURED FIBROCYTES FROM SYSTEMIC SCLEROSIS PATIENTS / M. Cutolo* - P. Montagna - S. Soldano - A. C. Trombetta - B. Ruaro - P. Contini - A. Sulli - S. Scabini - E. Stratta - R. Brizzolara FRI0419 INTRAVENOUS IMMUNOGLOBULINS PREVENTS EXPERIMENTAL FIBROSIS IN A MURINE MODEL OF SYSTEMIC SCLEROSIS / M.-M. Farhat* - S. Speca - M. Jendoubi - C. Hauspie - T. Guerrier - V. Sobanski - S. Sanges - E. Hachulla - G. Lefevre - M. Labalette - S. Dubucquoi - D. Launay FRI0420 ALTERED TRANSCRIPTOME OF CIRCULATING CD14+ MONOCYTES IN SYSTEMIC SCLEROSIS / M. Rudnik* - M. Stellato - P. Blyszczuk - O. Distler - G. Kania FRI0421 TOLL LIKE RECEPTOR-7/8 ACTIVATION EXACERBATES MURINE EXPERIMENTAL AUTOIMMUNE MYOSITIS / R. De Lorenzo - C. Sciorati - A. Monno - M. G. Doglio - E. Rigamonti - D. Ascherman - A. Manfredi - P. Rovere-Querini* FRI0422 ROLE OF THE PROLYL 3-HYDROXYLASE LEPREL1 IN FIBROSIS / H. Lopez - B. Abdi Ahmed - D. Abraham - L. Bozec - C. Denton - A. Strange - G. Martin - R. Stratton* FRI0423 EFFECTS OF SELEXIPAG IN CULTURED SCLERODERMA SKIN FIBROBLASTS / M. Cutolo - B. Ruaro - P. Montagna - R. Brizzolara - A. C. Trombetta - S. Scabini - P. P. Tavilla - A. Parodi - C. Corallo - N. Giordano - S. Paolino - C. Pizzorni - A. Sulli - V. Smith - S. Soldano* 15 June 2018 * Presenting author

120 118 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 FRI0424 COMPARATIVE ANALYSIS OF CLINICALLY AFFECTED AND UNAFFECTED SKIN BIOPSIES FROM SCLERODERMA PATIENTS BASED ON RNA-SEQUENCING / Z. Makowska* - A. Buttgereit - S. Babaei - N. Limaye - C. Galant - F. Houssiau - B. Weiss - R. Lesche - F. McDonald - B. Lauwerys TOPIC: SCLERODERMA, MYOSITIS AND RELATED SYNDROMES 15 June 2018 FRI0425 ASSOCIATION BETWEEN TISSUE OXYGEN DELIVERY AND DIGITAL ULCERS IN SYSTEMIC SCLEROSIS / A. Sari* - Y. Z. Sener - M. Oksul - B. Armagan - A. Erden - L. Kilic - A. Akdogan FRI0426 RESPONSE OF THE REACTIVE SPECIES INTERACTOME TO HYPOTHERMIA INDUCED RAYNAUD S ATTACK IN PRIMARY RAYNAUD AND SYSTEMIC SCLEROSIS / A. Eman Abdulle* - A. M. van Roon - A. J. Smit - A. Pasch - M. van Meurs - H. Bootsma - B. O. Fernandez - M. Feelisch - H. van Goor - D. J. Mulder FRI0427 CAPILLAROSCOPY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW / A. Vanhaecke* - V. Smith - S. Paolino - K. Melsens - Y. Piette - C. Pizzorni - E. Vandecasteele - S. Wijnant - C. Carton - F. De Keyser - M. Cutolo on behalf of the EULAR study group on microcirculation in Rheumatic diseases FRI0428 MEAN NUMBER OF CAPILLARIES IS ASSOCIATED WITH DISEASE ACTIVITY AT 6 MONTHS FOLLOW-UP IN SYSTEMIC SCLEROSIS PATIENTS / A. M. Gheorghiu* - R. Oneata - A. Radu - A. Briceag - C. Draganescu - C. Vranceanu - S. Magda - T. Constantinescu - A. Soare - R. Dobrota - I. Ancuta - C. Ciofu - L. Macovei - M. Milicescu - M. Sasu - A. Enuica - O. Linte - G. Stan - B. Comanescu - T. Necsoiu - M. Bojinca - V. Stoica - C. Mihai FRI0429 DISTINCT CLINICAL AND IMMUNOLOGICAL PICTURE OF MCTD PATIENTS WITH SKIN INVOLVEMENT / A. Felis- Giemza* - E. Kontny - J. Nałęcz-Janik - K. Walkiewicz-Pielaszek - Z. Czuszyńska - Z. Zdrojewski - A. Paradowska- Gorycka - M. Olesińska FRI0430 EFFECT OF ORAL NUTRITIONAL INTERVENTION ON NUTRITIONAL STATUS IN PATIENTS WITH SYSTEMIC SCLEROSIS / A. Wojteczek* - M. Ziętkiewicz - S. Małgorzewicz - Z. Zdrojewski FRI0431 DYSREGULATION OF LYMPHANGIOGENETIC FACTORS IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION / A.-M. Hoffmann-Vold* - H. Didriksen - H. Fretheim - E. Gude - V. Palchevskiy - T. Garen - Ø. Midtvedt - A. Andreassen - J. Belperio - Ø. Molberg FRI0432 SINGLE-PORT THORACOSCOPIC SYMPATHICOTOMY FOR TREATMENT RESISTANT RAYNAUD S PHENOMENON. FIRST REPORT OF A NOVEL MINIMALLY-INVASIVE ENDOSCOPIC TECHNIQUE / A. Van Roon* - M. Kuijpers - A. Eman Abdulle - S. Van de Zande - M. Mariani - R. Bos - T. Klinkenberg - H. Bootsma - A. Smit - D. J. Mulder FRI0433 ASSESSING MORTALITY MODELS IN SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE / R. L. Mango - E. L. Matteson - C. S. Crowson - J. H. Ryu - A. Makol* FRI0434 PATIENTS WITH INFLAMMATORY MYOPATHIES ADMITTED IN ICU ARE CHARACTERIZED BY RECENT ONSET AND UNTREATED ACTIVE DISEASE AS WELL AS OLDER AGE AND HIGH COMORBIDITIES / B. Michard* - T. Artzner - F. Severac - M. Schenck - J.-E. Herbrecht - R. Janssen-Langenstein - O. Collange - G. Freys - J. Pottecher - J. Sibilia - T. Martin - F. Meziani - F. Schneider - A. Meyer FRI0435 CLINICOPATHOLOGICAL CORRELATION IN INFLAMMATORY MYOSITIS: ANALYSIS OF THE REMICAM COHORT (REGISTRY OF INFLAMMATORY MYOSITYS FROM MADRID, SPAIN) / B. E. Joven* - F. Lozano - L. Nuño - F. J. López-Longo - O. Toldos - E. Rabadán - A. Hernández - J. Martínez-Barrios - C. Larena - M. Blazquez - C. Barbadillo - I. Llorente - A. Pérez - T. Cobo - R. Almodovar - L. Lojo - R. Calvo - M. J. García de Yébenes - P. E. Carreira on behalf of REMICAM group FRI0436 COMPARISON OF THE 2017 EULAR/ACR CRITERIA WITH BOHAN AND PETER CRITERIA FOR THE CLASSIFICATION OF ADULT AND JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES / B. Pinto* - R. Janardana - R. Nadig - A. Mahadevan - A. Bhatt - J. M. Raj - V. Shobha FRI0437 IS EXTENDED AUTO ANTIBODY PROFILING ASSOCIATED WITH THE PREVALENCE OF DISEASE COMPLICATIONS? / B. Kersten* - R. Smeets - F. van den Hoogen - R. van der Molen - W. Alkema - E. van den Ende - M. Vonk FRI0438 HOSPITALIZATION MORTALITY AND ASSOCIATED RISK FACTORS IN PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS: A RETROSPECTIVE CASE-CONTROL STUDY / C. Wu* - Q. Wang - L. HE - E. Yang - X. ZENG FRI0439 THE PROMISING ROLE OF LUNG MRI IN DETECTING SYSTEMIC SCLEROSIS (SSC)-RELATED INTERSTITIAL LUNG DISEASE (ILD) / L. Gargani - C. Bruni* - D. De Marchi - C. Romei - S. Guiducci - S. Bellando-Randone - G. D. Aquaro - A. Pepe - F. Falaschi - A. Pingitore - M. Matucci-Cerinic FRI0440 RENAL INVOLVEMENT IN MIXED CONNECTIVE TISSUE DISEASE: A SINGLE CENTER EXPERIENCE / E. Martin Nares* - S. E. Ramírez Andrade - N. O. Uribe Uribe - T. S. Rodríguez Reyna FRI0441 IDIOPATHIC INFLAMMATORY MYOPATHIES: CLINICAL CHARACTERISTICS, SURVIVIAL AND POOR PROGNOSTIC FACTORS OF 110 PATIENTS FROM TURKEY / E. Oguz* - M. Erdugan - B. A. Esen - A. Gul - L. Ocal - M. Inanc FRI0442 LONG-TERM TREATMENT WITH RITUXIMAB IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS: OUR CLINICAL EXPERIENCE / F. Lumetti* - A. Spinella - A. Ariani - E. Cocchiara - M. Colaci - M. Silva - N. Sverzellati - C. Ferri - C. Salvarani - D. Giuggioli FRI0443 DIGITAL ARTERY VOLUME INDEX: THE FIRST OBJECTIVE, AUTOMATED, NON-INVASIVE IMAGING DIAGNOSTIC OF MACROVASCULAR INVOLVEMENT IN SSC / G. Lettieri - G. Abignano - G. Bagnato - S. Eng - J. P. Ridgeway - J. N. Kaftan - M. Hinton - O. Kubassova - M. H. Buch - P. Emery - P. O Connor - F. Del Galdo* FRI0444 PERIOSTIN IN SYSTEMIC SCLEROSIS: SERUM LEVELS AND SKIN EXPRESSION OF A NOVEL POSSIBLE BIOMARKER / G. De Luca* - C. Campochiaro - S. Franchini - S. Burastero - S. Sartorelli - A. Giachi - G. Cavalli - C. Doglioni - L. Dagna FRI0445 A RANDOMISED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF ORAL MYCOPHENOLATE MOFETIL WITH PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS RELATED EARLY INTERSTITIAL LUNG DISEASE / G. Naidu* - S. Sharma - V. Dhir - S. Dhooria - A. Sinha - A. Mb - S. Jain FRI0446 INITIAL PREDICTORS FOR MORTALITY IN PATIENTS WITH CANCER-ASSOCIATED MYOSITIS: A MULTICENTER RETROSPECTIVE COHORT IN JAPAN / H. Kadota* - T. Gono - Y. Yamaguchi - E. Watanabe - Y. Okazaki - Y. Nakajima - S. Kobayashi - Y. Shirai - M. Takeno - C. Terai - M. Kuwana * Presenting author

121 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 119 FRI0447 WORLDWIDE EXPERT AGREEMENT ON UPDATED EULAR/ EUSTAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS / J. De Vries-Bouwstra* - Y. Allanore - M. Matucci-Cerinic - A. Balbir-Gurman FRI0448 MDA5 ANTIBODY POSITIVE CLINICAL AMYOPATHIC DERMATOMYOSITIS (CADM): A SINGLE TERTIARY CENTRE CASE SERIES OF 13 PATIENTS / K. Huang* - K. Shojania - J. Yeung - A. Avina-Zubieta FRI0449 OVERLAP MYOSITIS AND PRIMARY MYOSITIS: CLINICAL OUTCOMES AND PROGNOSIS / L. Nuño* - B. E. Joven - P. E. Carreira - J. Martínez Barrio - V. Maldonado-Romero - C. Larena-Grijalba - I. Llorente Cubas - E. G. Tomero - M. C. Barbadillo-Mateos - P. García de la Peña Lefebvre - L. Ruiz-Gutiérrez - J. C. López-Robledillo - H. Moruno-Cruz - A. Pérez - T. Cobo-Ibáñez - R. Almodóvar González - M. J. García-de Yébenes - L. Lojo - F. J. López-Longo on behalf of REMICAM study group FRI0450 ASSOCIATIONS OF ALTERATIONS OF PERIPHERAL REGULATORY T AND TH17 ABSOLUTE CELL NUMBERS WITH CLINICAL FEATURES IN PATIENTS WITH SYSTEMIC SCLEROSIS / L. Shang* - J. Luo - J. Yuan - Q. Li - X. Liu - C. Gao - X. Li - H. Gao FRI0451 CONTINUOUS PRESENCE OF IGM ANTI-TOPOISOMERASE I ANTIBODIES INDICATES AN ONGOING IMMUNE RESPONSE IN SYSTEMIC SCLEROSIS / M. Boonstra* - J. A. Bakker - A. Grummels - M. K. Ninaber - N. Ajmone Marsan - H. U. Scherer - R. E. Toes - T. W. Huizinga - J. K. de Vries-Bouwstra FRI0452 NAILFOLD CAPILLAROSCOPY IN ANTISYNTHETASE SYNDROME (NASCAR): RESULTS OF A MULTICENTER, INTERNATIONAL STUDY OF THE AMERICAN AND EUROPEAN NETWORK OF ANTISYNTHETASE SYNDROME (AENEAS) / M. Sebastiani* - K. Triantafyllias - A. Manfredi - M. A. González-Gay - N. Palmou-Fontana - G. Cassone - U. Drott - C. Delbrück - J. Rojas-Serrano - C. Bertolazzi - L. Nuño - M. Giannini - F. Iannone - E. F. Vicente - S. Castañeda - A. Selva-O Callaghan - E. Trallero Araguas - G. Emmi - A. Iuliano - J. Bauhammer - N. Miehle - S. Parisi - L. Cavagna - V. Codullo - C. M. Montecucco - F. J. Lopez Longo - J. Martínez-Barrio - J. C. Nieto- González - S. Vichi - M. Confalonieri - R. Bergner - A. Sulli - F. Bonella - F. Furini - C. A. Scirè - C. Specker - S. Barsotti - R. Neri - J. Weinmann-Menke - A. Schwarting - V. Smith - M. Cutolo on behalf of NASCAR study group FRI0453 HOSPITALIZATION AND SURVIVAL ANALYSIS IN SYSTEMIC SCLEROSIS PATIENTS WITH CONCOMITANT OR ISOLATED PULMONARY HYPERTENSION AND INTERSTITIAL LUNG DISEASE IN THE MULTIETHNIC SCLERODERMA COHORT SINGAPORE / M. Noviani* - E. S. Seyed - S. M. Y. Kua - G. Y. L. Chan - G. G. Teng - W. G. Law - A. Santosa - A. Lim - J. L. Tan - E. L. W. Tay - J. W. L. Yip - S. C. Ng - A. H. L. Low FRI0454 ARTERIAL STIFFNESS OF THE FOREARM IS ASSOCIATED WITH NAIL-FOLD CAPILLARY COUNT IN SSC: A NOVEL MARKER OF EARLY VASCULOPATHY? / M. M. Habing* - A. Eman Abdulle - A. M. van Roon - A. M. van Roon - H. van Goor - H. Bootsma - A. J. Smit - D. J. Mulder FRI0455 INCREASING INCIDENCE OF ADULT IDIOPATHIC INFLAMMATORY MYOPATHIES: A TEN-YEAR UK EPIDEMIOLOGICAL STUDY / M. J. S. Parker* - A. Oldroyd - M. E. Roberts - R. G. Cooper - H. Chinoy on behalf of UKMYONET FRI0456 PREDICTORS FOR DISEASE WORSENING DEFINED BY ORGAN FAILURE IN DIFFUSE SYSTEMIC SCLEROSIS: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS / M. O. Becker* - N. Graf - R. Sauter - Y. Allanore - J. Curram - C. Denton - D. Khanna - M. Matucci-Cerinic - J. Pena - J. E. Pope - O. Distler FRI0457 RELATIONSHIP BETWEEN DIGITAL ULCERS AND SEVERITY OF LUNG FUNCTION TEST IN SYSTEMIC SCLEROSIS OVER A FIVE-YEAR PERIOD / O. B. Ovsyannikova* - O. Koneva - L. Ananieva FRI0458 THE ONSET, CLINICAL COURSE AND OUTCOMES OF SSC- OVERLAP WITH PM/ DM OR RA (SSC-PM/DM AND SSC-RA) / O. Desinova* - M. Starovoytova - L. Ananieva FRI0459 MICROVACULATURE CHANGES AND ANGIOGENIC FACTORS IN SYSTEMIC SCLEROSIS - A SINGLE CENTER STUDY / R. Bečvář* - H. Hulejová - I. Půtová - M. Tomčík FRI0460 THE COMPARISON BETWEEN PATIENTS WITH SYSTEMIC SCLEROSIS, POSITIVE FOR FOR ANTIBODIES TO RIBONUCLEOPROTEIN AND CLASSICAL SUBTYPES OF SYSTEMIC SCLEROSIS / R. Shayakhmetova* - L. Ananieva - O. Koneva - M. Starovoitova - O. Desinova - O. Ovsyannikova - L. Garzanova FRI0461 EFFICACY AND SAFETY OF ANTIFIBROTIC AGENTS IN IDIOPATHIC PULMONARY FIBROSIS / L. Nuñez-García - C. Valenzuela - T. Alonso - E. F. Vicente - J. Ancochea - S. Castañeda* FRI0462 SERUM KL-6 IS A STRONG PREDICTOR FOR RELAPSE OF MYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE / S. Takanashi* - N. Nishina - M. Nakazawa - Y. Kaneko - T. Takeuchi FRI0463 A NEW COMPUTED TOMOGRAPHY INDEX FOR QUANTIFICATION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS IS ASSOCIATED WITH LUNG FUNCTION PARAMETERS IN THE SHORT TERM FOLLOW-UP / S. Vettori* - M. Bocchino - D. Bruzzese - M. D Alto - P. Argiento - V. Giacco - E. Romeo - A. Capaccio - G. Rea - T. Valente - A. Sanduzzi-Zamparelli - G. Valentini FRI0464 CLINICAL MANIFESTATIONS OF PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS / S. Myriam* - V. Sobanski - A. Lemaire - J. Giovannelli - E. Hachulla - B. Lopez - M. Lambert - P.-Y. Hatron - S. Dubucquoi - D. Launay FRI0465 QUANTITATIVE ASSESSMENT OF INTERSTITIAL LUNG DISEASE IN IDIOPATHIC INFLAMMATORY MYOPATHIES: VISUAL SCORE AND COMPUTERIZED PROCESSING ANALYSIS OF HIGH RESOLUTION COMPUTERIZED TOMOGRAPHY / S. Barsotti* - C. Romei - E. Cioffi - E. Perrone - C. Giovannetti - M. Mosca - F. Falaschi - R. Neri FRI0466 ARTICULAR AFFECTION IN SYSTEMIC SCLEROSIS: CORRELATION OF ULTRASOUND FINDINGS WITH CLINICAL, BIOLOGICAL AND RADIOGRAPHICAL FINDINGS / C. De la Puente - J. Quiñones - S. Zegarra* FRI0467 THE RELATIONSHIP BETWEEN 99MTC-PERTECHNETATE HAND PERFUSION SCINTIGRAPHY AND NAIFOLID CAPILLOSCOPY IN SYSTEMIC SCLEROSIS PATIENTS: A PILOT STUDY / S. R. Pavlov-Dolijanovic* - N. Petrovic - N. Vujasinovic Stupar - N. Damjanov - G. Radunovic - V. Zugic - D. Babic - D. Sobic-Saranovic - V. Artiko FRI0468 ABNORMAL OESOPHAGEAL MOTILITY DURING A SOLID TEST MEAL IN SYSTEMIC SCLEROSIS - DETECTION IN VERY EARLY DISEASE AND ASSOCIATION WITH DISEASE PROGRESSION / S. Bütikofer - S. Jordan* - M. Sauter - M. Hollenstein - H. Heinrich - N. Freitas-Queiroz - T. Kuntzen - P. Valli - D. Ang - M. Oberacher - B. Maurer - W. Schwitzer - M. Fox - O. Distler - B. Misselwitz FRI0469 ACUTE AND CHRONIC EFFECTS OF TWO DIFFERENT INTRAVENOUS ILOPROST REGIMENS IN SYSTEMIC SCLEROSIS: A SINGLE CENTRE PRAGMATIC NON-RANDOMISED TRIAL / T. Schioppo* - A. Orenti - P. Boracchi - O. De Lucia - A. Murgo - F. Ingegnoli 15 June 2018 * Presenting author

122 120 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 FRI0470 A PHASE 2 STUDY OF SAFETY AND EFFICACY OF LENABASUM (JBT-101), A CANNABINOID RECEPTOR TYPE 2 AGONIST, IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS / V. P. Werth* - E. Hejazi - S. M. Pena - J. S. Haber - J. Okawa - R. Feng - K. Gabre - J. S. Concha - C. Cornwall - N. Dgetluck - S. Constantine - B. White FRI0471 PREDICTION OF PROGRESSION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS: THE SPAR MODEL / W. Wu* - S. Jordan - M. O. Becker - R. Dobrota - B. Maurer - H. Fretheim - S. Ye - E. Siegert - Y. Allanore - A. M. Hoffmann-Vold - O. Distler FRI0472 TOWARDS A MULTIDIMENSIONAL PATIENT REPORTED OUTCOME MEASURES ASSESSMENT: DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE FOR PATIENTS WITH SYSTEMIC SCLEROSIS / SCLERODERMA / Y. El Miedany* - M. El Gaafary - N. El Aroussy - S. Youssef - Y. Atef - D. Palmer FRI0473 MPO-ANCA POSITIVITY IS RELATED TO INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS / Y. Ichimura* - Y. Kawaguchi - K. Takagi - A. Tochimoto - T. Higuchi - H. Yamanaka TOPIC: VASCULITIS Poster tour F10: Clinical and therapeutic advances in vasculitis Leonard Calabrese (United States), Valentin Schäfer (Germany) Abstracts N : FRI0474-FRI June 2018 FRI0474 CLASSIFICATION OF SKIN INVOLVEMENT IN LEVAMISOLE-ADULTERATED COCAINE INDUCED VASCULOPATHY / C. H. Muñoz-Vahos* - S. Herrera-Uribe - Á. Arbeláez-Cortés - D. Jaramillo-Arroyave - L. A. González-Naranjo - G. Vásquez-Duque - M. Restrepo-Escobar - L. A. Correa-Londoño - J. Hernández-Zapata - A. L. Vanegas-García FRI0475 LUNG DAMAGE IN PATIENTS WITH MICROSCOPIC POLYANGIITIS / E. Shchegoleva* - A. Zykova - N. Bulanov - A. Meshkov - P. Novikov - S. Moiseev FRI0476 THE MYRIAD OF NEPHRITIS IN LEVAMISOLE-ADULTERATED COCAINE VASCULOPATHY / C. H. Munoz* - S. Herrera-Uribe - Á. Arbeláez-Cortés - D. Jaramillo-Arroyave - L. A. González-Naranjo - G. Vásquez-Duque - M. Restrepo-Escobar - J. Hernández-Zapata - L. F. Arias-Restrepo - A. L. Vanegas-García FRI0477 IMMUNOGENICITY OF INFLIXIMAB AMONG PATIENTS WITH BEHCET S SYNDROME: A CONTROLLED STUDY / S. N. Esatoglu* - F. N. Akkoc - Y. Ozguler - F. Ozbakir - O. K. Nohut - D. Cevirgen - V. Hamuryudan - I. Hatemi - A. F. Celik - H. Yazici - G. Hatemi FRI0478 OCCURRENCE OF GENUINE VASCULITIS IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS / P. Novikov - E. Zagvozdkina - V. Kazarina - N. Bulanov - S. Moiseev* FRI0479 PRIMARY CENTRAL NERVOUS SYSTEM VASCULITIS WITH TUMOR-LIKE PRESENTATION / C. Salvarani* - R. D. Brown - T. J. Christianson - C. Giannini - J. Huston III - G. G. Hunder FRI0480 TOCILIZUMAB MONO-THERAPY FOR POLYMYALGIA RHEUMATICA ~ RESULTS OF 104-WEEK TREATMENT OF A PROSPECTIVE, SINGLE-CENTER, OPEN TRIAL / K. Amano* - K. Chino - Y. Okada - A. Shibata - S. Saito - T. Kurasawa - A. Okuyama - H. Takei - R. Sakai - T. Kondo FRI0481 GIANT CELL ARTERITIS AND INFLAMMATORY BOWEL DISEASE - IS THERE A CONNECTION? RESULTS FROM A POPULATION-BASED STUDY / Y. Yavne* - S. Tiosano - A. Watad - D. Comaneshter - A. D. Cohen - H. Amital FRI0482 CAUSES OF DEATH IN CONNECTIVE TISSUE DISEASE (CTD S) AND VASCULITIDES; DATA FROM THE NORWEGIAN CONNECTIVE TISSUE DISEASES AND VASCULITIS REGISTRY (NOSVAR) / T. Garen - K. Lerang - H. Andersson - Ø. Midtvedt - K. Kilian - S. Reister - R. Gunnarsson - B. Gudbrandsson - Ø. Molberg - Ø. Palm* FRI0483 SULFASALAZINE AS A POTENTIAL TREATMENT FOR IGA-VASCULITIS (HENOCH-SCHÖNLEIN PURPURA) IN ADULTS / S. Giliaev* - A. Semenovykh FRI0484 OVERALL SURVIVAL AND MORTALITY RISK FACTORS IN TAKAYASU S ARTERITIS: A MULTICENTER STUDY OF 318 PATIENTS / A. Mirouse* - C. Comarmond - L. Biard - M. Lambert - A. Mékinian - J.-E. Kahn - E. Hachulla - E. Messas - M. Resche-Rigon - P. Cacoub - D. Saadoun on behalf of French Takayasu network FRI0485 PHENOTYPE OF ANCA ASSOCIATED VASCULITIS ASSOCIATES WITH MAJOR CARDIOVASCULAR EVENTS: A RETROSPECTIVE OBSERVATIONAL STUDY FROM THE LEEDS VASCULITIS COHORT / A. Giollo* - E. M. A. Hensor - J. Andrews - M. H. Buch FRI0486 POTENTIAL PREDICTORS OF VISCERAL INVOLVEMENT IN ADULT IGA VASCULITIS / A. Hocevar* - Ž. Rotar - V. Jurčić - M. Tomšič FRI0487 SERUM INTERLEUKIN-6 LEVELS IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS / A. Berti* - R. Warner - K. Johnson - D. Cornec - D. Schroeder - B. Kabat - C. A. Langford - G. S. Hoffman - C. G. Kallenberg - P. Seo - R. Spiera - W. E. St. Clair - F. Fervenza - J. Stone - P. Monach - U. Specks - P. A. Merkel on behalf of the RAVE-ITN Research Group FRI0488 INSUFFICIENT IMMUNOSUPPRESSIVE USE IS THE LEADING CAUSE OF VASCULAR RELAPSES IN BEHCET S DISEASE / A. Aksoy* - F. Alibaz Öner - T. Ergun - R. H. Direskeneli FRI0489 UTILITY OF APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÇET S DISEASE / B. Atienza-Mateo* - J. Loricera - M. D. García-Armario - I. Castellví - F. Sivera - J. Graña - J. Calvo-Alen - I. de la Morena - F. Ortiz-Sanjuán - J. A. Román-Ivorra - A. Pérez-Gómez - S. Heredia - C. Díez - J. J. Alegre - C. Moriano - E. Díez - T. Pérez - M. Martín - A. Ybáñez - J. Narváez - A. I. Turrión - S. Romero-Yuste - L. C. Domínguez-Casas - N. Vegas-Revenga - J. L. Martín-Varillas - J. L. Hernández - C. González-Vela - M. Á. González-Gay - R. Blanco FRI0490 MORTALITY AND EARLY SEVERE INFECTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS / D. Waki* - K. Nishimura - K. Kadoba - H. Mukoyama - R. Saito - T. Yokota FRI0491 SMOKING AS A RISK FACTOR FOR GIANT CELL ARTERITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS / D. Brennan* - P. Ungprasert - K. J. Warrington - M. J. Koster FRI0492 CLINICAL CHARACTERISTICS OF PARENCHYMAL NEURO-BEHCET S DISEASE: A RETROSPECTIVE ANALYSIS / D. Yan* - J. Liu - D. Wu - L. Peng - Z. Liu - W. Zheng * Presenting author

123 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 121 FRI0493 PET/CT IN PATIENTS WITH GIANT CELL ARTERITIS AFTER 1 YEAR OF TREATMENT WITH TOCILIZUMAB PLUS PREDNISONE TAPER OR ONLY PREDNISONE TAPER / A. Ishai - E. Brouwer* - C. Maldini - J. H. Stone - G. F. Espigol-Frigole - M. C. Cid - D. Blockmans - D. Carmellino - M. Cimmino - F. Muratore - R. Slart - C. Salvarani - F. Narvaez Garcia - S. De Vita - B. Hellmich - S. Dimonaco - M. Klearman - A. Petho-Schramm - K. Tuckwell - N. Collinson - A. Tawakol - S. Unizony FRI0494 SPECTRUM OF VISUAL INVOLVEMENT IN GIANT CELL ARTERITIS / F. Laskou* - T. Aung - D. Gayford - S. Banerjee - C. S. Crowson - E. L. Matteson - B. Dasgupta FRI0495 BEHÇET S SYNDROME IN NEW YORK AND AMSTERDAM: EVOLUTION FROM PROBABLE BEHÇET S TO ISG CRITERIA POSITIVE BEHÇET S / F. Kerstens* - F. Turkstra - C. J. Swearingen - Y. Yazici FRI0496 POLYARTERITIS NODOSA: OVER 20 YEARS CLINICAL EXPERIENCE / H. E. Sönmez* - B. Armağan - G. Ayan - K. Barut - E. D. Batu - A. Erden - S. Uğurlu - Y. Bilginer - Ö. Kasapçopur - Ö. Karadağ - S. A. Bilgen - H. Özdoğan - S. Özen FRI0497 CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF PATIENTS WITH BEHÇET S DISEASE AND VASCULAR INVOLVEMENT / H. Kim* - Y. Eun - I. Y. Kim - H. Jeong - E.-J. Park - J. Hwang - J. Y. Chai - J. K. Ahn - J. Lee - E.-M. Koh - D.-K. Kim - H.-S. Cha FRI0498 COMPARATIVE STUDY OF THE TREATMENT OF REFRACTORY CYSTOID MACULAR EDEMA TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY: TOCILIZUMAB VS ANTI-TNF. MULTICENTER STUDY OF 59 PATIENTS / J. L. Martín-Varillas* - V. Calvo-Río - R. Demetrio-Pablo - B. Atienza-Mateo - J. Loricera - M. V. Hernández - A. Adán - M. Mesquida - S. Insua - J. M. Herreras - O. Maíz - A. Blanco - M. Gandía - D. Díaz - L. Martínez - E. Valls - G. Díaz - M. Díaz - I. Calvo - I. Torre - A. Atanes - L. Linares - M. Hernández - E. Beltrán - M. Cordero - E. Aurrecoechea - F. F. Hernández - R. Almodovar - Ó. Ruiz - F. Jiménez - J. M. Nolla - C. Modesto - M. A. González-Gay - R. Blanco FRI0499 A MULTINATIONAL QUALITATIVE STUDY IN GIANT CELL ARTERITIS: PATIENT PERCEPTIONS OF DIAGNOSIS, TREATMENT, IMPACT ON HEALTH-RELATED QUALITY OF LIFE AND CONTEXTUAL FACTORS / J. C. Robson* - C. Almeida - J. Dawson - A. Bromhead - S. L. Mackie - C. Hill - E. Hoon - C. Davis - R. Greenwood - R. Luqmani - B. Dasgupta - C. Guly - J. D. Pauling - R. Watts - E. Dures FRI0500 EXTRACRANIAL VASCULAR AFFECTION IN GIANT CELL ARTERITIS / J. L. Martín-Varillas* - J. Loricera - D. Prieto-Peña - J. Narváez - E. Aurrecoechea - I. Villa - S. Castañeda - C. Gómez-Arango - A. Mera - E. Pérez-Pampín - V. Aldasoro - N. Álvarez-Rivas - N. Fernández-Llanio - M. Álvarez de Buergo - L. Marena-Rojas - F. Sivera - E. Galíndez-Aguirregoikoa - R. Solans-Laqué - S. Romero-Yuste - N. Ortego - M. Revenga - C. Larena - Í. Hernández - F. J. Maceiras-Pan - E. Salgado - S. Fernández - M. Calderón-Goercke - I. Martínez-Rodríguez - J. I. Banzo - V. Calvo-Río - B. Atienza-Mateo - N. Palmou-Fontana - C. González-Vela - J. L. Hernández - M. A. González-Gay - R. Blanco FRI0501 NEGATIVE TEMPORAL ARTERY BIOPSIES: COMPARISON BETWEEN BIOPSY-NEGATIVE GCA AND NON-GCA PATIENTS / K. Yeruva* - K. J. Warrington - C. S. Crowson - M. J. Koster FRI0502 RISK OF CANCER IN PATIENTS DIAGNOSED WITH GIANT CELL ARTERITIS IN WESTERN NORWAY / L. K. Brekke* - A. P. Diamantopoulos - B.-T. Fevang - J. Assmus - C. G. Gjesdal FRI0503 RISK FACTORS OF CARDIAC VALVULAR INVOLVEMENT IN PATIENTS WITH TAKAYASU S ARTERITIS / L. Pan* FRI0504 DIFFUSE ALVEOLAR HEMORRHAGE IN ANCA-ASSOCIATED VASCULITIS: CAN WE PREDICT OUTCOME? AN ITALIAN MULTICENTRE RETROSPECTIVE LONG-TERM STUDY OF 102 PATIENTS / L. Quartuccio* - M. Bond - S. Monti - M. Felicetti - F. Furini - S. Murgia - A. Berti - G. Emmi - G. Pazzola - E. Bozzolo - P. Leccese - B. Raffeiner - I. Leccese - F. Cianci - S. Bettio - P. Sainaghi - A. Ianniello - V. Ravagnani - S. Bellando Randone - P. Faggioli - C. Lomater - P. Stobbione - S. Barsotti - M. Colaci - G. Alfieri - F. Carubbi - G. Erre - A. Giollo - N. Franzolini - S. Balduzzi - R. Padoan - R. Bortolotti - A. Bortoluzzi - A. Cariddi - A. Padula - E. Silvestri - G. Di Scala - E. Gremese - F. Conti - S. D Angelo - M. Isola - L. Dagna - G. Paolazzi - C. Salvarani - D. Roccatello - F. Schiavon - M. Govoni - R. Caporali - S. De Vita on behalf of the Italian Society of Rheumatology study group for Lung Involvement in Rheumatic Diseases FRI0505 VALIDATION OF THE PROGNOSTIC VALUE OF THE HISTOPATHOLOGICAL CLASSIFICATION OF ANCA- ASSOCIATED GLOMERULONEPHRITIS: A META-ANALYSIS / M. Wester Trejo* - E. van Daalen - J. Schoones - O. Dekkers - J. Bruijn - I. Bajema FRI0506 CLINICAL ANALYSIS OF BEHÇET S DISEASE MANIFESTATIONS IN 453 EGYPTIAN PATIENTS: GENDER COMPARISON / M. Elshahaly* - I. Omar - H. Bassiouni FRI0507 THE PREVALENCE OF LATENT TUBERCULOSIS INFECTION IN INDIAN PATIENTS OF TAKAYASU ARTERITIS / N. V. Negalur* - G. Ekbote - D. Tanna - N. Mendiratta - R. Gupta - A. Bhan FRI0508 ANALYSIS OF RISK FACTORS OF ADVERSE OBSTETRICAL OUTCOME IN PATIENTS WITH TAKAYASU ARTERITIS / N. Abisror* - A. Mekinian - V. Le Guern - N. Costedoat - E. Hachulla - M. Lambert - N. Morel - C. Chapelon - N. Martis - J. G. Fuzibet - P. Belenotti - L. Swiader - R. Dhote - L. Mouthon - F. Sarrot-Reynault - M. Andre - S. Amar - J. B. Gauthier - P. Cathebras. FRI0509 THE FACTORS ASSOCIATED WITH ANXIETY/ DEPRESSIVE DISORDERS IN BEHÇET S DISEASE PATIENTS / P. Ovcharov* - T. Lisitsyna - D. Veltishchev - O. Seravina - O. Kovalevskaya - Z. Alekberova - E. Nasonov FRI0510 INCREASED EXPRESSION OF V-DOMAIN IG SUPPRESSOR OF T CELL ACTIVATION (VISTA) ON LEUKOCYTES OF GRANULOMATOSIS WITH POLYANGIITIS (GPA) PATIENTS / R. Hid Cadena* - J. Yuan - M. G. Huitema - A. M. Boots - C. Stegeman - E. Brouwer - A. Rutgers - P. Heeringa - W. H. Abdulahad FRI0511 THYROID ARTERY INVOLVEMENT DETECTED BY COLOUR-DOPPLER ULTRASONOGRAPHY IN AN INCIPIENT, SINGLE CENTRE GIANT CELL ARTERITIS COHORT / R. Ješe* - Ž. Rotar - M. Tomšič - A. Hočevar FRI0512 RISK OF OPPORTUNISTIC INFECTIONS IN PATIENTS WITH ANTINEUTROPHIL CYTOPLASMIC ANTIBODY- ASSOCIATED VASCULITIS USING JAPANESE HEALTH INSURANCE DATABASE / R. Sakai* - E. Tanaka - H. Nishina - H. Yamanaka - M. Harigai FRI0513 THE IMPACT OF DEPRESSION, ANXIETY AND FATIGUE IN PATIENTS WITH BEHÇET S DISEASE / S. Can Sandikci* - S. Colak - A. Omma - M. E. Enecik FRI0514 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES POSITIVITY IN INTERSTITIAL LUNG DISEASE PATIENTS / S. Barsotti* - L. Cavagna - F. Ferro - P. Tomietto - A. Pesci - G. Dei - S. Prieto-González - F. Hernández-González - L. Saracino - A. Manfredi - G. Emmi - M. L. Urban - M. Mosca - C. Baldini - R. Neri on behalf of ILD-ANCA study group 15 June 2018 * Presenting author

124 122 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 FRI0515 EFFECTIVENESS OF DIRECT-ACTING ANTIVIRAL THERAPY ON CRYOGLOBULINEMIA ASSOCIATED WITH HEPATITIS C VIRUS / S. Zegarra Mondragon* - J. R. Quiñones - J. Bachiller Corral - M. Vazquez Diaz FRI0516 INSIGHT INTO INFLAMMATORY CELL AND CYTOKINE PROFILES IN ADULT IGA VASCULITIS / T. Kuret* - K. Lakota - P. Žigon - M. Ogrič - S. Sodin-Šemrl - S. Čučnik - M. Tomšič - A. Hočevar FRI0517 VESSEL WALL MORPHOLOGY IN GIANT CELL ARTERITIS- A LONGTERM SONOGRAPHIC FOLLOW-UP STUDY / E. Schegk - C. T. Berger - S. Imfeld - D. Staub - M. Recher - D. Kyburz - M. Aschwanden - T. Daikeler* FRI0518 INCIDENCE, CHARACTERISTICS AND MANAGEMENT OF GIANT CELL ARTERITIS IN FRANCE: A STUDY BASED ON NATIONAL HEALTH INSURANCE CLAIMS DATA / V. Devauchelle Pensec* - E. Hachulla - M. Paccalin - S. Gandon - I. Idier - M. Nolin - M. Belhasen - A. Mahr FRI0519 WORK PRODUCTIVITY IS IMPAIRED IN PATIENTS WITH BEHÇET S SYNDROME / N. Serin - Y. Ozguler* - S. N. Esatoglu - V. Hamuryudan - G. Hatemi TOPIC: OSTEOARTHRITIS Poster tour F11: Novelties in osteoarthritis: clinical aspects Francis Berenbaum (France), Féline Kroon (Netherlands) Abstracts N : FRI0520-FRI June 2018 FRI0520 DISCOVERY OF POTENTIAL BIOMARKERS FOR THE DIAGNOSIS OF EROSIVE AND NODAL HAND OSTEOARTHRITIS / M. Camacho Encina* - V. Calamia - F. Picchi - I. Ortega - P. Fernández Puente - L. González Rodríguez - C. Ruiz Romero - F. J. Blanco FRI0521 COMBINING FRACTAL- AND ENTROPY-BASED BONE TEXTURE ANALYSIS FOR THE PREDICTION OF OSTEOARTHRITIS: DATA FROM THE MULTICENTER OSTEOARTHRITIS STUDY (MOST) / R. Ljuhar* - Z. Bertalan - S. Nehrer - B. Norman - H.-P. Dimai - A. Fahrleitner-Pammer - D. Ljuhar FRI0522 VITAMIN D SUPPLEMENTATION IMPROVES DEPRESSION IN KNEE OSTEOARTHRITIS PATIENTS OVER 24 MONTHS / S. Zheng* - L. Tu - F. Cicuttini - W. Han - Z. Zhu - B. Antony - A. Wluka - T. Winzenberg - D. Aitken - L. Blizzard - G. Jones - C. Ding FRI0523 ZOLEDRONIC ACID PLUS PREDNISOLONE VERSUS ZOLEDRONIC ACID ALONE OR PLACEBO IN THE TREATMENT OF KNEE OSTEOARTHRITIS: A RANDOMISED TRIAL / G. Cai* - L. Laslett - D. Aitken - T. Winzenberg - G. Jones FRI0524 CENTRAL SENSITIZATION IN HAND OSTEOARTHRITIS AND ASSOCIATIONS WITH RADIOGRAPHIC SEVERITY, SYNOVITIS ON ULTRASOUND AND SYMPTOM DURATION / P. Steen Pettersen* - T. Neogi - K. Magnusson - H. B. Hammer - T. Uhlig - T. K. Kvien - I. K. Haugen FRI0525 ASSOCIATION BETWEEN DIETARY VITAMIN K INTAKE WITH KNEE SYMPTOMS AND BACK PAIN IN PATIENTS WITH KNEE OSTEOARTHRITIS / Z. Liao* - J. Chang - Z. Zhu - W. Han - T. Meng - S. Zheng - T. Winzenberg - A. Wluka - F. Cicuttini - C. Ding FRI0526 THE IMPACT OF DISEASE CHARACTERISTICS IN KNEE AND HIP OSTEOARTHRITIS ON RECOMMENDATIONS FOR JOINT REPLACEMENT / J. Callhoff* - A. Postler - K. Albrecht - A. Zink - K.-P. Günther FRI0527 EFFICACY OF BIO-OPTIMISED CURCUMA EXTRACT (FLEXOFYTOL ) FOR PAINFUL KNEE OSTEOARTHRITIS: DATA FROM COPRA, A MULTICENTER RANDOMISED CONTROLLED STUDY / Y. Henrotin* - M. Malaise - R. Wittoek - K. Devlam - J.-P. Brasseur - F. Luyten - Q. Jiangang - M. van den Berghe - R. Uhoda - J. Bentin - T. De Vroey - L. Erpicum - Y. Dierckxsens FRI0528 LONG-TERM EFFECTS OF VITAMIN D SUPPLEMENTATION AND MAINTAINING VITAMIN D SUFFICIENCY ON KNEE OSTEOARTHRITIS OVER 5 YEARS / B. S. Eathakkattu Antony* - S. Zheng - J. Burgess - C. Ding FRI0529 PREOPERATIVE PAIN SEEMS TO MODIFY THE EFFECT OF RADIOGRAPHIC OSTEOARTHIRITIS SEVERITY ON POSTOPERATIVE PAIN AND FUNCTION 1 YEAR AFTER TOTAL KNEE ARTHROPLASTY / R. van de Water - C. Leichtenberg - R. Nelissen - H. Kroon - H. Kaptijn - R. Onstenk - S. Verdegaal - T. Vliet Vlieland - M. Gademan* on behalf of the LOAS Study group FRI0530 TOTAL JOINT REPLACEMENT (TJR) AS CLINICAL ENDPOINT IN OA; PREVALENCE AND INCIDENCE RATES OF TJRS FROM THE PROSPECTIVE EPIDEMIOLOGIC RISK FACTOR (PERF I) STUDY / A. C. Bay-Jensen* - C. Bager - A. Bihlet - C. S. Thudium - I. Byrjalsen - H. B. Nielsen - J. R. Andersen - B. J. Riis - C. Christiansen - M. A. Karsdal FRI0531 DETERMINANTS OF CLINICAL AND RADIOLOGICAL PROGRESSION OF HAND OSTEOARTHRITIS OVER 2 YEARS / A. Neuprez* - A. H. Neuprez - E. Maheu - O. Bruyère - J.-F. Kaux - J.-Y. Reginster FRI0532 RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES AND PROPRIOCEPTIVE ACUITY IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY / B. Ünver* - M. Eymir - V. Karatosun FRI0533 ASIAN MITOCHONDRIAL DNA HAPLOGROUP B IS ASSOCIATED WITH THE DEVELOPMENT OF KNEE OSTEOARTHRITIS IN KOREAN / B. S. Koo* - Y. Song - S. Lee - Y.-K. Sung - K.-J. Shin - N. H. Cho - J.-B. Jun FRI0534 RADIOGRAPHIC OUTCOMES WERE ASSOCIATED WITH PAIN AND FUNCTION RESPONSES: POST-HOC ANALYSIS FROM A PHASE 2 STUDY OF A WNT PATHWAY INHIBITOR, SM04690, FOR KNEE OSTEOARTHRITIS TREATMENT / C. Swearingen* - J. Tambiah - A. Gibofsky - N. Lane - T. McAlindon - M. Hochberg FRI0535 THE CLINICAL AND RADIOGRAPHIC EARLY COURSE OF KNEE AND HIP OSTEOARTHRITIS OVER 10 YEARS IN CHECK (COHORT HIP AND COHORT KNEE) / D. Schiphof* - J. Runhaar - J. Waarsing - W. van Spil - M. van Middelkoop - S. Bierma-Zeinstra FRI0536 PREGABALIN EFFICACY IN TREATMENT OF CHRONIC PAIN IN PATIENTS WITH KNEE OSTEOARTHRITIS / E. Filatova* - E. Turovskaya - L. Alekseeva FRI0537 NEUROPHYSIOLOGICAL DATA IN PATIENTS WITH CHRONIC PAIN IN KNEE OSTEOARTHRITIS / E. Turovskaia* - L. Alekseeva - E. Filatova - C. Chimienti FRI0538 STRUCTURAL EFFECTS OF INTRA-ARTICULAR SPRIFERMIN IN SYMPTOMATIC RADIOGRAPHIC KNEE OSTEOARTHRITIS: A POST-HOC ANALYSIS OF CARTILAGE AND NON-CARTILAGINOUS TISSUE ALTERATIONS OF THE 2-YEAR DATA FROM A 5-YEAR RANDOMISED, PLACEBO-CONTROLLED, PHASE II STUDY / F. Roemer* - J. Kraines - A. Aydemir - S. Wax - M. Crema - M. Hochberg - A. Guermazi * Presenting author

125 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 123 FRI0539 A SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) STUDY WITH INCREASING ORAL DOSES OF GLPG1972 ADMINISTERED DAILY FOR 29 DAYS SHOWS A STRONG BIOMARKER EFFECT IN PATIENTS WITH KNEE AND/OR HIP OA / H. M. Deckx* - S. Hatch - M. Robberechts - S. Dupont - J. Desrivot - H. Coleman - S. Larsson - A. Struglics - E. M. van der Aar - A. Fiew FRI0540 IDENTIFICATION OF BIOMARKERS OF OA ASSOCIATED TO DEFECTIVE AUTOPHAGY / I. Lorenzo-Gomez* - N. Oreiro - J. A. Pinto-Tasende - F. J. Blanco - B. Carames FRI0541 INCREASING A PERSON S OWN PHYSICAL ACTIVITY AND STRENGTH CAN MINIMIZE CARTILAGE VOLUME LOSS IN OLDER-ADULTS: A BETWEEN- AND WITHIN- PERSON ANALYSIS ON A POPULATION-BASED PROSPECTIVE COHORT / I. P. Munugoda* - S. Balogun - K. Wills - F. Cicuttini - G. Jones - M. L. Callisaya - D. Aitken FRI0542 POTENTIAL NOCICEPTIVE PAIN RELIEF OF INTRA-ARTICULAR SALINE CONTROL IN CLINICAL TRIALS OF KNEE OSTEOARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED TRIALS / I. Simsek* - T. Phalen - A. Bedenbaugh - J. Tambiah FRI0543 HEALTH RESOURCE USE AND COST-OF-ILLNESS OF SYMPTOMATIC KNEE AND/OR HIP OSTEOARTHRITIS: DATA FROM KHOALA COHORT / J. H. Salmon* - A. C. Rat - H. Achit - W. Ngueyon Sime - C. Gard - F. Guillemin - D. Jolly - B. Fautrel FRI0544 URINARY 6-SULFATOXYMELATONIN EXCRETION AND GALECTIN-3 PLASMA LEVEL IN PATIENTS WITH OSTEOARTHRITIS / K. Zaichko* - O. Gumeniuk - M. Stanislavchuk FRI0545 RISK FACTORS PREDICTING RADIOLOGICAL PROGRESSION OF KNEE OSTEOARTHRITIS / L. Alekseeva* - S. Anikin - N. Kashevarova - E. Sharapova - E. Taskina - T. Korotkova - T. Raskina - E. Otteva - A. Dubikov - E. Zonova - I. Vinogradova FRI0546 RELATIVE EFFICACY OF DIFFERENT EXERCISES IN KNEE AND HIP OSTEOARTHRITIS / S. L. Goh* - M. S. M. Persson - J. Stocks - Y. F. Hou - J. H. Lin - M. Hall - M. Doherty - W. Zhang FRI0547 IN HAND OSTEOARTHRITIS, DECREASE IN SYNOVITIS RESULTS IN LESS JOINT PAIN; A LONGITUDINAL MAGNETIC RESONANCE IMAGING STUDY / S. Van Beest* - W. Damman - R. Liu - M. Reijnierse - F. R. Rosendaal - J. L. Bloem - M. Kloppenburg FRI0548 ASSOCIATION OF OMERACT CORE DOMAINS OF PAIN AND FUNCTION WITH PATIENT SATISFACTION AFTER TOTAL JOINT REPLACEMENT / S. M. Goodman* - B. Mehta - L. A. Mandl - J. Szymonifka - M. P. Figgie - I. Navarro-Millan - M. Bostrom - D. E. Padgett - A. S. McLawhorn - S. Lyman - J. Singh FRI0549 OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA) PATIENTS HAVE SIMILAR DISEASE BURDENS AT FIRST VISIT TO AN ACADEMIC RHEUMATOLOGY SETTING, BUT OA PATIENTS HAVE A HIGHER BURDEN AT A 6-MONTH FOLLOW-UP VISIT / J. Chua - I. Castrejon - J. A. Block - A.-M. Malfait - T. Pincus* FRI0550 DIFFERENTIAL IMPACT OF OBESITY, STRUCTURAL SEVERITY AND THEIR COMBINATION ON THE EFFICACY OF VISCOSUPPLEMENTATION IN PATIENTS WITH KNEE OSTEOARTHRITIS. POST-HOC ANALYSIS OF A DOUBLE-BLIND, CONTROLLED, MULTICENTER, RANDOMISED TRIAL / T. Conrozier* - F. Eymard - X. Chevalier - J.-C. Balblanc FRI0551 COMPARISON OF PHYSICAL ACTIVITY (PA) BETWEEN PATIENTS WITH DIFFERENT STAGES OF OSTEOARTHRITIS (OA) AND THE GENERAL POPULATION: A CROSS-SECTIONAL STUDY / T. Pelle* - A. Claassen - J. Meessen - W. Peter - T. Vliet Vlieland - K. Bevers - J. van der Palen - F. van den Hoogen - C. van den Ende FRI0552 SM04690, A WNT PATHWAY INHIBITOR: ANTI-INFLAMMATORY AND CARTILAGE PROTECTIVE EFFECTS IN PRECLINICAL OA MODELS / V. Deshmukh* - T. Seo - C. Swearingen - Y. Yazici FRI0553 THE ROLE OF AGE-RELATED SARCOPENIA IN OSTEOARTHRITIS OF LOWER EXTREMITY / Y. Safonova* - E. Zotkin 15 June 2018 TOPIC: DIAGNOSTICS AND IMAGING PROCEDURES FRI0554 WHICH AXIAL MAGNETIC RESONANCE IMAGING COMBINATION IS OPTIMAL FOR ASSESSING ACTIVITY IN SPONDYLOARTHRITIS? / M. Plier - F. Lecouvet - N. Michoux - M. S. Stoenoiu - B. R. Lauwerys - A. Nzeusseu Toukap* FRI0555 MUSCLE ELASTOGRAPHY AS A POTENTIAL NOVEL IMAGING BIOMARKER IN MYOSITIS / A. M. Alfuraih - A. L. Tan* - P. O Connor - P. Emery - R. J. Wakefield FRI0556 AUTOMATED SCORING OF KNEE OSTEOARTHRITIS (OA) ON ROUTINE RADIOGRAPHS IDENTIFIES DISEASE SEVERITY IN OA / A. Law* - L. Assi - A. Harrison - F. A. Howe - N. Sofat FRI0557 THERMOGRAPHIC ANALYSIS OF HANDS AND WRISTS OF RHEUMATOID ARTHRITIS PATIENTS / A. Gatt - A. Borg* - C. Mercieca - A. Grech Scalpello - L. Camilleri - C. Gatt - N. Chockalingam - C. Formosa FRI0558 FURTHER VALIDATION OF THE US7 SCORE IN A LARGE COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH DIFFERENT DISEASE STAGES / A. F. Podewski* - A.-M. Glimm - I. Fischer - G. A. W. Bruyn - G.-R. Burmester - M. Backhaus - S. Ohrndorf FRI0559 BIOMECHANICAL PROPERTIES OF RADIAL BONE ARE DIFFERENT BETWEEN AUTO-ANTIBODY POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS / F. Stemmler - D. Simon - A.-M. Liphardt - M. Englbrecht - J. Rech - A. Hueber - K. Engelke - G. Schett - A. Kleyer* FRI0560 QUANTITATIVE CT INDEXES IN THE EVALUATION OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS / C. Bertolazzi* - M. Silva - J. Rojas-Serrano - A. Carnevale - N. Sverzellati - M. Gutierrez - A. Alfaro- Rodriguez - A. Ariani FRI0561 MACROPHAGE PET IMAGING FOR PREDICTING TREATMENT OUTCOME OF DE NOVO RHEUMATOID ARTHRITIS / N. Verweij - S. Bruijnen - L. Rasch - S. Turk - M. Yaqub - A. Lammertsma - O. Hoekstra - D. van Schaardenburg - A. Voskuyl - W. Lems - C. van der Laken* FRI0562 ASSOCIATION BETWEEN JOINT REGIONS WITH ULTRASOUND-DETERMINED SYNOVITIS AND SYSTEMIC INFLAMMATORY MARKERS / D. Nakagomi* - K. Ikeda - K. Kobayashi - S. Hanai - M. Yamagata - R. Koh - S. Furuta - H. Nakajima - K. Kitamura FRI0563 MUSCULOSKELETAL ULTRASOUND (MSUS) IS SUPERIOR TO CLINICAL EXAMINATION REGARDING DETECTION OF ARTHRITIS IN PATIENTS WITH SYSTEMIC SCLEROSIS / D. Feldmann* - R. E. Voll - F. Kollert - S. Finzel * Presenting author

126 124 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0564 ULTRASONOGRAPHIC EVALUATION OF SHOULDER TENDONS IN PATIENTS WITH HASHIMOTO S DISEASE / D. E. Buyuksireci* - D. Tecer - B. Bolayir - M. E. E. Yon - M. Akturk - F. Gogus FRI0565 ERAMRS: A NEW MR SCORING SYSTEM FOR EARLY RHEUMATOID ARTHRITIS / F. Xiao* - J. Yue - L.-S. Tam - J. Griffith FRI0566 OEDEMA-FIBROSIS IN SYSTEMIC SCLEROSIS: COMPARISON OF A PARAMETRIC CARDIOVASCULAR MAGNETIC RESONANCE MODEL TO THE LAKE LOUISE CRITERIA / G. Markousis-Mavrogenis* - L. Koutsogeorgopoulou - D. Apostolou - G. Katsifis - P. Argyriou - S. Velitsista - L. Papa - M. Kanoupaki - E. Agelopoulos - E. Vernardos - G. Kanoupakis - G. Kolovou - S. I. Mavrogeni FRI0567 THE DIAGNOSTIC VALUE OF AUTOANTIBODY ISOTYPES IN RHEUMATOID ARTHRITIS / D. Sieghart - A. Platzer - P. Studenic - F. Alasti - M. Grundhuber - S. Swiniarski - S. Blueml - H. Haslacher - J. Smolen - G. Steiner* FRI0568 MR - ENTEROGRAPHY FINDINGS OF INTESTINAL INFLAMMATION IN SPONDYLOARTHRITIS WITH HIGH FAECAL CALPROTECTIN LEVELS / I. Ergenç* - E. Uner - R. Ergelen - G. Haklar - N. İmeryüz - Ö. Atuğ - P. Atagündüz FRI0569 TO WHAT EXTENT IS INTEROBSERVER RELIABILITY FOR DETECTING ULTRASOUND URATE CRYSTAL DEPOSITS DEPENDENT ON THE EXPERIENCE OF THE ULTRASONOGRAPHER? / J. Uson* - E. Garmendia - C. Moragues - J. J. de Agustin - L. Mayordomo - E. de Miguel - H. Corominas - J. Garrido - E. Naredo FRI0570 SERUM KL-6 LEVEL REFLECTS SEVERITY OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONNECTIVE TISSUE DISEASE / J. S. Lee* - E. Y. Lee - J. K. Park - Y.-J. Ha - E. H. Kang - Y. J. Lee - Y. W. Song FRI0571 ADDITIONAL SCREENING FOR LOW THORACIC BONE MINERAL DENSITY IN PATIENTS REFERRED FOR CARDIAC CT - A DANISH, MULTI-CENTER, AND CROSS-SECTIONAL STUDY / J. Therkildsen* - S. Winther - H. S. Jørgensen - L. Nissen - J. Thygesen - P. Ivarsen - E.-M. Hauge - M. Böttcher FRI0572 PREVALENCE OF ECHOCARDIOGRAPHIC FINDINGS IN CONNECTIVE TISSUE DISEASES - A RETROSPECTIVE COHORT STUDY / K. Weiss* - W. A. Schmidt - A. Krause - V. S. Schäfer FRI0573 ULTRASONOGRAPHY AND HISTOLOGICAL DIAGNOSIS CONCORDANCE IN PATIENS WITH SUSPECTED PRIMARY SJÖGREN SYNDROME / L. Barrio Nogal* - C. Bohórquez - A. Perez Gómez - A. Castelló - M. J. León - P. Pretel - M. Álvarez de Mon FRI0574 RADIOFREQUENCY ECHOGRAPHIC MULTI SPECTROMETRY (REMS) FOR THE NON-IONIZING DIAGNOSIS OF OSTEOPOROSIS AT FEMORAL NECK: RESULTS OF A MULTICENTER CLINICAL STUDY COMPARING REMS AND DXA / L. Cavalli* - G. Arioli - G. Bianchi - C. Caffarelli - M. Matucci Cerinic - L. Cianferotti - F. Conversano - M. Di Paola - D. Gatti - G. Girasole - A. Giusti - S. Gonnelli - M. Manfredini - M. Muratore - R. Nuti - P. Pisani - E. Quarta - M. Rossini - O. Viapiana - M. L. Brandi FRI0575 EVALUATION OF SCREENING QUESTIONNAIRES FOR PSORIASIC ARTHRITIS IN A SAMPLE OF PATIENTS WITH PSORIASIS IN A THIRD LEVEL HOSPITAL / M. D. Ruiz Montesino* - V. MOREIRA NAVARRETE - A. M. Carrizosa Esquivel - C. León Caro - J. J. Pérez Venegas - D. Mendoza Mendoza FRI0576 PULMONARY ULTRASOUND IN THE ASSESSMENT OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS / M. Moreno* - K. Almaguer - J. Gutierrez - A. Bernal-Gonzalez - C. Bertolazzi - E. Cruz-Arenas - C. Pineda - S. Ruta - M. Gutierrez FRI0577 MRI-BONE MARROW OEDEMA COMBINED WITH LOW-DOSE CT SCANNING PERFORM OPTIMALLY IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS / L. Ye - M. A. Brown* - D. Chen FRI0578 INCREASED VEIN WALL THICKNESS IN BEHÇET S SYNDROME / M. Gjoni* - E. S. Durmaz - S. Akbaş - A. S. Dikici - I. Mihmanlı - H. Yazıcı - E. Seyahi FRI0579 DIAGNOSTIC UTILITY OF METATARSOPHALANGEAL SYNOVITIS IDENTIFIED BY ULTRASONOGRAPHY FOR EARLY RHEUMATOID ARTHRITIS / M. Okamoto* - K. Fujikawa - A. Mizokami - Y. Endo - M. Mine - A. Kawakami FRI0580 QUANTITATIVE MRI OF SINGLE VS. MULTIPLE JOINTS IN JUVENILE IDIOPATHIC ARTHRITIS AS PREDICTIVE MEASURE OF CLINICAL OUTCOMES / N. Tzaribachev* - O. Kubassova - M. Hinton - M. Boesen FRI0581 ULTRASONOGRAPHY IN THE DETECTION OF JOINT DESTRUCTION IN RA PATIENTS: A COMPARISON WITH CONVENTIONAL RADIOGRAPHY / O. Alekseeva* - A. Smirnov - S. Glukhova - A. Volkov - E. Nasonov FRI0582 CHANGE IN MUSCLE VOLUME AND MUSCLE FAT FRACTION AS POTENTIAL NON-INVASIVE BIOMARKERS OF DISEASE PROGRESSION: MACHINE LEARNING FRAMEWORK FOR QUANTITATIVE ANALYSIS OF MRI DATA / D. Fischer - P. Hafner - S. Schmidt - M. Hinton - J. Gonzalez - O. Kubassova* FRI0583 CLINICAL UTILITY OF ANA-ELIA VS ANA-IMMUNOFLUORESCENCE IN CONNECTIVE TISSUE DISEASE / O. Alsaed* - L. Alamilah - O. Al-Radideh - M. Elkhalifa - A.-W. Al-Allaf FRI0584 FLUORESCENCE OPTICAL IMAGING ENHANCEMENT IS ASSOCIATED WITH JOINT PAIN IN HAND OSTEOARTHRITIS / Ø. Maugesten* - S. Ohrndorf - S. V. Hestetun - B. Slatkowsky-Christensen - T. K. Kvien - T. Uhlig - I. K. Haugen FRI0585 PREVALENCE OF ANTI-ACETYLATED PROTEIN ANTIBODIES IN INFLAMMATORY ARTHRITIS, OSTEOARTHRITIS, CONNECTIVE TISSUE DISEASES AND ITS DISCRIMINATIVE CAPACITY AS DIAGNOSTIC MARKER FOR EARLY RHEUMATOID ARTHRITIS / P. Studenic* - H. Bang - A. Alunno - D. Sieghart - D. Aletaha - S. Blüml - H. Haslacher - J. S. Smolen - G. Steiner FRI0586 LONGITUDINAL ASSESSMENT OF CORTICAL INTERRUPTIONS AND VBMD IN RA AND HEALTHY SUBJECTS USING HR-PQCT / M. Peters - J. van den Bergh - P. Geusens* - A. Scharmga - D. Loeffen - R. Weijers - B. van Rietbergen - A. van Tubergen FRI0587 LOW BACK PAIN DUE TO ENTHESOPATHY OF ERECTOR SPINE MUSCLE: A COMPARATIVE US AND MRI STUDY IN PATIENTS WITH ILIAC CREST PAIN SYNDROME / P. T. Todorov* - M. Kalcheva - A. Marinkov - A. Batalov FRI0588 ULTRASOUND COULD HAVE PREVENTED DMARD ESCALATION IN RHEUMATOID ARTHRITIS WITH FIBROMYALGIA / R. Chakr* - J. C. O. Santos - L. D. S. Alves - N. P. B. D. Andrade - A. Ranzolin - C. V. Brenol FRI0589 A JOINT PROCEDURAL RECOMMENDATION ON FDG-PET/CT(A) IMAGING IN LARGE VESSEL VASCULITIS AND POLYMYALGIA RHEUMATICA FROM THE CARDIOVASCULAR AND INFLAMMATION & INFECTION COMMITTEES OF THE EANM, THE CARDIOVASCULAR COUNCIL OF THE SNMMI, THE PET INTEREST GROUP (PIG), AND ENDORSED BY THE ASNC / R. Slart* on behalf of Members of EANM Cardiovascular, EANM Infection & Inflammation Committees, SNMMI Cardiovascular Council, PET Interest Group, and ASNC FRI0590 ULTRASOUND EXAMINATOIN OF THE WRIST JOINTS: FREQUENCY OF CRISTAL DEPOSITS (CHONDROCALCINOSIS) IN PATIENTS WITH DIFFERENT ARTHROPATHIES / R. Osipyants* - M. Eliseev - S. Vladimirov - K. Ilinykh * Presenting author

127 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 125 FRI0591 WHOLE-BODY MRI DEMONSTRATES REDUCTION OF INFLAMMATION IN PERIPHERAL JOINTS AND ENTHESES DURING TNF-INHIBITOR TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, BUT ALSO AGE- DEPENDENT PERSISTENT INFLAMMATION IN JOINTS PRONE TO OSTEOARTHRITIS / S. Krabbe* - M. Østergaard - I. Eshed - I. J. Sørensen - J. Møller - B. Jensen - O. R. Madsen - M. Klarlund - S. J. Pedersen FRI0592 SCORING MRI INFLAMMATION AND STRUCTURAL LESIONS IN SACROILIAC JOINTS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: IS INTER-READER RELIABILITY DEPENDENT ON THE NUMBER OF MRI SLICES? / S. Krabbe* - G. Kröber - M. Østergaard - S. J. Pedersen - J. Møller - I. J. Sørensen - B. Jensen - O. R. Madsen - M. Klarlund - U. Weber FRI0593 MANTOUX TEST IS INADEQUATE TO DEFINE ALL SUBJECTS WITH LATENT TUBERCULAR INFECTION / S. Arya* - S. Kumar - A. Nath - P. Kapoor - A. Aggarwal - R. Misra - S. Sinha FRI0594 RETROCALCANEAL BURSITIS PRECEDES OR ACCOMPANIES ACHILLES TENDON ENTHESITIS IN THE EARLY PHASE OF RHEUMATOID ARTHRITIS / T. Suzuki* - Y. Hidaka - Y. Seri FRI0595 THE BEACH TOOL: A QUANTITATIVE MRI-BASED METHOD FOR MEASURING OEDEMA AND FAT METAPLASIA IN SPONDYLOARTHRITIS / T. J. Bray* - A. Dudek - N. Sakai - K. Rajesparan - C. Fisher - C. Ciurtin - D. Sen - A. Bainbridge - M. A. Hall-Craggs FRI0596 FEASIBILITY OF JOINT STRUCTURAL ANALYSIS IN HEMOCHROMATOSIS HAND ARTHROPATHY USING HIGH- RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY - FIRST RESULTS AND CLINICAL CORRELATIONS / U. R. Heilmeier* - A. J. Burghard - P. Kapoor - R. E. Voll - S. Finzel FRI0597 VALIDATION OF WEB-BASED CALIBRATION MODULES FOR IMAGING SCORING SYSTEMS BASED ON PRINCIPLES OF ARTIFICIAL INTELLIGENCE: THE SPARCC MRI SACROILIAC JOINT INFLAMMATION SCORE / W. P. Maksymowych* - S. Krabbe - D. Biko - P. Weiss - M. P. Maksymowych - J. Cheah - G. Kröber - U. Weber - K. Danebod - P. Bird - P. Chiowchanwisawakit - J. Moeller - M. Francavilla - J. Stimec - T. Kogay - V. Zubler - M. Battish - N. Winn - D. Rumsey - R. Guglielmi - S. J. Pedersen - H. Boutrup - S. Shafer - J. Jaremko - F. Malik - E. Heffernan - M. P. Johansson - B. Trinh - J. Paschke - R. G. Lambert FRI0598 THE AGREEMENTS BETWEEN CLINICAL SIGNS AND ULTRASOUND-DETERMINED JOINT INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / X. Sun* - X. Deng - W. Xie - Y. Geng - L. Ji - X. Zhang - Z. Zhang FRI0599 THE RELEVANCE OF THERMOGRAPHY AND NAILFOLD CAPILLAROSCOPY IN OLDER PATIENTS WITH PRIMARY AND SECONDARY RAYNAUD S PHENOMENON / S. van Vugt - Y. Vreeburg* - L. van Vugt - G. Schardijn 15 June 2018 TOPIC: PUBLIC HEALTH, HEALTH SERVICES RESEARCH AND HEALTH ECONOMICS Poster tour F12: You can do better studies if you know how Loreto Carmona (Spain), Antonis Fanouriakis (Greece) Abstracts N : FRI0600-FRI0609 FRI0600 METHODS FOR THE ANALYSIS OF ADHERENCE DATA FROM A MEDICATION EVENT MONITORING SYSTEM (MEMS): A SYSTEMATIC REVIEW / L. Hartman* - W. Lems - M. Boers FRI0601 THE NATURE AND EXTENT OF DATA ITEMS COLLECTED ACROSS EUROPEAN PREGNANCY REGISTERS - FIRST RESULTS OF THE EUROPEAN NETWORK OF PREGNANCY REGISTERS IN RHEUMATOLOGY (EUNEP) / Y. Meissner* - A. Strangfeld - N. Costedoat-Chalumeau - F. Förger - A. Molto - M. Wallenius - R. Fischer-Betz FRI0602 EULAR POINTS TO CONSIDER FOR THE CONDUCTION OF WORKFORCE REQUIREMENT STUDIES IN RHEUMATOLOGY / C. Dejaco* - P. Putrik - J. Unger - D. Aletaha - G. Bianchi - J. W. Bijlsma - A. Boonen - N. Cikes - A. Finckh - L. Gossec - T. K. Kvien - J. Madruga Dias - E. Matteson - F. Sivera - T. Stamm - Z. Szekanecz - D. Wiek - A. Zink - S. Ramiro - F. Buttgereit FRI0603 THE POTENTIAL USES OF AN INFODEMIOLOGY APPROACH FOR HEALTH-CARE SERVICES IN RHEUMATOLOGY / A. Gallardo-Castro* - G. Martinez-Arroyo - S. Ramos-Gomez - A. Villarreal-Castellanos - A. S. Meza-Lopez - A. Barajas-Ochoa - E. K. Rojero-Gil - J. D. Castillo-Ortiz - L. P. Bustamante-Montes - C. Ramos-Remus FRI0604 TRENDS OF INFORMED CONSENT FORMS FOR INDUSTRY-SPONSORED CLINICAL TRIALS IN RHEUMATOLOGY OVER A 17-YEAR PERIOD: READABILITY, AND ASSESSMENT OF PATIENTS HEALTH LITERACY AND PERCEPTIONS / A. S. Meza-Lopez* - A. Gallardo-Castro - A. Villarreal-Castellanos - A. Barajas-Ochoa - J. Yanez - L. P. Bustamante-Montes - C. Ramos-Remus FRI0605 THE DEVELOPMENT PROCESS OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES IS HETEROGENEOUS AND OFTEN INCOMPLETE: RESULTS OF A SYSTEMATIC LITERATURE REVIEW / A. Najm* - E. Nikiphorou - L. Gossec - F. Berenbaum FRI0606 THE LIFT STUDY S DIRECT-TO-PATIENT DESIGN PROVIDES RELIABLE SELF-REPORTED DATA FROM LUPUS PATIENTS / A. Cheeks - L. Borisov - K. Warren - R. Terbrueggen* FRI0607 HOW TO DESIGN CLINICAL TRIALS TO BE MORE PATIENT ORIENTED: AN EXAMPLE FROM PREVENTATIVE TREATMENTS FOR RHEUMATOID ARTHRITIS / N. Bansback* - M. Hudson - C. Koehn - T.-L. Laba - M. Harrison FRI0608 A SYSTEMATIC REVIEW AND CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS / S. P. Gavan* - I. N. Bruce - K. Payne FRI0609 EUROPEAN MEDICINES AGENCY S GUIDELINE ON THE CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS / D. Da Silva* - E. Rook - N. Semis-Costa - J. Mueller-Berghaus - R. Vesely on behalf of the Rheumatology and Immunology Working Party of the Committee for Medicinal Products for Human Use from the European Medicines Agency FRI0610 PATIENT NON-ATTENDANCE CHARACTERISTICS AT RHEUMATOLOGY OUTPATIENT CLINICS WITHIN A LARGE MULTI-ETHNIC REGION / A. Takyi* - K. Sunmboye FRI0611 ENGLISH LANGUAGE PROFICIENCY AND TOTAL KNEE / HIP REPLACEMENT OUTCOMES: IS THERE A RELATIONSHIP? / B. Mehta* - J. Szymonifka - S. A. Dey - I. Y. Navarro-Millan - S. V. Grassia - L. A. Mandl - A. R. Bass - L. A. Russell - M. L. Parks - M. P. Figgie - Y.-Y. Lee - J. T. Nguyen - S. M. Goodman FRI0612 HOW EFFECTIVE ARE INTERVENTIONS TARGETING PATIENT ACTIVATION IN PEOPLE WITH LONG-TERM PHYSICAL CONDITIONS? A SYSTEMATIC REVIEW / B. Jones* - S. Hewlett - D. Harcourt - A. Hunt - E. Dures * Presenting author

128 126 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0613 USEFULNESS OF SMARTPHONES APPLICATIONS IN THE FOLLOW-UP OF PATIENTS WITH INFLAMMATORY RHEUMATOLOGICAL DISEASES: ARE THEY REALLY BENEFICIAL IN OBJECTIVE TERMS? / C. A. Guillen-Astete* - B. Laso-Jimeno FRI0614 PHYSICIAN-PATIENT INTERACTIONS IN AFRICAN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. Drenkard* - G. Bao - T. T. Lewis - B. F. Pobiner - J. Priest - S. S. Lim FRI0615 NORMALISED TOXICITY TO PREGABALIN DID NOT INCREASE WITH CHANGES IN APPROVAL MECHANISM AND USE IN AUSTRALIA / C. McMaster - D. F. L. Liew* - E. Joules - J. Robinson - S. Greene - R. R. C. Buchanan - A. G. Frauman FRI0616 COST-EFFECTIVENESS OF SWAPPING STRATEGY FOR ESTABLISHED PSORIATIC ARTHRITIS AND IMMEDIATE VERSUS STANDARD SWAPPING STRATEGY FOR EARLY PSORIATIC ARTHRITIS / D. Wu* - T. Xu - I. T. Cheng - S. H.M. Lam - J. Yue - P. Wong - E. K. Li - T. K. Li - L.-S. Tam FRI0617 UPTAKE ON FLU AND PNEUMONIA VACCINATION AT THE RHEUMATOLOGY CLINIC AT A UK DISTRICT GENERAL HOSPITAL- ARE WE BETTER THAN 10 YEARS AGO? / E. Ntatsaki* - A. Tahir - A. Jiskani - A. Mohammed - V. Vassiliou - R. Watts FRI0618 CONCORDANCE WITH LATEST GUIDELINES FOR DMARD SCREENING AND MONITORING IN SECONDARY CARE / E. Cefai* - D. Xhaxho - C. Mercieca - A. Borg FRI0619 PREDICTORS AND TEMPORAL TREND OF SEASONAL INFLUENZA VACCINATION IN AUTO-IMMUNE RHEUMATIC DISEASES IN THE UK: A NATIONWIDE PROSPECTIVE COHORT STUDY / G. Nakafero* - M. Grainge - P. Myles - C. Mallen - W. Zhang - M. Doherty - J. Van-Tam Nguyen - A. Abhishek FRI0620 LOW EDUCATIONAL ATTAINMENT IS ASSOCIATED WITH POOR PATIENT STATUS AT THE INITIAL VISIT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR OSTEOARTHRITIS (OA) AT THE INITIAL VISIT TO A RHEUMATOLOGY SETTING, WITH SIMILAR PATTERNS IN PATIENTS WITH EITHER DIAGNOSIS / J. Schmukler - I. Castrejon* - T. Pincus - J. Block FRI0621 HOSPITAL ADMISSIONS AND READMISSIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS. ASSOCIATED FACTORS AND DIRECT HEALTH-CARE COSTS IN A THIRD LEVEL UNIVERSITY HOSPITAL / J. E. Ruiz-Sará* - N. Lozano-Rivas - P. Castillo Dayer - C. García-Belando - A. Paños-Iniesta - L. F. Linares - A. Bermudez - F. A. Martínez-Angosto - J. Martínez-Ferrín - M. J. Moreno - M. Castaño - P. Mesa del Castillo - F. García Gambín - F. Andrade Rodado - C. Marras-Fernández Cid FRI0622 TRENDS IN ENCOUNTERS WITH RHEUMATOLOGISTS IN A PUBLICLY-FUNDED SINGLE PAYER HEALTHCARE SYSTEM / J. Widdifield* - S. Bernatsky - V. Ahluwalia - C. Barber - L. Eder - B. Kuriya - V. Ling - A. Lyddiatt - M. Paterson - J. Pope - C. Thorne FRI0623 COST-EFFECTIVENESS ANALYSIS FOR THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) COMPARED TO STANDARD OF CARE IN SINGAPORE / J. N. Chua* - M. Lahiri - P. P. Cheung - J. Yoong FRI0624 MUSCULOSKELETAL PROBLEMS AMONGST TRAIN OPERATORS: A COLLABORATIVE APPROACH TO IDENTIFY SOLUTIONS / J. Erwin* - J. Howarth - L. Chauhan - A. Webster - A. Woolf FRI0625 DIFFERENT STRATEGIES TO IMPLEMENT THE EULAR GUIDELINE FOR CARDIOVASCULAR RISK MANAGEMENT IN DAILY PRACTICE / J. Weijers* - P. Dessein - D. Galarza-Delgado - M. González-Gay - B. Kuriya - E. Myasoedova - A. Semb - S. Wållberg-Jonsson - P. van Riel on behalf of Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA) FRI0626 SCREENING FOR TUBERCULOSIS BEFORE TNF INHIBITOR THERAPY REMAINS SUBOPTIMAL: A MULTI-SPECIALTY, REAL WORLD, NATIONWIDE EXPERIENCE IN THE UNITED STATES / K. Ladak* - T. J. Pan - C. MacLean FRI0627 INADVERTENT YELLOW FEVER VACCINATION OF PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE IN PRIVATE PRACTICE / L. Fernandes* - M. Pippa - C. Macedo - J. Brudnewski - F. Palacios - H. Mahlmann - L. Aliberti - J. Kochen - R. Aurichio - E. Dourador - F. Omura - F. Hehn - M. Baricelli - P. Lerner - S. Lee - M. Anauate - E. Azeka - L. Rodrigues - T. Silva - M. Costa - A. Hayata - G. Pileggi - I. Laurindo FRI0628 DIGITAL TECHNOLOGIES TO PROMOTE SELF-MANAGEMENT IN MUSCULOSKELETAL HEALTH: A SYSTEMATIC REVIEW / L. Sammut* - N. Arafin - Y. Prior FRI0629 PATIENT-TARGETED SMARTPHONE APPS FOR SYSTEMIC LUPUS ERYTHEMATOSUS: A SYSTEMATIC REVIEW AND ASSESSMENT OF FEATURES AND QUALITY / M. Pourrahmat* - M. A. De Vera FRI0630 CAN COMMUNITY PHARMACY SERVICES BE THE MISSING LINK IN ACHIEVING EARLY DIAGNOSIS OF PSORIATIC ARTHRITIS? / P. Mehra - M. K. Nisar* FRI0631 WORKFORCE REQUIREMENTS IN RHEUMATOLOGY: A SYSTEMATIC LITERATURE REVIEW INFORMING THE DEVELOPMENT OF A WORKFORCE PREDICTION QUALITY APPRAISAL TOOL / P. Putrik - J. Unger* - F. Buttgereit - D. Aletaha - G. Bianchi - J. W. Bijlsma - A. Boonen - N. Cikes - J. Madruga Dias - L. Falzon - A. Finckh - L. Gossec - T. K. Kvien - E. Matteson - F. Sivera - T. Stamm - Z. Szekanecz - D. Wiek - A. Zink - C. Dejaco - S. Ramiro FRI0632 IMPACT OF A TIGHT CONTROL MULTIDISCIPLINARY RHEUMATOLOGY PROGRAM ON THE QUALITY OF LIFE OF PATIENTS WITH AUTOIMMUNE DISEASES IN COLOMBIA / R. Pineda-Tamayo* - M.-A. Alzate - D. Hernandez-Parra - D. Echeverry - P. Ortiz-Salazar - A. Rojas-Villarraga FRI0633 HOW DO WE IMPLEMENT THE EULAR RECOMMENDATION THAT RHEUMATOLOGISTS CAN SEE EARLY ARTHRITIS PATIENTS WITHIN SIX WEEKS AFTER SYMPTOM ONSET? A FIVE-YEAR COMPARATIVE STUDY OF AN EARLY ARTHRITIS RECOGNITION CLINIC / R. M. Ten Brinck* - B. T. van Dijk - H. W. van Steenbergen - A. H. van der Helm-van Mil FRI0634 COST SAVINGS OF USING HLA-B*27 TAG SNP GENOTYPING TO DETERMINE HLA-B*27 STATUS IN A CANADIAN POPULATION / S. Mital* - D. O Rielly - H. V. Nguyen - P. Rahman FRI0635 MEDICATION ADHERENCE IN PATIENTS WITH RHEUMATIC DISEASES: A QUALITATIVE STUDY IN A BIOLOGICS CLINIC / S. Raghunath* - R. Hijjawi - E. Hoon - E. M. Shanahan - F. Goldblatt FRI0636 THE VALUE OF PERSISTENCE IN TREATMENT WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS FOR ANKYLOSING SPONDYLITIS / M. Ivergård - J. Dalén - A. Svedbom - C. M. Black - R. H. Borse - S. Kachroo* FRI0637 BARRIERS TO REMAIN IN WORK: RESULTS FROM THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY SURVEY (NRAS) / S. Verstappen* - L. Lunt - A. Bosworth - M. Bezzant - K. Walker-Bone * Presenting author

129 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 127 FRI0638 A NOVEL GROUP CLINIC MODEL FOR NEW PATIENTS ENHANCES PATIENT ACTIVATION / T. Jones* - A. Morbi - M. Grove - F. Birrell FRI0639 THE IMPACT OF DISEASE ACTIVITY AND PAIN LEVEL ON PRODUCTIVITY IN RHEUMATOID ARTHRITIS (RA) PATIENTS / J. Galloway - J.-P. Capron - F. De Leonardis - W. Fakhouri - T. Burke* TOPIC: VALIDATION OF OUTCOME MEASURES AND BIOMARKERS Poster tour F13: Searching for outcome measures João E. Fonseca (Portugal), Vasco C. Romao (Portugal) Abstracts N : FRI0640-FRI0649 FRI0640 AUTOANTIBODIES TO TWO NOVEL PEPTIDES IN SERONEGATIVE AND EARLY RHEUMATOID ARTHRITIS IN THREE LARGE INDEPENDENT COHORTS / L. De Winter - P. Vandormael* - V. Stouten - H. W. van Steenbergen - P. Geusens - J. Lenaerts - A. H. M. van der Helm-van Mil - P. Verschueren - V. Somers FRI0641 DETECTION OF CHANGES IN SLE DISEASE ACTIVITY IS HIGHLY IMPROVED WITH SLE-DAS AS COMPARED TO SLEDAI: DERIVATION AND PRELIMINARY VALIDATION OF THE SLE DISEASE ACTIVITY SCORE (SLE-DAS) / D. Jesus* - A. Matos - C. Henriques - M. Zen - A. Doria - D. S. JAP - L. Inês FRI0642 SEPTIC ARTHRITIS SCREENING WITH A FAST DIAGNOSTIC TOOL USING MID INFRARED SPECTROSCOPY: A MULTI-CENTRIC STUDY / J.-D. Albert* - M. Le Corvec - A. Martin - X. Guennoc - C. David - S. Hoang - C. Guedes - M. Ferreyra - E. Hoppe - B. Legoff - S. Jousse-Joulin - H. Tariel - O. Sire - A. Jolivet-Gougeon - P. Guggenbuhl - O. Loreal FRI0643 AUTOANTIBODY STATUS IS NOT ASSOCIATED WITH EARLY TREATMENT RESPONSE TO FIRST-LINE METHOTREXATE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / J. S. Dekkers* - S. A. Bergstra - A. Chopra - M. Tikly - J. E. Fonseca - K. Salomon-Escoto - T. Huizinga - D. van der Woude FRI0644 THE USE OF MRI-DETECTED SYNOVITIS TO DETERMINE THE NUMBER OF INVOLVED JOINTS FOR THE 2010 ACR/EULAR CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS - IS IT OF ADDITIONAL BENEFIT? / A. C. Boer* - D. Boeters - A. H. M. van der Helm-van Mil FRI0645 ANTI-DRUG ANTIBODIES TO CERTOLIZUMAB PEGOL ARE ASSOCIATED WITH LOW DRUG LEVELS AND REDUCED CLINICAL RESPONSE AT 3 MONTHS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES. DATA FROM THE NOR-DMARD STUDY / J. E. Gehin* - G. L. Goll - D. J. Warren - S. W. Syversen - J. Sexton - E. K. Strand - T. K. Kvien - N. Bolstad - E. Lie FRI0646 SYNOVIAL TISSUE HISTOPATHOLOGY FINDINGS IN EARLY RA. IS IT USEFULL? ANALYSIS OF THE BELGIAN CAP48 COHORT / C. Galant* - L. Meric De Bellefon - B. Lauwerys - T. Sokolova - M. Stoenoiu - V. Badot - A. Nzeusseu - F. Houssiau - P. Durez FRI0647 ESTIMATION OF MINIMUM CLINICALLY IMPORTANT DIFFERENCE IN FIBROMYALGIA FOR FIQR USING BPI AS THE ANCHOR MEASURE / S. Surendran* - C. B. Mithun FRI0648 DIRECTLY COMPARING LATENT FUNCTIONAL ABILITY IN ADOLESCENTS WITH JIA USING THE CHAQ AND HAQ: AN ITEM RESPONSE THEORY ANALYSIS / S. J. W. Shoop-Worrall* - M. O. Voshaar - M. van de Laar - W. Thomson - K. L. Hyrich - J. E. McDonagh - S. M. M. Verstappen on behalf of CAPS FRI0649 SYSTEMIC LEVELS OF TYPE VI COLLAGEN METABOLITES ARE ELEVATED IN RA PATIENTS AND MODULATED BY TREATMENT WITH ANTI-IL6R THERAPY / C. S. Thudium* - N. S. Gudmann - M. Karsdal - A.-C. Bay-Jensen FRI0650 THE DIAGNOSTIC VALUE OF THE AESKULISA PR3 SENSITIVE & AESKULISA MPO IN THE EUVAS-COHORT / K. Prager - N. Marte - E. Csernok - A. Lerner* - T. Matthias FRI0651 QUANTITATIVE CHEST CT PREDICTS 8-YEARS-MORTALITY AND COMORBIDITY IN SYSTEMIC SCLEROSIS / A. Ariani* - M. Silva - E. Bravi - M. Saracco - S. Parisi - F. De Gennaro - L. Idolazzi - M. De Santis - F. Girelli - F. Lumetti - A. Volpe - D. Santilli - F. Mozzani - G. Lucchini - D. Giuggioli - V. Seletti - E. Bacchini - C. Benini - E. Arrigoni - F. C. Bodini - G. Paolazzi - D. Imberti - E. Fusaro - C. A. Scirè - N. Sverzellati FRI0652 THE DEVELOPMENT AND VALIDATION OF FAMILIAL MEDITERRENEAN FEVER QUALITY OF LIFE SCALE (FMF- QOL) / C. Unal* - M. T. Duruoz FRI0653 VALIDITY OF POLYMYALGIA RHEUMATICA DIAGNOSES, AND CLASSIFICATION CRITERIA, IN PRIMARY HEALTH CARE / C. Fors - U. Bergström - M. Willim - E. Pilman - C. Turesson* FRI0654 IS THE PATIENT-ACCEPTABLE STATUS SIMILAR ACROSS 7 DOMAINS OF HEALTH IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)? POST-HOC ANALYSES FROM THE VALIDATION IN 549 PATIENTS OF THE RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) SCORE / C. Duarte* - T. Kvien - J. A. Pereira da Silva - L. Gossec on behalf of RAID working group EULAR FRI0655 TITLE: THE CONSISTENCY OF OUTCOMES REPORTED IN TRIALS OF SYSTEMIC SCLEROSIS. IMPROVING OVER TIME? / D. J. Sumpton* - A. Bigot - B. Sautenet - J. C. Craig - G. Hassett - V. Thakkar - P. Tugwell - A. Tong FRI0656 PREDICTIVE VALIDITY OF PRESENTEEISM MEASURES WITH DUAL ANSWER KEYS IN INFLAMMATORY ARTHRITIS / M. Donaldson - A. Kobza - D. E. Beaton - H. Xie - E. C. Sayre - M. A. M. Gignac - D. Lacaille* FRI0657 CONSTRUCT VALIDITY AND RESPONSIVENESS OF THREE STIFFNESS ITEMS IN RHEUMATOID ARTHRITIS: AN APPLICATION OF THE OMERACT FILTER 2.1 / E. T. Craig* - C. O. Bingham III - S. J. Bartlett - U. Haque - A. Leong - A.-M. Orbai FRI0658 PROGNOSTIC MARKERS FOR RESPONSE ACCORDING TO THE NEW ACR/EULAR 2016 RESPONSE CRITERIA FOR IDIOPATHIC INFLAMMATORY MYOSITIS / F. Espinosa-Ortega* - M. Holmqvist - M. Dastmalchi - I. Lundberg - H. Alexanderson FRI0659 INVESTIGATION OF SELF-REPORTED PAINFUL JOINT COUNT AS OUTCOME MEASURE IN HAND OSTEOARTHRITIS / F. Kroon* - J. van der Plas - S. van Beest - W. Damman - M. Kloppenburg FRI0660 USEFULNESS OF MICHIGAN HAND OUTCOMES QUESTIONNAIRE (MHQ) IN HAND OSTEOARTHRITIS / F. Kroon* - A. Boersma - A. Boonen - S. van Beest - F. Rosendaal - M. Kloppenburg 15 June 2018 * Presenting author

130 128 / SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE June 2018 FRI0661 ULTRASOUND OF SUBTALAR JOINT SYNOVITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF AN OMERACT RELIABILITY EXERCISE USING CONSENSUAL DEFINITIONS / G. A. Bruyn* - H. Siddle - P. Hanova - F. Costantino - A. iagnocco - A. Delle Sedie - M. Gutierrez - H. Hammer - E. Jernberg - D. Loeille - M. Micu - I. Moller - C. Pineda - B. Richards - M. Stoenoiu - L. Terslev - V. Vlad - R. Wonink - M. A. d Agostino - R. Wakefield FRI0662 CALPROTECTIN S100 A8/A9 IN A SOUTH AFRICAN RHEUMATOID ARTHRITIS (RA) COHORT / P. Meyer - G. Van Rooyen* - R. Anderson - M. Ally - L. Winchow - N. Govind - M. Tickly - H. Bang FRI0663 THE FINE SPECIFICITY OF ANTI-DRUG ANTIBODY RESPONSES TO ORIGINATOR AND BIOSIMILAR INFLIXIMAB: ANALYSES ACROSS FIVE DISEASES FROM THE 52-WEEK RANDOMISED NOR-SWITCH STUDY / G. L. Goll* - N. Bolstad - I. Iria - R. A. Klaasen - K. K. Jorgensen - I. C. Olsen - A. Valido - M. J. Saavedra - J. E. Fonseca - K. Lundin - D. J. Warren - E. Haavardsholm - J. Jahnsen - T. K. Kvien - J. Goncalves FRI0664 BIOMARKERS FOR RELAPSE IN PATIENTS WITH ADULT ONSET STILL S DISEASE TREATED WITH IL-6 INHIBITOR / H. Yamada* - Y. Kaneko - T. Takeuchi FRI0665 IMPACT OF THE MULTI-BIOMARKER DISEASE ACTIVITY SCORE RESULTS ON WHETHER RHEUMATOLOGISTS CHANGED BIOLOGIC THERAPY FOR RA PATIENTS / J. Curtis* - K. Ford - L. Chen - H. Yun - F. Xie FRI0666 CIRCULATING MIR-99B-5P AS A PREDICTOR OF EROSION PROGRESSION IN EARLY RHEUMATOID ARTHRITIS: A 1-YEAR FOLLOW-UP STUDY BY HR-PQCT / J. Yue* - J. F. Griffith - J. Xu - F. Xiao - L. Shi - D. Wang - P. C. Wong - E. K. Li - M. Li - T. K. Li - T. Y. Zhu - V. Hung - L. Qin - L.-S. Tam FRI0667 DEVELOPMENT AND VALIDATION OF A RHEUMATOLOGIST SATISFACTION WITH PRACTICE SCALE- THE RHEUMATOLOGIST SATISFACTION SCALE (RSS) / K. Sheth* - A. Valenzuela - S. Shoor - P. Ritter - K. Lorig FRI0668 ITEM RESPONSE THEORY TO STANDARDIZE PATIENT REPORTED PHYSICAL FUNCTION OUTCOMES; LINKING 10 COMMONLY USED QUESTIONNAIRES TO A COMMON METRIC / M. Oude Voshaar* - H. Vonkeman - D. Courvoisier - A. Finckh - L. Gossec - K. Leung Ying Ying - K. Michaud - G. Pinheiro - E. Soriano - N. Wulfraat - A. Zink - M. van de Laar FRI0669 PHYSICIAN GLOBAL ASSESSMENTS FOR DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS ARE ALL OVER THE MAP! / M. A. Turk* - J. Pope FRI0670 VALIDATION OF THE ERS-RA RISK SCORE IN THE DUTCH CARRÉ STUDY / M. Baniaamam* - M. Nurmohamed FRI0671 ADAPTATION AND VALIDATION OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE FOR USE IN SERBIA / M. I. Zlatkovic-Svenda* - M. M. Radak-Perovic - J. Milicevic - R. Stojanovic - B. Lazovic - P. Ostojic - J. Wilburn - S. McKenna FRI0672 ANTI-SACCHAROMYCES CEREVISIAE ANTIBODIES IN SPONDYLARTHROPATHIES: PREVALENCE AND ASSOCIATIONS WITH DISEASE PHENOTYPE / R. M. Ferreira* - F. Aguiar - T. M. Rocha - S. Ganhão - A. Águeda - M. Guerra - S. Pimenta - M. Bernardes - L. Costa FRI0673 DO PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM (PROMIS) COMPUTER ADAPTIVE TESTS CORRELATE WITH DISEASE ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS? / R. Trachtman* - E. T. Murray - J. Szymonifka - A. B. Adams - N. Pan - S. F. Taber - K. B. Onel - L. A. Mandl FRI0674 APPLICABILITY OF THE PSAID12 QUESTIONNAIRE AS A CORE OUTCOME MEASUREMENT IN PSA CLINICAL TRIALS: AN EVALUATION USING OMERACT FILTER 2.1 INSTRUMENT SELECTION CRITERIA / R. Holland* - P. Højgaard - B. Shea - D. Beaton - P. Tugwell - M. de Wit - W. Tillett - R. Christensen - N. McHugh - P. Mease - A.-M. Orbai FRI0675 RABIOPRED, AN INNOVATIVE THERANOSTIC TOOL TO ASSIST CLINICIANS SELECT AN OPTIMAL ANTI-TNF ALPHA BIOLOGICAL THERAPY FOR RHEUMATOID ARTHRITIS PATIENTS / S. Danilin* - E. Schordan - M. Coq - S. AIT ABBI NAZI - M. Mehdi - H. Firat - N. Arber - V. Breuil - A.-L. Demoux - A. Gül - J.-E. Gottenberg - G. Hatemi - T. Huizinga - N. Inanç - J. Vencovský - C. Jorgensen on behalf of RABIOPRED Consortium - Horizon 2020 SME Instrument program FRI0676 RESPONSIVENESS OF PATIENT REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS ) COMPUTERIZED ADAPTIVE TESTS (CATS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / S. Kasturi* - J. Szymonifka - J. Berman - K. Kirou - A. Levine - L. Sammaritano - L. A. Mandl FRI0677 PREVALENCE AND SEROLOGICAL PROFILE OF ANTI-DFS70 POSITIVE SUBJECTS: DATA FROM A ROUTINE ANA COHORT / T. Carbone* - V. Pafundi - G. Tramontano - M. Gilio - C. Esposito - M. C. Padula - A. A. Padula - S. D Angelo FRI0678 VALIDITY OF THREE 0-10 VISUAL ANALOG SCALES (VAS) FOR QUANTITATIVE PHYSICIAN ASSESSMENT OF INFLAMMATION, DAMAGE, AND DISTRESS TO SUPPLEMENT A PHYSICIAN GLOBAL ASSESSMENT 0-10 VAS / T. Pincus* - I. Castrejon - J. A. Block FRI0679 HIGH SENSITIVITY CARDIAC TROPONIN T IN PSORIATIC ARTHRITIS PATIENTS: A CROSS-SECTIONAL CONTROLLED STUDY / V. Furer* - S. Shenhar-Tsarfaty - S. Berliner - U. Arad - D. Paran - O. Rogowski - I. Shapira - H. Matz - O. Elkayam FRI0680 TETHERIN, A NOVEL TYPE I INTERFERON BIOMARKER ON BLOOD LEUCOCYTES CAN CAPTURE INTERFERON STATUS AND CORRELATES WITH USTEKINUMAB (STELARA) THERAPY RESPONSE IN PSORIATIC DISEASE / Y. M. El-Sherbiny* - L. Savage - A. Alase - E. Vital - M. Wittmann - P. Emery - D. McGonagle FRI0681 FOUR COMORBIDITY INDEXES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / Y. J. Huang* - C. F. Kuo - J. S. Chen - S. F. Luo TOPIC: REHABILITATION FRI0682 FRI0683 FRI0684 EXERCISE MAY DECREASE SYNCOPE SECONDARY TO POSTURAL CHANGE IN FEMALES WITH RHEUMATOID ARTHRITIS: PILOT STUDY / D. C. Janse Van Rensburg* - J. A. Ker - C. C. Grant - L. Fletcher INVESTIGATION OF THE RELATIONSHIP BETWEEN PLANTAR PRESSURE DISTRIBUTION AND LUMBAR MULTIFIDUS MUSCLE THICKNESS / C. Karartı - S. Bilgin - Y. Dadalı - E. Dülger* - B. Büyükturan - Ö. Büyükturan EFFICIENCY OF COMPLEX REHABILITATION PROGRAM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ABATACEPT / E. Orlova* - D. Karateev - A. Kochetkov * Presenting author

131 SCIENTIFIC POSTER SESSION II / FRIDAY 15 JUNE 2018 / 129 FRI0685 HAND FUNCTIONS ARE AFFECTED DEPENDING ON THE CURVE PATTERN IN IDIOPATHIC SCOLIOSIS / G. Yagci* - D. A. Ozcan - C. Ayhan - Y. Yakut FRI0686 THE EFFECT OF FOOT ORTHOSES ON BALANCE IN RHEUMATOID ARTHRITIS PATIENTS: A RANDOMISED CLINICAL TRIAL / J. Z. Gaino* - M. B. Bertolo - C. S. Nunes - C. M. Barbosa - Z. Sachetto - M. Davitt - E. D. P. Magalhães FRI0687 EFFECT OF PERINEURAL INJECTION THERAPY IN MODERATE AND SEVERE KNEE OSTEOARTHRITIS; A COMPARATIVE STUDY / M. H. Abu-Zaid* - S. A. Tabra - S. Elmorsy FRI0688 FAST ACCESS TO ASSESSMENT SUPPORT AND TREATMENT (FAAST): INNOVATION TO IMPROVE SERVICE / R. Laxminarayan* - A. Dean - L. Bembridge - S. Redfern - H. Nutland - M. Nisar FRI0689 A CONSERVATIVE TREATMENT OPTION FOR CARPAL TUNNEL SYNDROME: EXTRACORPOREAL SHOCK WAVE THERAPY. PROSPECTIVE, RANDOMISED, DOUBLE BLIND PLACEBO CONTROLLED STUDY / R. Kocak Ulucaköy* - F. G. Yurdakul - H. Bodur FRI0690 COMPARISON OF EFFECTIVENESS OF DIFFERENT STRETCHING EXERCISES COMBINED WITH PRESSURE RELEASE TECHNIQUE ON LATENT TRIGGER POINTS IN THE PECTORALIS MINOR MUSCLE / T. Birinci* - R. Mustafaoglu - E. Kaya Mutlu - A. Razak Ozdincler TOPIC: EDUCATION Poster tour F14: Education for better patients care Chaiperson(s): Nemanja Damjanov (Serbia), Mirjana Bukilica (Serbia) Abstracts N : FRI0691-FRI0700 FRI0691 EFFECT OF AN EDUCATIONAL INTERVENTION BASED ON CLINICAL SIMULATION IN THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN LATIN AMERICAN DERMATOLOGISTS / S. A. Mora Alfonso* - D. G. Fernández Ávila on behalf of Sociedad para la Investigación, atención y educación en enfermedades reumáticas INVEDER SAS FRI0692 ANTI-TNF TREATMENTS FOR WOMEN WITH CHRONIC INFLAMMATORY DISEASES: COMPARING ATTITUDES AND PERCEPTIONS OF PHYSICIANS IN EUROPE AND THE US / A. Tincani* - P. Taylor - R. Fischer-Betz - C. Ecoffet - E. Chakravarty FRI0693 FEARS AND MISCONCEPTIONS OF WOMEN WITH CHRONIC RHEUMATIC DISEASES ON THEIR JOURNEY TO MOTHERHOOD / A. Tincani* - P. Taylor - R. Fischer-Betz - C. Ecoffet - E. Chakravarty FRI0694 TWITTER: A NEW PLATFORM FOR PUBLIC HEALTH CAMPAIGNS: SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS AS EXAMPLES / M. Mohameden* - B. Alkhairi - C. Yuvienco FRI0695 DMARD MONITORING GUIDELINES AND SHARED PRESCRIBING IN PRIMARY CARE - IS MORE EDUCATION REQUIRED? / G. Choudhury - M. K. Nisar* FRI0696 PATIENT ACTIVATION AND ADHERENCE TO BIOLOGICAL THERAPY: PRELIMINARY RESULTS / A. Sendra-García* - M. A. Portes-Peralta - A. Moya-Gil - J. P. Ordovás-Baines - J. J. Alegre-Sancho - M. Climente-Martí FRI0697 EXPECTATIONS, MOTIVATING FACTORS AND BARRIERS TO BASIC RESEARCH AMONG YOUNG RHEUMATOLOGISTS IN GERMANY- RESULTS OF A NATIONAL ONLINE SURVEY / J. Mucke* - M. Schneider - U. Wagner - H. Schulze-Koops - A. Skapenko - J. Leipe FRI0698 SURVEY OF 1,318 PATIENTS ON THEIR KNOWLEDGE OF THE PULMONARY MANIFESTATIONS OF RHEUMATOID ARTHRITIS AND THEIR NEEDS IN TERMS OF INFORMATION AND FOLLOW-UP / C. Beller - P. Preiss - Y. Allanore* FRI0699 RHEUMATOLOGY TALKS TO THE COMMUNITY: RESULTS OF AN EDUCATIONAL INTERVENTION / S. P. Chinchilla* - J. Atxotegi - I. Urionagüena Onaindia - F. Perez-Ruiz FRI0700 PATIENTS AND RELATIVES COPING WITH INFLAMMATORY ARTHRITIS: A TEAM WORK / M. Brignon - C. Vioulac - E. Boujut - C. Delannoy - C. Beauvais - J.-S. Giraudet Lequintrec - D. Poivret - J. Kivits - A. Untas - A.-C. Rat* FRI0701 FRENCH SPECIALISTS AND IMMUNE-RELATED ADVERSE EVENTS OF CANCER IMMUNOTHERAPY: A STATE OF THE ART FROM SEVERAL NATIONAL EXPERT NETWORKS / M. Kostine* - C. Richez - J.-E. Gottenberg - O. Lambotte 15 June 2018 * Presenting author

132 130 / SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE 2018 Scientific Programme Saturday 16 June 2018 Maurizio Cutolo (Italy) Rebecca Hasseli (Germany) Camelia Frantz (France) 09:05 Abstract N SP0143 Case 1 presentation: Armful hidden telangiectasia Yannick Allanore (France) 09:15 Case 1 discussion: Light at the upper GI tract Kristina Clark (United Kingdom) 09:45 Abstract N SP0144 Case 2 presentation: The importance of maintaining control Christopher Denton (United Kingdom) 09:55 Abstract N SP0145 Case 2 discussion: Light at the lower GT tract 09:00-10:30 Hall 7.2 Clinical Science session RA: is it all in your head? 16 June :00-15:00 Registration area (Hall 2) Registration 09:00-10:30 Auditorium What is New (WIN) & How to Treat (HOT) session WIN & HOT Lancet session Johannes W. J. Bijlsma (Netherlands) Jennifer Sargent (United States) Douglas Veale (Ireland) 09:05 Abstract N SP0142 WIN: What can new insights in the pathogenesis of psoriasis and psoriatic arthritis teach the rheumatologist? Filip van den Bosch (Belgium) 09:45 HOT: New approaches in the treatment of psoriatic arthritis 09:00-10:30 Elicium 2 Challenges in Clinical Practice session The GI tract in systemic sclerosis - is there light at both ends? Learning objectives: To understand the current diagnostic options To understand the different clinical challenges To outline the current treatment options Learning objectives: To explore the mechanisms that link inflammation to depression To outline the social psychological factors that influence RA To present an overview of neuro-imaging features in RA John D. Isaacs (United Kingdom) Thomas Huegle (Switzerland) Neil Harrison (United Kingdom) 09:05 Abstract N SP0146 The link between inflammation and depression Christian Apfelbacher (Germany) 09:25 Depression, social deprivation and RA: is it preventable and treatable? Jonathan Cavanagh (United Kingdom) 09:45 Neuroimaging in RA V. Bykerk (United States) 10:05 Y. C. Lee, O. Schieir, M.-F. Valois, S. J. Bartlett, G. Boire, B. Haraoui, C. Hitchon, E. Keystone, D. Tin, C. Thorne, J. Pope on behalf of CATCH Abstract N OP0349 Remaining pain and widespread pain distribution during the first 12 months after RA diagnosis G. E. Fragoulis (United Kingdom) 10:15 J. Cavanagh, M. H. Derakhshan, C. Paterson, D. Porter, I. B. McInnes, S. Siebert Abstract N OP0350 Depression and anxiety in an early rheumatoid arthritis inception cohort. Associations with epidemiological, socioeconomic and disease features

133 SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE 2018 / :00-10:30 Forum Paediatric Rheumatology session Battling hyperinflammation in paediatric rheumatic diseases Learning objectives: Understand the mechanisms of (hyper) inflammation Recognise clinical patterns of macrophage activation syndrome Knowledge of the newest therapeutic options for hyperinflammation Lovro Lamot (Croatia) Michael Beresford (United Kingdom) Sebastian Vastert (Netherlands) 09:05 Understanding inflammation in systemic JIA; a bird eye s view Angelo Ravelli (Italy) 09:30 The clinical conundrum of diagnosing macrophage activation syndrome Fabrizio de Benedetti (Italy) 09:55 From pathogenic insight to novel therapeutic approaches of hyperinflammation R. Davies (United Kingdom) 10:20 D. De Cock, L. Kearsley-Fleet, A. Ramanan, K. L. Hyrich on behalf of British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study Abstract N OP0351 First diagnosis of uveitis is not higher among juvenile idiopathic arthritis (JIA) patients receiving etanercept compared to methotrexate 09:00-10:30 Elicium 1 Basic and Translational Science session Gut bacteria: the boss of the immune system Learning objectives: To recognise the link between microbiota, immune responses and chronic inflammatory rheumatic diseases To learn how diets influence inflammation Gabriela Riemekasten (Germany) Yi Zhao (China) Sara Vieira-Silva (Belgium) 09:05 The microbiota and inflammation K. Mankia (United Kingdom) 10:20 Z. Cheng, T. Do, J. Kang, L. Hunt, J. Meade, V. Clerehugh, A. Speirs, A. Tugnait, E. Hensor, D. Devine, P. Emery Abstract N OP0352 An increased prevalence of periodontal disease, porphyromonas gingivalis and aggregatibacter actinomycetemcomitans in anti-ccp positive individuals at-risk of inflammatory arthritis 09:00-10:30 Amtrium Health Professionals session Multi-disciplinary management of complex persistent pain Learning objectives: To be aware of the bio-psychosocial impact of persistent pain from the patient and clinician perspectives To understand how people with complex regional pain syndrome present in clinical practice and how to manage their pain through multidisciplinary interventions To be aware of current and emerging functional rehabilitation strategies for pain management Emma Dures (United Kingdom) Yeliz Prior (United Kingdom) Lone Knudsen (Denmark) 09:05 Abstract N SP0148 Pain: the role of psychology Florian Brunner (Switzerland) 09:23 CRPS - early diagnosis and first therapeutic measures Robyn Connett (United Kingdom) 09:41 Abstract N SP0149 The patient s perspective of living with complex regional pain syndrome Candy McCabe (United Kingdom) 09:59 Abstract N SP0150 Functional rehabilitation for the relief of complex persistent pain A. Hammond (United Kingdom) 10:17 Y. Prior, C. Sutton, S. Cotterill, C. Heal, E. Camacho on behalf of the A-GLOVES research team Abstract N OP0353-HPR The effects of arthritis gloves on hand pain in people with rheumatoid or inflammatory arthritis: a randomised controlled trial (A-GLOVES trial) 16 June 2018 Mario Zaiss (Germany) 09:30 Abstract N SP0147 How the gut microbiota and its metabolites impact on bone homeostasis Harry Sokol (France) 09:55 Microbiota in Crohn s disease

134 132 / SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE June :00-10:30 Emerald From Bench to Bedside Osteoarthritis: a vascular disease Learning objectives: Understand why subchondral bone angiogenesis could be a driver of osteoarthritis initiation and progression Understand how imaging methods could help to support the role of vessels in osteoarthritis Learn the epidemiological evidence and the basic hypothesis on the potential role of hypertension as a risk factor for osteoarthritis Ellen M. Gravallese (United States) Francis Berenbaum (France) Marie-Hélène Lafage-Proust (France) 09:05 OA and angiogenesis: what is special about blood vessels in bone? Philip Conaghan (United Kingdom) 09:30 Abstract N SP0151 Does imaging support the vascular nature of OA? David Felson (United States) 09:55 Abstract N SP0152 Hypertension and OA Ø. Maugesten (Norway) 10:20 S. Ohrndorf, S. V. Hestetun, T. K. Kvien, T. Uhlig, I. K. Haugen Abstract N OP0354 Radiographic erosions are associated with fluorescence optical imaging enhancement in hand osteoarthritis 09:00-10:30 PARE Room Valerie Krafft (Switzerland) 09:35 Abstract N SP0155 Nutrition - how to talk about it Faculty 09:50 Group discussion and Q&A Dieter Wiek (Germany) 10:20 Resume of the group discussions 09:00-10:30 E106/E107 EULAR Projects in Education and Training Challenging projects in education and training Learning objectives: To illustrate and discuss the ongoing projects in education and training Annamaria Iagnocco (Italy) José A. P. da Silva (Portugal) Maarten Boers (Netherlands) 09:05 Abstract N SP0156 Theory of poster design and presentation** Annamaria Iagnocco (Italy) 09:40 Abstract N SP0157 The EULAR School of Rheumatology. A challenging educational EULAR Project. Where are we now? José A. P. da Silva (Portugal) 09:55 How to deliver a presentation? ** Session followed by a poster tour on poster design led by Maarten Boers, please register at the poster tours & workshops desk, located in the registration area, Hall 2 PARE session Workshop: Is there a diet for people with RMDs? Learning objectives: Share evidence based knowledge on nutrition Share best practice by patient organisations Dieter Wiek (Germany) Nele Caeyers (Belgium) Asta Linauskas (Denmark) 09:05 Abstract N SP0153 What evidence is there that diets help people with RMDs? Corinna Elling-Audersch (Germany) 09:20 Abstract N SP0154 How to offer seminars on nutrition 10:30-12:00 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and coffee break 10:30-12:00 Poster area Guided poster tours Guided poster tours on various topics are taking place during the official poster viewing. For details on the various tours on Saturday, please refer to page 137. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour.

135 SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE 2018 / :00-13:30 Auditorium EULAR Projects in Clinical Affairs Recommendation session ESSCA Ulf Müller-Ladner (Germany) Désirée van der Heijde (Netherlands) Ori Elkayam (Israel) 12:05 Abstract N SP EULAR Recommendations for vaccinations Soledad Retamozo (Spain) 12:25 Abstract N SP EULAR Recommendations for Sjögren s syndrome Frank Buttgereit (Germany) 13:05 Abstract N SP EULAR Recommendations for the use of glucocorticoid therapy Margreet Kloppenburg (Netherlands) 13:25 Abstract N SP EULAR Recommendations for management of hand osteoarthritis 12:00-13:30 Hall 7.2 Clinical Science session Emerging topics in the management of the antiphospholipid syndrome Learning objectives: To understand the different risk profiles and consequent need of prophylactic treatment for healthy subjects carrying a stable positivity for antiphospholipid antibodies To analyse the impact of antiphospholipid antibodies on the outcome of patients with systemic lupus erythematosus To recognise and differentiate the antiphospholipid antibody-related kidney damage and to apply the proper treatments Fabrizio Conti (Italy) Maarten Limper (Netherlands) Laura Andreoli (Italy) 12:05 Abstract N SP0164 How to manage asymptomatic carriers of antiphospholipid antibodies 12:00-13:30 Elicium 2 Challenges in Clinical Practice session Fractures: more than bone alone Learning objectives: To learn about frailty and cardiovascular comorbidities in patients with a (recent) fracture Willem F. Lems (Netherlands) Roland D. Chapurlat (France) Karine Briot (France) 12:05 Abstract N SP0162 Case 1 presenter: Look at the cascade Christian Roux (France) 12:15 Case 1 discussant: Frail patients with a fracture: how to handle? Gayani Weerasinghe (United Kingdom) 12:45 Abstract N SP0163 Case 2 presenter: A case of severe osteoporosis and ischaemic heart disease; what will be the future cardiovascular risk? Daniel Prieto-Alhambra (United Kingdom) 12:55 Case 2 discussant: Cardiovascular disease after a recent fracture Elisabet Svenungsson (Sweden) 12:25 Abstract N SP0165 The complex interplay between systemic lupus erythematosus and antiphospholipid syndrome Maria Tektonidou (Greece) 12:45 Abstract N SP0166 All you need to know about kidney disease in antiphospholipid syndrome C. Li (China) 13:05 J. L. Zhao, Y. Zhao, S. Liu, Q. Wang, M. T. Li Abstract N OP0355 Pulmonary thromboendarterectomy is a curative resolution for chronic thromboembolic pulmonary hypertension associated with primary antiphospholipid syndrome: a retrospective cohort study R. Hisada (Japan) 13:15 M. Kato, E. Sugawara, Y. Fujieda, K. Oku, T. Bohgaki, O. Amengual, S. Yasuda, T. Atsumi Abstract N OP0356 Plasmablast proliferation is associated with toll like receptor 7 polymorphisms and upregulation of type I interferon, contributing to the antibody production in antiphospholipid syndrome 16 June 2018

136 134 / SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE :00-13:30 Forum From Bench to Bedside The links between gout and kidney function Learning objectives: Understand the recent advances in the genetics of hyperuricemia and gout Become familiar with the function and clinical implications of different renal transporters Understand the influence of reduced renal function on the use of urate lowering treatments Alexander So (Switzerland) Nicola Dalbeth (New Zealand) Anna Koettgen (Germany) 12:05 Genetics of hyperuricemia Fernando Perez-Ruiz (Spain) 12:25 Abstract N SP0167 Renal urate transporters Nicola Dalbeth (New Zealand) 12:45 Abstract N SP0168 The use of XO inhibitors in CKD - pros and cons P. Martin (United Kingdom) 12:25 J. Ding, B. Mulhearn, S. Viatte, S. Eyre Abstract N OP0359 Exploration of T cell signatures following TCR stimulation using single cell RNA-seq to inform treatment response studies in rheumatoid arthritis Mark Coles (United Kingdom) 12:35 Combining systems modelling with experimentation to identify novel therapeutic targets S. Babaei (Germany) 12:55 Z. Makowska, S. Hayat, A. Buttgereit, G. Barturen, J. Kageyama, B. Weiss, J. Wojcik, R. Lesche, M. Alarcón Riquelme, F. McDonald on behalf of PRECISESADS Clinical Consortium Abstract N OP0360 RNA-sequencing of 800 human blood samples reveals shared and unique expression profiles across seven systemic autoimmune diseases Leonid Padyukov (Sweden) 13:05 Abstract N SP0169 Integration of Omics data for predicting response to anti-tnf 12:00-13:30 Amtrium 16 June 2018 T. Bardin (Vietnam) 13:05 K. M. Tran, Q. D. Nguyen, N. H. Le, P. Richette, P. Le van, J.-M. Correas, M. Resche-Rigon Abstract N OP0357 Hyperechoic deposits in the renal medulla are associated with severe gout and decreased EGFR: a transversal study in 503 Vietnamese patients Q. Ma (Germany) 13:15 M. Sellmayr, F. Preitner, H.-J. Anders, S. Steiger Abstract N OP0358 Why do not all chronic kidney disease patients get gout? Impaired neutrophil chemotaxis in hyperuricemia-related CK 12:00-13:30 Elicium 1 Basic and Translational Science session Big data in pre-clinical research Learning objectives: To learn about the challenges and opportunities of big data analysis To understand how big data analysis can be used to identify biomarkers and therapeutic targets Costantino Pitzalis (United Kingdom) Mojca F. Bertoncelj (Slovenia) Peter Lipsky (United States) 12:05 Have bioinformatic studies in rheumatic diseases informed us about changes of clinical studies and practice? Health Professionals session How do you sleep? Learning objectives: To provide overview of normal sleep patterns; sleep physiology, sleep and RMD; sleep quality; measuring sleep (outcome measure); treatment sleep To present clinical research on sleep issues in RMD Joke Vriezekolk (Netherlands) Lurdes Barbosa (Portugal) Bente Appel Esbensen (Denmark) 12:05 Abstract N SP0170 Re-evaluate life when broken sleep has a negative effect on inflammatory arthritis Katie Hackett (United Kingdom) 12:23 Abstract N SP0171 Sleep disturbances in primary Sjögren s syndrome: evidence from the literature, patient sleep diaries and a qualitative focus group study Sean.G. McKenna (Ireland) 12:41 Abstract N SP0172 What effect does exercise have on sleep in RMDs? Poul J. Jennum (Denmark) 12:59 How did you sleep last night? J. S. Malmborg (Sweden) 13:17 A. Bremander, M. C. Olsson, A.-C. Bergman, S. Brorsson, S. Bergman Abstract N OP0361-HPR Sleeping problems and anxiety is associated to chronic multisite musculoskeletal pain in Swedish high school students

137 SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE 2018 / :00-13:30 Emerald From Bench to Bedside Stratifying connective tissue diseases Learning objectives: To provide an update on recent advances in straification of systemic autoimmune diseases John D. Isaacs (United Kingdom) Martin Aringer (Germany) Wan-Fai Ng (United Kingdom) 12:05 Abstract N SP0173 Stratifying primary Sjögren s Lars Rönnblom (Sweden) 12:25 Abstract N SP0174 The value of type I IFN signature to stratify patients Jiri Vencovsky (Czech Republic) 12:45 Abstract N SP0175 Heterogeneity of myositis and therapeutic consequences D. Leonard (Sweden) 13:05 E. Svenungsson, J. Dahlqvist, A. Alexsson, L. Ärlestig, K. E. Taylor, J. K. Sandling, C. Bengtsson, M. Frodlund, A. Jönsen, S. Eketjäll, K. Jensen-Urstad, I. Gunnarsson, C. Sjöwall, A. A. Bengtsson, M.-L. Eloranta, A.-C. Syvänen, S. Rantapää-Dahlqvist, L. A. Criswell, L. Rönnblom Abstract N OP0362 Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis R. Knevel (Netherlands) 13:15 C. Terao, J. Cui, K. Slowikowski, T. Huizinga, B. Karlson, K. Liao, S. le Cessie, S. Raychaudhuri Abstract N OP0363 Optimising precision medicine by using genetics to assign diagnostic prior probabilities to patients with synovitis - proof of principle 12:00-13:30 PARE Room Joint session PARE/HPR Work and rehabilitation - key priorities for people with RMDs Learning objectives: To explore the current developments at EU level and the impact on member states To explore the impact of work rehabilitation on the quality of life and on employment To show the value of early intervention, prevention and better management of RMDs Tanja Stamm (Austria) Elsa Mateus (Portugal) Gerlinde Bendzuck (Germany) 12:05 Abstract N SP0176 It works?! Employment support for people with RMDs Erika Mosor (Austria) 12:25 Abstract N SP0177 Quality of life at the workplace - how early interventions of health professionals can support people with RMDs Sarah Copsey (Spain) 12:45 Abstract N SP0178 The contribution of occupational safety and health to working with RMDs M. Klokkerud (Norway) 13:05 E. Hasselknippe, A. Rønningen, H. Haveråen, A.-L. Sand-Svartrud Abstract N OP0364-PARE Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study M. Bezzant (United Kingdom) 13:15 A. Bosworth, L. Lunt, S. Verstappen Abstract N OP0365-PARE Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work 12:00-13:30 E106/E107 The Young Rheumatologist The challenges of rheumatology trainees in the clinical learning environment Learning objectives: To learn more about communication competencies in general and patient-education competencies in particular To understand, by using videoed outpatient consultations during the session at EULAR, how you can improve and refine your communication skills when dealing with challenging situations in daily practice Marloes van Onna (Netherlands) Alessia Alunno (Italy) Peter Boyd (Ireland) 12:05 Abstract N SP0179 Patient perspective: what could clinicians do better in clinical communication? Simone Gorter (Netherlands) 12:25 Abstract N SP0180 Communication skills, an essential competency in daily practice Elena Nikiphorou (United Kingdom) 12:45 The use of social media: weighing the risks and benefits 16 June 2018

138 136 / SCIENTIFIC PROGRAMME / SATURDAY 16 JUNE 2018 S. Stebbings (New Zealand) 13:05 L. Ward Abstract N OP0366 Ambulatory rheumatology teaching day - a 360-degree evaluation of stakeholder experiences R. Sengewein (Germany) 13:15 E. Schmok Abstract N OP0367 Using youtube to teach the fundamentals of rheumatology: a two-year retrospective analysis of four online lectures 13:45-14:45 Auditorium Highlight session Clinical and Basic Translational Highlight session 13:45-14:45 PARE Room Highlight session PARE Highlight session Learning objectives: To provide an overview of learning and outcomes from the EULAR 2018 Congress from health professionals and the scientific perspectives, and first feedback from the PARE delegates Dieter Wiek (Germany) Nele Caeyers (Belgium) Elena Nikiphorou (United Kingdom) 13:50 Highlights from the scientific programme Yvonne van Eijk-Hustings (Netherlands) 14:15 Highlights from the HPR programme Thomas Dörner (Germany) Robert B. M. Landewé (Netherlands) Leonie Taams (United Kingdom) 13:50 Basic and translational highlights John D. Isaacs (United Kingdom) 14:15 Clinical Highlights 16 June :45-14:45 Amtrium Highlight session HPR Highlight session Yeliz Prior (United Kingdom) Rikke H. Moe (Norway) Fernando Estévez-López (Spain) 13:50 Abstract N SP0181 Highlights from the Health Professionals in Rheumatology sessions Iain B. McInnes (United Kingdom) 14:08 Highlights from the scientific programme Trond Haugmark (Norway) 14:26 Abstract N SP0182 Highlights from the PARE programme

139 GUIDED POSTER TOURS / SATURDAY 16 JUNE 2018 / 137 Guided Poster Tours Saturday, 16 June 2018 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a 'first-come-first-served' basis on the date of the poster tour. 10:30-12:00 Poster area Poster tour S1: Born to be wild Martin Herrmann (Germany) Mario Zaiss (Germany) Abstracts N : SAT0001-SAT0007 See page 138 Poster tour S2: The good, the bad and the ugly: soluble mediators in inflammation Leonie Taams (United Kingdom), Mike O. Becker (Switzerland) Abstracts N : SAT0016-SAT0025 See page 139 Poster tour S3: The joint connection: cartilage, bone and synovial tissue Elena Neumann (Germany) Kerstin Klein (Switzerland) Abstracts N : SAT0048-SAT0057 See page 140 Poster tour S4: Predicting tomorrow today: prognosis, predictors and outcomes of RA John D. Isaacs (United Kingdom) Meghna Jani (United Kingdom) Abstracts N : SAT0073-SAT0082 See page 141 Poster tour S5: Breakout news on non-tnf biologics in RA Xavier Mariette (France) Diane van der Woude (Netherlands) Abstracts N : SAT0165-SAT0174 See page 145 Poster tour S6: Novel insights on non-biologics in RA Alexander So (Switzerland) Diego Kyburz (Switzerland) Abstracts N : SAT0212-SAT0220 See page 147 Poster tour S7: Treatment in SpA: does it matter? Sofia Ramiro (Netherlands), Victoria Navarro-Compán (Spain) Abstracts N : SAT0259-SAT0268 See page 150 Poster tour S9: Beware the bug! Elena Nikiphorou (United Kingdom) James Galloway (United Kingdom) Abstracts N : SAT0380-SAT0389 See page 155 Poster tour S10: SLE, Sjögren s and APS - novel predictors of disease activity and long-term outcomes Lai-Shan Tam (China) Priscilla Wong (China) Abstracts N : SAT0414-SAT0423 See page 157 Poster tour S11: SSc, myositis, related syndromes - novel ideas take place Ulf Müller-Ladner (Germany) Ingrid Lundberg (Sweden) Abstracts N : SAT0468-SAT0477 See page 159 Poster tour S12: Be familiar with orphan diseases Nemanja Damjanov (Serbia), Predrag Ostojic (Serbia) Abstracts N : SAT0587-SAT0596 See page 164 Poster tour S13: Imaging strategies in the management of arthritis Lene Terslev (Denmark) Mads Ammitzboll (Denmark) Abstracts N : SAT0630-SAT0639 See page 166 Poster tour S14: This poster tour might be risky! Laure Gossec (France) Paul Studenic (Austria) Abstracts N : SAT0677-SAT0686 See page 168 Special poster tour S15: Theory of poster design and presentation Maarten Boers (Netherlands) Attendance of the session EULAR Projects - challenging projects in education and training, 09:00-10:30, Room E106/E107 is required in order to participate in this special poster tour. 16 June 2018 Poster tour S8: PsA: a whole range of (subclinical) (co)morbidities! Filip van den Bosch (Belgium) Francesco Carubbi (Italy) Abstracts N : SAT0302-SAT0311 See page 152

140 138 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 Scientific Poster Session III Saturday, 16 June June 2018 Poster viewing 10:30-12:00 Guided poster tours 10:30-12:00 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. TOPIC: INNATE IMMUNITY IN RHEUMATIC DISEASES Poster tour S1: Abstracts N : Born to be wild Martin Herrmann (Germany), Mario Zaiss (Germany) SAT0001-SAT0007 SAT0001 MECHANISM AND SIGNIFICANCE OF COMPLEMENT C3 RECEPTOR IN COLLAGEN-INDUCED RHEUMATOID ARTHRITIS MICE MODEL / L. Dan* - L. Ke SAT0002 THE INTRACELLULAR ITAM TYROSINES OF FC RECEPTOR GAMMA-CHAIN ARE CRITICAL FOR EXPERIMENTAL AUTOIMMUNE ARTHRITIS / T. Nemeth* - K. Futosi - M. Szabo - T. Saito - Z. Jakus - A. Mocsai SAT0003 SYNOVIAL TISSUE CD1C+ DENDRITIC CELLS IN RHEUMATOID ARTHRITIS EXPRESS HIGH LEVELS OF THE EPIGENETIC REGULATOR OF INFLAMMATION, MICRORNA-155 AND INFLAMMATORY CYTOKINES / A. Elmesmari - S. Alivernini - B. Tolusso - L. Bui - D. Vaughan - M. R. Gigante - F. Federico - G. Ferraccioli - E. Gremese - I. B. McInnes - M. Kurowska-Stolarska* SAT0004 INTRA-ARTICULAR INJECTION OF ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS REDUCE EXPERIMENTAL OA PATHOLOGY VIA IL-1Β-MEDIATED REALLOCATION AND ENHANCED PHAGOCYTOSIS OF POLYMORPHONUCLEAR LEUCOCYTES / S. van Dalen* - M. van den Bosch - A. Blom - P. van der Kraan - T. Vogl - L. Casteilla - P. van Lent SAT0005 INTERLEUKIN-33 AMELIORATES MURINE LUPUS VIA INDUCTION OF REGULATORY T CELLS AND M2 MACROPHAGE POLARISATION / M. Y. Mok* - K. Law - W. Y. Kong - Y. Lo - E. Ng - C. Luo - F. Huang - G. Chan - K. Chan SAT0006 P2X7 RECEPTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). EXPLORING A NOVEL PATHOGENETIC PATHWAY IN LUPUS RELATED SEROSITIS / F. Furini* - A. Bortoluzzi - A. L. Giuliani - F. Di Virgilio - M. Govoni SAT0007 DISTINCT MACROPHAGE PHENOTYPE AND BIOENERGETIC PROFILES IN RHEUMATOID ARTHRITIS / M. M. Hanlon* - T. McGarry - M. Canavan - C. Lowe - S. Wade - D. J. Veale - U. Fearon SAT0008 DYSREGULATION OF THE CIRCULATING AND RENAL CLUSTERIN IN LUPUS NEPHRITIS / H.-J. Ma* - C. Liu - B.-Y. Shi - L.-Y. Sun SAT0009 TYROSINE KINASE PATHWAYS IN MONOSODIUM-URATE CRYSTAL-INDUCED INFLAMMATORY RESPONSES / K. Futosi* - T. Németh - A. Mócsai * Presenting author

141 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 139 SAT0010 EXCESSIVE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS HAVE A DIFFERENT ROLE IN THE PATHOGENESIS OF ANCA-ASSOCIATED VASCULITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS / L. S. van Dam* - T. Kraaij - S. W. Kamerling - H. U. Scherer - T. J. Rabelink - C. van Kooten - Y. O. Teng SAT0011 MERTK+ MONOCYTES ARE EXPANDED IN THE PERIPHERAL BLOOD OF PATIENTS WITH ACTIVE IGG4-RELATED DISEASE AND INFILTRATE AFFECTED ORGANS / L. Rovati* - E. Della Torre - C. Sciorati - E. Rigamonti - M. Lanzillotta - E. Bozzalla Cassione - E. Bozzolo - L. Dagna - A. Manfredi SAT0012 C-REACTIVE PROTEIN: NOT ONLY A MARKER, BUT ALSO A CAUSE OF INFLAMMATION THROUGH METABOLIC REPROGRAMMING OF HUMAN MACROPHAGES / M. Newling* - L. Sritharan - B. Everts - L. de Boer - S. Zaat - D. Baeten - J. den Dunnen SAT0013 IL-1Α AND ADAMTS5 MEDIATED TISSUE DAMAGE IN HUMAN CARTILAGE EXPLANTS LEADS TO GENERATION OF TLR2 ACTIVATING DAMPS / N. Sharma* - T. G. Christiansen - M. Karsdal - A.-C. Bay-Jensen - C. S. Thudium SAT0014 DRUG REPURPOSING TO BLOCK TLR4-ASSOCIATED INFLAMMATION IN OA CHONDROCYTES / E. Franco-Trepat - A. Alonso-Perez - M. Guillan Fresco - A. Jorge Mora - V. López - O. Gualillo - R. Gómez* on behalf of Musculoskeletal Pathology group SAT0015 IDENTIFICATION AND CHARACTERIZATION OF HIGH MOLECULAR WEIGHT HMGB1 PROTEIN COMPLEXES: IMPLICATIONS FOR STRESS RESPONSE, INNATE IMMUNITY AND AUTOIMMUNE DISEASE / W. Willis* - L. Wang - T. T. Wada - M. Garder - O. Abdouni - G. Valiente - S. Agarwal - M. A. Freitas - L.-C. Wu - W. N. Jarjour TOPIC: CYTOKINES AND INFLAMMATORY MEDIATORS Poster tour S2: Abstracts N : The good, the bad and the ugly: soluble mediators in inflammation Leonie Taams (United Kingdom), Mike O. Becker (Switzerland) SAT0016-SAT0025 SAT0016 SAT0017 IL-12 SUPPRESS TR1 CELLS IN THE SJÖGREN S SYNDROME / G. Yao* - J. Qi - L. Sun THE RHEUMATOID FACTOR RESPONSE IS COMPOSED OF MULTIPLE REACTIVITIES AGAINST DIFFERENT EPITOPES / W. Falkenburg* - J. Koers - P. Oijevaar-de Heer - D. van Schaardenburg - G. Wolbink - T. Rispens SAT0018 BLOOD CHEMOKINE SYSTEM PROFILE ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / A. Petrackova - G. Gabcova - M. Skacelova* - Z. Mikulkova - A. Smrzova - M. Schubertova - F. Mrazek - P. Horak - E. Kriegova SAT0019 TNF-Α REGULATES PLASMACYTOID DENDRITIC CELLS BY SUPPRESSING IFN-Α PRODUCTION AND ENHANCING TH1 AND TH17 CELL DIFFERENTIATION / A. Psarras* - A. Antanaviciute - I. Carr - M. Wittmann - P. Emery - G. Tsokos - E. M. Vital SAT0020 IMPACT OF IL12B SINGLE NUCLEOTIDE POLYMORPHISMS ON CIRCULATING PRO-INFLAMMATORY CYTOKINES IL-12P40 AND IL-23 IN ANKYLOSING SPONDYLITIS / M. G. Ivanova* - I. Manolova - R. Stoilov - L. Miteva - S. Stanilova SAT0021 INNATE LYMPHOID CELLS ARE NOT A MAIN SOURCE OF IL-17A IN THE INFLAMED SPONDYLOARTHRITIS JOINT / N. Yeremenko* - I. C. J. Blijdorp - L. J. J. Van Mens - S. Menegatti - S. Chen - H. S. Hreggvidsdottir - T. Noordenbos - T. E. Latuhihin - J. H. Bernink - L. Rogge - H. Spits - D. L. P. Baeten SAT0022 MIR-15A/16 SUPPRESS INFLAMMATORY RESPONSE AND CELL INVASION AND MIGRATION IN FIBROBLAST- LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS VIA TARGETING SOX5 / W. Tan* - Q. WU - A. Luo - Y. Wei - F. Wang - M. Zhang SAT0023 CONTROL OF CYTOKINE MRNA DEGRADATION BY THE HISTONE DEACETYLASE INHIBITOR ITF2357 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES / C. Angiolilli* - P. Kabala - A. Grabiec - M. Rossato - W. Lai - P. Blackshear - K. Reedquist - D. Baeten - T. Radstake SAT0024 IL-36 AXIS IS AN EMERGING THERAPEUTIC TARGET IN PSORIATIC ARTHRITIS SYNOVIAL TISSUE / M.-A. Boutet - A. Nerviani* - G. Lliso-Ribera - K. Goldmann - M. Lewis - C. Pitzalis SAT0025 CXCL4 ALTERS TRANSCRIPTOMIC AND EPIGENETIC IMPRINTING OF DENDRITIC CELLS THEREBY DRIVING FIBROSIS THROUGH EXTRACELLULAR MATRIX FORMATION / S. C. SIlva-Cardoso - W. Tao - C. Angiolilli - A. P.P. Lopes - C. Bekker - J. van Laar - E. Hack - M. Boes - A. Pandit - T. R.D.J. Radstake* SAT0026 DIFFERENTIAL LEVELS OF IL-7 EXPRESSION IN ADVENTITIA OF NON-RA AND RA PATIENTS WITH CORONARY ARTERY DISEASE / A. N. Burska* - K. Sime - A. Wiliams - K. Mikkelsen - K. Saatvedt - S. M. Almdahl - I. Risnes - C. Goodyear - I. Hollan - F. Ponchel SAT0027 CO-EXPRESSION OF RECEPTORS TO TNFΑ AMONG NAÏVE T CELLS AND MEMORY T CELLS IS ALTERED IN RHEUMATOID ARTHRITIS AND THE CHANGES CORRELATE WITH DISEASE ACTIVITY / A. A. Alshevskaya* - J. Lopatnikova - O. Chumasova - N. Shkaruba - A. Sizikov - V. Gladkikh - S. Sennikov SAT0028 THE IMPORTANCE OF PROPER HANDLING OF HUMAN SYNOVIAL FLUID FOR ARTHRITIS RESEARCH / H. Brouwers - J. H. von Hegedus - R. E. M. Toes - T. W. J. Huizinga - M. A. Giera - M. Kloppenburg - A. Ioan- Facsinay* SAT0029 IMPACT OF GLUCOCORTICOIDS ON SIRTUIN 1 EXPRESSION AND PROINFLAMMATORY CYTOKINE PRODUCTION IN RATS WITH ADJUVANT-INDUCED ARTHRITIS / D. Wendling* - W. Abbas - A. Kumar - S. Pasquereau - F. Verhoeven - C. Prati - C. Demougeot - G. Herbein SAT0030 VISFATIN DOWN-REGULATES GROWTH PROMOTING LNCRNA H19 IN OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STROMAL CELLS / D. M. Küppers* - L. Tsiklauri - M.-L. Hülser - K. Frommer - S. Rehart - U. Müller-Ladner - E. Neumann SAT0031 INTERLEUKIN 29 INHIBITS OSTEOCLAST DIFFERENTIATION AND FUNCTION IN RANKL-INDUCED OSTEOCLASTOGENESIS / F. Wang* - A. Luo - Q. Wu - Z. Zhou - Q. Peng - W. Xuan - W. Tan SAT0032 MESENCHYMAL STEM CELLS ALLEVIATE EXPERIMENTAL AUTOIMMUNE CHOLANGITIS THROUGH IMMUNOSUPPRESSION MEDIATED BY GALECTIN-9 / J. Fan* - X. Tang - H. Chen - L. Sun - Q. Wang 16 June 2018 * Presenting author

142 140 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0033 TIME-DEPENDENT RELATIONSHIPS BETWEEN BIOLOGICAL PARAMETERS AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS / K. Connelly* - H. Nim - F. Vincent - F. Petitjean - A. Hoi - R. Kohlmeyer - S. Boyd - E. Morand SAT0034 POSSIBLE INVOLVEMENT OF BAFF AND MATRIXMETALLOPROTEINASE-9 IN THE ACTIVATION OF MONOCYTES OF PATIENTS WITH PRIMARY SJÖGREN S SYNDROME / K. Yoshimoto* - K. Suzuki - T. Takeuchi SAT0035 THE EFFECTS OF VISFATIN, RESISTIN AND IL-17 ON SYNOVIAL FIBROBLASTS FROM DIFFERENT RHEUMATIC DISEASE BACKGROUNDS / K. Frommer* - S. Rehart - M. Sauerbier - U. Müller-Ladner - E. Neumann SAT0036 NICOTINE PROMOTES MMP-3 AND RANKL SECRETION THROUGH OVEREXPRESSED NICOTINIC ACETYLCHOLINE RECEPTOR Α7 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES / J.-D. Ma - Y.-S. Mou - T. Yan - J. Jing - Y.-Q. Mo - Y.-L. Chen - L. Dai* SAT0037 IGURATIMOD AMELIORATES BLEOMYCIN-INDUCED ALVEOLAR INFLAMMATION AND PULMONARY FIBROSIS IN MICE BY SUPPRESSING EXPRESSION OF MMP-9 / L. Zhao* - B. Mu - R. Zhou - C. Huang SAT0038 MEMBRANE-ASSOCIATED AMPD2, A NOVEL REGULATOR IN SHIFTING THE BALANCE BETWEEN EXTRACELLULAR ATP AND ADENOSINE? / L. Ehlers* - A. Kuppe - A. Damerau - Y. Chen - F. Buttgereit - T. Gaber SAT0039 LL37 UP-REGULATION AND ANTI-LL37 REACTIVITY ARE SHARED BY PSORIASIS AND PSORIATIC ARTHRITIS PATIENTS / L. Frasca* - R. Palazzo - M. S. Chimenti - E. Botti - S. E. Auteri - F. Spadaro - S. Alivernini - B. Tolusso - E. Gremese - B. Marinari - I. Pietraforte - F. R. spinelli - G. L. Fonti - T. Colasanti - C. Alessandri - F. Conti - A. Costanzo - L. Bianchi - G. Valesini - R. Perricone - R. Lande SAT0040 SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY: RESULTS FROM THE FIRST-IN-HUMAN SINGLE DOSE ESCALATION STUDY IN HEALTHY VOLUNTEERS / P. Khlyabova* - A. Eremeeva - A. Lutckii - E. Dokukina - E. Chernyaeva - R. Ivanov SAT0041 COMPARISON OF DIFFERENT TYPE 1 IFN SIGNATURES DEMONSTRATES CONCORDANCE IN A REAL WORLD, HOME MONITORED SYSTEMIC LUPUS ERYTHEMATOSUS COHORT / M. Abedi - F. Flores - P. Naranatt - J. Spangler - L. Pan - R. Terbrueggen* SAT0042 EVIDENCE OF NETOSIS IN CIRCULATING NEUTROPHILS AND SKIN LESIONS WITH VASCULITIS AND PANNICULITIS IN BEHÇET S DISEASE / R. Kallas* - R. Safi - R. Hamam - I. Uthman - D. Nassar SAT0043 IL-33/ST2-MEDIATED INFLAMMATION IN ENDOTHELIAL CELL IS DIRECTLY AGGRAVATED BY IL-6 DURING LUPUS NEPHRITIS / S. L. Yu* - Y. B. Huo - C. H. Huang - Y. Tao - W. H. Huang - C. K. Wong - L. S. Tam - H. N. Qiu - R. L. Chen - C. H. Huang - L. Zhong SAT0044 LIN28A IS OVEREXPRESSED IN OSTEOARTHRITIS AND IS ESSENTIAL FOR THE STABILITY AND HIGH LEVEL EXPRESSION OF IL-6 AND COX-2 IN HUMAN CHONDROCYTES / I. Ahmad - M. Y. Ansari - M. N. Khan - T. M. Haqqi* SAT0045 DNA METHYLATION OF SOCS3 AS A POSSIBLE MECHANISM FOR PERSISTENT URATE INDUCED INFLAMMATION / V. Klück* - T. Crisan - M. Cleophas - S. Keating - B. Novakovic - N. Dalbeth - L. Stamp - A. Phipps-Green - M. Black - D. Macartney-Coxson - T. Merriman - L. Joosten SAT0046 TRANSCRIPT-PROTEIN ASSOCIATIONS IN EARLY RA PATIENTS ACHIEVING SUSTAINED DRUG-FREE REMISSION AFTER TREATMENT WITH TOCILIZUMAB / X. M. Teitsma* - J. W. Jacobs - A. N. Concepcion - A. Pethö-Schramm - M. E. Borm - J. M. van Laar - J. W. Bijlsma - F. P. Lafeber SAT0047 PTEN REGULATION ALLEVIATES THE ALCOHOL-INDUCED OSTEOPENIA IN RAT VIA AKT/GSK-3Β/Β-CATENIN PATHWAY IN BMSCS / Y. Chen* - Y. Gao - C. Zhang TOPIC: CARTILAGE, SYNOVIUM AND BONE Poster tour S3: Abstracts N : The joint connection: cartilage, bone and synovial tissue Elena Neumann (Germany), Kerstin Klein (Switzerland) SAT0048-SAT0057 SAT0048 ANALYSIS OF DIFFERENT THERAPEUTIC REGIMES IN PATIENTS WITH HEMOPHILIC ARTHROPATHY / L. Mendez Diaz* - C. aguilera cros - M. D. Arcila Duran - A. Ruiz Roman - N. Garrido Puñal - M. Lisbona Muñoz - R. J. Nuñez Vazquez - J. Povedano Gomez SAT BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 REGULATES CHRONIC SYNOVITIS WITH LOCAL AND SYSTEMIC COMPLICATIONS / R. S. Hardy* - C. Fenton - A. Croft - A. Naylor - C. D. Buckley - G. G. Lavery - M. S. Cooper - K. Raza SAT0050 STANDARDIZATION OF SYNOVIAL BIOPSIES ANALYSIS: A EULAR SYNOVITIS STUDY GROUP INITIATIVE USING A DELPHI SURVEY / A. Najm* - B. Le Goff - C. Orr - J. Fonseca - B. Lauwerys - D. Veale on behalf of EULAR Synovitis study group SAT0051 EXAMINING THE ROLE OF TRPC5 IN OSTEOARTHRITIS PAIN / J. Sousa-Valente* - F. Ayaz - X. Kodji - S. D. Brain SAT0052 THE COLL2-1 PEPTIDE OF COLLAGEN TYPE II: A NEW ACTOR OF SYNOVITIS IN OSTEOARTHRITIS / C. Lambert - D. Borderie - F. Rannou - Y. Henrotin* SAT0053 IDENTIFICATION OF NOVEL DRUGS WITH SENOLYTIC ACTIVITY AS OSTEOARTHRITIS THERAPEUTICS / U. Nogueira-Recalde* - F. J. Blanco - M. I. Loza - D. Grassi - P. Robbins - E. Dominguez - B. Carames SAT0054 SIGNIFICANT DECREASE OF T CELLS BUT NOT MACROPHAGES IN THE SYNOVIUM OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER TREATMENT WITH TOCILIZUMAB / K. Chatzidionysiou* - M. Engström - E. af Klint - A. Hensvold - A. I. Catrina SAT0055 SIMULATING THE PATHOGENESIS OF ARTHRITIS IN VITRO BY DEVELOPING A HUMAN-BASED MULTICOMPONENT 3D JOINT MODEL / A. Damerau* - Y. Chen - A. Lang - I. Ponomarev - M. Pfeiffenberger - F. Buttgereit - T. Gaber SAT0056 OSTEOARTHRITIS SEVERITY IS REDUCED BY INTRA-ARTICULAR ADMINISTRATION OF HYDROGEN SULFIDE / E. F. Burguera* - Á. Vela-Anero - T. Hermida-Gómez - P. Filgueira-Fernández - L. Gato-Calvo - R. Meijide-Failde - F. J. Blanco * Presenting author

143 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 141 SAT0057 THE EFFECT OF EXOSOMES FROM BONE MARROW MESENCHYMAL STEM CELLS ON OSTEOARTHRITIS / H. Zhu - J. Ji - T. Fu - J. Yang - Z. Gu* SAT0058 ADALIMUMAB: TNF COMPLEXES ARE CLEARED MORE EFFICIENTLY BY HUMAN OSTEOCLASTS THAN THOSE WITH ETANERCEPT THROUGH FCG-RECEPTOR BINDING AND INTERNALIZATION / B. P. Harvey* - J. Cohen-Solal - Z. Kaymakcalan SAT0059 IMPAIRMENT IN HYDROGEN SULFIDE SYNTHESIS IN OSTEOARTHRITIC CHONDROCYTES FROM DIABETIC PATIENT AND UNDER A HIGH GLUCOSE STRESS / C. Vaamonde-Garcia* - F. Blanco - R. Meijide-Faílde SAT0060 PROTEOMIC ANALYSIS OF OSTEOBLASTS SECRETOME PROVIDES NEW INSIGHTS IN MECHANISMS UNDERLYING OSTEOARTHRITIS SUBCHONDRAL BONE SCLEROSIS / C. Sanchez* - G. Mazzucchelli - F. Comblain - C. Lambert - E. DePauw - Y. Henrotin SAT0061 TARGETING ACTIVATED SYNOVIAL FIBROBLASTS USING PHOTODYNAMIC THERAPY IN RHEUMATOID ARTHRITIS / D. N. Dorst* - M. Rijpkema - M. Buitinga - M. Brom - D. L. Bos - A. Freimoser - C. Klein - B. Walgreen - P. van der Kraan - M. Gotthardt - M. I. Koenders SAT0062 METABOLOMICS AND METABOLIC FUNCTION ANALYSIS OF THE SECRETOME OF ARTICULAR CARTILAGE AND CHONDROCYTES IN RESPONSE TO PRO-INFLAMMATORY CYTOKINES / C. Fellows - H. Quasnichka* - N. R. Chowdhury - E. Budd - D. J. Skene - A. Mobasheri SAT0063 EFFECTS OF INTRA-ARTICULAR INJECTED DIACEREIN-LOADED NANOPARTICLES ON JOINT IN RAT MODEL OF OSTEOARTHRITIS / J. H. Jung* - G. G. Song - S. J. Choi - J. D. Ji - Y. H. Lee - J.-H. Kim SAT0064 CD14+CD16+ MONOCYTE SUBPOPULATION IS DOMINANT IN THE INFLAMMATION OF OSTEOARTHRITIS SYNOVIAL FLUID / J. Kim* - S.-J. Yoo - Y. Kim - S. W. Kang - S. C. Shim - S. M. Kim SAT0065 CHONDROCYTES UNDER PATHOLOGICAL CONDITIONS PREFERENTIALLY DEGRADES SELECTED TRNAS TO INHIBIT PROTEIN SYNTHESIS / J. Green* - T. Haqqi SAT0066 THE LONG NONCODING RNA (LNCRNA) HOTTIP IS A MASTER REGULATOR OF CELL CYCLE IN HAND SYNOVIAL FIBROBLASTS IN ARTHRITIS / M. Frank Bertoncelj* - T. Masterson - E. Karouzakis - C. Kolling - A. Filer - C. D. Buckley - S. Gay - O. Distler - C. Ospelt SAT0067 ROLE OF NOX2-DERIVED REACTIVE OXYGEN SPECIES IN S100A8/A9-DRIVEN INFLAMMATORY OSTEOARTHRITIS / N. Kruisbergen* - S. van Dalen - M. van den Bosch - A. Blom - P. van Lent SAT0068 BILIRUBIN PROMOTES DOWN-REGULATION OF RUNX2 AND UP-REGULATION OF RANKL GENE EXPRESSION IN BONE EXPLANTS AND IN OSTEOBLASTIC AND OSTEOCYTIC CELL LINES / S. Ruiz-Gaspà* - A. Parés - A. Combalia - P. Peris - A. Monegal - N. Guañabens SAT0069 ABNORMAL BONE AND CARTILAGE METABOLISM COULD BE ANTAGONIZED BY PULSED ELECTROMAGNETIC FIELDS (PEMFS) AND TNF-Α AND IL-6 GENE KNOCKOUTS IN A SIMILAR MECHANISM / S. Z. Zhu* - H. He - Q. Wang - D. Wang - H. Wang - C. Gao - C. Zhang - X. Yu - C. He SAT0070 ROLE OF C/EBPΒ IN 1,25D-INDUCED ACTIVATION OF RANKL EXPRESSION / S. Jo* - Y. L. Lee - I.-H. Sung - T.-H. Kim SAT0071 SUBCHONDRAL OSTEOPENIA BUT NOT CARTILAGE DAMAGE IS PREVALENT IN KNEE JOINTS OF PREMATURELY AGING MITOCHONDRIAL DNA MUTATOR MICE / J. Geurts - S. Nasi - T. A. Prolla - G. C. Kujoth - U. A. Walker - T. Hügle* SAT0072 MIRNA-146A IS A KEY PLAYER IN BONE METABOLISM AND OSTEOPOROSIS / V. Saferding* - M. Hofmann - J. S. Brunner - M. F. Militaru - A. Puchner - S. Hayer - M. Timmen - R. Stange - J. S. Smolen - S. Blüml 16 June 2018 TOPIC: RHEUMATOID ARTHRITIS - PROGNOSIS, PREDICTORS AND OUTCOME Poster tour S4: Abstracts N : Predicting tomorrow today: prognosis, predictors and outcomes of RA John D. Isaacs (United Kingdom), Meghna Jani (United Kingdom) SAT0073-SAT0082 SAT0073 SAT0074 SAT0075 SAT0076 SAT0077 SAT0078 SAT0079 ACPA AND RF AS PREDICTORS OF SUSTAINED CLINICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / J. E. Pope* - M. Movahedi - E. Rampakakis - A. Cesta - J. S. Sampalis - C. Bombardier on behalf of other OBRI investigators IDENTIFICATION OF A PROTEIN PANEL USEFUL FOR THE PREDICTION OF RESPONSE TO METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS / C. Ruiz-Romero* - F. Picchi - L. González-Rodríguez - P. Fernández-Puente - R. Hands - V. Calamia - M. Camacho-Encina - C. Bessant - C. Pitzalis - F. J. Blanco ADDITIONAL TARGET OF NORMAL SERUM MATRIX METALLOPROTEINASE-3 IS A POTENTIAL BIOMARKER FOR LESS ONE-YEAR RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS / L.-F. Chen - J.-D. Ma - Y.-Q. Mo - X.-Y. Du - D.-H. Zheng - L. Dai* SYNOVIAL MAST CELLS AND RESPONSES TO SYNTHETIC AND BIOLOGIC DMARDS IN EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS / F. Rivellese* - A. Nerviani - D. Mauro - S. Pagani - F. Humby - C. Pitzalis CHANGE IN FREQUENCY OF ARTHROPLASTY SURGERY IN RHEUMATOID ARTHRITIS: A 13 YEAR POPULATION HEALTH STUDY / J. G. Hanly* - L. Lethbridge - C. Skedgel WHICH CDMARD STRATEGY IS MOST EFFECTIVE IN NEWLY DIAGNOSED SERONEGATIVE RHEUMATOID ARTHRITIS PATIENTS; POST-HOC ANALYSIS OF THE TREACH STUDY / N. Luurssen-Masurel* - A. E. A. M. Weel - J. M. W. Hazes - P. H. P. de Jong TREATMENT EXPECTATIONS INFLUENCE BOTH SUBJECTIVE AND OBJECTIVE OUTCOME PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PROSPECTIVE COHORT STUDY / J. Mucke* - R. Brinks - A. Dimitriou - J. Richter - M. Schneider * Presenting author

144 142 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0080 SECULAR TRENDS PRIOR TO-AND AFTER DISSEMINATION OF BEST PRACTICE RECOMMENDATIONS SHOWED EARLIER INTENSIFIED MEDICATION STRATEGIES AND IMPROVED OUTCOMES IN CANADIANS WITH EARLY INFLAMMATORY ARTHRITIS / O. Schieir - S. J. Bartlett - M.-F. Valois - J. E. Pope - C. Thorne - C. Hitchon - B. Haraoui - G. Boire - D. Tin - E. C. Keystone - V. P. Bykerk* on behalf of the CATCH Investigators SAT0081 CHANGES IN INCIDENCE OF SHOULDER, ELBOW, WRIST AND FINGER REPLACEMENT SURGERY AMONG RHEUMATOID ARTHRITIS PATIENTS FOLLOWING THE INTRODUCTION OF BIOLOGICAL DMARDS: AN INTERRUPTED TIME SERIES ANALYSIS USING DANISH HEALTH CARE REGISTERS / R. L. Cordtz* - S. Hawley - D. Prieto-Alhambra - P. Højgaard - K. Zobbe - A. Odgaard - S. Overgaard - L. E. Kristensen - L. Dreyer SAT0082 OSTEOPONTINE AND OSTEOPROTEGRINE AS MARKERS OF ALTERED PRECLINICAL BONE METABOLISM IN RHEUMATOID FIRST DEGREE RELATIVES / E. Soliman* - M. Zehairy - A. Aly - K. Mattarawy - A. Alhadidy SAT0083 THE GENETIC AND CLINICAL PREDICTION MODELS FOR EFFICACY AND HEPATOTOXICITY OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Onishi* - M. Nishida - M. Takahashi - Y. Yoshida - M. Kobayashi - S. Kamitsuji - M. Kawate - K. Nishimura - K. Misaki - Y. Nobuhara - S. Hatachi - T. Nakazawa - G. Tsuji - S. Kumagai SAT0084 ANTI-CARBAMYLATED PROTEIN ANTIBODIES AS POTENTIAL BIOMARKERS OF DISEASE ACTIVITY IN EARLY ARTHRITIS PATIENTS / A. Gonzalez* - C. Regueiro - A. M. Ortiz - L. Nuño - D. Peiteado - A. Villalba - D. Pascual-Salcedo - A. Martinez-Feito - A. Balsa - I. Gonzalez-Alvaro SAT0085 RELATIONSHIP BETWEEN SERUM CALPROTECTIN, DISEASE ACTIVITY PARAMETERS AND THE 7-JOINT ULTRASOUND SCORE IN RHEUMATOID ARTHRITIS / M. Torgutalp - A. B. Kelesoglu Dincer - E. M. Yayla - E. Uslu Yurteri - E. I. Okatan - G. E. Aydemir Guloksuz - S. Serdar - U. Ebru - G. Kinikli - M. T. Turgay - A. Ates* SAT0086 EVALUATION OF DIAGNOSTIC PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) AND ULTRASOUND (US) TOWARD EARLY RHEUMATOID ARTHRITIS FROM NAGASAKI EARLY ARTHRITIS COHORT / A. Takatani* - M. Tamai - N. Ohki - Y. Nakashima - Y. Endo - S. Tsuji - T. Shimizu - M. Umeda - S. Fukui - R. Sumiyoshi - A. Nishino - T. Koga - S.-Y. Kawashiri - N. Iwamoto - T. Igawa - K. Ichinose - K. Arima - H. Nakamura - T. Origuchi - S. Sato - M. Uetani - A. Kawakami SAT0087 ASSOCIATION OF BIOMETRICS WITH DISEASE CHARACTERISTICS AND SYNOVIAL PHENOTYPE IN INFLAMMATORY ARTHRITIS / C. Low* - R. Conway - F. Young - K. Murray - H. Convery - M. Biniecka - U. Fearon - D. Veale SAT0088 PREDICTIVE FACTORS FOR INTERSTITIAL LUNG DISEASE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A ROLE FOR BIOLOGICAL INFLAMMATION AND DISEASE MODIFIED ANTI RHEUMATIC DRUGS (DMARDS) / C. Lucas* - S. Jouneau - M. Lederlin - S. Guillot - C. Salliot - L. Joffres - E. Solau-Gervais - M. Herbette - A. Saraux - J.-B. Cren - B. Bouvard - J.-D. Albert - G. Coiffier - P. Guggenbuhl - A. Perdriger SAT0089 INITIATING TOFACITINIB IN A TREAT TO TARGET STRATEGY FOR RHEUMATOID ARTHRITIS LEADS TO BLUNTED MULTI-BIOMARKER DISEASE ACTIVITY SCORES AS COMPARED TO ANTI-TUMOR NECROSIS FACTOR AGENTS / C. Wiesenhutter* SAT0090 EVALUATION OF THE USE OF ULTRASOUND TO MANAGE PATIENTS WITH RHEUMATOID ARTHRITIS OVER TIME: RESULTS FROM THE CORRONA REGISTRY / D. A. Pappas* - K. C. Saunders - C. J. Etzel - D. W. Hua - K. Deering - P. Zueger - V. Garg SAT0091 CLINICAL REMISSION PREDICTION USING BASELINE GENE EXPRESSION IN THE PERIPHERAL BLOOD OF DMARD-NAÏVE RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE / E. V. Tchetina* - N. V. Demidova - G. A. Markova SAT0092 PALINDROMIC RHEUMATISM (PR): EXPERIENCE IN A REAL WORLD SETTING - THE NOTTINGHAM CASEMIX REGISTER (NCR) / F. Kynaston-Pearson* - I. Pande - I. Gaywood SAT0093 MALE SEX PREDICTS A FAVOURABLE OUTCOME IN SERONEGATIVE EARLY RHEUMATOID ARTHRITIS / G. Cagnotto* - E. Rydell - L. Jacobsson - C. Turesson SAT0094 PHYSICAL FUNCTION AND HEALTH RELATED QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED ONLY LOW DISEASE ACTIVITY COMPARED WITH REMISSION / H. M. Lam* - M. C. Wan - L. S. Tam on behalf of the Hong Kong CRYSTAL study group SAT0095 A PERCEIVED BIOLOGICAL CAUSE OF RHEUMATOID ARTHRITIS ONSET IS ASSOCIATED WITH LOWER LEVELS OF DEPRESSED AND ANXIOUS MOOD OVER ONE YEAR COMPARED TO PATIENTS WHO ATTRIBUTED ONSET TO OTHER CAUSES / J. Gwinnutt* - S. Verstappen - K. Hyrich - M. Lunt - A. Barton - L. Cordingley on behalf of RAMS coinvestigators SAT0096 WINDOW OR NO WINDOW: EARLIER IS BETTER WHEN TREATING RHEUMATOID ARTHRITIS / J. A. van der Pol* - S. A. Bergstra - N. Riyazi - Y. P. Goekoop-Ruiterman - A. Chopra - P. Kerstens - W. F. Lems - R. Tsonaka - T. W. Huizinga - C. F. Allaart SAT0097 RISK OF PREVENTABLE HOSPITALIZATION BEFORE AND AFTER DIAGNOSIS AMONG RHEUMATOID ARTHRITIS PATIENTS COMPARED TO CONTROLS / C.-F. Kuo - P. B. Burns - J.-S. Chen* - L. Wang - K. C. Chung SAT0098 PATIENT AND DISEASE CHARACTERISTICS THAT PREDICT SWITCHING FROM A TNF INHIBITOR TO ANOTHER BIOLOGIC OR TARGETED SYNTHETIC DMARD IN PATIENTS WITH RA IN CLINICAL PRACTICE / L. R. Harrold* - H. J. Litman - S. E. Connolly - E. Alemao - S. Kelly - S. Rebello - T. Blachley - J. M. Kremer SAT0099 SARCOPENIA IS ASSOCIATED WITH JOINT DAMAGE IN RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY / J.-Z. Lin - Y.-Y. Wang - P.-J. Liu - Y.-Q. Mo - Q.-H. Li - W.-M. Cheng - X.-L. He - L. Dai* SAT0100 THE DETERMINANTS OF REFRACTORY RHEUMATOID ARTHRITIS / M. Bécède* - J. Smolen - D. Aletaha SAT0101 ATLANTOEPISTROPHIC MAGNETIC RESONANCE IMAGING INVOLVEMENT IN EARLY RHEUMATOID ARTHRITIS / M. Carotti* - F. Salaffi - M. Di Carlo - F. Sessa - A. Giovagnoni SAT0102 PRISTANE-INDUCED ARTHRITIS IN DARK AGOUTI RAT: A NEW ANIMAL MODEL TO STUDY CARDIOVASCULAR DYSFUNCTION IN RHEUMATOID ARTHRITIS / M. Chouk* - R. Bordy - J. Moretto - M. Tournier-Nappey - C. Prati - D. Wendling - P. Totoson - C. Demougeot SAT0103 THREE-MONTHLY ULTRASOUND MONITORING OF RHEUMATOID ARTHRITIS PATIENTS TAPERING THEIR MEDICATION HAS LIMITED VALUE IN PREDICTING DISEASE RELAPSE / M. van der Ven* - M. Kuijper - A. Gerards - I. Tchetverikov - A. Weel - D. van Zeben - C. Bijkerk - Y. de Man - M. Hazes - J. Luime * Presenting author

145 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 143 SAT0104 SAT0105 SAT0106 SAT0107 SAT0108 SAT0109 SAT0110 SAT0111 SAT0112 SAT0113 SAT0114 SAT0115 SAT0116 TREATMENT WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS ON STABLE BIOLOGICAL TREATMENT GIVES BETTER OUTCOMES OVER TIME / N. Boone* - A. Sepriano - R. Janknegt - H. van der Kuy - R. Peeters - R. Landewé PRELIMINARY ANALYSIS OF GENETIC VARIANTS IN THE IMMUNE SYSTEM RELATED TO THE BODY MASS INDEX IN EARLY ARTHRITIS PATIENTS / P. Moreno* - N. Montes - J. Martín - D. Carmona - C. M.Mora - R. P.Gomáriz - A. Lamana - A. Triguero - A. M. Ortiz - I. G. Álvaro ADVANCES IN THERAPEUTIC MANAGEMENT WITH FIRST BIOLOGICAL THERAPY IN RHEUMATOID ARTHRITIS THROUGHOUT 15 YEARS / P. Bogas* - C. Plasencia - V. Navarro-Compán - D. Benavent - G. Bonilla - L. Nuño - I. Monjo - G. González - J. Molina - A. Balsa SEQUENTIAL ULTRASOUND SHOWS A LATE INCREASE IN INFLAMMATORY BURDEN IN ANTI-CCP POSITIVE PATIENTS WITH NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS JUST BEFORE PROGRESSION TO INFLAMMATORY ARTHRITIS / P. Pentony* - K. Mankia - E. M. Hensor - J. L. Nam - L. Hunt - L. Garcia-Montoya - L. Duquenne - P. Emery EFFICACY OF ABATACEPT VERSUS ADALIMUMAB ON THE PROPORTION OF PATIENTS WITH SEROPOSITIVE, EROSIVE EARLY RA ACHIEVING DAS28 (CRP) <2.6 OR VALIDATED MEASURES OF REMISSION: A POST HOC ANALYSIS OF THE 2-YEAR AMPLE TRIAL / R. Fleischmann* - M. E. Weinblatt - H. A. Ahmad - M. A. Maldonado - E. Alemao - Y. Elbez - M. Schiff ULTRASONIC EVALUATION OF JOINT INVOLVEMENT IN ESTABLISHED RA: ACTIVE SYNOVITIS PREDICTS SUSTAINED TREATMENT CHANGES IN SUSPECTED BIOLOGIC FAILURE / R. L. Batten* - O. Mohammed - L. Probert - D. Wright - I. Atchia TRAJECTORIES OF FUNCTIONAL DISABILITY IN PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS AND MODERATE DISEASE ACTIVITY: RESULTS FROM THE EARLY RHEUMATOID ARTHRITIS NETWORK AND NORFOLK ARTHRITIS REGISTER / S. Norton* - J. Gwinnutt - Y. Pan - D. Symmons - A. MacGregor - A. Young - P. Kiely - D. Walsh - S. Verstappen EFFICACY OF TOFACITINIB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS BY BASELINE C-REACTIVE PROTEIN LEVELS AND ERYTHROCYTE SEDIMENTATION RATES / S. Schwartzman* - R. van Vollenhoven - A. Matsumoto - D. Orange - S. Shah - R. DeMasi - H. Fan - P. Dahl - A. Wouters - E. Keystone GUIDELINE-BASED CARE IMPROVES OUTCOMES THAT MATTER TO PATIENTS: TIGHTER CONTROL, LESS SUFFERING, AND GREATER WELL-BEING OVER THE PAST DECADE IN CANADIAN RA PATIENTS / S. J. Bartlett* - O. Schieir - M.-F. Valois - B. Haraoui - G. Boire - C. Thorne - C. Hitchon - D. Tin - E. C. Keystone - J. Pope - V. P. Bykerk on behalf of CATCH: Canadian Early Arthritis Cohort CLUSTERIN SERUM LEVELS ARE ELEVATED IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND PREDICT DISEASE ACTIVITY AND TREATMENT RESPONSE / T. Lennerová* - H. Mann - O. Růžičková - O. Šléglová - L. Vernerová - M. Tomčík - K. Pavelka - J. Vencovský - L. Šenolt TRENDS IN THE INCIDENCE OF SOLID TUMORS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN. A NATIONAL OBSERVATIONAL COHORT STUDY / V. Villaverde* - M. Fernandez-Prada - R. Mazzucchelli - E. Perez-Fernandez - C. Macía-Villa - M. Espinosa - J. Quiros - M. Peña - J. L. Morell - C. Morado-Quiñoa - C. Martínez-Prada - C. Barbadillo - H. Godoy - N. Crespí - O. Guzón-Illescas - M. Galindo - A. Herranz - A. García-Vadillo TRENDS IN THE ACTIVITY OF RHEUMATOID ARTHRITIS AS THE CONSEQUENCE OF TREAT-TO-TARGET STRATEGY: EIGHT-YEAR DATA FROM 2009 TO 2016 / W. Xie* - J. Li - X. Zhang - G. Li - Y. Hao - J. Zhao - L. Wang - X. Sun - Y. Fan - Z. Zhang THE STUDY OF BASELINE SERUM SICAM-1 AND CXCL13 LEVELS IN PREDICTING RESPONSE TO TUMOR NECROSIS FACTOR-Α INHIBITOR THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS / X. Ye* - J. Zhao - Z. Zhang 16 June 2018 TOPIC: RHEUMATOID ARTHRITIS - COMORBIDITY AND CLINICAL ASPECTS SAT0117 HIGH URIC ACID AS A RISK FACTOR FOR CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS PATIENTS / A. Al-Herz* - A. Aldei - K. Saleh - A. Al-Awadhi - W. Al-Kandari - E. Hasan - A. Ghanem - M. Hussain - E. Nahar - F. Abutiban - A. Alenizi - Y. Ali - H. Alhajeri - S. Hayat - A. Khadrawy - A. Fazal - K. Mokaddem - A. Zaman - G. Mazloum - Y. Bartella - S. Hamed - R. Alsouk - A. Al-Saber SAT0118 ASSOCIATION OF RENIN-ANGIOTENSIN SYSTEM IMBALANCE WITH SUBCLINICAL ATHEROSCLEROSIS AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / N. F. T. Braz - M. R. C. Pinto - É. L. M. Vieira - A. L. Teixeira - A. C. S. Silva - A. M. Kakehasi* SAT0119 PHYSICAL ACTIVITY IN TUNISIAN ADULTS WITH RHEUMATOID ARTHRITIS / A. Feki* - A. Fazaa - S. Miladi - K. Ouenniche - S. Kassab - S. Chekili - K. Ben Abdelghani - A. Laatar SAT0120 MULTIFOCAL RECURRENT PANCREATITIS CAUSED BY SYSTEMIC SECONDARY AA AMYLOIDOSIS IN RHEUMATOID ARTHRITIS - A POSTMORTEM CLINICOPATHOLOGIC STUDY OF 161 PATIENTS / Á. Apáthy* - M. Bély SAT0121 PREVALENCE OF FIBROMYALGIA AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN DUBAI (WHAT IS THE CLINICAL RELEVANCE?) / A. A. Negm* - J. Al Saleh SAT0122 EXPERIENCE OF MUSCULOSKELETAL ULTRASOUND SCANNING IMPROVES SKILL OF PHYSICAL EXAMINATION IN ASSESSMENT OF SYNOVITIS / A. Saku* - S. Furuta - H. Furuya - K. Suzuki - M. Fukuta - S. Makita - T. Ito - K. Ikeda - H. Nakajima SAT0123 THE EFFECTS OF TRIMETHOPRIM-SULFAMETHOXAZOLE ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / A. Onishi* - K. Akashi - M. Hashimoto - W. Yamamoto - K. Murata - M. Katayama - H. Amuro - Y. Son - S. Yoshida - K. Nagai - R. Hara - K. Ebina - T. Hirano - Y. Yamamoto - H. Yamada - Y. Ichise - I. Naka - T. Okano - S. Takahashi - Y. Ueda - S. Sendo - J. Saegusa - A. Morinobu on behalf of ANSWER cohort study group SAT0124 AORTIC STIFFNESS AND TIME TO WAVE REFLECTION ARE ASSOCIATED WITH LEFT VENTRICULAR DIASTOLIC DYSFUNCTION MEASURES IN RHEUMATOID ARTHRITIS / A. M. Millen* - L. Mokotedi - S. Gunter - C. Robinson - F. Michel - A. J. Woodiwiss - L. Tsang - G. R. Norton - P. H. Dessein * Presenting author

146 144 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0125 THE IMPACT OF SELECTED COMORBIDITIES ON TREATMENT OUTCOME IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY COHORT STUDY / A. Emamifar* - I. M. Jensen Hansen SAT0126 CHARACTERIZING HETEROGENEOUS CARE PATHWAYS OF INCIDENT RHEUMATOID ARTHRITIS PATIENTS / A. A. Kawatkar* - J. An - A. Marshall - T. C. Cheetham - E. Haupt - G. Okano - K. Gupta - T. G. Curtice SAT0127 THE EFFICACY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS STRATIFIED BY BASELINE BODY MASS INDEX / A. Dikranian* - M. A. Gonzalez-Gay - F. Wellborne - J. M. Alvaro-Gracia - L. Takiya - L. Stockert - D. Chapman - S. Tatulych - P. Dahl - J. R. Curtis SAT0128 THE RISK FACTORS FOR SEVERE EXACERBATION OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS DURING BDMARD THERAPY / A. Tanaka* - K. Kurasawa - T. Miyao - Y. Takamura - R. Yamazaki - S. Arai - T. Owada - R. Maezawa - M. Arima SAT0129 TRENDS IN THE INCIDENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN: AN OBSERVATIONAL COHORT STUDY OF HOSPITAL DISCHARGES FROM 1999 TO 2015 (TREND-AR STUDY) / C. Macía Villa* - R. Mazzucchelli - E. Perez Hernandez - J. Quirós - J. L. Morell Hita - N. Crespí - M. Peña - C. Barbadillo - M. Espinosa - H. Godoy - M. Fernandez Prada - M. Galindo - A. Garcia Vadillo - O. Guzon Illescas - A. Herranz - C. Martinez Prada - C. Morado Quiñoa - V. Villaverde on behalf of TREND-AR SAT0130 IMPROVEMENT OF NUTRITIONAL CONDITIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS STARTING FIRST DISEASE MODIFYING ANTI-RHEUMATIC DRUGS / D. Kobayashi* - S. Ito - E. Hasegawa - I. Narita - K. Nakazono SAT0131 THE ROLE OF ULTRASOUND FOR THE ASSESSMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / S. Farietta - E. Castillo* - D. Buitrago-Garcia - L. Villarreal - P. Santos-Moreno SAT0132 COMORBIDITIES AFFECT THE RETENTION RATE BUT NOT THE CLINICAL RESPONSE IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS / E. G. Favalli* - M. Biggioggero - A. Becciolini - C. Crotti - L. Sinigaglia SAT0133 PREVALENCE OF TYPE 2 DIABETES AND EVALUATION OF PATIENT CHARACTERISTICS AMONG PATIENTS WITH AND WITHOUT RA FROM COMMUNITY RHEUMATOLOGY CLINICS / E. Alemao* - L. Ferri - D. Paul - A. Marshall - L. McDonald - A. Rao - V. R. Anupindi - G. Craig - K. Knapp SAT0134 MORTALITY AND MULTIPLE CAUSES OF DEATH IN RHEUMATOID ARTHRITIS PATIENTS. RESULTS FROM A LARGE POPULATION-BASED COHORT IN THE VENETO REGION, / F. Ometto* - U. Fedeli - C. Botsios - E. Schievano - M. C. Corti - L. Punzi SAT0135 CYTOKINE ACTIVATION AND FORMATION OF NEPHROPATHY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND PATHOPHYSIOLOGICAL PARALLELS / D. Rekalov - G. Prytkova* - R. Kulynych SAT0136 THE INFLUENCE OF HDL-CHOLESTEROL AND CRP ON INCREASED INSULIN RESISTANCE AND IMPAIRED BETA- CELL FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. G. Ristić* - V. Subota - D. Stanisavljević - B. Glišić - M. Petronijević - D. Stefanović SAT0137 CAROTID INTIMA-MEDIA THICKNESS AND ATHEROSCLEROTIC PLAQUE IN PATIENTS WITH REACTIVE AND RHEUMATOID ARTHRITIS / H. Palhuyeva* - A. Litviakov - N. Podolinskaya SAT0138 A DELAY TO DIAGNOSIS, BUT NOT TO TREATMENT INITIATION, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IS ASSOCIATED WITH ETHNIC GROUP AT ONE US ACADEMIC SITE / I. Castrejon* - T. Pincus - J. Chua - N. Shakoor - S. Hassan - J. A. Block SAT0139 SUBCLINICAL IMPAIRMENT OF MYOCARDIAL FUNCTIONALITY DURING THE VERY EARLY STAGE OF INFLAMMATORY JOINT DISEASES / A. Lo Gullo - J. Rodríguez-Carrio* - F. Savarino - C. O. Aragona - G. Dattilo - C. Zito - A. Suárez - S. Loddo - M. Atteritano - A. Saitta - G. Mandraffino SAT0140 RISK OF VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC AND NON-BIOLOGIC DMARDS / J. C. Maro - T. Menzin - K. Hornbuckle - J. T. Giles* - A. Kavanaugh - T. Dörner - D. Martin - T. Huang - C. A. Salinas SAT0141 TRENDS IN THE INCIDENCE OF LYMPHOMAS AND LEUKEMIAS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN: AN OBSERVATIONAL COHORT STUDY OF HOSPITAL DISCHARGES FROM 1999 TO 2015 (TREND-AR STUDY) / J. L. Morell Hita* - R. Mazzucchelli - E. Perez Fernandez - J. Quiros - C. Macía Villa - N. Crespi - M. Peña - C. Barbadillo - M. Espinosa - H. Godoy - M. Fernandez Prada - M. Galindo - A. Garcia Vadillo - O. Guzon Illescas - A. Herranz - C. Martinez Prada - C. Morado Quiñoa - V. Villaverde SAT0142 PULMONARY HYPERTENSION AMONG HISPANIC PATIENTS WITH RHEUMATOID ARTHRITIS: A CASE- CONTROL STUDY / J. R. Azpiri-López* - D. A. Galarza-Delgado - I. J. Colunga-Pedraza - J. A. Dávila-Jiménez - E. E. Abundis-Márquez - A. H. Guillén-Lozoya - F. J. Torres-Quintanilla - R. E. Ramos-Cázares - R. Vera-Pineda - J. A. Cárdenas-de la Garza SAT0143 THE ARREST OF BONE MINERAL DENSITY LOSS AT THE LUMBAR SPINE AND HIP IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DURING RITUXIMAB THERAPY / K. Keywani* - H. G. Raterman - M. M. ter Wee - M. T. Nurmohamed - A. E. Voskuyl - I. E. Bultink - W. F. Lems SAT0144 EFFECT OF AGING ON BONE MASS AND SKELETAL MUSCLE MASS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS: TOMORROW STUDY / K. Inui* - T. Koike - Y. Sugioka - T. Okano - K. Mamoto - Y. Yamada - K. Mandai - M. Tada - H. Nagata - H. Nakamura SAT0145 FEATURES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHOSE DEBUT JOINT IS A FOOT OR ANKLE JOINT: A 5,479 CASES STUDY FROM THE IORRA COHORT / K. Yano* - K. Ikari - K. Okazaki - A. Taniguchi - H. Yamanaka SAT0146 AT DIAGNOSIS OF RHEUMATOID ARTHRITIS, AT-RISK PATIENTS FOLLOWED IN CCP+ CLINIC SHOWED MILDER DISEASE ACTIVITY THAN CONVENTIONALLY REFERRED PATIENTS / L. Duquenne* - P. Pentony - K. Mankia - J. Nam - L. Hunt - A. L. Tan - L. Garcia-Montoya - P. Emery SAT0147 PRESENCE OF HEPATITIS B VIRUS IN SYNOVIUM AND ITS CLINICAL SIGNIFICANCE IN RHEUMATOID ARTHRITIS / L.-J. Yang - Y.-L. Chen - J. Jing - Y.-Q. Mo - J.-D. Ma - L.-F. Chen - J.-Z. Lin - Z.-H. Yang - T. Yan - D.-H. Zheng - F. Pessler - L. Dai* SAT0148 ORAL CARE AND HEALTH IN RHEUMATOID ARTHRITIS PATIENTS BASED ON A SELF- ASSESSMENT QUESTIONNAIRE INVESTIGATION / L. L. Strandbygaard* - M. Radwan-Oczko - I. Dus - A. M. Thomsen - K. Schmøkel - C. Rasmussen * Presenting author

147 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 145 SAT0149 IS ESTABLISHED SERONEGATIVE RHEUMATOID ARTHRITIS EVEN A MILD FORM OF THE DISEASE? / L. D. Fajardo Hermosillo* SAT0150 INADEQUATE CARDIOVASCULAR RISK MANAGEMENT IS NOT RHEUMATOID ARTHRITIS SPECIFIC AMONG PATIENTS WITH PREVALENT RHEUMATIC AND MUSCULOSKELETAL DISEASES / M. Reyskens* - L. Tsang - M. Walschot - F. Fleurinck - A. O. Solomon - A. Millen - P. Dessein SAT0151 CARDIORESPIRATORY FITNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. H. Liff* - M. Hoff - T. Fremo - U. Wisløff - R. Thomas - V. Videm SAT0152 SYSTEMIC AND RENAL AA AMYLOIDOSIS IN RHEUMATOID ARTHRITIS - A COMPARATIVE POSTMORTEM CLINICOPATHOLOGIC STUDY OF 161 PATIENTS / M. Bély* - Á. Apáthy SAT0153 ANALYSIS OF CLINICAL-ANALYTICAL CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND INTERSTITIAL LUNG DISEASE (ILD): CASE-CONTROL STUDY / N. Mena-Vázquez* - S. Manrique-Arija - C. Romero-Barco - I. Ureña-Garnica - M. Ordóñez-Cañizares - F. Jiménez-Núñez - G. Díaz-Cordovés - M. Rojas-Giménez - C. Fuego - R. Caparrós-Ruiz - L. Cano-Garcia - A. Belmonte - M. Irigoyen-Oyarzábal - A. Fernández-Nebro SAT0154 ASSESSMENT OF BONE TURNOVER MARKERS IN PRE- AND POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS / O. Garmish* - T. Orlyk - A. Romanovskyi - T. Gavrylenko SAT0155 TRADITIONAL AND NONTRADITIONAL CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH EARLY ONSET ARTHRITIS OF THE PANLAR-EOA / I. Acosta Colman - P. Delgadillo* - G. Avila-Pedretti - S. Cabrera-Villalba - P. Melgarejo - G. Elizaur - M. Franco - A. Ramagli - J. Mazzoleni - P. Abreu SAT0156 ASSOCIATION BETWEEN CUMULATIVE METHOTREXATE DOSE, NON-INVASIVE SCORING SYSTEM AND HEPATIC FIBROSIS DETECTED BY FIBROSCAN IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING METHROTREXATE / R. Lertnawapan* - S. Chonprasertsuk - S. Siramolpiwat SAT0157 THE PREVALENCE OF DYSLIPIDEMIA AND DAILY NUTRITIONAL INTAKE IN RHEUMATOID ARTHRITIS PATIENTS: A STUDY OF THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHANES) / S. H. Joo* - Y. W. Song SAT0158 THE ASSESSMENT OF SAFETY AND EFFICACY OF USING SELF-MONITORING OF DISEASE ACTIVITY VIA WEB PORTAL IN THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS / G. Bagirova* - E. Lygina - S. Iakushin - A. Vorobyev SAT0159 THYROID FUNCTION IN EARLY VERSUS ESTABLISHED RHEUMATOID ARTHRITIS / S. Hannawi* - H. Hannawi - I. Al Salmi SAT0160 EFFECT OF PERIODONTAL TREATMENT ON E-SELECTIN LEVEL IN RHEUMATOID ARTHRITIS PATIENTS / S. A. Kusumo* - H. Isbagio - S. Marhamah - C. Intan - D. Antono - K. Harimurti SAT0161 INFLUENCE OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS ON RADIOGRAPHIC PROGRESSION OF CONCOMITANT INTERPHALANGEAL JOINT OSTEOARTHRITIS / C. Lechtenboehmer - V. Jaeger - D. Kyburz - U. A. Walker - T. Hügle* SAT0162 WHERE SHOULD WE SEEK FOR SUBCLINICAL SYNOVITIS USING ULTRASOUND IN RHEUMATOID ARTHRITIS? / W. Hamdi* - M. Sellami - H. Riahi - D. Kaffel - K. Maatallah - M. Chelli-Bouaziz - M. F. Ladeb - M. M. Kchir SAT0163 ABSOLUTE NUMBER OF PERIPHERAL CD4-CD25+FOXP3+T CELLS DECREASES AND RESTORES AFTER LOW- DOSE INTERLEUKIN-2 TREATMENT IN RHEUMATOID ARTHRITIS / X. Jia* - H. An - K. Fan - F. Li - C. Gao - X. Li SAT0164 ADVERSE DRUG REACTIONS DUE TO DISEASE MODIFYING DRUGS IN PATIENTS WITH INCIDENT RHEUMATOID ARTHRITIS / Z. Rosales Rosado* - D. D. Freites Núñez - C. Lajas Petisco - E. Pato Cour - L. León Mateos - L. Abásolo Alcázar 16 June 2018 TOPIC: RHEUMATOID ARTHRITIS - BIOLOGICAL DMARDS Poster tour S5: Abstracts N : Breakout news on non-tnf biologics in RA Xavier Mariette (France), Diane van der Woude (Netherlands) SAT0165-SAT0174 SAT0165 REASONS FOR BDMARD CESSATION AND SUBSEQUENT PERSISTENCE OF SECOND LINE TREATMENT IN A LARGE REAL WORLD RHEUMATOID ARTHRITIS REGISTRY / P. Youssef* - B. Marcal - P. Button - M. Truman - P. Bird - H. Griffiths - L. Roberts - K. Tymms - G. Littlejohn SAT0166 WHICH BIOLOGIC AGENT IS MOST SUITABLE FOR AN EXTENDED-INTERVAL TREATMENT FOR RHEUMATOID ARTHRITIS? RESULTS FROM A MULTICENTER STUDY / K. Katayama* - H. Matsuno - T. Matsubara SAT0167 COMPARISON OF THE EFFICACY AND TOLERABILITY OF TOCILIZUMAB, SARILUMAB, AND SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS / Y. H. Lee* - Y. H. Seo SAT0168 MRI RESULTS FOLLOWING DISCONTINUATION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB: RESULTS FROM A RANDOMISED CONTROLLED TRIAL / C. Peterfy* - J. Kremer - W. Rigby - N. Singer - C. Birchwood - D. Gill - W. Reiss - J. Pei - M. Michalska SAT0169 NO EVIDENCE THAT CONCOMITANT GLUCOCORTICOID THERAPY AFFECTS EFFICACY AND SAFETY OF TOCILIZUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS CLINICAL TRIALS / M. Safy* - J. W. G. Jacobs - M. Edwardes - J. Pei - M. De Hair - X. Teitsma - P. Welsing - M. Borm - Y. Luder - J. Van Laar - A. Pethö-Schramm - J. W. J. Bijlsma SAT0170 ANTI-IL-6 THERAPY MODULATES LEPTIN IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. López-Mejías* - F. Genre - S. Remuzgo-Martínez - V. Mijares - J. Calvo-Alen - R. Blanco - J. Llorca - S. Castañeda - M. A. González-Gay SAT0171 REVERSIBLE DECREASES IN ABSOLUTE NEUTROPHIL COUNT (ANC) IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS) ON SARILUMAB: COMPARISON OF DOSE DELAY AND DOSE DECREASE VS CONTINUED TREATMENT / J. R. Curtis* - G. St John - M. Panucci - J. A. Maldonado-Cocco * Presenting author

148 146 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0172 LONG-TERM EFFICACY WITH 5-YEAR-RADIOGRAPHIC RESULTS AND SAFETY OF SARILUMAB IN COMBINATION WITH CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. R. Burmester* - Y. Lin - G. St John - S. Wang - J. J. Gomez-Reino - J. A. Maldonado-Cocco - J. C. Salazar - D. van der Heijde - M. C. Genovese SAT0173 EFFECTS OF DENOSUMAB, A SUBCUTANEOUS RANKL INHIBITOR, ON THE PROGRESSION OF STRUCTURAL DAMAGE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CSDMARDS: RESULT FROM THE LONG-TERM TREATMENT OF PHASE 3, DESIRABLE STUDY / T. Takeuchi* - Y. Tanaka - S. Soen - H. Yamanaka - T. Yoneda - S. Tanaka - T. Nitta - N. Okubo - H. Genant - D. van der Heijde SAT0174 DOES ABATACEPT INCREASE PERIOPERATIVE ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING DRUGS? - A RETROSPECTIVE MULTICENTER NESTED CASE-CONTROL STUDY - / H. Ito* - S. Tsuji - M. Nakayama - Y. Mochida - K. Nishida - H. Ishikawa - T. Kojima - T. Matsumoto - A. Kubota - T. Mochizuki - K. Sakuraba - I. Matsushita - A. Nakajima - R. Hara - A. Haraguchi - T. Matsubara - K. Kanbe - N. Nakagawa - M. Haraguchi - S. Momohara on behalf of JOSRA consortium SAT0175 RESPONSE TO BIOLOGIC TREATMENT IMPROVES SEXUAL HEALTH ASSESSED BY THE QUALISEX SCORE IN RA / A. Perdriger* - C. Lucas - J. Sibilia - J.-E. Gottenberg SAT0176 CONTRIBUTION OF CD4+ T CELLS DECREASE ON CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS / A. Bensalem* - D. Mulleman - G. Thibault - N. Azzopardi - G. Paintaud - P. Goupille - D. Ternant SAT0177 REAL-WORLD INTERRUPTIONS IN JANUS KINASE INHIBITOR THERAPY OBSERVED AMONG BIOLOGIC-NAÏVE AND BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS PATIENTS / B. Chastek* - E. Koep - U. G. Mallya - A. Cockerham - J. Choi - S. Boklage - D. E. Furst SAT0178 PREDICTORS OF DRUG SURVIVAL OF ABATACEPT IN RHEUMATOID ARTHRITIS - RESULTS FROM A LARGE NATIONAL QUALITY REGISTER COHORT STUDY / G. Cagnotto - M. Willim - J.-Å. Nilsson - S. Saevarsdottir - C. Turesson* SAT0179 THE BLOOD B CELL SUBSETS AND EFFECT OF TOCILIZUMAB THERAPY ON THEM IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Gerasimova* - T. Popkova - A. Aleksankin - S. Davidyan - A. Martinova - E. Aleksandrova SAT0180 TWO-YEAR CONSOLIDATED SAFETY DATA FOR ABP 501 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS / E. Krishnan* - N. Zhang - H. Wang SAT0181 EFFECT OF ANTI-IL-6 THERAPY ON SERUM LEVELS OF METABOLIC SYNDROME-RELATED BIOMARKERS IN RHEUMATOID ARTHRITIS PATIENTS / F. Genre* - S. Remuzgo-Martínez - R. López-Mejías - V. Mijares - J. Calvo-Alen - R. Blanco - J. Llorca - S. Castañeda - M. Á. González-Gay SAT0182 TOCILIZUMAB S.C. - IMPROVEMENT OF THE DEPRESSIVENESS, FATIGUE AND PAIN IN RA THERAPY / F. Behrens* - M. Englbrecht - W. A. Biewer - G.-R. Burmester - M. Feuchtenberger - J.-P. Flacke - M. Hofmann - P. Kästner - H. Kellner - T. Klopsch - C. Kühne - H.-P. Tony - C. Amberger SAT0183 SWITCHING FROM ADALIMUMAB TO SARILUMAB IS ASSOCIATED WITH COMPARABLE EFFICACY BUT LOWER FUNCTIONAL IMPROVEMENT VERSUS CONTINUOUS SARILUMAB MONOTHERAPY THROUGH 48-WEEK OPEN- LABEL EXTENSION (OLE) OF THE PHASE 3 MONARCH TRIAL / G. R. Burmester* - G. St John - M. Iglesias- Rodriguez - C.-C. Hu - T. Raskina - H. Amital - A. Gomez Centeno - A. Rubbert-Roth SAT0184 THE EFFECT OF SMOKING ON RESPONSE TO TUMOR NECROSIS FACTOR-ALPHA INHIBITOR TREATMENT IN ANKYLOSING SPONDYLITIS PATIENTS: RESULTS FROM THE TURKBIO REGISTRY / H. Yarkan Tuğsal* - G. Can - S. Çapar - B. Zengin - G. Kenar - S. Akar - E. Dalkılıç - S. Şenel - S. S. Koca - A. Tufan - A. Yazıcı - N. İnanç - H. Ellidokuz - N. Akkoç - F. Önen SAT0185 CERTOLIZUMAB PEGOL SERUM LEVELS 20 MG/L ARE ASSOCIATED WITH IMPROVEMENT IN DAS28 IN RHEUMATOID ARTHRITIS PATIENTS. DATA FROM THE NOR-DMARD STUDY / J. E. Gehin* - S. W. Syversen - D. J. Warren - G. L. Goll - J. Sexton - E. K. Strand - T. K. Kvien - N. Bolstad - E. Lie SAT0186 TREATMENT RESPONSE OF INTRAVENOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON THE LEVEL OF PRIOR EXPOSURE TO BIOLOGIC THERAPY: RESULTS FROM THE KOBIO / K. Shin* - S.-K. Lee - S. Oh - H.-A. Kim - Y. W. Song SAT0187 GOLIMUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA): 1-YEAR RESULTS FROM A NON- INTERVENTIONAL TRIAL IN GERMANY / I. Klaudius - K. Krueger* - S. Remstedt - A. Thiele SAT0188 TOCILIZUMAB IN EARLY RHEUMATOID ARTHRITIS DELIVERS CLINICAL AND ULTRASOUND-CONFIRMED RAPID AND DEEP REMISSION WITH ABOLITION OF PD - TREMERA STUDY / L. Hunt* - E. Hensor - K. Naraghi - R. J. Wakefield - P. Emery - M. H. Buch SAT0189 DYNAMICS OF CIRCULATING TNF DURING ADALIMUMAB TREATMENT OF RHEUMATOID ARTHRITIS USING A NOVEL DRUG-TOLERANT TNF ASSAY / L. C. Berkhout* - M. J. l Ami - J. Ruwaard - M. H. Hart - P. Ooijevaar-de Heer - K. Bloem - M. T. Nurmohamed - R. F. van Vollenhoven - M. Boers - C. Smith - G. Wolbink - T. Rispens SAT0190 RISK FOR OPPORTUNISTIC INFECTIONS IN RHEUMATOID ARTHRITIS TREATED WITH BDMARDS IN CLINICAL PRACTICE, 10 YEARS OF FOLLOW UP / L. Leon* - M. Peñuela - F. J. Candel - D. Freites - L. Rodriguez-Rodriguez - L. Abasolo SAT0191 THE PATIENT PERSPECTIVE ON BDMARD DOSE REDUCTION: A MIXED METHODS STUDY / L. M. Verhoef* - E. M. Selten - J. E. Vriezekolk - A. J. de Jong - F. H. van den Hoogen - A. A. den Broeder - M. E. Hulscher SAT0192 COMPETITIVE ELISA AND BRIDGING ELISA WITH ACID DISSOCIATION DETECT ANTI-DRUG ANTIBODIES IN A GREATER PROPORTION OF PATIENTS TREATED WITH TNF-ΑLPHA INHIBITORS THAN CLASSICAL BRIDGING ELISA / M. Ogrič* - P. Žigon - K. Lakota - S. Praprotnik - D. Drobne - B. Štabuc - S. Sodin-Semrl - S. Čučnik SAT0193 EARLY DISCONTINUATION OF FIRST LINE BIOLOGICAL TREATMENT WITH ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE ITALIAN GISEA REGISTRY / M. Sebastiani* - A. Manfredi - F. Iannone - E. Gremese - A. Bortoluzzi - E. G. Favalli - R. Gorla - F. Salaffi - E. Fusaro - R. Foti - L. Cantarini - R. Caporali - A. Cauli - S. Alivernini - F. P. Cantatore - A. Carletto - F. Conti - S. D Angelo - O. Epis - G. Cassone - R. Ramonda - V. Grosso - P. Sarzi-Puttini - G. Ferraccioli - G. Lapadula on behalf of GISEA (Gruppo Italiano Studio Early Arthritis) * Presenting author

149 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 147 SAT0194 SIGNIFICANT OVERTREATMENT WITH BIOLOGICAL DRUGS IS COMMON IN ROUTINE CARE FOR PATIENTS WHERE SERUM DRUG LEVELS ARE MONITORED / M. E. Perry* SAT0195 OPTIMIZATION OF BIOLOGIC THERAPIES IN RHEUMATOID AND PSORIASIC ARTHRITIS: A SINGLE-CENTRE EXPERIENCE / M. Sgrulletti* - S. Salemi - R. Di Rosa - R. Petruccelli - B. Laganà - M. L. Sorgi - G. Meneguzzi - S. Quarta - M. Catoni - A. Picchianti Diamanti - S. Caporuscio - G. Salerno - R. D Amelio SAT0196 TIME TO DISCONTINUATION OF BIOLOGIC THERAPY BY MECHANISM OF ACTION IN RHEUMATOID ARTHRITIS: RESULTS FROM THE ONTARIO BEST PRACTICE RESEARCH INITIATIVE (OBRI) COHORT / M. Movahedi* - S. Couta - A. Cesta - C. Bombardier on behalf of Other OBRI Investigators SAT0197 ADHERENCE TO BIOLOGIC THERAPY OF RHEUMATOID ARTHRITIS PATIENTS - IS THERE ANY RELATION WITH DISEASE ACTIVITY? / N. Madeira* - A. Cardoso - R. Trinca - C. Silva - H. Santos - C. Miguel - F. Barcelos - D. Medeiros - R. Campanilho Marques - L. Cunha Miranda SAT0198 DRUG SURVIVAL AND EFFICACY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS IN ROUTINE CARE - 7 YEAR EXPERIENCE FROM A SINGLE CENTRE IN THE UNITED KINGDOM / N. Nolkha* - T. Sheeran - S. Venkatachalam SAT0199 SWITCH FROM INNOVATOR ETANERCEPT TO BIOSIMILAR ETANERCEPT IN INFLAMMATORY RHEUMATIC DISEASES: THE EXPERIENCE OF COCHIN UNIVERSITY HOSPITAL PARIS-FRANCE / O. Al Tabaa* - A. Etcheto - C. Miceli-Richard - M. Anna - M. Dougados SAT0200 LONG-TERM SAFETY OF FILGOTINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: WEEK 108 DATA FROM A PHASE 2B OPEN-LABEL EXTENSION STUDY / R. Westhovens* - R. Alten - K. Winthrop - M. Greenwald - L. Ponce - F. Enriquez-Sosa - M. Stanislavchuk - M. Mazur - A. Spindler - R. Cseuz - N. Nikulenkova - M. Glowacka-Kulesz - I. Szombati - A. Dudek - N. Mozaffarian - J. Greer - R. Kunder - D. An - P. Harrison - A. van der Aa - A. Kavanaugh - M. Genovese SAT0201 REAL WORLD EVIDENCE ON SWITCHING BETWEEN ETANERCEPT AND ITS BIOSIMILAR IN RHEUMATIC DISEASES / R. Alten* - H. Jones - C. Curiale - T. Meng - L. Lucchese - C. Miglio SAT0202 COMPARISON OF THE BIOAVAILABILITY OF A SINGLE DOSE OF CERTOLIZUMAB PEGOL INJECTED BY PRE- FILLED SYRINGE OR BY ELECTRO-MECHANICAL AUTO-INJECTION E-DEVICE: A PHASE 1, OPEN-LABEL, RANDOMISED, PARALLEL GROUP, SINGLE-CENTRE BIOEQUIVALENCE STUDY / R. Oliver* - B. VanLunen - I. Mountian - E. Brown - D. Tatla SAT0203 OPTIMIZATION OF BIOLOGIC TAPERING USING ULTRASOUND IN RA PATIENTS / S. Bawa* - M. Todd - J. France SAT0204 NAÏVE AND RECENT THYMIC EMIGRANT CD4+ T CELLS INCREASE IN RHEUMATOID PATIENTS TREATED WITH ABATACEPT / S. Piantoni* - F. Regola - A. Tincani - P. Airò SAT0205 COMPARISON OF DISEASE STATUS IN UK PATIENTS WITH RA RECEIVING TNFI VS CDMARD / J. Addison - S. Lobosco* - B. Hoskin - E. Sullivan - J. Pike - S. Fenwick SAT0206 RESULTS OF THE ALTERRA CLINICAL TRIAL - THE EFFICACY OF THE ALTERNATIVE DOSING REGIMEN FOR RITUXIMAB BIOSIMILAR IN BDMARDS NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS / V. Mazurov* - L. Denisov - I. Gordeev - O. Nesmeyanova - T. Plaksina - E. Ilivanova - D. Krechikova - E. Zonova - L. Knyazeva - A. Artemeva - E. Dokukina - E. Chernyaeva - R. Ivanov SAT0207 DEPRESSIVE SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SARILUMAB TARGET AND MOBILITY TRIALS AND IMPACT OF TREATMENT / V. Strand* - O. Hagino - S. Guillonneau - S. Boklage - M. Reaney - J. Sadeh - N. Narcisse - E. Mangan - T. Kirmura SAT0208 HOW GOOD ELDERLY RHEUMATOID ARTHRITIS PATIENTS RESPOND AT FIRST YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL? / V. Torrente-Segarra* - M. Fernandez Prada - R. Expósito - N. Garrido Puñal - A. Sánchez-Andrade - J. R. Lamúa-Riazuelo - A. Olivé - J. V. Tovar on behalf of RENACER study group (REgistro NAcional CERtolizumab) SAT0209 A COMPARATIVE REAL-WORLD UTILIZATION PATTERNS OF INNOVATOR AND BIOSIMILAR INFLIXIMAB IN A TREATMENT NAÏVE AND SWITCH POPULATION FROM GERMANY: A PRESCRIPTION CLAIMS ANALYSIS / E. M. Ewara - L. Ellis - K. Goyal* - V. Jairath - A. M. Marrache - X. Baraliakos SAT0210 TREATMENT RETENTION RATE OF BIOLOGICAL TREATMENT IN ELDERLY RHEUMATOID ARTHRITIS PATIENTS COMPARED WITH YOUNGER RHEUMATOID ARTHRITIS PATIENTS - A SINGLE CENTER COHORT STUDY / Y. Hirano* - K. Hattori - R. Yamada - Y. Oishi SAT0211 IS THERE A POTENTIAL FOR THERAPEUTIC DRUG MONITORING OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY PRACTICE? / Z. Layegh* - M. J. L `Ami - C. Bastida - A. D. Huitema - C. Krieckaert - M. T. Nurmohamed - T. Rispens - G. Wolbink 16 June 2018 TOPIC: RHEUMATOID ARTHRITIS - NON BIOLOGIC TREATMENT AND SMALL MOLECULES Poster tour S6: Abstracts N : Novel insights on non-biologics in RA Alexander So (Switzerland), Diego Kyburz (Switzerland) SAT0212-SAT0220 SAT0212 SAT0213 SAT0214 THE SAFETY AND TOLERABILITY OF INTRA-ARTICULAR INJECTION OF TOLEROGENIC DENDRITIC CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE PRELIMINARY RESULTS / Y. Kurochkina* - M. Tikhonova - T. Tyrinova - O. Leplina - A. Sizikov - A. Sulutian - O. Chumasova - A. Ostanin - E. Chernykh TIGHT TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN THE EARLY STAGES OF DISEASE LEADS TO HIGH LEVELS OF REMISSION AND REDUCED USE OF BIOLOGICS / K. Levasseur - S. Raizada* EFFECTIVENESS OF A RANDOMISED STEP-DOWN TO METHOTREXATE OR LEFLUNOMIDE MAINTENANCE THERAPY IN PATIENTS WITH LOW DISEASE ACTIVITY, 40 WEEKS AFTER STARTING COMBINED METHOTREXATE- LEFLUNOMIDE REMISSION INDUCTION THERAPY IN EARLY RHEUMATOID ARTHRITIS: RESULTS FROM THE CARERA TRIAL / V. Stouten* - S. Michiels - A. Belba - R. Westhovens - P. Verschueren on behalf of the CareRA study group * Presenting author

150 148 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0215 SAT0216 SAT0217 SAT0218 SAT0219 SAT0220 SAT0221 SAT0222 SAT0223 SAT0224 SAT0225 SAT0226 SAT0227 SAT0228 SAT0229 SAT0230 SAT0231 SAT0232 SAT0233 SAT0234 SAT0235 SAT0236 LIVER BLOOD TEST ABNORMALITIES ARE RARE IN PATIENTS ON METHOTREXATE: EVIDENCE FROM A LARGE COHORT OF INFLAMMATORY ARTHRITIS PATIENTS / T. Malley* - G. Corfield - D. Heneghan - J. Kitchen THE ADDITION OF COLCHICINE TO METOTREXATE MIGHT HELP ACHIEVE LOW DISEASE ACTIVITY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS BY DOWNREGULATING THE ACTIVITY OF CASPASE-1 / D. Ramos-Bello* - A. J. Pedro-Martínez - G. Aguilera Barragán-Pickens - E. S. Acevedo-Castañeda - H. López-Ferretis - G. Martínez-Flores - T. A. Luna-Zúñiga - E. Santillán-Guerrero - R. Moreno-Valdés - M. Saldaña-Baard - E. Cuevas-Orta - C. Álvares-Quiroga - R. González-Amaro - C. Abud-Mendoza IDENTIFICATION OF DISTINCT DISEASE ACTIVITY TRAJECTORIES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OVER 12 MONTHS / V. P. Bykerk - R. van Vollenhoven - C. Connell - D. Gruben - L. Fallon - J. Woolcott - E. Keystone* EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE) / Z. Li* - J. Hu - C. Bao - X. Li - X. Li - J. Xu - A. Spindler - X. Zhang - J. Xu - Z. Li - G. Wang - J. Sun - F. Ji - H. Tao - L. Zhan - T. Rooney - C. Zerbini UPADACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS: A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF A SELECTIVE JAK1 INHIBITOR / M. C. Genovese* - R. Fleischmann - B. Combe - S. Hall - Y. Zhang - Y. Zhou - M. F. Mohamed - S. Meerwein - A. L. Pangan EVALUATION OF LIVE ZOSTER VACCINE IN A SUBSET OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB WITH OR WITHOUT METHOTREXATE, AND ADALIMUMAB WITH METHOTREXATE: RESULTS FROM A PHASE 3B/4 RANDOMISED TRIAL / L. H. Calabrese* - C. Abud-Mendoza - S. Lindsey - S.-H. Lee - L. Takiya - N. Iikuni - K. Soma - Z. Luo - R. Fleischmann EFFECT OF TOFACITINIB ON REDUCING PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS / A. Ogdie* - K. de Vlam - I. B. McInnes - P. J. Mease - P. Baer - T. Lukic - K. Kwok - C. Wang - M.-A. Hsu - A. Maniccia CLINICAL RISK STRATIFICATION FOR HYDROXYCHLOROQUINE PRESCRIBING IN A LARGE URBAN DISTRICT GENERAL HOSPITAL / A. Saravanan* - T. Ahmed PREDICTIVE FACTORS OF EARLY FAILURE TO FIRST LINE TREATMENT WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS. RESULTS FROM THE GISEA REGISTRY / A. Manfredi* - M. Sebastiani - F. Iannone - E. Gremese - A. Bortoluzzi - E. G. Favalli - R. Gorla - F. Salaffi - E. Fusaro - R. Foti - L. Cantarini - R. Caporali - A. Cauli - S. Alivernini - F. P. Cantatore - A. Carletto - F. Conti - S. D Angelo - O. Epis - R. Ramonda - A. Marchesoni - F. Atzeni - P. Sarzi-Puttini - G. Ferraccioli - G. Lapadula on behalf of GISEA (Gruppo Italiano Studio Early Arthritis) AMELIORATION OF INFLAMMATORY DISEASE ACTIVITY AND VASCULAR INFLAMMATION WITH HMG-COA REDUCTASE INHIBITION AND ANGIOTENSIN RECEPTOR BLOCKADE IN RHEUMATOID ARTHRITIS / A. Syngle* - N. Garg - P. Krishan COMPARATIVE EFFECTIVENESS IN PAIN AND HAQ-DI IMPROVEMENT FOR BARICITINIB VERSUS ADALIMUMAB, TOCILIZUMAB, AND TOFACITINIB MONOTHERAPIES IN CSDMARD-NAÏVE RHEUMATOID ARTHRITIS PATIENTS: A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) / B. Fautrel* - B. Zhu - P. C. Taylor - M. van de Laar - P. Emery - F. De Leonardis - C. Gaich - C. Nicolay - Z. Kadziola - I. De La Torre - R. Fleischmann A PHASE 1, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-RISING DOSE STUDY OF THE BTK INHIBITOR TAK-020 IN HEALTHY VOLUNTEERS / E. Esfandiari* - H. Gevorkyan - H. Faessel - Z. Zhao - K. Hanna - G. Smithson - J. Wagner - E. R. Fedyk - L. Mclean RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A LOW-DOSE AND SHORT-TERM GLUCOCORTICOID WERE SATISFIED WITH EARLIER IMPROVEMENT AND REPORTED DECREASED ANXIETY REGARDING ADVERSE EVENTS / E. Torikai* - D. Suzuki - M. Suzuki - Y. Matsuyama STEP-DOWN METHOTREXATE THERAPY IN RHEUMATOID ARTHRITIS (STEMETRA): A PILOT STUDY TO ASSESS THE SAFETY AND THE TOLERABILITY OF HIGH-DOSE METHOTREXATE / G. Bianchi* - D. Camellino - A. Locaputo - P. Diana - A. Giusti - G. Girasole - J. Kremer - M. Weinblatt RHEUMATOID ARTHRITIS TREATMENT WITH COMBINATION OF THREE CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) AND ITS EFFECTIVENESS ON DISEASE CONTROL IN A SHORT TERM COMPARED TO BIOLOGIC DMARDS TREATMENT AFTER PROPENSITY SCORE MATCHING PROCEDURE IMPLEMENTED / I. Yoshii* - T. Chijiwa COMPARISON OF EFFICACY OF TOFACITINIB VS. ETANERCEPT TREATMENT IN RHEUMATOID ARTHTRITIS PATIENTS WITH HIGH ACTIVITY DISEASE BY ULTRASOUND EVALUATION WITH POWER DOPPLER (1 YEAR TREATMENT PERIOD) / I. Menshikova* - N. Dzhenzhera - Y. Pak - I. Kolosova EFFECTS OF THE JAK1-SELECTIVE INHIBITOR FILGOTINIB ON GENE EXPRESSION PROFILE IN BLOOD OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / P. C. Taylor - J. Tarrant* - L. Zhao - Y. Gindin - A. Mirza - P. Harrison - C. Tasset - R. Galien - A. van der Aa - B. Downie REACTIVATION OF IMMUNE CHECKPOINTS BY AN EPITOPE-SPECIFIC VACCINE REINSTATES TOLEROGENIC PATHWAYS AND INDUCES CLINICAL AMELIORATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. H. S. Chan* - T. van den Broek - J. Y. Leong - M. Rossetti - R. Spreafico - S. Albani METHOTREXATE TREATMENT IN RHEUMATOID ARTHRITIS AND ELEVATED LIVER ENZYMES: A LONG-TERM FOLLOW-UP OF OCCURRENCE, PREDICTORS, SURVEILLANCE, AND OUTCOME IN CLINICAL PRACTICE / J. Sundbaum* - N. Ericsson - P. Hallberg - N. Lehto - M. Wadelius - E. Baecklund TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 9 YEARS / J. Wollenhaupt* - J. Silverfield - E. B. Lee - K. Terry - K. Kwok - S. Strengholt - R. DeMasi - L. Wang SUBCUTANEOUS METHOTREXATE IS SAFER AND MORE EFFECTIVE THAN ORAL METHOTREXATE ALONE AND IN COMBINATION / K. H. C. Li* - T. Jones - M. Grove - A. Roberts - F. Birrell LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK-1 INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN AN OPEN LABEL EXTENSION STUDY / M. C. Genovese* - J. Kremer - S. Zhong - A. Friedman * Presenting author

151 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 149 SAT0237 EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO FAILED 2 OR MORE DMARDS / M. C. Genovese* - M. Dougados - S. Schwartzman - D. Schlichting - S. Beattie - L. Xie - A. Cardoso - J. S. Smolen SAT0238 RAPID ELEVATION OF ERYTHROCYTE METHOTREXATE-POLYGLUTAMATE3 (MTX-PG3) LEVELS RELATED TO THE EFFICACY OF MTX IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / M. Nishida* - G. Tsuji - M. Takahashi - T. Saitou - Y. Noda - K. Yoneda - N. Amano - S. Sendo - A. Onishi - A. Morinobu - M. Shinohara - S. Kumagai SAT0239 RAPID RESPONSE WITH UPADACITINIB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS OR BDMARDS / O. FitzGerald* - A. Rubbert-Roth - K. Chen - S. Meerwein - J. Enejosa - T. Shaw - A. F. Wells SAT0240 VAGUS NERVE STIMULATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: TWO-YEAR SAFETY AND EFFICACY / F. A. Koopman - A. Musters - M. J. Backer - D. Gerlag - S. Miljko - S. Grazio - S. Sokolovic - Y. A. Levine - D. Chernoff - N. de Vries - P.-P. Tak* SAT0241 PATIENTS PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOIDS IN RA - AN INITIATIVE UNDER THE GLORIA PROJECT / P. D. Carvalho* - N. Goel - M. Voshaar - M. Boers - J. A. P. D. Silva SAT0242 EFFECTIVENESS OF CONVENTIONAL DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED UNDER A TREAT TO TARGET MODEL - LESSONS FROM A REAL-LIFE COHORT / P. Santos-Moreno* - D. Buitrago-Garcia - L. Villarreal - M. Cabrera - E. Castillo - E. Cardozo - S. Farietta - R. Giraldo - D. Gomez SAT0243 INCIDENCE OF THROMBOEMBOLIC EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS, PSORIASIS, PSORIATIC ARTHRITIS AND ULCERATIVE COLITIS DEVELOPMENT PROGRAMMES / P. J. Mease* - J. Kremer - S. Cohen - J. R. Curtis - C. Charles-Schoeman - E. V. Loftus Jr - J. Greenberg - N. Palmetto - K. S. Kanik - D. Graham - C. Wang - P. Biswas - G. Chan - R. DeMasi - H. Valdez - T. Hendrikx - T. V. Jones SAT0244 IMPACT OF 12 WEEKS OF UPADACITINIB TREATMENT ON INDIVIDUAL AND COMPOSITE DISEASE MEASURES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC OR BIOLOGIC DMARDS / R. van Vollenhoven* - R. Dore - K. Chen - H. S. Camp - J. Enejosa - T. Shaw - J. L. Suboticki - S. Hall SAT0245 AZD9567: A NOVEL ORAL SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR, DEMONSTRATED TO HAVE AN IMPROVED THERAPEUTIC RATIO COMPARED TO PREDNISOLONE IN PRE-CLINICAL STUDIES, IS SAFE AND WELL TOLERATED IN FIRST CLINICAL STUDY / R. Hendrickx* - T. Hegelund-Myrbäck - M. Dearman - S. Prothon - G. Edenro - J. Leander - R. Fuhr - T. Körnicke - P. Svanberg - A. R. Berggren - T. Drmota - C. Keen - U. G. Eriksson SAT0246 AT WHICH POINT AND FOR WHICH REASONS ARE ORAL MTX FORMULATIONS SWITCHED TO INJECTABLE ONES IN RA PATIENTS? COMBINED RESULTS FROM 3 INDEPENDENT OBSERVATIONAL AND CLINICAL TRIALS / R.-M. Flipo* - A. Saraux - C. Hudry - C. Gaujoux-Viala - E. Senbel - S. Tropé - E. Zinovieva - H. Herman-Demars SAT0247 IMPACT OF GLUCOCORTICOIDS ON EFFICACY AND SAFETY OF TOFACITINIB WITH AND WITHOUT METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE FOR RHEUMATOID ARTHRITIS: RESULTS FROM A PHASE 3B/4 RANDOMISED TRIAL / R. Fleischmann* - J. Wollenhaupt - S. Cohen - J. S. Smolen - P. Dahl - N. Iikuni - H. Shi - S. Tatulych - L. Takiya SAT0248 A MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF REPOSITORY CORTICOTROPIN INJECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: PRELIMINARY INTERIM DATA FROM THE OPEN-LABEL TREATMENT PERIOD / R. Fleischmann* - D. E. Furst - R. Brasington - E. Connolly-Strong - J. Liu - M. E. Barton SAT0249 REDUCTION OF MONOCYTE ACTIVATION BY BOWEL CLEANSE AND ONE WEEK FASTING SUGGESTS PERMANENT PATHOGENETIC TRIGGERING FROM THE GUT IN RHEUMATOID ARTHRITIS / T. Häupl* - T. Sörensen - M. Boyer - J. Scheder-Bieschin - B. Smiljanovic - N. Steckhan - G.-R. Burmester - B. Stuhlmüller - C. Kessler - M. Bonin - A. Grützkau - A. Michalsen SAT0250 THE DOSING OF INTRA-ARTICULAR TRIAMCINOLONE HEXACETONIDE FOR KNEE SYNOVITIS IN CHRONIC POLYARTHRITIS - A RANDOMISED CONTROLLED STUDY / T. Weitoft* - K. Öberg SAT0251 SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR SHOWS POTENT ANTI-INFLAMMATORY EFFECT WITH IMPROVED METABOLIC PROFILE IN A PHASE I STUDY SUPPORTED BY IN VITRO DATA / T. Hegelund Myrbäck* - S. Prothon - M. Dearman - G. Edenro - J. Leander - M. Hashemi - G. de Miquel - R. Fuhr - T. Körnicke - Z. Tahib - E.-M. Andersson - P. Svanberg - K. Edman - R. Hendrickx - C. Keen - M. Kraan - K. Johansson - U. G. Eriksson - B. Carlsson - O. Vaarala SAT0252 CLINICAL AND FUNCTIONAL RESPONSE TO TOFACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: PROBABILITY PLOT ANALYSIS OF RESULTS FROM THE ORAL STRATEGY TRIAL / T. Takeuchi* - J. S. Smolen - R. Fleischmann - N. Iikuni - H. Fan - K. Soma - E. Akylbekova - T. Hirose SAT0253 DOSE REDUCTION OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACHIEVING SUSTAINED DISEASE CONTROL: RESULTS OF A PROSPECTIVE STUDY / T. Takeuchi* - M. C. Genovese - B. Haraoui - Z. Li - L. Xie - R. Klar - A. P. Correia - S. Otawa - P. Lopez-Romero - I. De La Torre - T. Rooney - J. S. Smolen SAT0254 UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: RESULTS FROM SELECT-NEXT / V. Strand* - J. Pope - N. Tundia - A. Friedman - H. S. Camp - A. Pangan - A. Ganguli - M. Fuldeore - D. Goldschmidt - M. Schiff SAT0255 PATIENT REPORTED OUTCOMES OF UPADACITINIB: RESULTS FROM BIOLOGIC INADEQUATE RESPONDERS (SELECT BEYOND PHASE III TRIAL) / V. Strand* - M. Schiff - N. Tundia - A. Friedman - S. Meerwein - A. Pangan - A. Ganguli - M. Fuldeore - Y. Song - J. Pope SAT0256 TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS ADALIMUMAB WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: PATIENT-REPORTED OUTCOMES FROM A PHASE 3B/4 RANDOMISED TRIAL / V. Strand* - E. Mysler - R. J. Moots - G. Wallenstein - R. DeMasi - D. Gruben - K. Soma - N. Iikuni - R. Fleischmann SAT0257 A PHASE 2B/3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB, A SELECTIVE JAK1 INHIBITOR, IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS / Y. Tanaka* - T. Takeuchi - K. Yamaoka - M. Oribe - M. Kawano - Y. Zhou - A. A. Othman - A. L. Pangan - S. Kitamura - N. Matsuda - S. Meerwein - H. Kameda 16 June 2018 * Presenting author

152 150 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 SAT0258 WEEKLY SPLIT DOSE COMPARED WITH SINGLE DOSE ORAL METHOTREXATE REDUCED POLYGLUTAMYLATION IN RED BLOOD CELLS AND INCREASED THE RISK OF ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Yoshioka* - K. Katayama - T. Kasama - M. Sato - S. Ohno - Y. Amasaki - H. Kataoka - D. Kanai - A. Suda - M. Okamoto - M. Sasano - S. Nagaoka - A. Sagawa on behalf of ADDMe trial Group TOPIC: SPONDYLOARTHRITIS - TREATMENT Poster tour S7: Abstracts N : Treatment in SpA: does it matter? Sofia Ramiro (Netherlands), Victoria Navarro-Compán (Spain) SAT0259-SAT June 2018 SAT0259 LOW RATE OF SPINAL RADIOGRAPHIC PROGRESSION OVER 2 YEARS IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH SECUKINUMAB: A HISTORICAL COHORT COMPARISON / J. Braun* - H. Haibel - M. de Hooge - R. Landewé - M. Rudwaleit - T. Fox - A. Readie - H. B. Richards - B. Porter - R. Martin - D. Poddubny - J. Sieper - D. van der Heijde SAT0260 ELIGIBILITY CRITERIA FOR TNFI THERAPY IN AXSPA: GOING BEYOND BASDAI / J. A. Marona* - A. Sepriano - S. Rodrigues-Manica - F. Pimentel-Santos - A. F. Mourão - N. Gouveia - J. C. Branco - F. Vinagre - R. Roque - J. Rovisco - M. L. Marques - J. Tavares-Costa - J. Silva - H. Santos - N. Madeira - E. Vieira-Sousa - R. Machado - M. Bernardes - R. Ferreira - S. Ramiro SAT0261 CERTOLIZUMAB PEGOL SERUM LEVELS 20 MG/L ARE ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. DATA FROM THE NOR-DMARD STUDY / J. E. Gehin* - S. W. Syversen - D. J. Warren - G. L. Goll - J. Sexton - E. K. Strand - T. K. Kvien - N. Bolstad - E. Lie SAT YEAR FOLLOW-UP OF A DOSE TAPERING PROTOCOL OF ANTI-TNF THERAPY IN A COHORT OF PATIENTS WITH SPONDYLOARTHRITIS (SPA) IN CLINICAL REMISSION UNDER CONDITIONS OF CLINICAL PRACTICE / M. D. C. Castro Villegas* - E.-L. Saldarriaga - P. Font Ugalde - M. Romero Gómez - J. Calvo Gutierrez - R. Ortega Castro - E. C. López-Medina - R. A. Altamirano - A. Escudero-Contreras - E. Collantes Estévez SAT0263 PREDICTORS OF REMISSION MAINTENANCE AND SUCCESSFUL THERAPY DISCONTINUATION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) WHO ACHIEVED SUSTAINED REMISSION ON OPEN-LABEL ADALIMUMAB (ADA) TREATMENT / J. Sieper* - R. Landewé - M. Magrey - J. Anderson - S. Zhong - X. Wang - A. Lertratanakul SAT0264 DOES BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUG NAÏVE VERSUS NON-NAÏVE PATIENTS WITH INFLAMMATORY JOINT DISEASES HAVE SIMILAR GOLIMUMAB DRUG SURVIVAL AND EFFICACY? DATA FROM THE PROSPECTIVE OBSERVATIONAL NOR-DMARD STUDY / B. Michelsen* - J. Sexton - T. K. Kvien SAT0265 THE RESPONSE TO TNF-BLOCKERS TREATMENT OF SPA PATIENTS IS INFLUENCED BY THE INTERPLAY BETWEEN HLA-B27 AND GUT MICROBIOTA COMPOSITION AT BASELINE / M. Vallier* - M. Chamaillard - S. Ferreira - S. Menegatti - E. Bianchi - L. Rogge - M. Dougados - C. Miceli-Richard SAT0266 USE OF CONVENTIONAL SYNTHETIC DMARDS AND BIOLOGICAL DMARDS IN PATIENTS WITH ENTEROPATHIC SPONDYLOARTHRITIS: A COMBINED GASTRO-RHEUMATOLOGICAL APPROACH / M. S. Chimenti - P. Conigliaro - P. Triggianese* - C. Canofari - F. Cedola - S. Onali - E. Calabrese - C. Petruzziello - A. Ruffa - G. Monteleone - L. Biancone - R. Perricone SAT0267 EFFICACY AND SAFETY OF BCD-055, PROPOSED INFLIXIMAB BIOSIMILAR, COMPARED TO INFLIXIMAB: 54-WEEK RESULTS FROM ASART-2 PHASE 3 CLINICAL STUDY / L. Denisov* - P. Shesternya - T. Plaksina - T. Kropotina - N. Soroka - E. Kunder - A. Lutskii - A. Eremeeva - E. Dokukina - E. Chernyaeva - R. Ivanov - V. Mazurov SAT0268 SECUKINUMAB DEMONSTRATES LOW RADIOGRAPHIC PROGRESSION AND SUSTAINED EFFICACY THROUGH 4 YEARS IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS / X. Baraliakos* - J. Braun - A. Deodhar - D. Poddubny - P. Emery - E. M. Delicha - Z. Talloczy - B. Porter SAT0269 THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (AXSPA): A SYSTEMATIC LITERATURE REVIEW / A. R. Cruz-Machado* - S. R. Manica - J. L. Silva - F. M. Pimentel-Santos - J. Tavares-Costa - E. Vieira-Sousa SAT0270 LOW INCIDENCE OF BOTH NEW-ONSET AND FLARES OF UVEITIS IN SECUKINUMAB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL TRIAL AND POST-MARKETING SAFETY ANALYSIS / A. Deodhar* - C. Miceli-Richard - X. Baraliakos - H. Marzo-Ortega - D. D. Gladman - R. Martin - J. Safi Jr - B. Porter - A. Shete SAT0271 SECUKINUMAB, A FULLY HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, EXHIBITS LOW IMMUNOGENICITY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS DURING A 52- WEEK TREATMENT PERIOD / A. Deodhar* - D. Gladman - I. McInnes - M. Ren - S. Spindeldreher - L. Pricop - B. Porter - J. Safi - A. Shete - G. Bruin SAT0272 DO TNF INHIBITORS IMPACT THE COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS, AND THEREBY ALTER THE NATURAL HISTORY OF ANKYLOSING SPONDYLITIS? / A. Deodhar* - K. L. Winthrop - R. L. Bohn - B. K. Chan - R. Y. Suruki - J. L. Stark - H. Yun - S. A. R. Siegel - L. Chen - M. Yassine - J. R. Curtis SAT0273 GOLIMUMAB RETENTION RATE IN PATIENTS WITH SPONDYLOARTHRITIS. DIFFERENCES BETWEEN ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS / B. Serrano-Benavente* - C. M. González Fernández - L. Valor - J. C. Nieto-González - R. D. González-Benítez - I. Janta - C. Sáenz Tenorio - J. G. Ovalles- Bonilla - J. Martínez-Barrio - M. Correyero Plaza - L. García-Montoya - F. J. López-Longo - I. Monteagudo Saez SAT0274 RETENTION RATES OF CERTOLIZUMAB PEGOL IN ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: HUR-BIO REAL LIFE RESULTS / B. Armagan* - A. Sari - A. Erden - G. K. Yardimci - L. Kilic - U. Kalyoncu - O. Karadag - S. Apras Bilgen - S. Kiraz - A. Akdogan - I. Ertenli SAT0275 VITAMIN D INSUFFICIENCY IS ASSOCIATED WITH VERTEBRAL FRACTURES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / C. Romera-Lopez* - C. Fernández-Carballido - M. P. Martínez-Vidal - T. Pedraz SAT0276 UVEITIS DURING ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A PARADOXICAL EVENT OR DISEASE MANIFESTATION? / C. Ancuta* - C. Pomirleanu - R. Paiu - G. Strugariu - L. Petrariu - C. Bran - E. Ancuta - R. Chirieac * Presenting author

153 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 151 SAT0277 IMMUNOGENICITY AND LOSS OF RESPONSE TO TNF INHIBITORS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM AN OBSERVATIONAL COHORT STUDY / C. I. Ancuta* - C. Pomirleanu - R. Paiu - G. Strugariu - L. Petrariu - E. Ancuta - C. Iordache - R. Chirieac SAT0278 NSAIDS REDUCES RADIOGRAPHIC PROGRESSION IN SACLOILIAC JOINTS IN EARLY AXIAL SPONDYLOARTHRITIS / D. Rumiantceva* - T. Dubinina - O. Rumyantseva - A. Demina - S. Erdes SAT0279 COMPARISON OF RETENTION RATES BETWEEN TUMOR NECROSIS FACTOR-Α INHIBITORS IN ANKYLOSING SPONDYLITIS PATIENTS: DATA FROM THE KOREAN COLLEGE OF RHEUMATOLOGY BIOLOGICS REGISTRY / E. H. Park* - S. Oh - H.-A. Kim - Y.-B. Park - K. Shin SAT0280 RAPAMYCIN RESTORES THE BALANCE BETWEEN TH17 AND REGULATORY T CELLS IN USPA PATIENTS / F. Jinnan* - X. Dan - G. Chong - L. Xiaofeng SAT0281 BIOLOGICS IN SAPHO SYNDROME. A SYSTEMATIC REVIEW / D. Daoussis - G. Konstantopoulou* - I. Antonopoulos - S.-N. Liossis SAT0282 OCCURRENCE OF ANTERIOR UVEITIS IN PATIENTS WITH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS TREATED WITH TUMOR NECROSIS FACTOR INHIBITORS: A RESTROSPECTIVE MONOCENTRIC STUDY COMPARING THE SOLUBLE RECEPTOR TO THE MONOCLONAL ANTIBODIES / G. Khoury* - B. Combe - J. Morel - C. Lukas SAT0283 SECUKINUMAB 150 MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE III TRIAL, MEASURE 2 / H. Marzo-Ortega* - J. Sieper - A. Kivitz - R. Blanco - M. Cohen - E. M. Delicha - S. Rohrer - H. Richards on behalf of MEASURE 2 study group SAT0284 AN ADD-ON TRAINING PROGRAM INVOLVING BREATHING EXERCISES, COLD EXPOSURE, AND MEDITATION ATTENUATES INFLAMMATION AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS / G. A. Buijze - H. M. Y. De Jong* - M. Kox - D. van Schaardenburg - R. M. van Vugt - C. Popa - P. Picckers - D. L. Baeten SAT0285 EFFICACY OF EARLY VERSUS DELAYED INITIATION OF ANTI-TNF-ALPHA TREATMENT IN AXIAL SPONDYLOARTHRITIS. DATA FROM THE CZECH REGISTRY ATTRA / H. Mann* - K. Bubová - J. Závada - Š. Forejtová - Z. Křístková - L. Szczuková - P. Horák - J. Vencovský - K. Pavelka on behalf of ATTRA registry SAT0286 RETENTION RATE AND SAFETY DATA OF BIOSIMILAR CT-P13 IN ANKYLOSING SPONDYLITIS PATIENTS: DATA FROM THE KOREAN COLLEGE OF RHEUMATOLOGY BIOLOGICS REGISTRY / H.-A. Kim* - E.-Y. Lee - S.-K. Lee - Y.-B. Park - K. Shin SAT0287 WHAT ARE THE ECONOMIC IMPLICATIONS OF ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS? - RESULTS OF A HEALTH INSURANCE CLAIMS DATA ANALYSIS / I. Redeker* - F. Hoffmann - J. Callhoff - H. Haibel - J. Sieper - A. Zink - D. Poddubnyy SAT0288 SECUKINUMAB DEMONSTRATES RAPID AND SUSTAINED EFFICACY IN ANKYLOSING SPONDYLITIS PATIENTS WITH NORMAL OR ELEVATED BASELINE CRP LEVELS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES / J. Braun* - J. Sieper - R. Landewé - X. Baraliakos - C. Miceli-Richard - E. Quebe-Fehling - B. Porter - K. Gandhi - D. van der Heijde SAT0289 LONG-TERM EFFECTS OF TNF-ALPHA INHIBITORS ON BONE MINERAL DENSITY AND THE INCIDENCE OF VERTEBRAL FRACTURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Beek* - M. van der Weijden - T. Rusman - W. Lems - C. van denderen - M. Nurmohamed - I. van der Horst-Bruinsma SAT0290 CANADIAN ADALIMUMAB POST-MARKETING OBSERVATIONAL EPIDEMIOLOGICAL STUDY ASSESSING THE EFFECTIVENESS OF ADALIMUMAB VS. NON-BIOLOGIC DMARDS IN ANKYLOSING SPONDYLITIS (COMPLETE-AS): 12-MONTH EFFECTIVENESS DATA / L. Bessette* - M. Khraishi - A. Chow - V. Pavlova - S. Silverberg - J. Stewart - V. Remple SAT0291 CREATION OF A EUROPEAN DATABASE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED IN CLINICAL PRACTICE- INITIAL, PRELIMINARY FINDINGS FROM THE EUROSPA RESEARCH NETWORK COLLABORATION / L. M. Ørnbjerg* - M. Østergaard - F. Onen - G. Can - Z. Rotar - M. Tomsic - B. Gudbjornsson - A. J. Geirsson - M. J. Santos - A. Barcelos - D. Nordström - K. Aaltonen - M. J. Nissen - A. Ciurea - E. K. Kristianslund - T. Kvien - C. Codreanu - E.-M. Hauge - L. Jacobsson - H. Mann - G. Jones - F. Iannone - M. V. Hernandez - I. van der Horst-Bruinsma - L. H. Hyldstrup - N. S. Krogh - M. L. Hetland SAT0292 EVALUATION OF RADIOGRAPHIC PROGRESSION AFTER 4 YEARS OF ETANERCEPT (ETN) IN ANKYLOSING SPONDYLITIS (AS): RESULTS FROM THE OPEN-LABEL EXTENSION (OLE) OF THE PHASE 3 CLINICAL TRIAL / N. Haroon* - R. D. Inman - M. Fairbairn SAT0293 SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 36 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE THIRD INTERIM ANALYSIS OF OPAL BALANCE, AN OPEN- LABEL, LONG-TERM EXTENSION STUDY / P. Nash* - L. C. Coates - A. J. Kivitz - P. J. Mease - D. D. Gladman - J. A. Covarrubias-Cobos - D. Fleishaker - C. Wang - E. Kudlacz - S. Menon - L. Fallon - T. Hendrikx - K. S. Kanik SAT0294 ASSOCIATION OF ENTHESITIS WITH ACHIEVEMENT OF NORMAL QUALITY OF LIFE AND CLINICAL RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TREATED WITH ADALIMUMAB / P. J. Mease* - F. van den Bosch - U. Kiltz - P. Zueger - K. Chen - M. Wu - J. K. Anderson SAT0295 TOOL FOR THE PRESCRIPTION OF EXERCISE IN SPONDYLOARTHRITIS WITH MULTIMEDIA ANIMATIONS (EJES- 3D): PILOT STUDY / R. Almodóvar* - M. T. Florez - P. Zarco - L. Carmona on behalf of EJES -3D GROUP SAT0296 PATIENTS WITH DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS AND LOW BACK PAIN - EVALUATION AND REHABILITATION / R. Traistaru* - D. Kamal - A. M. Bumbea - C. Kamal - O. Rogoveanu SAT0297 THE ROLE OF BASELINE CONCOMITANT USE OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTI- RHEUMATIC DRUGS WITH TNF INHIBITORS IN SPONDYLOARTHRITIS PATIENTS / S. Akar* - S. Kiraz - O. Gercik - I. Ertenli - O. Kucuksahin - E. Dalkilic - C. Bes - T. Kasifoglu - H. Emmungil - S. S. Koca - M. Cinar - V. Yazisiz - B. Kelesoglu Dincer - A. Ates - N. Alpay Kanitez - S. Erten - S. Turan - Y. Pehlivan - B. Oz - S. Yasar Bilge - A. Erden - B. Armagan - B. N. Coşkun - U. Kalyoncu SAT0298 TRANSCUTANEOUS VAGUS NERVE STIMULATION IN PATIENTS WITH PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS / S. E. Rasmussen* - C. Brock - A. Mohr Drewes - M. Pfeiffer Jensen 16 June 2018 * Presenting author

154 152 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 SAT0299 SAT0300 SAT0301 REAL WORLD SECUKINUMAB STUDY IN AS AND PSA - COMORBIDITIES AND EXTRAARTICULAR MANIFESTATIONS: INCIDENCE AND STATUS THROUGHOUT NON-INTERVENTIONAL AQUILA STUDY IN GERMANY / U. Kiltz* - P. Kästner - H. Krauel - I. Schwarze - J. Brandt-Jürgens - M. Maier-Peuschel - C. Legeler - J. Veit - H.-P. Tony TREATMENT EXPERIENCE AND SATISFACTION IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH SECUKINUMAB: RESULTS FROM A US WEB-BASED SURVEY / M. Magrey - M. Bozyczko - D. Wolin - M. Mordin - L. Mcleod - E. Davenport - Y. Park* SIMILAR EFFICACY OF RHU-TNFR-FC TEPERING AND MAINTENANCE FOR HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS / Z. Huang* - X. Huang - W. Deng - X. Guo - Y. Huang - T. Li TOPIC: PSORIATIC ARTHRITIS Poster tour S8: Abstracts N : PsA: a whole range of (subclinical) (co)morbidities! Filip van den Bosch (Belgium), Francesco Carubbi (Italy) SAT0302-SAT June 2018 SAT0302 EVALUATION OF SUBCLINICAL GUT INFLAMMATION USING FECAL CALPROTECTIN LEVEL AND COLONIC MUCOSAL BIOPSY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS / M. B. Adarsh* - S. K. Sinha - S. Dogra - K. Vaiphei - C. Vaishnavi - A. Sharma SAT0303 PAIN MECHANISMS AND ULTRASONIC INFLAMMATORY ACTIVITY AS PROGNOSTIC FACTORS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A DANISH PROSPECTIVE, EXPLORATORY COHORT STUDY / P. Højgaard - K. Ellegaard - S. M. Nielsen - R. Christensen - J. Guldberg-Møller - C. Ballegaard - L. Dreyer - P. Mease - M. de Wit - L. Skov - B. Glintborg - H. Bliddal - E. M. Bartels - K. Amris - L. E. Kristensen* SAT0304 PRECLINICAL PHASES OF PSORIATIC ARTHRITIS: A CROSS-SECTIONAL ULTRASONOGRAPHIC STUDY ON PSORIASIS AND PSORIATIC ARTHRALGIA PATIENTS / A. Zabotti* - F. Zuliani - E. Errichetti - I. Tinazzi - S. Sacco - L. Quartuccio - A. Zanetti - A. Batticciotto - O. De Lucia - L. Idolazzi - G. Stinco - A. Iagnocco - S. De Vita SAT0305 ASSESSMENT OF SUB CLINICAL HAND JOINT SYNOVITIS IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS BY ULTRASOUND AND ITS RELATIONSHIP WITH CLINICAL DISEASE ACTIVITY / S. Mondal* - R. P. Goswami - D. Sinha - G. B. Sircar - A. K. Das - P. Ghosh - A. Ghosh SAT0306 FINGER FLEXOR TENDON PULLEY COMPLEX INVOLVEMENT IN PSA DACTYLITIS: AN ULTRASONOGRAPHY STUDY / I. Tinazzi* - D. Mc Gonagle - A. Zabotti - P. Macchioni - S. Z. Aydin SAT0307 IMPACT OF THE MODIFIED RHEUMATIC DISEASE COMORBIDITY INDEX (MRDCI) ON DRUG SURVIVAL OF FIRST LINE ANTI-TNFΑ DRUGS IN PATENTS AFFECTED WITH PSORIATIC ARTHRITIS IN REAL LIFE SETTING / M. Fornaro* - V. Venerito - L. Cantarini - M. G. Anelli - F. Cacciapaglia - G. Lopalco - G. Lapadula - F. Iannone SAT0308 PROSPECTIVE OBSERVATIONAL STUDY ON OCULAR INVOLVEMENT IN PATIENTS AFFECTED BY MODERATE TO SEVERE PSORIATIC ARTHRITIS / C. Canofari* - M. S. Chimenti - P. Conigliaro - F. Sunzini - P. Triggianese - G. Draghessi - F. Ambrifi - A. G. Salandri - M. Cesareo - R. Perricone SAT0309 UNDERESTIMATION OF CARDIOVASCULAR EVENTS BY CARDIOVASCULAR RISK SCORES IN PSORIATIC ARTHRITIS PATIENTS / H. M. Lam* - S. H. O. Ngai - S. H. Cho - T. K. Chun - K. L. Kot - C. T. Yim - E. F. Yu - E. W. L. Kun - L. S. Tam SAT0310 THE ASSOCIATIONS OF SERUM IL18 AND OSTEOPROTEGERIN (OPG) LEVELS WITH THE LIPID PROFILE IN PSORIATIC ARTHRITIS (PSA) PATIENTS / K. Bonek - P. Gluszko* - E. Kontny SAT0311 PREVALENCE AND FACTORS RELATED TO INAPPROPRIATELY HIGH LEFT VENTRICULAR MASS IN PATIENTS WITH PSORIATIC ARTHRITIS WITHOUT OVERT CARDIAC DISEASE / A. Giollo* - N. Farina - G. Orsolini - G. Cioffi - F. Ognibeni - L. Idolazzi - D. Gatti - M. Rossini - O. Viapiana SAT0312 INCIDENCE OF INFECTIONS IN CLINICAL TRIALS OF TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS / J. Crowley - C. Leonardi - S. Sturgill-Koszycki - A. Menter - A. M. Mendelsohn* - Q. Li - N. Cichanowitz - C. La Rosa SAT0313 LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS. A FIVE-YEAR STUDY / M. Migkos - E. Kaltsonoudis - T. E. Markatseli - A. A. Drosos* - P. V. Voulgari SAT0314 TO DESCRIBE AND CHARACTERIZE THE PATIENT GROUP DEFINED AS COMPLEX IN A JOINT RHEUMATOLOGY/ DERMATOLOGY CLINIC (PAIDER) / A. Garcia-Guillen* - A. Laiz - A. Lopez-Ferrer - P. Moya - I. Castellví - B. Magallares - C. Diaz-Torné - H. Corominas - H. Park SAT0315 ABATACEPT IN PSORIATIC ARTHRITIS: A SINGLE CENTRE, PLACEBO-CONTROLLED, CROSSOVER STUDY IN 20 PATIENTS; A PILOT PROTEOMIC FEASIBILITY STUDY / A. Kwasnik* - S. Pennington - O. FitzGerald SAT0316 RAPID AND SUSTAINED IMPROVEMENTS IN BOTH SKIN AND MUSCULOSKELETAL SYMPTOMS CORRELATES WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / A. F. Kavanaugh* - J. Birt - C.-Y. Lin - O. Benichou - M. Hufford - A. B. Gottlieb SAT0317 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND METABOLIC SYNDROME: A POST-HOC ANALYSIS OF PHASE 3 STUDIES / C. Ritchlin* - J. Giles - A. Ogdie - J. Gomez-Reino - L. Stockert - P. Young - C. Wang - A. B. Romero - E. Kudlacz SAT0318 DO PATIENTS IN REMISSION IN PSORIATIC ARTHRITIS, HAVE LESS FATIGUE? AND DOES THIS DEPEND ON THE DEFINITION OF REMISSION? AN ANALYSIS OF 304 PATIENTS / C. Gorlier - D. Puyraimond-Zemmour - U. Kiltz - A.-M. Orbai - Y. Y. Leung - P. Palominos - J. D. Cañete - R. Scrivo - A. Balanescu - E. Dernis - S. Talli - A. Ruyssen-Witrand - M. Soubrier - S. Aydin - L. Eder - I. Gaydukova - E. Lubrano - L. Coates - U. Kalyoncu - J. Smolen - M. De Wit - L. Gossec* SAT0319 DESCRIPTION OF MUSCULOSKELETAL SYMPTOMS IN A COHORT OF PATIENTS WITH PSORIASIS / C. Magee* - F. Farkas - N. Ikumi - A. Szentpetery - P. Gallagher - B. Kirby - O. Fitzgerald SAT0320 RELIABILITY ANALYSIS OF THE MADRID SONOGRAPHIC ENTHESIS INDEX (MASEI) AND DIFFERENT DOPPLER SUBGROUPS IN PSORIATIC ARTHRITIS / C. Macía Villa* - S. Falcao - E. De Miguel * Presenting author

155 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 153 SAT0321 IXEKIZUMAB TREATMENT SIGNIFICANTLY IMPROVES ENTHESITIS AND DACTYLITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM THE SPIRIT TRIALS / D. D. Gladman* - A.-M. Orbai - G. Gallo - J. Birt - S. Rathmann - H. Marzo-Ortega SAT0322 THE EFFECT OF GUSELKUMAB ON DACTYLITIS: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / D. Gladman* - W.-H. Boehncke - A. B. Gottlieb - P. Helliwell - P. Nash - X. L. Xu - S. Xu - Y. Wang - E. C. Hsia - C. S. Karyekar - A. Deodhar SAT0323 ADVERSE DRUG REACTIONS RELATED TO DISEASE-MODIFYING DRUGS (DMARD) IN PSORIATIC ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE / D. Freites Nuñez* - Z. Rosales - L. León - J. Font - P. Lois - C. Vadillo - E. Pato - B. Fernández - L. Rodríguez-Rodríguez - J. A. Jover - L. Abasalo SAT0324 CERTOLIZUMAB PEGOL PROVIDES SUSTAINED REMISSION AND MINIMAL DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS OVER 4 YEARS TREATMENT / D. van der Heijde* - A. Deodhar - O. FitzGerald - R. Fleischmann - D. Gladman - A. B. Gottlieb - L. C. Coates - B. Hoepken - L. Bauer - L. Peterson - M. Khraishi - P. J. Mease SAT0325 COMPARATIVE ANALYSIS OF GENDER DIFFERENCES, HLA-B27 STATUS AND SKIN LESION SEVERITY IN EARLY AXIAL AND PERIPHERAL PSORIATIC ARTHRITIS PATIENTS / E. E. Gubar* - E. Y. Loginova - T. V. Korotaeva - S. I. Glukhova SAT0326 DURATION OF REMISSION AND MINIMAL DISEASE ACTIVITY AFTER STARTING AND DISCONTINUATION OF BIOLOGIC (B) DMARDS IN EARLY PSORIATIC ARTHRITIS PATIENTS TREATED ACCORDING TO TREAT-TO- TARGET STRATEGY (RESULTS OF AN OPEN-LABEL REMARCA STUDY) / E. Loginova* - T. Korotaeva - E. Gubar - S. Glukhova - E. Nasonov SAT0327 BASELINE CHARACTERISTICS AND REASONS FOR APREMILAST PRESCRIPTION IN A LARGE ITALIAN COHORT OF PSORIATIC ARTHRITIS PATIENTS / E. G. Favalli* - C. Zuccaro - M. Biggioggero - C. Selmi - R. Bucci - F. D onofrio - G. Carlino - L. Santo - A. Semeraro - S. Monti - D. Mazzotta - F. Atzeni - R. Caporali - F. Iannone SAT0328 WEIGHT-LOSS IMPROVES DISEASE ACTIVITY IN OBESE PATIENTS WITH PSORIATIC ARTHRITIS / E. Klingberg* - A. Bilberg - S. Björkman - B. Eliasson - I. Larsson SAT0329 FIBROMYALGIA IN PATIENT WITH PSORIATIC ARTHRITIS: RELATIONSHIP WITH ENTHESOPATHY, SLEEP, FATIGUE AND QUALITY OF LIFE / F. Ulutatar* - C. Unal - M. T. Duruoz SAT0330 CHANGES IN LYMPHOCYTES AND LYMPHOCYTE SUBSETS IN TOFACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS / G. Burmester* - W. F. C. Rigby - E. Choy - P. Nash - K. Winthrop - P. J. Mease - P. Young - T. Hendrikx - C. Wang - S. Menon - D. Graham SAT0331 INFLAMMATORY MARKERS AND ADIPOKINES RELATED TO CARDIOVASCULAR RISK AND METABOLIC COMORBIDITIES IN PSORIATIC ARTHRITIS. IN VIVO EFFECTS OF APREMILAST / I. Arias De La Rosa* - M. D. López-Montilla - C. Pérez-Sánchez - M. D. C. Ábalos-Aguilera - M. Ruiz-Ponce - Y. Jiménez-Gómez - A. Escudero - E. Collantes-Estévez - C. López-Pedrera - N. Barbarroja SAT0332 A HIGH-DIMENSIONAL APPROACH TO DISSECTING THE ROLE OF THE TISSUE MICROENVIRONMENT IN SHAPING THE IMMUNE RESPONSE IN PSORIATIC ARTHRITIS / J. H. S. Chan* - Y. Y. Leung - W. Fong - Y. W. K. Yeo - B. Paleja - L. Lai - S. Saidin - C. Chua - S. Nur Hazirah - S. L. Poh - H. L. A. Low - S. Albani SAT0333 DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB / C. García-Porrúa - F. Maceiras-Pan - L. Fernandez-Dominguez - J. A. Mosquera-Martinez - B. Correa-Rey - M. Pombo-Suarez - J. Pinto-Tasende* SAT0334 CLINICAL AND SONOGRAPHIC ANALYSIS OF PSORIASIS PATIENTS WITHOUT MUSCULOSKELETAL COMPLAINTS. PREELIMINARY RESULTS OF A PROSPECTIVE STUDY: THE PRE-APS COHORT / J. Ramírez García* - A. Cuervo - M. Alsina - R. Celis - V. Ruiz-Esquide - R. Castellanos - M. V. Hernández - R. Sanmarti - J. D. Cañete SAT0335 SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 / L. C. Coates* - D. McGonagle - G. Schett - P. J. Mease - E. Quebe-Fehling - D. L. Asquith - L. Rasouliyan - S. Mpofu - C. Gaillez on behalf of the FUTURE 2 and FUTURE 3 study groups SAT0336 MEASUREMENT PROPERTIES OF THE MINIMAL DISEASE ACTIVITY CRITERIA FOR PSORIATIC ARTHRITIS / L. C. Coates* - V. Strand - H. Wilson - B. S. Stolshek - A. Samad - J. Chung - D. D. Gladman - P. Mease SAT0337 BIOLOGIC DMARDS AND PSORIATIC ARTHRITIS IN EUROPE IN 2016/2017: CHARACTERISTICS OF PATIENTS STARTING TNF-INHIBITORS OR USTEKINUMAB IN THE ONGOING PSABIO OBSERVATIONAL COHORT STUDY / L. Gossec* - P. Athanassiou - P. Bergmans - K. de Vlam - E. Gremese - B. Joven-Ibáñez - T. V. Korotaeva - F. Lioté - M. T. Nurmohamed - P. P. Sfikakis - S. Siebert - P. Smirnov - E. Theander - J. S. Smolen SAT0338 PREDICTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PSORIATIC ARTHRITIS: PERFORMANCE OF FIVE RISK ALGORITHMS IN AN ITALIAN BICENTRIC STUDY / L. Navarini* - D. P. E. Margiotta - F. Caso - D. Currado - M. Tasso - S. Angeletti - M. Ciccozzi - R. Scarpa - A. Afeltra - L. Costa SAT0339 IMPACT OF ALTERNATE MECHANISM OF ACTION BIOLOGICS ON TUMOR NECROSIS FACTOR INHIBITOR (TNF) PRESCRIBING IN PSORIATIC ARTHRITIS: RESULTS FROM A NATIONAL PATIENT CHART AUDIT / J. Robinson - L. Price* SAT0340 PSA-DISK, A NOVEL VISUAL INSTRUMENT TO ASSESS THE BURDEN OF DISEASE IN PSORIATIC ARTHRITIS PATIENTS / M. S. Chimenti* - M. Esposito - M. Teoli - D. Graceffa - G. Peluso - D. Birra - G. Moretta - A. Galossi - V. Carboni - F. Sensi - A. Mazzotta - S. Urbani - E. Del Duca - N. Bernardini - R. Caccavale - P. Sessa - A. Richetta - C. De Simone - E. Gremese - C. Bonifati - K. Peris - R. Perricone on behalf of PsA Disk Study group- S. Persechino, D. Kostaki,M. Paroli, M.C. Potenza, G. Sebastiani, L. Bianchi, R. Scrivo, F. Ceccarelli, S. Calvieri, G. Valesini SAT0341 EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY / M. C. Genovese* - B. Combe - J. Kremer - D. Adams - C. Lee - L. Kerr - P. Nash SAT0342 INFLAMMATORY BACK PAIN IN PSORIATIC ARTHRITIS IS SIGNIFICANTLY MORE RESPONSIVE TO CORTICOSTEROIDS COMPARED TO BACK PAIN IN ANKYLOSING SPONDYLITIS: A PROSPECTIVE, OPEN- LABELLED, CONTROLLED PILOT STUDY / M. Haroon* - M. Ahmad - N. Baig - O. Mason - J. Rice - O. FitzGerald SAT0343 CARDIOVASCULAR DISEASE RISK IN CLINICAL SUBTYPES OF PSORIATIC ARTHRITIS / N. Hassan* - M. Bradley - R. Davies - E. Choy 16 June 2018 * Presenting author

156 154 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0344 THE EFFECT OF GUSELKUMAB ON ENTHESITIS: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS / P. Helliwell* - A. B. Gottlieb - A. Deodhar - W.-H. Boehncke - D. McGonagle - X. L. Xu - S. Xu - Y. Wang - E. C. Hsia - C. S. Karyekar - P. Mease SAT0345 QUALITY INDICATORS IN THE CARE OF PSORIATIC ARTHRITIS / P. Helliwell* - G. Favier - D. Gladman - E. Soriano - B. Kirkham - L. Coates - L. Puig - W.-H. Boehncke - D. Thaci SAT0346 CLINICALLY MEANINGFUL IMPROVEMENT IN SKIN AND NAIL PSORIASIS IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: RESULTS THROUGH WEEK 24 OF THE GO- VIBRANT STUDY / P. J. Mease* - M. E. Husni - S. D. Chakravarty - S. Kafka - D. D. Harrison - D. Parenti - L. Kim - K. H. Lo - E. C. Hsia - A. Kavanaugh SAT0347 BASELINE CHARACTERISTICS OF PATIENTS WITH PSORIATIC ARTHRITIS INITIATED ON APREMILAST IN THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY / P. J. Mease* - E. Rosenstein - H. Feng - M. Liu - B. Guerette - L. Teng - S. Rebello - A. R. Ogdie-Beatty SAT0348 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF THREE CLINICAL TRIALS / P. Goupille* - E. Roussou - G. Burmester - P. J. Mease - A. B. Gottlieb - S. Garces - O. Benichou - D. Adams - W. Xu - P. Nash SAT0349 A NOVEL SCORING SYSTEM TO DIFFERENTIATE PSORIATIC ARTHRITIS FROM NODAL OSTEOARTHRITIS ON PLAIN-FILM RADIOGRAPHS / R. Mandegaran - E. Nikiphorou* - S. Bahadur - C. Hughes - B. Kirkham - A. Zavareh SAT0350 CONTENT AND FACE VALIDITY AND FEASIBILITY OF FIVE CANDIDATE INSTRUMENTS FOR PSORIATIC ARTHRITIS RANDOMISED CONTROLLED TRIALS: RESULTS FROM THE PSA OMERACT CORE SET WORKSHOP AT THE GRAPPA 2017 ANNUAL MEETING / R. Holland* - W. Tillett - A. Ogdie - Y. Y. Leung - D. D. Gladman - K. Callis Duffin - L. C. Coates - P. Mease - L. Eder - V. Strand - M. Elmamoun - P. Højgaard - I. Campbell - J. Chau - M. de Wit - N. Goel - C. A. Lindsay - O. FitzGerald - B. Shea - D. Beaton - A.-M. Orbai SAT0351 VERY LOW DISEASE ACTIVITY, DAPSA REMISSION, AND PATIENT-ACCEPTABLE SYMPTOM STATE IN PSORIATIC ARTHRITIS / R. Queiro* - J. D. Cañete - C. Montilla - M. A. Abad - S. Gómez - A. Cabez on behalf of MAAPs study group. SAT0352 PREVALENCE AND CHARACTERISTICS OF CORONARY DISEASE AND CARDIOVASCULAR RISK FACTORS IN A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS / S. A. Rodríguez Montero* - N. Plaza Aulestia - M. J. Pérez Quintana - M. L. Velloso Feijoo - J. L. Marenco de la Fuente SAT0353 GEOGRAPHICAL DIFFERENCES IN PSORIATIC ARTHRITIS: A TRANSATLANTIC COMPARISON / S. B. Üreyen - D. Solmaz - G. Kimyon - E. K. Gunal - A. Dogru - O. Bayindir - E. Dalkiliç - C. Ozisler - M. Can - S. Akar - G. Y. Cetin - E. F. Tarhan - S. Yavuz - L. Kilic - O. Kucuksahin - A. Omma - E. Gonullu - F. Yildiz - E. D. Ersozlu - M. A. Tufan - M. Cinar - A. Erden - S. Yilmaz - S. Pehlevan - T. Duruoz - U. Kalyoncu - S. Z. Aydin* on behalf of PsArt-ID (Psoriatic Arthritis- International Database) SAT0354 THE WORK PRODUCTIVITY AND ACTIVITY INDEX SPECIFIC HEALTH PROBLEM (WPAI-SHP) AND ITS ASSOCIATION WITH PSORIATIC ARTHRITIS (PSA) ACTIVITY BY DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA) IN ROUTINE CARE: DATA OF THE RUSSIAN PSORIATIC ARTHRITIS REGISTRY (RU-PSART) / T. Korotaeva* - E. Loginova - A. Koltakova - E. Gubar - Y. Korsakova - E. Nasonov - A. Lila - M. Sedunova - T. Salnikova - I. Umnova - I. Bondareva - G. Zagidulina - P. Zemtzova on behalf of the RU-PsART study group TOPIC: CRYSTAL DISEASES, METABOLIC BONE DISEASES AND BONE DISEASES OTHER THAN OSTEOPOROSIS SAT0355 THE VALIDITY OF GOUT DIAGNOSIS IN PRIMARY AND SECONDARY CARE - RESULTS FROM A PATIENTS SURVEY / A. J. Landgren* - L. T. H. Jacobsson - U. Bergsten - M. I. Dehlin SAT0356 FACTORS INFLUENCING TOPHUS RESOLUTION IN PATIENTS WITH PERSISTENT URATE LOWERING RESPONSES TO PEGLOTICASE / B. Mandell* - A. Yeo - P. Lipsky SAT0357 COMPLIANCE AND PERSISTENCE TO URATE LOWERING THERAPY FOR THE TREATMENT OF GOUT AND HYPERURICEMIA: A RETROSPECTIVE ANALYSIS OF MEDICATION PRESCRIPTION RECORDS / C. A. Janssen* - M. A. Oude Voshaar - H. E. Vonkeman - M. Krol - M. A. van de Laar SAT0358 DIABETES AND GOUT: REAL-WORLD EVIDENCE EVALUATING PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE UTILIZATION / D. C. Taylor* - A.-C. Fu - R. Morlock SAT0359 EVOLUTION OF RENAL FUNCTION IN GOUT AFTER NORMALIZATION OF SERUM URIC ACID LEVEL / E. Gazaix-Fontaine* - A. Ostertag - H.-K. Ea - F. Lioté SAT0360 A SUMMARY OF CLINICAL EVIDENCE FOR COMMONLY USED URICOSURICS FOR GOUT IN EUROPE / F. Perez-Ruiz* - P. Kandaswamy - R. Karra Gurunath - H. Burton - T. Jansen SAT0361 TRABECULAR BONE SCORE IN OSTEOGENESIS IMPERFECTA. IS IT USEFUL? / H. Florez* - A. Muxi - E. Gonzalez - A. Monegal - N. Guañabens - P. Peris SAT0362 PERFORMANCE OF THE 2015 ACR/EULAR CLASSIFICATION CRITERIA FOR GOUT IN KOREAN PATIENTS PRESENTING WITH ACUTE ARTHRITIS / I. A. Choi* - Y.-J. Ha - E. H. Kang - Y. J. Lee - K. Shin - E. Y. Lee - E. B. Lee - Y. W. Song SAT0363 ARE TARGET-URATE AND REMISSION CRITERIA POSSIBLE IN SEVERE GOUT? A REAL LIFE EXPERIENCE IN A COHORT / J. Vazquez-Mellado* - C. O. Lopez-Lopez - E. Alvarez-Hernandez - I. Pelaez-Ballestas - C. Gomez-Ruiz - A. Vazquez-Mellado - R. Burgos-Vargas on behalf of GRESGO cohort SAT0364 HIGH PREVALENCE OF ENTHESOPATHIES IN PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA / A. Salcion Picaud - L. Lassalle - V. Merzoug - A. Usardi - A. Rothenbuhler - P. Kamenicky - C. Roux - A. Linglart - K. Briot* SAT0365 SECULAR TRENDS IN THE INCIDENCE AND PREVALENCE OF GOUT IN DENMARK FROM : A NATIONWIDE REGISTER-BASED STUDY / K. Zobbe* - D. Prieto-Alhambra - R. Cordzt - P. Højgaard - J. S. Hindrup - L. E. Kristensen - L. Dreyer SAT0366 SERUM URIC ACID INCREASES AFTER ABROGATION OF SYSTEMIC INFLAMMATION BY TNF INHIBITION / L. Petru* - H. Hulejova - A. Mahajan - M. Herrmann - J. Zavada * Presenting author

157 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 155 SAT0367 PATIENTS HOSPITALISED WITH GOUT AS MAIN DIAGNOSIS: COSTS AND EFFICIENCY ACCORDING TO HOSPITAL DEPARTMENTS / M. Hernández Hurtado* - M. Á. Martínez Huedo - A. Balsa Criado - D. Peiteado López - E. De Miguel Mendieta SAT0368 ROLE OF JOINT ULTRASONOGRAPHY IN PATIENTS WITH GOUT STARTING TREATMENT WITH FEBUXOSTAT / M. Novella-Navarro* - J. L. Cabrera-Alarcón - E. Calvo-Aranda - T. Rodríguez-Araya - J.-J. González-Martín - P. Alcocer-Amores - F. Aramburu-Muñoz - C. Marín-Huertas - A. Gómez-Gómez - I. Amil-Casas - C. Vergara-Dangond - M. Valero-Expósito - S. Rodríguez-Rubio - P. García de la Peña- Lefebvre SAT0369 COMPARISON OF RISK FACTORS FOR CARDIOVASCULAR DISEASES IN PTS WITH CPPD GOUT AND OSTEOARTHRITIS / S. Vladimirov - M. Eliseev* - O. Zhelyabina - M. Chikina SAT0370 ASSOCIATION OF RENAL DYSFUNCTION AND DEVELOPMENT OF TOPHI IN SUBJECTS WITH CHRONIC REFRACTORY GOUT AND RESPONSE TO TREATMENT WITH PEGLOTICASE / N. L. Edwards* - J. Singh - O. Troum - A. Yeo - P. Lipsky SAT0371 FACTORS ASSOCIATED WITH ALLOPURINOL ADHERENCE AND TREATMENT OUTCOME AMONG GOUT PATIENTS / S. Asaiphanit - P. Narongroeknawin* SAT0372 INCREASED CAROTID INTIMA-MEDIA THICKNESS IN HYPERURICEMIC INDIVIDUALS MAY BE EXPLAINED BY HYPERHOMOCYSTEINEMIA ASSOCIATED WITH RENAL DYSFUNCTION / S. Choi* - J. H. Park - J.-S. Song - E.-J. Kang - K.-H. Lee SAT0373 PREVENTING A LARGE MAJORITY OF INCIDENT GOUT CASES BY MODIFYING KEY RISK FACTORS: FINDINGS FROM A PROSPECTIVE COHORT OF 44,629 MEN OVER 26 YEARS / S. K. Rai* - N. Lu - C. Yokose - H. K. Choi SAT0374 LESINURAD (LESU) ADJUNCTIVE THERAPY WITH ALLOPURINOL (ALLO) IN PATIENTS NOT RESPONDING TO ALLO MONOTHERAPY: POOLED POST HOC SAFETY AND EFFICACY ANALYSIS IN A PATIENT SUBGROUP USING CONCOMITANT DIURETICS AT BASELINE (BL) / T. Bardin* - R. G. Karra - A. So - A.-K. Tausche - I. Wild - H. Hagedorn - P. Kandaswamy - F. Perez-Ruiz SAT0375 IMPACT OF FEBUXOSTAT ON RENAL FUNCTION AMONG GOUT PATIENTS WITH DIFFERENT RENAL FUNCTION / T.-T. Chung* - C.-F. Kuo - J.-S. Chen - M.-J. Chiou SAT0376 THE INCIDENCE, PREVALENCE AND USE OF URATE LOWERING AGENTS IN HONG KONG: A POPULATION STUDY FROM 2006 TO 2016 / T. T. Cheung* - M. F. Tsoi - M. H. Chung - B. M. Y. Cheung - W. C. S. Lau SAT0377 THE BURDEN OF MONOSODIUM URATE CRYSTALS ASSESSED BY DUAL-ENERGY CT AND ULTRASONOGRAPHY IS NOT CORRELATED TO CARDIOVASCULAR RISK / T. Pascart* - B. Capon - A. Grandjean - J. Legrand - N. Namane - E. Houvenagel - L. Norberciak - J.-F. Budzik SAT0378 THE TREND OF TREG AND TH17 CELLS CHANGES IN P2X7R-REGULATED ACUTE GOUTY ARTHRITIS MODEL RATS / X.-J. Dai* - J.-H. Tao - X. Fang - Q. Lin - M.-Y. Li - Y. Xia - X.-M. Li - X.-P. Li - Y.-P. Wang SAT0379 VACUUM-ASSISTED CLOSURE VERSUS CONVENTIONAL WOUND CARE IN THE MANAGEMENT OF CHRONIC ULCERS IN PATIENTS WITH TOPHACEOUS GOUT: A PROSPECTIVE ANALYSIS / X. Pan - Z. Huang* - M. Liu - D. Li - Z. Huang - Y. Huang - X. Huang - M. Liu - X. Li - X. Yao - Y. Wang - Q. Huang - X. Guo - S. Zheng - T. Li TOPIC: INFECTION-RELATED RHEUMATIC DISEASES Poster tour S9: Abstracts N : Beware the bug! Elena Nikiphorou (United Kingdom), James Galloway (United Kingdom) SAT0380-SAT June 2018 SAT0380 PANLAR-ACCAR RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF CHIKUNGUNYA-RELATED INFLAMMATORY ARTHROPATHIES IN LATIN AMERICA / P. Monge* - A. M. Sapag - I. Y. Moreno - R. A. Montúfar - V. Khoury - P. Camilo - R. E. Rivera - J. C. Rueda - D. Jaramillo-Arroyave - J. Londoño - M. C. Ruiz - F. Fernández-Castillo - M. Quintero - Y. Fuentes - J. L. Aguilar - C. V. Caballero-Uribe - H. Sandoval - C. Pineda on behalf of Pan-American League of Associations for Rheumatology (PANLAR), in collaboration with the Central American, Caribbean and Andean Rheumatology Association (ACCAR by its Spanish acronym) SAT0381 NEUTROPHIL-RELATED BIOMARKERS DISCRIMINATE SEPTIC ARTHRITIS FROM OTHER INFLAMMATORY ARTHRITIDES: DATA FROM THE BOSSA TRIAL / A. Baillet* - C. Trocmé - A. Courtier - C. Nguyen - B. Toussaint - O. Epaulard SAT0382 UTILITY OF NEUTROPHIL CD64 & SERUM TREM-1 IN DISTINGUISHING BACTERIAL INFECTION FROM DISEASE FLARE IN SLE AND ANCA ASSOCIATED VASCULITIS / S. Ajmani* - H. Singh - S. Chaturvedi - R. Mishra - M. K. Rai - A. Jain - D. P. Misra - V. Agarwal SAT0383 RHEUMATOLOGICAL DISORDERS FOLLOWING CHIKUNGUNYA INFECTION - A RETROSPECTIVE STUDY OF 882 CASES FROM NEW DELHI / N. Gupta* SAT0384 EVOLVING PATTERNS OF REACTIVE ARTHRITIS / K. M. Hayes* - R. Hayes - J. Pope SAT0385 MULTIPLE INFECTION IS INDEPENDENTLY RELATED TO DEATH IN ADULT PATIENTS WITH HEMOPHAGOCYTIC SYNDROME: ETIOPATHOGENICALLY-DRIVEN MULTIVARIATE ANALYSIS IN 151 PATIENTS / S. Retamozo* - P. Brito-Zerón - B. Kostov - P. Moral-Moral - A. Martínez-Zapico - C. Díaz-Pedroche - G. Fraile - P. Pérez-Guerrero - E. Fonseca - A. Robles - M. Vaquero-Herrero - M. A. Calvo - M. J. Forner - C. Morcillo - J. Larrañaga - M. Rodriguez-Carballeira - M. Ruiz-Muñoz - R. Hurtado-García - S. Prieto-González - A. Aljibe Aguilar - L. Caminal-Montero - P. Hernández-Jiménez - C. Rodríguez Fernández - P. Castro - V. Morell Massó - A. Flores-Chavez - M. Ramos-Casals SAT0386 ADJUDICATION OF INFECTIONS FROM THE PHARMACOVIGILANCE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS (PHARMACHILD) TREATED WITH BIOLOGIC AGENTS AND/OR METHOTREXATE: UPDATE ON RESULTS WITH A FOCUS ON OPPORTUNISTIC INFECTIONS / G. Giancane* - J. F. Swart - E. Castagnola - A. Groll - G. Horneff - H.-I. Huppertz - D. J. Lovell - T. Wolfs - M. Hofer - E. Alexeeva - V. Panaviene - S. Nielsen - J. Antón López - F. Uettwiller - V. Staņevicha - M. Trachana - F. De Benedetti - L. M. Ailioaie - E. Tsitsami - S. Kamphuis - T. Herlin - P. Doležalová - G. Susic - B. Flatø - F. Sztajnbok - E. Fueri - F. Bovis - F. Bagnasco - A. Pistorio - A. Martini - N. Wulffraat - N. Ruperto on behalf of PRINTO * Presenting author

158 156 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0387 DESCRIPTIVE ANALYSIS OF LEISHMANIASIS CASES IN THE FUENLABRADA OUTBREAK (SPAIN) ASSOCIATED WITH THE USE OF BILOGICAL THERAPY / M. P. M. Ahijado Guzmán* - R. M. Veiga Cabello - M. Cantalejo Moreira - J. Ruiz Ruiz - A. Zapatero Gaviria - L. Cebrian Méndez SAT0388 FACTORS ASSOCIATED WITH THE PERSISTENCE OF ARTICULAR SYMPTOMS IN PATIENTS WITH CHIKUNGUNYA FEVER - CHIKBRASIL COHORT / C. Marques* - A. Duarte - A. Dantas - A. Ranzolin - N. Cavalcanti - M. Medeiros - M. Bezerra - V. Marques - L. Rocha Jr - P. Melo - L. Valadares - C. da Fonte - E. Freire - A. K. Melo - R. A. Ocea SAT0389 MRI PREDICTIVE FACTORS FOR POSITIVE CT-GUIDED BIOPSY IN SUSPECTED SEPTIC SPONDYLODISCITIS / E. Chotard* - H. Jacquier - P. Richette - C. Rioux - V. Joly - E. Palazzo - M. Forien - G. Jelin - Y. Yazdanpanah - P. Dieudé - S. Ottaviani SAT0390 CLINICAL SPECTRUM OF CHIKUNGUNYA EPIDEMIC- OBSERVATIONAL STUDY FROM A TERTIARY REFERRAL CENTRE IN CENTRAL INDIA / A. Pandey* - V. Prakash - M. Pandey SAT0391 MUSCULOSKELETAL MANIFESTATIONS OF CHIKUNGUNYA FEVER IN ELDERLY PATIENTS - CHIKBRASIL COHORT / A. Dantas* - A. Duarte - C. Marques - A. Ranzolin - N. Cavalcanti - M. Medeiros - M. Bezerra - V. Marques - L. Rocha Jr - P. Melo - L. Valadares - C. da Fonte - E. Freire - A. K. Melo - R. A. Ocea SAT0392 THE RELEVANCE OF SERUM PROCALCITONIN QUANTIFICATION FOR DIFFERENTIAL DIAGNOSIS OF INFECTIONS AND RHEUMATIC DISEASES / A. Dilbaryan* - B. Belov - G. Tarasova - D. Bukhanova SAT0393 DEVELOPMENT OF A SCORE FOR THE DIAGNOSIS OF INFECTIOUS ARTHRITIS IN DIFFICULT TO PUNCTURE JOINTS / C. A. Guillen-Astete* - B. Blanco Cáceres SAT0394 IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL VACCINE IN RA PATIENTS: RESULTS OF A 4- YEAR FOLLOW UP STUDY / D. Bukhanova* - M. Sergeeva - B. Belov - G. Tarasova - M. Cherkasova - Y. Muraviev - G. Lukina - N. Demidova SAT0395 ASSESSMENT OF EFFICACY AND SAFETY OF A TRIVALENT SPLIT-VIRUS INFLUENZA VACCINE IN PATIENTS WITH RHEUMATIC DISEASES / D. Bukhanova* - B. Belov - G. Trasova - S. Erdes - T. Dubinina - G. Lukina - N. Demidova - A. Volkov - N. Yudkina SAT0396 THE RISK FACTORS OF SERIOUS INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / E. Hasegawa* - D. Kobayashi - S. Ito - I. Narita - K. Nakazono SAT0397 SAFETY AND IMMUNOGENICITY OF 23-VALENT PNEUMOCOCCAL VACCINE IN SLE PATIENTS / G. Tarasova* - B. Belov - D. Bukhanova - S. Soloviev - E. Aseeva - T. Popkova - M. Cherkasova SAT0398 SPINE IMMOBILIZATION AND NEUROLOGICAL COMPLICATIONS IN VERTEBRAL OSTEOMYELITIS: RESULTS FROM A MULTICENTER PROSPECTIVE STUDY / G. Bart* - G. Coiffier - O. Merot - M. Couderc - E. Hoppe - G. Cormier - J.-M. Ziza - B. Le Goff SAT0399 CHIKUNGUNYA FEVER IN KARACHI: CLINICAL AND LABORATORY FEATURES AND FACTORS ASSOCIATED WITH PERSISTENT ARTHRALGIA / H. Alam* - T. P. Umer - L. Nazir SAT0400 INFECTIOUS SPONDYLODISCITIS: 7-YEAR ANALYSIS OF CLINICAL AND PROGNOSTIC VARIABLES IN A TERTIARY HOSPITAL / J. Fragio* - R. Gonzalez Mazario - E. Labrador Sanchez - E. Grau Garcia - K. R. Arevalo Ruales - M. de la Rubia Navarro - C. Alcañiz Escandell - L. Gonzalez Puig - J. Ivorra Cortes - I. Martinez Cordellat - I. Canovas Olmos - C. V. Inmaculada - C. Najera Herranz - C. Feced Olmos - R. Negueroles Albuixech - J. E. Oller Rodriguez - F. M. Ortiz Sanjuan - V. Fornes Ferrer - M. Tasias Pitarch - E. Calabuig Muñoz - M. Salavert Lleti - J. A. Roman Ivorra SAT0401 RISK OF HOSPITAL ADMISSION DUE TO SEVERE INFECTION IN PATIENTS UNDER TREATMENT WITH ANTI-TNF DRUGS: DATA FROM A LOCAL REGISTRY / J. Rosas* - M. Pucciarelli - J. M. Senabre-Gallego - J. A. García-Gómez - J. Ena - G. Santos-Soler - X. Barber - E. Salas - A. Pons-Bas - C. Cano - E. Ivars - M. Lorente on behalf of AIRE- MB Group SAT0402 LEISHMANIASIS IN PATIENTS ON TUMOR NECROSIS FACTOR INHIBITORS TREATMENT / L. Montolio Chiva* - E. Valls Pascual - D. Ybañez Garcia - A. Martínez Ferrer - M. Fernández Matilla - J. Lluch Pons - X. Juanola Roura - J. Marcoval Caus - M.-I. García Briz - J. M. Paredes Arquiola - I. López Cruz - A. Salazar Cifre - M. Aguilar Zamora - A. V. Orenes Vera - A. Garcia Sendra - V. Núñez Monje - I. Torner Hernández - J. J. Alegre Sancho SAT0403 BLOOD B CELL SUBSET PROFILE DISTURBANCE IN WHIPPLE S DISEASE / M. Le Goff* - D. Cornec - D. Guellec - T. Marhadour - V. Devauchelle-Pensec - S. Jousse-Joulin - M. Herbette - J. M. Cauvin - C. Le Guillou - Y. Renaudineau - J.-O. Pers - A. Saraux SAT0404 CLINICAL CHARACTERISTICS AND OUTCOME AFTER TREATMENT OF A NATIONAL COHORT OF PCR-POSITIVE LYME ARTHRITIS / M. Scherlinger* - A. Grillon - J. Sibilia - L. Arnaud - B. Jaulhac SAT0405 FINDINGS OF A COHORT OF PATIENTS WITH CHIKUNGUNYA IN A COLOMBIAN POPULATION / M. A. López* - R. Badillo - E. Rojas - M. Gelvez - Y. Santamaría on behalf of Association Colombian of rheumatology SAT0406 CHIKUNGUNYA VIRUS AND THE RHEUMATOLOGY: OBSERVATION OF 76 CASES DURING AN EPIDEMIC IN BRAZIL / M. C. D. F. Salgado* - Y. D. F. B. Chagas - J. L. P. Vaz - F. C. Freire - V. Vigneron - A. Vaz SAT0407 MYCOBACTERIAL INFECTIONS IN A RHEUMATOLOGY UNIT OF A TERTIARY HOSPITAL / M. Espinosa Malpartida* - C. Ramos Giráldez - C. Merino Argumánez - O. Rusinovich - M. García Moreno - C. Barbadillo Mateos - J. Campos Esteban - H. Godoy Tundidor - J. Sanz Sanz - C. M. Isasi - M. Jiménez Palop - J. L. Andreu Sánchez - L. F. Villa SAT0408 SAFETY OF CONCOMITANT TREATMENT WITH DENOSUMAB AND OTHER BIOLOGICAL DRUGS / M. Garijo Bufort* - M. Guerra González - C. Moriano Morales - C. Iñiguez Ubiaga - A. Crespo Golmar - I. González Fernández - A. López Robles - E. Diez Álvarez - C. Álvarez Castro - M. Martin Martínez - M. E. Vallejo Pascual - T. Pérez Sandoval SAT0409 AEROCOCCUS URINAE: FIRST REPORT OF SEPTIC OLIGOARTHRITIS AND SYSTEMATIC REVIEW OF AN EMERGING GERM IN MUSCULOSKELETAL INFECTIONS / M. Greco* - Í. Rúa-Figueroa - S. Ghiglione - E. Santana Medina - J. C. Quevedo Abeledo - C. Rodriguez-Lozano - I. Altabás SAT0410 CHARACTERISTICS OF ABSCESSES DURING BRUCELLAR SPONDYLODISCITIS / O. Saidane* - I. Oueslati - I. Mahmoud - A. Ben Tekaya - R. Tekaya - L. Abdelmoula SAT0411 INVESTIGATIONS FOR THE DIAGNOSIS OF SEPTIC ARTHRITIS IN THE ACUTE SETTING. RESULTS FROM A SINGLE TERTIARY CENTRE OVER 5 YEARS / P. Shamdasani* - D. Liew - C. McMaster - A. Foote - A. Hardidge - R. Buchanan * Presenting author

159 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 157 SAT0412 TUBERCULOSIS REACTIVATION DURING BIOLOGICAL THERAPY / R. Carlan* - S. P. Simon - L. Muntean - M. M. Tamas - L. Damian - I. Felea - I. Filipescu - S. Rednic SAT0413 THE TREND OF INCIDENCE RATE, FREQUENCY, OUTCOMES AND HLA PHENOTYPE OF REACTIVE ARTHRITIS AND UVEITIS IN JAPANESE PATIENTS WITH BLADDER CANCER FOLLOWING INTRAVESICAL BCG THERAPY: A 20-YEAR, TWO-CENTER RETROSPECTIVE STUDY / Y. Nakatani* - Y. Taniguchi - S. Inotani - H. Nishikawa - T. Karashima - Y. Yoshinaga - Y. Terada TOPIC: SLE, SJÖGREN S AND APS - CLINICAL ASPECTS (OTHER THAN TREATMENT) Poster tour S10: SLE, Sjögren s and APS - novel predictors of disease activity and long-term outcomes Lai-Shan Tam (China), Priscilla Wong (China) Abstracts N : SAT0414-SAT0423 SAT0414 DEVELOPMENT OF MALIGNANCY IN KOREAN SJÖGREN S SYNDROME PATIENTS; WHOLE NATIONAL HEALTH INSURANCE DATA BASED ANALYSIS / C. H. Lee* - J. S. Park - H. S. Lim - H. Y. Pak SAT0415 THE MRZ REACTION HELPS TO DISTINGUISH RHEUMATOLOGIC DISORDERS WITH CENTRAL NERVOUS INVOLVEMENT FROM MULTIPLE SCLEROSIS / N. Venhoff* - J. Thiel - A. C. Venhoff - S. Rauer - D. Huzly - M.-T. Schleyer - C. Hentze - R. E. Voll - M. Rizzi - U. Salzer - T. Hottenrott SAT0416 LIFE-THREATENING PRIMARY SJÖGREN SYNDROME: CLINICAL CHARACTERIZATION AND OUTCOMES IN 1535 PATIENTS (GEAS-SS REGISTRY) / S. Retamozo* - A. Flores-Chávez - B. Kostov - R. Solans - G. Fraile - B. Maure - C. Feijoo - F. J. Rascón - R. Pérez-Alvarez - M. Zamora - A. García-Pérez - M. Lopez-Dupla - M. Á. Duarte Millán - M. Ripoll - E. Fonseca - P. Guisado-Vasco - B. Pinilla - G. de la Red - S. Rodríguez Rodríguez - M. J. Soto-Cárdenas - P. Fanlo - C. Morcillo - M. Ramos-Casals - P. Brito-Zerón SAT0417 PREDICTIVE VALUE OF FETAL UMBILICAL ARTERY DOPPLER IN PRETERM BIRTH IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / Z. Zhan* - D. Chen - Q. Qiu - X. Wang - Y. Zhan SAT0418 CAN THE AUTOMATED NEUROPSYCHOLOGICAL ASSESSMENT METRICS (ANAM) PREDICT COGNITIVE IMPAIRMENT COMPARED TO A COMPREHENSIVE NEUROPSYCHOLOGICAL BATTERY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)? / Z. Touma* - D. Beaton - C. Tartaglia - L. Ruttan - S. Lombardi - J. Su - J. Wither - M. Fritzler - R. Green SAT0419 RENAL AND OVERALL SURVIVAL ANALYSIS IN A COHORT OF PATIENTS WITH LUPUS NEPHRITIS WITH UP TO 40 YEARS OF FOLLOW UP / F. Farinha* - R. Pepper - B. S. Bernstein - D. A. Isenberg - A. Rahman SAT0420 INCREASED RESISTANT HYPERTENSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE COHORT STUDY / J. S. Gandelman - M. Shuey - O. Khan - J. Neal - A. Dickson - A. Barnado - L. Wang - W. Dupont - C. M. Stein - C. P. Chung* SAT0421 LONG-TERM IMMUNOGENICITY OF A QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / C. C. Mok* - L. Y. Ho - C. H. To SAT0422 INDIRECT PATHOGENIC ROLES OF CEREBROSPINAL FLUID ANTI-U1RNP ANTIBODIES IN THE PRESENCE OF ANTI-NR2 ANTIBODIES IN PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / T. Fujii* - S. Kondo-Ishikawa - N. Ishigooka - H. Yoshifuji - K. Ohmura - T. Mimori SAT0423 MOLECULAR PROFILES ASSOCIATE WITH CLINICAL DISEASE ACTIVITY AND INFORM PATIENT SUBSETTING IN ADULT SYSTEMIC LUPUS ERYTHEMATOSUS / J. M. Guthridge - R. Lu - C. Arriens - T. Aberle - S. Kamp - M. E. Munroe - T. Gross - W. DeJager - S. R. Macwana - R. L. Bourn - S. Apel - H. Chen - E. F. Chakravarty - A. Thanou - J. T. Merrill - J. A. James* SAT0424 COMPLEMENT C4 GENE COPY NUMBER VARIATIONS BESTOW LARGE RANGES OF SERUM C4 PROTEIN LEVELS IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND CONTRIBUTE TO ORGAN AND CARDIOVASCULAR DAMAGES OVER TIME / C. C. Mok* - E. King - B. Zhou - G. Yu - Y. L. Wu - C. Y. Yu SAT0425 PHENOTYPING PRIMARY SJÖGREN S SYNDROME (PSS) BY USING SALIVARY GLAND ULTRASONOGRAPHY: A STEP FORWARD TO INDIVIDUALIZED THERAPIES / C. Baldini* - F. Ferro - N. Luciano - E. Calabresi - E. Elefante - V. Donati - M. Mosca - S. Bombardieri SAT0426 SERUM URIC ACID LEVELS PREDICT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / C. Elera-Fitzcarrald* - C. Reategui-Sokolova - R. V. Gamboa-Cárdenas - M. Medina - F. Zevallos - V. Pimentel-Quiroz - J. M. Cucho-Venegas - J. L. Alfaro-Lozano - Z. J. Rodríguez-Bellido - C. A. Pastor-Asurza - R. A. Perich-Campos - G. Alarcón - M. F. Ugarte-Gil SAT0427 PREDICTIVE VALUE OF FETAL UMBILICAL ARTERY DOPPLER IN ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH LUPUS NEPHRITIS / D. Chen* - Z. Zhan SAT0428 ASSOCIATION BETWEEN ORGAN DAMAGE AND HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A SYSTEMATIC REVIEW / E. R. Hammond* - D. H. Lin - I. B. Murimi - H. Nab - H. Kan - O. Onasanya - J. C. Tierce - X. Wang - B. Desta - G. C. Alexander SAT0429 HOW PHENOTYPE OF THE SMALL FIBRE NEUROPATHY (SFN) IN PRIMARY SJÖGREN SYNDROME (PSS) DIFFERS FROM OTHERS CAUSES OF SMALL FIBRE NEUROPATHY? / E. Descamps* - J. Henry - C. Labeyrie - D. Adams - D. Aiello - X. Mariette - R. Seror SAT0430 ASSESSMENT OF ACR AND SLICC CLASSIFICATION CRITERIA IN THE ASIA PACIFIC LUPUS COLLABORATION COHORT / R. Kandane-Rathnayake - V. Golder - W. Louthrenoo - S.-F. Luo - Y.-J. Wu - A. Lateef - S. Sockalingam - S. Navarra - L. Zamora - L. Hamijoyo - Y. Katsumata - M. Harigai - M. Chan - S. O Neill - F. Goldblatt - C. S. Lau - A. Hoi - M. Nikpour - E. Morand* SAT0431 THE ACR-EULAR CLASSIFICATION CRITERIA IN PRIMARY SJÖGREN S SYNDROME: THE CONTRIBUTING ROLE OF ULTRASOUND / E. Mossel* - J. F. van Nimwegen - M. S. van Ginkel - K. Delli - A. J. Stel - F. G. Kroese - F. K. Spijkervet - A. Vissink - S. Arends - H. Bootsma 16 June 2018 * Presenting author

160 158 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0432 MEMBRANOUS VERSUS PROLIFERATIVE LUPUS NEPHRITIS: TWO DIFFERENT DISEASES? / F. Farinha* - B. S. Bernstein - R. Pepper - D. A. Isenberg - A. Rahman SAT0433 APPLICATION OF THE DORIS ALGORITHM FOR THE DEFINITION OF DISEASE REMISSION OVER A 2-YEAR PERIOD IN A COHORT OF ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / F. Dall ara* - L. Andreaoli - G. Armentaro - F. Migliorati - M. Frassi - F. Franceschini - S. Calza - A. Tincani SAT0434 PARTICIPATION IN SYSTEMIC LUPUS ERYTHEMATOSUS - A CROSS-SECTIONAL ANALYSIS OF THE LULA- COHORT IN GERMANY 2015 / G. Chehab* - J. G. Richter - R. Fischer-Betz - R. Brinks - B. Winkler-Rohlfing - M. Schneider SAT0435 PLASMA PTX3 LEVELS CORRELATE WITH SYSTEMIC LUPUS ERYTHEMATOSUS ACTIVITY AND ARE INFLUENCED BY CORTICOSTEROIDS / G. A. Ramirez* - E. P. Bozzolo - V. Canti - B. Bottazzi - A. Mantovani - L. Dagna - P. Rovere-Querini - A. A. Manfredi SAT0436 TRANSJUGULAR RENAL BIOPSY: A SAFE AND EFFECTIVE WAY TO PERFORM RENAL BIOPSY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODY SYNDROME PATIENTS TREATED WITH ANTI- THROMBOTIC DRUGS - A MONOCENTRIC EXPERIENCE OF 256 PROCEDURES / H. Nielly* - A. Mathian - M. Cazenave - H. Izzedine - J. Haroche - F. Cohen-Aubart - P. Rouvier - I. Brocheriou - P. Cluzel - Z. Amoura SAT0437 INITIAL MANIFESTATIONS OF CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF SINGLE CENTER RETROSPECTIVE STUDY / M. I. Kaleda - E. A. Aseeva - I. P. Nikishina* - S. K. Soloviev SAT0438 INCREASED RISK OF DEPRESSION IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS: A DANISH NATIONWIDE COHORT STUDY / J. H. Hesselvig - A. Egeberg - K. Kofoed - G. Gislason - L. Dreyer* SAT0439 DIFFERENTIAL LEVELS OF NOVEL AND CLASSIC ANTIPHOSPHOLIPID ANTIBODIES AMONG PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS / J. A. Gómez-Puerta* - T. Urrego - A. Hernández - S. Ruiz - S. M. Osorno - C. Rua - J. Duque Botero - A. L. Vanegas-García - C. H. Muñoz - L. A. González - G. Vásquez SAT0440 PHENOTYPIC FEATURES AND PREDICTORS OF THE CLINICAL SEVERITY OF KERATOCONJUNCTIVITIS SICCA AND SALIVARY GLAND DYSFUNCTION IN PATIENTS WITH SJÖGREN S SYNDROME: A LONGITUDINAL ANALYSIS OF THE KISS COHORT / J. H. Koh* - Y. S. Suh - J. Lee - S.-K. Kwok - S.-H. Park SAT0441 PREDICTIVE VALUE OF ANTIPHOSPHOLIPID ANTIBODIES IN THE ACUTE PHASE OF DEEP VEIN THROMBOSIS / K. Perdan Pirkmajer* - A. Boc - S. Čučnik - A. Mavri - P. Žigon - E. Podovšovnik - M. Štalc - N. Vene - A. Ambrožič SAT0442 RISK FACTORS FOR HEART VALVE DISEASES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME / K. Hiramoto* - J. Kikuchi - Y. Kaneko - T. Takeuchi SAT0443 DIAGNOSTIC AND PREDICTIVE EVALUATION USING SALIVARY GLAND ULTRASONOGRAPHY IN PRIMARY SJÖGREN S SYNDROME / K.-A. Lee* - S.-H. Lee - H.-R. Kim SAT0444 INCIDENCE AND PREDICTORS OF IMMUNOSUPPRESSANT DISCONTINUATION AND RISK OF SUBSEQUENT FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. Zen* - F. Saccon - M. Gatto - M. Larosa - L. Iaccarino - A. Doria SAT0445 THE CORRELATION BETWEEN THE TYPE OF CELLS IN MINOR SALIVARY GLANDS INFILTRATES AND THE SELECTED IMMUNOLOGICAL, CLINICAL AND LABORATORY PARAMETERS, IN PRIMARY SJÖGREN S SYNDROME PATIENTS WITH HISTORY OF EPSTEIN - BARR VIRUS INFECTION / M. Maślińska* - M. Prochorec-Sobieszek - B. Kwiatkowska SAT0446 SERUM CONCENTRATIONS OF 25-HYDROXYVITAMIN D AND METABOLIC SYNDROME AND ITS COMPONENTS IN NONDIABETIC SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / M. García-Carrasco* - C. Mendoza Pinto - M. Cabrera-Jiménez - S. Méndez-Martínez - I. Etchegaray-Morales - I. Zamora-Guinez - A. Ruiz-Arguelles - R. Cervera SAT0447 VALIDATION OF THE 2017 ACR/EULAR CLASSIFICATION CRITERIA OF SYSTEMIC LUPUS ERYTHEMATOSUS / M. Suda* - H. Yanaoka - R. Rokutanda - T. Tsuda - M. Kishimoto - K. Yamaguchi - M. Okada SAT0448 REPORT OF 86 CASES OF CONGENITAL HEART BLOCK: DATA FROM THE ITALIAN REGISTRY (LU.NE REGISTRY) / M. Fredi* - L. Andreoli - T. Bertero - A. Bortoluzzi - S. Breda - V. Cappa - F. Ceccarelli - R. Cimaz - F. Franceschini - M. Gerosa - M. Govoni - A. Hoxha - A. Lojacono - L. Marozio - A. Mathieu - A. Minniti - M. Muscarà - M. Padovan - M. Piga - R. Priori - V. Ramoni - A. Ruffatti - M. Tonello - S. Zatti - S. Calza - A. Brucato - A. Tincani SAT0449 JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS OUTCOME IN ADULTHOOD: A MONOCENTRIC RETROSPECTIVE COHORT / M. Pha* - A. Mathian - J. Haroche - F. Cohen Aubart - M. Hié - D. Lê Thi Huong - M. Pineton de Chambrun - T. Kwon - Z. Amoura SAT0450 ESTIMATING DURATION OF RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS TRIALS / M. Kim* - J. Merrill - K. Kalunian - L. Hanrahan - P. Izmirly SAT0451 DISEASE COURSE PATTERNS IN SYSTEMIC LUPUS ERYTHEMATOSUS / K. Tselios - D. Gladman - Z. Touma - J. Su - N. Anderson - M. Urowitz* SAT0452 ENDOTHELIUM DYSFUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH AND WITHOUT NEPHRITIS / N. Mohannad* - A. I. El Zawawy - M. Elbordeny - D. Emara - S. Ibrahim SAT0453 ASSOCIATION OF COMORBID PULMONARY CONDITIONS WITH PATIENT-REPORTED OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS / P. Katz* - S. Pedro - E. Alemao - J. Mukherjee - K. Michaud SAT0454 IN PRIMARY SJÖGREN S SYNDROME BLOOD CD180-NEGATIVE B CELLS ARE INCREASED IN PATIENTS WITH HIGH SYSTEMIC DISEASE ACTIVITY / R. Felten* - C. Mayeur-Rousse - L. Miguet - L. Arnaud - E. Chatelus - R.-M. Javier - H. Petit - J. Sibilia - C. Sordet - L. Fornecker - L. Mauvieux - J.-E. Gottenberg SAT0455 CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF PATIENTS WITH SUSPECTED SJÖGREN SYNDROME AND ANTI-RO52 POSITIVE ANTIBODIES / R. Solans-Laque* - J. Loureiro - A. Marin - F. Martinez-Valle - M. Alberola - J. J. Puig - J. Mestre - S. Bujan SAT0456 THE INCIDENCE OF CARDIOVASCULAR EVENTS IN ITALIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IS LOWER THAN IN NORTH EUROPEAN AND AMERICAN COHORTS: IMPLICATION OF DISEASE-ASSOCIATED AND TRADITIONAL RISK FACTORS AS EMERGED BY A 16-YEAR RETROSPECTIVE GIRRCS STUDY / S. Fasano* - D. P. Margiotta - R. Gualtierotti - A. Corrado - O. Berardicurti - D. Iacono - L. Pierro - A. Riccardi - R. Giacomelli - F. P. Cantatore - P. Meroni - A. Afeltra - G. Valentini on behalf of GIRRCS= Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale * Presenting author

161 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 159 SAT0457 SJÖGREN BIG DATA PROJECT, THE FIRST EXAMPLE OF DATA SHARING IN AUTOIMMUNE DISEASES: ANALYSIS OF WORLDWIDE PATIENTS / S. Retamozo* - N. Acar-Denizli - W. Fai Ng - M. Zeher - A. Rasmussen - T. Mandl - R. Seror - X. Li - C. Baldini - J.-E. Gottenberg - D. Danda - L. Quartuccio - A. Minniti - G. Hernandez-Molina - U. Kalyoncu - A. A. Kruize - S.-K. Kwok - M. Wahren-Herlenius - S. Praprotnik - D. Sene - E. Bartoloni - R. Solans - M. Rischmueller - Y. Suzuki - D. Isenberg - V. Valim - P. Wiland - G. Nordmark - G. Fraile - H. Bootsma - T. Nakamura - R. Giacomelli - V. Devauchelle-Pensec - B. Hofauer - M. Bombardieri - V. Fernandes Moça Trevisani - D. Hammenfors - S. G. Pasoto - T. A. Gheita - F. Atzeni - J. Morel - C. Vollenveider - P. Brito-Zerón - M. Ramos-Casals SAT0458 URINE SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A POTENTIAL BIOMARKER OF LUPUS NEPHRITIS ACTIVITY / S. Burcsár* - G. Toldi - B. Szalay - B. Vásárhelyi - L. Kovács - A. Balog SAT0459 OCCURRENCE OF LYMPHOMA IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-SERIES OF 38 PATIENTS / T. Huscenot* - A. Mathian - M. Martin - C. Deligny - J.-S. Allain - M. Pha - N. Costedoat-Chalumeau - V. Le Guern - G. Pugnet - F. Cohen-Aubart - C. Lavigne - J. Haroche - M. Hié - M. Roriz - S. Mouly - M. Samson - H. Devilliers - B. Bonnotte - M. Versini - P.-Y. Jeandel - A.-S. Korganow - T. Martin - V. Leblond - F. Charlotte - S. Choquet - Z. Amoura SAT0460 LONG-TERM IMMUNE PROTECTION FOLLOWING PNEUMOCOCCAL 13-VALENT/23-VALENT POLYSACCHARIDE VACCINE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Goulenok* - M. Bahuaud - C. Francois - J.-F. Alexandra - P. Aucouturier - M. Hurtado-Nedelec - H. Moins - F. Batteux - T. Papo - K. Sacre SAT0461 ULTRASONOGRAPHY OF SALIVARY GLANDS IN PRIMARY SJÖGREN S SYNDROME AND ASSOCIATION WITH DISEASE ACTIVITY, SEROLOGICAL MARKERS AND BIOPSY OF MINOR SALIVARY GLANDS / V. Milic* - G. Radunovic - J. Marinkovic - N. Damjanov SAT0462 PD-1+CXCR5-CD4+T CELLS MAY PLAY AN IMPORTANT ROLE IN THE SEVERITY OF SYSTEMIC ERYTHEMATOSUS LUPUS / W. Chen* - Y. Yu - J. LIn SAT0463 OLFACTORY IMPAIRMENT IN PATIENTS WITH PRIMARY SJÖGREN S SYNDROME AND ITS CORRELATION WITH ORGAN INVOLVEMENT AND IMMUNOLOGICAL ABNORMALITIES / X. Xu* - L.-Y. Geng - Z.-Y. Chen - J. Liang - L.-Y. Sun SAT0464 COMPARISON OF DISEASE ACTIVITY SCORES PREDICTING MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN COLOMBIA / Y. Santamaria-Alza* - J. D. Sánchez-Bautista - J. Fajardo-Rivero - C. L. Figueroa-Pineda SAT0465 CLINICAL MANIFESTATIONS AND PROGNOSIS OF SLE WITH CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES / Y. Zhang* - X. Feng - L. Sun SAT0466 SERUM VITAMIN D DEFICIENCY IS ASSOCIATED WITH ACTIVE RENAL DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS / Y.-J. Park* - I.-W. Baek - K.-J. Kim - W.-U. Kim - C.-S. Cho SAT0467 CEREBRAL VENOUS THROMBOSIS OCCURRENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS WITHOUT ANTI- PHOSPHOLIPID ANTIBODY SYNDROME: A MONOCENTRIC SERIE OF 10 CASES / Z. Lepine* - A. Mathian - M. Pineton De Chambrun - F. Cohen - J. Haroche - M. Hie - M. Pha - Z. Amoura TOPIC: SCLERODERMA, MYOSITIS AND RELATED SYNDROMES Poster tour S11: SSc, myositis, related syndromes - novel ideas take place Ulf Müller-Ladner (Germany), Ingrid Lundberg (Sweden) Abstracts N : SAT0468-SAT June 2018 SAT0468 SCLERODERMA - INTERSTITIAL LUNG DISEASE: DOES MAINTENANCE THERAPY MAKE A DIFFERENCE / S. K. Sharma* - A. Chattopadhyay - S. Naidu - V. Dhir - S. Jain SAT0469 INTERSTITIAL LUNG DISEASE IN IDIOPATHIC INFLAMMATORY MYOPATHIES: ULTRASOUND ASSESSMENT OF PLEURAL IRREGULARITIES AND COMPARISON WITH HIGH RESOLUTION COMPUTED TOMOGRAPHY / E. Cioffi - S. Barsotti* - C. Romei - C. Giovanetti - C. Roncella - F. Ferro - E. Perrone - M. Mosca - F. Falaschi - R. Neri SAT0470 MYOSITIS, OFTEN SUSPECTED, IS ACTUALLY RARE IN PRIMARY SJÖGREN S SYNDROME: DATA FROM THE FRENCH COHORT ASSESS / R. Felten* - R. Seror - O. Vittecoq - E. Hachulla - A. Perdriger - P. Dieude - J.-J. Dubost - A.-L. Fauchais - V. Le Guern - C. Larroche - E. Dernis - D. Guellec - D. Cornec - J. Sibilia - J.-E. Gottenberg - A. Meyer SAT0471 ABNORMAL NAILFOLD CAPILLAROSCOPIC PATTERNS ARE COMMON IN UNDERWEIGHT SUBJECTS WITH RAYNAUD S PHENOMENON / A. Eman Abdulle* - A. M. van Roon - M. M. Habing - A. J. Stel - A. J. Smit - H. van Goor - D. J. Mulder SAT0472 ULNAR OCCLUSION IS A MARKER OF GLOBAL VASCULAR DAMAGE IN SYSTEMIC SCLEROSIS: RESULTS FROM A MONOCENTRIC PROSPECTIVE STUDY OF 99 PATIENTS / C. M. Yelnik* - D. Elodie - C. Lamotte - V. Sobanski - S. Morell-Dubois - H. Maillard - M. Lambert - P.-Y. Hatron - D. Launay - E. Hachulla SAT0473 CLINICAL AND ECHOCARDIOGRAPHIC ASSOCIATES OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH SYSTEMIC SCLEROSIS / S. E. van Wijngaarden - M. Boonstra* - B. Bloem - D. Cassani - F. C. Tanner - S. Jordan - O. Distler - V. Delgado - J. J. Bax - J. K. de Vries-Bouwstra - N. Ajmone Marsan SAT0474 RACIAL DIFFERENCES IN SSC DISEASE PRESENTATION: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP STUDY / V. K. Jaeger* - E. Siegert - E. Hachulla - P. Airò - G. Valentini - M. Matucci-Cerinic - O. Distler - F. Cozzi - Y. Allanore - M. Li - M. Tikly - U. A. Walker SAT0475 ANTI-MDA5 (+) CLINICALLY AMYOPATHIC DERMATOMYOSITIS-ASSOCIATED RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE: ROLE OF HEMOPERFUSION WITH POLYMYXIN / A. Selva-O callaghan* - C. Vizcaino - J. C. Ruiz-Rodriguez - E. Trallero-Araguás - N. Ramos - C. Berastegui - A. Gil Vila - M. A. Martinez - X. Solanich - R. Ferrer * Presenting author

162 160 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0476 INCIDENCE, PREVALENCE, MORTALITY AND PERFORMANCE OF THE ACR/EULAR 2013 CLASSIFICATION CRITERIA IN PHYSICIAN DIAGNOSED SYSTEMIC SCLEROSIS: RESULTS FROM A POPULATION BASED US COHORT ( ) / A. S. Sandhu - C. S. Crowson - P. R. Bauer - E. L. Matteson - A. Makol* SAT0477 INTENSIFIED B CELL DEPLETION THERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS PATIENTS: 24 MONTHS FOLLOW-UP / D. Rossi - I. Cecchi* - S. Sciascia - M. Radin - E. Rubini - D. Roccatello SAT0478 DISEASE-SPECIFIC AUTOANTIBODIES ASSOCIATE WITH REMARKABLY DIFFERENT RISK OF DEVELOPMENT OF SIGNIFICANT LUNG FIBROSIS IN SYSTEMIC SCLEROSIS / A. Sari* - S. I. Nihtyanova - A. Gill - V. H. Ong - C. P. Denton SAT0479 LASER SPECKLE CONTRAST ANALYSIS: A PILOT STUDY AND SYSTEMATIC LITERATURE REVIEW OF RELIABILITY OF THE QUANTITATIVE ASSESSMENT OF PERIPHERAL BLOOD PERFUSION IN SYSTEMIC SCLEROSIS / A. Vanhaecke* - M. Cutolo - B. Ruaro - L. Deroo - C. Ickinger - K. Melsens - Y. Piette - F. De Keyser - V. Smith on behalf of the EULAR study group on microcirculation in Rheumatic diseases SAT0480 EVALUATION OF STANDARDIZED TEACHING OF MODIFIED RODNAN SKIN SCORE ASSESSMENT IN SYSTEMIC SCLEROSIS / A. H. Low* - S.-A. Ng - V. Berrocal - B. Brennan - G. Chan - S.-C. Ng - D. Khanna SAT0481 SETTING THE STANDARD FOR LONGITUDINAL FOLLOW-UP OF SYSTEMIC SCLEROSIS; A EUSTAR DELPHI- BASED EXPERT CONSENSUS / A.-M. Hoffmann-Vold* - O. Distler - M. Baron - O. Kowal-Bielecka - D. Khanna - Y. Allanore on behalf of EUSTAR, SCTC SAT0482 UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE AT RISK FOR SYSTEMIC SCLEROSIS: PREDICTIVE ROLE OF ANTI-TOPOISOMERASE AND AVASCULAR AREAS / A. Riccardi* - V. Messiniti - S. Fasano - G. Valentini SAT0483 FEMALE SEXUAL DYSFUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS / B. Hermankova* - M. Spiritovic - H. Smucrova - S. Oreska - H. Storkanova - K. Pavelka - J. Vencovsky - L. Senolt - R. Becvar - M. Tomcik SAT0484 PERFORMANCE OF THE 2017 EULAR/ACR CLASSIFICATION CRITERIA FOR INFLAMMATORY MYOSITIS AND THEIR MAJOR SUBGROUPS IN THE REMICAM (REGISTRY OF INFLAMMATORY MYOPATHIES IN THE MADRID COMMUNITY) / E. Rabadán* - B. E. Joven - F. Lozano - L. Nuño - F. J. López-Longo - J. Martínez-Barrios - C. Larena - M. Blazquez - C. Barbadillo - I. Llorente - A. Pérez - T. Cobo - R. Almodovar - L. Lojo - R. Calvo - M. J. García de Yébenes - P. E. Carreira on behalf of REMICAM group SAT0485 WHAT IS THE EFFECT OF CYCLOPHOSPHAMIDE IV PULSE THERAPY IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS ON SKIN INVOLVEMENT: AN OBSERVATIONAL STUDY / B. Kersten* - N. den Broeder - F. van den Hoogen - E. van den Ende - M. Vonk SAT0486 MYELOABLATION FOLLOWED BY AUTOLOGOUS STEM CELL RESCUE LEADS TO NORMALIZATION OF SERUM IL-6 LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS / C. Bellocchi* - K. Sullivan - E. Goldmuntz - J. Ying - L. Keyes-Elstein - J. Varga - M. E. Hinchcliff - P. McSweeney - D. E. Furst - R. Nash - L. J. Crofford - B. Welch - A. Pinckney - M. D. Mayes - S. Assassi SAT0487 A COHORT STUDY OF MACROVASCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS / C. Caimmi* - S. De Marchi - G. Astorino - E. Bertoldo - P. Caramaschi - M. Rossini SAT0488 ORGAN INVOLVEMENT AND ILD PROGRESSION IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I SPECIFICITY AND LIMITED CUTANEOUS FORM / E. Zanatta* - P. Polito - F. Ometto - M. Felicetti - M. Tonello - A. Scanu - L. Punzi - F. Cozzi SAT0489 ASSESMENT OF PERSISTENT ORGAN DAMAGE ACCORDING TO IMACS (INTERNATIONAL MYOSITIS ASSESMENT AND CLINICAL STUDIES) MYOSITIS DAMAGE INDEX IN 92 PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS / E. Oguz* - E. Sahin - M. Erdugan - B. A. Esen - A. Gul - L. Ocal - M. Inanc SAT0490 INCIDENCE AND PREVALENCE OF SYSTEMIC SCLEROSIS IN AN ITALIAN ALPINE VALLEY DURING A 18-YEAR LONG PERIOD / F. Dall ara* - A. Premoli - S. Zingarelli - M. G. Lazzaroni - A. Tincani - M. G. Fenini - F. Inverardi - R. Furloni - M. Scarsi - P. Airò SAT0491 CLINICAL FEATURES AND COMPLICATIONS IN A LARGE INTERNATIONAL COHORT OF ANTIMDA5 PATIENTS: A CHALLENGE FOR THE FUTURE / F. Locatelli* - S. Castaneda - G. Zanframundo - A. Meyer - F. Iannone - M. Giannini - S. Prieto Gonzalez - C. Scire - M. Govoni - C. Montecucco - F. Furini - J. Vega - H. Lorenz - G. Emmi - I. Villa Blanco - S. Barsotti - R. Neri - M. Mosca - A. Pesci - G. Dei - M. F. Moraes-Fontes - D. Cammelli - P. Parronchi - B. Biagioni - A. Mathieu - M. Piga - C. Nannini - R. Gerli - E. Bartoloni Bocci - J. E. Fonseca - R. Marques - F. Romero Bueno - L. Damian - M. Belliato - S. De Vita - L. Quartuccio - F. Maurier - J. Cifrian - G. Zampogna - A. Mera Varela - N. Perez Gomez - P. Da Silva - C. J. Matos Costa - J. Rojas-Serrano - L. Vazquez - U. Schneider - E. Feist - I. Cavazzana - F. Franceschini - G. Cagnotto - I. Chiapparoli - S. Bellando-Randone - M. Matucci-Cerinic - R. Caporali - M. A. Gonzalez-Gay - L. Cavagna on behalf of AENEAS collaborative group SAT0492 PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS / G. Cuomo* - F. Danzo - F. Masini - R. Ferrara - E. Pinotti - C. Romano - L. E. Adinolfi SAT0493 PLASMA LEVELS OF HSP90 ARE INCREASED IN INTERSTITIAL LUNG DISEASE AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS / H. Storkanova* - S. Oreska - M. Spiritovic - B. Hermankova - K. Pavelka - J. Vencovsky - J. H. Distler - L. Senolt - R. Becvar - M. Tomcik SAT0494 CLINICAL AND ELECTROPHYSIOLOGICAL DIAGNOSIS OF SYMMETRICAL POLYNEUROPATHY IN SYSTEMIC SCLEROSIS: STUDY FROM A SINGLE TERTIARY CENTRE IN MALAYSIA / T. Balaikerisnan - K. J. Goh - L. P. Ramanaidu - J. Raja* SAT0495 PLASMA D-DIMER CONCENTRATION, MACROVASCULAR DISEASE AND MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS / J. J. Alegre-Sancho* - M. Robustillo-Villarino - M. Aguilar-Zamora - L. Montolio-Chiva - E. Valls-Pascual - D. Ybáñez-García - À. Martínez-Ferrer - I. Torner-Hernández - V. Núñez-Monje - A. V. Orenes-Vera - A. Sendra-García SAT0496 INCIDENCE, CARDIOVASCULAR EVENTS AND MORTALITY OF ADULT INFLAMMATORY MYOPATHIES IN SOUTH KOREA: A NATIONWIDE POPULATION-BASED STUDY / K. H. Jung* - H. J. Kim - W. Park - S. R. Kwon - H. S. Ahn SAT0497 FOLLOW-UP OF DISEASE ACTIVITY IN HUNGARIAN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY / L. Bodoki* - M. Nagy-Vincze - Z. Griger - Z. Szekanecz - K. Dankó SAT0498 ABNORMAL ELECTROCARDIOGRAPHIC FINDINGS IN A SCANDINAVIAN COHORT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES / S. S. Korsholm - M. Dastmalchi - A. C. Diederichsen - D. C. Andersson - I. E. Lundberg - N. Witting - M. E. Krogager - T. Friis - S. Jacobsen - J. B. Knudsen - L. P. Diederichsen* * Presenting author

163 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 161 SAT0499 ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND OTHER SYSTEMIC AUTO-IMMUNE DISEASES: STUDY IN TWO UNIVERSITY HOSPITALS COHORTS / M. Scherlinger - J. Lutz* - J. Sibilia - E. Chatelus - M.-E. Truchetet SAT0500 MYOCARDIAL INVOLVEMENT AT MAGNETIC RESONANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MINOR ARRHYTHMIAS: ASSOCIATION WITH CLINICAL FEATURES AND IMPACT OF TREATMENT / M. De Santis* - L. Monti - M. Briani - E. Indolfi - E. Generali - N. Isailovic - A. Ceribelli - G. M. Guidelli - M. Caprioli - M. Meroni - C. Selmi SAT0501 EARLY VERSUS LATE-ONSET SYSTEMIC SCLEROSIS: ARE THERE CLINICAL AND IMMUNOLOGICAL DIFFERENCES? / M. Luís* - F. Costa - A. Carmo - J. Ferreira - T. Santiago - R. Cunha - M. J. Salvador - J. da Silva SAT0502 COMPARISON OF THE CREATININE-BASED AND THE CYSTATIN C-BASED ESTIMATED GLOMERULAR FUNCTION (EGFR) IN PATIENTS WITH SYSTEMIC SCLEROSIS PATIENTS / M. Krusche* - T. Kubacki - R. Osei-Davies - I. Kötter SAT0503 ASSESSMENT OF PROSTANOIDS (ILOPROST, ALPROSTADIL) EFFICACY IN TREATMENT OF ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS / M. Starovoytova* - O. Desinova - O. Koneva - O. Ovsyannikova - L. Garzanova SAT0504 THE ASSOCIATION OF MYOSITIS SPECIFIC ANTIBODIES IN PATIENTS WITH INFLAMMATORY MYOSITIS: PRELIMINARY DATA IN INDIAN PATIENTS / N. V. Negalur* - D. Raval - M. Bindroo - W. Kazi - U. Baveja - R. Gupta SAT0505 COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD) / O. Koneva* - O. Ovsyannikova - O. Desiniva - L. Garzanova - L. Ananieva - M. Starovoytova SAT0506 SSC IN OLDER AGE: FREQUENT AND WITH A DIFFERENT PHENOTYPE. DATA OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS / P. Moinzadeh* - G. Riemekasten - N. Blank - J. Henes - I. Koetter - E. Siegert - C. Pfeiffer - G. Zeidler - M. Schmalzing - C. Guenther - L. Susok - M. Worm - A. Kreuter - C. Sunderkoetter - U. Mueller-Ladner - A. Juche - E. Aberer - T. Schmeiser - T. Krieg - K. Kuhr - N. Hunzelmann SAT0507 IMPLANTABLE LOOP RECORDER CAN SCREEN FOR INCIDENTAL SIGNIFICANT ARRHYTHMIAS IN SCLERODERMA, WITH CARDIAC MRI ECV AND TROPONIN BIOMARKER, USEFUL FOR RISK STRATIFICATION / R. Dumitru* - L.-A. Bissell - G. Abignano - B. Erhayiem - G. Fent - H. Donica - A. Burska - F. Del Galdo - J. Greenwood - S. Plein - L. Graham - M. H. Buch SAT0508 ACE-INHIBITORS IN ARTERIAL HYPERTENSION IN SSC PATIENTS DISPLAY A RISK FACTOR FOR SCLERODERMA RENAL CRISIS - A EUSTAR ANALYSIS / S. Adler* - P. A. Varisco - O. Distler - L. Buetikofer - O. Kowal-Bielecka - Y. Allanore - G. Riemekasten - P. M. Villiger SAT0509 HOW MONEY SHOULD BE SPENT: PATIENTS PERSPECTIVES ON SCLERODERMA RESEARCH FUNDING / S. Divani - J. Patel* - R. Stratton SAT0510 CUTANEOUS MANIFESTATIONS IN IDIOPATHIC INFLAMATORY MYOPATHIES: FACTORS ASSOCIATED WITH CALCINOSIS / T. Cobo-Ibáñez* - F. J. López-Longo - B. Joven - S. Muñoz-Fernández - P. Carreira - M. Á. Blázquez - I. Llorente - J. C. López Robledillo - R. Almodóvar - P. García-De la Peña - M. C. Barbadillo - A. Pérez - L. Lojo - M. J. García de Yébenes - L. Nuño SAT0511 PRACTICAL SUGGESTIONS ON INTRAVENOUS ILOPROST IN RAYNAUD S PHENOMENON AND DIGITAL ULCER SECONDARY TO SYSTEMIC SCLEROSIS: SYSTEMATIC LITERATURE REVIEW AND EXPERT CONSENSUS / T. Schioppo* - F. Ingegnoli - Y. Allanore - R. Caporali - M. Colaci - O. Distler - D. E. Furst - N. Hunzelmann - F. Iannone - D. Khanna - M. Matucci-Cerinic SAT0512 SAFETY AND EFFICACY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS SUBJECTS TREATED IN AN OPEN LABEL EXTENSION OF TRIAL JBT101-DM-001 / V. P. Werth* - B. Patel - J. S. Concha - J. Okawa - D. Pearson - E. Hejazi - R. Feng - C. Cornwall - N. Dgetluck - S. Constantine - A. Aggarwal - B. White SAT0513 PROGRESSIVE SKIN FIBROSIS IS ASSOCIATED WITH A DECLINE IN LUNG FUNCTION AND POORER SURVIVAL IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS / W. Wu* - S. Jordan - N. Graf - J. Pena - J. Curram - Y. Allanore - M. Matucci-Cerinic - J. E. Pope - C. Denton - D. Khanna - O. Distler on behalf of EUSTAR coauthors SAT0514 MRI - GUIDED THERAPY FOR SYSTEMIC SCLEROSIS ASSOCIATED MYOSITIS / Y. Braun-Moscovici* - D. Militianu - N. Puchkov - D. Markovits - M. Braun - M. A. Nahir - A. Balbir-Gurman SAT0515 CLINICAL CHARACTERISTICS OF PATIENTS WITH CANCER-ASSOCIATED MYOSITIS COMPLICATED BY INTERSTITIAL LUNG DISEASE / Y. Kaneko* - T. Nunokawa - Y. Taniguchi - Y. Yamaguchi - T. Gono - K. Masui - A. Kawakami - Y. Kawaguchi - S. Sato - M. Kuwana on behalf of JAMI investigators 16 June 2018 TOPIC: VASCULITIS SAT0516 TWO DISTINCT SUBSETS OF LOW DENSITY GRANULOCYTES IN ANCA ASSOCIATED VASCULITIS / A. Endo* - Y. Komagata - K. Yamagishi - N. Ikegaya - K. Fukuoka - M. Karube - Y. Arimura - S. Kaname SAT0517 GENDER DIFFERENCES INFLUENCES CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS: AN ITALIAN MONOCENTRIC STUDY / A. Tomelleri* - C. Campochiaro - S. Sartorelli - A. Cariddi - G. Cavalli - E. Baldissera - L. Dagna SAT0518 THE ROLE OF LEFLUNOMIDE IN THE TREATMENT OF GIANT CELL ARTERITIS / A. Hocevar* - R. Ješe - Ž. Rotar - M. Tomšič SAT0519 INTERSTITIAL LUNG DISEASE IN ANCA-ASSOCIATED VASCULITIS PATIENTS: COMPARISON WITH IDIOPATIC PULMONARY FIBROSIS AND INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES / A. Abril* - M. Kwon - C. Rojas - A. Khoor - I. Mira-Avendano SAT0520 ANTI-IL6-RECEPTOR TOCILIZUMAB IN REFRACTORY UVEITIS ASSOCIATED TO EXTRAOCULAR MANIFESTATIONS IN PATIENTS WITH BEHÇET S DISEASE. MULTICENTER STUDY OF 11 PATIENTS / B. Atienza-Mateo* - J. L. Martín-Varillas - V. Calvo-Río - E. Beltrán - L. Martinez - E. Valls - M. Hernandez - A. Atanes - M. Cordero - J. M. Nolla - C. Carrasco - J. Loricera - N. Palmou-Fontana - E. Pons - M. C. González-Vela - R. Demetrio-Pablo - M. A. González-Gay - R. Blanco SAT0521 A PROSPECTIVE OBSERVATIONAL STUDY ON THE SAFETY AND EFFICACY OF INFLIXIMAB-BIOSIMILAR IN PATIENTS WITH TAKAYASU S ARTERITIS (TAKASIM): PRELIMINARY DATA / C. Campochiaro* - A. Tomelleri - S. Sartorelli - C. Sembenini - G. Cavalli - E. Baldissera - L. Dagna * Presenting author

164 162 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0522 VASCULAR AND JOINT INFLAMMATION ARE NEGATIVELY CORRELATED IN PATIENTS WITH POLYMYALGIA RHEUMATICA, GIANT CELL ARTERITIS AND FEVER OF UNKNOWN ORIGIN / D. Camellino* - M. Bauckneht - S. Morbelli - M. Marchiano - G. Pesce - D. Saverino - M. Bagnasco - M. A. Cimmino SAT0523 EVOLUTION OF VISUAL AFFECTION IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB / D. Prieto-Peña* - J. Loricera - C. Moriano - E. Díez - J. Nárvaez - A. Mera - E. Pérez-Pampín - V. Aldasoro - M. Varela - N. Álvarez-Rivas - C. Barbazán - C. Ordás-Calvo - F. Sivera - C. Gómez - J. Toyos - A. Conesa - M. Belmonte - F. Navarro - V. Calvo-Río - C. González-V - N. Palmou-Fontana - L. Domínguez-Casas - M. Calderón-Goercke - J. Hernández - M. González-Gay - R. Blanco SAT0524 THE ROLE OF POLYMORPHISMS OF HEMOSTASIS GENES IN VENOUS THROMBOEMBOLIC EVENTS IN ANCA- ASSOCIATED VASCULITIDES / E. Makarov* - N. Bulanov - P. Novikov - T. Krasnova - A. Balatskiy - L. Samokhodskaya - S. Moiseev SAT0525 AN UPDATE ON PULMONARY ARTERY INVOLVEMENT IN BEHCET S SYNDROME: MORE PULMONARY ARTERY THROMBOTIC DISEASE AND A BETTER OUTCOME / Y. Ozguler - E. Dincses - S. Bakan - G. Hatemi - M. Melikoglu - S. Ugurlu - S. Yurdakul - H. Yazici - E. Seyahi* SAT0526 IS RELAPSE RATE OF GIANT CELL ARTERITIS IN REAL-LIFE EXPERIENCE LOWER THAN IN THE CONTROLLED TRIALS? RESULTS OF A RETROSPECTIVE, MULTI-CENTER COHORT STUDY / F. Alibaz-Oner* - M. A. Balcı - O. N. Pamuk - O. Zengin - M. Tascı - A. Dogru - O. Bayındır - S. Yavuz - A. Cefle - M. E. Tezcan - M. F. Oksuz - O. Kucuksahin - A. Omma - S. Yasar Bilge - T. Kasifoglu - Z. Erturk - C. Bes - A. U. Unal - B. Armagan - E. Gonullu - A. Yazici - O. Karadag - E. Dalkilic - K. Aksu - G. Keser - H. Direskeneli SAT0527 RITUXIMAB PRESCRIPTION PATTERNS AND EFFICACY IN THE INDUCTION TREATMENT OF ANCA-ASSOCIATED VASCULITIS IN A BELGIAN MULTICENTRIC COHORT / F. Vandergheynst* - P. Chasseur - J.-B. Nicolas - C. von Frenckell - D. Blockmans SAT0528 EFFECTIVENESS OF REMISSION-INDUCTION THERAPY WITH CONCOMITANT CYCLOPHOSPHAMIDE AND GLUCOCORTICOID FOR MICROSCOPIC POLYANGIITIS AND GRANULOMATOSIS WITH POLYANGIITIS IN JAPAN: A PROPENSITY SCORE MATCHED ANALYSIS OF TWO NATIONWIDE PROSPECTIVE COHORT STUDIES / H. Watanabe* - K.-E. Sada - Y. Matsumoto - M. Harigai - H. Makino on behalf of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) SAT0529 SHORT-TERM EFFICACY AND SAFETY OF BIOSIMILAR RITUXIMAB IN PATIENTS WITH SYSTEMIC VASCULITIDES / I. Smitienko* - P. Novikov - S. Moiseev - A. Zykova - T. Shevtsova SAT0530 CLINICAL FEATURES ASSOCIATION WITH HLA-B ALLELIC TYPES (B27, B51) IN KOREAN PATIENTS OF BEHCET S DISEASE / J. H. Kim* - J. H. Jung - S. J. Choi - Y. H. Lee - J. D. Ji - G. G. Song SAT0531 ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL / J. H. Stone* - K. Tuckwell - S. Dimonaco - M. Klearman - M. Aringer - D. Blockmans - E. Brouwer - M. C. Cid - B. Dasgupta - J. Rech - C. Salvarani - H. Schulze-Koops - G. Schett - R. Spiera - S. H. Unizony - N. Collinson on behalf of GiACTA Investigators SAT0532 TREATMENT WITH METHOTREXATE AND RISK OF ISCHEMIC RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS IN CLINICAL PRACTICE / J. Font Urgelles* - Z. Rosales Rosado - D. D. Freites Núñez - P. M. Lois Bermejo - L. León Mateos - I. C. Morado Quiñoa - E. Pato Cour - J. A. Jover Jover - L. Abásolo Alcázar SAT0533 POLVAS - RETROSPECTIVE REGISTRY OF POLISH PATIENTS WITH ANCA-ASSOCIATED VASCULITIDES / K. Wójcik* - J. Kur-Zalewska - A. Masiak - A. Dębska-Ślizień - J. Jeleniewicz - K. Jakuszko - P. Głuszko - M. Wisłowska - I. Brzosko - A. Hawrot-Kawecka - J. Musiał on behalf of POLVAS SAT0534 ANNUAL INCIDENCE OF GIANT CELL ARTERITIS IN URBAN AND RURAL AREAS IN WESTERN NORWAY / L. K. Brekke* - B.-T. S. Fevang - G. Myklebust SAT0535 EULAR 2018 CORE SET OF DATA TO BE COLLECTED IN GIANT CELL ARTERITIS REGISTRIES AND DATABASES VIEWPOINTS FROM A EULAR TASK FORCE / L. Ehlers* - J. Askling - J. W. Bijlsma - M. C. Cid - M. Cutolo - B. Dasgupta - C. Dejaco - W. G. Dixon - N. Feltelius - A. Finckh - K. Gilbert - S. Mackie - A. Mahr - E. L. Matteson - L. Neill - C. Salvarani - W. A. Schmidt - A. Strangfeld - R. van Vollenhoven - F. Buttgereit SAT0536 MULTIPLE RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS / M. Banjari* - E. LIOZON - S. Dumonteil - G. Gondran - S. Palat - H. Bezanahary - S. Nadalon - A.-L. Fauchais - K. H. Ly SAT0537 IS BALANCE AFFECTED IN BEHCET S DISEASE AND WHAT ARE THE FACTORS THAT EFFECT THE BALANCE? / A. Celik - M. A. Melikoğlu* SAT0538 AORTIC INVOLVEMENT IN RELAPSING POLYCHONDRITIS: A SYSTEMATIC REVIEW / M. Erdogan* - S. N. Esatoglu - G. Hatemi - V. Hamuryudan SAT0539 THE FREQUENCY OF RECURRENT ORAL ULCERS IN FAMİLY MEMBERS OF PATİENTS WITH BEHÇET S DISEASE / N. Çakır* - B. Çelik Yıldırım - N. İmeryüz SAT0540 TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN IN THE VASCULITIS ANCA POSITIVE. 27 CASES STUDIED IN A SINGLE REFERENCE CENTRE / N. Aviles Mendez* - V. Calvo Rio - J. Loricera - B. Atienza Mateo - J. L. Martin Varillas - J. Blanco - R. Blanco - M. A. Gonzalez-Gay SAT0541 INCIDENCE OF LARGE VESSEL GCA IN NORTHERN ITALY DURING A 12-YEAR PERIOD ( ) / P. Macchioni* - L. Boiardi - G. Restuccia - F. Muratore - P. Mancuso - M. Catanoso - C. Salvarani SAT0542 INTERLEUKIN-12 AND INTERLEUKIN-23 ARE KEY PATHOGENIC PLAYERS IN GIANT CELL ARTERITIS / R. Conway* - L. O Neill - P. Gallagher - G. McCarthy - C. Murphy - D. Veale - U. Fearon - E. Molloy SAT0543 QUALITY OF LIFE IN BEHÇET S SYNDROME: THE ROLE OF PATIENT REPORTED OUTCOME / R. Talarico* - A. d Ascanio - R. Neri - C. Tani - C. Baldini - M. Mosca SAT0544 COMPARING THE CLINICAL PROFILE OF ADULTS AND CHILDREN WITH BEHÇET S SYNDROME IN THE UK / S. Myers* - E. Makmur - L. Hanns - D. Huskard - P. Brogan - N. Ambrose SAT0545 GIANT CELL ARTERITIS AND HEMATOLOGIC MALIGNANCIES: A REAL-LIFE EXPERIENCE / S. Tiosano* - L. Dar - O. Gendelman - D. Comaneshter - A. Watad - A. D. Cohen - H. Amital SAT0546 SENSORINEURAL HEARING LOSS IN TAKAYASU S ARTERITIS / U. Kimyon - S. N. Esatoglu* - E. Kara - A. Atas - E. E. Gunay - E. Karaman - E. D. Gozen - V. Hamuryudan - H. Yazici - E. Seyahi * Presenting author

165 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 163 SAT0547 PROGNOSTIC NUTRITIONAL INDEX FOR ESTIMATING BIRMINGHAM VASCULITIS ACTIVITY SCORE IN ANCA- ASSOCIATED VASCULITIS / S. S. Ahn* - J. Yoo - S. M. Jung - J. J. Song - Y.-B. Park - S.-W. Lee SAT0548 PROGNOSTIC FACTORS FOR INTERSTITIAL LUNG DISEASE WITH MICROSCOPIC POLYANGIITIS / T. Shoda* - T. Takeuchi - K. Isoda - J. Komma - T. Kotani - S. Makino SAT0549 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS (AAV) - A EBMT RETROSPECTIVE SURVEY / T. Alexander* - C. Samuelson - T. Daikeler - J. Henes - L. Skagerlind - M. Akil - G. Ehninger - E. Jantunen - D. Farge - J. Snowden on behalf of EBMT Autoimmune Diseases Working Party SAT0550 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMISED CONTROLLED TRIAL / V. Strand* - S. Dimonaco - K. Tuckwell - M. Klearman - N. Collinson - J. H. Stone on behalf of GiACTA Investigators SAT0551 LEG ULCERS IN BEHCET S SYNDROME: AN OBSERVATIONAL SURVEY IN 24 PATIENTS / Y. Ozguler* - Z. Kutlubay - A. S. Dikici - M. Melikoglu - C. Mat - H. Yazıcı - E. Seyahi TOPIC: OSTEOARTHRITIS SAT0552 BASELINE PREDICTORS OF UPPER LEG MUSCLE STRENGTH OVER 2 AND 4 YEARS IN SUBJECTS WITH KNEE OSTEOARTHRITIS:DATA FROM THE OSTEOARTHRITIS INITIATIVE / A. H. De Zwart* - M. van der Leeden - L. D. Roorda - M. van der Esch - J. W. R. Twisk - W. F. Lems - J. Dekker SAT0553 CHONDROCALCINOSIS OF THE KNEE AND THE RISK FOR KNEE OR HIP OSTEOARTHRITIS PROGRESSION: DATA FROM THE KHOALA COHORT / A. Latourte* - A. C. Rat - W. Ngueyon Sime - C. Roux - F. Guillemin - P. Richette SAT0554 PREOPERATIVE PHYSICAL FUNCTION INFLUENCES ON STAIR CLIMBING ABILITY 1 MONTH AFTER TOTAL KNEE ARTHROPLASTY/ B. R. Kim* SAT0555 ON THE WAY TO KNEE REPLACEMENT: TRAJECTORY AND CORRELATION OF KNEE OA MRI CARTILAGE THICKNESS, RADIOGRAPHIC JOINT SPACE WIDTH, AND WOMAC KNEE PAIN IN THE OAI / C. K. Kwoh* - E. L. Ashbeck - M. J. Hannon - S. Wax - J. Kraines SAT0556 COST-EFFECTIVENESS OF A BLENDED PHYSIOTHERAPY INTERVENTION IN PATIENTS WITH HIP AND/OR KNEE OSTEOARTHRITIS: A CLUSTER RANDOMISED CONTROLLED TRIAL / C. Kloek* - J. M. van Dongen - D. Bossen - J. Dekker - C. Veenhof SAT YEAR TRAJECTORIES OF PAIN IN EARLY KNEE AND HIP OSTEOARTHRITIS; THE CHECK STUDY / J. Runhaar - J. Waarsing - D. Schiphof* - W. van Spil - M. van Middelkoop - S. Bierma-Zeinstra SAT0558 PHARMACOTHERAPY OF OBESITY IN PATIENTS WITH KNEE OSTEOARTHRITIS AND METABOLIC SYNDROME / E. Strebkova* - L. Alekseeva SAT0559 SYSTEMATIC LITERATURE REVIEW (SLR) FOR THE 2018 UPDATE OF THE EULAR MANAGEMENT RECOMMENDATIONS FOR HAND OSTEOARTHRITIS (OA) / F. Kroon* - M. Kloppenburg - J. Schoones - L. Carmona SAT0560 FROM A 2-YEAR MULTICENTRE CLINICAL TRIAL IN KNEE OSTEOARTHRITIS, A METABOLOMIC ANALYSIS REVEALS THAT OVER ACTIVATION OF THE CONVERSION PATHWAY OF PHOSPHATIDYLCHOLINE TO LYSOPHOSPHATIDYLCHOLINE IS ASSOCIATED WITH KNEE CARTILAGE VOLUME LOSS OVER TIME / G. Zhai* - J.-P. Pelletier - M. Liu - E. Randell - J. Martel-Pelletier SAT0561 MITOCHONDRIAL BACKGROUND INFLUENCES THE JOINT EVOLUTION IN A CONPLASTIC MOUSE MODEL OF AGING / I. Rego-Pérez* - A. V. Lechuga-Vieco - M. Scotece - P. Filgueira-Fernández - S. Pértega - J. A. Enríquez - F. J. Blanco SAT0562 HIP SHAPE PREDICTS KNEE OSTEOARTHRITIS OUTCOMES OVER A DECADE IN OLDER-ADULTS / I. P. Munugoda* - H. G. Ahedi - R. M. Aspden - K. Wills - S. E. Graves - M. Lorimer - F. Cicuttini - J. S. Gregory - G. Jones - M. L. Callisaya - D. Aitken SAT0563 IDENTIFICATION AND VALIDATION OF PHYSICAL ACTIVITY PHENOTYPES FOR KNEE OSTEOARTHRITIS: A POPULATION-BASED COHORT STUDY / I. P. Munugoda* - F. Pan - K. Wills - F. Cicuttini - S. E. Graves - M. Lorimer - G. Jones - M. L. Callisaya - D. Aitken SAT0564 EFFECTS OF EDUCATION AND INCOME ON PREVALENCE, INCIDENCE, AND PROGRESSION OF RADIOGRAPHIC KNEE OSTEOARTHRITIS: AN ANALYSIS OF THE OSTEOARTHRITIS INITIATIVE DATA / I. Shirinsky* - V. Shirinsky SAT0565 ADJUSTING FOR THE INTRA-ARTICULAR PLACEBO EFFECT IN KNEE OSTEOARTHRITIS THERAPIES / I. Simsek - T. Phalen - A. Bedenbaugh - M. Phillips - J. Tambiah* SAT0566 ASSOCIATIONS OF OSTEOCLASTS AND MACROPHAGES IN SUBCHONDRAL BONE WITH SYMPTOMS IN PEOPLE WITH KNEE OA / K. Aso* - M. Shahtaheri - R. Hill - D. Wilson - D. A. Walsh SAT0567 THE LEADING RISK FACTORS FOR DEVELOPING INTENSIVE PAIN SYNDROME IN THE KNEE JOINTS IN PATIENTS WITH OSTHEOARTRITIS / L. I. Alekseeva* - E. A. Taskina - N. G. Kashevarova - S. G. Anikin - E. P. Sharapova - E. A. Strebkova - T. A. Korotkova - A. U. Feklistov SAT0568 EFFECT OF DIACERIN VS GLUCOSAMINE-CHONDROITIN ON DISEASE PROGRESSION, AND MEASURES OF FUNCTION IN PERSONS WITH KNEE OSTEOARTHRITIS: A 2-YEAR RANDOMISED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL / M. A. Khan* - M. Chinoy - S. Iftikhar - D. Siddiqui - S. Ashfaq SAT0569 IMPACT OF BARIATRIC SURGERY ON RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS / M. Moly* - B. Combe - T. Barnetche - C. Daien - C. Gaujoux-Viala - C. Lukas - J. Morel - C. Hua SAT0570 RESTING-STATE FMRI BRAIN CONNECTIVITY IN HAND OSTEOARTHRITIS / M. D. Russell* - F. A. Howe - T. R. Barrick - N. Sofat SAT0571 THE RADIOLOGICAL, CLINICAL AND FUNCTIONAL PROPERTIES OF HAND OSTEOARTHRITIS AND THEIR RELATION WITH RADIOLOGICAL FINDINGS IN A TURKISH POPULATION: TLAR-OA STUDY / M. T. Duruöz* - D. Erdem - T. Tuncer - L. Altan - F. Ayhan - A. Bal - L. Cerrahoglu - E. Capkin - R. Cevik - D. Dulgeroglu - S. Gursoy - S. Hizmetli - C. Kacar - E. Kaptanoglu - T. Kaya - H. Kocabaş - K. Nas - S. Ozcakir - D. Sindel - O. Sahin - G. Tasci Bozbas - C. Tikiz - H. Ugurlu 16 June 2018 * Presenting author

166 164 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0572 INITIAL STRUCTURAL RESPONSE PREDICTS LONG-TERM SURVIVAL OF KNEE JOINT DISTRACTION AS A TREATMENT FOR KNEE OSTEOARTHRITIS / M. Jansen* - G. van der Weiden - R. Custers - S. Mastbergen - F. Lafeber SAT0573 PROGRESSION OF PAIN, STIFFNESS, FUNCTION CHANGES, AND ULTRASOUND DETECTED SYNOVITIS AND OSTEOPHYTE FORMATION IN PATIENTS WITH HAND OSTEOARTHRITIS OVER THREE YEARS / O. Sleglova* - O. Ruzickova - K. Pavelka - L. Senolt SAT0574 SENSITIZATION AND PAIN SEVERITY IN PATIENTS WITH HAND OSTEOARTHRITIS / P. Steen Pettersen* - T. Neogi - K. Magnusson - H. B. Hammer - T. Uhlig - T. K. Kvien - I. K. Haugen SAT0575 SAFETY AND EFFICACY OF LUTIKIZUMAB (ABT-981), AN ANTI-INTERLEUKIN-1 ALPHA/BETA DUAL VARIABLE DOMAIN (DVD) IMMUNOGLOBULIN, IN SUBJECTS WITH KNEE OSTEOARTHRITIS: RESULTS FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE 2 TRIAL / R. Fleischmann* - H. Bliddal - F. Blanco - T. Schnitzer - C. Peterfy - S. Chen - L. Wang - P. Conaghan - F. Berenbaum - J.-P. Pelletier - J. Martel-Pelletier - O. Vaeterlein - W. Liu - G. Levy - L. Zhang - J. Medema - M. Levesque SAT0576 BIOMARKERS PREDICTIVE OF PAIN IMPROVEMENT IN KNEE OSTEOARTHRITIS SUBJECTS TREATED WITH THE ANTI-IL-1 ALPHA/BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN LUTIKIZUMAB (ABT-981) / S. Feng* - S. Chen - L. Wang - C. Peterfy - V. Kraus - R. Kamath - L. Zhang - Y. Luo - L. Cui - J. Medema - M. Levesque SAT0577 EVALATUION OF SARCOPENIA MULTIDIMENSIONALLY IN PATIENTS WITH KNEE OSTEOARTHRITIS / S. Gümrük Aslan* - M. Saraçoğlu - H. Genç - B. D.Çakıt - B. Nacır SAT0578 PATELLAR TENDON ENTHESIS ABNORMALITIES AND THEIR ASSOCIATION WITH KNEE PAIN AND STRUCTURAL ABNORMALITIES IN OLDER ADULTS / S. M. Mattap* - D. Aitken - K. Wills - A. Halliday - C. Ding - W. Han - F. Cicuttini - G. Jones - L. Laslett SAT0579 PRESENCE OF AUTOANTIBODIES IN EROSIVE HAND OSTEOARTHRITIS AND ASSOCIATION WITH CLINICAL PRESENTATION / M. A. van Delft - S. Van Beest* - M. Kloppenburg - L. A. Trouw - A. Ioan-Facsinay SAT0580 ASSOCIATION OF CHILDHOOD AND ADULTHOOD ADIPOSITY MEASURES WITH KNEE CARTILAGE THICKNESS, CARTILAGE VOLUME AND BONE AREA IN YOUNG ADULTS / T. Meng* - A. Venn - F. Eckstein - W. Wirth - F. Cicuttini - L. March - T. Dwyer - M. Cross - L. L. Laslett - G. Jones - C. Ding - B. Antony SAT0581 PREDICTIVE FACTORS OF RESPONSE TO A SINGLE INJECTION OF MANNITOL-MODIFIED CROSS-LINKED HYALURONIC ACID (HANOX-M-XL) IN PATIENTS WITH TRAPEZIOMETACARPAL OSTEOARTHRITIS. RESULTS OF A MULTICENTRE PROSPECTIVE OPEN-LABEL PILOT STUDY (INSTINCT TRIAL) / J. DAUVISSAT - T. Conrozier* - H. Lellouche - B. MAILLET - C. Rizzo - V. Travers - V. locquet - S. Mellac-Ducamp SAT0582 BONE MARROW LESION TYPE AND PAIN IN KNEE OSTEOARTHRITIS / T. A. Perry* - T. W. O Neill - M. J. Parkes - D. T. Felson - R. Hodgson - N. K. Arden SAT0583 THE IMMEDIATE EFFECT OF A SOFT KNEE BRACE ON DYNAMIC KNEE INSTABILITY IN PERSONS WITH KNEE OSTEOARTHRITIS / T. Cudejko* - M. van der Esch - J. Schrijvers - R. Richards - T. Wrigley - J. van den Noort - M. van der Leeden - L. D. Roorda - W. Lems - J. Harlaar - J. Dekker SAT0584 CLINICAL VALIDATION OF TWO PANELS OF BIOMARKERS TO PREDICT SYMPTOMATIC DRUGS RESPONSE IN KNEE OA / V. Calamia* - F. Picchi - I. Rego - M. Camacho - L. González - P. Fernández-Puente - M. Herrero - H. Martínez - J. Vergés - C. Ruiz-Romero - F. J. Blanco SAT0585 DECREASED SYNOVIAL LEVELS OF DICKKOPF-1 ARE ASSOCIATED WITH RADIOLOGICAL PROGRESSION IN KNEE OSTEOARTHRITIS PATIENTS / W. A. Hassan* - E. G. Behiry SAT0586 RESULTS FROM A 52 WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, WNT PATHWAY INHIBITOR (SM04690) FOR KNEE OSTEOARTHRITIS TREATMENT / Y. Yazici* - T. McAlindon - A. Gibofsky - N. Lane - D. Clauw - C. Swearingen - A. DiFrancesco - J. Tambiah - M. Hochberg TOPIC: OTHER ORPHAN DISEASES Poster tour S12: Be familiar with orphan diseases Nemanja Damjanov (Serbia), Predrag Ostojic (Serbia) Abstracts N : SAT0587-SAT0596 SAT0587 MAJOR SALIVARY GLANDS ULTRASONOGRAPHY IN DIFFERENTIAL DIAGNOSIS OF IGG4-RELATED DISEASE AND PRIMARY SJÖGREN S SYNDROME / E. Sokol* - E. Rodionova - V. Vasilyev - S. Palshina - M. Burtseva SAT0588 RHEUMATOLOGIC IMMUNE-RELATED ADVERSE EFFECTS OF CHECKPOINT INHIBITOR THERAPY: A SINGLE CENTER COHORT OF 29 PATIENTS / M. D. Richter* - C. S. Crowson - L. A. Kottschade - H. D. Finnes - S. N. Markovic - U. Thanarajasingam SAT0589 MUSCULOSKELETAL MANIFESTATIONS OCCUR PREDOMINANTLY IN PATIENTS WITH OLDER ONSET FAMILIAL MEDITERRANEAN FEVER / Y. Endo* - T. Koga - M. Umeda - M. Ishida - Y. Fujita - S. Tsuji - A. Takatani - T. Shimizu - R. Sumiyoshi - T. Igawa - S. Fukui - A. Nishino - S.-Y. Kawashiri - N. Iwamoto - K. Ichinose - M. Tamai - H. Nakamura - T. Origuchi - K. Agematsu - A. Yachie - J. Masumoto - K. Mitiga - A. Kawakami SAT0590 LONG-TERM EFFICACY AND SAFETY OF ADALIMUMAB BY ETIOLOGY IN PATIENTS WITH NON-INFECTIOUS UVEITIS IN THE VISUAL III TRIAL / P. T. Merrill - A. Vitale - M. Zierhut - E. Fortin - H. Goto - M. Kron - A. Song - K. Douglas* - S. Pathai SAT0591 DEMOGRAPHIC AND CLINICAL FEATURES OF FAMILIAL MEDITERRANEAN FEVER PATIENTS / O. Ozdemir Isik* - B. Gonul - A. Erol - S. Tekeoglu - D. Temiz Karadag - A. Yazici - A. Cefle SAT0592 HRCT PULMONARY MANIFESTATIONS IN PATIENTS WITH SYNOVITIS, ACNE, PUSTULOSIS, HYPEROSTOSIS, AND OSTEITIS (SAPHO)SYNDROME / S. Liu - C. Li* - W. Song - W. Xu - K. Xu - W. Zhang - X. Tian SAT0593 PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES / A. Fischer* - M. Wijsenbeek - M. Kreuter - B. Mounir - L. Zouad-Lejour - V. Acciai - C. D. Wells - M. Quaresma - C. Denton * Presenting author

167 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 165 SAT0594 WHICH ONE IS MORE VALUABLE FOR DIAGNOSIS OF ADULT ONSET STILL S DISEASE? SOLELY NEUTROPHILIA OR LEUKOCYTOSIS WITH NEUTROPHILIA? / E. Bilgin* - A. Erden - B. Armagan - L. Kılıç - A. Sarı - G. Yardımcı - E. Bilgin - A. Akdoğan - Ö. Karadağ - S. Apraş Bilgen - I. Ertenli - S. Kiraz - U. Kalyoncu SAT0595 ANALYSIS OF RECURRENCES AFTER SUSPENSION OF IMMUNOSUPPRESSIVE TREATMENT IN NON-INFECTIOUS UVEITIS / M. Uriarte* - C. Martín - J. Gonzalez - R. García de Vicuña - E. Pato - M. Gorroño - Á. M. Aparicio - M. Cordero SAT0596 THORACIC INVOLVEMENT AT DIAGNOSIS DRIVES A DIFFERENTIATED CLINICAL PRESENTATION OF SARCOIDOSIS: ANALYSIS OF 1245 PATIENTS (SARCOGEAS-SEMI) / S. Retamozo* - P. Brito-Zerón - R. Pérez-Alvarez - B. Kostov - C. Feijoo Masso - G. Fraile - R. Gómez-de-la-Torre - B. De-Escalante - M. López-Dupla - A. Alguacil - J. Chara-Cervantes - M. Pérez-Conesa - J. Rascón - J. S. Garcia-Morillo - P. Perez-Guerrero - E. Fonseca - M. Akasbi - M. Bonet - J. L. Callejas - G. De-la-Red - E. Calvo - C. Soler - E. Peral-Gutiérrez - J. F. Gómez-Cerezo - G. Cruz-Caparrós - S. Rodríguez-Fernández - B. Pinilla - A. Gato - A. Rolo - C. Morcillo - A. Robles - I. Ojeda - M. J. Vives - B. de-miguel - M. Penadés - M. De-Vicente - X. Bosch - M. Pérez-de-Lis - A. González-García - C. Yllera - B. Gracia-Tello - A. Perez-Gonzalez - M. Pedrosa - C. Tolosa - L. Pallarés - M. Ramos-Casals SAT0597 NEW AUTOINFLAMMATORY PHENOTYPE MANIFESTING AS HYPOCOMPLEMENTEMIC URTICARIAL VASCULITIS AND ASSOCIATED WITH HOMOZYGOUS AGBL3 VARIANT / A. Gül* - N. Abaci - S. Sirma Ekmekci SAT0598 SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY AND SAFETY OF IMMUNOMODULATORY DRUGS IN PATIENTS WITH NONIFECTIOUS INTERMEDIATE AND POSTERIOR UVEITIS, PANUVEITIS AND MACULAR EDEMA / A. Gómez Gómez* - E. Loza - M. P. Rosario - G. Espinosa - J. M. García Ruiz de Morales - J. M. Herreras - S. Muñoz - M. Cordero-Coma SAT0599 IDIOPATHIC GRANULOMATOUS MASTITIS MAY RESPONSE WELL TO COMBINATION OF IMMUNOSUPRESIVES AND GLUCOCORTICOIDS / A. Sari* - A. Konan - M. Akpinar - B. Armagan - A. Erden - L. Kilic - O. Karadag - A. Akdogan - S. Apras Bilgen - S. Kiraz - I. Ertenli - U. Kalyoncu SAT0600 MULTICENTRIC RETICULOHISTIOCYTOSIS ( ): CLINICAL CORRELATES, TREATMENT OUTCOMES & ASSOCIATION WITH AUTOIMMUNITY & MALIGNANCY / A. S. Sandhu - C. S. Crowson - D. A. Wetter - G. A. McKenzie - A. Makol* SAT0601 ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES ORBITOPATHY. MULTICENTER STUDY OF 29 PATIENTS / B. Atienza-Mateo* - V. Calvo-Río - J. L. Martín-Varillas - R. Demetrio-Pablo - E. Valls-Pascual - B. Valls-Espinosa - O. Maiz-Alonso - A. Blanco - I. Torre - V. Rodriguez-Mendez - Á. García-Aparicio - R. Veroz González - V. Jovaní Casano - D. Peiteado López - M. Sanchez Orgaz - S. Castañeda Sanz - E. Tomero - F. J. Toyos Sáenz - M. Valvanera Pinillos - E. Aurrecoechea - Á. Mora - M. Á. González-Gay - R. Blanco SAT0602 CLINICAL SIGNIFICANCE OF AUTOANTIBODY POSITIVITY IN IDIOPATHIC PULMONARY FIBROSIS / B. Ghang* - J. Lee - O. C. Kwon - J. S. Oh - W. J. Seo - S. Hong - Y.-G. Kim - B. Yoo - J. W. Song - C.-K. Lee SAT0603 CAN HOMOZYGOUS OR HETEROZYGOUS MEFV MUTATIONS LEAD TO DIFFERENT PRESENTATION OF FAMILIAL MEDITERRANEAN FEVER? / A. Aktaş - M. Karadavut - D. Üsküdar Cansu - C. Korkmaz* SAT0604 SECONDARY HEMOPHAGOCYTIC SYNDROME: RETROSPECTIVE STUDY ACCORDING TO THE UNDERLYING DISEASE / C. A. Egües Dubuc* - J. A. Valero - A. De Diego - J. R. Furundarena - O. Maiz - L. M. López - J. J. Cancio - E. Uriarte - M. M. Yagüe - J. Calvo Alen - J. M. Belzunegui SAT0605 THE PRESENCE OF UVEITIS PREDICTS THE RESPONSE TO THE INTERLEUKIN (IL)-1 INHIBITORS ANAKINRA AND CANAKINUMAB IN BEHÇET S DISEASE / C. Fabiani* - A. Vitale - G. Emmi - G. Lopalco - D. Rigante - J. Sota - I. Orlando - B. Frediani - R. Franceschini - M. Galeazzi - F. Iannone - G. M. Tosi - L. Cantarini SAT0606 DISEASE MODIFYING ANTI RHEUMATIC DRUGS IN THE TREATMENT OF SAPHO SYNDROME: SYSTEMATIC LITERATURE ANALYSIS / M. Monet - C. Prati - X. Guillot - M. Sondag - F. Verhoeven - F. Aubin - D. Wendling* SAT0607 DRUGS USED OFF LABEL IN A RHEUMATOLOGY SERVICE OF A TERCIARY HOSPITAL / D. Martinez-Quintanilla Jimenez* - N. García Castañeda - P. Moreno Fresneda - M. Perez Abanades - R. Garcia De Vicuña - I. G. Alvaro - E. Tomero Muriel SAT0608 HOW TO DIFFERENTIATE ADULT ONSET STILL S DISEASE FROM OVERALL OTHER CAUSES OF FEVER OF UNKNOWN ORIGIN: RESULTS OF A PROSPECTIVE STUDY FROM A TERTIARY REFERRAL CENTER / E. Bilgin* - A. Erden - B. Armagan - L. Kılıç - A. Sarı - G. Yardımcı - M. K. Hayran - A. Akdoğan - Ö. Karadağ - S. Apraş Bilgen - I. Ertenli - S. Kiraz - U. Kalyoncu SAT0609 VENOUS VESSEL WALL THICKNESS IN LOWER EXTREMITY IS INCREASED IN MALE BEHCET S DISEASE PATIENTS WITH AND WITHOUT VASCULAR INVOLVEMENT / F. Alibaz-Oner* - R. Ergelen - A. Mutis - Z. Erturk - R. Asadov - T. Ergun - H. Direskeneli SAT0610 A DECLINING TREND IN FREQUENCY OF SECONDARY AMYLOIDOSIS IN BEHÇET S SYNDROME / G. Karatemiz* - S. N. Esatoglu - Y. Ozguler - S. Yurdakul - V. Hamuryudan - I. Fresco - M. Melikoglu - E. Seyahi - S. Ugurlu - H. Ozdogan - H. Yazıcı - G. Hatemi SAT0611 CANAKINUMAB USE IN ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS: A LARGE SINGLE CENTER EXPERIENCE / H. Babaoglu* - O. Varan - H. Kucuk - N. Atas - H. Satis - R. B. Salman - M. A. Ozturk - B. Goker - A. Tufan - S. Haznedaroglu SAT0612 THE EFFICACY OF CALCINEURIN INHIBITORS IN PATIENTS WITH ADULT-ONSET STILL S DISEASE: SINGLE- CENTRE HISTORICAL COHORT STUDY / H. Nakamura* - Y. Fujieda - M. Kato - K. Oku - T. Bohgaki - O. Amengual - S. Yasuda - T. Atsumi SAT0613 INCREASED SERUM LEVEL OF IL-36 RECEPTOR ANTAGONIST IS ASSOCIATED WITH ACTIVE DISEASE IN PATIENTS WITH ADULT-ONSET STILL S DISEASE / H. Kim* - J. Kang - B. Nam - J. S. Kim - D.-H. Yoo SAT0614 NEW VARIANT IN THE IL1RN-GENE ASSOCIATED WITH LATE ONSET AND ATYPICAL PRESENTATION OF DIRA / J. B. Kuemmerle-Deschner* - K. Hoertnagel - S. Schlipf - S. Hansmann - A. Hospach - X. Liu - S. M. Benseler - A. N. Weber SAT0615 SYMPATHETIC JOINT EFFUSION IN AN URBAN HOSPITAL / J. L. Barlow* - I. J. Tan SAT0616 TEN-YEAR RETENTION RATE OF INFLIXIMAB IN PATIENTS WITH BEHÇET S DISEASE-RELATED UVEITIS / J. Sota* - C. Fabiani - A. Vitale - G. Emmi - G. Lopalco - V. Venerito - I. Orlando - R. Franceschini - B. Frediani - M. Galeazzi - F. Iannone - G. M. Tosi - L. Cantarini 16 June 2018 * Presenting author

168 166 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 SAT0617 COMORBIDITY IN PATIENTS AFFECTED BY AVASCULAR NECROSIS OF THE FEMORAL HEAD AND IMPACT OF COEXISTENT DISEASES ON CONTRALATERAL JOINT INVOLVEMENT / K. Gudkevich* - N. Martusevich - A. Murzich SAT0618 RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND DISEASE DURATION IN BEHCET S DISEASE / K. Ayar* - B. Sensoy - M. E. Aslancı - T. Teker - S. Cekic SAT0619 ASSOCIATIONS BETWEEN CLINICAL MANIFESTATIONS OF BEHCET S SYNDROME AND WORK OUTCOMES: RESULTS FROM A UK CROSS-SECTIONAL ANALYSIS / L. Chadwick* - N. J. Goodson - R. J. Moots SAT0620 FURTHER EVIDENCES OF SECONDARY AMYLOIDOSIS IN ALKAPTONURIA / B. Frediani - L. Millucci* - G. Bernardini - D. Braconi - M. Bardelli - B. Marzocchi - O. Spiga - M. Orlandini - S. Sestini - M. Galeazzi - A. Santucci SAT0621 CLINICAL SIGNIFICANCE OF INTERLEUKIN-18 AND INTERLEUKIN -6 ON DISEASE COURSE OF ADULT-ONSET STILL S DISEASE / M. G. Ahmed* SAT0622 HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT IN SEVERE UVEITIS: A MULTICENTER STUDY OF 129 PATIENTS / N. Vegas-Revenga* - V. Calvo-Río - I. González-Mazón - L. Sánchez-Bilbao - E. Beltrán - A. Follonosa - O. Maíz - A. Blanco - M. Cordero - N. Ortego - I. Torre - F. Hernández - S. Muñoz - M. Esteban - M. Diaz-Llopis - J. Cañal - J. A. Ventosa - R. Demetrio - M. Agudo - L. Dominguez-Casas - M. A. González-Gay - R. Blanco SAT0623 CLINICAL FEATURES AND TREATMENT OF IDIOPATHIC RECURRENT ACUTE PLEURO-PERICARDITIS / K. Dietz - H.-M. Lorenz - N. Blank* SAT0624 INCIDENCE AND BASELINE CHARACTERISTICS OF RELAPSE OR EXACERBATION IN PATIENTS WITH PULMONARY SARCOIDOSIS: A SINGLE CENTER LONG-TERM OBSERVATIONAL COHORT STUDY / O. Murata* - A. Kudo - K. Suzuki SAT0625 SARCOIDOSIS IS ASSOCIATED WITH AN INCREASED RISK OF GASTROINTESTINAL EVENTS: A POPULATION- BASED RETROSPECTIVE COHORT STUDY / P. Ungprasert* - C. S. Crowson - E. L. Matteson SAT0626 ANAKINRA TREATMENT IN REFRACTORY CASES OF ADULT-ONSET STILL DISEASE: CASE SERIES / S. Ugurlu* - B. Yurttas - G. Guzelant - B. Ergezen - H. Ozdogan SAT0627 FABRY DISEASE: DIAGNOSTIC ERRORS IN RHEUMATOLOGY PRACTICE / S. Moiseev* - P. Novikov - N. Bulanov - E. Karovaikina - A. Moiseev - V. Fomin SAT0628 A RETROSPECTIVE OBSERVATIONAL STUDY OF AZATHIOPRINE MAINTENANCE THERAPY ON BEHCET S DISEASE WITH VASCULAR INVOLVEMENT / S. Girgin* - S. Yurumez - A. Omma - C. Bes - S. Celik - N. Alpay Kanitez SAT0629 IGG4 RELATED CASTLEMAN S DISEASE OR SECONDARY IGG4 RELATED DISEASE OF MULTICENTER CASTLEMAN S DISEASE? / X. Zhang* - P. Zhang - L. Peng - Y. Fei - W. Zhang - R. Feng - W. Zhang 16 June 2018 TOPIC: DIAGNOSTICS AND IMAGING PROCEDURES Poster tour S13: Imaging strategies in the management of arthritis Lene Terslev (Denmark), Mads Ammitzboll (Denmark) Abstracts N : SAT0630-SAT0639 SAT0630 AGREEMENT BETWEEN PATIENT-REPORTED SWOLLEN AND TENDER JOINTS, CLINICAL EXAMINATION AND SYNOVITIS DETECTED BY ULTRASONOGRAPHY IN RHEUMATOID ARTHRITIS PATIENTS AT THE TIME OF PATIENT-REPORTED FLARE / D. Kuettel* - L. Terslev - U. Weber - M. Østergaard - J. Primdahl - R. Petersen - M. A. Danielsen - K. Hørslev-Petersen SAT0631 LACK OF ASSOCIATION BETWEEN CLINICAL AND ULTRASOUND MEASURES OF DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS CLINICAL REMISSION: A CROSS-SECTIONAL ANALYSIS / K. F. Baker* - B. Thompson - D. Lendrem - A. G. Pratt - J. D. Isaacs SAT0632 ULTRASOUND IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING A NOVEL PRAGMATIC ALGORITHM: A MULTICENTRIC OBSERVATIONAL STUDY / K. R. Bonfiglioli* - R. Chakr - R. Lima - E. Paiva - I. Moss - R. Giorgi - M. Rassi - R. Cardoso - F. Nadaf - R. Santos - D. Ribeiro - L. Arruda - E. Melo - D. Furtado - A. Funke - N. Andrade - M. Fantinel - L. Rossi - M. Resmini - N. Sacilotto - J. A. Mendonça - I. Laurindo SAT0633 ULTRASOUND PREDICTIVE VALUE IN PREARTHRITIS. A PROSPECTIVE LONGITUDINAL STUDY / D. Peiteado* - I. Monjo - L. Nuño - A. Villalba - M. E. Miranda - P. Fortea - E. De Miguel - A. Balsa SAT0634 DOES THE PRESENCE OF MRI-DETECTED OSTEITIS AT DIAGNOSIS WITH RHEUMATOID ARTHRITIS LOWERS THE RISK FOR ACHIEVING DMARD-FREE SUSTAINED REMISSION? RESULTS OF A LONGITUDINAL STUDY / L. E. Burgers* - D. M. Boeters - M. Reijnierse - A. H. M. van der Helm-van Mil SAT0635 MAGNETIC RESONANCE IMAGING OF THE CERVICAL SPINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PRESENTING WITH CHRONIC NECK PAIN - A SYSTEMATIC COMPARISON OF CLINICAL ASSESSMENTS / X. Baraliakos* - M. Soltani - U. Kiltz - J. Braun SAT0636 REPEATABILITY OF MRI DIFFUSION WEIGHTED IMAGING OF SACROILIAC JOINTS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND HEALTHY SUBJECTS / J. M. Møller* - M. Østergaard - H. S. Thomsen - I. J. Sørensen - O. R. Madsen - S. J. Pedersen SAT0637 RADIOGRAPHIC AND MRI DETECTED SACROILIITIS IS MORE OFTEN OBSERVED IN PATIENTS WITH LUMBOSACRAL TRANSITIONAL VERTEBRA IN THE DESIR COHORT / G. Carvajal Alegria* - M. Voirin-Hertz - F. Garrigues - A. Simon - A. Feydy - D. van der Heijde - M. Reijnierse - D. Loeuille - P. Claudepierre - T. Marhadour - A. Saraux on behalf of In behalf of the DESIR cochort SAT0638 ULTRASONOGRAFHY THE PREVALENCE OF MONOSIDIUM URATE CRYSTAL DEPOSITION IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE: ASSOCIATION WITH LABORATORY, RADIOGRAPHIC PARAMETERS AND MICROSCOPY OF SYNOVIAL FLUID / M. Eliseev - R. Osipyants* - S. Vladimirov - K. Ilinykh - A. Smirnov * Presenting author

169 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 167 SAT0639 INTEROBSERVER AGREEMENT OF THE OMERACT ULTRASONOGRAPHIC CRITERIA FOR THE DIAGNOSIS OF CALCIUM PYROPHOSPHATE DEPOSITION DISEASE AT THE WRIST, AMONG PANEL OF RADIOLOGISTS AND RHEUMATOLOGISTS / P. Zufferey* - G. Filippou - F. Becce - M. Nissen - L. Brulhart - S. Revaz - R. Valcov - F. Gianinazzi - C. Benaim - P. Omoumi SAT0640 WHOLE BODY-MRI IN AXIAL SPONDYLOARTHRITIS (AXSPA): DIFFUSION WEIGHTED IMAGING (DWI) OUTPERFORMS THE STIR SEQUENCE / A. Nzeusseu Toukap* - N. Vander Maren - L. Collette - N. Michoux - P. Triqueneaux - M. S. Stoenoiu - F. Houssiau - J. Malghem - F. E. Lecouvet SAT0641 PERFORMANCE AND AGREEMENT OF DIFFERENT OPERATORS AND HISTOLOGICAL TECHNIQUES FOR THE ASSESSMENT OF GERMINAL CENTERS IN MINOR SALIVARY GLANDS IN PRIMARY SJÖGREN S SYNDROME / A. Alunno* - P. Cipriani - G. Coletti - B. Bigerna - M. Manetti - P. Di Benedetto - O. Bistoni - G. Cipolloni - V. Liakouli - P. Ruscitti - R. Gerli - R. Giacomelli - F. Carubbi SAT0642 A CAD SYSTEM IN HEP-2 IIF READING: A MULTICENTRE STUDY / A. Rigon* - M. Infantino - M. Merone - G. Iannello - C. Sansone - A. Tincani - I. Cavazzana - M. Manfredi - A. Radice - P. Soda - A. Afeltra SAT0643 ULTRASOUND ABNORMALITIES IN WRIST, MCP2 AND MTP5 ARE MOST DISCRIMINATIVE IN PREDICTING ARTHRITIS DEVELOPMENT IN SEROPOSITIVE ARTHRALGIA PATIENTS / A. Blanken* - M. van Beers-Tas - M. Nielen - M. Meursinge Reynders - F. Turkstra - C. van der Laken - D. van Schaardenburg SAT0644 T1RHO MAPPING IN THE ASSESSMENT OF ARTICULAR CARTILAGE INTEGRITY OF THE KNEE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / A. M. Barendregt* - V. Mazzoli - C. van Gulik - M. van den Berg - A. Nassar Sheikh Rashid - K. M. Dolman - D. Schonenberg-Meinema - T. W. Kuijpers - M. Maas - A. J. Nederveen - R. Hemke SAT0645 DIAGNOSTIC ACCURACY OF SERUM AUTOANTIBODIES MULTI-TESTING IN RHEUMATOID ARTHRITIS AND ECONOMIC CONSEQUENCES ACROSS EUROPE / B. Mascialino* - S. Swiniarski - I. Gehring - M. Poorafshar SAT0646 DEVELOPMENT AND VALIDATION OF A DEEP LEARNING ALGORITHM FOR CLASSIFYING ANTI-NUCLEAR ANTIBODY PATTERNS IN INDIRECT IMMUNOFLUORESCENCE IMAGES / C.-H. Lin* - C.-F. Kuo - Y.-F. Fang - P.-H. Tsai - Y.-F. Chen SAT0647 PREDICTIVE FACTORS OF POSITIVE POSITRON EMISSION TOMOGRAPHY FOR DIAGNOSING AORTITIS IN PATIENTS WITH POLYMYALGIC SYNDROME / D. Prieto-Peña* - J. Loricera - I. Martínez-Rodríguez - J. Banzo - M. Calderón-Goercke - V. Calvo-Río - C. González-Vela - M. González-Gay - R. Blanco - J. Hernández SAT0648 COXALGIA IN HEMOPHILIC PATIENTS. SONOGRAPHIC EVALUATION OF A NOT TARGET JOINT / D. Melchiorre* - G. Castaman - S. Linari - M. Matucci-Cerinic SAT0649 CORRELATION BETWEEN CLINICAL MANIFESTATIONS AND 18F-FDG UPTAKE IN PATIENTS WITH POLYMYALGIA RHEUMATICA / D. Prieto-Peña* - J. Loricera - I. Martínez-Rodríguez - J. Banzo - M. Calderón-Goercke - V. Calvo- Río - C. González-Vela - M. González-Gay - J. Hernández - R. Blanco SAT0650 MUSCULOSKELETAL ULTRASOUND IN FIRST DEGREE RELATIVES OF RHEUMATOID ARTHRITIS PATIENTS / E. Soliman* SAT0651 CAROTID ULTRASOUND IN PATIENTS WITH ARTHRITIS: IN WHICH PATIENTS DOES IT RE-STRATIFY CV RISK? / F. Sivera* - N. Martinez-Alberola - R. Martin-Domenech - G. Albert-Espi - C. Fernandez-Carballido - T. Pedraz-Penalva SAT0652 STUDY OF NAIL UNIT WITH ULTRASONOGRAPHY IN SEVERAL RHEUMATOLOGICAL CONDITIONS: A CROSS SECTIONAL STUDY OF DISTAL INTERPHALANGEAL JOINT AND NAIL / G. Adami* - E. Vantaggiato - C. Benini - A. Fassio - A. Giollo - G. Orsolini - L. Idolazzi - D. Gatti SAT0653 RELATIONSHIP BETWEEN CARDIAC VALVULAR CALCIFICATION, CAROTID ATHEROSCLEROSIS, AND CORONARY CALCIFICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS / H. Udachkina* - D. Novikova - T. Popkova - E. Markelova - I. Kirillova - E. Gerasimova SAT0654 ASSOCIATION OF PREDNISONE AND ANTIMALARIALS AND ECHOCARDIOGRAPHIC FINDINGS IN ASYMPTOMATIC CARDIOVASCULAR PATIENTS WITH SLE / I. Jochims* - L. M. H. Mota - L. Muniz - D. F. Vasconcelos - L. L. Santos- Neto SAT0655 MYOSITIS AND FASCIITIS BY MAGNETIC RESONANCE IMAGING IN RECENT-ONSET POLYMYALGIA RHEUMATICA AND EFFECT OF TOCILIZUMAB THERAPY / J. P. Laporte* - F. Garrigues - A. Huwart - S. Jousse-Joulin - T. Marhadour - D. Guellec - D. Cornec - V. Devauchelle-Pensec - A. Saraux SAT0656 CIRCULATING MIR-99B-5P IS A MARKER OF INFLAMMATION AND STRUCTURAL DAMAGE ON MRI IN EARLY RHEUMATOID ARTHRITIS / J. Yue* - F. Xiao - J. Xu - P. C. Wong - E. K. Li - L. P. Tam - M. Li - L. Qin - J. F. Griffith - L.-S. Tam SAT0657 MICROWAVE RADIOMETRY-DERIVED THERMAL CHANGES OF SACROILIAC JOINTS AS A BIOMARKER OF SACROILIITIS IN PATIENTS WITH SPONDYLOARTHROPATHY / K. Laskari* - D. A. Pitsilka - G. Pentazos - E. Siores - M. G. Tektonidou - P. P. Sfikakis SAT0658 QUANTITATIVE ANALYSIS OF JOINT STRUCTURE BY HR-PQCT IN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATION BETWEEN CARTILAGE LOSS AND BONE DETERIORATION / K. Chiba* - N. Iwamoto - N. Oki - K. Watanabe - M. Osaki - A. Kawakami SAT0659 IS SYNOVIAL HYPERTROPHY WITHOUT DOPPLER ACTIVITY IN RHEUMATOID ARTHRITIS JOINTS SENSITIVE TO CHANGE? - RESULTS OF A LONGITUDINAL ULTRASOUND STUDY / L. Terslev* - M. Østergaard - J. Sexton - H. B. Hammer SAT0660 CLINICAL SIGNIFICANCE OF ANTI-RA33 AUTOANTYBODIES IN RHEUMATOID ARTHRITIS / M. Volkava* - A. Kundzer SAT0661 MEASUREMENT OF THE INTIMA MEDIA THICKNESS OF TEMPORAL AND AXILLARY ARTERIES IN SUBJECTS WITH DIFFERENT RISKS OF CARDIOVASCULAR DISEASE: AN ULTRASOUND STUDY / M. V. Martire* - A. Di Matteo - E. Filippucci - E. Cipolletta - D. Jesus - M. Di Carlo - W. Grassi SAT0662 SCREENING RESEARCH OF ULTRASONOGRAPHIC PERIPHERAL ARTHRITIS AND ENTHESITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE / M. Uematsu* - T. Okano - K. Inui - Y. Yamada - K. Mandai - Y. Sugikoka - K. Mamoto - T. Koike - H. Nakamura 16 June 2018 * Presenting author

170 168 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE June 2018 SAT0663 A NEW OPERATOR INDIPENDENT AUTOMATIC TOOL FOR ACCURATE IDENTIFICATION OF VERTEBRAL FRAGILITY FRACTURES / F. Conversano - R. Franchini - E. Quarta - P. Pisani - E. Casciaro - D. Lobreglio - M. Muratore* SAT0664 CARTILAGE DAMAGE QUANTITATIVELY ASSESSED BY MRI USING T2 MAPPING IN CCP-POSITIVE RA PATIENTS / N. Renner - A. Kleyer - G. Krönke - D. Simon - J. Rech - G. Schett - G. Welsch - M. L. Pachowsky* SAT0665 SYNOVITIS AS A PREDICTOR OF EROSIONS IN THE HAND OSTEOARTHRITIS / O. Balueva* - A. Sarapulova - O. Teplyakova SAT0666 INFLAMATION BEYOND CLINICAL REMISSION: ULTRASOUND AS A TOOL TO GUIDE US TO REMISSION / P. Estrada* - C. Diaz-Torné - V. Torrente - P. Moya - C. Moragues - D. De La Fuente - S. Ros - J. Ramirez - M. Moreno - E. García - M. Puyol - N. Busquets - A. Ponce - J. De Agustín on behalf of ECOCAT SAT0667 IMPLEMENTATION AND ROLE OF MODERN MUSCULOSKELETAL IMAGING IN RHEUMATOLOGICAL PRACTICE IN EUROPE / P. Mandl* - A. Ciechomska - X. Baraliakos - P. G. Conaghan - M.-A. D Agostino - A. Iagnocco - C. J. van der Laken - M. Ostergaard - L. Terslev - E. Naredo SAT0668 ARTICULAR INVOLVEMENT IN CHRONIC HEPATITIS C INFECTION - A PRELIMINARY ULTRASOUND STUDY / R. A. Ionescu* - L. M. Pana - V. M. Pompilian - A. Voicu - S. Caraiola - D. Ramba - C. R. Baicus - A. Dan SAT MTC-HDP SPECT/CT - A NEW METHOD IN EARLY DIAGNOSIS OF SACROILEITIS / R. A. Hemelein* - Z. Besenyi - A. Bakos - L. Kovács - L. Pávics SAT0670 DYNAMIC THIOL/DISULFIDE HOMEOSTASIS AS A NOVEL OXIDATIVE MARKER IN BEHÇET S DISEASE / S. Can Sandikci* - S. Colak - A. Omma - M. E. Enecik - Z. Ozbalkan - S. Neselioglu - O. Erel SAT0671 INITIAL DEVELOPMENT OF A WHOLE-BODY MAGNETIC RESONANCE IMAGING INFLAMMATION INDEX FOR ACTIVE DISEASE OF PERIPHERAL JOINTS AND ENTHESES IN PATIENTS WITH INFLAMMATORY ARTHRITIS / S. Krabbe* - P. Bird - I. Eshed - V. Foltz - F. Gandjbakhch - D. Glinatsi - J. L. Jaremko - R. G. Lambert - W. P. Maksymowych - A. J. Mathew - S. J. Pedersen - R. Poggenborg - M. S. Stoenoiu - P. G. Conaghan - C. E. Althoff - C. Peterfy - K.-G. Hermann - M. Østergaard on behalf of OMERACT MRI working group SAT0672 IS ULTRASOUND REMISSION ACHIEVABLE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS? / T. Serban* - I. Azzolin - I. Satulu - C. M. Mihai - G. Massazza - M. Bojinca - A. Iagnocco SAT0673 MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / T. J. Bray* - A. Jones - P. Mandl - H. Marzo-Ortega - M. A. Hall-Craggs - P. M. Machado on behalf of British Society of Spondyloarthritis (BRITSpA) SAT0674 THE USE OF QUANTITATIVE MUSCLE ULTRASOUND AS A FOLLOW-UP TOOL IN INFLAMMATORY MYOSITIS AND DUCHENNE MUSCULAR DYSTROPHY IN CHILDREN / W. A. Hassan* - A. E. S. Elbrashy - S. S. Ganeb - D. R. Lasheen - E. A. Mohammady SAT0675 SOLUBLE VASCULAR ADHESION MOLECULE-1 IS OVEREXPRESSED IN PATIENTS WITH VASCULITIS, RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS / W. Laaraj* - M. F. Seidel SAT0676 ULTRASOUND DETECTED INFLAMMATION IN RHEUMATOID ARTHRITIS: ELUCIDATING THE RELATIONSHIP WITH CLINICAL MANIFESTATIONS AT THE WRIST / Y. K. Tan* - R. B. Moorakonda - J. C. Allen Jr - P. G. Conaghan - L. C. Chew - J. Thumboo TOPIC: EPIDEMIOLOGY, RISK FACTORS FOR DISEASE OR DISEASE PROGRESSION Poster tour S14: This poster tour might be risky! Chaiperson(s): Laure Gossec (France), Paul Studenic (Austria) Abstracts N : SAT0677-SAT0686 SAT0677 PREVOTELLA COPRI IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS / D. Alpizar-Rodriguez* - T. R. Lesker - A. Gronow - E. Raemy - C. Lamacchia - D. Courvoisier - C. Gabay - A. Finckh - T. Strowig SAT0678 SEASONALITY OF NEW EARLY INFLAMMATORY ARTHRITIS CASES: PRELIMINARY RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT / F. Kudaeva* - M. Speechley - N. Klar - O. Schieir - S. Bartlett - C. Hitchon - G. Boire - B. Haraoui - E. Keystone - D. Tin - C. Thorne - V. Bykerk - J. Pope on behalf of CATCH investigators SAT0679 CIGARETTE SMOKING AND RISK OF BEHCET S DISEASE: A CASE-CONTROL STUDY / A. Khabbazi* - A. Malekmahdavi SAT0680 THE DEVELOPMENT AND VALIDATION OF INTERSTITIAL LUNG DISEASE PREDICTION MODELS IN THREE INTERNATIONAL MIXED CONNECTIVE TISSUE DISEASE COHORTS: THE NORWEGIAN MCTD COHORT, THE HUNGARIAN MCTD COHORT AND THE MCTD COHORT FROM MINNESOTA, US / S. Reiseter* - P. Ungprasert - R. Gunnarsson - Ø. Molberg - M. B. Lund - T. M. Aaløkken - P. Szodoray - E. Bodolay SAT0681 THE CAUSAL ASSOCIATION BETWEEN CHILDHOOD AND ADULTHOOD BODY MASS INDEX AND OSTEOARTHRITIS: A MENDELIAN RANDOMIZATION STUDY / A. Prats-Uribe* - S. Sayols-Baixeras - A. Fernández-Sanlés - T. Duarte- Salles - J. Logue - R. Elosua - D. Prieto-Alhambra SAT0682 INCIDENCE AND REGIONAL VARIATION OF ANKYLOSING SPONDYLITIS AND SPONDYLOARTHRITIS : A NATIONWIDE COHORT STUDY / A. Nygaard* - P. M. Ljungdalh - M. Iachina - B. Schiøttz-Christensen SAT0683 A NORTH-SOUTH WORLDWIDE GRADIENT IN SYSTEMIC ACTIVITY OF PRIMARY SJÖGREN SYNDROME: INCREASED SEVERE DISEASE IN PATIENTS FROM SOUTHERN COUNTRIES / S. Retamozo* - N. Acar-Denizli - W. Fai Ng - M. Zeher - A. Rasmussen - R. Seror - X. Li - C. Baldini - J.-E. Gottenberg - D. Danda - L. Quartuccio - R. Priori - G. Hernandez-Molina - B. Armagan - A. A. Kruize - S.-K. Kwok - M. Wahren-Herlenius - S. Praprotnik - D. Sene - E. Bartoloni - R. Solans - M. Rischmueller - T. Mandl - Y. Suzuki - D. Isenberg - V. Valim - P. Wiland - G. Nordmark - G. Fraile - H. Bootsma - T. Nakamura - R. Giacomelli - V. Devauchelle-Pensec - B. Hofauer - M. Bombardieri - V. Fernandes Moça Trevisani - D. Hammenfors - S. G. Pasoto - T. A. Gheita - F. Atzeni - J. Morel - C. Vollenveider - P. Brito-Zerón - M. Ramos-Casals * Presenting author

171 SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 / 169 SAT0684 APPENDICITIS AND THE RISK OF NEWLY DIAGNOSED SYSTEMIC SCLEROSIS: A NATIONWIDE, POPULATION- BASED, CASE-CONTROL STUDY IN TAIWAN / H.-H. Chen* - K.-L. Lai - D.-Y. Chen SAT0685 TEMPERATURE AND SMALL PARTICULATE MATTER POLLUTION ARE ASSOCIATED WITH ORGAN SPECIFIC LUPUS FLARES: A SPATIO -TEMPORAL ANALYSIS / G. Stojan* - A. Kvit - F. Curriero - M. Petri SAT0686 ARE MRI-DETECTED EROSIONS IN PATIENTS WITH UNDIFFERENTIATED ARTHRITIS PREDICTIVE FOR THE DEVELOPMENT OF RHEUMATOID ARTHRITIS? A LARGE LONGITUDINAL STUDY / D. M. Boeters* - A. C. Boer - A. H. van der Helm-van Mil SAT0687 SILICONE BREAST IMPLANTS AND THE RISK OF AUTOIMMUNE DISEASES: REAL WORLD ANALYSIS / A. Watad* - V. Rosenberg - S. Tiosano - J. W. Cohen Tervaert - Y. Yavne - Y. Shoenfeld - V. Shalev - G. Chodick - H. Amital SAT0688 PROGRESSIVE DRIFT OF PATIENT POPULATIONS IN RHEUMATOID ARTHRITIS CLINICAL TRIALS OVER TIME / A. Kerschbaumer* - B. Bierbaumer - J. S. Smolen - D. Aletaha SAT0689 THYMECTOMY IN PATIENTS WITH MYASTHENIA GRAVIS AND THE RISK OF AUTOIMMUNE RHEUMATIC DISEASES: A NATIONWIDE COHORT STUDY / C. C. Chang* - J.-H. Chen SAT0690 THE ASSOCIATION BETWEEN SARCOIDOSIS AND ISCHEMIC HEART DISEASE - A BIG DATA ANALYSIS / D. Katz* - S. Tiosano - D. Comaneshter - A. D. Cohen - H. Amital SAT0691 ADHERENCE TO DISEASE-MODIFYING DRUGS IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES: SEVERAL QUESTIONNAIRES, DIVERSE PATIENT CHARACTERISTICS AND SOME EFFICACIOUS INTERVENTIONS - A SYSTEMATIC LITERATURE REVIEW / D. Puyraimond-Zemmour* - X. Romand - M. Lavielle - A. Molto - P. Gaudin - M. Soubrier - C. Beauvais - D. Wendling - E. Senbel - S. Pouplin - R.-M. Flipo - C. Richez - A. Saraux - L. Gutermann - M. Mézière - M. Dougados - L. Gossec SAT0692 BREASTFEEDING IS NOT ASSOCIATED WITH ANTI-CITRULLINATED ANTIBODIES DEVELOPMENT IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS / D. Alpizar-Rodriguez* - M. Ruediger - B. Möller - J. Dudler - A. Ciurea - P. Zufferey - D. Kyburz - U. Walker - I. von Mühlenen - P. Roux-Lombard - C. Lamacchia - C. Gabay - A. Finckh SAT0693 GENETIC POLYMORPHISMS AND EFFICACY OF METOTHREXATE IN RHEUMATOID ARTHRITIS / E. Chamizo* - E. González - C. Carrasco - S. Rojas - J. J. Aznar - P. Dorado - A. Llerena SAT0694 DETERMINANTS OF TRAJECTORIES OF MULTI-SITE PAIN IN KNEE OSTEOARTHRITIS: A 10.7-YEAR PROSPECTIVE STUDY IN OLDER ADULTS / F. Pan* - J. Tian - F. Cicuttini - C. Ding - G. Jones SAT0695 HOSPITALIZATION RATES AMONG PATIENTS WITH PRIMARY SJÖGREN S SYNDROME: A POPULATION-BASED STUDY, / G. Maciel* - L. Servioli - C. Nannini - A. Berti - C. Crowson - S. Achenbach - E. Matteson - D. Cornec SAT0696 ASSOCIATIONS BETWEEN ANTIBIOTICS FOR NON-TUBERCULOUS MYCOBACTERIAL INFECTION AND INCIDENT SJÖGREN S SYNDROME: A NATIONWIDE, POPULATION-BASED CASE-CONTROL STUDY / H.-H. Chen* - W.-C. Chao SAT0697 ASSOCIATION BETWEEN TONSILLITIS AND NEWLY DIAGNOSED ANKYLOSING SPONDYLITIS: A NATIONWIDE, POPULATION-BASED, CASE-CONTROL STUDY / H.-H. Chen* - W.-C. Chao - D.-Y. Chen SAT0698 MORTALITY OF PATIENTS WITH DIAGNOSED RHEUMATOID ARTHRITIS (RA) IN GERMANY 2012: ANALYSIS OF CLAIMS DATA FROM 60 MILLION PEOPLE / I. Haase* - G. Pongratz - O. Sander - M. Schneider - R. Brinks SAT0699 PREDICTION OF CARDIOVASCULAR EVENTS IN RHEUMATOID ARTHRITIS PATIENTS USING A MULTI-BIOMARKER OF DISEASE ACTIVITY / F. Xie - L. Chen - H. Yun - J. R. Curtis* SAT0700 THE RELATIONSHIP BETWEEN MUSCULOSKELTAL PAIN, INFLAMMATION AND DEPRESSION IN MEN / J. McBeth* - M. J. Cook - G. Bartfai - F. Casanueva - M. Maggi - A. Giwercman - D. Vanderschueren - J. Slowikowska-Hilczer - M. Punab - T. W. O Neill SAT0701 PREGNANCY OUTCOME IS IMPROVED AND SIMILAR TO THAT OF THE GENERAL OBSTETRIC POPULATION IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO FOLLOW THE IDEAL CLINICAL PATHWAY BEFORE AND DURING PREGNANCY / L. Andreoli* - A. Bortoluzzi - G. Carrara - V. Ramoni - M. Padovan - M. Govoni - A. Tincani - C. A. Scirè on behalf of RECORD SIR SAT0702 INFLUENCE OF OBESITY AND GENDER ON DRUG EFFECTIVENESS IN RHEUMATOID ARTHRITIS DEPENDS ON THE OUTCOME CONSIDERED / M. Schäfer* - Y. Meissner - J. Kekow - S. Berger - S. Remstedt - A. Strangfeld - J. Listing - A. Zink SAT0703 RACIAL DISPARITIES IN GOUT AND HYPERURICEMIA - A UNITED STATES GENERAL POPULATION STUDY / M. Chen-Xu* - C. Yokose - H. K. Choi SAT0704 COLLECTION OF ANTI-RHEUMATIC MEDICATION DATA FROM BOTH PATIENTS AND RHEUMATOLOGISTS SHOWS STRONG AGREEMENT IN A REAL WORLD CLINICAL COHORT: RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Movahedi* - A. Cesta - X. Li - C. Bombardier on behalf of other OBRI Investigators SAT0705 ASSOCIATION BETWEEN FRACTURE SITES IN PATIENTS WITH A HISTORY OF PARENTAL FRACTURE / M. Dey* - M. Bukhari SAT0706 INCIDENCE OF PSORIATIC ARTHRITIS IN GERMANY: ANALYSIS OF CLAIMS DATA FROM 65 MILLION PEOPLE FROM 2009 TO 2012 / P. Sewerin* - I. Haase - M. Schneider - B. Ostendorf - R. Brinks SAT0707 TRENDS IN THE INCIDENCE OF RHEUMATOID ARTHRITIS IN DENMARK FROM : A NATIONWIDE REGISTER-BASED STUDY / R. L. Cordtz* - P. Højgaard - K. Zobbe - L. Dreyer SAT0708 WILLINGNESS TO PARTICIPATE IN RESEARCH AND REPRESENTATIVENESS OF AN ONLINE HEALTH COMMUNITY AND A PATIENT ORGANISATION POPULATION WITH RHEUMATOID ARTHRITIS / R. Costello* - J. McBeth - W. G. Dixon SAT0709 SUBCLINICAL HEPATITIS C VIRUS INFECTION IN EGYPTIAN PATIENTS WITH RHEUMATOLOGIC DISEASES: A MULTI-CENTER STUDY / S. Mahran* - M. Hassanien - D. A. Nigm - A. Moshrif - M. Hasanein - M. Z. A. Abu Rahma - M. I. Risha - M. A. Hanafy - A. H. Shalaby - M. Abdelkareem - H. Hamoud - S. Ghanem - S. Abd-Elsalam - F. El- Nouby - A. fehr - E. F. Kholef - A. O. B. S. Osman - D. G. Mahran SAT0710 RISK ASSOCIATION FOR ANKYLOSING SPONDYLITIS USING A GENETIC RISK SCORE COMBINING 110 SNPS OF GENOME-WIDE SIGNIFICANCE IN THE POPULATION-BASED HUNT STUDY / S. Rostami* - M. Hoff - M. A. Brown - K. Hveem - O. L. Holmen - V. Videm 16 June 2018 * Presenting author

172 170 / SCIENTIFIC POSTER SESSION III / SATURDAY 16 JUNE 2018 SAT0711 SENSE OF COHERENCE PREDICTS DEVELOPMENT OF CHRONIC WIDESPREAD PAIN OVER TIME / S. Hägerström - S. Bergman* SAT0712 EVALUATION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / T. Gudu* - I. Janta - R. Ionescu SAT0713 INCIDENCE OF EROSIVE INTERPHALANGEAL OA IS STRONGLY ASSOCIATED WITH AGE, FEMALE GENDER, WHITE RACE, AND PRE-EXISTING HAND OA: DATA FROM THE OSTEOARTHRITIS INITIATIVE / T. McAlindon* - M. Roberts - L. Schaefer - J. Driban - I. K. Haugen - S. E. Smith - J. Duryea - C. Eaton SAT0714 IMPACT OF PM10 ON THE BURDEN OF RAYNAUD S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS / T. Schioppo* - V. Bollati - S. Iodice - O. De Lucia - A. Murgo - F. Ingegnoli SAT0715 RISK FACTORS OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB / Y. Eun* - I. Y. Kim - H. Kim - J. K. Ahn - E.-J. Park - J. Hwang - H. Jeong - J. Y. Chai - H.-S. Cha - E.-M. Koh - J. Lee 16 June 2018 * Presenting author

173 HPR Programme Health Professionals in Rheumatology HEALTH PROFESSIONALS / WEDNESDAY 13 JUNE 2018 / :15-17:45 Amtrium Joint session HPR/PARE New drugs - new perspectives: clinical and regulatory issues concerning biosimilars Learning objectives: To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars Yvonne van Eijk-Hustings (Netherlands) Dieter Wiek (Germany) Tore K. Kvien (Norway) 16:20 Abstract N SP0024 An up-date on biosimilars WEDNESDAY, 13 JUNE :00-14:00 Hall 7.1 EULAR 2018 Opening Plenary session 14:15-15:45 Amtrium Health Professionals session Health Professionals Welcome session Learning objectives: To give attendees a view into the HPR 'machinery' Tanja Stamm (Austria) Wilfred F. Peter (Netherlands) Rikke H. Moe (Norway) 14:20 Abstract N SP0014 Welcome to Amsterdam by the new chair of ESCHPR Mwidimi Ndosi (United Kingdom) 14:38 What is a EULAR Study Group? Example from the study group on patient education (STOPE) Kate Betteridge (United Kingdom) 14:56 Abstract N SP0015 What s new? Presentation of the HPR Newsletter Annette de Thurah (Denmark) 15:14 Places to go and things to see during the congress Faculty 15:32 Q&A 15:45-16:15 Exhibition and EULAR Village (Hall 1) Coffee break Tracy French (United Kingdom) 16:38 Abstract N SP0025 Shared decision making in switching to biosimilars Franz König (Austria) 16:56 Statistical and regulatory aspects of biosimilars Dieter Wiek (Germany) 17:14 Abstract N SP0026 Biosimilars - the changing views of EULAR's Member Organisations of PARE M. Cvancarova Småstuen (Norway) 17:32 M. Brandvold, R. Andenæs Abstract N OP0070-HPR Is patients satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey 18:15-19:45 Amtrium Health Professionals session Delay in treatment and the role of health professionals Learning objectives: To provide awareness of different types of treatment delay in RMDs To provide knowledge of reasons and present possible interventions to address patient delay Jette Primdahl (Denmark) Erika Mosor (Austria) Rebecca Stack (United Kingdom) 18:20 Abstract N SP0030 Reasons for delay in help seeking at the onset of symptoms 13 June 2018

174 172 / HEALTH PROFESSIONALS / WEDNESDAY 13 JUNE AND THURSDAY 14 JUNE June 2018 Kristien van der Elst (Belgium) 18:38 Abstract N SP0031 Are illness perception and coping style associated with patient delay? Souzi Makri (Belgium) 18:56 Abstract N SP0032 The patients perspective on delay in treatment Bruno Fautrel (France) 19:14 Abstract N SP0033 Delay in treatment from the GP perspective S. J. Bartlett (Canada) 19:32 O. Schieir, M.-F. Valois, C. Hitchon, G. Boire, B. Haraoui, C. Thorne, D. Tin, J. Pope, E. C. Keystone, V. P. Bykerk on behalf of CATCH (Canadian Early Arthritis Cohort) Investigators Abstract N OP0106 Who is not reaching remission in early RA and why? Predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment 20:00-22:00 Strand Zuid Networking Platform THURSDAY, 14 JUNE :15-11:45 Amtrium HPR Abstract session Singing power to the people Thea Vliet Vlieland (Netherlands) Agnes Kocher (Switzerland) M. Røisland (Norway) 10:20 M. Rygg, E. B. Nordal, A. M. Selvaag Abstract N OP0157-HPR Agreement between JIA patients and parents on disease perception analysed by the Norwegian version of the JAMAR questionnaire R. Zuidema (Netherlands) 10:30 B. van Gaal, I. Meek, E. van den Ende, S. van Dulmen, J. Fransen, R. Nijhuis Abstract N OP0158-HPR Effectiveness of an e-health tailored self-management program for patients with rheumatoid arthritis: an explorative RCT S. Rongen-van Dartel (Netherlands) 10:40 W. Müskens, F. Lamers-Karnebeek, B. Radovits-Persijn, E. Denissen-Cranenburg, C. Vogel, F. Hoeks-van Dinther, A. Wennemers, P. van Riel Abstract N OP0159-HPR Reumanet Bernhoven: introduction and evaluation of an online self-management tool and personal health environment for patients with rheumatoid arthritis (RA) E. Santos (Portugal) 10:50 C. Duarte, R. Ferreira, A. M. Pinto, R. Geenen, J. A. P. da Silva on behalf of Promoting happiness through excellence of care Abstract N OP0160-HPR Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modeling approach S. Halls (United Kingdom) 11:00 E. Dures, S. Hewlett, S. Ryan, R. Jenkins, J. van Tonder Abstract N OP0161-HPR The development of self-management training for innovative departments (STRIDE): a skills-training programme for rheumatology teams to enhance support for self-management F. Pérez-Ruiz (Spain) 11:10 A. So, P. Kandaswamy, R. Karra, K. Kelton, S. Perk, T. Bardin Abstract N OP0162-HPR Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials Y. Prior (United Kingdom) 11:20 L. Sammut, C. Vasilica on behalf of the MSKHUB Patient and Public Research Advisory Group (PRAG) and the MSKHUB Health Professionals Reference Group (HPRG) Abstract N OP0163-HPR Development of an online self-management platform for people with rheumatic and musculoskeletal conditions (mskhub.com) A. Moltó (France) 11:30 A. Etchieto, S. Poiraudeau, L. Gossec, P. Claudepierre, M. Soubrier, F. Fayet, D. Wendllng, P. Gaudin, E. Dernis, S. Guis, S. Pouplin, A. Ruyssen-Witrand, M. Dougados Abstract N OP0164-HPR Impact of a nurse-led program of patient self-assessment and self-management axial spondyloarthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDSPA) 11:45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 11:50-13:30 Poster area Guided poster tour The HPR guided poster tour is taking place during the official poster viewing. For details on the tour refer to page 177. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour.

175 HEALTH PROFESSIONALS / THURSDAY 14 JUNE 2018 / :30-15:00 Amtrium Health Professionals session Sustainable healthcare in rheumatology and the role of health professionals Learning objectives: To describe how integrated care in rheumatology contributes to sustainable healthcare To provide and overview of the roles of various members of the integrated healthcare team To discuss barriers and challenges towards expanding the role of integrated care Annette de Thurah (Denmark) Sandra Mintz (United States) Hubertus J.M. Vrijhoef (Netherlands) 13:35 Abstract N SP0055 How can integrated healthcare contribute to sustainable healthcare in rheumatology? Yvonne van Eijk-Hustings (Netherlands) 14:00 Sustainable healthcare, and the role of the nurses Barbara Slusher (United States) 14:25 Abstract N SP0056 Sustainable healthcare - it takes a village A.-M. T. Sweeney (Denmark) 14:50 O. R. Madsen, L. Dreyer, A. Hansen Abstract N OP0206-HPR Outpatient follow up on demand for patients with rheumatoid arthritis - a two-year randomised controlled trial Karen Hambly (United Kingdom) 16:11 Abstract N SP0078 The patient perspective on physical activity and work participation in RMDs Maura D. Iversen (United States) 16:29 Abstract N SP0079 Major achievements and future challenges in physical activity T. Thomsen (Denmark) 16:47 M. Aadahl, N. Beyer, M. L. Hetland, K. B. Løppenthin, J. Midtgaard, R. Christensen, S. M. Nielsen, M. Østergaard, P. Jennum, B. A. Esbensen Abstract N OP0219-HPR The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial 15:30-17:00 E106/E107 EULAR Projects in Health Professionals The EULAR Exercise Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis Learning objectives: To learn about the work of the task force that developed the EULAR Recommendations for physical activity in inflammatory and osteoarthritis, i.e. the process and its results 15:00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 Amtrium Health Professionals session It s your move: promoting physical activity in people with RMDs Learning objectives: To understand current, state-of-the-art physical activity in RMDs Els van den Ende (Netherlands) Thomas Davergne (France) Keegan Knittle (Finland) 15:35 Abstract N SP0077 New insights into strategies to effectively promote physical activity Zhivko Yankov (Bulgaria) 15:53 Patient s perspective on physical activity: good reasons for being active Bente Appel Esbensen (Denmark) Thijs Swinnen (Belgium) Maura D. Iversen (United States) 15:35 Abstract N SP0084 Why physical activity and exercise works Anne-Kathrin Rausch Osthoff (Switzerland) 15:53 Abstract N SP0085 The evidence for physical activity in inflammatory arthritis and osteoarthritis Karin Niedermann (Switzerland) 16:11 Abstract N SP0086 The development and purpose of the EULAR Recommendations for physical activity in people with inflammatory arthritis and osteoarthritis Michael Nurmohamed (Netherlands) 16:29 Abstract N SP0087 How to deal with cardiovascular risk factors for physical activity and implement the PA recommendations in the rheumatologic practice 14 June 2018

176 174 / HEALTH PROFESSIONALS / THURSDAY 14 JUNE AND FRIDAY 15 JUNE June 2018 S. Pettersson (Sweden) 16:47 I. Demmelmaier, B. Nordgren, A. B. Dufour, C. H. Opava Abstract N OP0222-HPR Physical capacity contributes marginally in explaining variations of fatigue in persons moderately affected by rheumatoid arthritis FRIDAY, 15 JUNE :15-11:45 Amtrium Abstract session HPR Supporting self-management Mwidimi Ndosi (United Kingdom) Fernando Estévez-López (Spain) G. Fernandes (Brazil) 10:20 F. Jennings, M. Cabral, R. Santos, J. Natour Abstract N OP0274-HPR A functional exercise programme improves pain and health related quality of life in patients with fibromyalgia: a randomised controlled trial S. G. Mckenna (Ireland) 10:30 M. P. Herring, A. Donnelly, A. Fraser, L. Comber, N. Kennedy Abstract N OP0275-HPR The effects of exercise on depressive and anxiety symptoms in rheumatoid arthritis: a systematic review and meta-analysis I. Ahlstrand (Sweden) 10:40 P. Wagman, C. Håkansson, M. Björk Abstract N OP0276-HPR Occupational balance and its relation to performance of valued life activities in persons with rheumatoid arthritis in working age M. C. Vassalli (Brazil) 10:50 A. Jones, J. Natour, R. Silva Abstract N OP0277-HPR Evaluation of the effectiveness of a progressive resistance training program for patients with fibromyalgia: a randomised controlled trial S. A. Just (Denmark) 11:00 F. Humby, H. Lindegaard, L. Meric de Bellefon, P. Durez, E. Vieira-Sousa, R. Teixeira, M. Stoenoiu, J. Werlinrud, S. Rosmark, P. V. Larsen, C. Pitzalis, A. Filer Abstract N OP0278-HPR Patient reported outcomes and safety in patients undergoing synovial biopsy: comparison of arthroscopic, ultrasound-guided portal-forceps and ultrasound-guided needle biopsy techniques, in five centres across Europe M. Martin (United Kingdom) 11:10 A. Gilbert, C. Jeffries Abstract N OP0279-HPR A national survey of the utilisation and experience of hydrotherapy in the management of axial spondyloarthritis: the patients perspective A. Bremander (Sweden) 11:20 K. Malm, M. L. Andersson on behalf of the BARFOT study group Abstract N OP0280-HPR Physical activity in established RA and variables associated with physical activity maintenance over a seven year period M. van Heuckelum (Netherlands) 11:30 E. Mathijssen, M. Vervloet, A. Boonen, A. Pasma, R. Hebing, H. Vonkeman, M. Wenink, B. van den Bemt, L. van Dijk Abstract N OP0281-HPR Preferences of patients with rheumatoid arthritis regarding disease modifying anti-rheumatic drugs: a discrete choice experiment 11:45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 11:50-13:30 Poster area Guided poster tour The HPR guided poster tour is taking place during the official poster viewing. For details on the tour refer to page 180. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour. 13:30-15:00 Amtrium Health Professionals session New approaches in measuring what matters to patients Learning objectives: To be able to describe and discuss new quantitative approaches in the area of measuring what matters to patients Anthony Redmond (United Kingdom) Valentin Ritschl (Austria) Valentin Ritschl (Austria) 13:35 Abstract N SP0107 What can Bayes statistics contribute to measuring patient perspectives?

177 HEALTH PROFESSIONALS / FRIDAY 15 JUNE AND SATURDAY 16 JUNE 2018 / 175 Hilary Bekker (United Kingdom) 13:55 Abstract N SP0108 Decision aid tools Mara Kaldeweide (Germany) 14:15 Patient s view on measuring what matters to patients J. Primdahl (Denmark) 14:35 D. V. Jensen, R. H. Meincke, K. V. Jensen, C. Ziegler, S. W. Nielsen, L. Dalsgaard, M. Kildemand, M. L. Hetland, B. A. Esbensen Abstract N OP0328-HPR Patients views on routine collection of patient-reported outcomes in rheumatology care - a DANBIO focus group study M. Oude Voshaar (Netherlands) 14:45 Z. Das Gupta, M. A. van de Laar, H. E. Vonkeman on behalf of International Consortium for Health Outcome Measurement (ICHOM) working group for inflammatory arthritis minuscules Abstract N OP0329-HPR Outcomes that matter to people living with inflammatory arthritis; a global standard set, developed by the international consortium for health outcome measurement (ICHOM) working group for inflammatory arthritis 15:00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 Amtrium Health Professionals session Navigating the world of digital health Learning objectives: To discuss the challenges for patients to seek, find and appraise health information from electronic resources Ann Bremander (Sweden) Mari Klokkerud (Norway) Elizabeth Heron (United Kingdom) 15:35 Abstract N SP0131 Digital health literacy, state of the art Constance Drossaert (Netherlands) 15:53 Abstract N SP0132 Measuring digital health literacy Maria Suarez-Almazor (United States) 16:11 Multi-media patient education based on entertainment education delivered to patients with low HL Line Raunsbaek - Knudsen (Denmark) 16:29 Abstract N SP0133 Patient experiences from a tele-health intervention on disease activity in RA. The keen and the reluctant patient M. Ferwerda (Netherlands) 16:47 S. van Beugen, H. van Middendorp, H. Visser, H. Vonkeman, M. Creemers, P. van Riel, W. Kievit, A. Evers Abstract N OP0343-HPR An economic evaluation of a tailored guided internetbased cognitive behavioural intervention for patients with rheumatoid arthritis as an addition to usual care SATURDAY, 16 JUNE :00-10:30 Amtrium Health Professionals session Multi-disciplinary management of complex persistent pain Learning objectives: To be aware of the bio-psychosocial impact of persistent pain from the patient and clinician perspectives To understand how people with complex regional pain syndrome present in clinical practice and how to manage their pain through multidisciplinary interventions To be aware of current and emerging functional rehabilitation strategies for pain management Emma Dures (United Kingdom) Yeliz Prior (United Kingdom) Lone Knudsen (Denmark) 09:05 Abstract N SP0148 Pain: the role of psychology Florian Brunner (Switzerland) 09:23 CRPS - early diagnosis and first therapeutic measures Robyn Connett (United Kingdom) 09:41 Abstract N SP0149 The patient s perspective of living with complex regional pain syndrome Candy McCabe (United Kingdom) 09:59 Abstract N SP0150 Functional rehabilitation for the relief of complex persistent pain A. Hammond (United Kingdom) 10:17 Y. Prior, C. Sutton, S. Cotterill, C. Heal, E. Camacho on behalf of the A-GLOVES research team Abstract N OP0353-HPR The effects of arthritis gloves on hand pain in people with rheumatoid or inflammatory arthritis: a randomised controlled trial (A-GLOVES trial) 10:30-12:00 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and coffee break June 2018

178 176 / HEALTH PROFESSIONALS / SATURDAY 16 JUNE June :00-13:30 Amtrium Health Professionals session How do you sleep? Learning objectives: To provide overview of normal sleep patterns; sleep physiology, sleep and RMD; sleep quality; measuring sleep (outcome measure); treatment sleep To present clinical research on sleep issues in RMD Joke Vriezekolk (Netherlands) Lurdes Barbosa (Portugal) Bente Appel Esbensen (Denmark) 12:05 Abstract N SP0170 Re-evaluate life when broken sleep has a negative effect on inflammatory arthritis Katie Hackett (United Kingdom) 12:23 Abstract N SP0171 Sleep disturbances in primary Sjögren s syndrome: evidence from the literature, patient sleep diaries and a qualitative focus group study Sean.G. McKenna (Ireland) 12:41 Abstract N SP0172 What effect does exercise have on sleep in RMDs? Poul J. Jennum (Denmark) 12:59 How did you sleep last night? J. S. Malmborg (Sweden) 13:17 A. Bremander, M. C. Olsson, A.-C. Bergman, S. Brorsson, S. Bergman Abstract N OP0361-HPR Sleeping problems and anxiety is associated to chronic multisite musculoskeletal pain in Swedish high school students 12:00-13:30 PARE Room Joint session PARE/HPR Work and rehabilitation - key priorities for people with RMDs Learning objectives: To explore the current developments at EU level and the impact on member states To explore the impact of work rehabilitation on the quality of life and on employment To show the value of early intervention, prevention and better management of RMDs Tanja Stamm (Austria) Elsa Mateus (Portugal) Gerlinde Bendzuck (Germany) 12:05 Abstract N SP0176 It works?! Employment support for people with RMDs Erika Mosor (Austria) 12:25 Abstract N SP0177 Quality of life at the workplace - how early interventions of health professionals can support people with RMDs Sarah Copsey (Spain) 12:45 Abstract N SP0178 The contribution of occupational safety and health to working with RMDs M. Klokkerud (Norway) 13:05 E. Hasselknippe, A. Rønningen, H. Haveråen, A.-L. Sand-Svartrud Abstract N OP0364-PARE Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study M. Bezzant (United Kingdom) 13:15 A. Bosworth, L. Lunt, S. Verstappen Abstract N OP0365-PARE Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work 13:45-14:45 Amtrium Highlight session HPR Highlight session Yeliz Prior (United Kingdom) Rikke H. Moe (Norway) Fernando Estévez-López (Spain) 13:50 Abstract N SP0181 Highlights from the Health Professionals in Rheumatology sessions Iain B. McInnes (United Kingdom) 14:08 Highlights from the scientific programme Trond Haugmark (Norway) 14:26 Abstract N SP0182 Highlights from the PARE programme

179 HEALTH PROFESSIONALS POSTER TOURS / THURSDAY 14 JUNE 2018 / 177 HPR Guided Poster Tours & Posters Health Professionals in Rheumatology Thursday, 14 June 2018 Poster area Poster viewing 11:45-13:30 Guided poster tours 11:50-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. Poster tour T14: Winds of change Annette de Thurah (Denmark), Anne-Kathrin Rausch Osthoff (Switzerland) Abstracts N : THU0710-HPR-THU0719-HPR THU0710-HPR QUALITIES OF PARTICIPATION AS DESCRIBED BY PEOPLE WITH EARLY RA IN WORKING AGE / A. Sverker* - I. Thyberg - E. Valtersson - M. Björk - G. Östlund - S. Hjalmarsson THU0711-HPR WIDESPREAD PAIN IN AXIAL SPONDYLOARTHRITIS: CLINICAL IMPORTANCE AND GENDER DIFFERENCES / T. W. Swinnen* - W. Dankaerts - R. Westhovens - K. de Vlam THU0712-HPR TRAJECTORIES OF PAIN AND PHYSICAL FUNCTION IN PATIENTS WITH SYMPTOMATIC KNEE AND HIP OSTEOARTHRITIS: RESULTS FROM THE FRENCH POPULATION-BASED KHOALA COHORT / M. Wieczorek - C. Rotonda - F. Guillemin - A.-C. Rat* THU0713-HPR BEHAVIOUR CHANGE INTERVENTIONS TARGETING PHYSICAL ACTIVITY IN ADULTS WITH FIBROMYALGIA SYNDROME: A SYSTEMATIC REVIEW / T. O Dwyer* - L. Durcan - S. Maguire - D. Mockler - F. Wilson THU0714-HPR INTERPROFESSIONAL COLLABORATION IN RHEUMATOLOGY REHABILITATION - THE CLASH BETWEEN IDEOLOGY AND PRACTICE / T. M. Kristiansen* - M. H. Persson - M. Stauner - J. Primdahl THU0715-HPR STRATIFIED EXERCISE THERAPY BY PHYSICAL THERAPISTS IN PRIMARY CARE IS FEASIBLE IN PATIENTS WITH KNEE OSTEOARTHRITIS / J. Knoop* - M. van der Leeden - M. van der Esch - M. de Rooij - W. F. Peter - K. L. Bennell - M. P. Steultjens - A. Hakkinen - L. D. Roorda - W. F. Lems - J. Dekker THU0716-HPR THE IMPACT OF EXERCISE ON SLEEP IN PEOPLE WITH RHEUMATOID ARTHRITIS: A PILOT RANDOMISED CONTROLLED TRIAL / S. G. Mckenna* - A. Donnelly - B. Appel Esbensen - L. Comber - W. L. Ng - A. Maqsood - A. Fraser - N. Kennedy THU0717-HPR IMPAIRED MUSCLE FUNCTION AND SHOULDER-ARM MOVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS / H. Pettersson* - C. Boström - F. Bringby - R. Walle-Hansen - L. Jacobsson - E. Svenungsson - A. Nordin - H. Alexanderson THU0718-HPR THE PSYCHOSOCIAL IMPACT OF JOINT HYPERMOBILITY SYNDROME AND EHLERS-DANLOS SYNDROME (HYPERMOBILITY TYPE): A QUALITATIVE INTERVIEW STUDY / S. E. Bennett* - S. Palmer - N. Walsh - T. Moss THU0719-HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: ROOM FOR IMPROVEMENT? / J. K. Stöcker* - J. Spierings - C. H. M. van den Ende - M. C. Vonk on behalf of ARCH study group TOPIC: HPR INTERVENTIONS (EDUCATIONAL, PHYSICAL, SOCIAL AND PSYCHOLOGICAL) THU0720-HPR FACTORS ASSOCIATED WITH POOR SLEEP QUALITY IN PATIENTS WITH CHRONIC WIDESPREAD PAIN: RESULTS FROM THE AMSTERDAM PAIN COHORT / A. de Rooij* - M. van der Leeden - L. D. Roorda - M. Rinkema - W. Beuving - J. Dekker THU0721-HPR THE EFFECTS OF UPPER AND LOWER LIMB EXERCISE ON THE MICROVASCULAR REACTIVITY IN SYSTEMIC SCLEROSIS PATIENTS / A. M. Mitropoulos* - A. Gumber - H. Crank - M. Akil - M. Klonizakis THU0722-HPR PHYSICAL THERAPY IS EFFECTIVE IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RANDOMISED CONTROLLED TRIAL / A. Ünal Enginar* - H. Uğurlu THU0723-HPR NICE GUIDANCE ON SPONDYLOARTHRITIS: RECOMMENDATIONS SUPPORTING RECOGNITION AND REFERRAL BY PHYSIOTHERAPISTS & PODIATRISTS / C. McCrum* THU0724-HPR INVESTIGATION OF IMMEDIATE EFFECT OF CERVICAL STABILIZATION EXERCISES ON PROPRIOCEPTION IN PATIENTS WITH NECK PAIN / E. Tonga* - T. Özen - E. Timurtaş - G. M. Polat THU0725-HPR EULAR POINTS TO CONSIDER/RECOMMENDATIONS FOR THE HEALTH PROFESSIONALS PREVENTION AND MANAGEMENT OF OSTEOPOROTIC FRACTURES / E. Hurkmans* - N. Wilson - T. Stamm - J. Adams on behalf of task force group HP management osteoporotic fractures THU0726-HPR ADHERENCE TO BIOLOGICAL THERAPY IN CHRONIC INFLAMMATORY RHEUMATISM: RESULTS OF A RETROSPECTIVE STUDY IN AUVERGNE, FRANCE / F. Fayet* - M. R. Rodere - C. Savel - B. Pereira - M. Soubrier - M. Couderc THU0727-HPR COMPARISON OF KINESIO TAPE APPLICATION AND MANUAL LYMPHATIC DRAINAGE ON LOWER EXTREMITY EDEMA AND FUNCTIONS AFTER TOTAL KNEE ARTHROPLASTY / H. Guney Deniz* - G. I. Kinikli - S. Onal - C. Sevinc - O. Caglar - I. Yuksel THU0728-HPR A MIXED METHODS STUDY OF A GROUP PHYSIOTHERAPY PROGRAMME INCORPORATING EXERCISE AND EDUCATION IN FIBROMYALGIA PATIENTS / J. Parreira* - C. Caeiro - R. Fernandes - E. Cruz THU0729-HPR PATIENT WITH RHEUMATOID ARTHRITIS ARE STILL NOT SUFFICIENTLY PHYSICAL ACTIVE. TIME FOR A PERSONALISED PHYSICAL ACTIVITY PROGRAMME! / J. Weijers* - S. Rongen-van Dartel - P. van Riel * Presenting author 14 June 2018

180 178 / HEALTH PROFESSIONALS POSTERS / THURSDAY 14 JUNE AND FRIDAY 15 JUNE June 2018 THU0730-HPR A SYSTEMATIC REVIEW OF ONLINE INTERVENTIONS FOR ADDRESSING PSYCHOLOGICAL DISTRESS IN RHEUMATOID ARTHRITIS AND OTHER LONG-TERM CONDITIONS / K. Fishpool* - B. Jones - S. Hewlett - M. Ndosi THU0731-HPR THE ABDOMINAL HYPOPRESSIVE TECHNIQUE CAN BE USED TO TREAT LOW BACK PAIN? / L. Soriano - L. Carmona - J. B. Negrón* THU0732-HPR INDIVIDUAL RESPONDER ANALYSIS OF THE EFFECTIVENESS OF MANUAL THERAPY AND EXERCISE VERSUS USUAL CARE IN PATIENTS WITH CHRONIC NONSPECIFIC NECK PAIN: PRELIMINARY RESULTS OF A RANDOMISED CONTROLLED TRIAL / L. A. Domingues* - F. M. Pimentel-Santos - E. B. Cruz - J. C. Branco THU0733-HPR EFFECT OF CUSTOM-MADE FOOT ORTHOSES VERSUS PLACEBO IN PATIENTS WITH RHEUMATOID ARTHRITIS: RANDOMISED CLINICAL TRIAL / M. Reina-Bueno* - P. V. Munuera-Martínez - C. Vázquez-Bautista - S. Pérez-García - C. Rosende-Bautista THU0734-HPR NOVEL EXPERIENCE EQUIPMENT FOR RHEUMATOID HAND-FINGERS / M. Kusumoto* - S. Tsuji - M. Toshiharu - Y. Kushimoto - N. Ise - N. Yoshida - S. Kawai - T. Kyrosawa - E. Oguro - Y. Okita - K. Kuzuya - H. Matsuoka - S. Teshigawara - M. Yoshimura - Y. Harada - T. Noguchi - M. Matsushita - K. Hagio - S. Tsuji - S. Akita - S. Ohshima - J. Hashimoto - Y. Saeki THU0735-HPR HOW RHEUMATOLOGY SPECIALIST NURSE DETECTS SMOKING HABIT IN RHEUMATOID CHRONIC INFLAMMATORY DISEASE PACIENTS / M. Serra Miralles* - F. Abella - N. Montalà - M. Mateu - A. Palau - M. Conde - L. Roselló THU0736-HPR THE EFFECTIVENESS OF SHORT TRAINING IN PSYCHOLOGICAL SUPPORT FOR NURSES IN RHEUMATIC CARE / M. Fusama* - H. Nakahara - K. Higashi - M. Mori - M. Mabuchi - Y. Sakai - T. Motonaga - T. Takeuchi THU0737-HPR THE EFFECTIVENESS OF RELAXATION EXERCISES ON PAIN, FUNCTIONAL LEVEL AND MUSCLE STRENGTH IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY: A PRELIMINARY RESULTS / M. Eymir* - B. Ünver - V. Karatosun THU0738-HPR COMPARISON OF THE FUNCTIONAL PROFILE OF THE FOOT BETWEEN THE PATIENTS WITH PATELLOFEMORAL OSTEOARTRITIS AND TIBIOFEMORAL OSTEOARTHRITIS / N. B. Sari* - H. Güney Deniz - G. Baltaci on behalf of Hande Guney Deniz, Gul Baltaci THU0739-HPR EFFECTIVE PREVENTION AND MANAGEMENT OF OSTEOPOROTIC FRACTURES: A SYSTEMATIC LITERATURE REVIEW OF NON-PHYSICIAN HEALTH PROFESSIONALS INTERVENTIONS FOR A EULAR POINTS-TO-CONSIDER PROJECT / N. Wilson* - E. Hurkmans - J. Adams - T. Stamm THU0740-HPR DETERMINATION OF EXERCISE BEHAVIOR IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / N. Arman - E. Tarakcı - A. Adrovic - S. Sahin - K. Barut - O. Kasapcopur* on behalf of Cerrahpasa THU0741-HPR MAPPING THE BEHAVIOUR CHANGE TECHNIQUES USED IN A PRACTICE-BASED FIBROMYALGIA SELF- MANAGEMENT PROGRAMME: A QUALITATIVE STUDY / J. Pearson - K. Whale - N. Walsh - S. Derham* - J. Russell - F. Cramp THU0742-HPR HOW TO OPTIMIZE EXERCISE BEHAVIOUR IN AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INTERVENTION MAPPING STUDY / S. Hilberdink* - S. van Weely - F. van der Giesen - M. Nijkamp - N. Lopuhaä - T. Vliet Vlieland THU0743-HPR SUPPORTED SELF-MANAGEMENT INTERVENTIONS FOR FAMILIES AND CHILDREN AGED 4 TO 11 YEARS OLD LIVING WITH ARTHRITIS, ASTHMA AND TYPE ONE DIABETES: AN INTEGRATIVE REVIEW / S. R. Stones* on behalf of ismart research group THU0744-HPR EFFECTIVENESS OF PROFIBRO MOBILE APP ON QUALITY OF LIFE, SYMPTOMS AND SELF-CARE AGENCY IN PATIENTS WITH FIBROMYALGIA: A RANDOMISED, SINGLE-BLIND TRIAL / S. L. K. Yuan* - A. P. Marques THU0745-HPR USE OF WEARABLE ACTIVITY TRACKERS TO IMPROVE PHYSICAL ACTIVITY BEHAVIOR IN RHEUMATIC CONDITIONS - A SYSTEMATIC REVIEW / T. Davergne* - A. Pallot - L. Gossec - B. Fautrel THU0746-HPR EFFICACY OF SURGICAL TREATMENTS FOR PAIN ASSOCIATED WITH TRAPEZIOMETACARPAL (THUMB BASE) OSTEOARTHRITIS: A SYSTEMATIC REVIEW / T. Hamasaki* - S. Laprise - P. G. Harris - D. Ziegler - H. T. V. Zomahoun - N. J. Bureau - N. Gaudreault - M. Choinière THU0747-HPR THE EFFECT OF CLINICAL PILATES EXERCISES ON DISEASE SPECIFIC-INDICES, CORE STABILIZATION AND BALANCE IN PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Acar* - B. Gürpınar - G. Can - F. Önen - N. Özdemir THU0748-HPR EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS / Y. C. Lim* - W. G. Teo - M. N. Eng - H. M. Cheen - X. Y. Tay - S. I. Yeo - T. G. Lim Friday, 15 June 2018 Poster area Poster viewing 11:45-13:30 Guided poster tours 11:50-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. TOPIC: HPR PATIENTS PERSPECTIVES, FUNCTIONING AND HEALTH (DESCRIPTIVE: QUALITATIVE OR QUANTITATIVE) FRI0702-HPR TREATMENT SATISFACTION IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / A. Tollisen* - A. M. Selvaag - T. Ingebrigtsen - A. Aasland - A. Lerdal - B. Flatø FRI0703-HPR EVALUATION OF AN INDIVIDUAL TARGETED INTERVENTION WITH THE PURPOSE OF REDUCING SEDENTARY TIME IN PEOPLE WITH RHEUMATOID ARTHRITIS - A MIXED METHODS STUDY BASED ON QUESTIONNAIRES AND FOCUS GROUP INTERVIEWS / B. A. Esbensen* - T. Thomsen - M. R. Petersen - M. Aadahl * Presenting author

181 HEALTH PROFESSIONALS POSTERS / FRIDAY 15 JUNE 2018 / 179 FRI0704-HPR SESAME QUIZ: A PLAYFUL ONLINE QUESTIONNAIRE TO ASSESS PATIENTS KNOWLEDGE ABOUT SJÖGREN S SYNDROME / C. Ménage-Anjuère* - R. Belkhir - E. Bergé - A. Decottignies - A. Rieutord - X. Mariette - R. Seror FRI0705-HPR COMPARISON OF PAIN BEHAVIOR OF INDIVIDUALS WITH DIFFERENT RHEUMATIC DISEASE / E. Ünal* - G. Arın - N. B. Karaca - S. Öksüz - F. B. Oflaz - A. Özçadırcı - Y. Yakut - S. Apraş Bilgen FRI0706-HPR VALUES UNDERLYING DISEASE-MODIFYING ANTIRHEUMATIC DRUG PREFERENCES OF PATIENTS WITH RHEUMATOID ARTHRITIS / E. Mathijssen* - J. Vriezekolk - B. van den Bemt FRI0707-HPR PATIENTS EXPERIENCES OF HEALTH IN EARLY RHEUMATOID ARTHRITIS - A QUALITATIVE STUDY / E. Landgren* - A. Bremander - E. Lindqvist - K. van der Elst - I. Larsson FRI0708-HPR THE USE OF TECHNOLOGY FOR SYMPTOM MEASUREMENT IN RHEUMATOID ARTHRITIS: A QUALITATIVE INVESTIGATION / F. Matcham* - R. Williams - E. Foncel - H.-Y. Tung - S. Norton - J. Galloway - M. Hotopf FRI0709-HPR LEVELS OF SATISFACTION WITH PSORIATIC ARTHRITIS (PSA) TREATMENT AND ASSOCIATED ALIGNMENT BETWEEN RHEUMATOLOGISTS AND THEIR PATIENTS ACROSS LATIN AMERICA / F. Zazzetti* - E. R. Soriano - D. Rocio Gil - J. Maldonado cocco - D. Vega Morales - I. Alves Pereira - G. Guerra - W. Bautista Molano - J. C. Cassola - V. Azevedo - L. M. Aldunate - S. Lobosco FRI0710-HPR OBJECTIVE AND SUBJECTIVE MEASURES OF PHYSICAL FUNCTIONING IN WOMEN WITH FIBROMYALGIA: WHAT TYPE OF MEASURE IS ASSOCIATED MOST CLEARLY WITH SUBJECTIVE WELL-BEING? THE AL-ÁNDALUS PROJECT / F. Estevez-Lopez* - F. M. Acosta - P. Acosta-Manzano - M. Rodriguez-Ayllon - B. Gavilán-Carrera - M. Herrador-Colmenero - A. Carbonell-Baeza - R. Geenen - B. Walitt - D. Munguía-Izquierdo - M. Pulido-Martos FRI0711-HPR KINESIOPHOBIA IN ADULT PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: ASSOCIATION WITH PHYSICAL ACTIVITY, DEPRESSION AND ANXIETY / I. Karanki* - E. I. Günaydın - A. Çetinkaya - S. Saka - M. G. Yavuzer FRI0712-HPR THE EXPERIENCE OF PATIENTS WITH DIFFERENT CHRONIC DISEASES WITH HEALTH CARE. A SURVEY WITH THE IEXPAC INSTRUMENT / J. de Toro* - L. Cea-Calvo - M. L. García-Vivar - L. Pantoja - C. Lerín - S. García-Díaz - M. J. Galindo - I. Marín-Jiménez - M. Mosquera - M. J. Arteaga - D. Orozco-Beltrán FRI0713-HPR THE PATIENTS PERSPECTIVES TOWARDS THE PROVISION OF INFORMATION DURING TRANSITION TO A BIOSIMILAR / J. Kreuk* - A. Twisk - J. Meilink - R. Alblas - W. van der Weele - R. C. Hebing - J. Ruwaard - M. l Ami - Z. Layegh - G. Wolbink FRI0714-HPR THE PATIENT S JOURNEY FROM ONSET OF BACK PAIN TO DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS: RESULTS FROM A QUALITATIVE STUDY / L. Passalent* - L. Soever - K. Bednis - C. Hawke - A. Bidos - J. Bloom - Y. R. Rampersaud - N. Haroon - R. Inman FRI0715-HPR PATIENTS, RELATIVES AND HEALTH PROFESSIONALS VIEWS ON GOALSETTING IN RHEUMATOLOGY REHABILITATION / L. B. Jensen* - T. Mechlenborg Kristiansen - L. Ovens - J. Primdahl FRI0716-HPR ASSESSING THE BURDEN OF TREATED AND UNTREATED OSTEOARTHRITIS PAIN IN EUROPE / M. J. Doane - D. H. Jaffe - E. Dragon - L. Abraham* - L. Viktrup - A. G. Bushmakin - J. C. Cappelleri FRI0717-HPR ASSESSING THE BURDEN OF TREATED AND UNTREATED CHRONIC LOW BACK PAIN IN EUROPE / M. J. Doane - D. H. Jaffe - E. Dragon - L. Abraham* - L. Viktrup - A. G. Bushmakin - J. C. Cappelleri FRI0718-HPR ARE PAIN, ACTIVITY LIMITATIONS AND QUALITY OF LIFE ASSOCIATED WITH OBJECTIVELY MEASURED PHYSICAL ACTIVITY IN PATIENTS WITH END-STAGE OSTEOARTHRITIS OF THE HIP OR KNEE? / C. Leichtenberg - F. van Tol - T. Krom - C. Tilbury - H. Horemans - H. Bussmann - R. Nelissen - M. Gademan* - T. Vliet Vlieland on behalf of the LOAS study group FRI0719-HPR SELF-ASSESSMENT OF QUALITY OF LIFE OF PATIENTS WITH RHEUMATIC DISEASES AND OTHER CHRONIC DISEASES IN THE IEXPAC PROJECT / M. L. García-Vivar* - L. Cea-Calvo - J. de Toro - L. Pantoja - C. Lerín - S. García-Díaz - M. J. Galindo - I. Marín-Jiménez - S. Fernández - Y. Mestre - D. Orozco-Beltrán FRI0720-HPR THE EFFECT OF OVERWEIGHT ON KNEE PROPRIOCEPTION INPATIENTS WITH KNEE PROSTHESIS DUE TO KNEE OSTEOARTHRITIS / M. Eymir* - B. Ünver - V. Karatosun FRI0721-HPR WE ARE IN IT TOGETHER: EXPLORING RHEUMATOLOGY PRACTICE WITH PATIENTS AS RESEARCHER PARTNERS / O. Gjønnes Tvedten* - J. Croker - A. Croker - N. Perry - K. Williams - M. Lawrence FRI0722-HPR POSTURAL PROBLEMS AND PAIN IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / E. Tarakci - N. Arman - S. Sahin - A. Adrovic - K. Barut - O. Kasapcopur* on behalf of CERRAHPASA FRI0723-HPR PHYSICAL ACTIVITY AWARENESS AND PREFERENCES IN RHEUMATIC DISEASES: A QUALITATIVE STUDY / P. Vitalis* - D. Kouvelas - N. Kousouri - I. Lahart - Y. Koutedakis - G. Kitas - G. Metsios FRI0724-HPR DISEASE ACTIVITY AFFECTS FAT MASS INDEX AND FUNCTIONAL CAPACITY OF RA PATIENTS OVER 12 MONTHS / R. C. E. Cavalheiro Do Espírito Santo* - J. Miranda de Souza Silva, - P. Lora - L. Isabel Filippin - R. Machado Xavier FRI0725-HPR UNDERSTANDING THE BURDEN OF RHEUMATOID ARTHRITIS USING QUALITATIVE RESEARCH: WHICH IMPACTS ARE NOT CAPTURED BY PATIENT-REPORTED MEASURES? / Y. Shaw* - C. Zhang - R. Schumacher - D. McDonald - T. A. Simon - K. Michaud 15 June 2018 TOPIC: HPR SERVICE DEVELOPMENTS, INNOVATION AND ECONOMICS IN HEALTHCARE FRI0726-HPR STUDY ON THE EFFICACY OF CURCUMIN THERAPY IN EARLY STAGES OF JUVENILE OLIGOARTHRITIS / C. Ailioaie* - L. M. Ailioaie FRI0727-HPR IMPLEMENTATION OF A MODEL FOR THE MEDICATION RECONCILIATION PROCESS IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. Mendez* - J. Urrego - P. Santos-Moreno FRI0728-HPR COST-REDUCING AND IMPROVING QUALITY OF LIFE IN JUVENILE ARTHRITIS BY BLUE LASER AND ULTRABIOAVAILABLE CURCUMIN / L. M. Ailioaie* - C. Ailioaie FRI0729-HPR RHEUMATOLOGY ADVANCED NURSE PRACTITIONERS TREAT TO TARGET PERSON CENTERED CARE: IRELAND S POLICY FRAMEWORK / P. Minnock* - A.-M. Ryan on behalf of Irish Rheumatology Nursing Forum FRI0730-HPR THE CONCEPT OF PATIENT CENTERED CARE IN SPONDYLOARTHRITIS BASED ON A MULTIDISCIPLINARY MODEL / P. Santos-Moreno* - L. Villarreal - D. Buitrago-Garcia - M. Cabrera * Presenting author

182 180 / HEALTH PROFESSIONALS POSTERS / FRIDAY 15 JUNE 2018 TOPIC: HPR PROFESSIONAL EDUCATION, TRAINING AND COMPETENCIES FRI0731-HPR FRI0732-HPR FRI0733-HPR FRI0734-HPR FRI0735-HPR FRI0736-HPR SWITCH MANAGEMENT BETWEEN SIMILAR BIOLOGICAL MEDICINES, A COMMUNICATION INFORMATION GUIDE FOR NURSES / J. E. Voorneveld-Nieuwenhuis* - L. Moortgat - M. Pavic Nikolic - P. Crombez - B. Oomen on behalf of European Specialist Nurses Organisations (ESNO): representatives of five organisations: Oncology, Diabetes, Dermatology, Rheumatology and Inflammatory Bowel Diseases are involved RHEUMATOLOGY NURSE SPECIALISTS AND CORTICOSTEROID PRESCRIBING - DOES IT CONFORM TO EULAR GUIDELINES / J. Begum* - M. K. Nisar AN INTERACTIVE COURSE ON EXERCISE THERAPY FOR KNEE OSTEOARTHRITIS AND COMORBIDITY: A FEASIBILITY STUDY / M. De Rooij* - M. van der Leeden - M. van der Esch - W. F. Lems - J. Meesters - W. F. Peter - L. D. Roorda - M. Terbraak - T. Vredeveld - T. P. Vliet Vlieland - J. Dekker PHYSICAL ACTIVITY AND AEROBIC CAPACITY ASSESSMENT - A SURVEY AMONG RHEUMATOLOGY HEALTH PROFESSIONALS IN FOUR EUROPEAN COUNTRIES / N. Kennedy* - S. G. McKenna - A. O Neill - B. A. Esbensen - T. Swinnen - B. Nordgren - S. Willemijns - N. Hammer - N. Brodin KNOWLEDGE, CONFIDENCE AND EDUCATIONAL NEEDS OF PRIMARY CARE NURSES ON PATIENT EDUCATION AND CONTINUITY CARE IN RHEUMATIC DISEASES / R. J. O. Ferreira* - A. Marques - I. Barbosa A STUDY AIMING FOR THE IMPLEMENTATION OF THE EULAR RECOMMENDATIONS FOR THE ROLE OF THE NURSE IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS IN CHINA / L. Ma - Y. Liang - S. N. Yu* on behalf of Ying Wang, Susan M Oliver, Yan-ling Chen, Yi Zhao, Yu-qiong Cao, Xue-mei Liu, Zi-yun Zhang, Li-hong Chen, Yi Liu, National Collaborative Group of Rheumatic and Immunological Disease Management Poster tour F15: Bread and butter for clinicians Annette de Thurah (Denmark), Andrea Marques (Portugal) Abstracts N : FRI0737-HPR-FRI June 2018 FRI0737-HPR WOMEN S EXPERIENCES OF COPING WITH CHRONIC WIDESPREAD PAIN - A QUALITATIVE STUDY / K. Aili* - S. Bergman - A. Bremander - E. Haglund - I. Larsson FRI0738-HPR NURSE-LED SCREENING: CHANGES IN CARDIOVASCULAR RISK PROFILE AND ASSOCIATION TO SOCIO- ECONOMIC STATUS IN OUTPATIENTS WITH INFLAMMATORY ARTHRITIS / J. Primdahl* - A. Kjeldgaard - R. D. Christensen - J. Søndergaard - K. Hørslev-Petersen FRI0739-HPR EXPERT RECOMMENDATIONS ON PSYCHOLOGICAL NEEDS OF PATIENTS WITH RHEUMATOID ARTHRITIS / L. León* - M. Redondo - A. Fernández-Nebro - S. Gómez - E. Loza - M. Montoro - R. García-Vicuña - M. Galindo FRI0740-HPR RESPONDING RESILIENTLY TO CHRONIC DISEASE: RHEUMATOID ARTHRITIS PATIENTS DISCOURSE ON COPING STRATEGIES AND CHALLENGES / Y. Shaw* - M. Bradley - A. Dominique - K. Michaud - D. McDonald - T. A. Simon FRI0741-HPR DISCUSSIONS OF LIFESTYLE HABITS AS AN INTEGRAL PART OF CARE MANAGEMENT IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS / K. Malm* - S. Bergman - A. Bremander - I. Larsson - M. L. Andersson on behalf of The BARFOT study group FRI0742-HPR EULAR RECOMMENDATIONS FOR THE ROLE OF THE NURSE IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS: 2018 UPDATE / B. Bech* - J. Primdahl - M. Scholte-Voshaar - H. A. Zangi - A. van Tubergen - Y. van Eijk-Hustings FRI0743-HPR NURSE-LED OUTPATIENT MANAGEMENT FOR IMPROVED TREATMENT OF GIANT CELL ARTERITIS (GCA) AND POLYMYALGIA RHEUMATIC (PMR) IN A RHEUMATOLOGY OUTPATIENT CLINIC / M. T. Poder* - B. A. Esbensen - M. B. T. Pedersen - N. G. Andersen - J. J. Lykkegaard - A. M. Johansen - T. Lundbak - B. Bech FRI0744-HPR THE ASSOCIATION OF LOCAL DISEASE ACTIVITY AND FOREFOOT DEFORMITIES WITH PLANTAR PRESSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND FOREFOOT SYMPTOMS: A CROSS-SECTIONAL STUDY IN THE AMSTERDAM FOOT COHORT / A. Konings-Pijnappels* - M. Tenten-Diepenmaat - R. Dahmen - J. Dekker - J. Twisk - L. Roorda - M. van der Leeden FRI0745-HPR IMPLICIT AND EXPLICIT ATTITUDES AND ASSOCIATIONS OF RHEUMATOID ARTHRITIS PATIENTS TOWARDS CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AS POSSIBLE TARGETS FOR IMPROVING MEDICATION ADHERENCE / M. Van Heuckelum* - E. van den Ende - L. Vandeberg - S. van Dulmen - A. Linn - B. van den Bemt FRI0746 NURSING CONSULTATION VERSUS RHEUMATOLOGIST FOLLOW UP FOR PATIENTS WITH STABLE RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED TRIAL / G. S. K. Kwok* - T. T. Cheung - M. L. M. Tang - C. K. Y. Yuen - H. Y. Chung - W. C. S. Lau * Presenting author

183 HEALTH HEALTH PROFESSIONALS PROFESSIONALS POSTER POSTERS TOUR / WEDNESDAY / SATURDAY JUNE 2018 / 181 Saturday, 16 June 2018 Poster viewing 10:30-12:00 TOPIC: HPR MEASURING HEALTH (DEVELOPMENT AND MEASUREMENT PROPERTIES OF PROS, TESTS, DEVICES) SAT0716-HPR PATIENTS PREFERENCE GOES TO METHOTREXATE AUTOINJECTORS OVER PREFILLED SYRINGES: RESULTS FROM A PHASE III TRIAL, SELFI / A. Saraux* - C. Hudry - E. Zinovieva - H. Herman-Demars on behalf of All ivestigators of SELFi study SAT0717-HPR PSYCHOMETRIC TESTING OF A GERMAN VERSION OF THE EVALUATION OF DAILY ACTIVITY QUESTIONNAIRE IN RHEUMATOID ARTHRITIS / A. Hammond* - K. Niedermann - S. Tyson - A. Tennant SAT0718-HPR ARE THERE SYMPTOMS DISTINGUISHING FIBROMYALGIA FROM CHRONIC PAIN THAT ARE MISSING FROM THE 2016 CRITERIA? / A. W. St John* - K. D. Jones - R. Friend - R. M. Bennett SAT0719-HPR PERFORMANCE-BASED PHYSICAL FUNCTION MEASURE WAS MORE SENSITIVE TO DETECT RESPONDERS THAN SELF-REPORTED MEASURE AFTER A PHYSICAL THERAPY EXERCISE INTERVENTION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / C. Fongen* - S. H. Sveaas - A. Bilberg - E. Pedersen - M. W. Johansen - S. van Weely - K. B. Hagen - H. Dagfinrud SAT0720-HPR MORE PRECISE MEASUREMENTS OF SPINAL MOBILITY WHEN ASSESSED WITH A SENSOR IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS / C. Fongen* - C. H. Franke - D. M. Soldal - V. Berre - J. H. Relbe-Moe - J. Hagfors - A. T. Tveter - N. Østerås - K. B. Hagen SAT0721-HPR IMPROVEMENT IN CLINICAL RESULTS BY ENHANCING ADHERENCE TO A HEALTHCARE MODEL IN RHEUMATOID ARTHRITIS / D. Buitrago-Garcia* - L. Villarreal - F. Rodriguez - I. Mendez - P. Santos-Moreno SAT0722-HPR THE VALIDITY AND TEST-RETEST RELIABILITY OF THE TURKISH PATIENT SPECIFIC FUNCTIONAL SCALE IN CHRONIC NECK PAIN PATIENTS / G. Yalcinkaya* - B. Kara - M. N. Arda SAT0723-HPR COMPARISON OF PHYSICAL ACTIVITY, FATIGUE, HEALTH-RELATED QUALITY OF LIFE, ANXIETY AND DEPRESSION BETWEEN ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS PATIENTS / G. I. Kinikli* - M. E. Yayla - A. Ates - M. Turgay - G. Kinikli SAT0724-HPR TECHNOLOGICAL ASSISTED REHABILITATION FOLLOWING TOTAL KNEE JOINT REPLACEMENT. A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL / H. H. Andersen* SAT0725-HPR COMPARATIVE ANALYSES OF RESPONSIVENESS BETWEEN THE RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) SCORE, OTHER PATIENT REPORTED OUTCOMES AND DISEASE ACTIVITY MEASURES: SECONDARY ANALYSES FROM THE ARCTIC STUDY / K. Holten* - J. Sexton - T. K. Kvien - E. A. Haavardsholm - A.-B. Aga SAT0726-HPR IMPROVEMENT OF HAND FUNCTION, PHYSICAL CAPACITY AND QUALITY OF LIFE OF SYSTEMIC SCLEROSIS PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION / K. R. Costa Pereira* - J. B. Elias - D. A. Moraes - A. L. C. Guimaraes - J. T. Garcia - M. C. Oliveira - V. Leopoldo - A. F. Zombrilli - T. M. Costa - A. B. P. Stracieri - B. P. Simoes - M. C. C. Oliveira SAT0727-HPR CRITERION VALIDITY AND RELIABILITY OF A SUBMAXIMAL TREADMILL TEST IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / K. Risum* - E. Edvardsen - A. M. Selvaag - Ø. Molberg - H. Dagfinrud - H. Sanner SAT0728-HPR EVALUATION OF THE EFFECTIVENESS OF AN EDUCATIONAL PROGRAM IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEES / L. Y. Miura* - A. Jones - C. Brumini - J. Natour SAT0729-HPR FIRST EXPERIENCES WITH ONLINE REMOTE MONITORING IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES / L. Renskers* - S. A. A. Rongen - A. M. P. Huis - P. L. C. M. van Riel SAT0730-HPR DEVELOPMENT OF PSYCHOMETRICALLY EQUIVALENT SHORT FORMS TO MEASURE DISEASE AND TREATMENT ASSOCIATED KNOWLEDGE IN RHEUMATOID ARTHRITIS: APPLICATION OF ITEM RESPONSE THEORY (IRT) / M. Oude Voshaar* - M. de Jonge - L. Renskers - S. Rongen - M. van de Laar - A. Huis - P. Van Riel SAT0731-HPR EARLY POSTOPERATIVE OUTCOMES OF UNILATERAL VERSUS BILATERAL TOTAL KNEE ARTHROPLASTY / M. Eymir* - B. Ünver - V. Karatosun SAT0732-HPR RATING OF PERCEIVED EXERTION IN PATIENTS WITH RHEUMATOID ARTHRITIS - WHICH ARE THE CORRELATES? / N. Brodin* - N. Bobst - C. H. Opava SAT0733-HPR DUTCH RECOMMENDATIONS FOR PHYSICAL THERAPY IN AXIAL SPONDYLOARTRHRITIS (AXSPA) / S. van Weely* - F. van der Giesen - F. van Gaalen - I. van der Horst-Bruinsma - S. Ramiro - A. Weel - N. Lopuhaä - T. Vliet Vlieland SAT0734-HPR CORRELATES OF PAIN AND PREDICTORS OF PAIN RELIEF IN A CONTROLLED RA STUDY IN INDIAN PATIENTS / T. Kianifard* - M. Saluja - S. Samukaddam - A. Chopra SAT0735-HPR SEX DIFFERENCES IN ILLNESS PERCEPTIONS AND SELF-MANAGEMENT IN PATIENTS WITH GOUT / U. Bergsten* - M. Dehlin - E. Klingberg - A. Landgren - L. Jacobsson SAT0736-HPR COMPARISON OF CORE STABILIZATION AND BALANCE IN HEALTHY CONTROLS AND PATIENTS WITH ANKYLOSING SPONDYLITIS / Y. Acar* - G. Can - N. İlçin??? 16 June 2018 * Presenting author

184 182 / HEALTH PROFESSIONALS POSTER TOUR / SATURDAY 16 JUNE 2018 TOPIC: HPR EPIDEMIOLOGY AND PUBLIC HEALTH (INCLUDING PREVENTION) SAT0737-HPR MEASURES OF PHYSICAL ACTIVITY AND FEAR AVOIDANCE IN PEOPLE WITH CHRONIC PAIN / A. Bremander* - E. Haglund - S. Bergman SAT0738-HPR FACTORS ASSOCIATED WITH RISK OF FALLING IN ADULTS WITH KNEE OSTEOARTHRITIS: A CROSS-SECTIONAL STUDY / D. G. Manlapaz* - P. Jayakaran - G. Sole - C. M. Chapple SAT0739-HPR OCCUPATIONAL EXPOSURE TO PESTICIDES INCREASES THE RISK OF RHEUMATOID ARTHRITIS: RESULTS FROM THE MALAYSIAN POPULATION-BASED CASE-CONTROL STUDY / C. L. Too - L. K. Tan - A. F. Nurul Aain - I. S. Lau* - M. L. Nor Asiah - S. Salsabil - H. Heselynn - S. Nor Shuhaila - S. Wahinuddin - S. C. Gun - B. Eashwary - M. S. Mohd Shahrir - M. Ainon - R. Azmillah - O. Muhaini - B. Camilla - L. Padyukov - L. Alfredsson - L. Klareskog - M. L. Shahnaz SAT0740-HPR PARITY AND THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS: EVIDENCE FROM THE MALAYSIAN EPIDEMIOLOGICAL INVESTIGATION OF RHEUMATOID ARTHRITIS CASE-CONTROL STUDY / C. L. Too - A. F. Nurul Aain - L. K. Tan - I. S. Lau* - M. L. Nor Asiah - S. Salsabil - H. Heselynn - S. Nor Shuhaila - S. Wahinuddin - S. C. Gun - B. Eashwary - M. S. Mohd Shahrir - M. Ainon - R. Azmillah - O. Muhaini - B. Camilla - L. Padyukov - L. Alfredsson - L. Klareskog - M. L. Shahnaz SAT0741-HPR COGNITIVE-BEHAVIORAL AND SOCIAL FACTORS DO NOT PREDICT RECURRENT SECONDARY HEALTH CARE USE IN PATIENTS WITH FIBROMYALGIA: A LONGITUDINAL STUDY / J. E. Vriezekolk* - V. M. Vervoort - T. C. olde Hartman - T. van Helmond - W. H. van der Laan - R. Geenen - C. H. van den Ende SAT0742-HPR EUROPEAN LEAGUE AGAINST RHEUMATISM RECOMMENDATIONS FOR THE ROLE OF THE NURSE (EULAR- RN) IN THE MANAGEMENT OF CHRONIC INFLAMMATORY ARTHRITIS (CIA): RESULTS OF PATIENTS IN NORDIC COUNTRIES / M. L. Kukkurainen* - M. Kauppi - Y. van Eijk-Hustings SAT0743-HPR RELATION BETWEEN SERUM ALBUMIN AND PHYSICAL PERFORMANCE AND MOBILITY IN A COMMUNITY- BASED ELDERLY PEOPLE WITH OSTEOPOROSIS / M. Karapinar* - A. Abit Kocaman - N. Kirdi - B. Balam Yavuz SAT0744-HPR PREVALENCE OF COMMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CORRELATION WITH DISEASE ACTIVITY AND TYPE OF THERAPY / M. Cabrera* - L. Villarreal - D. Buitrago-Garcia - P. Santos-Moreno SAT0745-HPR TIME TO DIAGNOSIS, BUT NOT DISEASE DURATION, IS ASSOCIATED WITH POOR QUALITY OF LIFE IN SPONDYLOARTHRITIS: RESULTS FROM THE ASAS-COMOSPA STUDY / M. H. Derakhshan* - N. Goodson - J. Packham - R. Sengupta - A. Molto - H. Marzo-Ortega - S. Siebert on behalf of BRITSpA and ASAS-COMOSPA investigators SAT0746-HPR COFFEE DECREASES METHOTREXATE INTOLERANCE AND INCREASES ITS COMPLIANCE IN RHEUMATOID ARTHRITIS (RA): A STUDY BY RHEUMATOLOGY NURSE COUNSELORS / S. S. Baghel* - R. D. Thakran - C. Messi - S. Kapoor - S. Garg - V. Kashyap - Q. Zaheer - A. N. Malaviya SAT0747-HPR THE IMPACT OF NON-PERSISTENCE ON THE DIRECT AND INDIRECT COSTS IN PATIENTS TREATED WITH SUBCUTANEOUS TUMOR NECROSIS FACTOR-ALPHA INHIBITORS IN GERMANY / K. Ziegelbauer - M. Hübinger - S. Dombrowski - K. Kostev - M. Friedrichs - H. Friedel - S. Kachroo* 16 June 2018 * Presenting author

185 PARE Programme People with Arthritis/Rheumatism in Europe PARE PROGRAMME / WEDNESDAY 13 JUNE 2018 / 183 S. R. Stones (United Kingdom) 15:20 on behalf of Young PARE working group Abstract N OP0011-PARE A week to tweet: findings from young PARE s online course for twitter novices S. Trope (France) 15:30 J.-D. Cohen, C. Beauvais, G. Dugoua Jacques, D. Poivret, A. Saraux, D. Vacher, H. Barkatz, P. Lacoste, V. Weill, G. Thibaud on behalf of ANDAR patient organisation Abstract N OP0012-HPR Creation of the first digital training designed for patients with rheumatoid arthritis by patient organisation in rheumatology 15:45-16:15 Exhibition and EULAR Village (Hall 1) Coffee break WEDNESDAY, 13 JUNE :00-14:00 Hall 7.1 EULAR 2018 Opening Plenary session 16:15-17:45 Amtrium Joint session HPR/PARE New drugs - new perspectives: clinical and regulatory issues concerning biosimilars 14:15-15:45 PARE Room PARE session E-health for better care Learning objectives: To present digital health care solutions that enable better access to health care To show how apps can contribute to patient health care and to organisation attractiveness To outline relevant issues of data protection and patient safety Kristijonas Mazuras (Lithuania) Gerlinde Bendzuck (Germany) Jutta Richter (Germany) 14:20 Abstract N SP0017 Bits and bytes: fitting medical information - PICASO the platform for improved personal, coordinated care Victoria Romero Pazos (Spain) 14:40 Ésaude - a digital platform that unites tools to provide personalised health Mitchell Silva (Belgium) 15:00 Abstract N SP0018 Smart wearables - the right tool for health monitoring and improving quality of health? Learning objectives: To provide healthcare professionals with reference information on both science and regulation underpinning the use of biosimilars Yvonne van Eijk-Hustings (Netherlands) Dieter Wiek (Germany) Tore K. Kvien (Norway) 16:20 Abstract N SP0024 An up-date on biosimilars Tracy French (United Kingdom) 16:38 Abstract N SP0025 Shared decision making in switching to biosimilars Franz König (Austria) 16:56 Statistical and regulatory aspects of biosimilars Dieter Wiek (Germany) 17:14 Abstract N SP0026 Biosimilars - the changing views of EULAR's Member organisations of PARE M. Cvancarova Småstuen (Norway) 17:32 M. Brandvold, R. Andenæs Abstract N OP0070-HPR Is patients satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey 13 June 2018

186 184 / PARE PROGRAMME / WEDNESDAY 13 JUNE AND THURSDAY 14 JUNE :15-17:45 PARE Room PARE session Don t Delay, Connect Today! Learning objectives: To enable national patient organisations to adopt the EULAR Campaign at national level To share best practices of successful activities around the EULAR Campaign Helena Canhão (Portugal) Boryana Boteva (Bulgaria) Gerd R. Burmester (Germany) 16:20 Why we need the Don t Delay Connect Today campaign Tanja Stamm (Austria) 16:40 How HPRs can support the campaign Ruxandra Ionescu (Romania) 17:00 Abstract N SP0027 Don't Delay, Connect Today - implementation of the EULAR Campaign in Romania H. L. Bankova (Bulgaria) 17:20 B. Boteva Abstract N OP0079-PARE Awareness week for rheumatic diseases May 2017 K. Koutsogianni (Greece) 17:30 E. Tsourlidaki, J. Papadakis, R. Stara, L. Papadaki on behalf of the Arthritis Foundation of Crete Abstract N OP0080-PARE Photo album of people with rheumatic diseases under the title: there are some people our people!!! 20:00-22:00 Strand Zuid Networking Platform Els Janssens (Belgium) 10:20 Abstract N SP0037 Bednet: learning opportunities for bedridden children Sophie Ainsworth (United Kingdom) 10:38 Abstract N SP0038 Raising awareness of invisible illnesses in schools and education Tanita Wilhelmer (Austria) 10:56 Abstract N SP0039 I graduated! Education for children and adolescents with RMDs Mirjam Kepic (Slovenia) 11:14 Abstract N SP0040 Parents support for children with RMDs in education L. van Nieuwkoop (Netherlands) 11:32 L. van Geene, R. Janssen Abstract N OP0173-PARE Youth-r-coach, a program for youth with a chronic disease 11:45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 12:00-13:30 Poster area Guided poster tour The PARE guided poster tour is taking place during the official poster viewing. For details on the tour, please refer to page 188. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour June 2018 THURSDAY, 14 JUNE :15-11:45 PARE Room PARE session Inclusive school environment for young people with RMDs Learning objectives: To showcase the role of patient organisations in supporting children with RMDs to access education To present the ideal world versus the reality - the view of the young people with RMDs Peter Boyd (Ireland) Alessia Alunno (Italy) 13:30-15:00 PARE Room PARE session Patient involvement in research: The future of collaborative research. Lessons from the field of rheumatology and beyond Learning objectives: To learn from best practices of patient engagement in different disease areas To explore patient involvement in guideline development and health care innovations To explore how to evaluate patient involvement Jürgen Clausen (Germany) Laure Gossec (France) Courtney Coleman (United Kingdom) 13:35 Abstract N SP0058 Patient involvement in research in pneumology

187 PARE PROGRAMME / THURSDAY 14 JUNE AND FRIDAY 15 JUNE 2018 / 185 Iain B. McInnes (United Kingdom) 13:55 EULAR s RheumaMap - research to transform the lives of people with RMDs Codruta Zabalan (Romania) 14:15 Abstract N SP0059 EULAR s Patient research partner network - patients future involvement in research E. R. Dorris (Ireland) 14:35 N. Nestor, A. G. Wilson Abstract N OP0209-PARE The patient voice in arthritis research: a collaborative approach to embedding PPI into research strategy C. G. Schoemaker (Netherlands) 14:45 W. Armbrust, J. F. Swart, E. Versluis, W. Olsder, N. M. Wulffraat Abstract N OP0210-PARE Dutch juvenile idiopathic arthritis patients, carers and clinicians creating a research agenda together following the James Lind alliance method T. Ngcozana (United Kingdom) 16:45 A. Bhatia Abstract N OP0221-PARE Know their numbers: what do RA patients know about their own biomedical data? FRIDAY, 15 JUNE :15-11:45 PARE Room Abstract session PARE Abstract session Learning objectives: From abstract to concrete - the variety of activities of PARE organisations Kate Betteridge (United Kingdom) Polina Pchelnikova (Russian Federation) 15:00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 PARE Room PARE session Challenges of patient organisations in the 21 st century Learning objectives: To outline organisations challenges in a society that is getting older - less - more colorful To showcase how organisations can achieve sustainability To portrait organisations efforts to overcome gaps in patient health care Neil Betteridge (United Kingdom) Corinna Elling-Audersch (Germany) Winfried Kösters (Germany) 15:35 Abstract N SP0081 Patient organisations challenges in a world that is getting older - less - more colorful Elsa Mateus (Portugal) 15:55 Abstract N SP0082 How a user-led organisation for RMDs enables citizen participation in Portugal Katerina Koutsogianni (Greece) 16:15 Abstract N SP0083 Gaps in patient treatment - what patient organisations can do V. Krafft (Switzerland) 16:35 S. M. Engel Abstract N OP0220-PARE Development of the Swiss national strategy musculoskeletal diseases by the Swiss league against rheumatism Magdalena Misuno (Poland) 10:20 Edgar Stene Prize 2018: My personal champion - supporting my everyday life with a rheumatic and musculoskeletal disease (RMD) C. R. Ziegler (Denmark) 10:30 Abstract N OP0290-PARE Keep an eye out for invisible pains - a Danish campaign J. F. M. Holla (Netherlands) 10:40 J. Brontsema, N. Schenk, R. Jansen, R. Vreenegoor, M. Fluit, W. F. Peter, I. E. Bultink Abstract N OP0291-PARE Running with rheumatism: a 7-week training programme for novice runners with inflammatory rheumatic disease A. Lacovou (Cyprus) 10:50 Abstract N OP0292-PARE The creation of the aqua re-action. A methodologically based aquatic physical intervention/rehabilitation program for people with RMDs P. Wegscheider (Austria) 11:00 G. Schaffer Abstract N OP0293-PARE Problems, goals and urgent wishes of young Austrians diagnosed with rheumatic disorders: a report A. Higginbottom (United Kingdom) 11:20 S. Blackburn, R. Taylor, C. Rhodes, L. Campbell, K. Dziedzic Abstract N OP0294-PARE Addressing key challenges of lay involvement in musculoskeletal research: co-applicants and trial steering committees S. De Jong (Netherlands) 11:20 Abstract N OP0295-PARE Kweek begrip : the launch of our creative campaign across the Netherlands on worldarthritisday aims to increase awareness about RMDs in general and people living with RMDs in particular June 2018

188 186 / PARE PROGRAMME / FRIDAY 15 JUNE 2018 B. Kuriya (Canada) 11:30 J. Widdifield, J. Luo, S. Vigod, N. Haroon Abstract N OP0296 The risk of deliberate self-harm in rheumatoid arthritis and ankylosing spondylitis: a population-based cohort study L. Alemo Munters (Sweden) 14:45 A. Beerman Abstract N OP0331-PARE Behavior change experiences and needs of persons with rheumatic disease 11:45-13:30 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and lunch 12:00-13:30 Poster area Guided poster tour The PARE guided poster tour is taking place during the official poster viewing. For details on the tour, please refer to page 188. Please note that you need to register in order to participate in a guided poster tour. The number of participants per tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 2, on a first-come-first-served basis the day of the poster tour. 15:00-15:30 Exhibition and EULAR Village (Hall 1) Coffee break 15:30-17:00 PARE Room PARE session What s new: Latest advances in treatment in JIA and osteoarthritis Learning objectives: To show the latest advances in treatment and care in JIA and osteoarthritis Philip Conaghan (United Kingdom) Victoria Romero Pazos (Spain) 15 June :30-15:00 PARE Room Joint session PARE/Clinical Innovative treatments for a better quality of life Learning objectives: To present new innovative drugs To outline health interventions and technology assessment in support of people with RMDs To learn what drug safety parameters the patient has to consider when being treated with innovative drugs José A. P. da Silva (Portugal) Eva Tzigounaki-Kritza (Greece) Johannes W. J. Bijlsma (Netherlands) 13:35 Why JAK inhibitors can make a difference? Jürgen Clausen (Germany) 13:55 Abstract N SP0109 Involvement of a patient organisation in health technology assessment Ailsa M. Bosworth (United Kingdom) 14:15 Patient rights and safety concerns in an era of innovative therapies A. M. Bosworth (United Kingdom) 14:35 S. Arora Abstract N OP0330-PARE Love your heart, an online, interactive cardiovascular risk assessment programme for people with RA/IA Margreet Kloppenburg (Netherlands) 15:35 Abstract N SP0136 Latest advances in treatment and management of OA L. Campbell (United Kingdom) 16:05 JIGSAW-E Patient Champions, S. Blackburn, J. Meesters, M. De Wit, D. Schiphof, T. Vliet Vlieland, S. Bierma-Zeinstra, N. Østerås, S. Pais, E. Roos, N. Evans, K. Dziedzic Abstract N OP0346-PARE A partnership in implementation: adapting an osteoarthritis guidebook across European cultures - with patients, for patients Tadej Avcin (Slovenia) 16:15 Latest advances in treatment and management of JIA Y. El Miedany (United Kingdom) 16:45 H. Lotfy, N. El Aroussy, D. Mekkawy, S. I. Nasef, W. Hassan, Y. Farag, S. Almedany, G. El Deriny, M. Eissa, M. El Gaafary on behalf of PRINTO Egypt Abstract N OP0347 Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking

189 PARE PROGRAMME / SATURDAY 16 JUNE 2018 / 187 SATURDAY, 16 JUNE :00-10:30 PARE Room PARE session Workshop: Is there a diet for people with RMDs? Learning objectives: Share evidence based knowledge on nutrition Share best practice by patient organisations Dieter Wiek (Germany) Nele Caeyers (Belgium) Asta Linauskas (Denmark) 09:05 Abstract N SP0153 What evidence is there that diets help people with RMDs? Corinna Elling-Audersch (Germany) 09:20 Abstract N SP0154 How to offer seminars on nutrition Valerie Krafft (Switzerland) 09:35 Abstract N SP0155 Nutrition - how to talk about it Faculty 09:50 Group discussion and Q&A Dieter Wiek (Germany) 10:20 Resume of the group discussions 10:30-12:00 Exhibition, EULAR Village (Hall 1) and Poster areas Poster viewing and coffee break 12:00-13:30 PARE Room Sarah Copsey (Spain) 12:45 Abstract N SP0178 The contribution of occupational safety and health to working with RMDs M. Klokkerud (Norway) 13:05 E. Hasselknippe, A. Rønningen, H. Haveråen, A.-L. Sand-Svartrud Abstract N OP0364-PARE Work status and work barriers in patients receiving BDMARDs as infusions in rheumatology hospital clinics in Norway. A cross-sectional study M. Bezzant (United Kingdom) 13:15 A. Bosworth, L. Lunt, S. Verstappen Abstract N OP0365-PARE Work matters: a UK wide survey of adults with rheumatoid arthritis and juvenile idiopathic arthritis on the impact of their disease on work 13:45-14:45 PARE Room Highlight session PARE Highlight session Learning objectives: To provide an overview of learning and outcomes from the EULAR 2018 Congress from health professionals and the scientific perspectives, and first feedback from the PARE delegates Dieter Wiek (Germany) Nele Caeyers (Belgium) Elena Nikiphorou (United Kingdom) 13:50 Highlights from the scientific programme Yvonne van Eijk-Hustings (Netherlands) 14:15 Highlights from the HPR programme Joint session PARE/HPR Work and rehabilitation - key priorities for people with RMDs Learning objectives: To explore the current developments at EU level and the impact on member states To explore the impact of work rehabilitation on the quality of life and on the employment To show the value of early intervention, prevention and better management of RMDs Tanja Stamm (Austria) Elsa Mateus (Portugal) 16 June 2018 Gerlinde Bendzuck (Germany) 12:05 Abstract N SP0176 It works?! Employment support for people with RMDs Erika Mosor (Austria) 12:25 Abstract N SP0177 Quality of life at the workplace - how early interventions of health professionals can support people with RMDs

190 188 / PARE POSTER TOURS & POSTERS / THURSDAY 14 JUNE TO FRIDAY 15 JUNE 2018 PARE Guided Poster Tours & Posters People with Arthritis/Rheumatism in Europe Poster Session Thursday, 14 June 2018 Poster area Poster viewing 11:45-13:30 Guided poster tours 12:00-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. Poster tour T15: PARE Poster Tour I Dieter Wiek (Germany), Elsa Mateus (Portugal) PARE0001 #DOESNTSHOWDOESNTEXIST / #SYNSINTEFINNSINTE - AN AWERNESS CAMPAIGN FOR PUBLIC TRANSPORT BY SWEDISH NATIONAL ORGANIZATION FOR YOUNG RHEUMATICS / K. Nordlund* - M. Beermann PARE0002 ADHERENCE TO THERAPY AND PATIENTS ENGAGEMENT IN ITALY: A CLOSE LINK / U. G. Viora* - R. Broggini - G. Campolieti - F. Leonardi - F. Padovani - S. Tonolo on behalf of ANMAR Italia PARE0003 PROVIDING PATIENT AND FAMILY EDUCATION AND SUPPORT FOR CHILDREN WITH RHEUMATIC DISEASES AND THEIR FAMILIES: CASSIE AND FRIENDS ANNUAL FAMILY DAY IN BC / J. Wilson* - L. Tucker on behalf of Tucker, Petty, Setton, Houghton, Morishita, Guzman, Brown, Green, Tekano, Davidson, Best, Eccles, Cabral. PARE0004 LET S MOVE WITH ARTHRITIS! - NORDIC WALKING FOR PEOPLE WITH RMDS / P. Balazova* - J. Dobsovicova Cernakova PARE0005 DEVELOPMENT & DISSEMINATION OF A RESOURCE ABOUT METHOTREXATE USE FOR AND BY PATIENTS WITH INFLAMMATORY ARTHRITIS / D. Richards* - N. Robertson - L. Wilhelm - L. Proulx - A. McKinnon - J. Gunderson - C. Reece - A. Sirois PARE0006 A SUMMARY OF KEY FINDINGS FROM THE SJÖGREN S SYNDROME FOUNDATION S NATIONAL PATIENT SURVEY RELATED TO TREATMENTS AND MEDICATIONS USED / S. Taylor - K. M. Hammitt* PARE0007 FAMILY DAY BY THE SWISS LEAGUE AGAINST RHEUMATISM: A NETWORKING EVENT FOR CHILDREN AFFECTED BY JIA AND THEIR FAMILIES / M. Roffler* - V. Krafft PARE0008 SURVEY RESULTS FROM A NATIONWIDE ONLINE AWARENESS CAMPAIGN SUGGEST A CLEAR DIFFERENCE IN TREATMENT AND PERCEPTION OF QUALITY OF HEALTHCARE FOR PATIENTS DIAGNOSED WITH PSORIASIS ARTHRITIS, PSA, VERSUS PATIENTS WITH SYMPTOMS SIMILAR TO PSORIASIS ARTHRITIS I.E. PSORIASIS AND JOINT PAIN / N. Unesi* - E.-M. Dufva - L. Håkansson Friday, 15 June 2018 Poster area Poster viewing 11:45-13:30 Guided poster tours 12:00-13:30 Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area in Hall 2, on a first-come-first-served basis on the date of the poster tour. Poster tour F16: PARE Poster Tour II Nele Caeyers (Belgium), Boryana Boteva (Bulgaria) June 2018 PARE0009 CANADIAN ARTHRITIS PATIENT ALLIANCE: UNDERSTANDING MEMBER PROFILES AND NEEDS / N. Robertson* - L. Wilhelm - D. P. Richards - L. Proulx - A. McKinnon - J. Gunderson - C. Reece - A. Sirois PARE0010 NATURALLY HEALING THE CHRONIC PAIN AND HEALTH MAINTENANCE / A. Phoka Charalambous* PARE0011 FUNKA UTAN SKAM - TO FUNCTION WITHOUT SHAME / T. Diao* PARE0012 THE FRENCH PATIENT S ASSOCIATION AFLAR: HAS GENERATED THE FRENCH NATIONAL ALLIANCE AGAINST OSTEOPOROSIS AND THE FIRST GENERAL CONVENTION FOR OSTEOPOROSIS, THAT IS A CAMPAIGN TO CREATE A NATIONAL PROMOTING TOOL TO IMPROVE THE MANAGEMENT OF OSTEOPOROSIS.: 7 PRIORITIES TO BETTER TREAT PATIENTS I / L. Grange* - B. Cortet - T. Thomas - F. Srour - P. Guggenbuhl - C. Roux - P. Monod - J. M. Feron - F. Alliot- launois - F. Tremollières - G. Chalés - J. Giraud - E. Senbel - G. Thibaud - P. Niemczynski - D. R. Bertholon - C. F. Roques - D. Buchon - C. Bonnet - H. Blain - C. Rolland - D. Lafarge - L. Carton on behalf of French National Alliance Against Osteoporosis PARE0013 SOURCES OF INFORMATION AND KNOWLEDGE ABOUT RHEUMATIC DISEASES AMONG PEOPLE WITH RHEUMATIC DISEASES IN POLAND AND IN OTHER EUROPEAN COUNTRIES / J. Grygielska* - A. Kłak - J. Owoc - E. Gawińska-Drużba - F. Raciborski PARE0014 GETTING THE PULSE ON WORKPLACE EXPERIENCES AND ACCOMMODATIONS / L. Proulx* - N. Robertson - D. P. Richards - L. Wilhelm - J. Gunderson - A. Sirois - A. McKinnon PARE0015 LARGE-SCALE SURVEY OFFERS GENERAL INSIGHT AND BASIS FOR POLICY DRAFTING / S. De Jong* - I. Koopmans - M. Feith PARE0016 THE ROLE OF EMPATHY QUOTIENT IN PATIENT-PHYSICIAN COMMUNICATION: A TOOL TO IMPROVE MEDICATION ADHERENCE / A. Celano* PARE0017 SUPPORTING YOUNG PEOPLE WITH RMDS IN MANAGING ISSUES AROUND RELATIONSHIPS, PREGNANCY AND SEXUALITY / W. Olsder* - L. van Nieuwkoop - A. A. J. Haenen * Presenting author

191 EULAR RELATED MEETINGS / 189 EULAR Related Meetings By invitation only Wednesday, 13 June 2018 Start - End Room Meeting Title 08:00-10:00 D304 EULAR Standing Committee on Clinical Affairs Business meeting 09:00-12:00 D407 IMI2 project RTCure: Criteria and outcome measures in RTCure Cohorts - WP2 10:30-12:30 E102 GRAPPA Adjacent to EULAR :00-19:00 D302 Arthritis Research & Therapy Section and Associate Editor meeting 18:00-19:00 D404 Meeting of the ScleroID Study Group 18:00-19:00 E103 ARD Editorial Board meeting 18:00-20:00 D301 OMERACT handbook group 18:00-20:00 D304 Synovitis study group 18:00-20:00 D402 TICOSPA investigators meeting 18:00-20:00 D403 EULAR Recommendations for the use and interpretation of laboratory diagnostic tests for the management of systemic autoimmune rheumatic diseases 18:00-20:00 D406 GLORIA investigators meeting 18:00-20:00 E101 ASIF Ankylosing Spondylitis International Federation meeting 18:15-19:45 E104 EULAR Standing Committee of PARE Business meeting 19:00-20:00 E103 RMD Open Editorial Board meeting Thursday, 14 June 2018 Start - End Room Meeting Title 08:00-10:00 D301 OMERACT PRP s 08:00-10:00 D302 SLEuro Board meeting 08:00-10:00 D303 World Scleroderma Foundation Board meeting 08:00-10:00 D304 EULAR Standing Committee on Health Professionals Business meeting 08:00-10:00 D402 EULAR Study Group for Collaborative Research 08:00-10:00 D406 AGORA meeting 08:00-10:00 D408 EULAR Standing Committee on Musculoskeletal Imaging Business meeting 08:00-10:00 E101 Steering Committee meeting ATACC-RA 08:00-10:00 E102 EMEUNET Business meeting 08:00-10:00 E103 MyoNet study group 08:00-10:00 E104 UEMS Rheumatology Section and Board 08:15-09:45 D401 EULAR Public Affairs Group meeting 08:30-10:00 D403 EULAR Standing Committee on Paediatric Rheumatology 08:30-10:00 E105 EULAR Study Group on Microcirculation in Rheumatic Diseases 09:00-10:00 D407 Rheumatology Editorial Board meeting 17:00-18:00 D304 Clinical Nurse study group

192 190 / EULAR RELATED MEETINGS Thursday, 14 June :00-18:00 D402 EULAR Study Group on Patient Education 17:00-18:00 D404 Nurse Research & Strategy Group study group meeting 17:00-18:00 D406 Online courses author LMS tutoring 17:00-18:00 D407 EMEUNET Country Liaison meeting 17:00-18:00 D408 Foot & Ankle study group 17:00-18:30 D302 Study group for Epidemiology and Registries of Observational Studies (RODS) 17:00-19:00 D301 OMERACT MRI Taskforce 17:00-19:00 D303 Editorial Board meeting - Rheumatology International 17:00-19:00 D403 EULAR Standing Committee on Investigative Rheumatology Business meeting 17:00-19:00 E103 Study group for Risk Factors for RA 17:00-19:00 E104 Business meeting ATACC-RA 17:00-19:00 E105 Journal of Scleroderma and Related Disorders - Editorial Board meeting 18:00-19:00 D304 Physical Activity & Exercise study group Friday, 15 June 2018 Start - End Room Meeting Title 08:00-09:30 E103 EULAR Standing Committee on Education and Training Business meeting 08:00-10:00 D301 OMERACT Consensus 08:00-10:00 D302 Board meeting Scandinavian Society of Rheumatology 08:00-10:00 D304 EULAR HPR Scientific and Educational Subcommittee meeting :00-10:00 D401 SLE Classification Criteria Steering Committee 08:00-10:00 D402 EuroSpa Collaboration Network, Scientific Committee meeting 08:00-10:00 D403 EUSTAR Board meeting 08:00-10:00 D404 EUROGOUT Consortium 08:00-10:00 D406 EMEUNET Mentor - Mentee meeting 08:00-10:00 E101 EULAR PARE CEO Interim meeting 08:00-10:00 E102 OMERACT Ultrasound Working group 08:00-10:00 E104 EULAR Sjögren's syndrom study group - Essential 09:00-10:00 D303 German Commission of Students Education 17:00-18:00 D302 SSc Subset meeting 17:00-18:00 E101 HarmonicSS Project meeting Patient Group 17:00-18:30 E104 EULAR Standing Committee for Epidemiology and Health Services Research meeting 17:00-19:00 D301 OMERACT Methods working group 17:00-19:00 D304 European Alliance for Patient Access Patient Advocacy meeting 17:00-19:00 E102 ASAS meeting

193 SATELLITE SYMPOSIA / WEDNESDAY 13 JUNE 2018 / 191 Satellite Symposia Status as of 1 May 2018 WEDNESDAY, 13 JUNE :15-19:45 Hall 3 Vindico Medical Education supported by Bristol-Myers Squibb Rheumatic complications of cancer immunotherapy: a new and emerging field in rheumatology Leonard H. Calabrese (United States) Jan Leipe (Germany) Xavier Mariette (France) Introduction and pre-test 18:15 Biology of T cell exhaustion and the evolution 18:25 of immune checkpoint inhibitors Diagnosis and management of rheumatic iraes 18:50 from cancer immunotherapy Clinical cases 19:15 Post-test and question and answer 19:35 18:15-19:45 Auditorium Andrea Rubbert-Roth (Germany) 18:40 Beyond methotrexate: the role of JAK inhibitors when csdmards fail Peter Nash (Australia) 19:00 Beyond biologics: JAK inhibitors as a novel alternative in bdmard-ir patients All 19:20 Panel discussion and Q&A 18:15-19:45 Elicium 2 Pfizer Evolution or Revolution? How JAK inhibitors are changing the standard of care in RA Ronald van Vollenhoven (Netherlands) Ronald van Vollenhoven (Netherlands) 18:15 Welcome and introductions Where we are today: treatment trends in RA from the clinician s perspective Eduardo Mysler (Argentina) 18:25 Proactive search: the best treatment for each patient AbbVie RA treatment beyond the conventional: will JAK inhibitors disrupt our treatment paradigms? Peter Nash (Australia) Peter Nash (Australia) 18:15 Welcome and introduction John Isaacs (United Kingdom) 18:25 Influencing the JAK pathway: does selective inhibition make mechanistic sense? Ernest Choy (United Kingdom) 18:50 JAK inhibitors: novel therapies offering efficacious options for patients with RA Torsten Witte (Germany) 19:15 Safety and real-world data offer a wider window into advanced therapies for patients with RA Ronald van Vollenhoven (Netherlands) 19:40 RA therapy tomorrow: the road ahead 13 June 2018

194 192 / SATELLITE SYMPOSIA / WEDNESDAY 13 JUNE :15-19:45 Hall 7.2 GSK Leading the way towards a holistic approach to managing SLE Welcome and introduction 18:15 Patient and physician priorities 18:18 in SLE management Why we shouldn t be tired of hearing 18:30 about fatigue Reducing long-term organ damage: 19:00 Are we shooting for the moon? Summing up and concluding remarks 19:30 18:15-19:45 Forum Celltrion Healthcare REdefining the future with InflixiMab biosimilar Rieke Alten (Germany) Rieke Alten (Germany) 18:15 Welcome and introduction Laurent Grange (France) 18:20 Perspectives on living with rheumatic diseases Rieke Alten (Germany) 18:35 Physicians perspective on early introduction of biologics Ki Chul Shin (Republic of Korea) 18:50 Drug retention of infliximab in ankylosing spondylitis: data from KOBIO Rene Westhovens (Belgium) 19:05 Future of infliximab: introduction of the subcutaneous formulation All 19:20 Panel discussion 18:15-19:45 Emerald UCB The reality of risk how are we responding to fragility fracture in rheumatology? Socrates Papapoulos (Netherlands) Socrates Papapoulos (Netherlands) 18:15 Why should we be vigilant for fragility fracture? Ian Bruce (United Kingdom) 18:30 Ivo Vlaev (United Kingdom) What are the complexities of decisions facing the rheumatologist? Clinical and behavioural perspectives Ian Bruce (United Kingdom) 18:50 Socrates Papapoulos (Netherlands) Improving the odds in fragility fracture: how can we act on risk factors in the rheumatology consultation? Ivo Vlaev (United Kingdom) 19:10 How does our perception of risk influence how we make decisions in the rheumatology clinic? Socrates Papapoulos (Netherlands) 19:20 Collaborative care in fragility fracture: recommendations for risk assessment and referral All 19:30 Audience Q&A 18:15-19:45 E106/E107 IBSA The treatment of OA: new concepts for an old disease Cem Gabay (Switzerland) Cem Gabay (Switzerland) 18:15 Welcome and introduction Xavier Chevalier (France) 18:20 Treat to target in osteoarthritis: towards a better benefit/risk ratio of oral drugs Cem Gabay (Switzerland) 18:40 Osteoarthritis of the hand: current evidence on its management Jean Dudler (Switzerland) 19:00 Additional analysis on CONCEPT study data Chiara Schiraldi (Italy) 19:15 Pharmaceutical-grade chondroitin sulphate vs food supplements: are they equivalent? All 19:30 Question and answer session 13 June 2018 Cem Gabay (Switzerland) 19:40 Concluding remarks

195 SATELLITE SYMPOSIA / THURSDAY 14 JUNE 2018 / 193 THURSDAY, 14 JUNE :15-09:45 Hall 3 AbbVie Transforming developments: the dynamic face of rheumatology Ferry Breedveld (Netherlands) Ferry Breedveld (Netherlands) 08:15 Welcome and introduction Transforming treatments: how TNF inhibitors led the field in the biologic revolution Boulos Haraoui (Canada) 08:30 Transforming standards: treat to target and the PASSIONate revolution Wouter Bos (Netherlands) 08:45 Transforming outcomes: the role of patients in assessing their own disease Lisa Olson (United States) 09:05 Transforming targets: drug discovery and development All 09:25 Panel discussion and Q&A 08:15-09:45 Auditorium Novartis Making the invisible visible: the impact of IL-17A inhibition in psoriatic arthritis Dafna Gladman (Canada) Dafna Gladman (Canada) 08:15 Welcome and introductions Georg Schett (Germany) 08:20 Enthesitis: the link between the skin and joints in PsA Laura Coates (United Kingdom) 08:40 A 360 overview on the evolving unmet needs in PsA Philip Conaghan (United Kingdom) 08:55 Insights into PsA from modern imaging Philip Mease (United States) 09:10 GRAPPA treatment recommendations: are they met with IL-17A inhibition? All 09:30 Panel discussion and conclusions 08:15-09:45 Elicium 2 Lilly IL-17A inhibition: optimising the PsA management Michael Nurmohamed (Netherlands) Michael Nurmohamed (Netherlands) 08:15 Welcome and introduction Helena Marzo-Ortega (United Kingdom) 08:20 Is the management of patients with PsA optimal? Frank Behrens (Germany) 08:35 Overview of ixekizumab benefits and safety results Diamant Thaçi (Germany) 08:50 Peter Nash (Australia) PsA management in the real world: the rheumatologist and dermatologist perspective All 09:20 Panel discussion Michael Nurmohamed (Netherlands) 09:30 Summary and symposium close 08:15-09:45 Hall 7.2 Roche Journey from clinical trials to patient care Ernest Choy (United Kingdom) Ernest Choy (United Kingdom) 08:15 Welcome & introduction Ernest Choy (United Kingdom) 08:20 Exploring the value of real-world evidence (RWE) Deborah Symmons (United Kingdom) 08:30 Confidence in treating the at-risk and elderly population Fabrizio de Benedetti (Italy) 08:50 Advancing knowledge of the paediatric population Frank Buttgereit (Germany) 09:10 Optimising the use of glucocorticoids in clinical practice Ernest Choy (United Kingdom) 09:30 Summary All Faculty 09:35 Question & answer session 14 June 2018

196 194 / SATELLITE SYMPOSIA / THURSDAY 14 JUNE :15-09:45 Forum Biogen Anti-TNF in rheumatic diseases: inventory and outlook Peter Taylor (United Kingdom) Peter Taylor (United Kingdom) 08:15 Opening, intro & overview: the treatment landscape in RA Short presentations integrated at various time points into an interactive faculty/audience discussion Raj Sengupta (United Kingdom) Preparing a switch: the perfect time to re-evaluate the clinical status of patients with RA/AS Paul Enck (Germany) Preparing a switch: the perfect time to re-evaluate the patient s psychosocial status Juergen Braun (Germany) Successful switching: shared decision making with the patient is critical Glenn Haugeberg (Norway) Post-switch patient follow-up in busy daily clinical practice - opportunities and challenges of remote patient monitoring All 09:40 Summary and conclusion 08:15-09:45 Amtrium medac Methotrexate new insights into the anchor drug Daniel Aletaha (Austria) Daniel Aletaha (Austria) Benefits of subcutaneous MTX in daily practice Jens Thiel (Germany) Relevance of the microbiome for RA treatment outcomes Ronald van Vollenhoven (Netherlands) JAK-inhibitors: will they change the treatment paradigm? Ivan Foeldvari (Germany) How to optimize JIA treatment 08:15-09:45 Emerald Menarini Multimodal approach for acute pain in rheumatology - a new paradigm targeting multiple mechanisms Serge Perrot (France) Serge Perrot (France) 08:15 Introduction Stefano Coaccioli (Italy) 08:30 Low back pain and osteoarthritis: from clinical features to complex mechanisms Serge Perrot (France) 08:50 Multimodal approach, a step forward in the current therapeutic strategy Magdi Hanna (United Kingdom) 09:10 Rationale of the new oral fixed dose combination of dexketoprofen/tramadol in targeting multiple mechanisms of moderate to severe acute pain Discussion and final remarks 08:15 08:15-09:45 E106/E107 Amgen Ready for the next biosimilar? Key stakeholder insights to guide choice Thierry Thomas (France) Fernando Perez-Ruiz (Spain) Thierry Thomas (France) 08:15 Welcome and introduction Murray Aitken (United States) 08:25 Assessing biosimilar attitudes and use: a marketplace evaluation Fernando Perez-Ruiz (Spain) 08:45 Clinical perspectives: what to consider when selecting the next anti-tnf biosimilar Alison Kent (United Kingdom) 09:10 Patient perspectives on anti-tnf biosimilars: understanding attitudes, beliefs and expectations All 09:30 Panel discussion Fernando Perez-Ruiz (Spain) 09:40 Closing remarks 14 June 2018

197 SATELLITE SYMPOSIA / THURSDAY 14 JUNE 2018 / :30-19:00 Auditorium AbbVie Solving the patient puzzle: a pragmatic approach to SpA management Georg Schett (Germany) Georg Schett (Germany) 17:30 Welcome and introduction The many faces of SpA: how does inflammation lead to multifaceted disease? Denis Poddubnyy (Germany) 17:45 Disease progression: under control or still a cause for concern? Philip Mease (United States) 18:05 Optimising long-term treatment: lessons from clinical practice Dirk Elewaut (Belgium) 18:25 Integrated care: a practical approach to patient management All 18:45 Panel discussion and Q&A 17:30-19:00 Hall 7.2 Pfizer How to detect and treat unresolved symptoms in the patient with psoriatic arthritis Désirée van der Heijde (Netherlands) Désirée van der Heijde (Netherlands) 17:30 Welcome and introductions Laure Gossec (France) 17:35 Diagnostic hot spots : defining targets, detecting patients symptoms Enrique Soriano (Argentina) 17:55 New products, new opportunities in PsA Frank Behrens (Germany) 18:20 Optimising treatments: the physician and nurse practitioner partnership Désirée van der Heijde (Netherlands) 18:40 Audience Q&A/panel discussion summary and close 17:30-19:00 Forum Sanofi Genzyme The challenges of multi-morbidities in RA: IL-6 and chronic inflammation Peter Taylor (United Kingdom) Peter Taylor (United Kingdom) 17:30 Meeting the challenge of multi-morbidities in RA Michael Nurmohamed (Netherlands) 17:40 Multi-morbidities associated with RA: defining the systemic manifestations of the disease Ernest Choy (United Kingdom) 17:55 The multi-faceted role of IL-6 in RA and other RA-associated conditions Mark Genovese (United States) 18:15 The effects of IL-6R blockade inside and outside the RA joint All 18:35 Moderated discussion with faculty and audience Q&A Peter Taylor (United Kingdom) 18:55 Close 17:30-19:00 Amtrium Janssen A practical guide to new treatments in psoriatic arthritis and psoriasis Dennis McGonagle (United Kingdom) Costantino Pitzalis (United Kingdom) Dennis McGonagle (United Kingdom) 17:30 Costantino Pitzalis (United Kingdom) Welcome and introduction Costantino Pitzalis (United Kingdom) 17:35 Pathophysiology of joint and skin diseases and implications for treatment Lluis Puig (Spain) 17:55 Lessons from the skin: therapeutic options for psoriasis in clinical practice Dennis McGonagle (United Kingdom) 18:20 Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice All 18:45 Q&A Conclusions and close of meeting 18:55 14 June 2018

198 196 / SATELLITE SYMPOSIA / THURSDAY 14 JUNE AND FRIDAY 15 JUNE :30-19:00 Emerald Bristol-Myers Squibb Modulating the wayward T cell: the new horizon in autoimmunity and cancer Leonard Calabrese (United States) Leonard Calabrese (United States) 17:45 Welcome and introduction Leonard Calabrese (United States) 17:47 T-cell co-stimulation in health and disease Roberto Caporali (Italy) 18:12 T cell-b cell communication in autoimmune diseases, with a focus on RA Christian Blank (Netherlands) 18:37 Expanding our understanding of T-cell modulation through learnings from cancer All 19:02 Panel discussion and Q&A 17:30-19:00 E106/E107 Samsung Bioepis The era of biosimilars: reshaping the healthcare environment Josef Smolen (Austria) Josef Smolen (Austria) 17:30 Welcome and introduction Josef Smolen (Austria) 17:40 Anti-TNF biosimilars in rheumatology João Gonçalves (Portugal) 17:55 Reinvestigating biologics quality excellence Mark Quinn (United Kingdom) 18:10 Biosimilar adoption: improving rheumatology services for patients Fabrizio Benedetti (Italy) 18:25 Understanding the nocebo effect All 18:40 Q&A Josef Smolen (Austria) 18:50 Closing FRIDAY, 15 JUNE :15-09:45 Auditorium Lilly Challenging the rheumatoid arthritis treatment standards with JAK inhibitors Désirée van der Heijde (Netherlands), Mark C. Genovese (United States) Désirée van der Heijde (Netherlands) 08:15 Mark C. Genovese (United States) Welcome and introduction Peter Taylor (United Kingdom) 08:20 JAK inhibitors - are they all the same? Paul Emery (United Kingdom) 08:35 JAK inhibitor baricitinib: how is it different from the standard of care (anti-tnf)? Ronald van Vollenhoven (Netherlands) 08:50 JAK inhibitors position in the treatment algorithm of rheumatoid arthritis Ulf Müller-Ladner (Germany) 09:05 JAK inhibitors in clinical practice Désirée van der Heijde (Netherlands) 09:20 Mark C. Genovese (United States) Panel discussion and Q&A Symposium close 09:45 08:15-09:45 Elicium 2 Novartis IL-17A inhibition in axial spondyloarthritis: new insights and implications for clinical practice Filip van den Bosch (Belgium) Filip van den Bosch (Belgium) 08:15 Welcome and introductions Merryn Jongkees (Netherlands) 08:20 Axial spondyloarthritis: what matters to a patient? Atul Deodhar (United States) 08:35 Clinical intervention in axial spondyloarthritis: why, when and how? Rik Lories (Belgium) 08:55 Underlying pathophysiology of axial spondyloarthritis: clinical assessments and implications June 2018 Xenofon Baraliakos (Germany) 09:10 IL-17A inhibition in axial spondyloarthritis: current and future perspectives All 09:30 Panel discussion and conclusions

199 SATELLITE SYMPOSIA / FRIDAY 15 JUNE 2018 / :15-09:45 Forum Integritas supported by Gilead Sciences, Inc. Clinical issues in rheumatoid arthritis: discussions and debates on the evolving roles of targeted synthetic DMARDs Rieke Alten (Germany) Rieke Alten (Germany) 08:15 Welcome and pre-activity questionnaire Josef Smolen (Austria) 08:20 Pathophysiology: a focus on JAK enzymes Joel Kremer (United States) 08:35 Long-term assessment of patient with RA: understanding treatment targets as a foundation for therapeutic tailoring Rieke Alten (Germany) 08:55 Targeted synthetic DMARDs in the treatment of RA All 09:15 Case study panel discussion: putting the evidence to practice All 09:30 Post-activity questionnaire and Q&A session 08:15-09:45 Amtrium UCB Axial spondyloarthritis in 2018: new data, less compromise? Martin Rudwaleit (Germany) Martin Rudwaleit (Germany) 08:15 Welcome and introduction from the symposium chair Lianne Gensler (United States) 08:20 Diagnostic delay, establishing disease control and starting a family Maxime Dougados (France) 08:45 The right management strategy for the right patient Denis Poddubnyy (Germany) 09:05 Taking control of structural damage progression and exploring new horizons 08:15-09:45 Emerald Celgene Towards a targeted approach in psoriatic arthritis with PDE4 inhibition Laure Gossec (France) Laure Gossec (France) 08:15 Opening statement Laure Gossec (France) 08:20 Guidelines in evolution and their applicability in treatment decisions Frank Behrens (Germany) 08:35 Evidence from homogeneous clinical trials for a diverse patient population the challenge in PsA patient care Philip J. Mease (United States) 09:00 Optimising the clinical utility of PDE4 inhibition Audience Q&A Laure Gossec (France) 09:20 Summary and close 08:15-09:45 E106/E107 Boehringer Ingelheim Interstitial lung disease in autoimmune rheumatic diseases moving towards better patient care Frank van den Hoogen (Netherlands) Frank van den Hoogen (Netherlands) 08:15 How relevant is ILD in autoimmune rheumatic diseases? Athol Wells (United Kingdom) 08:25 How should we diagnose and monitor ILD? Christopher Denton (United Kingdom) 08:45 Treatment of ILD in autoimmune rheumatic diseases Jörg Distler (Germany) 09:05 Future perspectives on the treatment of fibrosis All 09:25 Questions and answers Martin Rudwaleit (Germany) 09:25 Wrap-up and conclusion All 09:40 Question and answer session moderated by the symposium chair 15 June 2018

200 198 / SATELLITE SYMPOSIA / FRIDAY 15 JUNE :30-19:00 Auditorium Pfizer Unraveling chronic pain: from defining to modulating Francis Berenbaum (France) Francis Berenbaum (France) 17:30 Welcome and faculty introductions Francis Berenbaum (France) 17:35 Defining the humanistic and societal burden of chronic pain Martin Koltzenburg (United Kingdom) 17:55 Overview of pain pathways and mediators of pain sensitization Richard Langford (United Kingdom) 18:20 Current and future approaches to modulate chronic pain All 18:45 Panel discussion and Q&A Francis Berenbaum (France) 18:55 Closing remarks 17:30-19:00 Forum RMEI supported by Sanofi Genzyme & Regeneron Global perspectives in RA: the role of new biologics for optimal management Paul Emery (United Kingdom) Speakers: Paul Emery (United Kingdom) Leonard H. Calabrese (United States) Josef F. Smolen (Austria) Paul Emery (United Kingdom) 17:30 Introductions and overview of panel topics Faculty Panel Discussion #1 17:40 The patient with RA who fails to respond Faculty Panel Discussion #2 18:05 The patient with RA who becomes non-responsive Faculty Panel Discussion #3 18:30 The patient with poor response and comorbidities Paul Emery (United Kingdom) 18:55 Summary remarks 17:30-19:00 Amtrium Rheumatology Today Highlights of EULAR 2018 Matthias Schneider (Germany) Speakers: Peer M. Aries (Germany) Xenofon Baraliakos (Germany) Frank Behrens (Germany) Christof Iking-Konert (Germany) Christof Specker (Germany) Torsten Witte (Germany) Round table experts: Frank Buttgereit (Germany) Jens Gert Kuipers (Germany) Ulf Müller-Ladner (Germany) Presentation of six trials presented at EULAR 2018 featuring the following topics: Axial spondylarthritis Biologica monotherapy Collagenoses Novelties in RA treatment Psoriatic arthritis Vasculitis 17:30-19:00 Emerald Janssen Lupus: now and in the future David Isenberg (United Kingdom) Ronald van Vollenhoven (Netherlands) David Isenberg (United Kingdom) 17:30 Angela Tincani (Italy) Welcome and introduction Eisabet Svenungsson (Sweden) 17:40 Current options: limitations of current treatment in lupus Ronald van Vollenhoven (Netherlands) 18:00 How to assess lupus in clinical care David Isenberg (United Kingdom) 18:20 Biologics: what s coming next? David Isenberg (United Kingdom) 18:40 Elisabet Svenungsson (Sweden) Angela Tincani (Italy) Ronald van Vollenhoven (Netherlands) Panel discussion Angela Tincani (Italy) 18:55 Ronald van Vollenhoven (Netherlands) Conclusions and close of meeting 15 June 2018

201 SATELLITE SYMPOSIA / FRIDAY 15 JUNE 2018 / :30-19:00 E106/E107 Menarini Hyperuricemia with deposition: a multisystemic disease Fernando Perez-Ruiz (Spain) Fernando Perez-Ruiz (Spain) Introduction Claudio Borghi (Italy) Hyperuricemia with deposition: a cardio metabolic disorder Leonardo Punzi Interaction between hyperuricemia with deposition and rheumatic diseases Fernando Perez-Ruiz (Spain) Hyperuricemia with deposition: the importance of adherence to treatment Fernando Perez-Ruiz (Spain) Summary and meeting close 15 June 2018

202 200 / GENERAL INFORMATION Different people. Different symptoms. Same disease. I get heartburn and find it difficult to swallow Mike My hands are puffy and I find it hard to catch my breath Susan I have tight, thick skin and get tired easily Mandy My joints and muscles ache and my fingertips are pale Jessica Systemic sclerosis (also known as scleroderma) is a rare autoimmune disease and highly heterogeneous in terms of organ involvement and clinical progression. 1 4 The symptoms of systemic sclerosis include: Raynaud s phenomenon,* puffy hands or fingers,* acid reflux or epigastric discomfort, tight or thickening skin, dyspnoea, tiredness and fatigue, joint and muscle aches, and dysphagia. 5 7 You can ensure a prompt diagnosis of systemic sclerosis with capillaroscopy and a blood test to check for antibodies specific to the disease. 6 Please visit us at Stand 660 to find out more. Discover morethanscleroderma.com Date of preparation: April 2018 SC-CRP *Very early signs of systemic sclerosis. 7 References: 1. Derrett-Smith E and Denton C. Systemic sclerosis: clinical features and management. Medicine. 2010;38(2): Varga J and Abraham D. Systemic sclerosis: a multisystem fibrotic disorder. J Clin Invest. 2007;117: European Commission. Rare Diseases. rare_diseases/policy_en [Accessed: March 2018]. 4. U.S. Food & Drug Administration. Orphan Drugs Act - Relevant Excerpts. Updated Aug developingproductsforrarediseasesconditions/howtoapply%20 fororphanproductdesignation/ucm htm [Accessed: March 2018]. 5. Allanore Y, et al. Systemic sclerosis. Nat Rev Dis Primers 2015;1: van der Hoogen F, et al. American College of Rheumatology/ European League Against Rheumatism Collaborative Initiative. Arth Rheum 2013;65(11): Minier T, et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2014;73:

203 COMPANY PROFILES / 201 Company Profiles Status as of 1 May 2018 Booth N ABBVIE 1 North Waukegan Road North Chicago, IL United States AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world s most complex and critical conditions. The company s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at on Twitter, Facebook or LinkedIn. Booth N V25 AGORA 6 Kosmon Heraklion-Crete Greece Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since Agora aims to raise awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives. Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as promote supportive attitudes towards RMDs and enable patients to live independently and participate fully in society.

204 202 / COMPANY PROFILES Booth N 607 ALPINION MEDICAL SYSTEMS 7FL Verdi Tower 72, Digital-ro 26-gil Guro-gu, Seoul Korea ALPINION has focused on acoustic engineering and frontend technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted the attention to the front-end with a focus on the signal quality sent to system processors. Based upon proprietary superior acoustic technology, ALPINION provides users with uniform image quality and continuous support throughout the product lifetime. ALPINION continuously strives to expand the medical business from diagnostic ultrasound (E-CUBE) to therapeutic ultrasound (ALPIUS). Booth N V04 APLAR Scotts Road #24-10 Singapore Singapore Established in 1963 at Sydney, four nations, Australia, India, Japan and New Zealand together formed SEAPAL (South East Asia and Pacific Area League Against Rheumatism), which grew from strength to strength with increasing member nations, now known as APLAR. APLAR s mission and goals focus on providing state of the art care to patients with arthritis and other musculoskeletal diseases through continuing professional development, increasing the awareness and understanding about rheumatic diseases, patient advocacy and empowerment, and fostering research in the field of rheumatic diseases. Booth N V16 AMERICAN COLLEGE OF RHEUMATOLOGY 2200 Lake Boulevard, NE Atlanta, GA United States The American College of Rheumatology is a professional membership society that serves over 9,500 physicians, health professionals and scientists worldwide and is committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Stop by the ACR stand for information on: the Annual Meeting, October 19-24, Chicago, Illinois; educational programs and products, such as ACR Beyond; the Rheumatology Image Library; Arthritis & Rheumatology, Arthritis Care & Research, The Rheumatologists; and the benefits of membership. Booth N 600B AMGEN (EUROPE) GmbH Dammstrasse 23, P.O Box 1557, CH 6301 Zug, Switzerland Amgen is at the forefront of biotechnology, helping invent the processes and tools that built the global biotechnology industry into the leading source of therapies for patients with few other options. Since 1980, Amgen has developed a range of innovative therapies focusing on biologic medicines. This expertise is now also used to develop high quality, therapeutic biosimilars in order to deliver more value to patients and healthcare systems. Our mission is to serve patients. We dedicate our days to turning the tide on serious illnesses - pushing the boundaries of science to transform medicine. Booth N 214 ARTHREX GMBH Erwin-Hielscher-Straße München Germany We are a global medical device company and leader in new product development and medical education in orthopedics. With a corporate mission of Helping Surgeons Treat Their Patients Better, Arthrex has pioneered the field of arthroscopy and developed more than innovative products and surgical procedures to advance minimally invasive orthopedics worldwide. Booth N V19 ARTHRITIS RESEARCH UK AND ARTHRITIS CARE Saffron House, 6-10 Kirby Street London, EC1N 8EQ United Kingdom Last year, Arthritis Research UK and Arthritis Care joined together so that we can do more to help people with arthritis live full and active lives. We invest in breakthrough treatments, the best information and vital support for everyone affected by arthritis. We believe in harnessing the power of exceptional science and supporting those living with the condition. Whether it s through our helpline, online information or face to face services, everything we do is about helping people overcome the pain, isolation and fatigue arthritis causes. To date, our work has already uncovered breakthrough treatments and helped support millions of people living with arthritis. Together, we are determined to do more and uncover new ideas to help more people live the pain free life they deserve

205 COMPANY PROFILES / 203 Booth N V24 Ankylosing Spondylitis International Federation (ASIF) 27 Old Gloucester Street London WC1N 3AX United Kingdom office@asif.info ASIF is a global umbrella organisation established to increase public awareness of Ankylosing Spondylitis and to disseminate knowledge of the disease around the world. Ankylosing Spondylitis (AS) is a rheumatic inflammatory auto-immune disease primarily affecting the spine and sacroiliac joints, it is also called Morbus Bechterew in some European countries. ASIF has 39 Patient Organisation members 37 countries. Our most recent members are Chile, Columbia and South Africa. We aim to share the most up-to date in science and treatment with our members around the world and we encourage the sharing of information between our member societies. ASIF leads on World AS Day which falls on the first Saturday in May each year. Booth N V20 ASSOCIATION OF WOMEN IN RHEUMATOLOGY 2125 Valleygate Drive Fayetteville, NC United States Our mission is to promote the science and practice of rheumatology, foster the advancement and education of women in rheumatology, and advocate access to the highest quality health care, and management of patients with rheumatic diseases. Booth N 700 BIOGEN INTL GMBH Landis Gyr Strasse Zug Switzerland Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is the world s oldest independent biotechnology company. In 2012, Biogen entered into a joint venture with Samsung Biologics to form Samsung Bioepis to develop, manufacture and market biosimilars of advanced biologics. Biogen has commercialization rights for three anti-tnf biosimilar candidates in Europe, Japan, Turkey and Russia. These therapies will be manufactured in the company s largescale manufacturing facility in Hillerød, Denmark, which is one of the largest in the world. Booth N V01 BMJ BMA House Tavistock Square London WC1H 9JP United Kingdom Annals of the Rheumatic Diseases (ARD), a collaboration between EULAR and BMJ, is the #1 ranked journal in the field of rheumatology (impact factor ) and the flagship in the Essential Rheumatology portfolio. It is supported by RMD Open, an open access journal expanding the breadth of rheumatic and musculoskeletal diseases, and Lupus Science & Medicine the world s first lupus-specific open access journal. The package also comprises the newest edition of the EULAR Textbook on Rheumatic Diseases, the EULAR textbook on Systemic Sclerosis and the EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology. Booth N 660 BOEHRINGER INGELHEIM Binger Strasse Ingelheim am Rhein Germany At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a family owned company we plan in generations. Aiming to make significant contributions to health care, we focus on diseases which have so far not been satisfactorily treated. We innovate to make breakthrough therapies and life-enhancing improvements available to patients and to provide advanced, preventive animal healthcare. Wherever we are active, we feel responsible for our communities and are respectful of our resources. For more information, go to Booth N 480 BRISTOL-MYERS SQUIBB 3401 Princeton Pike Lawrenceville, NJ United States Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world s most vulnerable people. Each day, our employees around the world work together for patients it drives everything we do.

206 204 / COMPANY PROFILES Booth N V23 BRITISH SOCIETY OF RHEUMATOLOGY Bride House, Bride Lane EC4Y 8EE, London United Kingdom British Society for Rheumatology is the leading United Kingdom membership society for rheumatology and musculoskeletal care health professionals. We are member driven, supporting them in delivering the best care, at all stages of the care pathway, improving the lives of children and adults with rheumatic and musculoskeletal disease. Visit us at stand V23 to learn more about the society, including our conferences, courses, academic journal and the benefits of membership. Tweet Booth N 620D BÜHLMANN LABORATORIES AG Baselstrasse Schönenbuch Switzerland Calprotectin is a very efficient biomarker for disease monitoring of chronic inflammation patients like rheumatoid arthritis and other inflammatory arthritis patients. The Switzerland based company BÜHLMANN is the leading manufacturer of IVD CE certified calprotectin (MRP8/14) diagnostics tests on the market, as well as exclusively offering the only combination available of calprotectin (MRP8/14) and therapeutic drug monitoring on the quantitative rapid test device Quantum Blue to provide a comprehensive characterization of patient with chronic inflammation treated with biologic drugs. Booth N 420 CELGENE Morris Avenue 07901, Summit United States Celgene Corporation (Nasdaq: CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industryleading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information visit Booth N 120 CELLTRION HEALTHCARE 4F, 19, Academy-ro51 beon-gil Yeonsu-gu Incheon South Korea CelltrionHealthcare is a global biopharmaceutical company which conducts worldwide marketing and distribution of Celltrion, Inc. s biosimilarsand biologics. CelltrionHealthcare endeavors to offer high-quality, cost-effective and advanced therapeutics for patients in rheumatology, gastroenterology, immunology and oncology. Booth N PC5 CYTOKINE SIGNALLING FORUM Gothic Cottage White Lion Street Stafford ST17 BW United Kingdom Developed under the auspices of the University of Glasgow and with a Steering Committee of rheumatology experts the Cytokine Signalling Forum is an online resource providing rapid reviews and slide resources of the latest literature, CME courses to further learning, congress highlights with the key data from EULAR and ACR, and our new podcast channel with our monthly review and interviews with authors of key papers. All this is accessible for free by visiting our stand or logging on to Booth N V18 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Via Santa Maria Pisa Italy Clinical and Experimental Rheumatology is an international journal focused on the latest developments in rheumatology. Every issue contains original articles, editorials, reviews, case reports and articles on paediatric rheumatology, aimed at updating readers in this complex and growing field. The journal also publishes regular annual supplements on monothematic topics, facing the most new and controversial aspects in rheumatology, such as Contemporary Advances in Clinical Rheumatology, Vasculitis, Behc et s disease and Autoinflammatory conditions, Systemic Sclerosis, Fibromyalgia and Sjögren s syndrome.

207 COMPANY PROFILES / 205 Booth N 217 DS MEDICA SRL DS Medica srl STAND Viale Monza Milan Italy Since 1979 DS Medica has been involved in project development, production, distribution and marketing of medical technologies (hardware and software) as well as in the pharmaceutical advertising. DS Medical is a leader in capillaroscopic techniques for the early diagnosis of many rheumatologic diseases. Videocap is an epiluminescence video-bio-microscope product line for multi-modality microscopy (immersion microscopy, polarized light microscopy and contact mode). Videocap is the ultimate instrument suited for diagnostic and research applications in the fields of rheumatology and dermatology. Booth N 400 ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN United States Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring lifechanging medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at Booth N V11 ERN ReCONNET Via Roma , Pisa Italy The European Reference Network ReCONNET is a virtual network for rare and complex connective tissue diseases (CTDs). The Network involves healthcare providers across Europe and aims at improving the clinical approach to rare and complex CTDs, the quality of the specialized care provided to patients, the activity of the physicians, the empowerment of the patients. All these activities are addressed to create a highly specialized network, in which the knowledge travels rather than the patient. Booth N V31 ESOR - EULAR School of Rheumatology Seestrasse Kilchberg Switzerland EULAR School of Rheumatology (ESOR) is a pre-eminent provider and facilitator of high quality education for physicians, health professionals and people with rheumatic and musculoskeletal diseases. It is a fully integrated operational entity within EULAR, offering individual membership primarily to physicians, health professionals and people with RMDs. Recent activities and products of ESOR include: Online courses, mentored learning programs, live courses, educational content of the EULAR Annual Congress and others (textbooks, educational exchanges, transfer programs, grants, awards and bursaries). Booth N V34 EULAR EXECUTIVE SECRETARIAT Booth N V32 EMEUNET Seestrasse Kilchberg Switzerland EMEUNET, the EMerging EULAR NETwork, is a EULAR network of young clinicians and researchers in rheumatology that promotes education and, research, developing existing and new collaborations and integrating younger members within all EULAR activities. The main objectives of EMEUNET include the development of a European-wide network of young emerging rheumatologist and rheumatology-oriented researchers, enabling continued excellence in research and promoting and facilitating a comprehensive higher educational platform for all rheumatology trainees across Europe. Seestrasse Kilchberg Switzerland The European League against Rheumatism (EULAR) is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.

208 206 / COMPANY PROFILES Booth N V30 EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY Seestrasse Kilchberg Switzerland The EULAR Standing Committee of Health Professionals in Rheumatology represents non-physician health professionals including nurses, physio and occupational therapists, podiatrists, psychologists, social workers and pharmacists in the European rheumatology field. We aim to improve the standard of care for people with rheumatic and musculoskeletal diseases (RMDs), with them as active and empowered individuals. We collaborate to improve the quality of education and research undertaken and implemented by health professionals in their area of practice, and participate in activities to raise awareness of how health professionals contribute to the health and wellbeing of patients with RMDs. Booth N 440A EXPANSCIENCE 1 Place des Saisons Paris La Défense Cedex France In 2017, Expanscience generated a turnover of million, 61.9% of which was through exports, and employed 1105 people. Over more than 60 years, we have built up a solid international reputation as an innovator and expert. Our products are distributed in almost 100 countries (including 16 subsidiaries). The whole value chain is an integral part of the business from research to production and distribution. Our CSR policy was introduced 15 years ago and has been recognised as exemplary by the AFAQ assessment. Booth N V13 Booth N V29 EULAR PARE Seestrasse Kilchberg Switzerland The EULAR Standing Committee of PARE gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for the more than 120 million people in Europe living with these conditions. The committee s vision is of people with rheumatic and musculoskeletal diseases (RMDs) in Europe being empowered to lead full and independent lives. To achieve this, the committee organises a range of high-quality activities and programmes. Activities may include advocacy at the national level, e.g. raising awareness of the disease, defending the civil rights of people with RMDs, or having access to the latest and most appropriate treatments. EYELED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES Science Park Saarbrücken Germany Eyeled the mobile IT specialists With our knowledge and experience from more than 250 mobility projects, we offer our customers comprehensive advice, implement mobile solutions and provide long-term support for them. On site, we offer battery recharge, support for troubleshooting smartphones and other mobile devices as well as assistance for downloading the EULAR Congress App. Visit us at booth V13 in the EULAR Village. Booth N B F. HOFFMANN-LA ROCHE AG Booth N V35 EULAR STUDY GROUPS Seestrasse Kilchberg Switzerland EULAR Study Groups are focus groups in the sphere of one of EULAR s Standing Committee that has received EULAR endorsement. These groups promote activities/scientific networking under their own guidance without any financial support from EULAR. They are open for participation to anyone who is interested in the field in question and who brings background knowledge in the subject area. Grenzacherstrasse 124 CH-4070 Basel Switzerland Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. For more information, please visit roche.com.

209 COMPANY PROFILES / 207 Booth N V09 FESCA (FED OF SCLERODERM ASSOCIATIONS) Le Versailles, Av. des Etats-Unis 20/ Tournai Belgium FESCA aisbl., founded in 2007, is an umbrella group of currently 24 national scleroderma patient support and advocacy organizations in 19 European countries. Friends of FESCA aisbl, includes the United States, Canada, and Australia, giving us a global presence and unity of purpose with other groups in the world. FESCA s objectives include encouraging the active involvement of politicians and pharmaceutical companies, working with doctors to secure earlier diagnosis and better treatments, and creating greater awareness of scleroderma so that those who suffer from it can access proper, equitable care. Booth N 611 FIDIA FARMACEUTICI Via Ponte della Fabbrica 3/A Abano Terme Italy Fidia farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based on natural and functionalised hyaluronic acid (over 650 patents), in joint care, wound healing, ophthalmology, aesthetics and regenerative medicine. Manufacturing operations are FDA-inspected and approved, and the company extends its global reach through wholly-owned subsidiaries and partners in nearly 100 countries worldwide. Please visit the company website Booth N 608 FRESENIUS KABI Else-Kröner-Straße Bad Homburg Germany Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Products: I.V. generic drugs, infusion therapies, clinical nutrition products and medical devices for administering these products. Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. The company also develops biosimilars with a focus on oncology and autoimmune diseases. Booth N 215 GE HEALTHCARE Beethovenstrasse Solingen Germany GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. Booth N V33 FOREUM FOREUM Foundation for Research in Rheumatology Seestrasse Kilchberg Switzerland FOREUM Foundation for Research in Rheumatology is an independent non-profit organisation, devoted to promote research in rheumatic and musculoskeletal diseases (RMDs). FOREUM seeks to initiate research of the highest quality and periodically announces calls for research proposals. FOREUM seeks to raise funds from donors sharing FOREUM s vision and goals: recognising that research and innovation in this field are crucial for improving prevention and management of RMDs and, hence, the living, working and socio-economic conditions of the more than 120 million people in Europe afflicted by RMDs Booth N 720 GILEAD SCIENCE, INC 333 Lakeside Drive 94404, Foster City, CA United States Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple conditions, including Rheumatoid Arthritis and other rheumatic diseases. We are pursuing a comprehensive clinical trial program evaluating novel agents with the goal of advancing the care of patients suffering from inflammatory conditions.

210 208 / COMPANY PROFILES Booth N V22 GISEA Via degli Antichi Pastifici, Molfetta (BA) Italy The GISEA registry is an independent database that was established by the Italian Group for the Study of Early Arthritis (GISEA) in 2008, funded by the Italian Association of Rheumatic Patients (ANMAR - ONLUS). In line with the network s epidemiological strategy, the initial protocol was designed to collect long-term follow-up data concerning patients with rheumatic diseases treated with biological agents in order to investigate the real-world characteristics in terms of disease activity, comorbidities and survival on treatment. Booth N 520 GLAXOSMITHKLINE 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom GSK s purpose is to help people do more, feel better, and live longer. Our Pharmaceuticals business has a broad portfolio of innovative and established medicines. We are focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. To discover the next breakthrough for immune-mediated diseases, we are focusing on transformational medicines that could potentially alter the course of inflammatory disease and induce sustainable remission. Booth N 201 GRÜNENTHAL GMBH Zieglerstraße Aachen Germany Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a 2 bn company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation. More information: Follow us on LinkedIn: Grunenthal Group Booth N 218 HEMICS Torenallee BC Eindhoven Netherlands Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics developed the Hemics HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, perfectly fitting the workflow in the rheumatologist s office. Booth N 620C GRIFOLS Av. de la Generalitat Sant Cugat Barcelona Spain An experienced and trusted partner, Grifols advances patient care with innovative diagnostic solutions that improve disease detection and management and simplify laboratory operations. Today, we empower customers with diagnostic products that span the healthcare continuum from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring and that include a comprehensive transfusion medicine portfolio and a growing portfolio of specialized clinical diagnostics. Booth N 340B IBSA INSTITUT BIOCHIMIQUE SA Via Del Piano Pambio Noranco Lugano Switzerland IBSA Institut Biochimique SA is a pharmaceutical company headquartered in Lugano, Switzerland. With a focus on high quality manufacturing, IBSA s portfolio for OA and related syndromes includes different therapeutic options such as pharmaceutical-grade chondroitin sulphate for oral intake, a series of highly purified i.a. hyaluronic acids of biofermentative origin, topical/oral forms of diclofenac epolamine and an innovative low-dosage subcutaneous and iv bolus injection of diclofenac.

211 COMPANY PROFILES / 209 Booth N V16 International League of Associations for Rheumatology (ILAR) 2200 Lake Blvd NE Atlanta, GA United States The International League of Associations for Rheumatology s mission is to advance rheumatology in developing countries. The ILAR Executive Committee consists of the Presidents and Presidents-Elect of ACR, EULAR, PANLAR, APLAR and AFLAR. The collaboration of the leaders of these international organizations has resulted in a renewed commitment to provide grants to support programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need. The ILAR Grants Program, a funding initiative, was developed in response to the growing need for global advancements in rheumatology. Since 2008 ILAR has donated over a million dollars to fund 50+ Projects Worldwide. ILAR s next Call for Proposals will open July 2, Booth N 680 JANSSEN PHARMACEUTICA NV Turnhoutseweg Beerse Belgium Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on Follow us on for our latest news. Booth N V05 JAPAN COLLEGE OF RHEUMATOLOGY Toranomon Minato-ku, Tokyo Japan The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world. The JCR publishes its official journal, Modern Rheumatology and Modern Rheumatology Case Reports, which provides information on the latest developments in rheumatic diseases. Booth N PC1 LA LETTRE DU RHUMATOLOGUE 44, rue de Prony Paris France La Lettre du Rhumatologue is a French monthly publication specialized in rheumatology, which editor in chief is Pr. Bernard Combe. The publication is released in copies issued 10 times a year. Booth N 609 LCA PHARMACEUTICAL 9, Allée Prométhée Chartres France LCA Pharmaceutical is expert in design and manufacture of viscoelastic medical devices with sodium hyaluronate for osteoarthritis. All of our products have a high molecular weight and high concentration of sodium hyaluronate. We offer a wide range of products: - Treatment of 3 weekly intra-articular injections (40mg- 2mL); - Single injection for knee osteoarthritis (75mg/3mL); - Single injection for hip osteoarthritis (75mg/3mL); - Small joints injection (20mg/mL); Two other innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis: pain relief and joint function recovery. - Single injection (60mg NaHA + 60mg CS / 3mL); - Treatment of 3 weekly intra-articular injections (40mg NaHA + 40mg CS / 2mL)

212 210 / COMPANY PROFILES Booth N 600A LG CHEM LG Twin Towers 128 Yeoui-daero Yeoungdeungpo-gu Seoul, Korea LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area. Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical. Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products. LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world. Booth N V03 LUPUS ACADEMY Maasdijk AS Veen Netherlands The Lupus Academy is a long-term initiative committed to improving patient outcomes in SLE and allied diseases and to building a community of practitioners and advocates of best practice. By providing a highly interactive educational forum, the Lupus Academy is dedicated to sharing best clinical practice through the dissemination and discussion of cutting edge scientific and clinical research. Booth N V26 LUPUS EUROPE St. James House Eastern Road RM1 3NH Romford, Essex United Kingdom Since 1989, LUPUS EUROPE is the umbrella organisation federating national lupus self-help organisations all over Europe. Today it unites 26 members from 24 countries in Europe and represents more than 30,000 patients. Our Vision is a fulfilling life for all people with lupus in Europe until we have reached a world without lupus. Our Mission is to be the voice of lupus in Europe and to empower the national organisations for people living with lupus. We pursue this through 3 fundamental Strategic Drivers: 1. People with lupus in Europe participate in and benefit from research in lupus 2. Enthusiasm and empowerment to member organizations. 3. LUPUS EUROPE is heard & acting For more information or collaboration with LUPUS EUROPE, please contact secretariat@lupus-europe.org Booth N 200 MEDAC Theaterstrasse Wedel Germany medac Gesellschaft für klinische Spezialpräparate mbh Medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems. Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof. You can find further information about the company and its products at

213 COMPANY PROFILES / 211 Booth N 440B MENARINI GROUP Via Sette Santi Firenze Italy Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th in the world out of 20,862 companies, it has a turnover of over 3.5 billion and more than 16,700 employees. The Menarini Group has always held two clear strategic objectives: research and internationalisation. It has a presence in the most important treatment areas, including cardiologic, gastroenterologic, pneumological/antibiotic, diabetic and anti-inflammatory/analgesic products. With 16 production plants and 6 Research and Development centres, the Menarini Group has a strong presence across Europe, Asia, Africa and central and South America. Menarini s products are available in over 130 countries worldwide. For more information visit Menarini recently received the EMA approval for a New pain- killer indicated for symptomatic short term treatment of moderate to severe acute pain Booth N 140 MSD 2000 Galloping Hill Road Kenilworth, New Jersey United States For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. For more information, visit and connect with us on Twitter, LinkedIn and YouTube. Booth N 620B/2 NORDIC GROUP BV 254 Boulevard St Germain Paris France The Nordic Group is a privately owned, fully integrated, pharmaceutical company with a direct presence in 17 countries. Nordic s strategy is to focus on creating Added Value for specific unmet medical needs and for the true benefit of the patient and the healthcare stakeholders. With the patient in mind, Nordic has developed products which offer more autonomy and comfort in rheumatic disease management. Booth N NOVARTIS Fabrikstrasse Basel Switzerland Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis Group companies employ approximately 122,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. Booth N PC2 OXFORD UNIVERSITY PRESS Great Clarendon Street OX2 6DP, Oxford United Kingdom Oxford University Press is a leading publisher in rheumatology, publishing the official journals of the British Society for Rheumatology (BSR) and some of the most respected online resources, and books, including the Oxford Textbook of Rheumatology, the Oxford Handbook of Rheumatology, and Paediatric Rheumatology. Visit us to enter our prize draw, pick up a free copy of Rheumatology, find out more about our exciting new open access journal Rheumatology Advances in Practice, and browse our extensive collection of books, available to buy with an exclusive 20% conference discount. Booth N PFIZER Via Valbondione, Roma Italy Pfizer Inc.: Working together for a healthier world At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

214 212 / COMPANY PROFILES Booth N 500 REGENERON 777 Old Saw Mill River Road 10591, New York United States Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases. Booth N V27 ROMANIAN SOCIETY OF RHEUMATOLOGY 37-39, Ion Mihalache Blvd. Romania Romanian Society of Rheumatology (SRR) is the professional medical association that brings together all Romanian rheumatologists. Each year we organize a national meeting that usually involves about 800 participants and a summer school (one week dedicated to our trainees). Regional events and border-free scientific meetings organized together with specialists from other medical areas populate the whole year with moments of scientific debate and opportunities for education. The Journal of SRR serve its readers as an authoritative resource for clinical and fundamental research in rheumatology. Booth N V28 National AssociatioN ReumaZorg Nederland PO Box AB Nijmegen Netherlands The National Association ReumaZorg Nederland is the Dutch independent user-led patient organisation that strives to make a difference in the lives of people with RMDs. We work and lobby for an early diagnosis of RMDs, good healthcare and a healthy active life for our members and for the more than 1,95 million Dutch people, known to have an RMD. Our advocacy aims at supporting people with RMDs in the best way possible. F I W E voorzitter@reumazorgnederland.nl Booth N 209 SAMUMED, LLC 9381 Judicial Drive San Diego, CA United States Samumed, LLC is a pharmaceutical platform company that has made groundbreaking advances in the biology of tissue regeneration. Our platform is rooted in its discoveries of new targets and biological processes in the Wnt pathway, an essential component of cellular biology of tissue regeneration. Samumed is currently conducting clinical trials in osteoarthritis, degenerative disc disease, idiopathic pulmonary fibrosis, psoriasis, tendinopathy, androgenetic alopecia, and oncology. Booth N 620A SANDOZ Booth N V07 RHEUMATOLOGY NEWS 7 Century Drive Parsippany NJ United States Rheumatology News is the leading independent newspaper for the practicing rheumatologist. With specialty-focused news and insightful commentary--in a clear, concise, accessible format--rheumatology News keeps busy rheumatologists up-to-date on clinical advances that impact their daily practice of medicine. Rheumatology News is published 18X/year and circulates to nearly 8,000 rheumatologists, selected primary care physicians, and NP and PA specialists in rheumatology. All articles are researched, written, and produced by professional medical journalists. Rheumatology News can be found online at Industriestr Holzkirchen Germany Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to discover new ways to improve and extend people s lives. We pioneer novel approaches to drive access to medicine. Our portfolio comprises approximately 1000 molecules and our products reach well over 500 million patients.

215 COMPANY PROFILES / 213 Booth N 500 SANOFI GENZYME 50 Binney St Cambridge, MA United States Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain andw ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life Booth N V06 SCANDINAVIAN JOURNAL OF RHEUMATOLOGY Hospital,Norrebrogade Aarhus Denmark The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology. Subscriptions include print, online access, and supplements to the Journal. Published since 1955 by the Scandinavian Society for Rheumatology. Detailed information is available on our website www. scandjrheumatol.dk Booth N V10 EUROPEAN LUPUS SOCIETY Booth N PC6 MEDICINE MATTERS - SPRINGER HEALTHCARE The Campus, 4 Crinan Street London N1 9XW United Kingdom Medicine Matter rheumatology is provided by Springer Healthcare part of the Springer Nature group. Medicine Matters is a free to access professional rheumatology resource for healthcare professionals working with patients with rheumatology. Guided by our Advisory Board, Medicine Matters rheumatology will: Be a trusted online source of daily news, medical information, and expert opinion Provide regularly updated, peer-reviewed content Serve as an access point to the foremost sources of rheumatology information on the web Deliver educational tools and (CME) to support professional development Booth N 213 TILMAN ZI Sud, Baillonville Belgium Tilman is a Belgian pharmaceutical laboratory developing, manufacturing and distributing plant-based medicines for 60 years. By using industrial equipment in compliance with the GMP (Good Manufacturing Practices) pharmaceutical standards, Tilman is one of the most modern phytotherapy laboratories in Europe. Scientific rigour and compliance with the strictest of standards both contribute to the design of medicines with NOC (Notice of Compliance) and a full range of safe and effective products distributed by health professionals in numerous countries all over the world. Via G. Ripamonti Milan Italy The European Lupus Society is a non-profit association and pursues the following goals: Building up a community of clinicians and researchers interested in SLE at a European and international level, with special focus to engage younger physicians in the field Promoting and coordinating the organisation of research and educational meetings on SLE and related syndromes Promoting equal access to best standard of care for SLE patients across Europe Facilitating research projects and clinical trials in SLE To learn more about SLEuro, please visit us at org and follow us on Facebook and Twitter.

216 214 / COMPANY PROFILES Booth N V21 The Partnership of Turkish League Against Rheumatism (TLAR) and Rheumatology Society of Turkey (RST/TRD) Sisli Istanbul Turkey TURKISH LEAGUE AGAINST RHEUMATISM was established in 1947 by physical medicine and rehabilitation specialists.it became a member of EULAR in RHEUMATOLOGY SOCIETY OF TURKEY (TRD, Turkiye Romatoloji Dernegi) is the representative scientific society for rheumatologists based on internal medicine with more than 300 members. It was founded in 1993 and has been organizing National Congesses of Rheumatology since ( EULAR representation in Turkey has been carried on by the partnership of TRD and TLAR since 2014 aiming to promote and to improve the official and scientific connections between Turkish rheumatologists and EULAR. Booth N 640 UCB Allée de la Recherche Brussels Belgium At UCB, we aspire to be the patient-preferred biotech leader. Everything we do starts with a simple question: How will this create value for people living with severe diseases? UCB s patient value strategy aims to deliver, through a deep understanding of patient subpopulations, unique outcomes and the best patient experience to as many lives as possible within specific populations where UCB can lead. With more than 7,500 people in approximately 40 countries, UCB generated revenue of 4.5 billion in Booth N V08 WORLD SCLERODERMA FOUNDATION Elisabethenstrasse Basel Switzerland Based in Switzerland, promoting scleroderma research and supporting patients suffering from scleroderma. WSF is dedicated to initiating and supporting research in scleroderma in all its aspects in all regions of the world. It is also committed to improving the quality of life for scleroderma sufferers and their families. Support is in the form of project grants, expert advisory panels and knowledge dissemination platforms. Booth N 620E XIRALITE GMBH Robert-Koch-Platz Berlin Germany Xiralite GmbH is a medical device company located in the heart of Berlin, Germany. We offer innovative concepts for the diagnosis and therapy of several diseases, thereby providing significantly improved benefits to our customers. Xiralite s key technology is based on fluorescence optical imaging and our medical imaging devices enable diagnostics of microcirculation disorders. Through this unique technology, alterations of the microcirculation become visible allowing for the identification of different types of rheumatic diseases. Our devices are installed worldwide in clinical practices, hospitals and research institutions. Booth N PC4 WISEPRESS LTD 15 Lyon Road London, SW19 2RL United Kingdom Wisepress.com, Europe s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

217 Acknowledgements COMPANY PROFILES / 215 The EULAR 2018 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following partners: Mobile app Itinerary planner Mobile charging stations Wireless access & Pocket programme

218 216 / EXHIBITORS' LIST Exhibitors' List Status as of 1 May 2018 COMPANY STAND N Commercial Exhibition - Exhibitors' List ABBVIE ALPINION MEDICAL SERVICES 607 AMGEN 600B ARTHREX 214 BIOGEN 700 BOEHRINGER INGELHEIM 660 BRISTOL-MYERS SQUIBB 480 BÜHLMANN LABORATORIES 620D CELGENE 420 CELLTRION HEALTHCARE 120 DS MEDICA SRL 217 ELI LILLY AND COMPANY 400 EXPANSCIENCE 440A FIDIA FARMACEUTICI 611 FRESENIUS KABI 608 GE HEALTHCARE 215 GILEAD SCIENCE 720 GLAXOSMITHKLINE 520 GRIFOLS 620C GRÜNENTHAL GMBH 201 HEMICS 218 IBSA INSTITUT BIOCHIMIQUE SA 340B JANSSEN PHARMACEUTICA NV 680 LCA PHARMACEUTICAL 609 LG CHEM 600A MEDAC 200 MENARINI GROUP 440B MSD 140 NORDIC GROUP BV 620B/2 NOVARTIS PFIZER REGENERON 500 ROCHE B SAMUMED, LLC 209 SANDOZ 620A SANOFI GENZYME 500 TILMAN 213 UCB 640 XIRALITE GMBH 620E COMPANY STAND N Publishers' corner - Exhibitors' List CYTOKINE SIGNALLING FORUM LA LETTRE DU RHUMATOLOGUE OXFORD UNIVERSITY PRESS MEDICINE MATTERS - SPRINGER HEALTHCARE WISEPRESS LTD EULAR Village - Exhibitors List AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) AGORA APLAR ARTHRITIS RESEARCH UK & ARTHRITIS CARE ANKYLOSING SPONDYLITIS INTERNATIONAL FEDERATION (ASIF) ASSOCIATION OF WOMEN IN RHEUMATOLOGY BRITISH SOCIETY OF RHEUMATOLOGY BMJ CLINICAL AND EXPERIMENTAL RHEUMATOLOGY NATIONAL ASSOCIATION REUMAZORG NEDERLAND EMEUNET ERN RECONNET ESOR (EULAR SCHOOL OF RHEUMATOLOGY) EULAR EXECUTIVE SECRETARIAT EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY EULAR PARE EULAR STUDY GROUPS EYELED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES FESCA (FED OF SCLERODERM ASSOCIATIONS) FOREUM GISEA INTERNATIONAL LEAGUE OF ASSOCIATONS FOR RHEUMATOLOGY (ILAR) JAPAN COLLEGE OF RHEUMATOLOGY LUPUS ACADEMY LUPUS EUROPE REUMAZORG NEDERLAND RHEUMATOLOGY FEDERATION OF TURKEY RHEUMATOLOGY NEWS ROMANIAN SOCIETY OF RHEUMATOLOGY SCANDINAVIAN JOURNAL OF RHEUMATOLOGY EUROPEAN LUPUS SOCIETY WORLD SCLERODERMA FOUNDATION PC5 PC1 PC2 PC6 PC4 V16 V25 V04 V19 V24 V20 V23 V01 V18 V28 V32 V11 V31 V34 V30 V29 V35 V13 V09 V33 V22 V16 V05 V03 V26 V28 V21 V07 V27 V06 V10 V08

219 EXHIBITION PLAN / 217 Exhibition Plan Status as of 1 May 2018 Sessions Posters Posters Posters Posters G001 G002 G003 Hall Posters HS 26 HS 27 HS 28 HS 16 HS A 340B Hall HS 24 HS 23 HS 25 Hall5 HS 13 HS 11 HS 14 HS A 620B 620E HS 22 HS 09 HS 10 Hall A 440B 620C 620D HS 20 HS 18 HS 17 HS 21 HS 19 HS 07 HS 08 HS 05 HS 06 HS 03 HS 04 HS 06 HS 04 Registration A PARE Room room HS 02 HS 01 V35 EULAR Study Group 600B PARE posters HS 01 EULAR Village, EULAR Campus, Cyber café V33 V34 EULAR booth V28 V27 V26 V25 V24 V23 V22 V21 V20 V19 V18 V16 Amtrium Ground Floor PC6 PC4 PC5 PC1 PC2 Publishers corner Speakers preview K Main Entrance EULAR Social Social Media room Wall V32 V31 HS HS HS V29 Cyber café V30 V01 V02 V03 V04 V05 V06 V07 V08 V09 V10 V11 V13 Amtrium 1 Amtrium 2

220 E101 A 218 / CONGRESS VENUE OVERVIEW PLAN Congress Venue Overview Plan E102 Forum E103 E104 E105 E106 E107 E108 Emerald E rooms E rooms Prayer rooms E002 Female E001 Male Auditorium Balcony D502 - D507 D402 - D407 D301 - D304 D201 - D204 D rooms Auditorium 1 Elicium 2 G105 G106 G107 G108 G109 G110 G111 Amsterdam suite G rooms G001 G00 G002 G002 G003 G104 G101 G102 G103 G rooms Level 1 Hospitality Suites Europe Foyer Hall2 Registration Publishers Corner Level 0 Main Entrance K EULAR Village

221 PLAN / 219 Hall7.2 Hall3 Session room Session room Hall7.1 Hall1 Posters Session room Commercial exhibition area (restricted access) Hospitality suites PARE Posters PARE ROOM Hall5 Hospitality suites mtrium

222 220 / NOTES Notes

223 EULAR Online Courses All courses start in September th EULAR Online Course on Rheumatic Diseases 5th EULAR Online Course in Paediatric Rheumatology 4th EULAR Online Course for Health Professionals 8th EULAR Online Course on Systemic Sclerosis 10th EULAR Online Course on Connective Tissue Diseases 7th EULAR Online Introductory Ultrasound Course NEW! EULAR Online Course on Imaging in RMDs Individual course cost: EUR 150; reduced prices available for EULAR School of Rheumatology members! Learn more at

224 222 / NOTES Notes

225 Notes NOTES / 223

226 224 / NOTES Notes

227 2018 Gilead Sciences, Inc. All rights reserved. GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. Date of preparation 04/2018 FIL/IHQ/18-03//1006a

228 BIOSIMILARS FROM AMGEN EXPERIENCE CAN T BE REPLICATED Amgen brings nearly four decades of experience in the research, development, manufacturing, and supply of innovator biologics to its portfolio of novel and biosimilar therapies for inflammatory diseases. To learn more, please visit and EUHQ-P-BIO From the biotech pioneers.